FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Ferreira, LT
   Rodrigues, J
   Cassiano, GC
   Tavella, TA
   Tomaz, KCP
   Baia-da-Silva, DC
   Souza, MF
   Lima, MND
   Mottin, M
   Almeida, LD
   Calit, J
   Puca, MCSD
   Melo, GC
   Bargieri, DY
   Lopes, SCP
   Lacerda, MVG
   Bilsland, E
   Sunnerhagen, P
   Neves, BJ
   Andrade, CH
   Cravo, PVL
   Costa, FTM
AF Ferreira, Leticia Tiburcio
   Rodrigues, Juliana
   Cassiano, Gustavo Capatti
   Tavella, Tatyana Almeida
   Peralis Tomaz, Kaira Cristina
   Baia-da-Silva, Djane Clarys
   Souza, Macejane Ferreira
   do Nascimento Lima, Marilia Nunes
   Mottin, Melina
   Almeida, Ludimila Dias
   Calit, Juliana
   Silva de Barros Puca, Maria Carolina
   Melo, Gisely Cardoso
   Bargieri, Daniel Youssef
   Pinto Lopes, Stefanie Costa
   Guimaraes Lacerda, Marcus Vinicius
   Bilsland, Elizabeth
   Sunnerhagen, Per
   Neves, Bruno Junior
   Andrade, Carolina Horta
   Lemos Cravo, Pedro Vitor
   Maranhao Costa, Fabio Trindade
TI Computational Chemogenomics Drug Repositioning Strategy Enables the
   Discovery of Epirubicin as a New Repurposed Hit for Plasmodium
   falciparum and P. vivax (vol 64, e02041-19, 2020)
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Correction
C1 [Ferreira, Leticia Tiburcio; Cassiano, Gustavo Capatti; Tavella, Tatyana Almeida; Peralis Tomaz, Kaira Cristina; Andrade, Carolina Horta; Maranhao Costa, Fabio Trindade] Univ Campinas UNICAMP, Dept Genet Evolut Microbiol & Immunol, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Campinas, SP, Brazil.
   [Rodrigues, Juliana; do Nascimento Lima, Marilia Nunes; Mottin, Melina; Neves, Bruno Junior; Andrade, Carolina Horta] Univ Fed Goias, Fac Farm, LabMol, Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.
   [Cassiano, Gustavo Capatti; Lemos Cravo, Pedro Vitor] Univ Nova Lisboa, Inst Higiene & Med Trop, Global Hlth & Trop Med GHTM, Lisbon, Portugal.
   [Baia-da-Silva, Djane Clarys; Souza, Macejane Ferreira; Silva de Barros Puca, Maria Carolina; Pinto Lopes, Stefanie Costa] Fundacao Oswaldo Cruz FIOCRUZ, Inst Leonidas & Maria Deane, Manaus, Amazonas, Brazil.
   [Souza, Macejane Ferreira; Melo, Gisely Cardoso; Pinto Lopes, Stefanie Costa; Guimaraes Lacerda, Marcus Vinicius] Fundacao Med Trop Dr Heitor Vieira Dourado, Manaus, Amazonas, Brazil.
   [Almeida, Ludimila Dias; Bilsland, Elizabeth] Univ Estadual Campinas, Inst Biol, Dept Struct & Funct Biol, Synthet Biol Lab, Campinas, SP, Brazil.
   [Calit, Juliana; Bargieri, Daniel Youssef] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Sao Paulo, Brazil.
   [Sunnerhagen, Per] Univ Gothenburg, Dept Chem & Mol Biol, Gothenburg, Sweden.
   [Neves, Bruno Junior; Lemos Cravo, Pedro Vitor] Ctr Univ Anapolis UniEVANGELICA, LabChem Lab Cheminformat, Anapolis, Go, Brazil.
RP Andrade, CH; Costa, FTM (corresponding author), Univ Campinas UNICAMP, Dept Genet Evolut Microbiol & Immunol, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Campinas, SP, Brazil.; Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, LabMol, Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.; Cravo, PVL (corresponding author), Univ Nova Lisboa, Inst Higiene & Med Trop, Global Hlth & Trop Med GHTM, Lisbon, Portugal.; Cravo, PVL (corresponding author), Ctr Univ Anapolis UniEVANGELICA, LabChem Lab Cheminformat, Anapolis, Go, Brazil.
EM carolhandrade@gmail.com; pedrovcravo@gmail.com; fabiotmc72@gmail.com
CR Ferreira Leticia Tiburcio, 2020, Antimicrob Agents Chemother, V64, DOI 10.1128/AAC.02041-19
NR 1
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD NOV
PY 2020
VL 64
IS 11
AR e01843-20
DI 10.1128/AAC.01843-20
PG 1
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA OE6ML
UT WOS:000580642600014
PM 33082230
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU dos Santos, DB
   Moreira-Filho, JT
   Melo, AD
   Lemes, JA
   Silva, LD
   Rocha, TL
   Andrade, CH
   Neves, BJ
   Bezerra, JCB
AF Santos, Daniela Braz dos
   Moreira-Filho, Jose Teofilo
   Melo, Amanda de Oliveira
   Lemes, Josiel Araujo
   Damacena Silva, Luciana
   Rocha, Thiago Lopes
   Andrade, Carolina Horta
   Neves, Bruno Junior
   Bezerra, Jose Clecildo Barreto
TI In silico-driven identification of novel molluscicides effective against
   Biomphalaria glabrata (Say, 1818)
SO NEW JOURNAL OF CHEMISTRY
LA English
DT Article
ID APPLICABILITY; GENERATION; SCHISTOSOMIASIS; DERIVATIVES; TOXICITY;
   CURATION; LAPACHOL; VERIFY; MODEL; TRUST
AB Schistosomiasis control in endemic areas depends on several factors, including mass drug delivery programs and interrupting the transmission of disease by controlling the intermediate host snails in the freshwater ecosystem using molluscicides. However, the use of the gold standard molluscicide,i.e., niclosamide, has been considered problematic due to its high cost, toxicity for aquatic organisms, and the emergence of niclosamide-resistant snail populations. In this work, we report thein silicodriven identification of novel naphthoquinone compounds with high molluscicidal activity againstBiomphalaria glabrata. For this purpose, we developed statistically robust and validated shape-based and machine learning models usingB. glabratabioassay compounds data. Using these models, we prioritized fourteen naphthoquinone compounds for furtherin vivotesting against adult, newly-hatched, and embryo ofB. glabratasnails. Among them, compounds3,5,6,7, and12were the best candidates, presenting moderate potency against adult snails (LC50: 28.98-102.24 mu M) and high potency (LC50: 14.52-0.45 mu M) against newly-hatched snails and embryos. To summarize, thein silicoapproach explored here allowed us to discover five new molluscicidal candidates for prospective field studies.
C1 [Santos, Daniela Braz dos; Moreira-Filho, Jose Teofilo; Bezerra, Jose Clecildo Barreto] Univ Fed Goias, Inst Patol Trop & Saude Publ, Lab Studies Host Parasite Relationship, Goiania, Go, Brazil.
   [Moreira-Filho, Jose Teofilo; Andrade, Carolina Horta; Neves, Bruno Junior] Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.
   [Melo, Amanda de Oliveira; Lemes, Josiel Araujo] Ctr Univ Anapolis UniEVANGE LICA, Lab Cheminformat, Anapolis, Go, Brazil.
   [Damacena Silva, Luciana] Univ Estadual Goias, Lab Host Parasite Interact, Anapolis, Go, Brazil.
   [Rocha, Thiago Lopes] Univ Fed Goias, Lab Environm Biotechnol & Ecotoxicol, Inst Patol Trop & Saude Publ, Goiania, Go, Brazil.
RP Bezerra, JCB (corresponding author), Univ Fed Goias, Inst Patol Trop & Saude Publ, Lab Studies Host Parasite Relationship, Goiania, Go, Brazil.; Andrade, CH; Neves, BJ (corresponding author), Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.
EM carolina@ufg.br; brunoneves@ufg.br; clecildo@ufg.br
RI Lopes Rocha, Thiago/A-3864-2015
OI Lopes Rocha, Thiago/0000-0003-0551-6842; Moreira-Filho, Jose
   Teofilo/0000-0002-0777-280X
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brazil
   (CAPES)CAPES [001]; CNPqNational Council for Scientific and
   Technological Development (CNPq) [400760/2014-2, 425119/2018-1,
   470298/2014-6]; CAPESCAPES; FAPESPFundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2017/02353-9]; FAPEG [2020051000003]
FX This study was financed in part by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior - Brazil (CAPES) - Finance Code 001. The
   authors thank Brazilian funding agencies, CNPq, CAPES, FAPESP and FAPEG
   for financial support and fellowships. B. J. N. is supported by CNPq
   (grant 425119/2018-1). J. C. B. B. is supported by CNPq (grant
   470298/2014-6). C. H. A. is productivity fellow of CNPq. C. H. A. is
   supported by CNPq (grant 400760/2014-2), FAPESP (grant #2017/02353-9),
   and FAPEG (grant #2020051000003). We are grateful to ChemAxon
   (https://chemaxon.com/) and OpenEye Scientific Software Inc.
   (https://www.eyesopen.com/) for providing academic license of their
   program.
CR ANDERSON S, 1984, J MOL GRAPHICS, V2, P83, DOI 10.1016/0263-7855(84)80060-0
   Araujo PS, 2020, ACTA TROP, V211, DOI 10.1016/j.actatropica.2020.105644
   Barbosa TP, 2005, BIOORGAN MED CHEM, V13, P6464, DOI 10.1016/j.bmc.2005.06.068
   Braga RC, 2013, CURR TOP MED CHEM, V13, P1127, DOI 10.2174/1568026611313090010
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Caffrey CR, 2007, CURR OPIN CHEM BIOL, V11, P433, DOI 10.1016/j.cbpa.2007.05.031
   Camara CA, 2008, AN ACAD BRAS CIENC, V80, P329, DOI 10.1590/S0001-37652008000200011
   Colley DG, 2014, LANCET, V383, P2253, DOI 10.1016/S0140-6736(13)61949-2
   Consonni V, 2009, J CHEM INF MODEL, V49, P1669, DOI 10.1021/ci900115y
   de L., 2014, ECOTOX ENVIRON SAFE, V110, P208
   Dill J. D., 1981, 182 NAT M AM CHEM SO, P23
   Dobchev DA, 2014, CURR TOP MED CHEM, V14, P1913, DOI 10.2174/1568026614666140929124203
   dos Santos AF, 2000, INT J PARASITOL, V30, P1199, DOI 10.1016/S0020-7519(00)00114-4
   Durant JL, 2002, J CHEM INF COMP SCI, V42, P1273, DOI 10.1021/ci010132r
   Ekins S, 2019, NAT MATER, V18, P435, DOI 10.1038/s41563-019-0338-z
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   GADALETA D, 2016, INT J QUANT STRUCT P, V1, P45, DOI DOI 10.4018/IJQSPR.2016010102
   Golbraikh A, 2003, J COMPUT AID MOL DES, V17, P241, DOI 10.1023/A:1025386326946
   Grant JA, 1996, J COMPUT CHEM, V17, P1653, DOI 10.1002/(SICI)1096-987X(19961115)17:14<1653::AID-JCC7>3.0.CO;2-K
   Gryseels B, 2006, LANCET, V368, P1106, DOI 10.1016/S0140-6736(06)69440-3
   Hawkins PCD, 2007, J MED CHEM, V50, P74, DOI 10.1021/jm0603365
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Huang N, 2006, J MED CHEM, V49, P6789, DOI 10.1021/jm0608356
   Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   King CH, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004290
   King CH, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003504
   Li Z.-J., 2016, ADV PARASIT, P197
   Lima AN, 2016, EXPERT OPIN DRUG DIS, V11, P225, DOI 10.1517/17460441.2016.1146250
   Lima NMF, 2002, J BRAZIL CHEM SOC, V13, P822, DOI 10.1590/S0103-50532002000600015
   Lima NMF, 2002, ACTA TROP, V83, P43, DOI 10.1016/S0001-706X(02)00055-4
   Lo YC, 2018, DRUG DISCOV TODAY, V23, P1538, DOI 10.1016/j.drudis.2018.05.010
   Melo AD, 2019, CHEMOSPHERE, V216, P365, DOI 10.1016/j.chemosphere.2018.10.035
   Miyasato PA, 2012, PARASITOL RES, V110, P1873, DOI 10.1007/s00436-011-2712-x
   MORGAN HL, 1965, J CHEM DOC, V5, P107, DOI 10.1021/c160017a018
   Mysinger MM, 2012, J MED CHEM, V55, P6582, DOI 10.1021/jm300687e
   Netzeva TI, 2005, ATLA-ALTERN LAB ANIM, V33, P155, DOI 10.1177/026119290503300209
   Oliveira EC, 2010, CHEMOSPHERE, V81, P218, DOI 10.1016/j.chemosphere.2010.06.038
   R Development Core Team, LANG ENV STAT COMP
   Reau M, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00011
   Ribeiro KAL, 2009, ACTA TROP, V111, P44, DOI 10.1016/j.actatropica.2009.02.008
   Riniker S, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-26
   Rogers D, 2010, J CHEM INF MODEL, V50, P742, DOI 10.1021/ci100050t
   Ross AGP, 2017, INT J INFECT DIS, V54, P130, DOI 10.1016/j.ijid.2016.09.023
   Rush TS, 2005, J MED CHEM, V48, P1489, DOI 10.1021/jm040163o
   Santos Josefina, 2017, Curr Gerontol Geriatr Res, V2017, P8067094, DOI 10.1155/2017/8067094
   Silva HAMF, 2018, ACTA TROP, V178, P97, DOI 10.1016/j.actatropica.2017.09.019
   Silva TMS, 2005, BIOORGAN MED CHEM, V13, P193, DOI 10.1016/j.bmc.2004.09.043
   Thetiot-Laurent SAL, 2013, ANGEW CHEM INT EDIT, V52, P7936, DOI 10.1002/anie.201208390
   Tropsha A, 2007, CURR PHARM DESIGN, V13, P3494, DOI 10.2174/138161207782794257
   Vaz WF, 2020, J MOL STRUCT, V1206, DOI 10.1016/j.molstruc.2020.127732
   World Health Organization, SCHISTOSOMIASIS
NR 54
TC 0
Z9 0
U1 0
U2 0
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1144-0546
EI 1369-9261
J9 NEW J CHEM
JI New J. Chem.
PD OCT 21
PY 2020
VL 44
IS 39
BP 16948
EP 16958
DI 10.1039/d0nj03314f
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA OD0WY
UT WOS:000579576200027
DA 2020-12-01
ER

PT J
AU Ekins, S
   Mottin, M
   Ramos, PRPS
   Sousa, BKP
   Neves, B
   Foil, DH
   Zorn, KM
   Braga, RC
   Coffee, M
   Southan, C
   Puhl, AC
   Andrade, CH
AF Ekins, Sean
   Mottin, Melina
   Ramos, Paulo R. P. S.
   Sousa, Bruna K. P.
   Junior Neves, Bruno
   Foil, Daniel H.
   Zorn, Kimberley M.
   Braga, Rodolpho C.
   Coffee, Megan
   Southan, Christopher
   Puhl, Ana C.
   Andrade, Carolina Horta
TI Deja vu: Stimulating open drug discovery for SARS-CoV-2
SO DRUG DISCOVERY TODAY
LA English
DT Review
ID RESPIRATORY SYNDROME CORONAVIRUS; ACCURATE DOCKING; BINDING; GLIDE;
   MODEL; SPIKE; REMDESIVIR; INHIBITORS; PROTEASE; DOMAIN
AB In the past decade we have seen two major Ebola virus outbreaks in Africa, the Zika virus in Brazil and the Americas and the current pandemic of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There is a strong sense of deja vu because there are still no effective treatments. In the COVID-19 pandemic, despite being a new virus, there are already drugs suggested as active in in vitro assays that are being repurposed in clinical trials. Promising SARS-CoV-2 viral targets and computational approaches are described and discussed. Here, we propose, based on open antiviral drug discovery approaches for previous outbreaks, that there could still be gaps in our approach to drug discovery.
C1 [Ekins, Sean; Foil, Daniel H.; Zorn, Kimberley M.; Puhl, Ana C.] Collaborat Pharmaceut, 840 Main Campus Dr,Lab 3510, Raleigh, NC 27606 USA.
   [Mottin, Melina; Ramos, Paulo R. P. S.; Sousa, Bruna K. P.; Junior Neves, Bruno; Andrade, Carolina Horta] Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, BR-74605170 Goiania, Go, Brazil.
   [Braga, Rodolpho C.] InsilicAll, BR-04363090 Sao Paulo, SP, Brazil.
   [Coffee, Megan] NYU, Dept Med, Div Infect Dis & Immunol, New York, NY 10003 USA.
   [Coffee, Megan] Columbia Univ, Mailman Sch Publ Hlth, Dept Populat & Family Hlth, New York, NY 10027 USA.
   [Southan, Christopher] TW2Informatics Ltd, S-42166 Gothenburg, Sweden.
   [Andrade, Carolina Horta] Univ Estadual Campinas, Inst Biol, Dept Genet Evolut Microbiol & Immunol, BR-13083864 Campinas, SP, Brazil.
RP Ekins, S (corresponding author), Collaborat Pharmaceut, 840 Main Campus Dr,Lab 3510, Raleigh, NC 27606 USA.
EM sean@collaborationspharma.com
RI Braga, Rodolpho C/A-9655-2011; Neves, Bruno Junior/E-6295-2016; Coffee,
   Megan/AAY-6752-2020
OI Braga, Rodolpho C/0000-0003-3814-3464; Coffee,
   Megan/0000-0002-4581-111X; Foil, Daniel/0000-0003-0512-8997; Neves,
   Bruno/0000-0002-1309-8743
FU NIH from NCATS [R21TR001718]; NIH from NIGMS [R44GM122196-02A1];
   Brazilian funding agency CNPqNational Council for Scientific and
   Technological Development (CNPq); Brazilian funding agency FAPEG;
   Brazilian funding agency CAPESCAPES [001]; Brazilian CNPq/FAPEG
   [300508/2017-4]; L'Oreal-UNESCOABC Para Mulheres na Ciencia;
   L'Oreal-UNESCO International Rising Talents
FX We kindly acknowledge NIH funding: R21TR001718 from NCATS and
   R44GM122196-02A1 from NIGMS (PI-Sean Ekins). We also acknowledge
   Brazilian funding agencies, CNPq, FAPEG and CAPES (Finance Code 001) for
   the financial support and fellowships. M. M. and C.H.A. thank the
   support of the Brazilian CNPq/FAPEG (grant 300508/2017-4). C.H.A. also
   thanks the 'L'Oreal-UNESCOABC Para Mulheres na Ciencia' and
   'L'Oreal-UNESCO International Rising Talents' for the awards and
   fellowships received, which partially funded this work. C.H.A. is CNPq
   research fellow. We kindly acknowledge the support and encouragement of
   the IBM World Community Grid team, and the community of volunteers who
   donate their dormant computer power for our docking calculations. S.E.
   kindly thanks Biovia for providing Discovery Studio and the many
   collaborators on our Ebola and Zika projects. S.E. acknowledges Dr Alex
   Clark (Molecular Materials Informatics) for assistance with Assay
   Central<SUP>TM</SUP>.
CR Anantpadma M, 2019, ACS OMEGA, V4, P2353, DOI 10.1021/acsomega.8b02948
   Andrade CH, 2019, CURR MED CHEM, V26, P4355, DOI 10.2174/0929867325666180309114824
   Bajema KL, 2020, MMWR-MORBID MORTAL W, V69, P166, DOI 10.15585/mmwr.mm6906e1
   Barratt JLN, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007609
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Chong CR, 2007, NATURE, V448, P645, DOI 10.1038/448645a
   Chou CY, 2004, BIOCHEMISTRY-US, V43, P14958, DOI 10.1021/bi0490237
   Coleman CM, 2016, J VIROL, V90, P8924, DOI 10.1128/JVI.01429-16
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Dyall J., 2017, DRUGS, V77, P1935, DOI [10.1007/s40265-017-0830-1, DOI 10.1007/s40265-017-0830-1, DOI 10.1007/S40265-017-0830-1]
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Ekins S, 2015, F1000RES, V48, P4
   Ekins S, 2019, NAT MATER, V18, P435, DOI 10.1038/s41563-019-0338-z
   Ekins S, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.01711-17
   Ekins S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005023
   Ekins Sean, 2016, F1000Res, V5, P275
   Ekins Sean, 2016, F1000Res, V5, P150, DOI 10.12688/f1000research.8013.1
   Ekins Sean, 2015, F1000Res, V4, P1091, DOI 10.12688/f1000research.7217.1
   Ekins Sean, 2015, F1000Res, V4, P58, DOI 10.12688/f1000research.6181.1
   Ekins Sean, 2014, F1000Res, V3, P277, DOI 10.12688/f1000research.5741.2
   Ekins S, 2011, DRUG DISCOV TODAY, V16, P298, DOI 10.1016/j.drudis.2011.02.016
   FDA, 2019, CASE MED RES, DOI DOI 10.31525/CMR-24AB0C1
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Furuyama W, 2019, ANNU REV VIROL, V6, P435, DOI 10.1146/annurev-virology-092818-015708
   Gignoux E, 2016, NEW ENGL J MED, V374, P23, DOI 10.1056/NEJMoa1504605
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hwang WC, 2006, J BIOL CHEM, V281, P34610, DOI 10.1074/jbc.M603275200
   Jesus J.G., 2020, 1 REPORT COVID 19 S
   Kankanamalage ACG, 2018, EUR J MED CHEM, V150, P334, DOI 10.1016/j.ejmech.2018.03.004
   Lane TR, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.01142-19
   Li CC, 2019, DRUG DISCOV TODAY, V24, P726, DOI 10.1016/j.drudis.2019.01.018
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li H, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE002, DOI 10.3760/cma.j.issn.1001-0939.2020.0002
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Litterman Nadia, 2015, F1000Res, V4, P38, DOI 10.12688/f1000research.6120.1
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Liu X., 2020, CRYSTAL STRUCTURE CO
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Madrid PB, 2015, ACS INFECT DIS, V1, P317, DOI 10.1021/acsinfecdis.5b00030
   Madrid PB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060579
   Momattin H, 2019, TRAVEL MED INFECT DI, V30, P9, DOI 10.1016/j.tmaid.2019.06.012
   Mottin M, 2018, DRUG DISCOV TODAY, V23, P1833, DOI 10.1016/j.drudis.2018.06.014
   Mottin M, 2017, BIOCHEM BIOPH RES CO, V492, P643, DOI 10.1016/j.bbrc.2017.03.070
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Musso D, 2019, NEW ENGL J MED, V381, P1444, DOI 10.1056/NEJMra1808246
   Nishiura H, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020488
   Pan YY, 2020, EUR RADIOL, V30, P3306, DOI 10.1007/s00330-020-06731-x
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Russo DP, 2018, MOL PHARMACEUT, V15, P4361, DOI 10.1021/acs.molpharmaceut.8b00546
   Schrodinger, 2015, PYMOL MOL GRAPH SYST
   Shi JH, 2004, J BIOL CHEM, V279, P24765, DOI 10.1074/jbc.M311744200
   Silva S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54169-z
   Sisk JM, 2015, ACS INFECT DIS, V1, P401, DOI 10.1021/acsinfecdis.5b00089
   Smith N, 2020, AM J PUBLIC HEALTH, V110, P648, DOI 10.2105/AJPH.2020.305618
   Song H, 2016, NAT STRUCT MOL BIOL, V23, P456, DOI 10.1038/nsmb.3213
   Stoermer M., 2020, HOMOLOGY MODELS WUHA, DOI DOI 10.26434/CHEMRXIV.11637294.V1
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1126/science.abb2507, 10.1101/2020.02.11.944462]
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI [10.1080/03009742.2020.1825798, 10.1007/s11427-020-1637-5]
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yuan S, 2015, MBIO, V6, DOI 10.1128/mBio.01120-15
   Zhang C., 2020, STRUCTURE MODELS ALL
   Zhang H., 2020, DEEP LEARNING BASED, V1, P1, DOI DOI 10.20944/PREPRINTS202002.0061.V1
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhu Y., 2020, CRYSTAL STRUCTURE HR
   Ziebuhr J, 2003, J VIROL, V77, P1415, DOI 10.1128/JVI.77.2.1415-1426.2003
   Zorn KM, 2019, MOL PHARMACEUT, V16, P1620, DOI 10.1021/acs.molpharmaceut.8b01297
NR 73
TC 13
Z9 14
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6446
EI 1878-5832
J9 DRUG DISCOV TODAY
JI Drug Discov. Today
PD MAY
PY 2020
VL 25
IS 5
BP 928
EP 941
DI 10.1016/j.drudis.2020.03.019
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MA2LV
UT WOS:000541749200014
PM 32320852
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Sartori, DP
   Oliveira, NF
   Valentim, JT
   Silva, DMA
   Mallman, ASV
   Oliveira, ICM
   Chaves, RC
   Capibaribe, VC
   Carvalho, AMR
   Reboucas, MO
   Macedo, DS
   Chaves, AJM
   Fonteles, MMF
   Gutierrez, SJC
   Barbosa, JM
   Mottin, M
   Andrade, CH
   Sousa, FCF
AF Sartori, Danusio Pinheiro
   Oliveira, N. F.
   Valentim, Jose Tiago
   Silva, D. M. A.
   Mallman, A. S., V
   Oliveira, I. C. M.
   Chaves, R. C.
   Capibaribe, V. C.
   Carvalho, A. M. R.
   Reboucas, M. O.
   Macedo, Danielle Silveira
   Maia Chaves Filho, Adriano Jose
   Fonteles, M. M. F.
   Gutierrez, S. J. C.
   Barbosa-Filho, Jose Maria
   Mottin, Melina
   Andrade, Carolina Horta
   Sousa, F. C. F.
TI Involvement of monoaminergic targets in the antidepressant- and
   anxiolytic-like effects of the synthetic alkamide riparin IV:
   Elucidation of further mechanisms through pharmacological,
   neurochemistry and computational approaches
SO BEHAVIOURAL BRAIN RESEARCH
LA English
DT Article
DE Riparin; Depression; Antidepressant; Monoamines; Molecular docking
ID NEES MEZ LAURACEAE; FORCED SWIMMING TEST; ANIBA-RIPARIA; STRUCTURE
   VALIDATION; STRUCTURAL BASIS; DRUG DISCOVERY; MICE EVIDENCE; PLUS-MAZE;
   DEPRESSION; TYRAMINE
AB Despite recent advances, current antidepressants have considerable limitations: late onset of action and the high profile of refractoriness. Biomedical research with natural products has gained growing interest in the last years, and had provide useful candidates for new antidepressants. Riparins are a group of natural alkamides obtained from Aniba riparia, which had marked neuroactive effects, mainly as antidepressant and antinociceptive agents. We made modifications of the basic structure of riparins, originating a synthetic alkamide, also known as riparin IV (RipIV). RipIV demonstrated a superior analgesic effect than its congeners and a marked antidepressant-like effect. However, the basic mechanism for the central effects of RipIV remains unknown. Here, we aimed to investigate the participation of monoaminergic neurotransmission targets in the antidepressant-like effects of RipIV. To do this, we applied a combined approach of experimental (classical pharmacology and neurochemistry) and computer-aided techniques. Our results demonstrated that RipIV presented antidepressant- and anxiolytic-like effects without modifying locomotion and motor coordination of mice. Also, RipIV increased brain monoamines and their metabolite levels. At the higher dose (100 mg/kg), RipIV increased serotonin concentrations in all studied brain areas, while at the lower one (50 mg/kg), it increased mainly dopamine and noradrenaline levels. When tested with selective receptor antagonists, RipIV antidepressant effect showed dependence of the activation of multiple targets, including D1 and D2 dopamine receptors, 5-HT2A/2, 5-HT3 receptors and alpha 2 adrenergic receptors. Molecular docking demonstrated favorable binding conformation and affinity of RipIV to monoamine oxidase B (MAO-B), serotonin transporter (SERT), alpha 1 receptor, D2 receptor, dopamine transporter (DAT) and at some extent GABA-A receptor. RipIV also presented a computationally predicted favorable pharmacokinetic profile. Therefore, this study demonstrated the involvement of monoaminergic targets in the mechanism of RipIV antidepressant-like action, and provide evidence of it as a promising new antidepressant.
C1 [Sartori, Danusio Pinheiro; Oliveira, N. F.; Valentim, Jose Tiago; Silva, D. M. A.; Mallman, A. S., V; Oliveira, I. C. M.; Chaves, R. C.; Capibaribe, V. C.; Carvalho, A. M. R.; Reboucas, M. O.; Macedo, Danielle Silveira; Maia Chaves Filho, Adriano Jose; Sousa, F. C. F.] Univ Fed Ceara, Fac Med, Drug Res & Dev Ctr, Fortaleza, Ceara, Brazil.
   [Fonteles, M. M. F.] Univ Fed Ceara, Fac Pharm Odontol & Nursing, Dept Pharm, Fortaleza, Ceara, Brazil.
   [Maia Chaves Filho, Adriano Jose; Gutierrez, S. J. C.] Univ Fed Piaui, Lab Chem Bioact Nat & Synthet Prod, Teresina, Piaui, Brazil.
   [Barbosa-Filho, Jose Maria] Univ Fed Paraiba, Pharmaceut Technol Lab, Joao Pessoa, Paraiba, Brazil.
   [Mottin, Melina; Andrade, Carolina Horta] Univ Fed Goias, Fac Pharm, LabMol Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.
RP Sousa, FCF (corresponding author), Univ Fed Ceara, Drug Res & Dev Ctr, Rua Coronel Nunes de Melo 1000, BR-60430275 Fortaleza, Ceara, Brazil.
EM cleaflorenco@yahoo.com.br
RI Filho, Jose Maria Barbosa/B-3951-2010; Macedo, Danielle/E-3424-2014;
   Mottin, Melina/D-8700-2016; Chaves-Filho, Adriano/AAZ-1390-2020
OI Filho, Jose Maria Barbosa/0000-0002-9567-4096; Macedo,
   Danielle/0000-0001-8980-9970; Mottin, Melina/0000-0003-0878-9029; 
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq
   -BrazilNational Council for Scientific and Technological Development
   (CNPq) [306746/2013-1, 446120/2014-6, 465536/2014-0, 407567/2013-5];
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES-Brazil)CAPES [001]; Fundacao Cearense de Apoio ao Desenvolvimento
   Cientifico e Tecnologico (FUNCAP-CearaBrazil); Brazilian CNPq/FAPEG DCR
   [300508/2017-4]; L'Oreal-UNESCO-ABC Para Mulheres na Ciencia;
   L'Oreal-UNESCO International Rising Talents
FX We thank the Laboratory of Pharmaceutics Technology at Federal
   University of Paraiba, which provided us with the substance riparin-IV.
   We are also thankful for the financial support of Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico - CNPq -Brazil-process numbers:
   no 306746/2013-1 (PQ), no446120/2014-6 (UNIVERSAL), no 465536/2014-0
   (INCT-RENNOFITO) and no407567/2013-5 (RENORBIO); Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES-Brazil; finance code
   001); and Fundacao Cearense de Apoio ao Desenvolvimento Cientifico e
   Tecnologico (FUNCAP-CearaBrazil). MM and CHA thank the support of the
   Brazilian CNPq/FAPEG DCR (egrant 300508/2017-4). CHA is CNPq research
   fellow and also thanks the "L'Oreal-UNESCO-ABC Para Mulheres na Ciencia"
   and "L'Oreal-UNESCO International Rising Talents" for the awards and
   fellowships received, which partially funded this work.
CR Abelaira HM, 2013, REV BRAS PSIQUIATR, V35, pS112, DOI 10.1590/1516-4446-2013-1098
   [Anonymous], 2015, SCHROD REL 2015 2 PR
   [Anonymous], 2015, SCHROD REL 2015 2 GL
   [Anonymous], 2015, SCHROD REL 2015 2 EP
   ARCHER J, 1973, ANIM BEHAV, V21, P205, DOI 10.1016/S0003-3472(73)80065-X
   Banks JL, 2005, J COMPUT CHEM, V26, P1752, DOI 10.1002/jcc.20292
   Barbosa-Filho JM, 1990, REV LATINOAM QUIM, V21, P5
   Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bhattacharya D, 2016, NUCLEIC ACIDS RES, V44, pW406, DOI 10.1093/nar/gkw336
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Binfare R.W., 2009, INVESTIGACAO EFEITO
   Branchek TA, 2003, CURR OPIN PHARMACOL, V3, P90, DOI 10.1016/S1471-4892(02)00028-0
   BRANDAO F, 1980, N-S ARCH PHARMACOL, V311, P9, DOI 10.1007/BF00500297
   Chaves EMC, 2018, METAB BRAIN DIS, V33, P139, DOI 10.1007/s11011-017-0139-5
   Carlini E, 1979, REV BRAS PSIQUIATR, V1, P25
   Chaves RD, 2019, PHARMACOL BIOCHEM BE, V180, P44, DOI 10.1016/j.pbb.2019.03.005
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Cheng FX, 2012, J CHEM INF MODEL, V52, P3099, DOI 10.1021/ci300367a
   Cito MCO, 2015, BRAZ J MED BIOL RES, V48, P57, DOI 10.1590/1414-431X20144215
   Clark DE, 2003, DRUG DISCOV TODAY, V8, P927, DOI 10.1016/S1359-6446(03)02827-7
   Coleman JA, 2016, NATURE, V532, P334, DOI 10.1038/nature17629
   Lima EBC, 2016, J NAT MED-TOKYO, V70, P510, DOI 10.1007/s11418-016-0970-8
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Daniel R, 2014, NEUROBIOL LEARN MEM, V114, P90, DOI 10.1016/j.nlm.2014.05.002
   Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216
   de Sousa FCF, 2007, BIOL PHARM BULL, V30, P1212, DOI 10.1248/bpb.30.1212
   Dean J, 2017, ASIAN J PSYCHIATR, V27, P101, DOI 10.1016/j.ajp.2017.01.025
   deSouza F.C.B., 2017, ANXIETY DEPRESSION Q
   DETKE MJ, 1995, PSYCHOPHARMACOLOGY, V121, P66, DOI 10.1007/BF02245592
   Di L., 2014, DRUG PROPERTIES ADME
   Doan KMM, 2002, J PHARMACOL EXP THER, V303, P1029, DOI 10.1124/jpet.102.039255
   Dome P, 2019, BRAIN RES BULL, V146, P51, DOI 10.1016/j.brainresbull.2018.12.015
   DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322
   Ekins S, 2007, BRIT J PHARMACOL, V152, P9, DOI 10.1038/sj.bjp.0707305
   Elhwuegi AS, 2004, PROG NEURO-PSYCHOPH, V28, P435, DOI 10.1016/j.pnpbp.2003.11.018
   Fava M, 2008, AM J PSYCHIAT, V165, P342, DOI 10.1176/appi.ajp.2007.06111868
   de Araujo EJF, 2016, ACTA AMAZON, V46, P309, DOI 10.1590/1809-4392201505436
   de Sousa FCF, 2014, FUND CLIN PHARMACOL, V28, P95, DOI 10.1111/j.1472-8206.2012.01069.x
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gaynes BN, 2009, PSYCHIAT SERV, V60, P1439, DOI 10.1176/ps.2009.60.11.1439
   Greenwood JR, 2010, J COMPUT AID MOL DES, V24, P591, DOI 10.1007/s10822-010-9349-1
   Gu XS, 2014, SCI REP-UK, V4, DOI 10.1038/srep04433
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Hintze BJ, 2016, PROTEINS, V84, P1177, DOI 10.1002/prot.25039
   Ho SC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179290
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Hussein HA, 2017, DRUG DISCOV TODAY, V22, P404, DOI 10.1016/j.drudis.2016.11.021
   Ionescu DF, 2014, J CLIN PSYCHIAT, V75, pE932, DOI 10.4088/JCP.14m09049
   Jawad M, 2017, BANGL J PHARMACOL, V12, P439, DOI 10.3329/bjp.v12i4.33182
   Kesters D, 2013, EMBO REP, V14, P49, DOI 10.1038/embor.2012.189
   Kimura KT, 2019, NAT STRUCT MOL BIOL, V26, P121, DOI 10.1038/s41594-018-0180-z
   Kudlow PA, 2014, CNS DRUGS, V28, P601, DOI 10.1007/s40263-014-0171-5
   Leeson PD, 2016, ADV DRUG DELIVER REV, V101, P22, DOI 10.1016/j.addr.2016.01.018
   Teixeira CPL, 2013, FUND CLIN PHARMACOL, V27, P129, DOI [10.1, 10.1111/j.1472-8206.2011.00973.x]
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   LISTER RG, 1987, PSYCHOPHARMACOLOGY, V92, P180
   Liu Y, 2013, PHARMACOL BIOCHEM BE, V104, P27, DOI 10.1016/j.pbb.2012.12.024
   Lopez-Munoz F, 2009, CURR PHARM DESIGN, V15, P1563, DOI 10.2174/138161209788168001
   Meng XY, 2011, CURR COMPUT-AID DRUG, V7, P146
   Milczek EM, 2008, J MED CHEM, V51, P8019, DOI 10.1021/jm8011867
   Mohler H, 2012, NEUROPHARMACOLOGY, V62, P42, DOI 10.1016/j.neuropharm.2011.08.040
   Mori T, 2013, EUR J PHARMACOL, V718, P370, DOI 10.1016/j.ejphar.2013.07.046
   Morilak DA, 2005, PROG NEURO-PSYCHOPH, V29, P1214, DOI 10.1016/j.pnpbp.2005.08.007
   Nabavi SM, 2017, NUTR NEUROSCI, V20, P180, DOI 10.1080/1028415X.2015.1103461
   Nascimento OA, 2016, MOLECULES, V21, DOI 10.3390/molecules21121757
   NIELSEN JA, 1986, PHARMACOL BIOCHEM BE, V24, P795, DOI 10.1016/0091-3057(86)90413-2
   NIH, 2011, GUIDE CARE USE LAB A, DOI [10.17226/12910, DOI 10.17226/12910]
   Oliveira TD, 2017, J AFFECT DISORDERS, V219, P49, DOI 10.1016/j.jad.2017.05.022
   Pasquali MA, 2018, EUR ARCH PSY CLIN N, V268, P771, DOI 10.1007/s00406-017-0812-z
   PELLOW S, 1986, PHARMACOL BIOCHEM BE, V24, P525, DOI 10.1016/0091-3057(86)90552-6
   Peng Y, 2018, CELL, V172, P719, DOI 10.1016/j.cell.2018.01.001
   Penmatsa A, 2013, NATURE, V503, P85, DOI 10.1038/nature12533
   PORSOLT RD, 1978, EUR J PHARMACOL, V51, P291, DOI 10.1016/0014-2999(78)90414-4
   PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0
   Quesseveur G, 2013, CURR DRUG TARGETS, V14, P1277
   Rauhut AS, 2008, PHARMACOL BIOCHEM BE, V90, P598, DOI 10.1016/j.pbb.2008.05.002
   de Carvalho AMR, 2013, CHEM-BIOL INTERACT, V205, P165, DOI 10.1016/j.cbi.2013.07.007
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Schmidt N, 2004, BRAIN RES, V1012, P101, DOI 10.1016/j.brainres.2004.03.036
   Schrodinger Release 2015-2, 2015, SCHROD REL 2015 2 LI
   Shelley JC, 2007, J COMPUT AID MOL DES, V21, P681, DOI 10.1007/s10822-007-9133-z
   Siqueira -junior J.P., 2017, REV BRAS PLANTAS MED, V19, P458, DOI [10.1590/1983-084X/00648, DOI 10.1590/1983-084X/00648]
   Son SY, 2008, P NATL ACAD SCI USA, V105, P5739, DOI 10.1073/pnas.0710626105
   Sousa FCF, 2004, PHARMACOL BIOCHEM BE, V78, P27, DOI 10.1016/j.pbb.2004.01.019
   STERU L, 1985, PSYCHOPHARMACOLOGY, V85, P367, DOI 10.1007/BF00428203
   TRENDELENBURG U, 1987, BLOOD VESSELS, V24, P261
   Trivedi MH, 2013, AM J PSYCHIAT, V170, P633, DOI 10.1176/appi.ajp.2012.12020250
   Vasconcelos AS, 2015, FUND CLIN PHARMACOL, V29, P394, DOI 10.1111/fcp.12120
   Melo CTV, 2013, FUND CLIN PHARMACOL, V27, P104, DOI 10.1111/j.1472-8206.2011.00968.x
   Vismari L., 2008, DEPRESSION ANTIDEPRE
   Wang S, 2018, NATURE, V555, P269, DOI 10.1038/nature25758
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   WEINER N, 1968, J PHARMACOL EXP THER, V161, P21
   Whitebread S, 2005, DRUG DISCOV TODAY, V10, P1421, DOI 10.1016/S1359-6446(05)03632-9
   WHO, 2015, DEPR DEPR FACT SHEET
   Yankelevitch-Yahav R, 2015, JOVE-J VIS EXP, V97, P1, DOI [10.3791/52587, DOI 10.3791/52587]
   Zhu ST, 2018, NATURE, V559, P67, DOI 10.1038/s41586-018-0255-3
   Zolek T, 2017, EUR J PHARM SCI, V109, P486, DOI 10.1016/j.ejps.2017.08.036
NR 99
TC 0
Z9 0
U1 2
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-4328
EI 1872-7549
J9 BEHAV BRAIN RES
JI Behav. Brain Res.
PD APR 6
PY 2020
VL 383
AR 112487
DI 10.1016/j.bbr.2020.112487
PG 14
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA LD5IT
UT WOS:000526063900015
PM 31987932
DA 2020-12-01
ER

PT J
AU Neves, B
   Agnes, JP
   Gomes, MD
   Donza, MRH
   Goncalves, RM
   Delgobo, M
   Neto, LRD
   Senger, MR
   Silva, FP
   Ferreira, SB
   Zanotto, A
   Andrade, CH
AF Neves, Bruno Junior
   Agnes, Jonathan Paulo
   Gomes, Marcelo do Nascimento
   Henriques Donza, Marcio Roberto
   Goncalves, Rosangela Mayer
   Delgobo, Marina
   de Souza Neto, Lauro Ribeiro
   Senger, Mario Roberto
   Silva-Junior, Floriano Paes
   Ferreira, Sabrina Baptista
   Zanotto-Filho, Alfeu
   Andrade, Carolina Horta
TI Efficient identification of novel anti-glioma lead compounds by machine
   learning models
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Cancer; Glioblastoma; Machine learning; Predictive modeling; Orthotopic
   glioma model; Thioredoxin reductase
ID BLOOD-BRAIN-BARRIER; ASSAY INTERFERENCE; DRUG DISCOVERY; GLIOBLASTOMA;
   TEMOZOLOMIDE; PERMEABILITY; PENETRATION; DESCRIPTORS; MECHANISMS;
   REDUCTASE
AB Glioblastoma multiforme (GBM) is the most devastating and widespread primary central nervous system tumor. Pharmacological treatment of this malignance is limited by the selective permeability of the blood-brain barrier (BBB) and relies on a single drug, temozolomide (TMZ), thus making the discovery of new compounds challenging and urgent. Therefore, aiming to discover new anti-glioma drugs, we developed robust machine learning models for predicting anti-glioma activity and BBB penetration ability of new compounds. Using these models, we prioritized 41 compounds from our in-house library of compounds, for further in vitro testing against three glioma cell lines and astrocytes. Subsequently, the most potent and selective compounds were resynthesized and tested in vivo using an orthotopic glioma model. This approach revealed two lead candidates, 4m and 4n, which efficiently decreased malignant glioma development in mice, probably by inhibiting thioredoxin reductase activity, as shown by our enzymological assays. Moreover, these two compounds did not promote body weight reduction, death of animals, or altered hematological and toxicological markers, making then good candidates for lead optimization as anti-glioma drug candidates. (C) 2019 Published by Elsevier Masson SAS.
C1 [Neves, Bruno Junior] UniEVANGELICA, Ctr Univ Anapolis, LabChem Lab Cheminformat, BR-75083515 Anapolis, Go, Brazil.
   [Neves, Bruno Junior; Gomes, Marcelo do Nascimento; Andrade, Carolina Horta] Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, BR-74605510 Goiania, Go, Brazil.
   [Agnes, Jonathan Paulo; Goncalves, Rosangela Mayer; Delgobo, Marina; Zanotto-Filho, Alfeu] Univ Fed Santa Catarina, Ctr Ciencias Biol, Dept Farmacol, LabCanc Lab Farmacol & Bioquim Canc, Florianopolis, SC, Brazil.
   [Gomes, Marcelo do Nascimento] Univ Estadual Goias, InSiChem Drug Discovery, BR-74643090 Anapolis, Go, Brazil.
   [Henriques Donza, Marcio Roberto; Ferreira, Sabrina Baptista] Univ Fed Rio de Janeiro, Inst Quim, LSOPB, BR-21949900 Rio De Janeiro, RJ, Brazil.
   [de Souza Neto, Lauro Ribeiro; Senger, Mario Roberto; Silva-Junior, Floriano Paes] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, LaBECFar Lab Bioquim Expt & Computac Farm, BR-21040900 Rio De Janeiro, RJ, Brazil.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, BR-74605510 Goiania, Go, Brazil.; Zanotto, A (corresponding author), Univ Fed Santa Catarina, Ctr Ciencias Biol, Dept Farmacol, LabCanc Lab Farmacol & Bioquim Canc, Florianopolis, SC, Brazil.
EM alfeu.zanotto@ufsc.br; carolina@ufg.br
RI Neves, Bruno Junior/E-6295-2016; Delgobo, Marina/AAR-9732-2020;
   Goncalves, Rosangela/AAV-2408-2020; Silva-Jr, Floriano/B-1343-2013
OI Goncalves, Rosangela/0000-0001-5609-2280; Silva-Jr,
   Floriano/0000-0003-4560-1291; Neves, Bruno/0000-0002-1309-8743; Senger,
   Mario/0000-0003-2384-2692; Ferreira, Sabrina/0000-0002-5363-0888;
   Ribeiro de Souza Neto, Lauro/0000-0001-7357-875X
FU National Counsel of Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); State of Goias Research Foundation (FAPEG); State of Rio de
   Janeiro Research Foundation (FAPERJ)Carlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ); Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES)CAPES [001]
FX This work has been funded by the National Counsel of Technological and
   Scientific Development (CNPq), the State of Goias Research Foundation
   (FAPEG) and the State of Rio de Janeiro Research Foundation (FAPERJ).
   C.H.A., A.Z.F., F.RS-Jr and S.B.F. are CNPq productivity fellows. This
   study was financed in part by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior - Brasil (CAPES) - Finance Code 001. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Aldape K, 2015, ACTA NEUROPATHOL, V129, P829, DOI 10.1007/s00401-015-1432-1
   Alexander BM, 2017, J CLIN ONCOL, V35, P2402, DOI 10.1200/JCO.2017.73.0119
   ALTMAN NS, 1992, AM STAT, V46, P175, DOI 10.2307/2685209
   Alves VM, 2015, TOXICOL APPL PHARM, V284, P273, DOI 10.1016/j.taap.2014.12.013
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Baskin II, 2016, EXPERT OPIN DRUG DIS, V11, P785, DOI 10.1080/17460441.2016.1201262
   Beisken S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-257
   Bhujbal SV, 2014, ADV DRUG DELIVER REV, V67-68, P142, DOI 10.1016/j.addr.2014.01.010
   Bon RS, 2010, ACCOUNTS CHEM RES, V43, P1103, DOI 10.1021/ar100014h
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Cloughesy TF, 2014, ANNU REV PATHOL-MECH, V9, P1, DOI 10.1146/annurev-pathol-011110-130324
   COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104
   Dahlin JL, 2015, J MED CHEM, V58, P2091, DOI 10.1021/jm5019093
   Davis ME, 2016, CLIN J ONCOL NURS, V20, P2, DOI 10.1188/16.CJON.S1.2-8
   Dobchev DA, 2014, CURR TOP MED CHEM, V14, P1913, DOI 10.2174/1568026614666140929124203
   Ekins S, 2019, NAT MATER, V18, P435, DOI 10.1038/s41563-019-0338-z
   ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6
   Feng BY, 2006, NAT PROTOC, V1, P550, DOI 10.1038/nprot.2006.77
   Fillbrunn A, 2017, J BIOTECHNOL, V261, P149, DOI 10.1016/j.jbiotec.2017.07.028
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Friedman HS, 2000, CLIN CANCER RES, V6, P2585
   GADALETA D, 2016, INT J QUANT STRUCT P, V1, P45, DOI DOI 10.4018/IJQSPR.2016010102
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   Ghasemi F, 2018, DRUG DISCOV TODAY, V23, P1784, DOI 10.1016/j.drudis.2018.06.016
   Gobbi A, 1998, BIOTECHNOL BIOENG, V61, P47, DOI 10.1002/(SICI)1097-0290(199824)61:1&lt;47::AID-BIT9&gt;3.0.CO;2-Z
   Golbraikh A, 2003, J COMPUT AID MOL DES, V17, P241, DOI 10.1023/A:1025386326946
   Gomes MN, 2017, EUR J MED CHEM, V137, P126, DOI 10.1016/j.ejmech.2017.05.026
   GRAVINA GL, 2019, CANCERS, V11, DOI DOI 10.3390/CANCERSL1030359
   Heikamp K, 2014, EXPERT OPIN DRUG DIS, V9, P93, DOI 10.1517/17460441.2014.866943
   Irwin JJ, 2015, J MED CHEM, V58, P7076, DOI 10.1021/acs.jmedchem.5b01105
   Jackson PA, 2017, J MED CHEM, V60, P839, DOI 10.1021/acs.jmedchem.6b00788
   Korotcov A, 2017, MOL PHARMACEUT, V14, P4462, DOI 10.1021/acs.molpharmaceut.7b00578
   Koukourakis GV, 2009, MOLECULES, V14, P1561, DOI 10.3390/molecules14041561
   Kumari S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06888-4
   Lachance H, 2012, J MED CHEM, V55, P5989, DOI 10.1021/jm300288g
   Li H, 2005, J CHEM INF MODEL, V45, P1376, DOI 10.1021/ci050135u
   Lima AN, 2016, EXPERT OPIN DRUG DIS, V11, P225, DOI 10.1517/17460441.2016.1146250
   Lo YC, 2018, DRUG DISCOV TODAY, V23, P1538, DOI 10.1016/j.drudis.2018.05.010
   Martins IF, 2012, J CHEM INF MODEL, V52, P1686, DOI 10.1021/ci300124c
   Megalizzi V, 2009, EUR J CANCER, V45, P2893, DOI 10.1016/j.ejca.2009.07.011
   MORGAN HL, 1965, J CHEM DOC, V5, P107, DOI 10.1021/c160017a018
   Netzeva TI, 2005, ATLA-ALTERN LAB ANIM, V33, P155, DOI 10.1177/026119290503300209
   Neves BJ, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01275
   Neves BJ, 2016, J MED CHEM, V59, P7075, DOI 10.1021/acs.jmedchem.5b02038
   Newcomb EW, 2006, CLIN CANCER RES, V12, P4730, DOI 10.1158/1078-0432.CCR-06-0593
   Ng HL, 2017, J MED CHEM, V60, P1734, DOI 10.1021/acs.jmedchem.6b01253
   Omuro A, 2013, JAMA-J AM MED ASSOC, V310, P1842, DOI 10.1001/jama.2013.280319
   Owen SC, 2012, ACS CHEM BIOL, V7, P1429, DOI 10.1021/cb300189b
   Pan Q, 2012, CELL BIOCHEM BIOPHYS, V62, P185, DOI 10.1007/s12013-011-9280-7
   Riniker S, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-26
   Rogers D, 2010, J CHEM INF MODEL, V50, P742, DOI 10.1021/ci100050t
   Shen C, 2019, INT J NANOMED, V14, P101, DOI 10.2147/IJN.S173954
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Svetnik V, 2003, J CHEM INF COMP SCI, V43, P1947, DOI 10.1021/ci034160g
   Szatmari T, 2006, CANCER SCI, V97, P546, DOI 10.1111/j.1349-7006.2006.00208.x
   Thakkar JP, 2014, CANCER EPIDEM BIOMAR, V23, P1985, DOI 10.1158/1055-9965.EPI-14-0275
   Tropsha A, 2007, CURR PHARM DESIGN, V13, P3494, DOI 10.2174/138161207782794257
   Uesawa Y, 2018, BIOORG MED CHEM LETT, V28, P3400, DOI 10.1016/j.bmcl.2018.08.032
   Wang J, 2013, CANCER CHEMOTH PHARM, V72, P147, DOI 10.1007/s00280-013-2180-3
   Weller M, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.17
   Wu WS, 2017, AM J CHINESE MED, V45, P879, DOI [10.1142/S0192415X17500471, 10.1142/s0192415x17500471]
   Ye XW, 2014, BIOORG MED CHEM LETT, V24, P5157, DOI 10.1016/j.bmcl.2014.09.087
   Zanotto A, 2012, J NUTR BIOCHEM, V23, P591, DOI 10.1016/j.jnutbio.2011.02.015
   Zanotto A, 2011, BIOCHEM PHARMACOL, V81, P412, DOI 10.1016/j.bcp.2010.10.014
   Zhang BX, 2015, J MED CHEM, V58, P1795, DOI 10.1021/jm5016507
   Zhang LY, 2008, PHARM RES-DORDR, V25, P1902, DOI 10.1007/s11095-008-9609-0
   Zhao YH, 2007, J CHEM INF MODEL, V47, P170, DOI 10.1021/ci600312d
NR 70
TC 0
Z9 0
U1 4
U2 8
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD MAR 1
PY 2020
VL 189
AR 111981
DI 10.1016/j.ejmech.2019.111981
PG 14
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA KT0KS
UT WOS:000518700000023
PM 31978780
DA 2020-12-01
ER

PT J
AU Neto, LRD
   Moreira, JT
   Neves, BJ
   Maidana, RLBR
   Guimaraes, ACR
   Furnham, N
   Andrade, CH
   Silva, FP
AF de Souza Neto, Lauro Ribeiro
   Moreira-Filho, Jose Teofilo
   Neves, Bruno Junior
   Maidana, Rocio Lucia Beatriz Riveros
   Guimaraes, Ana Carolina Ramos
   Furnham, Nicholas
   Andrade, Carolina Horta
   Silva, Floriano Paes, Jr.
TI In silico Strategies to Support Fragment-to-Lead Optimization in Drug
   Discovery
SO FRONTIERS IN CHEMISTRY
LA English
DT Review
DE fragment-based; drug discovery; lead discovery; in silico methods;
   machine learning; de novo design; optimization; hot spot analysis
ID SYNTHETIC ACCESSIBILITY; CURRENT PERSPECTIVES; LIGAND SPECIFICITY;
   MOLECULAR DOCKING; CHEMICAL SPACE; BINDING-SITE; HOT-SPOTS; DESIGN;
   INHIBITORS; RECEPTOR
AB Fragment-based drug (or lead) discovery (FBDD or FBLD) has developed in the last two decades to become a successful key technology in the pharmaceutical industry for early stage drug discovery and development. The FBDD strategy consists of screening low molecular weight compounds against macromolecular targets (usually proteins) of clinical relevance. These small molecular fragments can bind at one or more sites on the target and act as starting points for the development of lead compounds. In developing the fragments attractive features that can translate into compounds with favorable physical, pharmacokinetics and toxicity (ADMET-absorption, distribution, metabolism, excretion, and toxicity) properties can be integrated. Structure-enabled fragment screening campaigns use a combination of screening by a range of biophysical techniques, such as differential scanning fluorimetry, surface plasmon resonance, and thermophoresis, followed by structural characterization of fragment binding using NMR or X-ray crystallography. Structural characterization is also used in subsequent analysis for growing fragments of selected screening hits. The latest iteration of the FBDD workflow employs a high-throughput methodology of massively parallel screening by X-ray crystallography of individually soaked fragments. In this review we will outline the FBDD strategies and explore a variety of in silico approaches to support the follow-up fragment-to-lead optimization of either: growing, linking, and merging. These fragment expansion strategies include hot spot analysis, druggability prediction, SAR (structure-activity relationships) by catalog methods, application of machine learning/deep learning models for virtual screening and several de novo design methods for proposing synthesizable new compounds. Finally, we will highlight recent case studies in fragment-based drug discovery where in silico methods have successfully contributed to the development of lead compounds.
C1 [de Souza Neto, Lauro Ribeiro; Maidana, Rocio Lucia Beatriz Riveros; Silva, Floriano Paes, Jr.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, LaBECFar, Rio De Janeiro, Brazil.
   [Moreira-Filho, Jose Teofilo; Neves, Bruno Junior; Andrade, Carolina Horta] Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.
   [Neves, Bruno Junior] Ctr Univ Anapolis UniEVANGELICA, Lab Cheminformat, Anapolis, Go, Brazil.
   [Maidana, Rocio Lucia Beatriz Riveros; Guimaraes, Ana Carolina Ramos] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Genom Func & Bioinformat, Rio De Janeiro, Brazil.
   [Furnham, Nicholas] London Sch Hyg & Trop Med, Dept Infect Biol, London, England.
RP Silva, FP (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, LaBECFar, Rio De Janeiro, Brazil.; Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.; Furnham, N (corresponding author), London Sch Hyg & Trop Med, Dept Infect Biol, London, England.
EM nick.furnham@lshtm.ac.uk; carolina@ufg.br; floriano@ioc.fiocruz.br
RI Neves, Bruno Junior/E-6295-2016; Moreira-Filho, Jose
   Teofilo/S-8333-2018; Silva-Jr, Floriano/B-1343-2013
OI Moreira-Filho, Jose Teofilo/0000-0002-0777-280X; Silva-Jr,
   Floriano/0000-0003-4560-1291; Furnham, Nicholas/0000-0002-7532-1269;
   Neves, Bruno/0000-0002-1309-8743
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES; FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); FAPEG; FIOCRUZ; United
   Kingdom's Academy of Medical Sciences Newton Fund [NAF\R2\180641]
FX The authors would like to thank Brazilian funding agencies CNPq, CAPES,
   FAPERJ, FAPEG, and FIOCRUZ for financial support and fellowships. This
   study was also supported by funding from the United Kingdom's Academy of
   Medical Sciences Newton Fund (NAF\R2\180641).
CR Abad-Zapatero C., 2013, LIGAND EFFICIENCY IN
   Abad-Zapatero C, 2017, DRUG DISCOV TODAY, V22, P195, DOI 10.1016/j.drudis.2016.12.002
   Alvarsson J, 2014, J CHEM INF MODEL, V54, P2647, DOI 10.1021/ci500361u
   Alves VM, 2018, J BRAZIL CHEM SOC, V29, P982, DOI 10.21577/0103-5053.20180013
   Andrade CH, 2018, CURR MED CHEM, V25, P1
   Awale M, 2019, J CHEM INF MODEL, V59, P1347, DOI 10.1021/acs.jcim.8b00902
   Barril X, 2013, WIRES COMPUT MOL SCI, V3, P327, DOI 10.1002/wcms.1134
   Benmansour F, 2017, EUR J MED CHEM, V125, P865, DOI 10.1016/j.ejmech.2016.10.007
   Berglund UW, 2016, ANN ONCOL, V27, P2275, DOI 10.1093/annonc/mdw429
   Boda K, 2007, J COMPUT AID MOL DES, V21, P311, DOI 10.1007/s10822-006-9099-2
   Boehr DD, 2009, NAT CHEM BIOL, V5, P789, DOI 10.1038/nchembio.232
   Boettcher A, 2010, J BIOMOL SCREEN, V15, P1029, DOI 10.1177/1087057110380455
   BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P61, DOI 10.1007/bf00124387
   Bollag G, 2012, NAT REV DRUG DISCOV, V11, P873, DOI 10.1038/nrd3847
   Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454
   Braga RC, 2015, MOL INFORM, V34, P698, DOI 10.1002/minf.201500040
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1899, DOI 10.2174/1568026614666140929120749
   Chen Y, 2009, NAT CHEM BIOL, V5, P358, DOI 10.1038/nchembio.155
   Cheng FX, 2012, J CHEM INF MODEL, V52, P3099, DOI 10.1021/ci300367a
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Chevillard F, 2018, J MED CHEM, V61, P1118, DOI 10.1021/acs.jmedchem.7b01558
   Chung SM, 2009, NAT CHEM BIOL, V5, P407, DOI 10.1038/nchembio.163
   Ciulli Alessio, 2013, Methods Mol Biol, V1008, P357, DOI 10.1007/978-1-62703-398-5_13
   Coutard B, 2014, ANTIVIR RES, V106, P61, DOI 10.1016/j.antiviral.2014.03.013
   Cox OB, 2016, CHEM SCI, V7, P2322, DOI 10.1039/c5sc03115j
   Cukuroglu E, 2014, PROG BIOPHYS MOL BIO, V116, P165, DOI 10.1016/j.pbiomolbio.2014.06.003
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Davis BJ, 2017, ANNU REP MED CHEM, V50, P371, DOI 10.1016/bs.armc.2017.07.002
   De Fusco C, 2017, BIOORGAN MED CHEM, V25, P3471, DOI 10.1016/j.bmc.2017.04.037
   Dey F, 2008, J CHEM INF MODEL, V48, P679, DOI 10.1021/ci700424b
   Donald A, 2007, J MED CHEM, V50, P2289, DOI 10.1021/jm0700924
   Dong HP, 2008, ANTIVIR RES, V80, P1, DOI 10.1016/j.antiviral.2008.05.003
   Dong J, 2018, J CHEMINFORMATICS, V10, DOI 10.1186/s13321-018-0283-x
   Durrant JD, 2013, J MOL GRAPH MODEL, V44, P104, DOI 10.1016/j.jmgm.2013.05.006
   Durrant JD, 2009, CHEM BIOL DRUG DES, V73, P168, DOI 10.1111/j.1747-0285.2008.00761.x
   Erlanson DA, 2019, CELL CHEM BIOL, V26, P9, DOI 10.1016/j.chembiol.2018.10.001
   Erlanson DA, 2016, NAT REV DRUG DISCOV, V15, P605, DOI 10.1038/nrd.2016.109
   Ertl P, 2009, J CHEMINFORMATICS, V1, DOI 10.1186/1758-2946-1-8
   Ferreira LLG, 2019, DRUG DISCOV TODAY, V24, P1157, DOI 10.1016/j.drudis.2019.03.015
   Fukunishi Y, 2014, J CHEM INF MODEL, V54, P3259, DOI 10.1021/ci500568d
   Gawehn E, 2018, EXPERT OPIN DRUG DIS, V13, P579, DOI 10.1080/17460441.2018.1465407
   Giordanetto F, 2019, J MED CHEM, V62, P3381, DOI 10.1021/acs.jmedchem.8b01855
   Godemann R, 2009, BIOCHEMISTRY-US, V48, P10743, DOI 10.1021/bi901061a
   Gomez-Bombarelli R, 2018, ACS CENTRAL SCI, V4, P268, DOI 10.1021/acscentsci.7b00572
   Grove L. E., 2016, FRAGMENT BASED DRUG, P197
   Gupta A, 2018, MOL INFORM, V37, DOI 10.1002/minf.201700111
   Hall DR, 2012, J CHEM INF MODEL, V52, P199, DOI 10.1021/ci200468p
   Hall RJ, 2017, J MED CHEM, V60, P6440, DOI 10.1021/acs.jmedchem.7b00809
   Hall RJ, 2014, PROG BIOPHYS MOL BIO, V116, P82, DOI 10.1016/j.pbiomolbio.2014.09.007
   Hann MM, 2001, J CHEM INF COMP SCI, V41, P856, DOI 10.1021/ci000403i
   Harel S, 2018, MOL PHARMACEUT, V15, P4406, DOI 10.1021/acs.molpharmaceut.8b00474
   Henzler-Wildman K, 2007, NATURE, V450, P964, DOI 10.1038/nature06522
   Hoffer L, 2018, J MED CHEM, V61, P5719, DOI 10.1021/acs.jmedchem.8b00653
   Hopkins AL, 2004, DRUG DISCOV TODAY, V9, P430, DOI 10.1016/S1359-6446(04)03069-7
   Hubbard R. E., 2011, EXPERIENCES FRAGMENT
   Hubbard R, 2015, ACTA CRYSTALLOGR A, V71, pS37, DOI 10.1107/S2053273315099416
   Hung AW, 2009, ANGEW CHEM INT EDIT, V48, P8452, DOI 10.1002/anie.200903821
   Hussein HA, 2017, DRUG DISCOV TODAY, V22, P404, DOI 10.1016/j.drudis.2016.11.021
   Hussein HA, 2015, NUCLEIC ACIDS RES, V43, pW436, DOI 10.1093/nar/gkv462
   Ichihara O, 2011, MOL INFORM, V30, P298, DOI 10.1002/minf.201000174
   Jacquemard C, 2019, J CHEMINFORMATICS, V11, DOI 10.1186/s13321-019-0346-7
   Joseph-McCarthy D, 2014, J CHEM INF MODEL, V54, P693, DOI 10.1021/ci400731w
   Kozakov D, 2015, NAT PROTOC, V10, P733, DOI 10.1038/nprot.2015.043
   Kumar A, 2012, CURR MED CHEM, V19, P5128, DOI 10.2174/092986712803530467
   Lamoree B, 2017, ESSAYS BIOCHEM, V61, P453, DOI 10.1042/EBC20170028
   Li YB, 2018, J CHEMINFORMATICS, V10, DOI 10.1186/s13321-018-0287-6
   Lin FY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00096
   Lo MC, 2004, ANAL BIOCHEM, V332, P153, DOI 10.1016/j.ab.2004.04.031
   Macarron R, 2011, NAT REV DRUG DISCOV, V10, P188, DOI 10.1038/nrd3368
   Mak KK, 2019, DRUG DISCOV TODAY, V24, P773, DOI 10.1016/j.drudis.2018.11.014
   Mannel B, 2017, ACS CHEM BIOL, V12, P2652, DOI 10.1021/acschembio.7b00493
   Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200
   Merk D, 2018, MOL INFORM, V37, DOI 10.1002/minf.201700153
   Mitcheson JS, 2000, P NATL ACAD SCI USA, V97, P12329, DOI 10.1073/pnas.210244497
   Miyake Y, 2019, BIOORGAN MED CHEM, V27, P1119, DOI 10.1016/j.bmc.2019.02.006
   Mondal M, 2015, MEDCHEMCOMM, V6, P1267, DOI 10.1039/c5md00157a
   Navratilova I, 2010, ACS MED CHEM LETT, V1, P44, DOI 10.1021/ml900002k
   Neves BJ, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01275
   Ngan CH, 2012, NUCLEIC ACIDS RES, V40, pW271, DOI 10.1093/nar/gks441
   Nikiforov PO, 2016, ORG BIOMOL CHEM, V14, P2318, DOI 10.1039/c5ob02630j
   Nissink JWM, 2009, J CHEM INF MODEL, V49, P1617, DOI 10.1021/ci900094m
   Olivecrona M, 2017, J CHEMINFORMATICS, V9, DOI 10.1186/s13321-017-0235-x
   Pascoini AL, 2019, J BIOMOL STRUCT DYN, V37, P1007, DOI 10.1080/07391102.2018.1447513
   Patel D, 2014, PROG BIOPHYS MOL BIO, V116, P92, DOI 10.1016/j.pbiomolbio.2014.08.004
   Pedro L, 2016, MOLECULES, V21, DOI 10.3390/molecules21080984
   Pegg SCH, 2001, J COMPUT AID MOL DES, V15, P911, DOI 10.1023/A:1014389729000
   Perez-Sianes J, 2019, CURR COMPUT-AID DRUG, V15, P6, DOI 10.2174/1573409914666181018141602
   Pierce AC, 2004, J MED CHEM, V47, P2768, DOI 10.1021/jm030543u
   Podolyan Y, 2010, J CHEM INF MODEL, V50, P979, DOI 10.1021/ci900301v
   Polinsky RJ, 1998, CLIN THER, V20, P634, DOI 10.1016/S0149-2918(98)80127-6
   Polykovskiy D, 2018, MOL PHARMACEUT, V15, P4398, DOI 10.1021/acs.molpharmaceut.8b00839
   Popova M, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aap7885
   Putin E, 2018, J CHEM INF MODEL, V58, P1194, DOI 10.1021/acs.jcim.7b00690
   Ramsundar B, 2017, J CHEM INF MODEL, V57, P2068, DOI 10.1021/acs.jcim.7b00146
   Reddy A. S., 2013, NOVO MOL DESIGN, P97, DOI [10.1002/9783527677016.ch4, DOI 10.1002/9783527677016.CH4]
   Riniker S, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-26
   Rodriguez D, 2016, ACS CHEM BIOL, V11, P2763, DOI 10.1021/acschembio.6b00357
   Rogers D, 2010, J CHEM INF MODEL, V50, P742, DOI 10.1021/ci100050t
   Rudling A, 2017, J MED CHEM, V60, P8160, DOI 10.1021/acs.jmedchem.7b01006
   Ryan A, 2017, BRIT J PHARMACOL, V174, P2209, DOI 10.1111/bph.13810
   Schmidtke P, 2010, J MED CHEM, V53, P5858, DOI 10.1021/jm100574m
   Schneider G, 2005, NAT REV DRUG DISCOV, V4, P649, DOI 10.1038/nrd1799
   Schneider G, 2019, ANGEW CHEM INT EDIT, V58, P10792, DOI 10.1002/anie.201814681
   Schneider G, 2018, MOL INFORM, V37, DOI 10.1002/minf.201880131
   Schuffenhauer A, 2005, CURR TOP MED CHEM, V5, P751, DOI 10.2174/1568026054637700
   Schulz MN, 2011, J COMPUT AID MOL DES, V25, P611, DOI 10.1007/s10822-011-9461-x
   Schyman P, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00889
   Segler MHS, 2018, ACS CENTRAL SCI, V4, P120, DOI 10.1021/acscentsci.7b00512
   Seo MH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4724
   Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531
   Shultz MD, 2013, BIOORG MED CHEM LETT, V23, P5980, DOI 10.1016/j.bmcl.2013.08.029
   Silvestre HL, 2013, P NATL ACAD SCI USA, V110, P12984, DOI 10.1073/pnas.1304045110
   Smits VAJ, 2014, CELL CYCLE, V13, P2330, DOI 10.4161/cc.29756
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Strecker C, 2019, CHEMMEDCHEM, V14, P1336, DOI 10.1002/cmdc.201900296
   Talesa VN, 2001, MECH AGEING DEV, V122, P1961, DOI 10.1016/S0047-6374(01)00309-8
   Thomas SE, 2017, J MOL BIOL, V429, P2677, DOI 10.1016/j.jmb.2017.06.014
   Torres PHM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184574
   Trevizani R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170131
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   TVERSKY A, 1977, PSYCHOL REV, V84, P327, DOI 10.1037/h0026750
   Vamathevan J, 2019, NAT REV DRUG DISCOV, V18, P463, DOI 10.1038/s41573-019-0024-5
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Verdonk ML, 2011, J MED CHEM, V54, P5422, DOI 10.1021/jm200558u
   Verdonk ML, 2004, CURR OPIN DRUG DISC, V7, P404
   Wang RX, 2000, J MOL MODEL, V6, P498, DOI 10.1007/s0089400060498
   Wang T, 2015, CURR PHARM BIOTECHNO, V16, P11, DOI 10.2174/1389201015666141122204532
   Whitehouse AJ, 2019, J MED CHEM, V62, P7210, DOI 10.1021/acs.jmedchem.9b00809
   Willighagen EL, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-23
   Xu XJ, 2017, BIOORG MED CHEM LETT, V27, P1325, DOI 10.1016/j.bmcl.2016.08.016
   Yang HB, 2019, BIOINFORMATICS, V35, P1067, DOI 10.1093/bioinformatics/bty707
   Yang X, 2019, CHEM REV, V119, P10520, DOI 10.1021/acs.chemrev.8b00728
   Yuan YX, 2011, J CHEM INF MODEL, V51, P1083, DOI 10.1021/ci100350u
NR 133
TC 7
Z9 7
U1 5
U2 12
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-2646
J9 FRONT CHEM
JI Front. Chem.
PD FEB 18
PY 2020
VL 8
AR 93
DI 10.3389/fchem.2020.00093
PG 18
WC Chemistry, Multidisciplinary
SC Chemistry
GA KT0GX
UT WOS:000518690100001
PM 32133344
OA DOAJ Gold, Green Accepted, Green Published
DA 2020-12-01
ER

PT J
AU Neves, BJ
   Braga, RC
   Alves, VM
   Lima, MNN
   Cassiano, GC
   Muratov, EN
   Costa, FTM
   Andrade, CH
AF Neves, Bruno J.
   Braga, Rodolpho C.
   Alves, Vinicius M.
   Lima, Marilia N. N.
   Cassiano, Gustavo C.
   Muratov, Eugene N.
   Costa, Fabio T. M.
   Andrade, Carolina Horta
TI Deep Learning-driven research for drug discovery: Tackling Malaria
SO PLOS COMPUTATIONAL BIOLOGY
LA English
DT Article
ID QSAR MODELS; BIG DATA; RESISTANCE; REPRESENTATION; PERMEABILITY;
   INTEGRATION; PARASITES; CURATION; BINDING; DESIGN
AB Malaria is an infectious disease that affects over 216 million people worldwide, killing over 445,000 patients annually. Due to the constant emergence of parasitic resistance to the current antimalarial drugs, the discovery of new drug candidates is a major global health priority. Aiming to make the drug discovery processes faster and less expensive, we developed binary and continuous Quantitative Structure-Activity Relationships (QSAR) models implementing deep learning for predicting antiplasmodial activity and cytotoxicity of untested compounds. Then, we applied the best models for a virtual screening of a large database of chemical compounds. The top computational predictions were evaluated experimentally against asexual blood stages of both sensitive and multi-drug-resistant Plasmodium falciparum strains. Among them, two compounds, LabMol-149 and LabMol-152, showed potent antiplasmodial activity at low nanomolar concentrations (EC50 < 500 nM) and low cytotoxicity in mammalian cells. Therefore, the computational approach employing deep learning developed here allowed us to discover two new families of potential next generation antimalarial agents, which are in compliance with the guidelines and criteria for antimalarial target candidates.
C1 [Neves, Bruno J.] Univ Ctr Anapolis, UniEVANGELICA, Lab Cheminformat, Anapolis, Go, Brazil.
   [Neves, Bruno J.; Alves, Vinicius M.; Lima, Marilia N. N.; Andrade, Carolina Horta] Univ Fed Goias, LabMol Lab Mol Modeling & Drug Design, Fac Pharm, Goiania, Go, Brazil.
   [Braga, Rodolpho C.] InsilicAll, Sao Paulo, SP, Brazil.
   [Alves, Vinicius M.; Muratov, Eugene N.] Univ N Carolina, UNC Eshelman Sch Pharm, Lab Mol Modeling, Chapel Hill, NC 27515 USA.
   [Cassiano, Gustavo C.; Costa, Fabio T. M.; Andrade, Carolina Horta] Univ Estadual Campinas, Dept Genet Evolut Microbiol & Immunol, Inst Biol, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Campinas, SP, Brazil.
   [Cassiano, Gustavo C.] Univ Nova Lisboa, IHMT, GHTM, Lisbon, Portugal.
   [Muratov, Eugene N.] Odessa Natl Polytech Univ, Dept Chem Technol, Odessa, Ukraine.
RP Andrade, CH (corresponding author), Univ Fed Goias, LabMol Lab Mol Modeling & Drug Design, Fac Pharm, Goiania, Go, Brazil.; Andrade, CH (corresponding author), Univ Estadual Campinas, Dept Genet Evolut Microbiol & Immunol, Inst Biol, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Campinas, SP, Brazil.
EM carolina@ufg.br
RI Alves, Vinicius M./G-7955-2015; Neves, Bruno Junior/E-6295-2016; Braga,
   Rodolpho C/A-9655-2011; Muratov, Eugene/C-4454-2014; Capatti Cassiano,
   Gustavo/G-5728-2013; Andrade, Carolina/C-3960-2014
OI Alves, Vinicius M./0000-0002-6182-1748; Braga, Rodolpho
   C/0000-0003-3814-3464; Muratov, Eugene/0000-0003-4616-7036; Capatti
   Cassiano, Gustavo/0000-0002-6971-5974; Neves, Bruno/0000-0002-1309-8743;
   Andrade, Carolina/0000-0003-0101-1492
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPEG; FAPESPFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [2012/16525-2, 2015/20774-6, 2017/18611-7, 2017/02353-9];
   CAPESCAPES; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [1U01CA207160];
   L'Oreal-UNESCO-ABC Para Mulheres na Ciencia; L'Oreal-UNESCO
   International Rising Talents
FX The authors would like to thank Brazilian funding agencies, CNPq, FAPEG,
   FAPESP, and CAPES for financial support and fellowships. FTMC, GCC, and
   CHA were supported by FAPESP (grants #2012/16525-2, #2015/20774-6,
   2017/18611-7 and #2017/02353-9). ENM appreciate financial support of NIH
   (grant 1U01CA207160). CHA and FTMC are CNPq research fellows. CHA also
   thanks the "L'Oreal-UNESCO-ABC Para Mulheres na Ciencia" and "L'Ore
   al-UNESCO International Rising Talents" for the awards and fellowships
   received, which partially funded this work. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ajay, 1998, J MED CHEM, V41, P3314, DOI 10.1021/jm970666c
   ALTMAN NS, 1992, AM STAT, V46, P175, DOI 10.2307/2685209
   Alves VM, 2015, TOXICOL APPL PHARM, V284, P273, DOI 10.1016/j.taap.2014.12.013
   Alves VM, 2015, TOXICOL APPL PHARM, V284, P262, DOI 10.1016/j.taap.2014.12.014
   Ashley EA, 2014, NEW ENGL J MED, V371, P411, DOI 10.1056/NEJMoa1314981
   Ashley EA, 2018, LANCET, V391, P1608, DOI 10.1016/S0140-6736(18)30324-6
   Bjerrum EJ, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8040131
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1899, DOI 10.2174/1568026614666140929120749
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1399, DOI 10.2174/1568026614666140506124442
   Burden FR, 1999, J MED CHEM, V42, P3183, DOI 10.1021/jm980697n
   Burrows JN, 2017, MALARIA J, V16, DOI 10.1186/s12936-016-1675-x
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Consonni V, 2009, J CHEM INF MODEL, V49, P1669, DOI 10.1021/ci900115y
   Corey VC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11901
   CRAMER RD, 1988, J AM CHEM SOC, V110, P5959, DOI 10.1021/ja00226a005
   Du HY, 2008, J AGR FOOD CHEM, V56, P10785, DOI 10.1021/jf8022194
   Ekins S, 2016, PHARM RES-DORDR, V33, P2594, DOI 10.1007/s11095-016-2029-7
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   GADALETA D, 2016, INT J QUANT STRUCT P, V1, P45, DOI DOI 10.4018/IJQSPR.2016010102
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   Ghasemi F, 2018, DRUG DISCOV TODAY, V23, P1784, DOI 10.1016/j.drudis.2018.06.016
   Gobbi A, 1998, BIOTECHNOL BIOENG, V61, P47, DOI 10.1002/(SICI)1097-0290(199824)61:1&lt;47::AID-BIT9&gt;3.0.CO;2-Z
   Goh GB, 2017, J COMPUT CHEM, V38, P1291, DOI 10.1002/jcc.24764
   Golbraikh A, 2003, J COMPUT AID MOL DES, V17, P241, DOI 10.1023/A:1025386326946
   Gomes MN, 2017, EUR J MED CHEM, V137, P126, DOI 10.1016/j.ejmech.2017.05.026
   Gomez-Bombarelli R, 2018, ACS CENTRAL SCI, V4, P268, DOI 10.1021/acscentsci.7b00572
   HANSCH C, 1964, J AM CHEM SOC, V86, P1616, DOI 10.1021/ja01062a035
   Hartung T, 2016, ALTEX-ALTERN ANIM EX, V33, P83, DOI 10.14573/altex.1603091
   Hartwig CL, 2013, METHODS MALARIA RES, P122
   Irwin JJ, 2015, J MED CHEM, V58, P7076, DOI 10.1021/acs.jmedchem.5b01105
   Katsuno K, 2015, NAT REV DRUG DISCOV, V14, P751, DOI 10.1038/nrd4683
   KUBINYI H, 1978, ARZNEIMITTEL-FORSCH, V28-1, P598
   Kuz'min VE, 2008, J COMPUT AID MOL DES, V22, P403, DOI 10.1007/s10822-008-9179-6
   LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287
   Lima MNN, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00146
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Ma JS, 2015, J CHEM INF MODEL, V55, P263, DOI 10.1021/ci500747n
   Melo CC, 2016, J CHEM INF MODEL, V56, P1357, DOI 10.1021/acs.jcim.6b00055
   MORGAN HL, 1965, J CHEM DOC, V5, P107, DOI 10.1021/c160017a018
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Netzeva TI, 2005, ATLA-ALTERN LAB ANIM, V33, P155, DOI 10.1177/026119290503300209
   Neves BJ, 2016, J MED CHEM, V59, P7075, DOI 10.1021/acs.jmedchem.5b02038
   Owen SC, 2012, ACS CHEM BIOL, V7, P1429, DOI 10.1021/cb300189b
   Phillips MA, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.50
   Popova M, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aap7885
   Ramsundar B, 2017, J CHEM INF MODEL, V57, P2068, DOI 10.1021/acs.jcim.7b00146
   Report from the Expert Group on (Quantitative) Structure-Activity Relationships [(Q)SARs] on the Principles for the Validation of (Q)SARs, 2004, OECD GUID TEST CHEM, P1
   Riniker S, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-26
   Rogers D, 2010, J CHEM INF MODEL, V50, P742, DOI 10.1021/ci100050t
   Rogers WO, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-10
   Schneider G, 2018, NAT REV DRUG DISCOV, V17, P97, DOI 10.1038/nrd.2017.232
   Srivastava IK, 1999, MOL MICROBIOL, V33, P704, DOI 10.1046/j.1365-2958.1999.01515.x
   Svetnik V, 2003, J CHEM INF COMP SCI, V43, P1947, DOI 10.1021/ci034160g
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   Triglia T, 1998, EMBO J, V17, P3807, DOI 10.1093/emboj/17.14.3807
   Tropsha A, 2007, CURR PHARM DESIGN, V13, P3494, DOI 10.2174/138161207782794257
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Varnek A, 2008, CURR COMPUT-AID DRUG, V4, P191, DOI 10.2174/157340908785747465
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Vityuk N., 1999, PATTERN RECOGNIT IMA, V3, P521
   Wang YL, 2012, NUCLEIC ACIDS RES, V40, pD400, DOI 10.1093/nar/gkr1132
   Wassmer SC, 2017, INT J PARASITOL, V47, P145, DOI 10.1016/j.ijpara.2016.08.002
   Wellems TE, 2001, J INFECT DIS, V184, P770, DOI 10.1086/322858
   Witkowski B, 2013, ANTIMICROB AGENTS CH, V57, P914, DOI 10.1128/AAC.01868-12
   Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130
   Zhu H, 2014, CHEM RES TOXICOL, V27, P1643, DOI 10.1021/tx500145h
NR 68
TC 1
Z9 1
U1 3
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-734X
EI 1553-7358
J9 PLOS COMPUT BIOL
JI PLoS Comput. Biol.
PD FEB
PY 2020
VL 16
IS 2
AR e1007025
DI 10.1371/journal.pcbi.1007025
PG 21
WC Biochemical Research Methods; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA LE4YJ
UT WOS:000526725200035
PM 32069285
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Mansouri, K
   Kleinstreuer, N
   Abdelaziz, AM
   Alberga, D
   Alves, VM
   Andersson, PL
   Andrade, CH
   Bai, F
   Balabin, I
   Ballabio, D
   Benfenati, E
   Bhhatarai, B
   Boyer, S
   Chen, JW
   Consonni, V
   Farag, S
   Fourches, D
   Garcia-Sosa, AT
   Gramatica, P
   Grisoni, F
   Grulke, CM
   Hong, HX
   Horvath, D
   Hu, X
   Huang, RL
   Jeliazkova, N
   Li, JZ
   Li, XH
   Liu, HX
   Manganelli, S
   Mangiatordi, GF
   Maran, U
   Marcou, G
   Martin, T
   Muratov, E
   Nguyen, DT
   Nicolotti, O
   Nikolov, NG
   Norinder, U
   Papa, E
   Petitjean, M
   Piir, G
   Pogodin, P
   Poroikov, V
   Qiao, XL
   Richard, AM
   Roncaglioni, A
   Ruiz, P
   Rupakheti, C
   Sakkiah, S
   Sangion, A
   Schramm, KW
   Selvaraj, C
   Shah, I
   Sild, S
   Sun, LX
   Taboureau, O
   Tang, Y
   Tetko, IV
   Todeschini, R
   Tong, WD
   Trisciuzzi, D
   Tropsha, A
   Van Den Driessche, G
   Varnek, A
   Wang, ZY
   Wedebye, EB
   Williams, AJ
   Xie, HB
   Zakharov, AV
   Zheng, ZY
   Judson, RS
AF Mansouri, Kamel
   Kleinstreuer, Nicole
   Abdelaziz, Ahmed M.
   Alberga, Domenico
   Alves, Vinicius M.
   Andersson, Patrik L.
   Andrade, Carolina H.
   Bai, Fang
   Balabin, Ilya
   Ballabio, Davide
   Benfenati, Emilio
   Bhhatarai, Barun
   Boyer, Scott
   Chen, Jingwen
   Consonni, Viviana
   Farag, Sherif
   Fourches, Denis
   Garcia-Sosa, Alfonso T.
   Gramatica, Paola
   Grisoni, Francesca
   Grulke, Chris M.
   Hong, Huixiao
   Horvath, Dragos
   Hu, Xin
   Huang, Ruili
   Jeliazkova, Nina
   Li, Jiazhong
   Li, Xuehua
   Liu, Huanxiang
   Manganelli, Serena
   Mangiatordi, Giuseppe F.
   Maran, Uko
   Marcou, Gilles
   Martin, Todd
   Muratov, Eugene
   Dac-Trung Nguyen
   Nicolotti, Orazio
   Nikolov, Nikolai G.
   Norinder, Ulf
   Papa, Ester
   Petitjean, Michel
   Piir, Geven
   Pogodin, Pavel
   Poroikov, Vladimir
   Qiao, Xianliang
   Richard, Ann M.
   Roncaglioni, Alessandra
   Ruiz, Patricia
   Rupakheti, Chetan
   Sakkiah, Sugunadevi
   Sangion, Alessandro
   Schramm, Karl-Werner
   Selvaraj, Chandrabose
   Shah, Imran
   Sild, Sulev
   Sun, Lixia
   Taboureau, Olivier
   Tang, Yun
   Tetko, Igor, V
   Todeschini, Roberto
   Tong, Weida
   Trisciuzzi, Daniela
   Tropsha, Alexander
   Van Den Driessche, George
   Varnek, Alexandre
   Wang, Zhongyu
   Wedebye, Eva B.
   Williams, Antony J.
   Xie, Hongbin
   Zakharov, Alexey, V
   Zheng, Ziye
   Judson, Richard S.
TI CoMPARA: Collaborative Modeling Project for Androgen Receptor Activity
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
ID ENDOCRINE-DISRUPTING CHEMICALS; NEAREST-NEIGHBOR CLASSIFICATION;
   IN-VITRO; ENVIRONMENTAL CHEMICALS; TOXCAST PROGRAM; DECISION FOREST;
   PLS-REGRESSION; ESTROGEN; TOXICITY; EXPOSURE
AB BACKGROUND: Endocrine disrupting chemicals (EDCs) are xenobiotics that mimic the interaction of natural hormones and alter synthesis, transport, or metabolic pathways. The prospect of EDCs causing adverse health effects in humans and wildlife has led to the development of scientific and regulatory approaches for evaluating bioactivity. This need is being addressed using high-throughput screening (HTS) in vitro approaches and computational modeling.
   OBJECTIVES: In support of the Endocrine Disruptor Screening Program, the U.S. Environmental Protection Agency (EPA) led two worldwide consortiums to virtually screen chemicals for their potential estrogenic and androgenic activities. Here, we describe the Collaborative Modeling Project for Androgen Receptor Activity (CoMPARA) efforts, which follows the steps of the Collaborative Estrogen Receptor Activity Prediction Project (CERAPP).
   METHODS: The CoMPARA list of screened chemicals built on CERAPP's list of 32,464 chemicals to include additional chemicals of interest, as well as simulated ToxCast (TM) metabolites, totaling 55,450 chemical structures. Computational toxicology scientists from 25 international groups contributed 91 predictive models for binding, agonist, and antagonist activity predictions. Models were underpinned by a common training set of 1,746 chemicals compiled from a combined data set of 11 ToxCast (TM)/Tox21 HTS in vitro assays.
   RESULTS: The resulting models were evaluated using curated literature data extracted from different sources. To overcome the limitations of single-model approaches, CoMPARA predictions were combined into consensus models that provided averaged predictive accuracy of approximately 80% for the evaluation set.
   DISCUSSION: The strengths and limitations of the consensus predictions were discussed with example chemicals; then, the models were implemented into the free and open-source OPERA application to enable screening of new chemicals with a defined applicability domain and accuracy assessment. This implementation was used to screen the entire EPA DSSTox database of similar to 875,000 chemicals, and their predicted AR activities have been made available on the EPA CompTox Chemicals dashboard and National Toxicology Program's Integrated Chemical Environment.
C1 [Mansouri, Kamel; Grulke, Chris M.; Richard, Ann M.; Shah, Imran; Williams, Antony J.; Judson, Richard S.] US EPA, Natl Ctr Computat Toxicol, Off Res & Dev, Res Triangle Pk, NC USA.
   [Mansouri, Kamel] ScitoVation LLC, Res Triangle Pk, NC USA.
   [Mansouri, Kamel] Integrated Lab Syst Inc, Morrisville, NC USA.
   [Kleinstreuer, Nicole] Natl Inst Environm Hlth Sci, Interagcy Ctr Evaluat Alternat Toxicol Methods NI, Natl Toxicol Program, Res Triangle Pk, NC USA.
   [Abdelaziz, Ahmed M.; Schramm, Karl-Werner] Tech Univ Munich, Dept Biowissensch Grundlagen, Wissenschaftszentrum Weihenstephan Ernahrung Land, Weihenstephaner Steig 23, D-85350 Freising Weihenstephan, Germany.
   [Alberga, Domenico; Mangiatordi, Giuseppe F.; Nicolotti, Orazio; Trisciuzzi, Daniela] Univ Bari, Dept Pharm Drug Sci, Bari, Italy.
   [Alves, Vinicius M.; Andrade, Carolina H.] Univ Fed Goias, Fac Pharm, Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.
   [Alves, Vinicius M.; Farag, Sherif; Muratov, Eugene; Tropsha, Alexander] Univ N Carolina, Lab Mol Modeling, Chapel Hill, NC 27515 USA.
   [Andersson, Patrik L.; Zheng, Ziye] Umea Univ, Chem Dept, Umea, Sweden.
   [Bai, Fang; Li, Jiazhong; Liu, Huanxiang] Lanzhou Univ, Sch Pharm, Lanzhou, Peoples R China.
   [Balabin, Ilya] Lockheed Martin, IS&GS, Washington, DC USA.
   [Ballabio, Davide; Consonni, Viviana; Grisoni, Francesca; Todeschini, Roberto] Univ Milano Bicocca, Dept Earth & Environm Sci, Milano Chemometr & QSAR Res Grp, Milan, Italy.
   [Nikolov, Nikolai G.; Wedebye, Eva B.] Tech Univ Denmark, Natl Food Inst, Div Risk Assessment & Nutr, Copenhagen, Denmark.
   [Benfenati, Emilio; Manganelli, Serena; Roncaglioni, Alessandra] IRCCS, Ist Ric Farmacol Mario Negri, Milan, Italy.
   [Bhhatarai, Barun; Gramatica, Paola; Papa, Ester; Sangion, Alessandro] Univ Insubria, Dept Theoret & Appl Sci, QSAR Res Unit Environm Chem & Ecotoxicol, Varese, Italy.
   [Boyer, Scott; Norinder, Ulf] Karolinska Inst, Swedish Toxicol Sci Res Ctr, Sodertalje, Sweden.
   [Chen, Jingwen; Li, Xuehua; Qiao, Xianliang; Wang, Zhongyu; Xie, Hongbin] Dalian Univ Technol, Sch Environm Sci & Technol, Dalian, Peoples R China.
   [Fourches, Denis; Van Den Driessche, George] North Carolina State Univ, Bioinformat Res Ctr, Dept Chem, Raleigh, NC USA.
   [Garcia-Sosa, Alfonso T.; Maran, Uko; Piir, Geven; Sild, Sulev] Univ Tartu, Inst Chem, Tartu, Estonia.
   [Hong, Huixiao; Sakkiah, Sugunadevi; Selvaraj, Chandrabose; Tong, Weida] US FDA, Natl Ctr Toxicol Res, Div Bioinformat & Biostat, Jefferson, AR 72079 USA.
   [Horvath, Dragos; Marcou, Gilles; Varnek, Alexandre] Univ Strasbourg, Lab Chemoinformat UMR7140, CNRS, Strasbourg, France.
   [Hu, Xin; Huang, Ruili; Dac-Trung Nguyen; Zakharov, Alexey, V] Natl Ctr Advancing Translat Sci, NIH, Rockville, MD USA.
   [Jeliazkova, Nina] IdeaConsult Ltd, Sofia, Bulgaria.
   [Martin, Todd; Rupakheti, Chetan] US EPA, Natl Risk Management Res Lab, Cincinnati, OH 45268 USA.
   [Petitjean, Michel; Taboureau, Olivier] Univ Paris, INSERM ERL U1133, Funct & Adaptat Biol BFA, INSERM UMR 8251,CMPLI, Paris, France.
   [Pogodin, Pavel; Poroikov, Vladimir] Inst Biomed Chem IBMC, 10 Bldg 8,Pogodinskaya St, Moscow 119121, Russia.
   [Ruiz, Patricia] Ctr Dis Control & Prevent, Computat Toxicol & Methods Dev Lab, Div Toxicol & Human Hlth Sci, Agcy Tox Subst & Dis Registry, Atlanta, GA USA.
   [Rupakheti, Chetan] Univ Chicago, Dept Biochem & Mol Biophys, Chicago, IL 60637 USA.
   [Sun, Lixia; Tang, Yun] East China Univ Sci & Technol, Sch Pharm, Dept Pharmaceut Sci, Shanghai, Peoples R China.
   [Tetko, Igor, V] BIGCHEM GmbH, Neuherberg, Germany.
   [Tetko, Igor, V] German Res Ctr Environm Hlth GmbH, Helmholtz Zentrum Muenchen, Neuherberg, Germany.
   [Manganelli, Serena] Nestle Res, Chem Food Safety Grp, Lausanne, Switzerland.
   [Mangiatordi, Giuseppe F.] CNR, Ist Cristallog, Via G Amendola 122-O, I-70126 Bari, Italy.
RP Mansouri, K; Judson, RS (corresponding author), 109 TW Alexander Dr, Res Triangle Pk, NC 27711 USA.; Mansouri, K (corresponding author), 601 Keystone Dr, Morrisville, NC 27650 USA.
EM kamel.mansouri@nih.gov; judson.richard@epa.gov
RI Marcou, Gilles/F-8592-2015; Selvaraj, Chandrabose/F-4168-2012; Alves,
   Vinicius M./G-7955-2015; Varnek, Alexandre/E-7076-2017; Tetko, Igor
   V./B-1540-2010; Pogodin, Pavel/F-1123-2017; Williams,
   Antony/C-3089-2009; Garcia-Sosa, Alfonso T./E-4551-2015; Ballabio,
   Davide/B-7470-2014; Maran, Uko/I-6066-2015; Horvath, Dragos/W-9789-2018;
   Piir, Geven/AAE-9017-2019; Kleinstreuer, Nicole/F-7203-2019
OI Marcou, Gilles/0000-0003-1676-6708; Selvaraj,
   Chandrabose/0000-0002-8115-0486; Alves, Vinicius M./0000-0002-6182-1748;
   Varnek, Alexandre/0000-0003-1886-925X; Tetko, Igor
   V./0000-0002-6855-0012; Pogodin, Pavel/0000-0003-1843-7668; Williams,
   Antony/0000-0002-2668-4821; Garcia-Sosa, Alfonso T./0000-0003-0542-4446;
   Ballabio, Davide/0000-0002-5748-147X; Maran, Uko/0000-0003-2506-0934;
   Horvath, Dragos/0000-0003-0173-5714; Piir, Geven/0000-0002-7381-2689;
   Jeliazkova, Nina/0000-0002-4322-6179; Kleinstreuer,
   Nicole/0000-0002-7914-3682; Zheng, Ziye/0000-0002-7898-341X; Nguyen,
   Dac-Trung/0000-0003-2591-9948; Petitjean, Michel/0000-0002-1745-5402;
   Wedebye, Eva Bay/0000-0002-2848-3273; Sild, Sulev/0000-0002-8189-4370
FU Oak Ridge Institute for Science and Education (ORISE) Research
   Participation Program at the EPA; Intramural Research Program of
   National Institute of Environmental Health Sciences (NIEHS); Integrated
   Laboratory Systems Inc. under MFRS [HHSN273201500010C]; Ministry of
   Education and Research, Republic of Estonia [IUT34-14]; European Union
   European Regional Development Fund through Foundation Archimedes (Centre
   of Excellence in Molecular Cell Engineering) [TK143]
FX This work was supported by Oak Ridge Institute for Science and Education
   (ORISE) Research Participation Program at the EPA, the Lush Prize (Young
   Researcher) (2017), and The Intramural Research Program of National
   Institute of Environmental Health Sciences (NIEHS). Technical support
   was provided by Integrated Laboratory Systems Inc. under MFRS contract
   HHSN273201500010C. S.S., G.P., A.T.G.S. and U.M. from University of
   Tartu arc grateful for support from the Ministry of Education and
   Research, Republic of Estonia (grant number IUT34-14) and the European
   Union European Regional Development Fund through Foundation Archimedes
   (grant number TK143, Centre of Excellence in Molecular Cell
   Engineering).
CR Ball N, 2016, ALTEX-ALTERN ANIM EX, V33, P149, DOI 10.14573/altex.1601251
   Ballabio D, 2018, CHEMOMETR INTELL LAB, V174, P33, DOI 10.1016/j.chemolab.2017.12.004
   Ballabio D, 2011, CHEMOMETR INTELL LAB, V105, P56, DOI 10.1016/j.chemolab.2010.10.010
   Benigni R, 2003, QUANTITATIVE STRUCTU
   Berk RA, 2008, SPRINGER SER STAT, P1, DOI 10.1007/978-0-387-77501-2_1
   Bolger R, 1998, ENVIRON HEALTH PERSP, V106, P551, DOI 10.1289/ehp.98106551
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Browne P, 2018, REPROD TOXICOL, V81, P259, DOI 10.1016/j.reprotox.2018.08.016
   Buttrey SE, 1998, COMPUT STAT DATA AN, V28, P157, DOI 10.1016/S0167-9473(98)00032-2
   Carlsson L., 2014, ARTIF INTELL, P231
   Chang X, 2015, APPL IN VITRO TOXICO, V1, P33, DOI [10.1089/aivt.2014.0005, DOI 10.1089/AIVT.2014.0005]
   COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890
   CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018
   COVER TM, 1967, IEEE T INFORM THEORY, V13, P21, DOI 10.1109/TIT.1967.1053964
   DAVIS DL, 1993, ENVIRON HEALTH PERSP, V101, P372, DOI 10.2307/3431889
   Dearden JC, 2009, SAR QSAR ENVIRON RES, V20, P241, DOI 10.1080/10629360902949567
   Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002
   Dionisio KL, 2015, TOXICOL REP, V2, P228, DOI 10.1016/j.toxrep.2014.12.009
   Dix DJ, 2007, TOXICOL SCI, V95, P5, DOI 10.1093/toxsci/kfl103
   Dunn WI, 1990, COMPREHENSIVE MED CH, V4.0., P691
   Egeghy PP, 2012, SCI TOTAL ENVIRON, V414, P159, DOI 10.1016/j.scitotenv.2011.10.046
   EnvironmentCanada, 2012, DSL DOM SUBS LIST
   European EnvironmentAgency, 2012, IMP END DISR WILDL P
   EuropeanCommission, 2013, QSAR MOD REP FORM QM
   Fang H, 2000, ENVIRON HEALTH PERSP, V108, P723, DOI 10.1289/ehp.00108723
   Ferrari T., 2011, Proceedings 2011 IEEE Symposium on Computational Intelligence and Data Mining (CIDM 2011), P120, DOI 10.1109/CIDM.2011.5949444
   Filimonov DA, 2009, SAR QSAR ENVIRON RES, V20, P679, DOI 10.1080/10629360903438370
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   FRANK IE, 1993, TECHNOMETRICS, V35, P109, DOI 10.2307/1269656
   Grace Patlewicz, 2017, Comput Toxicol, V3, P1, DOI 10.1016/j.comtox.2017.05.003
   Gray LE, 1997, REPROD TOXICOL, V11, P719, DOI 10.1016/S0890-6238(97)00025-7
   Grisoni F, 2019, J CHEM INF MODEL, V59, P1839, DOI 10.1021/acs.jcim.8b00794
   Grulke C. M., 2019, COMPUT TOXICOL, V12, DOI DOI 10.1016/J.COMTOX.2019.100096
   Guha R, 2005, CDK NEWS, V2, P2
   Haggard DE, 2018, TOXICOL SCI, V162, P509, DOI 10.1093/toxsci/kfx274
   HANSCH C, 1964, J AM CHEM SOC, V86, P1616, DOI 10.1021/ja01062a035
   Hong H, 2005, SAR QSAR ENVIRON RES, V16, P339, DOI 10.1080/10659360500203022
   Hong HX, 2004, DNA CELL BIOL, V23, P685, DOI 10.1089/dna.2004.23.685
   HSIA(HalogenatedSolventsIndustryAlliance), 2009, COMM OFF MAN BUDG CO
   JRC(JointResearchCenteroftheEuropeanCommission), 2017, Q SAR MOD REP FORM Q
   Judson R, 2016, TOXICOL SCI, V152, P323, DOI [10.1093/toxsci/kfw092, 10.1093/toxsci/kfw148]
   Judson R, 2014, BASIC CLIN PHARMACOL, V115, P69, DOI 10.1111/bcpt.12239
   Judson R, 2009, ENVIRON HEALTH PERSP, V117, P685, DOI 10.1289/ehp.0800168
   Judson Richard S., 2018, Current Opinion in Toxicology, V9, P40, DOI 10.1016/j.cotox.2018.10.002
   Judson RS, 2015, TOXICOL SCI, V148, P137, DOI 10.1093/toxsci/kfv168
   Karmaus AL, 2016, TOXICOL SCI, V150, P323, DOI 10.1093/toxsci/kfw002
   Kavlock R, 2012, CHEM RES TOXICOL, V25, P1287, DOI 10.1021/tx3000939
   Kleinstreuer NC, 2018, REPROD TOXICOL, V81, P272, DOI 10.1016/j.reprotox.2018.08.017
   Kleinstreuer Nicole C, 2018, Comput Toxicol, V8, P21, DOI 10.1016/j.comtox.2018.08.002
   Kleinstreuer NC, 2017, CHEM RES TOXICOL, V30, P946, DOI 10.1021/acs.chemrestox.6b00347
   Kleinstreuer NC, 2016, ENVIRON HEALTH PERSP, V124, P556, DOI 10.1289/ehp.1510183
   KOWALSKI BR, 1972, ANAL CHEM, V44, P1405, DOI 10.1021/ac60316a008
   Kowalski BR, 2013, CHEMOMETRICS MATH ST
   Lagunin A, 2011, MOL INFORM, V30, P241, DOI 10.1002/minf.201000151
   Leardi R, 1998, CHEMOMETR INTELL LAB, V41, P195, DOI 10.1016/S0169-7439(98)00051-3
   Leonard Jeremy A, 2018, Comput Toxicol, V6, P71, DOI 10.1016/j.comtox.2017.10.003
   Manganelli S, 2019, CHEMOSPHERE, V220, P204, DOI 10.1016/j.chemosphere.2018.12.131
   Mansouri K, 2016, SAR QSAR ENVIRON RES, V27, P911, DOI 10.1080/1062936X.2016.1253611
   Mansouri K, 2018, J CHEMINFORMATICS, V10, DOI 10.1186/s13321-018-0263-1
   Mansouri K, 2016, ENVIRON HEALTH PERSP, V124, P1023, DOI 10.1289/ehp.1510267
   Martin MT, 2010, CHEM RES TOXICOL, V23, P578, DOI 10.1021/tx900325g
   Martin TM, 2008, TOXICOL MECH METHOD, V18, P251, DOI 10.1080/15376510701857353
   Mazanetz MP, 2012, CURR TOP MED CHEM, V12, P1965
   McEachran AD, 2018, J CHEMINFORMATICS, V10, DOI 10.1186/s13321-018-0299-2
   Mueller Stefan O., 2001, Current Opinion in Pharmacology, V1, P613, DOI 10.1016/S1471-4892(01)00105-9
   Murphy KP, 2006, NAIVE BAYES CLASSIFI
   Norinder U, 2016, CHEM RES TOXICOL, V29, P1003, DOI 10.1021/acs.chemrestox.6b00037
   Nouwen J, 1997, ENVIRON SCI TECHNOL, V31, P2313, DOI 10.1021/es9609213
   Pinto CL, 2016, CHEM RES TOXICOL, V29, P1410, DOI 10.1021/acs.chemrestox.6b00079
   Richard AM, 2002, MUTAT RES-FUND MOL M, V499, P27, DOI 10.1016/S0027-5107(01)00289-5
   Richard AM, 2016, CHEM RES TOXICOL, V29, P1225, DOI 10.1021/acs.chemrestox.6b00135
   Rotroff DM, 2010, TOXICOL SCI, V117, P348, DOI 10.1093/toxsci/kfq220
   Safe SH, 1997, ENVIRON HEALTH PERSP, V105, P675, DOI 10.2307/3433388
   Sahigara F, 2014, CURR COMPUT-AID DRUG, V10, P137, DOI 10.2174/1573409910666140410110241
   Shanle EK, 2011, CHEM RES TOXICOL, V24, P6, DOI 10.1021/tx100231n
   Skakkebaek NE, 2011, J CLIN ENDOCR METAB, V96, P3056, DOI 10.1210/jc.2011-1269
   Soto AM, 1998, ADV EXP MED BIOL, V444, P9
   Sun JM, 2017, J CHEMINFORMATICS, V9, DOI 10.1186/s13321-017-0203-5
   Sushko I, 2011, J COMPUT AID MOL DES, V25, P533, DOI 10.1007/s10822-011-9440-2
   Tetko IV, 2002, NEURAL PROCESS LETT, V16, P187, DOI 10.1023/A:1019903710291
   Tetko IV, 2002, J CHEM INF COMP SCI, V42, P1136, DOI 10.1021/ci025515j
   Tice RR, 2013, ENVIRON HEALTH PERSP, V121, P756, DOI 10.1289/ehp.1205784
   Todeschini R, 2015, J CHEM INF MODEL, V55, P2365, DOI 10.1021/acs.jcim.5b00326
   Tong WD, 2003, J CHEM INF COMP SCI, V43, P525, DOI 10.1021/ci020058s
   Trisciuzzi D, 2017, J CHEM INF MODEL, V57, P2874, DOI 10.1021/acs.jcim.7b00420
   U.S. EPA, 2014, EDSP21 DASHB
   U.S. EPA, 2019, ALD BIOACT TOXCAST M
   U.S. EPA, 2019, BIC BIOACT TOXCAST M
   U.S. EPA, 2014, CPCAT CHEM PROD CAT
   U.S. EPA, 2015, FIFRA SCI ADV PAN M
   U. S. EPA, 2019, BIC CHEM DASHB
   U. S. EPA, 2019, HYDR BIOACT TOXCAST
   U.S. EPA, 2019, HYDR CHEM DASHB
   U.S. EPA, 2011, HERSHB ASS OCSPP GUI
   U. S. EPA, 2019, ALD CHEM DASHB
   U.S. EPA(U.S. EnvironmentalProtectionAgency), 2013, M MAT JAN 29 31 2013
   U. S. EPA-OCSPP, 2014, END DISR
   U.S. EPA-OCSPP, 2015, END DISR SCREEN PROG
   Waller CL, 1996, CHEM RES TOXICOL, V9, P1240, DOI 10.1021/tx960054f
   Waterbeemd HVD, 2008, CHEMOMETRIC METHODS
   WHO(WorldHealthOrganization), 2013, END DISR CHEM EDCS
   Williams AJ, 2017, J CHEMINFORMATICS, V9, DOI 10.1186/s13321-017-0247-6
   Williams AJ, 2011, DRUG DISCOV TODAY, V16, P747, DOI 10.1016/j.drudis.2011.07.007
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   Wold S, 2001, CHEMOMETR INTELL LAB, V58, P109, DOI 10.1016/S0169-7439(01)00155-1
   Worth A. P., 2005, CHARACTERISATION QUA
   Xie Q, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-S2-S4
   Yap CW, 2011, J COMPUT CHEM, V32, P1466, DOI 10.1002/jcc.21707
   Zakharov AV, 2014, J CHEM INF MODEL, V54, P713, DOI 10.1021/ci400704f
NR 110
TC 11
Z9 11
U1 11
U2 18
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
   RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
EI 1552-9924
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD FEB
PY 2020
VL 128
IS 2
AR 027002
DI 10.1289/EHP5580
PG 17
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Toxicology
GA KS8WS
UT WOS:000518589800006
PM 32074470
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Custodio, JMF
   Guimaraes-Neto, JJA
   Awad, R
   Queiroz, JE
   Verde, GMV
   Mottin, M
   Neves, BJ
   Andrade, CH
   Aquino, GLB
   Valverde, C
   Osorio, FAP
   Baseia, B
   Napolitano, HB
AF Custodio, J. M. F.
   Guimaraes-Neto, J. J. A.
   Awad, R.
   Queiroz, J. E.
   Verde, G. M. V.
   Mottin, M.
   Neves, B. J.
   Andrade, C. H.
   Aquino, G. L. B.
   Valverde, C.
   Osorio, F. A. P.
   Baseia, B.
   Napolitano, H. B.
TI Molecular modelling and optical properties of a novel fluorinated
   chalcone
SO ARABIAN JOURNAL OF CHEMISTRY
LA English
DT Article
DE Molecular modeling; NLO properties; Fluorinated chalcone
ID CAMBRIDGE STRUCTURAL DATABASE; CLAISEN-SCHMIDT CONDENSATION; DRUG TARGET
   IDENTIFICATION; WEB SERVER; EFFICIENT; DERIVATIVES; DOCKING; INHA;
   POLARIZATION; INHIBITION
AB Chalcones exhibit a broad spectrum of biological activities, mainly due to alpha, beta-unsaturated ketone, and are precursors of the biosynthesis of flavonoids present in plants. These compounds have been shown to be useful in the biological approach, proven by the broad spectrum of biological activities reported, and also in the technological approach, considering their potential as nonlinear optic (NLO) material. In this context, this work aimed to examine the crystallization and characterization of fluorinated chalcone (E)-1-(4-fluoropheny1)-3-(4-isopropylphenyeprop-2-e-n-1-one (DFC). A comprehensive structural study of DFC was carried out to understand the process of stabilizing the crystalline lattice through X-ray diffraction, infrared spectroscopy, and molecular modeling studies. Finally, the electrical properties of DFC were calculated by using the supermolecule method (SM). DFC molecules are connected by means of C-H center dot center dot center dot O and C-H center dot center dot center dot F intermolecular contacts, forming dimers which play an important role in the stabilization of crystal packing. Molecular modeling studies indicated that this compound could act as an anti-tuberculosis ligand because of its high binding affinity with the M. tuberculosis enoyl-acyl carrier protein, InhA. On the other hand, theoretical calculations were performed to evaluate the NLO properties of DFC and indicated that it showed good potential. (C) 2018 Production and hosting by Elsevier B.V. on behalf of King Saud University.
C1 [Custodio, J. M. F.; Mottin, M.; Neves, B. J.; Andrade, C. H.; Osorio, F. A. P.; Baseia, B.] Univ Fed Goias, Goiania, Go, Brazil.
   [Guimaraes-Neto, J. J. A.; Awad, R.; Queiroz, J. E.; Verde, G. M. V.; Aquino, G. L. B.; Valverde, C.; Napolitano, H. B.] Univ Estadual Goias, Anapolis, Go, Brazil.
   [Neves, B. J.; Napolitano, H. B.] Ctr Univ Anapolis, Anapolis, Go, Brazil.
   [Valverde, C.] Univ Paulista, Goiania, Go, Brazil.
   [Osorio, F. A. P.] Pontificia Univ Catolica Goias, Goiania, Go, Brazil.
RP Custodio, JMF (corresponding author), Univ Fed Goias, Goiania, Go, Brazil.
EM jeanmfcustodio@gmail.com
RI Mottin, Melina/D-8700-2016; Baseia, Basilio/AAJ-8355-2020; Valverde,
   Clodoaldo/L-8548-2015; , Gilberto/W-8821-2019; Aquino, Gilberto L
   B/O-5203-2014; Napolitano, Hamilton Barbosa/ABC-1986-2020; Aquino,
   Gilberto Lucio Benedito/I-3780-2015; Valverde, Clodoaldo/O-3547-2019;
   Custodio, Jean M F/R-4706-2017; Neves, Bruno Junior/E-6295-2016; De
   Queiroz, Jaqueline Evangelista/W-3132-2018; Baseia,
   Basilio/AAM-4614-2020; VERDE, GIULIANA M VILA/D-5260-2016; Andrade,
   Carolina/C-3960-2014
OI Mottin, Melina/0000-0003-0878-9029; Valverde,
   Clodoaldo/0000-0002-1656-4981; , Gilberto/0000-0001-9397-7803; Aquino,
   Gilberto L B/0000-0001-9397-7803; Aquino, Gilberto Lucio
   Benedito/0000-0001-9397-7803; Valverde, Clodoaldo/0000-0002-1656-4981;
   Custodio, Jean M F/0000-0002-2295-2112; De Queiroz, Jaqueline
   Evangelista/0000-0001-5149-263X; Baseia, Basilio/0000-0002-2464-9889;
   Neves, Bruno/0000-0002-1309-8743; Andrade, Carolina/0000-0003-0101-1492
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Fundacao de Amparo a Pesquisa do Estado de Goias (FAPEG)
FX The authors gratefully acknowledge the financial support of the Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Coordenacao
   de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) and Fundacao de
   Amparo a Pesquisa do Estado de Goias (FAPEG). We are also grateful to
   ChemAxon and OpenEye Inc., for providing us with academic licenses of
   their software.
CR Abu N, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-102
   Allen FH, 2002, ACTA CRYSTALLOGR B, V58, P380, DOI 10.1107/S0108768102003890
   AlMatara M, 2018, PHARMACOL REP, V70, P217, DOI 10.1016/j.pharep.2017.09.001
   Almeida LR, 2017, NEW J CHEM, V41, P1744, DOI 10.1039/c5nj03214h
   Anandakrishnan R, 2012, NUCLEIC ACIDS RES, V40, pW537, DOI 10.1093/nar/gks375
   Baseia B, 2017, CRYSTALS, V7, DOI 10.3390/cryst7060158
   Battle GM, 2010, J APPL CRYSTALLOGR, V43, P1208, DOI 10.1107/S0021889810024155
   BERSOHN R, 1966, J CHEM PHYS, V45, P3184, DOI 10.1063/1.1728092
   Calloway NO, 1937, J AM CHEM SOC, V59, P809, DOI 10.1021/ja01284a011
   Castro AN, 2017, CHEM PHYS LETT, V681, P110, DOI 10.1016/j.cplett.2017.05.066
   Castro AN, 2016, CHEM PHYS LETT, V653, P122, DOI 10.1016/j.cplett.2016.04.070
   CLIMENT MJ, 1995, J CATAL, V151, P60, DOI 10.1006/jcat.1995.1008
   Custodio JMF, 2018, J MOL STRUCT, V1157, P210, DOI 10.1016/j.molstruc.2017.12.023
   D'silva ED, 2012, MATER RES BULL, V47, P3552, DOI 10.1016/j.materresbull.2012.06.063
   Ferreira NHD, 2014, AUT GREG LAT, P85
   Das A, 2014, RSC ADV, V4, P26662, DOI 10.1039/c4ra04763j
   Diaz-Tielas C, 2016, PLANTA DANINHA, V34, P607, DOI 10.1590/S0100-83582016340300022
   Farrugia LJ, 2012, J APPL CRYSTALLOGR, V45, P849, DOI 10.1107/S0021889812029111
   Frisch M.J., 2009, GAUSSIAN 09 REVISION, DOI [10.1159/000348293., DOI 10.1159/000348293, 10.1159/000348293]
   Gharib A, 2014, BULG CHEM COMMUN, V46, P215
   Gomes MN, 2017, EUR J MED CHEM, V137, P126, DOI 10.1016/j.ejmech.2017.05.026
   Goncalves LM, 2014, J MED FOOD, V17, P633, DOI 10.1089/jmf.2013.0061
   Gordon JC, 2005, NUCLEIC ACIDS RES, V33, pW368, DOI 10.1093/nar/gki464
   Gunter P, 2000, SPRINGER SERIES OPTI, V72, P1
   Hameed A, 2016, BIOORG CHEM, V65, P175, DOI 10.1016/j.bioorg.2016.02.008
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Hea X, 2007, BIOORGAN MED CHEM, V15, P6649, DOI 10.1016/j.bmc.2007.08.013
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Jioui I, 2016, J IND ENG CHEM, V39, P218, DOI 10.1016/j.jiec.2016.06.003
   Matos MJ, 2015, EXPERT OPIN THER PAT, V25, P351, DOI 10.1517/13543776.2014.995627
   Jr PSC, 2017, J MOL MODEL, V23, DOI 10.1007/s00894-017-3245-8
   KLEINMAN DA, 1962, PHYS REV, V126, P1977, DOI 10.1103/PhysRev.126.1977
   Krawczyk P, 2016, J MOL MODEL, V22, DOI 10.1007/s00894-016-2990-4
   Liu XF, 2010, NUCLEIC ACIDS RES, V38, pW609, DOI 10.1093/nar/gkq300
   Macrae CF, 2006, J APPL CRYSTALLOGR, V39, P453, DOI 10.1107/S0021 88980600731X
   Mahapatra DK, 2015, EUR J MED CHEM, V92, P839, DOI 10.1016/j.ejmech.2015.01.051
   Marrakchi H, 2000, MICROBIOL-UK, V146, P289, DOI 10.1099/00221287-146-2-289
   McGann M, 2012, J COMPUT AID MOL DES, V26, P897, DOI 10.1007/s10822-012-9584-8
   McGann M, 2011, J CHEM INF MODEL, V51, P578, DOI 10.1021/ci100436p
   McGann MR, 2003, BIOPOLYMERS, V68, P76, DOI 10.1002/bip.10207
   Murugesan A, 2017, MATER CHEM PHYS, V188, P154, DOI 10.1016/j.matchemphys.2016.12.039
   Nardelli M., 1995, J APPL CRYSTALLOGR, V28, P659, DOI DOI 10.1107/S0021889895007138
   Nowakowska Z, 2007, EUR J MED CHEM, V42, P125, DOI 10.1016/j.ejmech.2006.09.019
   Rodrigues R.F.N., 2015, REV PROCESS QUIMICOS, V9, P213
   Rodrigues RFN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175859
   Rosa GP, 2017, ACS SUSTAIN CHEM ENG, V5, P7467, DOI 10.1021/acssuschemeng.7b01687
   Sheldrick GM, 2015, ACTA CRYSTALLOGR C, V71, P3, DOI 10.1107/S2053229614024218
   Spackman M.A., 2009, HIRSHFELD SURFACE AN, P19, DOI [10.1039/b818330a, DOI 10.1039/B818330A]
   Szczesna D, 2017, SYNLETT, V28, P113, DOI 10.1055/s-0036-1588599
   Valverde C, 2012, CHINESE PHYS B, V21, DOI 10.1088/1674-1056/21/3/030308
   Valverde C, 2018, CHEM PHYS LETT, V706, P170, DOI 10.1016/j.cplett.2018.06.001
   Valverde C, 2017, NEW J CHEM, V41, P11361, DOI 10.1039/c7nj00618g
   Valverde C, 2017, J MOL MODEL, V23, DOI 10.1007/s00894-017-3274-3
   Vaz W., 2016, R SOC CHEM, V6
   Vaz WF, 2016, RSC ADV, V6, P79215, DOI 10.1039/c6ra14961h
   Verbiest T., 2009, HIST SEXUALITY, DOI [10.1201/9781420070736, DOI 10.1201/9781420070736]
   Wan ZH, 2015, MOLECULES, V20, P11861, DOI 10.3390/molecules200711861
   Wang X, 2017, NUCLEIC ACIDS RES, V45, pW356, DOI 10.1093/nar/gkx374
   Zhou Bo, 2015, Med Chem (Los Angeles), V5, P388
NR 59
TC 6
Z9 6
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1878-5352
EI 1878-5379
J9 ARAB J CHEM
JI Arab. J. Chem.
PD JAN
PY 2020
VL 13
IS 1
BP 3362
EP 3371
DI 10.1016/j.arabjc.2018.11.010
PG 10
WC Chemistry, Multidisciplinary
SC Chemistry
GA JZ4MK
UT WOS:000505076000264
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Silva, S
   Shimizu, JF
   de Oliveira, DM
   de Assis, LR
   Bittar, C
   Mottin, M
   Sousa, BKD
   Mesquita, NCDR
   Regasini, LO
   Rahal, P
   Oliva, G
   Perryman, AL
   Ekins, S
   Andrade, CH
   Goulart, LR
   Sabino-Silva, R
   Merits, A
   Harris, M
   Jardim, ACG
AF Silva, Suely
   Shimizu, Jacqueline Farinha
   de Oliveira, Debora Moraes
   de Assis, Leticia Ribeiro
   Bittar, Cintia
   Mottin, Melina
   de Paula Sousa, Bruna Katiele
   de Moraes Roso Mesquita, Nathalya Cristina
   Regasini, Luis Octavio
   Rahal, Paula
   Oliva, Glaucius
   Perryman, Alexander Luke
   Ekins, Sean
   Andrade, Carolina Horta
   Goulart, Luiz Ricardo
   Sabino-Silva, Robinson
   Merits, Andres
   Harris, Mark
   Gomes Jardim, Ana Carolina
TI A diarylamine derived from anthranilic acid inhibits ZIKV replication
SO SCIENTIFIC REPORTS
LA English
DT Article
ID HEPATITIS-C VIRUS; NATURAL-PRODUCTS; DENGUE VIRUS; NS2B-NS3 PROTEASE;
   CRYSTAL-STRUCTURE; HELICASE ACTIVITY; STRUCTURAL BASIS; DRUG DISCOVERY;
   NS3 HELICASE; IN-VITRO
AB Zika virus (ZIKV) is a mosquito-transmitted Flavivirus, originally identified in Uganda in 1947 and recently associated with a large outbreak in South America. Despite extensive efforts there are currently no approved antiviral compounds for treatment of ZIKV infection. Here we describe the antiviral activity of diarylamines derived from anthranilic acid (FAMs) against ZIKV. A synthetic FAM (E3) demonstrated anti-ZIKV potential by reducing viral replication up to 86%. We analyzed the possible mechanisms of action of FAM E3 by evaluating the intercalation of this compound into the viral dsRNA and its interaction with the RNA polymerase of bacteriophage SP6. However, FAM E3 did not act by these mechanisms. In silico results predicted that FAM E3 might bind to the ZIKV NS3 helicase suggesting that this protein could be one possible target of this compound. To test this, the thermal stability and the ATPase activity of the ZIKV NS3 helicase domain (NS3(Hel)) were investigated in vitro and we demonstrated that FAM E3 could indeed bind to and stabilize NS3(Hel).
C1 [Silva, Suely; Shimizu, Jacqueline Farinha; de Oliveira, Debora Moraes; Gomes Jardim, Ana Carolina] Univ Fed Uberlandia, ICBIM, Inst Biomed Sci, Lab Virol, Uberlandia, MG, Brazil.
   [Silva, Suely; Shimizu, Jacqueline Farinha; Bittar, Cintia; Rahal, Paula; Gomes Jardim, Ana Carolina] Sao Paulo State Univ, IBILCE, Sao Jose Do Rio Preto, SP, Brazil.
   [de Assis, Leticia Ribeiro; Regasini, Luis Octavio] Sao Paulo State Univ, IBILCE, Lab Antibiot & Chemotherapeut, Sao Jose Do Rio Preto, SP, Brazil.
   [Mottin, Melina; de Paula Sousa, Bruna Katiele; Andrade, Carolina Horta] Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, BR-74605170 Goiania, Go, Brazil.
   [de Moraes Roso Mesquita, Nathalya Cristina; Oliva, Glaucius] Univ Sao Paulo, Inst Phys Sao Carlos, Sao Carlos, SP, Brazil.
   [Perryman, Alexander Luke] Rutgers State Univ, New Jersey Med Sch, Dept Pharmacol Physiol & Neurosci, Newark, NJ 07103 USA.
   [Perryman, Alexander Luke] Repare Therapeut, 7210 Rue Frederick Banting,Suite 100, Montreal, PQ H4S 2A1, Canada.
   [Ekins, Sean] Collaborat Pharmaceut Inc, 840 Main Campus Dr,Lab 3510, Raleigh, NC 27606 USA.
   [Goulart, Luiz Ricardo] Univ Fed Uberlandia, Lab Nanobiotechnol, Uberlandia, MG, Brazil.
   [Sabino-Silva, Robinson] Univ Fed Uberlandia, Integrat Physiol & Salivary Nanobiotechnol Grp, Uberlandia, MG, Brazil.
   [Merits, Andres] Univ Tartu, Inst Technol, Nooruse 1, EE-50411 Tartu, Estonia.
   [Harris, Mark] Univ Leeds, Sch Mol & Cellular Biol, Fac Biol Sci, Leeds LS2 9JT, W Yorkshire, England.
   [Harris, Mark] Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England.
RP Jardim, ACG (corresponding author), Univ Fed Uberlandia, ICBIM, Inst Biomed Sci, Lab Virol, Uberlandia, MG, Brazil.; Jardim, ACG (corresponding author), Sao Paulo State Univ, IBILCE, Sao Jose Do Rio Preto, SP, Brazil.
EM jardim@ufu.br
RI Mottin, Melina/D-8700-2016; Bittar, Cintia/A-5042-2015; Sabino-Silva,
   Robinson/I-2264-2012; Merits, Andres/H-3125-2015; Jardim, Ana Carolina
   Gomes/H-3615-2012
OI Mottin, Melina/0000-0003-0878-9029; Bittar, Cintia/0000-0002-2048-4589;
   Sabino-Silva, Robinson/0000-0002-2104-5780; Merits,
   Andres/0000-0001-8193-0071; Jardim, Ana Carolina
   Gomes/0000-0002-6348-7923; De Paula Sousa, Bruna
   Katiele/0000-0002-3204-5591; Ribeiro de Assis,
   Leticia/0000-0001-9869-8934; Farinha Shimizu,
   Jacqueline/0000-0002-9844-7745
FU Royal Society -Newton Advanced Fellowship [NA 150195]; CNPQ (National
   Counsel of Technological and Scientific Development)National Council for
   Scientific and Technological Development (CNPq) [445021/2014-4];
   CNPq/FAPEG DCR [300508/2017-4, 201710267000063]; FAPEMIG (Minas Gerais
   Research Foundation)Minas Gerais State Research Foundation (FAPEMIG)
   [APQ-00587-14, SICONV 793988/2013]; CAPES (Coordination for the
   Improvement of Higher Education Personnel)CAPES [001]; Brazilian funding
   agency CNPqNational Council for Scientific and Technological Development
   (CNPq) [CNPq-465669/2014-0, 440610/2016-8]; Brazilian funding agency
   CAPESCAPES [CNPq-465669/2014-0, 440610/2016-8]; Brazilian funding agency
   FAPEMIGMinas Gerais State Research Foundation (FAPEMIG)
   [CNPq-465669/2014-04, 40610/2016-8]; Wellcome TrustWellcome Trust
   [096670]; L'Oreal-UNESCO-ABC Para Mulheres na Ciencia; L'Oreal-UNESCO
   International Rising Talents Program; CNPqNational Council for
   Scientific and Technological Development (CNPq)
FX We would like to thank the Royal Society -Newton Advanced Fellowship
   (Grant reference NA 150195), CNPQ (National Counsel of Technological and
   Scientific Development -grant 445021/2014-4), CNPq/FAPEG DCR (Grant
   300508/2017-4 and 201710267000063), FAPEMIG (Minas Gerais Research
   Foundation -APQ-00587-14, SICONV 793988/2013) and CAPES (Coordination
   for the Improvement of Higher Education Personnel -Code 001), for
   financial support. The authors thank the Brazilian funding agencies
   CNPq, CAPES and FAPEMIG for providing financial support to the National
   Institute of Science and Technology in Theranostics and
   Nanobiotechnology -INCT-Teranano (CNPq-465669/2014-0;
   MCTIC/FNDCT-CNPq/MEC-CAPES/MS-DECIT; Preventing and Combating the Zika
   Virus ##440610/2016-8). Research in the MH laboratory was funded by a
   Wellcome Trust Investigator Award (grant reference 096670). CHA also
   thanks the "L'Oreal-UNESCO-ABC Para Mulheres na Ciencia" and "L'Ore '
   al-UNESCO International Rising Talents Program" for the awards and
   fellowships received. CHA has CNPq productivity fellowship. We also
   thank the computational contribution of the collaborators and volunteers
   of the OpenZika project (http://openzika.ufg.br), as well as the support
   from IBM's World Community Grid team.
CR Albulescu IC, 2017, ANTIVIR RES, V143, P230, DOI 10.1016/j.antiviral.2017.04.016
   Amines Robert W., 2000, ENCY CHEM TECHNOLOGY, P1
   Barba-Spaeth G, 2016, NATURE, V536, P48, DOI 10.1038/nature18938
   Basavannacharya C, 2014, BIOCHEM BIOPH RES CO, V453, P539, DOI 10.1016/j.bbrc.2014.09.113
   Butler MS, 2008, NAT PROD REP, V25, P475, DOI 10.1039/b514294f
   Byrd CM, 2013, ANTIMICROB AGENTS CH, V57, P1902, DOI 10.1128/AAC.02251-12
   Calland N, 2012, VIRUSES-BASEL, V4, P2197, DOI 10.3390/v4102197
   Cao XC, 2016, NUCLEIC ACIDS RES, V44, P10505, DOI 10.1093/nar/gkw941
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1960, DOI 10.3201/eid2011.141380
   Chan JFW, 2016, J INFECTION, V72, P507, DOI 10.1016/j.jinf.2016.02.011
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Coloma J, 2016, CELL REP, V16, P3097, DOI 10.1016/j.celrep.2016.08.091
   CRANCE JM, 1994, ANTIVIR RES, V23, P63, DOI 10.1016/0166-3542(94)90033-7
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   da Silva-Junior EF, 2017, BIOORGAN MED CHEM, V25, P4219, DOI 10.1016/j.bmc.2017.06.049
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Ekins S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005023
   Campos GRF, 2017, J GEN VIROL, V98, P1693, DOI 10.1099/jgv.0.000808
   Gniazdowski M, 2005, EXPERT OPIN THER TAR, V9, P471, DOI 10.1517/14728222.9.3.471
   Hanwell MD, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758-2946-4-17
   Heaton NS, 2010, P NATL ACAD SCI USA, V107, P17345, DOI 10.1073/pnas.1010811107
   Hou WH, 2017, GENE, V628, P117, DOI 10.1016/j.gene.2017.07.049
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Hussein HA, 2015, NUCLEIC ACIDS RES, V43, pW436, DOI 10.1093/nar/gkv462
   Huynh K, 2015, CURR PROTOC PROTEIN, V2015, P19261, DOI [10.1002/0471140864.ps1926s79, DOI 10.1002/0471140864.PS1926S79]
   Jardim ACG, 2015, ANTIVIR RES, V115, P39, DOI 10.1016/j.antiviral.2014.12.018
   Kitazato K, 2007, DRUG DISCOV THER, V1, P14
   Krawczyk M, 2009, BIOL CHEM, V390, P351, DOI 10.1515/BC.2009.040
   Kuivanen S, 2017, ANTIVIR RES, V139, P117, DOI 10.1016/j.antiviral.2016.12.022
   Kuno G, 1998, J VIROL, V72, P73, DOI 10.1128/JVI.72.1.73-83.1998
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lei J, 2016, SCIENCE, V353, P503, DOI 10.1126/science.aag2419
   Leung D, 2001, J BIOL CHEM, V276, P45762, DOI 10.1074/jbc.M107360200
   Li JWH, 2009, SCIENCE, V325, P161, DOI 10.1126/science.1168243
   Lim HJ, 2017, BIOTECHNOL LETT, V39, P415, DOI 10.1007/s10529-016-2261-6
   Macdonald A, 2003, J BIOL CHEM, V278, P17775, DOI 10.1074/jbc.M210900200
   Martinez JP, 2015, NAT PROD REP, V32, P29, DOI 10.1039/c4np00085d
   Mastrangelo E, 2012, J ANTIMICROB CHEMOTH, V67, P1884, DOI 10.1093/jac/dks147
   Matsumoto Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068992
   McCarthy M, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i720
   Merino-Ramos T, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00376-17, 10.1128/aac.00376-17]
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Mottin M, 2018, DRUG DISCOV TODAY, V23, P1833, DOI 10.1016/j.drudis.2018.06.014
   Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363
   Mutso M, 2017, J GEN VIROL, V98, P2712, DOI 10.1099/jgv.0.000938
   NanoTemper Technologies GmbH, 2007, US MAN MON NT 115, P1
   Newman DJ, 2000, NAT PROD REP, V17, P215, DOI 10.1039/a902202c
   Nicastri E, 2016, EUROSURVEILLANCE, V21, P6, DOI 10.2807/1560-7917.ES.2016.21.32.30314
   Nittoli T, 2007, J MED CHEM, V50, P2108, DOI 10.1021/jm061428x
   Paupy C, 2009, MICROBES INFECT, V11, P1177, DOI 10.1016/j.micinf.2009.05.005
   Robinson WE, 1996, P NATL ACAD SCI USA, V93, P6326, DOI 10.1073/pnas.93.13.6326
   Saiz JC, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00411-17, 10.1128/aac.00411-17]
   Schrodinger, 2015, PYMOL MOL GRAPHICS S
   Shang ZF, 2018, J MOL BIOL, V430, P948, DOI 10.1016/j.jmb.2018.02.006
   Sharma N, 2017, INT J BIOL MACROMOL, V104, P1046, DOI 10.1016/j.ijbiomac.2017.06.105
   Singh P, 2009, BIOORGAN MED CHEM, V17, P3973, DOI 10.1016/j.bmc.2009.04.026
   Sirohi D, 2017, J INFECT DIS, V216, pS935, DOI 10.1093/infdis/jix515
   Sirohi D, 2016, SCIENCE, V352, P467, DOI 10.1126/science.aaf5316
   Song BH, 2017, J NEUROIMMUNOL, V308, P50, DOI 10.1016/j.jneuroim.2017.03.001
   Soto-Acosta R, 2014, ANTIVIR RES, V109, P132, DOI 10.1016/j.antiviral.2014.07.002
   Stankiewicz-Drogon A, 2008, BIOORGAN MED CHEM, V16, P8846, DOI 10.1016/j.bmc.2008.08.074
   Terzian ACB, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34423-6
   Tian HL, 2016, PROTEIN CELL, V7, P562, DOI 10.1007/s13238-016-0293-2
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Upadhyay AK, 2017, ACTA CRYSTALLOGR F, V73, P116, DOI 10.1107/S2053230X17001601
   Vazquez-Calvo A, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01314
   Ventura CV, 2016, ARQ BRAS OFTALMOL, V79, P1, DOI 10.5935/0004-2749.20160002
   Vrontaki E, 2016, J ENZYM INHIB MED CH, V31, P38, DOI 10.3109/14756366.2014.1003925
   Wagstaff KM, 2012, BIOCHEM J, V443, P851, DOI 10.1042/BJ20120150
   Wan ZT, 2014, RETROVIROLOGY, V11, DOI 10.1186/s12977-014-0088-6
   Wong PSJ, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002348
   World Health Organization, 2016, HIST ZIK VIR
   Zanello PR, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0443-9
   Zhang ZZ, 2016, SCIENCE, V354, P1597, DOI 10.1126/science.aai9309
NR 75
TC 2
Z9 2
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 27
PY 2019
VL 9
AR 17703
DI 10.1038/s41598-019-54169-z
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA JQ8TJ
UT WOS:000499210500001
PM 31776405
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Lima, MNN
   Cassiano, GC
   Tomaz, KCP
   Silva, AC
   Sousa, BKP
   Ferreira, LT
   Tavella, TA
   Calit, J
   Bargieri, DY
   Neves, BJ
   Costa, FTM
   Andrade, CH
AF Lima, Marilia N. N.
   Cassiano, Gustavo C.
   Tomaz, Kaira C. P.
   Silva, Arthur C.
   Sousa, Bruna K. P.
   Ferreira, Leticia T.
   Tavella, Tatyana A.
   Calit, Juliana
   Bargieri, Daniel Y.
   Neves, Bruno J.
   Costa, Fabio T. M.
   Andrade, Carolina Horta
TI Integrative Multi-Kinase Approach for the Identification of Potent
   Antiplasmodial Hits
SO FRONTIERS IN CHEMISTRY
LA English
DT Article
DE malaria; shape-based; machine learning; virtual screening; Plasmodium
   falciparum; multi-target
ID DEPENDENT PROTEIN-KINASE; PLASMODIUM-FALCIPARUM; DRUG DISCOVERY; MALARIA
   PARASITES; QSAR; GENERATION; CALCIUM; MODEL; VALIDATION; RESISTANCE
AB Malaria is a tropical infectious disease that affects over 219 million people worldwide. Due to the constant emergence of parasitic resistance to the current antimalarial drugs, the discovery of new antimalarial drugs is a global health priority. Multi-target drug discovery is a promising and innovative strategy for drug discovery and it is currently regarded as one of the best strategies to face drug resistance. Aiming to identify new multi-target antimalarial drug candidates, we developed an integrative computational approach to select multi-kinase inhibitors for Plasmodium falciparum calcium-dependent protein kinases 1 and 4 (CDPK1 and CDPK4) and protein kinase 6 (PK6). For this purpose, we developed and validated shape-based and machine learning models to prioritize compounds for experimental evaluation. Then, we applied the best models for virtual screening of a large commercial database of drug-like molecules. Ten computational hits were experimentally evaluated against asexual blood stages of both sensitive and multi-drug resistant P. falciparum strains. Among them, LabMol-171, LabMol-172, and LabMol-181 showed potent antiplasmodial activity at nanomolar concentrations (EC50 <= 700 nM) and selectivity indices >15 folds. In addition, LabMol-171 and LabMol-181 showed good in vitro inhibition of P. berghei ookinete formation and therefore represent promising transmission-blocking scaffolds. Finally, docking studies with protein kinases CDPK1, CDPK4, and PK6 showed structural insights for further hit-to-lead optimization studies.
C1 [Lima, Marilia N. N.; Silva, Arthur C.; Sousa, Bruna K. P.; Andrade, Carolina Horta] Univ Fed Goias, Fac Pharm, LabMol Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.
   [Cassiano, Gustavo C.; Tomaz, Kaira C. P.; Ferreira, Leticia T.; Tavella, Tatyana A.; Costa, Fabio T. M.; Andrade, Carolina Horta] Univ Campinas UNICAMP, Inst Biol, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Dept Genet Evolut Microbiol & Immunol, Campinas, SP, Brazil.
   [Calit, Juliana; Bargieri, Daniel Y.] Univ Sao Paulo, Dept Parasitol, Inst Biomed Sci, Sao Paulo, SP, Brazil.
   [Neves, Bruno J.] Univ Ctr Anapolis UniEVANGELICA, Lab Cheminformat, Anapolis, Go, Brazil.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Pharm, LabMol Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.; Andrade, CH (corresponding author), Univ Campinas UNICAMP, Inst Biol, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Dept Genet Evolut Microbiol & Immunol, Campinas, SP, Brazil.
EM carolina@ufg.br
RI Neves, Bruno Junior/E-6295-2016; Costa, Fabio/E-1181-2012; de Carvalho e
   Silva, Arthur/S-7803-2018; Capatti Cassiano, Gustavo/G-5728-2013
OI Costa, Fabio/0000-0001-9969-7300; de Carvalho e Silva,
   Arthur/0000-0001-9866-3344; De Paula Sousa, Bruna
   Katiele/0000-0002-3204-5591; Capatti Cassiano,
   Gustavo/0000-0002-6971-5974; Calit, Juliana/0000-0002-4835-249X; Neves,
   Bruno/0000-0002-1309-8743
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [405996/2016-0, 400760/2014-2]; FAPESPFundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2018/05926-2, 2017/02353-9, 2012/16525-2,
   2017/18611-7, 2018/07007-4, 2013/13119-6, 2018/24878-9, 2015/20774-6];
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil
   (CAPES)CAPES [001]; Instituto Serrapilheira [G-1709-16618]
FX CA was supported by CNPq (grant 400760/2014-2) and FAPESP #2017/02353-9.
   FC was supported by FAPESP (Grants #2012/16525-2, #2017/18611-7, and
   2018/07007-4). DB was supported by FAPESP (Grant #2013/13119-6),
   Instituto Serrapilheira (Grant #G-1709-16618), and CNPq (Grant
   405996/2016-0). JC was supported by FAPESP (Fellowship #2018/24878-9).
   GC was supported by FAPESP (Fellowship 2015/20774-6). KT was supported
   by FAPESP (Fellowship 2018/05926-2). This study was financed in part by
   the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil
   (CAPES) - Finance Code 001.
CR Aher RB, 2017, SAR QSAR ENVIRON RES, V28, P390, DOI 10.1080/1062936X.2017.1326401
   ANDERSON S, 1984, J MOL GRAPHICS, V2, P83, DOI 10.1016/0263-7855(84)80060-0
   Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131
   Ashley EA, 2014, NEW ENGL J MED, V371, P411, DOI 10.1056/NEJMoa1314981
   Ashley EA, 2018, LANCET, V391, P1608, DOI 10.1016/S0140-6736(18)30324-6
   Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535
   Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797
   Bansal A, 2018, P NATL ACAD SCI USA, V115, P774, DOI 10.1073/pnas.1715443115
   Berthold MR, 2008, STUD CLASS DATA ANAL, P319, DOI 10.1145/1656274.1656280
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Billker O, 2004, CELL, V117, P503, DOI 10.1016/S0092-8674(04)00449-0
   Blagborough Andrew M, 2013, Methods Mol Biol, V923, P577
   Bordoli L, 2009, NAT PROTOC, V4, P1, DOI 10.1038/nprot.2008.197
   Bracchi-Ricard V, 2000, BIOCHEM J, V347, P255, DOI 10.1042/0264-6021:3470255
   Braga RC, 2013, CURR TOP MED CHEM, V13, P1127, DOI 10.2174/1568026611313090010
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Bullard Kristen M, 2013, Methods Mol Biol, V993, P205, DOI 10.1007/978-1-62703-342-8_14
   Burrows JN, 2017, MALARIA J, V16, DOI 10.1186/s12936-016-1675-x
   Calit J, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.01053-18, 10.1128/aac.01053-18]
   CARHART RE, 1985, J CHEM INF COMP SCI, V25, P64, DOI 10.1021/ci00046a002
   CHAKRABARTI D, 1993, P NATL ACAD SCI USA, V90, P12020, DOI 10.1073/pnas.90.24.12020
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Crowther GJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149996
   Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095
   Dill J. D., 1981, 182 NAT M AM CHEM SO, P23
   Durant JL, 2002, J CHEM INF COMP SCI, V42, P1273, DOI 10.1021/ci010132r
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   GADALETA D, 2016, INT J QUANT STRUCT P, V1, P45, DOI DOI 10.4018/IJQSPR.2016010102
   Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097
   Garuti L, 2015, CURR MED CHEM, V22, P695, DOI 10.2174/0929867321666141216125528
   Gedeck P, 2006, J CHEM INF MODEL, V46, P1924, DOI 10.1021/ci050413p
   Govindasamy K, 2016, MOL MICROBIOL, V102, P349, DOI 10.1111/mmi.13466
   Hartwig CL, 2013, METHODS MALARIA RES, P122
   Hawkins PCD, 2007, J MED CHEM, V50, P74, DOI 10.1021/jm0603365
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Huang ZN, 2016, J CHEM INF MODEL, V56, P21, DOI 10.1021/acs.jcim.5b00299
   Jain V, 2017, STRUCTURE, V25, P1495, DOI 10.1016/j.str.2017.07.015
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Jebiwott S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079171
   Katsuno K, 2015, NAT REV DRUG DISCOV, V14, P751, DOI 10.1038/nrd4683
   Ko J, 2012, NUCLEIC ACIDS RES, V40, pW294, DOI 10.1093/nar/gks493
   LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Lucet IS, 2012, FUTURE MED CHEM, V4, P2295, DOI [10.4155/fmc.12.183, 10.4155/FMC.12.183]
   MORGAN HL, 1965, J CHEM DOC, V5, P107, DOI 10.1021/c160017a018
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Nagamune Kisaburo, 2008, V47, P70
   National Center for Biotechnology Information, 2009, PUBCHEM BIOASSAY DAT
   Netzeva TI, 2005, ATLA-ALTERN LAB ANIM, V33, P155, DOI 10.1177/026119290503300209
   Neves BJ, 2016, EXPERT OPIN DRUG DIS, V11, P557, DOI 10.1080/17460441.2016.1178230
   Patel TS, 2019, ARCH PHARM, V352, DOI 10.1002/ardp.201900099
   Patel TS, 2019, BIOORGAN MED CHEM, V27, P3574, DOI 10.1016/j.bmc.2019.06.038
   Rogers D, 2010, J CHEM INF MODEL, V50, P742, DOI 10.1021/ci100050t
   Rogers WO, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-10
   Sebastian S, 2012, CELL HOST MICROBE, V12, P9, DOI 10.1016/j.chom.2012.05.014
   Sondergaard CR, 2011, J CHEM THEORY COMPUT, V7, P2284, DOI 10.1021/ct200133y
   Srivastava IK, 1999, MOL MICROBIOL, V33, P704, DOI 10.1046/j.1365-2958.1999.01515.x
   Svetnik V, 2003, J CHEM INF COMP SCI, V43, P1947, DOI 10.1021/ci034160g
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   Triglia T, 1998, EMBO J, V17, P3807, DOI 10.1093/emboj/17.14.3807
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Wang YL, 2012, NUCLEIC ACIDS RES, V40, pD400, DOI 10.1093/nar/gkr1132
   Ward P, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-79
   Waters NC, 2003, EXPERT OPIN THER TAR, V7, P7, DOI 10.1517/eott.7.1.7.21162
   Wellems TE, 2001, J INFECT DIS, V184, P770, DOI 10.1086/322858
   Who, 2017, WORLD MAL REP 2017, V196
   WHO, 2018, WORLD MAL REP 2018
   Witkowski B, 2013, ANTIMICROB AGENTS CH, V57, P914, DOI 10.1128/AAC.01868-12
   Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130
   Zhang SX, 2006, J CHEM INF MODEL, V46, P1984, DOI 10.1021/ci060132x
NR 75
TC 3
Z9 3
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-2646
J9 FRONT CHEM
JI Front. Chem.
PD NOV 21
PY 2019
VL 7
AR 773
DI 10.3389/fchem.2019.00773
PG 14
WC Chemistry, Multidisciplinary
SC Chemistry
GA JT9FC
UT WOS:000501286100001
PM 31824917
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Goncalves, RL
   Menezes, GD
   Sussuchi, L
   Moreli, ML
   Mottin, M
   Andrade, CH
   Pereira, M
   da Silva, RA
AF Goncalves, Ricardo Lemes
   Menezes, Gabriela de Lima
   Sussuchi, Luciane
   Moreli, Marcos Lazaro
   Mottin, Melina
   Andrade, Carolina Horta
   Pereira, Maristela
   da Silva, Roosevelt Alves
TI Dynamic behavior of Dengue and Zika viruses NS1 protein reveals
   monomer?monomer interaction mechanisms and insights to rational drug
   design
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article
ID MEMBRANE ASSOCIATION
AB Communicated by Ramaswamy H. Sarma
C1 [Goncalves, Ricardo Lemes; Menezes, Gabriela de Lima; Sussuchi, Luciane; Moreli, Marcos Lazaro; da Silva, Roosevelt Alves] Univ Fed Goias, Nucleo Colaborat BioSistemas, Jatai, Go, Brazil.
   [Mottin, Melina; Andrade, Carolina Horta] Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.
   [Pereira, Maristela] Univ Fed Goias, Lab Biol Mol, Goiania, Go, Brazil.
RP da Silva, RA (corresponding author), Univ Fed Goias, Nucleo Colaborat BioSistemas, Jatai, Go, Brazil.
EM rooseveltfisicaufg@gmail.com
RI da Silva, Roosevelt Alves/AAF-1577-2019; Mottin, Melina/D-8700-2016;
   Andrade, Carolina/C-3960-2014; Sussuchi da Silva, Luciane/A-8833-2019
OI da Silva, Roosevelt Alves/0000-0001-5624-4790; Mottin,
   Melina/0000-0003-0878-9029; Moreli, Marcos/0000-0002-9599-361X; Andrade,
   Carolina/0000-0003-0101-1492; de Lima Menezes,
   Gabriela/0000-0002-8944-8148; Sussuchi da Silva,
   Luciane/0000-0002-7470-4655; Lemes Goncalves,
   Ricardo/0000-0002-3498-965X
FU Ministerio da Ciencia e Tecnologia/Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (MCTI/CNPq)National Council for Scientific and
   Technological Development (CNPq); Fundacao de Amparo a Pesquisa do
   Estado de Goias (FAPEG); Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior -CAPESCAPES [23038010055/2013-29]; Financiadora de
   Estrategias de Interacao Patogeno-Hospedeiro (INCT-IPH); CAPESCAPES;
   CNPq/FAPEG DCR [300508/2017-4]; L'Oreal-UNESCO-ABC Para Mulheres na
   Ciencia; L'Oreal-UNESCO International Rising Talents
FX This work, performed at Universidade Federal de Goias, was supported by
   the Ministerio da Ciencia e Tecnologia/Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (MCTI/CNPq), Fundacao de Amparo
   a Pesquisa do Estado de Goias (FAPEG), Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior -CAPES (grant 23038010055/2013-29),
   Financiadora de Estrategias de Interacao Patogeno-Hospedeiro (INCT-IPH).
   Additionally, RLG, LS and GLM were supported by fellowships from CAPES.
   MM appreciate financial support of CNPq/FAPEG DCR (grant 300508/2017-4).
   CHA is CNPq research fellow and also thanks the 'L'Oreal-UNESCO-ABC Para
   Mulheres na Ciencia' and 'L'Oreal-UNESCO International Rising Talents'
   for the awards and fellowships received, which partially funded this
   work.
CR Akey DL, 2014, SCIENCE, V343, P881, DOI 10.1126/science.1247749
   Allonso D, 2015, J VIROL, V89, P11871, DOI 10.1128/JVI.01342-15
   Brown WC, 2016, NAT STRUCT MOL BIOL, V23, P865, DOI 10.1038/nsmb.3268
   Chang HH, 2017, B WORLD HEALTH ORGAN, V95, P517, DOI 10.2471/BLT.16.182105
   Collins MH, 2017, CLIN THER, V39, P1519, DOI 10.1016/j.clinthera.2017.07.001
   Ekins S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005023
   Lai YC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07308-3
   Mottin M, 2017, BIOCHEM BIOPH RES CO, V492, P643, DOI 10.1016/j.bbrc.2017.03.070
   Muller DA, 2013, ANTIVIR RES, V98, P192, DOI 10.1016/j.antiviral.2013.03.008
   Puerta-Guardo H, 2019, CELL REP, V26, P1598, DOI 10.1016/j.celrep.2019.01.036
   Raza S, 2020, IEEE ACM T COMPUT BI, V17, P1751, DOI 10.1109/TCBB.2019.2911081
   Scaturro P, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005277
   Silva EM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057514
   Watterson D, 2016, ANTIVIR RES, V130, P7, DOI 10.1016/j.antiviral.2016.02.014
   Xu XY, 2016, EMBO J, V35, P2170, DOI 10.15252/embj.201695290
NR 15
TC 3
Z9 3
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
PD SEP 21
PY 2020
VL 38
IS 14
BP 4353
EP 4363
DI 10.1080/07391102.2019.1677504
EA OCT 2019
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NC4CJ
UT WOS:000491024800001
PM 31594455
DA 2020-12-01
ER

PT J
AU Lima, MNN
   Neves, BJ
   Cassiano, GC
   Gomes, MN
   Tomaz, KCP
   Ferreira, LT
   Tavella, TA
   Calit, J
   Bargieri, DY
   Muratov, EN
   Costa, FTM
   Andrade, CH
AF Lima, Marilia N. N.
   Neves, Bruno J.
   Cassiano, Gustavo C.
   Gomes, Marcelo N.
   Tomaz, Kaira C. P.
   Ferreira, Leticia T.
   Tavella, Tatyana A.
   Calit, Juliana
   Bargieri, Daniel Y.
   Muratov, Eugene N.
   Costa, Fabio T. M.
   Andrade, Carolina Horta
TI Chalcones as a basis for computer-aided drug design: innovative
   approaches to tackle
SO FUTURE MEDICINAL CHEMISTRY
LA English
DT Article
DE drug design; experimental validation; molecular docking; pharmacophore;
   Plasmodium falciparum; virtual screening
ID PROTEIN; DISCOVERY; PREDICTION; CURATION; VERIFY; SERVER; TRUST; CDK
AB Aim: Computer-aided drug design approaches were applied to identify chalcones with antiplasmodial activity. Methodology: The virtual screening was performed as follows: structural standardization of in-house database of chalcones; identification of potential Plasmodium falciparum protein targets for the chalcones; homology modeling of the predicted P. falciparum targets; molecular docking studies; and in vitro experimental validation. Results: Using these models, we prioritized 16 chalcones with potential antiplasmodial activity, for further experimental evaluation. Among them, LabMol-86 and LabMol-87 showed potent in vitro antiplasmodial activity against P. falciparum, while LabMol-63 and LabMol-73 were potent inhibitors of Plasodium berghei progression into mosquito stages. Conclusion: Our results encourage the exploration of chalcones in hit-to-lead optimization studies for tackling malaria.
   [GRAPHICS]
   .
C1 [Lima, Marilia N. N.; Neves, Bruno J.; Gomes, Marcelo N.; Andrade, Carolina Horta] Univ Fed Goias, Fac Pharm, Lab Mol Modeling & Drug Design, LabMol, Rua 240,Qd 87, BR-74605170 Goiania, Go, Brazil.
   [Neves, Bruno J.] Univ Ctr Anapolis UniEVANGEL, Lab Cheminformat, BR-75083515 Anapolis, Go, Brazil.
   [Cassiano, Gustavo C.; Tomaz, Kaira C. P.; Ferreira, Leticia T.; Tavella, Tatyana A.; Costa, Fabio T. M.; Andrade, Carolina Horta] Univ Estadual Campinas, Prof Dr Luiz da Jacintho Silva Dept Genet Evolut, Lab Trop Dis, Inst Biol, BR-13083970 Campinas, SP, Brazil.
   [Gomes, Marcelo N.] FAMA, Metropolitan Coll Anapolis, BR-75064780 Anapolis, Go, Brazil.
   [Gomes, Marcelo N.] InSiChem Drug Discovery, BR-75132903 Anapolis, Go, Brazil.
   [Calit, Juliana; Bargieri, Daniel Y.] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Sao Paulo, SP, Brazil.
   [Muratov, Eugene N.] Univ N Carolina, Eshelman Sch Pharm, Div Chem Biol & Med Chem, Lab Mol Modeling, Chapel Hill, NC 27955 USA.
   [Muratov, Eugene N.] Odessa Natl Polytech Univ, Dept Chem Technol, UA-65000 Odessa, Ukraine.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Pharm, Lab Mol Modeling & Drug Design, LabMol, Rua 240,Qd 87, BR-74605170 Goiania, Go, Brazil.; Andrade, CH (corresponding author), Univ Estadual Campinas, Prof Dr Luiz da Jacintho Silva Dept Genet Evolut, Lab Trop Dis, Inst Biol, BR-13083970 Campinas, SP, Brazil.
EM carolina@ufg.br
RI Costa, Fabio/E-1181-2012; Neves, Bruno Junior/E-6295-2016; Capatti
   Cassiano, Gustavo/G-5728-2013
OI Costa, Fabio/0000-0001-9969-7300; Calit, Juliana/0000-0002-4835-249X;
   Neves, Bruno/0000-0002-1309-8743; Capatti Cassiano,
   Gustavo/0000-0002-6971-5974
FU Brazilian funding agency, CNPqNational Council for Scientific and
   Technological Development (CNPq); Brazilian funding agency, CAPESCAPES;
   Brazilian funding agency, FAPESPFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP); Brazilian funding agency, FAPEG; NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [1U01CA207160, R01-GM114015]; CNPqNational Council for Scientific
   and Technological Development (CNPq) [400760/2014-2, 405996/2016-0];
   FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2017/02353-9, 2012/16525-2, 2017/18611-7, 2018/0700-4, 2013/13119-6,
   2018/24878-9, 2017/20774-6, 2017/02031-1]; Instituto Serrapilheira
   [G-1709-16618]
FX The authors thank Brazilian funding agencies, CNPq, CAPES, FAPESP and
   FAPEG for financial support and fellowships. CH Andrade and FTM Costa
   are productivity fellows of CNPq. EN Muratov gratefully thank the NIH
   (grants 1U01CA207160 and R01-GM114015). CH Andrade is supported by CNPq
   (grant 400760/2014-2) and FAPESP #2017/02353-9. FTM Costa is supported
   by FAPESP (grants #2012/16525-2, #2017/18611-7 and 2018/0700-4). DY
   Bargieri is supported by FAPESP (grant #2013/13119-6), Instituto
   Serrapilheira (grant #G-1709-16618) and CNPq (grant 405996/2016-0). J
   Calit, GG Cassiano and LT Ferreira were supported by FAPESP (Fellowships
   #2018/24878-9, #2017/20774-6, and #2017/02031-1, respectively). We are
   grateful to ChemAxon (https://chemaxon.com/) for providing academic
   license of their program. The authors have no other relevant
   affiliations or financial involvement with any organization or entity
   with a financial interest in or financial conflict with the subject
   matter or materials discussed in the manuscript apart from those
   disclosed.
CR Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131
   Ashley EA, 2014, NEW ENGL J MED, V371, P411, DOI 10.1056/NEJMoa1314981
   Aurrecoechea C, 2009, NUCLEIC ACIDS RES, V37, pD539, DOI 10.1093/nar/gkn814
   Banks JL, 2005, J COMPUT CHEM, V26, P1752, DOI 10.1002/jcc.20292
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Blackman MJ, 2008, CELL MICROBIOL, V10, P1925, DOI 10.1111/j.1462-5822.2008.01176.x
   Blagborough Andrew M, 2013, Methods Mol Biol, V923, P577
   Bordoli L, 2009, NAT PROTOC, V4, P1, DOI 10.1038/nprot.2008.197
   BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201
   Burrows JN, 2017, MALARIA J, V16, DOI 10.1186/s12936-016-1675-x
   Calit J, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.01053-18, 10.1128/aac.01053-18]
   COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916
   Deshmukh AS, 2015, MOL MICROBIOL, V98, P17, DOI 10.1111/mmi.13099
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   Geyer JA, 2009, BIOORG MED CHEM LETT, V19, P1982, DOI 10.1016/j.bmcl.2009.02.042
   Gomes MN, 2017, MOLECULES, V22, DOI 10.3390/molecules22081210
   Gomes MN, 2017, EUR J MED CHEM, V137, P126, DOI 10.1016/j.ejmech.2017.05.026
   Gomes MN, 2017, BIOORG MED CHEM LETT, V27, P2459, DOI 10.1016/j.bmcl.2017.04.010
   Graeser R, 1996, MOL BIOCHEM PARASIT, V79, P125, DOI 10.1016/0166-6851(96)02643-6
   Graeser R, 1996, MOL BIOCHEM PARASIT, V82, P37, DOI 10.1016/0166-6851(96)02716-8
   Hartwig CL, 2013, METHODS MALARIA RES, P122
   Klabunde T, 2007, BRIT J PHARMACOL, V152, P5, DOI 10.1038/sj.bjp.0707308
   Ko J, 2012, NUCLEIC ACIDS RES, V40, pW294, DOI 10.1093/nar/gks493
   LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148
   Liu XF, 2010, NUCLEIC ACIDS RES, V38, pW609, DOI 10.1093/nar/gkq300
   LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0
   Moura PA, 2009, ANTIMICROB AGENTS CH, V53, P4968, DOI 10.1128/AAC.00882-09
   Plouffe DM, 2016, CELL HOST MICROBE, V19, P114, DOI 10.1016/j.chom.2015.12.001
   Pollastri MP, 2011, FUTURE MED CHEM, V3, P1307, DOI [10.4155/FMC.11.92, 10.4155/fmc.11.92]
   Rogers WO, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-10
   Rognan D, 2007, BRIT J PHARMACOL, V152, P38, DOI 10.1038/sj.bjp.0707307
   Sharma N, 2012, J MED CHEM, V55, P297, DOI 10.1021/jm201216y
   Singh A, 2017, CHEM BIOL DRUG DES, V90, P590, DOI 10.1111/cbdd.12982
   Smit FJ, 2014, BIOORGAN MED CHEM, V22, P1128, DOI 10.1016/j.bmc.2013.12.032
   Sondergaard CR, 2011, J CHEM THEORY COMPUT, V7, P2284, DOI 10.1021/ct200133y
   Sriwilaijaroen Nongluk, 2006, Southeast Asian Journal of Tropical Medicine and Public Health, V37, P607
   Tiwari H. K., 2011, Journal of Pharmacy Research, V4, P1253
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   Wang X, 2016, J CHEM INF MODEL, V56, P1175, DOI 10.1021/acs.jcim.5b00690
   Witkowski B, 2013, ANTIMICROB AGENTS CH, V57, P914, DOI 10.1128/AAC.01868-12
   Wright MH, 2014, NAT CHEM, V6, P112, DOI [10.1038/NCHEM.1830, 10.1038/nchem.1830]
NR 47
TC 0
Z9 0
U1 2
U2 8
PU FUTURE SCI LTD
PI LONDON
PA UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND
SN 1756-8919
EI 1756-8927
J9 FUTURE MED CHEM
JI Future Med. Chem.
PD OCT
PY 2019
VL 11
IS 20
BP 2635
EP 2646
DI 10.4155/fmc-2018-0255
PG 12
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA JQ3GW
UT WOS:000498838500003
PM 31556721
OA Green Published
DA 2020-12-01
ER

PT J
AU Dantas, RF
   Evangelista, TCS
   Neves, B
   Senger, MR
   Andrade, CH
   Ferreira, SB
   Silva, FP
AF Dantas, Rafael Ferreira
   Santos Evangelista, Tereza Cristina
   Neves, Bruno Junior
   Senger, Mario Roberto
   Andrade, Carolina Horta
   Ferreira, Sabrina Baptista
   Silva-Junior, Floriano Paes
TI Dealing with frequent hitters in drug discovery: a multidisciplinary
   view on the issue of filtering compounds on biological screenings
SO EXPERT OPINION ON DRUG DISCOVERY
LA English
DT Review
DE Chemical biology; cheminformatics; multi-target; PAINS;
   polypharmacology; privileged scaffolds
ID ASSAY INTERFERENCE COMPOUNDS; DIVERSITY-ORIENTED SYNTHESIS;
   FLUORESCENT-PROBE; COMPOUNDS PAINS; SYNTHETIC ACCESSIBILITY; PRIVILEGED
   STRUCTURES; ACTIVITY PROFILES; CHEMICAL PROBES; DESIGN; CURCUMIN
AB Introduction: The timely identification biologically active chemicals, in disease relevant screening assays, is a major endeavor in drug discovery. The existence of frequent hitters (FHs) in non-related assays poses a formidable challenge in terms of whether to consider these molecules as chemical gold or promiscuous non-selective reactive trash (also known as PAINS - pan assay interference compounds). Areas covered: In this review, the authors bring together expertize in synthetic chemistry, cheminformatics and biochemistry, three key areas for dealing with FHs. They discuss synthetic methods facilitating preparation of chemically diverse molecular libraries, while favoring activity in the biological space. They also survey and discuss recent computational advances in the prediction of PAINS from chemical structures. Finally, they review experimental approaches for the validation of the biological activity of screening hits and discuss alternatives for exploiting promiscuity and chemical reactivity. Expert opinion: It's essential to develop more efficient computational methods to reliably recognize PAINS in distinct molecular environments. Accordingly, advances in synthetic chemistry hold the promise to provide a better quality of chemical matter for drug discovery. Medicinal chemists should be more open to screening for hits showing biologically complex mechanisms of action rather than discarding molecules that may prove valuable as innovative disease treatments.
C1 [Dantas, Rafael Ferreira; Senger, Mario Roberto; Silva-Junior, Floriano Paes] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Bioquim Expt & Computac Farmacos, LaBECFar, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Santos Evangelista, Tereza Cristina; Ferreira, Sabrina Baptista] Univ Fed Rio de Janeiro, Inst Quim, Lab Sintese Organ & Prospeccao Biol, LaSOPB, Rio De Janeiro, Brazil.
   [Neves, Bruno Junior] UniEVANGELICA, Ctr Univ Anapolis, Lab Cheminformat, LabChem, Anapolis, Brazil.
   [Andrade, Carolina Horta] Univ Fed Goias, Fac Farm, Lab Mol Modeling & Drug Design, LabMol, Goiania, Go, Brazil.
RP Silva, FP (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Bioquim Expt & Computac Farmacos, LaBECFar, BR-21040900 Rio De Janeiro, RJ, Brazil.
EM floriano@ioc.fiocruz.br
RI Neves, Bruno Junior/E-6295-2016; Silva-Jr, Floriano/B-1343-2013;
   Ferreira, Sabrina Baptista/AAC-9368-2019; Andrade, Carolina/C-3960-2014
OI Silva-Jr, Floriano/0000-0003-4560-1291; Ferreira, Sabrina
   Baptista/0000-0002-5363-0888; Senger, Mario/0000-0003-2384-2692; Neves,
   Bruno/0000-0002-1309-8743; Andrade, Carolina/0000-0003-0101-1492
FU National Council of Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); State of Rio de Janeiro Foundation (FAPERJ)Carlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ);
   Coordination for the Improvement of Higher Education Personnel
   (CAPES)CAPES; Goias Research Foundation (FAPEG)
FX This work was funded by The National Council of Technological and
   Scientific Development (CNPq), the State of Rio de Janeiro and Goias
   Research Foundations (FAPERJ and FAPEG, respectively) and the
   Coordination for the Improvement of Higher Education Personnel (CAPES).
CR Aldrich C, 2017, J MED CHEM, V60, P2165, DOI 10.1021/acs.jmedchem.7b00229
   Alves VM, 2016, GREEN CHEM, V18, P4348, DOI [10.1039/C6GC01492E, 10.1039/c6gc01492e]
   [Anonymous], 2018, J MED CHEM
   Auld DS, 2018, INTERFERENCES LUCIFE
   Auld DS, 2017, ASSAY GUIDANCE MANUA, P875
   Baell J, 2014, NATURE, V513, P481, DOI 10.1038/513481a
   Baell JB, 2018, ACS CHEM BIOL, V13, P36, DOI 10.1021/acschembio.7b00903
   Baell JB, 2015, ACS MED CHEM LETT, V6, P229, DOI 10.1021/acsmedchemlett.5b00032
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Bajorath J, 2016, MOL INFORM, V35, P583, DOI 10.1002/minf.201600030
   Bajorath Jurgen, 2014, F1000Res, V3, P233, DOI 10.12688/f1000research.5426.1
   Baker M, 2010, NAT METHODS, V7, P787, DOI 10.1038/nmeth1010-787
   Baskin II, 2016, EXPERT OPIN DRUG DIS, V11, P785, DOI 10.1080/17460441.2016.1201262
   Bobba KN, 2017, CHEM COMMUN, V53, P11213, DOI 10.1039/c7cc05043g
   Bollag G, 2012, NAT REV DRUG DISCOV, V11, P873, DOI 10.1038/nrd3847
   Bolognesi ML, 2019, ACS MED CHEM LETT, V10, P273, DOI 10.1021/acsmedchemlett.9b00039
   Bose DS, 2012, EUR J MED CHEM, V50, P27, DOI 10.1016/j.ejmech.2012.01.014
   Bose DS, 2010, J COMB CHEM, V12, P100, DOI 10.1021/cc900129t
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Bruns RF, 2012, J MED CHEM, V55, P9763, DOI 10.1021/jm301008n
   Capuzzi SJ, 2017, J CHEM INF MODEL, V57, P417, DOI 10.1021/acs.jcim.6b00465
   Catto M, 2019, MULTITARGET DRUG DES, P93
   Coan KED, 2008, J AM CHEM SOC, V130, P9606, DOI 10.1021/ja802977h
   Coan KED, 2009, J MED CHEM, V52, P2067, DOI 10.1021/jm801605r
   Copeland RA, 2013, EVALUATION OF ENZYME INHIBITORS IN DRUG DISCOVERY: A GUIDE FOR MEDICINAL CHEMISTS AND PHARMACOLOGISTS, 2ND EDITION, P1, DOI 10.1002/9781118540398
   Dahlin JL, 2015, ASSAY GUIDANCE MANUA, P815
   Dai X, 2016, ANAL CHIM ACTA, V922, P64, DOI 10.1016/j.aca.2016.04.003
   DeSimone RW, 2004, COMB CHEM HIGH T SCR, V7, P473, DOI 10.2174/1386207043328544
   Dimova D, 2017, RSC ADV, V7, P58, DOI 10.1039/c6ra27247a
   Dobson CM, 2004, NATURE, V432, P824, DOI 10.1038/nature03192
   Dong H, 2015, BIOORG MED CHEM LETT, V25, P3585, DOI 10.1016/j.bmcl.2015.06.076
   EVANS BE, 1988, J MED CHEM, V31, P2235, DOI 10.1021/jm00120a002
   Feng BY, 2006, NAT PROTOC, V1, P550, DOI 10.1038/nprot.2006.77
   Fu RG, 2017, EUR J MED CHEM, V136, P195, DOI 10.1016/j.ejmech.2017.05.016
   Fukunishi Y, 2014, J CHEM INF MODEL, V54, P3259, DOI 10.1021/ci500568d
   Gaulton A, 2017, NUCLEIC ACIDS RES, V45, pD945, DOI 10.1093/nar/gkw1074
   Gerry CJ, 2018, NAT REV DRUG DISCOV, V17, P333, DOI 10.1038/nrd.2018.53
   Gilberg E, 2017, RSC ADV, V7, P35638, DOI 10.1039/c7ra06736d
   Gilberg E, 2016, J MED CHEM, V59, P10285, DOI 10.1021/acs.jmedchem.6b01314
   Goh GB, 2017, J COMPUT CHEM, V38, P1291, DOI 10.1002/jcc.24764
   Gomes MN, 2017, EUR J MED CHEM, V137, P126, DOI 10.1016/j.ejmech.2017.05.026
   Granseth E, 2007, MOL MEMBR BIOL, V24, P329, DOI 10.1080/09687680701413882
   Hajduk PJ, 2011, NATURE, V470, P42, DOI 10.1038/470042a
   Harris CJ, 2011, COMB CHEM HIGH T SCR, V14, P521
   Hasson SA, 2013, CURR OPIN CHEM BIOL, V17, P329, DOI 10.1016/j.cbpa.2013.04.018
   Hu Ye, 2013, F1000Res, V2, P144, DOI 10.12688/f1000research.2-144.v1
   Hu Y, 2017, CHEM BIOL DRUG DES, V89, P834, DOI 10.1111/cbdd.12919
   Hu Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126838
   Hu Y, 2014, COMPUT STRUCT BIOTEC, V9, DOI 10.5936/csbj.201401003
   Hu Y, 2013, EUR J MED CHEM, V69, P393, DOI 10.1016/j.ejmech.2013.08.044
   Huang Q, 2011, J CHEM INF MODEL, V51, P2768, DOI 10.1021/ci100216g
   Huang Q, 2010, J MOL GRAPH MODEL, V28, P775, DOI 10.1016/j.jmgm.2010.02.002
   Irwin JJ, 2015, J MED CHEM, V58, P7076, DOI 10.1021/acs.jmedchem.5b01105
   Jasial S, 2018, J MED CHEM, V61, P10255, DOI 10.1021/acs.jmedchem.8b01404
   Jasial S, 2017, J MED CHEM, V60, P3879, DOI 10.1021/acs.jmedchem.7b00154
   Jasial S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153873
   Karageorgis G, 2019, SYNTHESIS-STUTTGART, V51, P55, DOI 10.1055/s-0037-1610368
   Kenny PW, 2017, J CHEM INF MODEL, V57, P2640, DOI 10.1021/acs.jcim.7b00313
   Kidd SL, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00460
   Kim GJ, 2014, RSC ADV, V4, P18731, DOI 10.1039/c4ra01933d
   Komatsu H, 2014, ANGEW CHEM INT EDIT, V53, P3993, DOI 10.1002/anie.201311192
   Lagorce D, 2017, DRUG DISCOV TODAY, V22, P1131, DOI 10.1016/j.drudis.2017.05.017
   Lagorce D, 2011, BIOINFORMATICS, V27, P2018, DOI 10.1093/bioinformatics/btr333
   Laraia L, 2017, ANGEW CHEM INT EDIT, V56, P2145, DOI 10.1002/anie.201611670
   Li CE, 2018, BIOCONJUGATE CHEM, V29, P1823, DOI 10.1021/acs.bioconjchem.8b00180
   Lipkin MJ, 2008, COMB CHEM HIGH T SCR, V11, P482, DOI 10.2174/138620708784911492
   Liu YW, 2015, CHEM-EUR J, V21, P4747, DOI 10.1002/chem.201406004
   Low YS, 2018, J CHEM INF MODEL, V58, P2203, DOI 10.1021/acs.jcim.8b00450
   Macarron R, 2011, NAT REV DRUG DISCOV, V10, P188, DOI 10.1038/nrd3368
   Mayr LM, 2009, CURR OPIN PHARMACOL, V9, P580, DOI 10.1016/j.coph.2009.08.004
   McCarthy A, 2010, CHEM BIOL, V17, P549, DOI 10.1016/j.chembiol.2010.06.005
   Miljkovic F, 2019, J COMPUT AID MOL DES, V33, P559, DOI 10.1007/s10822-019-00198-9
   Miljkovic F, 2018, MOLECULES, V23, DOI 10.3390/molecules23102434
   Mogharbel BF, 2018, INT J NANOMED, V13, P5823, DOI 10.2147/IJN.S171099
   Morphy R, 2009, CURR PHARM DESIGN, V15, P587, DOI 10.2174/138161209787315594
   Muegge I, 2016, EXPERT OPIN DRUG DIS, V11, P137, DOI 10.1517/17460441.2016.1117070
   Neves BJ, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01275
   Neves BJ, 2016, J MED CHEM, V59, P7075, DOI 10.1021/acs.jmedchem.5b02038
   Pang LF, 2017, IND ENG CHEM RES, V56, P7650, DOI 10.1021/acs.iecr.7b02133
   Pavlinov I, 2019, ORG BIOMOL CHEM, V17, P1608, DOI 10.1039/c8ob02327a
   Peters JU, 2013, J MED CHEM, V56, P8955, DOI 10.1021/jm400856t
   Plamont MA, 2016, P NATL ACAD SCI USA, V113, P497, DOI 10.1073/pnas.1513094113
   Pourreza N, 2018, SPECTROCHIM ACTA A, V192, P251, DOI 10.1016/j.saa.2017.11.003
   Prabhu J, 2017, SENSOR ACTUAT B-CHEM, V238, P306, DOI 10.1016/j.snb.2016.07.018
   Qiao Z, 2019, TALANTA, V195, P850, DOI 10.1016/j.talanta.2018.12.014
   Ramsay RR, 2018, CLIN TRANSL MED, V7, DOI 10.1186/s40169-017-0181-2
   Rao HB, 2010, J COMPUT CHEM, V31, P752, DOI 10.1002/jcc.21347
   Reja SI, 2017, CHEM COMMUN, V53, P3701, DOI 10.1039/c6cc09127j
   Reker D, 2019, NAT CHEM, V11, P402, DOI 10.1038/s41557-019-0234-9
   Ruijter E, 2011, ANGEW CHEM INT EDIT, V50, P6234, DOI 10.1002/anie.201006515
   Sato T, 2018, BIOORG MED CHEM LETT, V28, P3520, DOI 10.1016/j.bmcl.2018.10.002
   Saubern S, 2011, MOL INFORM, V30, P847, DOI 10.1002/minf.201100076
   Senger MR, 2016, DRUG DISCOV TODAY, V21, P868, DOI 10.1016/j.drudis.2016.02.004
   Si GF, 2019, DYES PIGMENTS, V163, P509, DOI 10.1016/j.dyepig.2018.12.003
   Simeonov A., 2018, INTERFERENCE FLUORES
   Siramshetty VB, 2018, DRUG DISCOV TODAY, V23, P481, DOI 10.1016/j.drudis.2017.07.003
   Sittampalam SG, 2004, ASSAY GUIDANCE MANUA
   Son S, 2019, ANGEW CHEM INT EDIT, V58, P1739, DOI 10.1002/anie.201813032
   Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Stork C, 2019, J CHEM INF MODEL, V59, P1030, DOI 10.1021/acs.jcim.8b00677
   Stork C, 2018, CHEMMEDCHEM, V13, P564, DOI 10.1002/cmdc.201700673
   Svenda J, 2015, ANGEW CHEM INT EDIT, V54, P5596, DOI 10.1002/anie.201500112
   Tan L, 2008, J CHEM INF MODEL, V48, P2308, DOI 10.1021/ci800322y
   Thorne N, 2010, CURR OPIN CHEM BIOL, V14, P315, DOI 10.1016/j.cbpa.2010.03.020
   Vapnik V. N., 2010, NATURE STAT LEARNING
   Verma S, 2015, CURR MED CHEM, V22, P1603, DOI 10.2174/0929867322666150209151209
   Volochnyuk DM, 2019, DRUG DISCOV TODAY, V24, P390, DOI 10.1016/j.drudis.2018.10.016
   Walker JR, 2017, ACS CHEM BIOL, V12, P1028, DOI 10.1021/acschembio.6b01129
   Wang KP, 2019, TALANTA, V196, P243, DOI 10.1016/j.talanta.2018.12.060
   Wang P, 2017, CHEM-EUR J, V23, P10800, DOI 10.1002/chem.201701384
   Wang XS, 2016, DRUG DISCOV TODAY, V21, P118, DOI 10.1016/j.drudis.2015.08.004
   Wang YK, 2016, ACS MED CHEM LETT, V7, P852, DOI 10.1021/acsmedchemlett.6b00230
   Wassermann AM, 2015, NAT CHEM BIOL, V11, P958, DOI 10.1038/nchembio.1936
   Watanabe H, 2018, BIOORG MED CHEM LETT, V28, P3242, DOI 10.1016/j.bmcl.2018.08.009
   Weidel E, 2014, FUTURE MED CHEM, V6, P2057, DOI [10.4155/FMC.14.142, 10.4155/fmc.14.142]
   Williamson AE, 2016, ACS CENTRAL SCI, V2, P687, DOI 10.1021/acscentsci.6b00086
   Yang JJ, 2016, J CHEMINFORMATICS, V8, DOI 10.1186/s13321-016-0137-3
   Yao PHE, 2017, ACS COMB SCI, V19, P271, DOI 10.1021/acscombsci.7b00004
   Yuan ZW, 2019, TALANTA, V198, P323, DOI 10.1016/j.talanta.2019.02.009
   Yue YK, 2014, SENSOR ACTUAT B-CHEM, V202, P551, DOI 10.1016/j.snb.2014.05.119
   Zhang CY, 2018, CHEM COMMUN, V54, P3835, DOI 10.1039/c8cc01917g
   Zhang XL, 2015, SCI REP-UK, V5, DOI 10.1038/srep13116
   Zhao HY, 2015, EXPERT OPIN DRUG DIS, V10, P781, DOI 10.1517/17460441.2015.1041496
NR 124
TC 4
Z9 4
U1 4
U2 18
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1746-0441
EI 1746-045X
J9 EXPERT OPIN DRUG DIS
JI Expert. Opin. Drug Discov.
PD DEC 2
PY 2019
VL 14
IS 12
BP 1269
EP 1282
DI 10.1080/17460441.2019.1654453
EA AUG 2019
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA JJ1GF
UT WOS:000481554000001
PM 31416369
DA 2020-12-01
ER

PT J
AU de Oliveira, AA
   Neves, B
   Silva, LD
   Soares, CMD
   Andrade, CH
   Pereira, M
AF de Oliveira, Amanda Alves
   Neves, Bruno Junior
   Silva, Livia do Carmo
   de Almeida Soares, Celia Maria
   Andrade, Carolina Horta
   Pereira, Maristela
TI Drug Repurposing for Paracoccidioidomycosis Through a Computational
   Chemogenomics Framework
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE Paracoccidioides species; drug repurposing; genome-wide alignment; gene
   essentiality; molecular docking; in vitro assays
ID WEB SERVER; DATABASE; TARGET; TOR2; DISCOVERY; GENOME; MODEL; DEG
AB Paracoccidioidomycosis (PCM) is the most prevalent endemic mycosis in Latin America. The disease is caused by fungi of the genus Paracoccidioides and mainly affects low-income rural workers after inhalation of fungal conidia suspended in the air. The current arsenal of chemotherapeutic agents requires long-term administration protocols. In addition, chemotherapy is related to a significantly increased frequency of disease relapse, high toxicity, and incomplete elimination of the fungus. Due to the limitations of current anti-PCM drugs, we developed a computational drug repurposing-chemogenomics approach to identify approved drugs or drug candidates in clinical trials with anti-PCM activity. In contrast to the one-drug-one-target paradigm, our chemogenomics approach attempts to predict interactions between drugs, and Paracoccidioides protein targets. To achieve this goal, we designed a workflow with the following steps: (a) compilation and preparation of Paracoccidioides spp. genome data; (b) identification of orthologous proteins among the isolates; (c) identification of homologous proteins in publicly available drug-target databases; (d) selection of Paracoccidioides essential targets using validated genes from Saccharomyces cerevisiae; (e) homology modeling and molecular docking studies; and (f) experimental validation of selected candidates. We prioritized 14 compounds. Two antineoplastic drug candidates (vistusertib and BGT-226) predicted to be inhibitors of phosphatidylinositol 3-kinase TOR2 showed antifungal activity at low micromolar concentrations (< 10 mu M). Four antifungal azole drugs (bifonazole, luliconazole, butoconazole, and sertaconazole) showed antifungal activity at low nanomolar concentrations, validating our methodology. The results suggest our strategy for predicting new anti-PCM drugs is useful. Finally, we could recommend hit-to-lead optimization studies to improve potency and selectivity, as well as pharmaceutical formulations to improve oral bioavailability of the antifungal azoles identified.
C1 [de Oliveira, Amanda Alves; Silva, Livia do Carmo; de Almeida Soares, Celia Maria; Pereira, Maristela] Univ Fed Goias, Lab Biol Mol, Goiania, Go, Brazil.
   [de Oliveira, Amanda Alves; Neves, Bruno Junior] UniEVANGELICA, Ctr Univ Anapolis, Lab Cheminformat, Anapolis, Brazil.
   [Andrade, Carolina Horta] Univ Fed Goias, Lab Modelagem Mol & Design Medicamentos, Fac Farm, Goiania, Go, Brazil.
RP Pereira, M (corresponding author), Univ Fed Goias, Lab Biol Mol, Goiania, Go, Brazil.
EM maristelaufg@gmail.com
RI Neves, Bruno Junior/E-6295-2016; Silva, Livia do Carmo/ABA-3999-2020;
   Andrade, Carolina/C-3960-2014
OI Andrade, Carolina/0000-0003-0101-1492; Neves, Bruno/0000-0002-1309-8743
FU Programa de Apoio a Nucleos de Excelencia (PRONEX); Fundacao de Amparo a
   Pesquisa do Estado de Goias (FAPEG); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq) [201710267000506];
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES
   [001, 23038.010055/2013-29]; Instituto Nacional de Ciencia e Tecnologia
   para Inovacao Farmaceutica (INCT-IF) [201810267000022]
FX This work was supported by Programa de Apoio a Nucleos de Excelencia
   (PRONEX), Fundacao de Amparo a Pesquisa do Estado de Goias (FAPEG),
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) -
   processo numero 201710267000506, Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES) - Finance Code 001 processo numero
   23038.010055/2013-29, Instituto Nacional de Ciencia e Tecnologia para
   Inovacao Farmaceutica (INCT-IF) processo numero 201810267000022. CS, CA,
   and MP are research fellows of CNPq. We are also grateful to OpenEye
   Scientific Software, Inc. for providing academic licenses of their
   software.
CR Anandakrishnan R, 2012, NUCLEIC ACIDS RES, V40, pW537, DOI 10.1093/nar/gks375
   Andrade CH, 2019, CURR MED CHEM, V26, P4355, DOI 10.2174/0929867325666180309114824
   Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
   Aube J, 2012, ACS MED CHEM LETT, V3, P442, DOI 10.1021/ml300114c
   Beghyn TB, 2011, J MED CHEM, V54, P3222, DOI 10.1021/jm1014617
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Bordoli L, 2009, NAT PROTOC, V4, P1, DOI 10.1038/nprot.2008.197
   Bredel M, 2004, NAT REV GENET, V5, P262, DOI 10.1038/nrg1317
   Broad Institute, 2018, FUNGAL GENOMICS
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Chong CR, 2007, NATURE, V448, P645, DOI 10.1038/448645a
   Clinical Laboratory Standards Institute, 2008, REF METH BROTH DIL A, P13
   Silva ACADE, 2013, J CLIN MICROBIOL, V51, P1250, DOI 10.1128/JCM.02914-12
   Desjardins CA, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002345
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Goh GB, 2017, J COMPUT CHEM, V38, P1291, DOI 10.1002/jcc.24764
   HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105
   Hurle MR, 2013, CLIN PHARMACOL THER, V93, P335, DOI 10.1038/clpt.2013.1
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Janke C, 2014, J CELL BIOL, V206, P461, DOI 10.1083/jcb.201406055
   Jin GX, 2014, DRUG DISCOV TODAY, V19, P637, DOI 10.1016/j.drudis.2013.11.005
   Jing YK, 2018, AAPS J, V20, DOI 10.1208/s12248-018-0210-0
   Joffe LS, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00535
   KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F
   Sbaraglini ML, 2016, CURR TOP MED CHEM, V16, P2201, DOI 10.2174/1568026616666160216154309
   Law V, 2014, NUCLEIC ACIDS RES, V42, pD1091, DOI 10.1093/nar/gkt1068
   Li YH, 2018, NUCLEIC ACIDS RES, V46, pD1121, DOI 10.1093/nar/gkx1076
   Martinez R, 2017, J FUNGI, V3, DOI 10.3390/jof3010001
   McGann M, 2012, J COMPUT AID MOL DES, V26, P897, DOI 10.1007/s10822-012-9584-8
   Neves BJ, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003435
   Njoroge M, 2014, CHEM REV, V114, P11138, DOI 10.1021/cr500098f
   Novac N, 2013, TRENDS PHARMACOL SCI, V34, P267, DOI 10.1016/j.tips.2013.03.004
   OpenEye Scientific Software, 2019, OMEGA V 2 5 1
   OpenEye Scientific Software, 2013, QUACPAC V 1 6 3
   OpenEye Scientific Software, 2017, OEDOCKING V 3 2 0
   Queiroz-Telles F, 2017, LANCET INFECT DIS, V17, pE367, DOI 10.1016/S1473-3099(17)30306-7
   Rodrigues JPGLM, 2012, NUCLEIC ACIDS RES, V40, pW323, DOI 10.1093/nar/gks376
   Rose PW, 2015, NUCLEIC ACIDS RES, V43, pD345, DOI 10.1093/nar/gku1214
   Roskoski R, 2016, PHARMACOL RES, V103, P26, DOI 10.1016/j.phrs.2015.10.021
   Sagatova AA, 2015, ANTIMICROB AGENTS CH, V59, P4982, DOI 10.1128/AAC.00925-15
   Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780
   Shikanai-Yasuda MA, 2017, REV SOC BRAS MED TRO, V50, P715, DOI 10.1590/0037-8682-0230-2017
   Shikanai-Yasuda MA, 2015, REV INST MED TROP SP, V57, P31, DOI 10.1590/S0036-46652015000700007
   Silva LC, 2018, FUTURE MICROBIOL, V13, P1523, DOI 10.2217/fmb-2018-0175
   Wang Y, 2015, NUCLEIC ACIDS RES, V43, pW78, DOI 10.1093/nar/gkv487
   Zhang R, 2004, NUCLEIC ACIDS RES, V32, pD271, DOI 10.1093/nar/gkh024
   Zhang R, 2009, NUCLEIC ACIDS RES, V37, pD455, DOI 10.1093/nar/gkn858
NR 47
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD JUN 12
PY 2019
VL 10
AR 1301
DI 10.3389/fmicb.2019.01301
PG 10
WC Microbiology
SC Microbiology
GA IC7MF
UT WOS:000471157700001
PM 31244810
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Alves, VM
   Hwang, D
   Muratov, E
   Sokolsky-Papkov, M
   Varlamova, E
   Vinod, N
   Lim, C
   Andrade, CH
   Tropsha, A
   Kabanov, A
AF Alves, Vinicius M.
   Hwang, Duhyeong
   Muratov, Eugene
   Sokolsky-Papkov, Marina
   Varlamova, Ekaterina
   Vinod, Natasha
   Lim, Chaemin
   Andrade, Carolina H.
   Tropsha, Alexander
   Kabanov, Alexander
TI Cheminformatics-driven discovery of polymeric micelle formulations for
   poorly soluble drugs
SO SCIENCE ADVANCES
LA English
DT Article
ID DELIVERY-SYSTEMS; QUANTITATIVE STRUCTURE; SKIN SENSITIZATION; QSAR
   MODELS; SOLUBILITY; PREDICTION; RELEASE; CURATION; FRAGMENT; CARRIERS
AB Many drug candidates fail therapeutic development because of poor aqueous solubility. We have conceived a computer-aided strategy to enable polymeric micelle-based delivery of poorly soluble drugs. We built models predicting both drug loading efficiency (LE) and loading capacity (LC) using novel descriptors of drug-polymer complexes. These models were employed for virtual screening of drug libraries, and eight drugs predicted to have either high LE and high LC or low LE and low LC were selected. Three putative positives, as well as three putative negative hits, were confirmed experimentally (implying 75% prediction accuracy). Fortuitously, simvastatin, a putative negative hit, was found to have the desired micelle solubility. Podophyllotoxin and simvastatin (LE of 95% and 87% and LC of 43% and 41%, respectively) were among the top five polymeric micelle-soluble compounds ever studied experimentally. The success of the strategy described herein suggests its broad utility for designing drug delivery systems.
C1 [Alves, Vinicius M.; Muratov, Eugene; Tropsha, Alexander] Univ N Carolina, UNC Eshelman Sch Pharm, Div Chem Biol & Med Chem, Lab Mol Modeling, Chapel Hill, NC 27599 USA.
   [Alves, Vinicius M.; Varlamova, Ekaterina; Andrade, Carolina H.] Univ Fed Goias, Fac Pharm, Lab Mol Modeling & Drug Design, BR-74605170 Goiania, Go, Brazil.
   [Hwang, Duhyeong; Sokolsky-Papkov, Marina; Vinod, Natasha; Lim, Chaemin; Kabanov, Alexander] Univ N Carolina, UNC Eshelman Sch Pharm, Div Pharmacoengn & Mol Pharmaceut, Ctr Nanotechnol Drug Delivery, Chapel Hill, NC 27599 USA.
   [Muratov, Eugene] Univ Fed Paraiba, Dept Pharmaceut Sci, BR-58059 Joao Pessoa, Paraiba, Brazil.
   [Vinod, Natasha] Univ N Carolina, UNC NC State Joint Dept Biomed Engn, Chapel Hill, NC 27599 USA.
   [Kabanov, Alexander] Moscow MV Lomonosov State Univ, Fac Chem, Lab Chem Design Bionanomat, Moscow 119992, Russia.
RP Tropsha, A (corresponding author), Univ N Carolina, UNC Eshelman Sch Pharm, Div Chem Biol & Med Chem, Lab Mol Modeling, Chapel Hill, NC 27599 USA.; Kabanov, A (corresponding author), Univ N Carolina, UNC Eshelman Sch Pharm, Div Pharmacoengn & Mol Pharmaceut, Ctr Nanotechnol Drug Delivery, Chapel Hill, NC 27599 USA.; Kabanov, A (corresponding author), Moscow MV Lomonosov State Univ, Fac Chem, Lab Chem Design Bionanomat, Moscow 119992, Russia.
EM alex_tropsha@unc.edu; kabanov@email.unc.edu
RI Kabanov, Alexander V/N-3356-2013; Tropsha, Alexander/AAB-8324-2020;
   Alves, Vinicius M./G-7955-2015; Kabanov, Alexander/AAY-5751-2020;
   Andrade, Carolina/C-3960-2014; Muratov, Eugene/C-4454-2014
OI Kabanov, Alexander V/0000-0002-3665-946X; Alves, Vinicius
   M./0000-0002-6182-1748; Kabanov, Alexander/0000-0002-3665-946X; Tropsha,
   Alexander/0000-0003-3802-8896; Andrade, Carolina/0000-0003-0101-1492;
   Vinod, Natasha/0000-0003-1007-361X; Muratov, Eugene/0000-0003-4616-7036
FU Carolina Center of Cancer Nanotechnology Excellence of the National
   Cancer Institute Alliance for Nanotechnology in Cancer [U54CA198999];
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [1U01CA207160, GM5105946]; NC TraCS
   Institute [4DR11404]; UNC Eshelman School of Pharmacy; University Cancer
   Research Fund through the Lineberger Comprehensive Cancer Center;
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [400760/2014-2]; CAPESCAPES; NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [U54CA198999, U54CA198999,
   U54CA198999, U54CA198999, U54CA198999, U54CA198999, U54CA198999,
   U54CA198999, U54CA198999, U01CA207160, U54CA198999, U54CA198999,
   U54CA198999, U54CA198999, U54CA198999, U54CA198999, U54CA198999,
   U54CA198999, U54CA198999, U01CA207160, U54CA198999, U54CA198999,
   U54CA198999, U54CA198999] Funding Source: NIH RePORTER
FX This study was supported, in part, by Carolina Center of Cancer
   Nanotechnology Excellence (U54CA198999) of the National Cancer Institute
   Alliance for Nanotechnology in Cancer, the NIH (grants 1U01CA207160 and
   GM5105946), the NC TraCS Institute (award 4DR11404), and The Carolina
   Partnership, a strategic partnership between the UNC Eshelman School of
   Pharmacy and The University Cancer Research Fund through the Lineberger
   Comprehensive Cancer Center. V.M.A., E.M., and C.H.A. thank CNPq (grant
   400760/2014-2). V.M.A. also thanks CAPES for PhD scholarship.
CR Alves VM, 2018, FOOD CHEM TOXICOL, V112, P526, DOI 10.1016/j.fct.2017.04.008
   Alves VM, 2016, GREEN CHEM, V18, P6501, DOI [10.1039/c6gc01836j, 10.1039/C6GC01836J]
   Alves VM, 2015, TOXICOL APPL PHARM, V284, P262, DOI 10.1016/j.taap.2014.12.014
   Badalkhani-Khamseh F, 2017, J COMPUT AID MOL DES, V31, P1097, DOI 10.1007/s10822-017-0091-9
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Breiman L., 1984, STAT PROBABILITY SER, V19
   Caccavo D, 2017, EUR J PHARM BIOPHARM, V121, P24, DOI 10.1016/j.ejpb.2017.08.016
   Cern A, 2017, J CONTROL RELEASE, V252, P18, DOI 10.1016/j.jconrel.2017.02.015
   Cern A, 2012, J CONTROL RELEASE, V160, P147, DOI 10.1016/j.jconrel.2011.11.029
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Dearden J. C., 2016, IJQSPR, V1, P1, DOI DOI 10.4018/IJQSPR.2016010101
   Dhar S, 2011, P NATL ACAD SCI USA, V108, P1850, DOI 10.1073/pnas.1011379108
   Downs GM, 2002, REV COMP CH, V18, P1, DOI 10.1002/0471433519.ch1
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Frederix PWJM, 2018, CHEM SOC REV, V47, P3470, DOI 10.1039/c8cs00040a
   Golbraikh A, 2003, J COMPUT AID MOL DES, V17, P241, DOI 10.1023/A:1025386326946
   Han YC, 2012, MOL PHARMACEUT, V9, P2302, DOI 10.1021/mp300159u
   He ZJ, 2015, J CONTROL RELEASE, V208, P67, DOI 10.1016/j.jconrel.2015.02.024
   Heimbach T, 2007, BIOTECHNOL PHARM ASP, V5, P157
   Huynh L, 2012, NANOMED-NANOTECHNOL, V8, P20, DOI 10.1016/j.nano.2011.05.006
   Kabanov AV, 2009, ANGEW CHEM INT EDIT, V48, P5418, DOI 10.1002/anie.200900441
   Kabanov AV, 2002, J CONTROL RELEASE, V82, P189, DOI 10.1016/S0168-3659(02)00009-3
   Kuramochi H, 2009, J PHYS CHEM B, V113, P15181, DOI 10.1021/jp906155z
   Kuz'min VE, 2008, J COMPUT AID MOL DES, V22, P403, DOI 10.1007/s10822-008-9179-6
   Kuz'min VE, 2007, J MED CHEM, V50, P4205, DOI 10.1021/jm0704806
   Kuz'min VE, 2009, QSAR COMB SCI, V28, P664, DOI 10.1002/qsar.200860117
   Lipinski C., 2002, AM PHARM REV, V5, P82
   Lu J, 2011, J COMPUT AID MOL DES, V25, P885, DOI 10.1007/s10822-011-9472-7
   Luxenhofer R, 2010, BIOMATERIALS, V31, P4972, DOI 10.1016/j.biomaterials.2010.02.057
   Meunier M, 2017, INT J PHARMACEUT, V526, P157, DOI 10.1016/j.ijpharm.2017.04.043
   Muratov EN, 2012, MOL INFORM, V31, P202, DOI 10.1002/minf.201100129
   Muratov EN, 2010, FUTURE MED CHEM, V2, P1205, DOI 10.4155/FMC.10.194
   Murtaza G, 2012, ACTA POL PHARM, V69, P581
   Nag A., 2011, COMPUTER AIDED DRUG
   Oprisiu I, 2012, MOL INFORM, V31, P491, DOI 10.1002/minf.201200006
   Potta T, 2014, BIOMATERIALS, V35, P1977, DOI 10.1016/j.biomaterials.2013.10.069
   Rasulev B, 2017, ACS APPL MATER INTER, V9, P1781, DOI 10.1021/acsami.6b12766
   SCHULZ A, 2012, POLYM PREPR, V53, P354
   Schulz A, 2014, ACS NANO, V8, P2686, DOI 10.1021/nn406388t
   Seo Y, 2015, POLYM ADVAN TECHNOL, V26, P837, DOI 10.1002/pat.3556
   Shi CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8449
   Slowing II, 2008, ADV DRUG DELIVER REV, V60, P1278, DOI 10.1016/j.addr.2008.03.012
   Stegemann S, 2007, EUR J PHARM SCI, V31, P249, DOI 10.1016/j.ejps.2007.05.110
   Thota N, 2015, FRONT MATER, V2, DOI 10.3389/fmats.2015.00064
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Varnek A, 2008, CURR COMPUT-AID DRUG, V4, P191, DOI 10.2174/157340908785747465
   Vityuk N., 1999, PATTERN RECOGNIT IMA, V3, P521
   Wan XM, 2018, ACS NANO, V12, P2426, DOI 10.1021/acsnano.7b07878
   WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967
   Wu WS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119575
   Yamamoto T, 2007, J CONTROL RELEASE, V123, P11, DOI 10.1016/j.jconrel.2007.07.008
   Yang T, 2007, INT J PHARMACEUT, V338, P317, DOI 10.1016/j.ijpharm.2007.02.011
   Yu X, 2017, CHEM-EUR J, V23, P4467, DOI 10.1002/chem.201602472
   Zakharov AV, 2016, MOL PHARMACEUT, V13, P545, DOI 10.1021/acs.molpharmaceut.5b00762
NR 56
TC 5
Z9 5
U1 4
U2 12
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375-2548
J9 SCI ADV
JI Sci. Adv.
PD JUN
PY 2019
VL 5
IS 6
AR eaav9784
DI 10.1126/sciadv.aav9784
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA IG4UK
UT WOS:000473798500050
PM 31249867
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Oliveira, EA
   Brito, IA
   Lima, ML
   Romanelli, M
   Moreira, JT
   Neves, BJ
   Andrade, CH
   Sartorelli, P
   Tempone, AG
   Costa-Silva, TA
   Lago, JHG
AF Oliveira, Emerson A.
   Brito, Ivanildo A.
   Lima, Marta L.
   Romanelli, Maiara
   Moreira-Filho, Jose T.
   Neves, Bruno J.
   Andrade, Carolina H.
   Sartorelli, Patricia
   Tempone, Andre G.
   Costa-Silva, Thais A.
   Lago, Joao Henrique G.
TI Antitrypanosomal Activity of Acetogenins Isolated from the Seeds of
   Porcelia macrocarpa Is Associated with Alterations in Both Plasma
   Membrane Electric Potential and Mitochondrial Membrane Potential
SO JOURNAL OF NATURAL PRODUCTS
LA English
DT Article
ID TRYPANOSOMA-CRUZI; DRUG; MODELS; PREDICTION; ACID
AB As part of a drug discovery program aimed at the identification of anti-Trypanosoma cruzi metabolites from Brazilian flora, four acetogenins (1-4) were isolated from the seeds of Porcelia macrocarpa and were identified by NMR spectroscopy and HRESIMS. The new compounds 1 and 2 displayed activity against the trypomastigote (IC50 = 0.4 and 3.6 mu M) and amastigote (IC50 = 23.0 and 27.7 mu M) forms. The structurally related known compound 3 showed less potency to the amastigotes, with an IC50 value of 58 mu M, while the known compound 4 was inactive. To evaluate the potential mechanisms for parasite death, parameters were evaluated by fluorometric assays: (i) plasma membrane permeability, (ii) plasma membrane electric potential (Delta Psi(m)), (iii) reactive oxygen species production, and (iv) mitochondrial membrane potential (Delta Psi(m)). The results obtained indicated that compounds 1 and 2 depolarize plasma membranes, affecting Delta Psi(p), and Delta Psi(m) and contributing to the observed cellular damage and disturbing the bioenergetic system. In silico studies of pharmacokinetics and toxicity (ADMET) properties predicted that all compounds were nonmutagenic, noncarcinogenic, nongenotoxic, and weak hERG blockers. Additionally, none of the isolated acetogenins 1-4 were predicted as pan-assay interference compounds.
C1 [Oliveira, Emerson A.; Sartorelli, Patricia] Univ Fed Sao Paulo, Inst Environm Chem & Pharmaceut Sci, BR-09972270 Sao Paulo, Brazil.
   [Brito, Ivanildo A.; Costa-Silva, Thais A.; Lago, Joao Henrique G.] Fed Univ ABC, Ctr Nat & Human Sci, BR-09606045 Sao Paulo, Brazil.
   [Lima, Marta L.; Romanelli, Maiara; Tempone, Andre G.] Adolfo Lutz Inst, Ctr Parasitol & Mycol, BR-01246000 Sao Paulo, Brazil.
   [Moreira-Filho, Jose T.; Neves, Bruno J.; Andrade, Carolina H.] Univ Fed Goias, Fac Pharm, BR-74605170 Goiania, Go, Brazil.
   [Neves, Bruno J.] Univ Ctr Anapolis, Lab Cheminformat, BR-75083515 Anapolis, Go, Brazil.
RP Costa-Silva, TA; Lago, JHG (corresponding author), Fed Univ ABC, Ctr Nat & Human Sci, BR-09606045 Sao Paulo, Brazil.
EM tha_isbio@yahoo.com.br; joao.lago@ufabc.edu.br
RI Neves, Bruno Junior/E-6295-2016; Neves, Bruno/R-7068-2019; Sartorelli,
   Patricia/AAN-2911-2020; Moreira-Filho, Jose Teofilo/S-8333-2018; Lago,
   Joao/W-5238-2019; Tempone, Andre/ABA-2231-2020; Andrade,
   Carolina/C-3960-2014; Tempone, Andre Gustavo/E-5932-2012
OI Neves, Bruno/0000-0002-1309-8743; Moreira-Filho, Jose
   Teofilo/0000-0002-0777-280X; Lago, Joao/0000-0002-1193-8374; Tempone,
   Andre/0000-0003-2559-7344; Andrade, Carolina/0000-0003-0101-1492;
   Tempone, Andre Gustavo/0000-0002-9900-1470
FU CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior)CAPES; CNPq (Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico)National Council for Scientific and Technological
   Development (CNPq); Fundacao de Amparo a Pesquisa do Estado de Sao
   PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [FAPESP 2018/07885-1, 2018/10279-6]; CNPqNational Council for Scientific
   and Technological Development (CNPq)
FX The authors are grateful for the financial support and fellowships
   provided by CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior), CNPq (Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico), and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP 2018/07885-1 and 2018/10279-6). This publication is part of the
   activities of the Research Network Natural Products against Neglected
   Diseases (ResNetNPND): http://www.uni-muenster.de/ResNetNPND/.J.H.G.L.,
   A.G.T., C.H.A., and P.S. thank CNPq for the scientific awards.
CR Akatsuka A, 2016, PHARMACOL RES PERSPE, V4, DOI 10.1002/prp2.246
   Conserva GAA, 2019, PHYTOMEDICINE, V54, P302, DOI 10.1016/j.phymed.2018.09.236
   Baell J, 2014, NATURE, V513, P481, DOI 10.1038/513481a
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Barrett MP, 2012, BRIT MED BULL, V104, P175, DOI 10.1093/bmb/lds031
   Bestetti RB, 2011, INT J CARDIOL, V147, P172, DOI 10.1016/j.ijcard.2010.12.020
   Bradford C. V., 1986, TETRAHEDRON, V42, P1117
   Braga RC, 2015, MOL INFORM, V34, P698, DOI 10.1002/minf.201500040
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1399, DOI 10.2174/1568026614666140506124442
   Chaves MH, 1997, PHYTOCHEMISTRY, V44, P523, DOI 10.1016/S0031-9422(96)00542-0
   Cheng FX, 2012, J CHEM INF MODEL, V52, P3099, DOI 10.1021/ci300367a
   Cheng FX, 2011, J CHEM INF MODEL, V51, P996, DOI 10.1021/ci200028n
   Croft SL, 2005, TRENDS PARASITOL, V21, P508, DOI 10.1016/j.pt.2005.08.026
   Escobar-Khondiker M, 2007, J NEUROSCI, V27, P7827, DOI 10.1523/JNEUROSCI.1644-07.2007
   Hansen K, 2009, J CHEM INF MODEL, V49, P2077, DOI 10.1021/ci900161g
   Irwin JJ, 2015, J MED CHEM, V58, P7076, DOI 10.1021/acs.jmedchem.5b01105
   Keil VC, 2011, PFLUG ARCH EUR J PHY, V462, P693, DOI 10.1007/s00424-011-1012-8
   Konno H, 2004, BIOORG MED CHEM LETT, V14, P629, DOI 10.1016/j.bmcl.2003.11.057
   Lago JHG, 2007, PLANTA MED, V73, P292, DOI 10.1055/s-2007-967108
   Lagunin A, 2009, QSAR COMB SCI, V28, P806, DOI 10.1002/qsar.200860192
   Le Ven J, 2014, J AGR FOOD CHEM, V62, P8696, DOI 10.1021/jf501174j
   Li D, 2014, MOL PHARMACEUT, V11, P716, DOI 10.1021/mp400450m
   Londero VS, 2018, BIOORG CHEM, V78, P307, DOI 10.1016/j.bioorg.2018.03.025
   Mangoni ML, 2005, J BIOL CHEM, V280, P984, DOI 10.1074/jbc.M410795200
   Menna-Barreto RFS, 2009, MICRON, V40, P157, DOI 10.1016/j.micron.2008.08.003
   Morillo CA, 2015, NEW ENGL J MED, V373, P1295, DOI 10.1056/NEJMoa1507574
   Murray NA., 1993, SYSTEMATIC BOT MONOG, V40, P1, DOI DOI 10.2307/25027830
   Nakanishi S, 2011, BBA-BIOENERGETICS, V1807, P1170, DOI 10.1016/j.bbabio.2011.05.012
   Rea A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002556
   Reimao JQ, 2008, PARASITOL RES, V103, P1445, DOI 10.1007/s00436-008-1154-6
   Ribeiro GA, 2013, J ANTIMICROB CHEMOTH, V68, P789, DOI 10.1093/jac/dks498
   Luque-Ortega JR, 2010, METHODS MOL BIOL, V618, P393, DOI 10.1007/978-1-60761-594-1_25
   Romanha AJ, 2010, MEM I OSWALDO CRUZ, V105, P233, DOI 10.1590/S0074-02762010000200022
   Santos LD, 2015, MOLECULES, V20, P8168, DOI 10.3390/molecules20058168
   Segall MD, 2014, DRUG DISCOV TODAY, V19, P688, DOI 10.1016/j.drudis.2014.01.006
   Shen J, 2010, J CHEM INF MODEL, V50, P1034, DOI 10.1021/ci100104j
   Silva E.B., 2013, MOLECULES, V18, P13574, DOI DOI 10.3390/MOLECULES181113574
   Tempone AG, 2011, PLANTA MED, V77, P572, DOI 10.1055/s-0030-1250663
   van de Waterbeemd H, 2003, NAT REV DRUG DISCOV, V2, P192, DOI 10.1038/nrd1032
   Waring MJ, 2015, NAT REV DRUG DISCOV, V14, P475, DOI 10.1038/nrd4609
   Yang HB, 2019, BIOINFORMATICS, V35, P1067, DOI 10.1093/bioinformatics/bty707
   Zhao Y, 2005, HELV CHIM ACTA, V88, P349, DOI 10.1002/hlca.200590019
NR 42
TC 4
Z9 4
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0163-3864
EI 1520-6025
J9 J NAT PROD
JI J. Nat. Prod.
PD MAY
PY 2019
VL 82
IS 5
BP 1177
EP 1182
DI 10.1021/acs.jnatprod.8b00890
PG 6
WC Plant Sciences; Chemistry, Medicinal; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy
GA IA2RW
UT WOS:000469410200015
PM 31046273
DA 2020-12-01
ER

PT J
AU Correa, JWD
   Graca, ACD
   Andrade, CH
   Rocha, ML
   Pinheiro, CCD
AF do Nascimento Correa, Jose Wilson
   dos Santos Graca, Anne Carolline
   Andrade, Carolina Horta
   Rocha, Matheus Lavorenti
   de Souza Pinheiro, Carlos Cleomir
TI L-type Ca2+ channel (Ca(v)1.2) blocking by Z. zerumbet (L., SM) and its
   major compound sesquiterpene: In vitro, in vivo and in silico approaches
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Experimental Biology Meeting (EB)
CY APR 06-09, 2019
CL Orlando, FL
SP Amer Assoc Anat, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Pharmacol & Expt Therapeut
RI Correa, Jose/AAY-9641-2020
OI Correa, Jose/0000-0002-9580-3361
FU FAPEAMCAPESCNPq
FX FAPEAMCAPESCNPq
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2019
VL 33
SU 1
MA 818.1
PG 2
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA JM9WB
UT WOS:000496555204035
DA 2020-12-01
ER

PT J
AU Borba, J
   Alves, V
   Silva, A
   Overdahl, K
   Capuzzi, S
   Overdahl, E
   Korn, D
   Silva, R
   Hall, S
   Braga, R
   Kleinstreuer, N
   Andrade, C
   Muratov, E
   Tropsha, A
AF Borba, Joyce
   Alves, Vinicius
   Silva, Arhur
   Overdahl, Kirsten
   Capuzzi, Stephen
   Overdahl, Erik
   Korn, Daniel
   Silva, Ruither
   Hall, Steven
   Braga, Rodolpho
   Kleinstreuer, Nicole
   Andrade, Carolina
   Muratov, Eugene
   Tropsha, Alexander
TI In silico platform as an alternative to animal testing for acute
   toxicity
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT National Meeting of the American-Chemical-Society (ACS)
CY MAR 31-APR 04, 2019
CL Orlando, FL
SP Amer Chem Soc
C1 [Borba, Joyce; Alves, Vinicius; Capuzzi, Stephen; Overdahl, Erik; Korn, Daniel; Silva, Ruither; Muratov, Eugene; Tropsha, Alexander] Univ N Carolina, Lab Mol Modeling, Chapel Hill, NC 27515 USA.
   [Borba, Joyce; Silva, Arhur; Hall, Steven; Braga, Rodolpho; Andrade, Carolina] Univ Fed Goias, Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.
   [Overdahl, Kirsten] Duke Univ, Nicholas Sch Environm, Durham, NC 27708 USA.
   [Kleinstreuer, Nicole] ICVAM, NTP, Res Triangle Pk, NC USA.
EM joycevillaverde@gmail.com
RI Alves, Vinicius M./G-7955-2015; Braga, Rodolpho C/A-9655-2011; Tropsha,
   Alexander/AAB-8324-2020
OI Alves, Vinicius M./0000-0002-6182-1748; Braga, Rodolpho
   C/0000-0003-3814-3464; 
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 31
PY 2019
VL 257
MA 35
PG 2
WC Chemistry, Multidisciplinary
SC Chemistry
GA IN7KL
UT WOS:000478860503862
DA 2020-12-01
ER

PT J
AU Muratov, E
   Alves, V
   Borba, J
   Braga, R
   Capuzzi, S
   Silva, A
   Kleinstreuer, N
   Andrade, C
   Tropsha, A
AF Muratov, Eugene
   Alves, Vinicius
   Borba, Joyce
   Braga, Rodolpho
   Capuzzi, Stephen
   Silva, Arhur
   Kleinstreuer, Nicole
   Andrade, Carolina
   Tropsha, Alexander
TI Comprehensive computational approach for predicting human skin
   sensitization as suggested alternative to animal testing
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT National Meeting of the American-Chemical-Society (ACS)
CY MAR 31-APR 04, 2019
CL Orlando, FL
SP Amer Chem Soc
C1 [Braga, Rodolpho; Silva, Arhur; Andrade, Carolina] Univ Fed Goias, Fac Pharm, Goiania, Go, Brazil.
   [Borba, Joyce] Univ Fed Goias, Chapel Hill, NC USA.
   [Muratov, Eugene; Alves, Vinicius; Capuzzi, Stephen; Tropsha, Alexander] Univ North Carolina Chapel Hill, Chem Biol & Med Chem, Chapel Hill, NC USA.
   [Kleinstreuer, Nicole] NIEHS, Res Triangle Pk, NC USA.
EM murik@email.unc.edu
RI Braga, Rodolpho C/A-9655-2011; Alves, Vinicius M./G-7955-2015; Tropsha,
   Alexander/AAB-8324-2020
OI Braga, Rodolpho C/0000-0003-3814-3464; Alves, Vinicius
   M./0000-0002-6182-1748; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 31
PY 2019
VL 257
MA 116
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA IN7KL
UT WOS:000478860504026
DA 2020-12-01
ER

PT J
AU Conserva, GAA
   da Costa-Silva, TA
   Amaral, M
   Antar, GM
   Neves, BJ
   Andrade, CH
   Tempone, AG
   Lago, JHG
AF Alves Conserva, Geanne A.
   da Costa-Silva, Thais A.
   Amaral, Maiara
   Antar, Guilherme M.
   Neves, Bruno J.
   Andrade, Carolina H.
   Tempone, Andre G.
   Lago, Joao Henrique G.
TI Butenolides from Nectandra oppositifolia (Lauraceae) displayed
   anti-Trypanosoma cruzi activity via deregulation of mitochondria
SO PHYTOMEDICINE
LA English
DT Article
DE Nectandra oppositifolia; Butenolides; Anti-Trypanosoma activity;
   Mitochondrial membrane potential; In silico ADMET
ID IN-VITRO; PREDICTION; MODELS; ASSAY
AB Background: From a previous screening of Brazilian biodiversity for antitrypanosomal activity, the n-hexane extract from twigs of Nectandra oppositifolia (Lauraceae) demonstrated in vitro activity against Trypanosoma cruzi.
   Purpose: To perform the isolation and chemical characterization of bioactive compounds from n-hexane extract from twigs of N. oppositifolia and evaluate their therapeutical potential as well as to elucidate their mechanism of action against T. cruzi.
   Methods/Study design: Bioactivity-guided fractionation of the n-hexane extract from twigs of N. oppositifolia af-forded three related butenolides: isolinderanolide D (1), isolinderanolide E (2) and secosubamolide A (3). These compounds were evaluated in vitro against T. cruzi (trypomastigote and amastigote forms) and against NCTC (L929) cells for mammalian cytotoxicity. Additionally, phenotypic analyzes of compounds-treated parasites were performed: alterations in the plasma membrane permeability, plasma membrane electric potential (Delta Psi(p)), mitochondrial membrane potential (Delta Psi(m)) and induction of ROS.
   Results: Compounds 1-3 were effective against T. cruzi, with IC50 values of 12.9, 29.9 and 12.5 mu M for trypomastigotes and 25.3, 10.1 and 12.3 mu M for intracellular amastigotes. Furthermore, it was observed alteration in the mitochondrial membrane potential (Delta Psi(m)) of parasites treated with butenolides 1-3. These compounds caused no alteration to the parasite plasma membrane, and the deregulation of the mitochondria might be an early event to cell death. In addition, in silico studies showed that all butenolides were predicted to be non-mutagenic, non-carcinogenic, non hERG blockers, with acceptable human intestinal absorption, low inhibitory promiscuity with the main five CYP isoforms, and with high metabolic stability. Otherwise, tested butenolides showed unfavorable blood-brain barrier penetration (BBB +).
   Conclusion: Our results demonstrated the anti-T. cruzi effects of compounds 1-3 isolated from N. oppositifolia and indicated that the lethal effect of these compounds in trypomastigotes of T. cruzi could be associated to the alteration in the mitochondrial membrane potential (Delta Psi(m)).
C1 [Alves Conserva, Geanne A.; da Costa-Silva, Thais A.; Lago, Joao Henrique G.] Univ Fed ABC, Ctr Ciencias Nat & Humans, BR-09210180 Sao Paulo, Brazil.
   [Amaral, Maiara; Tempone, Andre G.] Adolfo Lutz Inst, Ctr Parasitol & Micol, BR-01246902 Sao Paulo, Brazil.
   [Antar, Guilherme M.] Univ Sao Paulo, Inst Biociencias, Dept Bot, BR-05508090 Sao Paulo, Brazil.
   [Neves, Bruno J.] Ctr Univ Ancipolis UniE, Lab Quimioinformat, BR-75070290 Goiania, Go, Brazil.
   [Neves, Bruno J.; Andrade, Carolina H.] Univ Fed Goias, Fac Farm, Lab Modelagem Mol & Drug Design, LabMol, BR-75070290 Goiania, Go, Brazil.
RP Lago, JHG (corresponding author), Chem Biol, Av Estados 5001, BR-09210580 Santo Andre, SP, Brazil.
EM joao.lago@ufabc.edu.br
RI Tempone, Andre/ABA-2231-2020; Neves, Bruno Junior/E-6295-2016; Neves,
   Bruno/R-7068-2019; Lago, Joao/W-5238-2019; Antar, Guilherme/U-7677-2019;
   Tempone, Andre Gustavo/E-5932-2012; Andrade, Carolina/C-3960-2014
OI Tempone, Andre/0000-0003-2559-7344; Neves, Bruno/0000-0002-1309-8743;
   Lago, Joao/0000-0002-1193-8374; Tempone, Andre
   Gustavo/0000-0002-9900-1470; Antar, Guilherme/0000-0001-8109-4544;
   Andrade, Carolina/0000-0003-0101-1492; Amaral,
   Maiara/0000-0002-4079-8905
FU Sao Paulo State Research FoundationFundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [FAPESP 2018/07885-1, 2016/20633-6,
   2015/23403-9]; CAPESCAPES; CNPqNational Council for Scientific and
   Technological Development (CNPq)
FX This work was supported by grants from Sao Paulo State Research
   Foundation (FAPESP 2018/07885-1, 2016/20633-6, and 2015/23403-9). We
   thank CAPES for scholarships for GMA, TACS and MA. We also thank CNPq
   for the grant award to JHGL, AGT and CHA.
CR Alqahtani S, 2017, EXPERT OPIN DRUG MET, V13, P1147, DOI 10.1080/17425255.2017.1389897
   Baell J, 2014, NATURE, V513, P481, DOI 10.1038/513481a
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Bestetti RB, 2011, INT J CARDIOL, V147, P172, DOI 10.1016/j.ijcard.2010.12.020
   Braga RC, 2015, MOL INFORM, V34, P698, DOI 10.1002/minf.201500040
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1399, DOI 10.2174/1568026614666140506124442
   Cheng FX, 2012, J CHEM INF MODEL, V52, P3099, DOI 10.1021/ci300367a
   Cheng FX, 2011, J CHEM INF MODEL, V51, P996, DOI 10.1021/ci200028n
   Corral MJ, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004525
   Croft SL, 2005, TRENDS PARASITOL, V21, P508, DOI 10.1016/j.pt.2005.08.026
   CUNNINGHAM LV, 1972, J GEN MICROBIOL, V70, P491, DOI 10.1099/00221287-70-3-491
   Don R, 2014, PARASITOLOGY, V141, P140, DOI 10.1017/S003118201300142X
   Macias-Villamizar VE, 2015, B LATINOAM CARIBE PL, V14, P317
   Grecco SS, 2016, TETRAHEDRON-ASYMMETR, V27, P793, DOI 10.1016/j.tetasy.2016.07.009
   Hansen K, 2009, J CHEM INF MODEL, V49, P2077, DOI 10.1021/ci900161g
   Hotez PJ, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000300
   Keil VC, 2011, PFLUG ARCH EUR J PHY, V462, P693, DOI 10.1007/s00424-011-1012-8
   Kuo SY, 2008, CHEM PHARM BULL, V56, P97, DOI 10.1248/cpb.56.97
   Lagunin A, 2009, QSAR COMB SCI, V28, P806, DOI 10.1002/qsar.200860192
   Lazarin-Bidoia D, 2016, ANTIMICROB AGENTS CH, V60, P890, DOI 10.1128/AAC.01360-15
   Mangoni ML, 2005, J BIOL CHEM, V280, P984, DOI 10.1074/jbc.M410795200
   Martins LF, 2016, J NAT PROD, V79, P2202, DOI 10.1021/acs.jnatprod.6b00256
   Morillo CA, 2015, NEW ENGL J MED, V373, P1295, DOI 10.1056/NEJMoa1507574
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   Nwaka S, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000440
   Ribeiro GA, 2013, J ANTIMICROB CHEMOTH, V68, P789, DOI 10.1093/jac/dks498
   Luque-Ortega JR, 2010, METHODS MOL BIOL, V618, P393, DOI 10.1007/978-1-60761-594-1_25
   Romanha AJ, 2010, MEM I OSWALDO CRUZ, V105, P233, DOI 10.1590/S0074-02762010000200022
   SEKI K, 1995, PHYTOCHEMISTRY, V40, P1175, DOI 10.1016/0031-9422(95)00399-R
   Shen J, 2010, J CHEM INF MODEL, V50, P1034, DOI 10.1021/ci100104j
   TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3
   Tempone AG, 2011, PLANTA MED, V77, P572, DOI 10.1055/s-0030-1250663
   van de Waterbeemd H, 2003, NAT REV DRUG DISCOV, V2, P192, DOI 10.1038/nrd1032
NR 33
TC 4
Z9 4
U1 0
U2 7
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944-7113
J9 PHYTOMEDICINE
JI Phytomedicine
PD FEB 15
PY 2019
VL 54
BP 302
EP 307
DI 10.1016/j.phymed.2018.09.236
PG 6
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA HN3XW
UT WOS:000460119500030
PM 30668381
DA 2020-12-01
ER

PT J
AU Pippione, AC
   Sainas, S
   Goyal, P
   Fritzson, I
   Cassiano, GC
   Giraudo, A
   Giorgis, M
   Tavella, TA
   Bagnati, R
   Rolando, B
   Caing-Carlsson, R
   Costa, FTM
   Andrade, CH
   Al-Karadaghi, S
   Boschi, D
   Friemann, R
   Lolli, ML
AF Pippione, Agnese C.
   Sainas, Stefano
   Goyal, Parveen
   Fritzson, Ingela
   Cassiano, Gustavo C.
   Giraudo, Alessandro
   Giorgis, Marta
   Tavella, Tatyana A.
   Bagnati, Renzo
   Rolando, Barbara
   Caing-Carlsson, Rhawnie
   Costa, Fabio T. M.
   Andrade, Carolina Horta
   Al-Karadaghi, Salam
   Boschi, Donatella
   Friemann, Rosmarie
   Lolli, Marco L.
TI Hydroxyazole scaffold-based Plasmodium falciparum dihydroorotate
   dehydrogenase inhibitors: Synthesis, biological evaluation and X-ray
   structural studies
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Malaria; Plasmodium falciparum; Dihydroorotate dehydrogenase (DHODH)
   inhibitors; X-ray-crystallography; Scaffold hopping; Pyrazole;
   Bioisosterism
ID POTENT; DESIGN; TARGET; DSM265
AB Plasmodium falciparum dihydroorotate dehydrogenase (PJDHODH) has been clinically validated as a target for antimalarial drug discovery, as a triazolopyrimidine class inhibitor (DSM265) is currently undergoing clinical development. Here, we have identified new hydroxyazole scaffold-based PJDHODH inhibitors belonging to two different chemical series. The first series was designed by a scaffold hopping strategy that exploits the use of hydroxylated azoles. Within this series, the hydroxythiadiazole 3 was identified as the best selective PJDHODH inhibitor (IC50 12.0 mu M). The second series was designed by modulating four different positions of the hydroxypyrazole scaffold. In particular, hydroxypyrazoles 7e and 7f were shown to be active in the low mu M range (IC50 2.8 and 5.3 mu M, respectively). All three compounds, 3, 7e and 7f showed clear selectivity over human DHODH (IC50> 200 mu M), low cytotoxicity, and retained micromolar activity in P. falciparum-infected erythrocytes. The crystallographic structures of PJDHODH in complex with compounds 3 and 7e proved their binding mode, supplying essential data for future optimization of these scaffolds. (C) 2018 Elsevier Masson SAS. All rights reserved.
C1 [Pippione, Agnese C.; Sainas, Stefano; Giraudo, Alessandro; Giorgis, Marta; Rolando, Barbara; Boschi, Donatella; Lolli, Marco L.] Univ Turin, Dept Sci & Drug Technol, Via Pietro Giuria 9, I-10125 Turin, Italy.
   [Goyal, Parveen; Caing-Carlsson, Rhawnie; Friemann, Rosmarie] Univ Gothenburg, Dept Chem & Mol Biol, Box 462, S-40530 Gothenburg, Sweden.
   [Goyal, Parveen] Inst Stem Cell Biol & Regenerat Med, Technol Adv Sci, Bengaluru 560065, India.
   [Fritzson, Ingela] Chemoswed, Celsiusgatan 35, S-21214 Malmo, Sweden.
   [Cassiano, Gustavo C.; Tavella, Tatyana A.; Costa, Fabio T. M.] Univ Estadual Campinas, Dept Genet Evolut & Bioagents, Lab Trop Dis Prof Luiz Jacintho da Silva, BR-13083864 Campinas, SP, Brazil.
   [Bagnati, Renzo] Ist Ric Farmacol Mario Negri IRCCS, Via La Masa 19, I-20156 Milan, Italy.
   [Andrade, Carolina Horta] Univ Fed Goias, LabMol, Fac Pharm, BR-74605170 Goiania, Go, Brazil.
   [Al-Karadaghi, Salam] Lund Univ, Dept Biochem & Struct Biol, Lund, Sweden.
   [Friemann, Rosmarie] Univ Gothenburg, Ctr Antibiot Resistance Res CARe, Box 440, S-40530 Gothenburg, Sweden.
RP Lolli, ML (corresponding author), Univ Turin, Dept Sci & Drug Technol, Via Pietro Giuria 9, I-10125 Turin, Italy.
EM marco.lolli@unito.it
RI Cassiano, Gustavo C/G-5728-2013; Sainas, Stefano/M-8224-2017; Costa,
   Fabio/E-1181-2012; Bagnati, Renzo/J-6492-2018; goyal,
   parveen/W-6345-2019; Andrade, Carolina/C-3960-2014; Goyal,
   Parveen/J-8435-2014
OI Cassiano, Gustavo C/0000-0002-6971-5974; Sainas,
   Stefano/0000-0001-5010-8536; Costa, Fabio/0000-0001-9969-7300; Bagnati,
   Renzo/0000-0002-6535-2686; GIRAUDO, ALESSANDRO/0000-0002-5291-0837;
   Andrade, Carolina/0000-0003-0101-1492; Goyal,
   Parveen/0000-0002-7808-8298
FU University of Turin [LOLM_-RILO_17_01, LOLM_RILO_18_01, BOSD_RILO_17_01,
   BOS-D_RILO_18_01]; Ministero degli Affari Esteri e della Cooperazione
   InternazionaleMinistry of Foreign Affairs and International Cooperation
   (Italy) [PGR00978]; CNPqNational Council for Scientific and
   Technological Development (CNPq); FAPESPFundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2015/20774-6]; CAPESCAPES
FX This research was supported by funding from the University of Turin,
   Ricerca Locale 2016 and 2017 (Grant numbers LOLM_-RILO_17_01,
   LOLM_RILO_18_01, BOSD_RILO_17_01 and BOS-D_RILO_18_01) and from
   Ministero degli Affari Esteri e della Cooperazione Internazionale (Grant
   number PGR00978). FTMC and CHA labs are supported by CNPq and FAPESP
   grants and they are CNPq research fellows. GCC and TAT received FAPESP
   (no 2015/20774-6) and CAPES fellowships, respectively. The authors would
   like to thank Davide Bonanni for the helpful discussions on the compound
   binding mode and for preparing the final crystallo-graphic figures,
   Livio Stevanato for maintaining the NMR instrumentation and Dale James
   Matthew Lawson for proofreading the final manuscript.
CR Boa AN, 2005, BIOORGAN MED CHEM, V13, P1945, DOI 10.1016/j.bmc.2005.01.017
   Bonomo S, 2013, J MOL MODEL, V19, P1099, DOI 10.1007/s00894-012-1643-5
   Burrows JN, 2017, MALARIA J, V16, DOI 10.1186/s12936-016-1675-x
   Deng XY, 2009, J BIOL CHEM, V284, P26999, DOI 10.1074/jbc.M109.028589
   Fritzson I, 2011, MEDCHEMCOMM, V2, P895, DOI 10.1039/c1md00118c
   Giorgis M, 2011, EUR J MED CHEM, V46, P383, DOI 10.1016/j.ejmech.2010.10.029
   Giraudo A, 2018, EUR J MED CHEM, V158, P311, DOI 10.1016/j.ejmech.2018.08.094
   Guillou S, 2010, CHEM-EUR J, V16, P4669, DOI 10.1002/chem.200903442
   Hoelz LVB, 2018, FUTURE MED CHEM, V10, P1853, DOI 10.4155/fmc-2017-0250
   Hurt DE, 2006, ACTA CRYSTALLOGR D, V62, P312, DOI 10.1107/S0907444905042642
   Kees KL, 1996, J MED CHEM, V39, P3920, DOI 10.1021/jm960444z
   Kokkonda S, 2018, ACS OMEGA, V3, P9227, DOI 10.1021/acsomega.8b01573
   Llanos-Cuentas A, 2018, LANCET INFECT DIS, V18, P874, DOI 10.1016/S1473-3099(18)30309-8
   Lolli M, 2015, DRUG DISCOV TODAY, V20, P1018, DOI 10.1016/j.drudis.2015.04.010
   Lolli ML, 2018, RECENT PAT ANTI-CANC, V13, P86, DOI 10.2174/1574892812666171108124218
   Lolli ML, 2012, EUR J MED CHEM, V49, P102, DOI 10.1016/j.ejmech.2011.12.038
   Lolli ML, 2010, J MED CHEM, V53, P4110, DOI 10.1021/jm1001452
   McCarthy JS, 2017, LANCET INFECT DIS, V17, P626, DOI [10.1016/S1473-3099(17)30171-8, 10.1016/s1473-3099(17)30171-8]
   Minkin VI, 2000, ADV HETEROCYCL CHEM, V76, P157, DOI 10.1016/S0065-2725(00)76005-3
   Neidhardt Edie A., 1999, Journal of Molecular Microbiology and Biotechnology, V1, P183
   Ohno R, 2010, J PESTIC SCI, V35, P15, DOI 10.1584/jpestics.G09-50
   Pavadai E, 2016, J CHEM INF MODEL, V56, P548, DOI 10.1021/acs.jcim.5b00680
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Phillips MA, 2008, J MED CHEM, V51, P3649, DOI 10.1021/jm8001026
   Phillips MA, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.50
   Phillips MA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa6645
   Pippione AC, 2018, MEDCHEMCOMM, V9, P963, DOI 10.1039/c8md00068a
   Pippione AC, 2017, MEDCHEMCOMM, V8, P1850, DOI 10.1039/c7md00278e
   Pippione AC, 2017, EUR J MED CHEM, V139, P936, DOI 10.1016/j.ejmech.2017.08.046
   Pippione AC, 2015, MEDCHEMCOMM, V6, P1285, DOI 10.1039/c5md00182j
   Pippione AC, 2018, EUR J MED CHEM, V150, P930, DOI 10.1016/j.ejmech.2018.03.040
   Rahman MT, 2003, TETRAHEDRON, V59, P8383, DOI 10.1016/j.tet.2003.08.054
   Sainas S., 2018, DHODH INHIBITORS LEU, V43, P1
   Sainas S., 2018, J HETEROCYCL CHEM
   Sainas S, 2018, ANNU REP MED CHEM, V51, P1, DOI 10.1016/bs.armc.2018.08.001
   Sainas S, 2018, J MED CHEM, V61, P6034, DOI 10.1021/acs.jmedchem.8b00373
   Sainas S, 2017, EUR J MED CHEM, V129, P287, DOI 10.1016/j.ejmech.2017.02.017
   Savitsky P, 2010, J STRUCT BIOL, V172, P3, DOI 10.1016/j.jsb.2010.06.008
   Singh A, 2017, EUR J MED CHEM, V125, P640, DOI 10.1016/j.ejmech.2016.09.085
   WEINSTOC.LM, 1967, J ORG CHEM, V32, P2823, DOI 10.1021/jo01284a040
NR 40
TC 6
Z9 6
U1 1
U2 11
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD FEB 1
PY 2019
VL 163
BP 266
EP 280
DI 10.1016/j.ejmech.2018.11.044
PG 15
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA HL3FC
UT WOS:000458597300020
PM 30529545
DA 2020-12-01
ER

PT J
AU Melo, CC
   Braga, RC
   Muratov, EN
   Franco, CH
   Moraes, CB
   Freitas, LH
   Andrade, CH
AF Melo-Filho, Cleber C.
   Braga, Rodolpho C.
   Muratov, Eugene N.
   Franco, Caio Haddad
   Moraes, Carolina B.
   Freitas-Junior, Lucio H.
   Andrade, Carolina Horta
TI Discovery of new potent hits against intracellular Trypanosoma cruzi by
   QSAR-based virtual screening
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Chagas disease; QSAR; Virtual screening; High content screening;
   Validated hits; ADMET
ID DRUG DISCOVERY; CHAGAS-DISEASE; RANDOM FOREST; MODELS; PERMEABILITY;
   VALIDATION; SOLUBILITY; CURATION
AB Chagas disease is a neglected tropical disease (NTD) caused by the protozoan parasite Trypanosoma cruzi and is primarily transmitted to humans by the feces of infected Triatominae insects during their blood meal. The disease affects 6-8 million people, mostly in Latin America countries, and kills more people in the region each year than any other parasite-born disease, including malaria. Moreover, patient numbers are currently increasing in non-endemic, developed countries, such as Australia, Japan, Canada, and the United States. The treatment is limited to one drug, benznidazole, which is only effective in the acute phase of the disease and is very toxic. Thus, there is an urgent need to develop new, safer, and effective drugs against the chronic phase of Chagas disease. Using a QSAR-based virtual screening followed by in vitro experimental evaluation, we report herein the identification of novel potent and selective hits against T. cruzi intracellular stage. We developed and validated binary QSAR models for prediction of anti-trypanosomal activity and cytotoxicity against mammalian cells using the best practices for QSAR modeling. These models were then used for virtual screening of a commercial database, leading to the identification of 39 virtual hits. Further in vitro assays showed that seven compounds were potent against intracellular T. cruzi at submicromolar concentrations (EC50 < 1 mu M) and were very selective (SI > 30). Furthermore, other six compounds were also inside the hit criteria for Chagas disease, which presented activity at low micromolar concentrations (EC50 < 10 mu M) against intracellular T. cruzi and were also selective (SI > 15). Moreover, we performed a multi-parameter analysis for the comparison of tested compounds regarding their balance between potency, selectivity, and predicted ADMET properties. In the next studies, the most promising compounds will be submitted to additional in vitro and in vivo assays in acute model of Chagas disease, and can be further optimized for the development of new promising drug candidates against this important yet neglected disease. (C) 2018 Published by Elsevier Masson SAS.
C1 [Melo-Filho, Cleber C.; Braga, Rodolpho C.; Andrade, Carolina Horta] Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, Rua 240,Qd 87, BR-74605510 Goiania, Go, Brazil.
   [Muratov, Eugene N.] Univ N Carolina, Eshelman Sch Pharm, Lab Mol Modeling, Div Chem Biol & Med Chem, Chapel Hill, NC 27599 USA.
   [Muratov, Eugene N.] Odessa Natl Polytech Univ, Dept Chem Technol, 1 Shevchenko Ave, UA-65000 Odessa, Ukraine.
   [Franco, Caio Haddad; Moraes, Carolina B.; Freitas-Junior, Lucio H.] CNPEM, Natl Lab Biosci LNBio, BR-13083970 Campinas, SP, Brazil.
   [Moraes, Carolina B.; Freitas-Junior, Lucio H.] Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, BR-05508900 Sao Paulo, SP, Brazil.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, Rua 240,Qd 87, BR-74605510 Goiania, Go, Brazil.
EM carolina@ufg.br
RI Moraes, Carolina Borsoi/I-4408-2014; Braga, Rodolpho C/A-9655-2011;
   Freitas-Junior, Lucio H/C-8677-2011; Freitas, Lucia Helena/W-1231-2019;
   Franco, Caio/C-2139-2019; Muratov, Eugene/C-4454-2014; Camilo
   Melo-Filho, Cleber/V-1119-2018; Andrade, Carolina/C-3960-2014
OI Moraes, Carolina Borsoi/0000-0002-0689-2770; Braga, Rodolpho
   C/0000-0003-3814-3464; Freitas-Junior, Lucio H/0000-0002-8904-7897;
   Freitas, Lucia Helena/0000-0001-6777-4703; Franco,
   Caio/0000-0003-2467-9401; Muratov, Eugene/0000-0003-4616-7036; Camilo
   Melo-Filho, Cleber/0000-0003-0056-6971; Andrade,
   Carolina/0000-0003-0101-1492
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES; FAPEG; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [1U01CA207160,
   R01-GM114015]; L'Oreal-UNESCO-ABC Para Mulheres na Ciencia;
   L'Oreal-UNESCO International Rising Talents
FX The authors would like to thank Brazilian funding agencies, CNPq, CAPES
   and FAPEG for financial support and fellowships. E.M. acknowledges NIH
   for his financial support (grants 1U01CA207160 and R01-GM114015). CHA
   thanks the "L'Oreal-UNESCO-ABC Para Mulheres na Ciencia" and
   "L'Oreal-UNESCO International Rising Talents" for the awards and
   fellowships received, which partially funded this work. We are also
   grateful to OpenEye Scientific Software Inc. and ChemAxon for providing
   us with academic licenses for their software. CHA is CNPq productivity
   research fellow.
CR ALTMAN NS, 1992, AM STAT, V46, P175, DOI 10.2307/2685209
   Alves VM, 2015, TOXICOL APPL PHARM, V284, P273, DOI 10.1016/j.taap.2014.12.013
   Alves VM, 2015, TOXICOL APPL PHARM, V284, P262, DOI 10.1016/j.taap.2014.12.014
   [Anonymous], 2017, ADME QSAR MOD PRED K
   [Anonymous], 2018, FILTER 2 5 OPENEYE S
   [Anonymous], 2018, LUMINESCENCE CELL BA
   Bern C, 2015, NEW ENGL J MED, V373, P456, DOI [10.1056/NEJMra1410150, 10.1056/NEJMc1510996]
   Berthold MR, 2008, STUD CLASS DATA ANAL, P319, DOI 10.1145/1656274.1656280
   Braga RC, 2015, MOL INFORM, V34, P698, DOI 10.1002/minf.201500040
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1399, DOI 10.2174/1568026614666140506124442
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Center for Disease Control and Prevention, 2016, TRIAT BUG FAQS
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   DNDi, 2018, WHAT IS CHAG DIS
   Field MC, 2017, NAT REV MICROBIOL, V15, DOI 10.1038/nrmicro.2016.193
   Flores-Chavez M, 2008, CLIN INFECT DIS, V46, pE44, DOI 10.1086/527448
   Fourches D., 2016, J CHEM INF MODEL, DOI [10.1021/acs.jcim.6b00129acs.jcim.6b00129, DOI 10.1021/ACS.JCIM.6B00129ACS.JCIM.6B00129]
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Fujita T, 2016, J CHEM INF MODEL, V56, P269, DOI 10.1021/acs.jcim.5b00229
   Gomes MN, 2017, BIOORG MED CHEM LETT, V27, P2459, DOI 10.1016/j.bmcl.2017.04.010
   Grinnage-Pulley T, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005302
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Kovdienko NA, 2010, MOL INFORM, V29, P394, DOI 10.1002/minf.201000001
   Kransdorf EP, 2014, CURR OPIN INFECT DIS, V27, P418, DOI 10.1097/QCO.0000000000000088
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Melo CC, 2016, J CHEM INF MODEL, V56, P1357, DOI 10.1021/acs.jcim.6b00055
   Moraes CB, 2014, SCI REP-UK, V4, DOI 10.1038/srep04703
   Neves BJ, 2016, J MED CHEM, V59, P7075, DOI 10.1021/acs.jmedchem.5b02038
   Neves BJ, 2016, EXPERT OPIN DRUG DIS, V11, P557, DOI 10.1080/17460441.2016.1178230
   Pedregosa F, 2011, J MACH LEARN RES, V12, P2825
   Polishchuk PG, 2009, J CHEM INF MODEL, V49, P2481, DOI 10.1021/ci900203n
   Python Software Foundation, PYTH VERS 2 7
   R Development Core Team, 2008, R LANG ENV STAT COMP
   Riniker S, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-26
   Rodriguez JB, 2016, EXPERT OPIN THER PAT, V26, P993, DOI 10.1080/13543776.2016.1209487
   Rogers D, 2010, J CHEM INF MODEL, V50, P742, DOI 10.1021/ci100050t
   Salomao K, 2016, CURR TOP MED CHEM, V16, P2266, DOI 10.2174/1568026616666160413125049
   Shikanai-Yasuda MA, 2012, CLIN INFECT DIS, V54, P845, DOI 10.1093/cid/cir956
   Svetnik V, 2003, J CHEM INF COMP SCI, V43, P1947, DOI 10.1021/ci034160g
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Wang T, 2015, EXPERT OPIN DRUG DIS, V10, P1283, DOI 10.1517/17460441.2015.1083006
   WHO, 2017, INT NEGL TROP DIS GL, P278
   WHO, 2015, INV OV GLOB IMP NEGL, P118
   WHO, 2018, CHAG DIS AM TRYP FAC
   Zhang SX, 2006, J CHEM INF MODEL, V46, P1984, DOI 10.1021/ci060132x
NR 47
TC 8
Z9 8
U1 1
U2 14
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD FEB 1
PY 2019
VL 163
BP 649
EP 659
DI 10.1016/j.ejmech.2018.11.062
PG 11
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA HL3FC
UT WOS:000458597300048
PM 30562700
DA 2020-12-01
ER

PT J
AU Hernandez, HW
   Soeung, M
   Zorn, KM
   Ashoura, N
   Mottin, M
   Andrade, CH
   Caffrey, CR
   de Siqueira-Neto, JL
   Ekins, S
AF Hernandez, Helen W.
   Soeung, Melinda
   Zorn, Kimberley M.
   Ashoura, Norah
   Mottin, Melina
   Andrade, Carolina Horta
   Caffrey, Conor R.
   de Siqueira-Neto, Jair Lage
   Ekins, Sean
TI High Throughput and Computational Repurposing for Neglected Diseases
SO PHARMACEUTICAL RESEARCH
LA English
DT Review
DE dengue; ebola; echinococcosis; elephantiasis; high throughput screening;
   kinetoplastids; lymphatic filariasis; neglected tropical diseases;
   onchocerciasis; repurposing; schistosoma; zika
ID SMALL-MOLECULE INHIBITORS; THIOREDOXIN GLUTATHIONE-REDUCTASE; FEMALE
   GENITAL SCHISTOSOMIASIS; CYSTEINE PROTEASE INHIBITORS; MARBURG VIRUS
   ENTRY; ACCESS MALARIA BOX; DRUG DISCOVERY; TRYPANOSOMA-BRUCEI; ZIKA
   VIRUS; CHAGAS-DISEASE
AB PurposeNeglected tropical diseases (NTDs) represent are a heterogeneous group of communicable diseases that are found within the poorest populations of the world. There are 23 NTDs that have been prioritized by the World Health Organization, which are endemic in 149 countries and affect more than 1.4 billion people, costing these developing economies billions of dollars annually. The NTDs result from four different causative pathogens: protozoa, bacteria, helminth and virus. The majority of the diseases lack effective treatments. Therefore, new therapeutics for NTDs are desperately needed.MethodsWe describe various high throughput screening and computational approaches that have been performed in recent years. We have collated the molecules identified in these studies and calculated molecular properties.ResultsNumerous global repurposing efforts have yielded some promising compounds for various neglected tropical diseases. These compounds when analyzed as one would expect appear drug-like. Several large datasets are also now in the public domain and this enables machine learning models to be constructed that then facilitate the discovery of new molecules for these pathogens.ConclusionsIn the space of a few years many groups have either performed experimental or computational repurposing high throughput screens against neglected diseases. These have identified compounds which in many cases are already approved drugs. Such approaches perhaps offer a more efficient way to develop treatments which are generally not a focus for global pharmaceutical companies because of the economics or the lack of a viable market. Other diseases could perhaps benefit from these repurposing approaches.
C1 [Hernandez, Helen W.] KAL Res Initiat LLC, Houston, TX 77042 USA.
   [Soeung, Melinda] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Zorn, Kimberley M.; Ekins, Sean] Collaborat Pharmaceut Inc, 840 Main Campus Dr,Lab 3510, Raleigh, NC 27606 USA.
   [Ashoura, Norah] Univ Texas Austin, Austin, TX 78712 USA.
   [Mottin, Melina; Andrade, Carolina Horta] Univ Fed Goias UFG, Fac Farm, LabMol Lab Mol Modeling & Drug Design, BR-74605170 Goiania, Go, Brazil.
   [Caffrey, Conor R.; de Siqueira-Neto, Jair Lage] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, Ctr Discovery & Innovat Parasit Dis, San Diego, CA 92093 USA.
RP Hernandez, HW (corresponding author), KAL Res Initiat LLC, Houston, TX 77042 USA.; Ekins, S (corresponding author), Collaborat Pharmaceut Inc, 840 Main Campus Dr,Lab 3510, Raleigh, NC 27606 USA.
EM helenwhernandez@kalresearchinitiatives.com;
   sean@collaborationspharma.com
RI Mottin, Melina/D-8700-2016; Andrade, Carolina/C-3960-2014
OI Mottin, Melina/0000-0003-0878-9029; Andrade,
   Carolina/0000-0003-0101-1492
FU NIH/NIGMSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [1R43GM122196-01, R44GM122196-02A1];
   NIH/NCATSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [1R21TR001718-0]; Brazilian CNPq/FAPEG
   DCR [300508/2017-4]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UH2TR002084, UH2TR002084, R21TR001718]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U19AI098461, U19AI098461,
   U19AI098461, U19AI098461, U19AI098461, U19AI098461, U19AI098461,
   U19AI098461, U19AI098461, U19AI098461, U19AI098461, U19AI098461,
   U19AI098461, U19AI098461, U19AI098461, U19AI098461] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS)
   [R43GM122196] Funding Source: NIH RePORTER
FX This work was supported by Award Numbers 1R43GM122196-01 and
   R44GM122196-02A1 "Centralized assay datasets for modelling support of
   small drug discovery organizations" from NIH/NIGMS. 1UH2TR002084-01
   "Repurposing pyronaridine as a treatment for Chagas disease" from
   NIH/NCATS 1R21TR001718-01 "Repurposing pyronaridine as a treatment for
   the Ebola virus" from NIH/NCATS. MM thanks the support of the Brazilian
   CNPq/FAPEG DCR (grant 300508/2017-4). We are very grateful for our many
   collaborators and colleagues who contributed to the various efforts
   referenced herein. HWH is a Managing Member of KAL Research Initiatives,
   LLC. KMZ is an employee and SE is an employee and owner of
   Collaborations Pharmaceuticals, Inc.
CR Abdulla MH, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000478
   Alonso-Padilla J, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003493
   Anantpadma M, 2016, ANTIMICROB AGENTS CH, V60, P4471, DOI 10.1128/AAC.00543-16
   ANDREWS P, 1983, MED RES REV, V3, P147, DOI 10.1002/med.2610030204
   Asarnow D, 2014, BIOINFORMATICS
   Bahia MT, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001870
   Baker NC, 2018, DRUG DISCOV TODAY, V23, P661, DOI 10.1016/j.drudis.2018.01.018
   Barrows NJ, 2016, CELL HOST MICROBE, V20, P259, DOI 10.1016/j.chom.2016.07.004
   Basavannacharya C, 2014, BIOCHEM BIOPH RES CO, V453, P539, DOI 10.1016/j.bbrc.2014.09.113
   Ben Khalaf N, 2012, PARASITOL RES, V110, P1911, DOI 10.1007/s00436-011-2717-5
   Berman J, 2017, AM J TROP MED HYG, V96, P11, DOI 10.4269/ajtmh.16-0099
   Bettiol E, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000384
   Bilsland E, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004401
   Blaazer AR, 2015, J BIOMOL SCREEN, V20, P131, DOI 10.1177/1087057114549735
   Bland ND, 2011, J MED CHEM, V54, P8188, DOI 10.1021/jm201148s
   Blatt J, 2014, DRUG DISCOV TODAY, V19, P1696, DOI 10.1016/j.drudis.2014.08.003
   Boguski MS, 2009, SCIENCE, V324, P1394, DOI 10.1126/science.1169920
   Uliana SRB, 2009, SCIENCE, V326, P935, DOI 10.1126/science.326.5955.935-a
   Boyom FF, 2014, ANTIMICROB AGENTS CH, V58, P5848, DOI 10.1128/AAC.02541-14
   Bulman CA, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003534
   Burns AR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8485
   Caffrey C.R, 2012, PARASITIC HELMINTHS
   Caffrey CR, 2007, CURR OPIN CHEM BIOL, V11, P433, DOI 10.1016/j.cbpa.2007.05.031
   Caffrey CR, 2015, FUTURE MED CHEM, V7, P675, DOI [10.4155/FMC.15.27, 10.4155/fmc.15.27]
   Caffrey CR, 2011, CURR OPIN INFECT DIS, V24, P410, DOI 10.1097/QCO.0b013e328349156f
   Caffrey CR, 2002, INT J ANTIMICROB AG, V19, P227, DOI 10.1016/S0924-8579(01)00488-5
   Caffrey CR, 2001, MOL BIOCHEM PARASIT, V118, P61, DOI 10.1016/S0166-6851(01)00368-1
   Calvo-Alvarez E, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003666
   CAMPBELL NRC, 1987, MOL PHARMACOL, V32, P813
   Chatelain E, 2015, J BIOMOL SCREEN, V20, P22, DOI 10.1177/1087057114550585
   Chen CK, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000651
   Cheng H, 2015, J VIROL
   Cheng H, 2015, J VIROL, V89, P9932, DOI 10.1128/JVI.01337-15
   Cheung YY, 2014, ANTIVIR RES, V111, P93, DOI 10.1016/j.antiviral.2014.09.007
   Chopra G, 2016, MOLECULES, V21, DOI 10.3390/molecules21121537
   Christinet V, 2016, INT J PARASITOL, V46, P395, DOI 10.1016/j.ijpara.2016.02.006
   Chu JJH, 2007, P NATL ACAD SCI USA, V104, P3520, DOI 10.1073/pnas.0611681104
   Coffee M, UNDERSTANDING ZIKA O
   Cole ST, 2017, DRUG DISCOV TODAY, V22, P477, DOI 10.1016/j.drudis.2016.09.026
   Colley DG, 2014, LANCET, V383, P2253, DOI 10.1016/S0140-6736(13)61949-2
   Coura JR, 2010, NATURE, V465, pS6, DOI 10.1038/nature09221
   Crowther GJ, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002628
   Cruz DJM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002471
   Cruz DJM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002073
   De Muylder G, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001253
   De Rycker M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004584
   De Rycker M, 2013, ANTIMICROB AGENTS CH, V57, P2913, DOI 10.1128/AAC.02398-12
   Diaz R, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003253
   Diaz-Gonzalez R, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001297
   DiMasi JA, 2001, CLIN PHARMACOL THER, V69, P286, DOI 10.1067/mcp.2001.115132
   Dudley JT, 2011, BRIEF BIOINFORM, V12, P303, DOI 10.1093/bib/bbr013
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Edwards MR, 2015, ACS INFECT DIS, V1, P380, DOI 10.1021/acsinfecdis.5b00053
   Ekins S., 2016, F1000RES, V4, P1091, DOI DOI 10.12688/f1000research.7217.2
   Ekins S, 2017, ANTIMICROB AGENTS CH
   Ekins S, 2017, DRUG DISCOV TODAY, V22, P479, DOI 10.1016/j.drudis.2017.03.002
   Ekins S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005023
   Ekins Sean, 2016, F1000Res, V5, P150, DOI 10.12688/f1000research.8013.1
   Ekins Sean, 2015, F1000Res, V4, P1091, DOI 10.12688/f1000research.7217.1
   Ekins S, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003878
   Ekins Sean, 2015, F1000Res, V4, P58, DOI 10.12688/f1000research.6181.1
   Ekpo UF, 2012, PARASITOLOGY, V139, P835, DOI 10.1017/S0031182012000029
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636
   FDA, TROP DIS PRIOR REW V
   FELDMEIER H, 1994, INT J STD AIDS, V5, P368, DOI 10.1177/095646249400500517
   Fonseca NC, 2015, ANTIMICROB AGENTS CH
   Frevert U, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043913
   Fricker SP, 2008, J INORG BIOCHEM, V102, P1839, DOI 10.1016/j.jinorgbio.2008.05.010
   Gabrielli AF, 2011, T ROY SOC TROP MED H, V105, P683, DOI 10.1016/j.trstmh.2011.08.013
   Gaffney A, REGULATORY EXPLAINER
   Greenbaum DC, 2004, J MED CHEM, V47, P3212, DOI 10.1021/jm030549j
   Guiguemde WA, 2012, CHEM BIOL, V19, P116, DOI 10.1016/j.chembiol.2012.01.004
   Guiguemde WA, 2010, NATURE, V465, P311, DOI 10.1038/nature09099
   Gunatilleke SS, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001736
   Guyett PJ, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.01865-16
   Hart CJS, 2017, INT J PARASITOL-DRUG, V7, P83, DOI 10.1016/j.ijpddr.2017.01.005
   Hay M, 2014, NAT BIOTECHNOL, V32, P40, DOI 10.1038/nbt.2786
   Hotez PJ, 2007, NEW ENGL J MED, V357, P1018, DOI 10.1056/NEJMra064142
   Hotez PJ, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005896
   Hotez PJ, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001498
   Hotez PJ, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000718
   Hotez PJ, 2012, PREFACE, pXI, DOI DOI 10.1017/CBO9781139095174.001
   Huang RL, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001862
   Ingram-Sieber K, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002610
   Johansen LM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa5597
   Johansen LM, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005471
   Johnston KL, 2014, INT J PARASITOL-DRUG, V4, P278, DOI 10.1016/j.ijpddr.2014.09.001
   Kaiser M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135556
   Kaiser M, 2015, J BIOMOL SCREEN, V20, P634, DOI 10.1177/1087057115569155
   Kannan S, 2014, J CHEM INF MODEL, V54, P3005, DOI 10.1021/ci5004653
   Karlas A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11320
   Keenan M, 2013, FUTURE MED CHEM, V5, P1733, DOI [10.4155/FMC.13.139, 10.4155/fmc.13.139]
   Keiser J, 2010, ADV PARASIT, V73, P197, DOI 10.1016/S0065-308X(10)73008-6
   Khare S, 2016, NATURE, V537, P229, DOI 10.1038/nature19339
   Kinnings SL, 2011, J CHEM INF MODEL, V51, P408, DOI 10.1021/ci100369f
   Kjetland EF, 2006, AIDS, V20, P593, DOI 10.1097/01.aids.0000210614.45212.0a
   Kobylinski KC, 2014, AM J TROP MED HYG
   Kotz J., 2012, SCIBX, V5, P15
   Kouznetsova J, 2014, EMERG MICROBES INFEC, V3, DOI 10.1038/emi.2014.88
   Kuntz AN, 2007, PLOS MED, V4, P1071, DOI 10.1371/journal.pmed.0040206
   Lane T, 2018, MOL PHARM
   Lee H, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-S1-S4
   Lee H, 2017, ANTIVIR RES, V139, P49, DOI 10.1016/j.antiviral.2016.12.016
   Li T, 2015, INFECT DIS POVERTY, V4, DOI 10.1186/s40249-015-0071-z
   Lim SP, 2013, ANTIVIR RES, V100, P500, DOI 10.1016/j.antiviral.2013.09.013
   Liu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064984
   Long T, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005680
   Love MS, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005373
   Mackey ZB, 2011, CHEM BIOL DRUG DES, V78, P454, DOI 10.1111/j.1747-0285.2011.01156.x
   Mackey ZB, 2004, J BIOL CHEM, V279, P48426, DOI 10.1074/jbc.M402470200
   Madrid PB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060579
   Mahmoudzadeh-Niknam H, 2004, EXP PARASITOL, V106, P158, DOI 10.1016/j.exppara.2004.03.005
   Mallari JP, 2008, J MED CHEM, V51, P545, DOI 10.1021/jm070760l
   Malone RW, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004530
   Mansour NR, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004659
   Manzano M, 2014, METHODS MOL BIOL, V1138, P331, DOI 10.1007/978-1-4939-0348-1_20
   Martorana A, 2016, CURR TOP MED CHEM, V16, P2088, DOI 10.2174/1568026616666160216153457
   Mashiyama ST, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001942
   Mathew MD, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005058
   McCall LI, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003588
   McCall LI, 2014, TRENDS PARASITOL, V30, P342, DOI 10.1016/j.pt.2014.05.001
   McCarthy SDS, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004364
   McKerrow JH, 2006, ANNU REV PATHOL-MECH, V1, P497, DOI 10.1146/annurev.pathol.1.110304.100151
   McKerrow JH, 2008, CURR OPIN INFECT DIS, V21, P668, DOI 10.1097/QCO.0b013e328315cca9
   MCKERROW JH, 1993, ANNU REV MICROBIOL, V47, P821, DOI 10.1146/annurev.mi.47.100193.004133
   Mhashilkar AS, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004772
   Mirza MU, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111748
   Molina I, 2014, NEW ENGL J MED, V370, P1899, DOI 10.1056/NEJMoa1313122
   Mottin M, 2018, DRUG DISCOV TODAY
   Mottin M, 2018, BRAZ J PHARM SCI, V54, DOI 10.1590/s2175-97902018000001002
   Mudhasani R, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003095
   Naing C, 2013, T ROY SOC TROP MED H, V107, P672, DOI 10.1093/trstmh/trt086
   Navarro G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046172
   Neves BJ, 2016, J MED CHEM, V59, P7075, DOI 10.1021/acs.jmedchem.5b02038
   Neves BJ, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003435
   Neves B, 2016, MEDCHEMCOMM, V7, P1176, DOI 10.1039/c5md00596e
   Njogu PM, 2016, ACS INFECT DIS, V2, P8, DOI 10.1021/acsinfecdis.5b00093
   Nuhs A, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004094
   Nwaka S, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000440
   Ochiana SO, 2013, EUR J MED CHEM, V62, P777, DOI 10.1016/j.ejmech.2012.07.038
   Oehler E, 2013, EUROSURVEILLANCE, V2014, P19, DOI DOI 10.2807/1560-7917.ES2014.19.9.20720
   Oprea TI, 2012, AAPS J, V14, P759, DOI 10.1208/s12248-012-9390-1
   Oprea TI, 2007, J COMPUT AID MOL DES, V21, P113, DOI 10.1007/s10822-007-9105-3
   Organization WH, UNPR PROGR AG NEGL T
   Paape D, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003363
   Panic G, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1233-3
   Panic G, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003962
   Pascoalino Bruno S, 2016, F1000Res, V5, P2523
   Patel G, 2013, J MED CHEM, V56, P3820, DOI 10.1021/jm400349k
   Paveley RA, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001762
   Payne DJ, 2007, NAT REV DRUG DISCOV, V6, P29, DOI 10.1038/nrd2201
   Pena I, 2015, SCI REP-UK, V5, DOI 10.1038/srep08771
   Planer JD, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002977
   Ponder EL, 2014, PHARM RES-DORDR, V31, P271, DOI 10.1007/s11095-013-1170-9
   Pothineni VR, 2016, DRUG DES DEV THER, V10, P1307, DOI 10.2147/DDDT.S101486
   RAETHER W, 1983, ANN TROP MED PARASIT, V77, P13, DOI 10.1080/00034983.1983.11811668
   Rassi A, 2010, LANCET, V375, P1388, DOI 10.1016/S0140-6736(10)60061-X
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Ribeiro I, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000484
   Ridley DB, 2017, AM J TROP MED HYG, V96, P14, DOI 10.4269/ajtmh.16-0600
   Riley J, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004014
   Rojo-Arreola L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087594
   Russo DP, 2018, MOL PHARM
   SABAH AA, 1986, EXP PARASITOL, V61, P294, DOI 10.1016/0014-4894(86)90184-0
   Sanchez LM, 2013, J NAT PROD, V76, P630, DOI 10.1021/np300834q
   Sanderson L, 2014, J ANTIMICROB CHEMOTH, V69, P1888, DOI 10.1093/jac/dku069
   Sandoval PJ, 2018, MOL PHARM
   Scheidt KA, 1998, BIOORGAN MED CHEM, V6, P2477, DOI 10.1016/S0968-0896(98)80022-9
   Selzer PM, 1999, P NATL ACAD SCI USA, V96, P11015, DOI 10.1073/pnas.96.20.11015
   Shahinas D, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00368
   Shan C, 2016, ACS INFECT DIS, V2, P170, DOI 10.1021/acsinfecdis.6b00030
   Singh R, 2009, IEEE S COMP BAS MED, P1
   Smith DW, 2016, LANCET, V387, P1486, DOI 10.1016/S0140-6736(16)00564-X
   Stadelmann B, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004535
   Sutherland CS, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003397
   Swenerton RK, 2011, J BIOL CHEM, V286, P429, DOI 10.1074/jbc.M110.138313
   Swinney DC, 2011, NAT REV DRUG DISCOV, V10, P507, DOI 10.1038/nrd3480
   Tarral A, 2014, CLIN PHARMACOKINET, V53, P565, DOI 10.1007/s40262-014-0136-3
   Torrico F, 2018, LANCET INFECT DIS, V18, P419, DOI 10.1016/S1473-3099(17)30538-8
   Towner JS, 2005, VIROLOGY, V332, P20, DOI 10.1016/j.virol.2004.10.048
   Troeberg L, 1999, EXP PARASITOL, V91, P349, DOI 10.1006/expr.1998.4386
   Troeberg L, 2000, MOL MED, V6, P660, DOI 10.1007/BF03402046
   Uebelhoer LS, 2014, ANTIVIR RES, V106, P86, DOI 10.1016/j.antiviral.2014.03.018
   van den Enden E, 2009, EXPERT OPIN PHARMACO, V10, P435, DOI [10.1517/14656560902722463 , 10.1517/14656560902722463]
   Van Voorhis WC, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005763
   Vicik R, 2006, BIOORG MED CHEM LETT, V16, P2753, DOI 10.1016/j.bmcl.2006.02.026
   Wang YZ, 2016, ANTIVIR RES, V125, P1, DOI 10.1016/j.antiviral.2015.11.003
   Watts KR, 2010, BIOORGAN MED CHEM, V18, P2566, DOI 10.1016/j.bmc.2010.02.034
   WHO, NEGLECTED TROPICAL D
   Wiggers HJ, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002370
   Witola WH, 2011, INFECT IMMUN, V79, P756, DOI 10.1128/IAI.00898-10
   World Health Organization (WHO), DENG SEV DENG
   XIAO SH, 1987, CHINESE MED J-PEKING, V100, P759
   Xu M, 2016, NAT MED
   Xu M, 2016, NAT MED, V22, P1101, DOI 10.1038/nm.4184
   Yang CC, 2014, ANTIMICROB AGENTS CH, V58, P110, DOI 10.1128/AAC.01281-13
   Zhang SY, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000648
   Zhao Z, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-0941-9
   Zmurko J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004695
NR 200
TC 11
Z9 11
U1 1
U2 32
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD FEB
PY 2019
VL 36
IS 2
AR 27
DI 10.1007/s11095-018-2558-3
PG 20
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA HE7QC
UT WOS:000453632900001
PM 30560386
OA Green Published, Green Accepted
DA 2020-12-01
ER

PT S
AU Moreira, JT
   Dantas, RF
   Senger, MR
   Silva, AC
   Campos, DMB
   Muratov, E
   Silva, FP
   Andrade, CH
   Neves, BJ
AF Moreira-Filho, Jose T.
   Dantas, Rafael F.
   Senger, Mario R.
   Silva, Arthur C.
   Campos, Dulcinea M. B.
   Muratov, Eugene
   Silva-Junior, Floriano P.
   Andrade, Carolina H.
   Neves, Bruno J.
BE Chibale, K
TI Shortcuts to schistosomiasis drug discovery: The state-of-the-art
SO MEDICINAL CHEMISTRY APPROACHES TO MALARIA AND OTHER TROPICAL DISEASES
SE Annual Reports in Medicinal Chemistry
LA English
DT Review; Book Chapter
ID FINGERPRINT SIMILARITY SEARCH; HIGH-THROUGHPUT; MOLECULAR COMPLEXITY;
   PRACTICAL GUIDE; LEAD DISCOVERY; MANSONI; INHIBITORS; DESIGN; ASSAY;
   IDENTIFICATION
C1 [Moreira-Filho, Jose T.; Andrade, Carolina H.; Neves, Bruno J.] Univ Fed Goias UFG, Fac Farm, LabMol Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.
   [Dantas, Rafael F.; Senger, Mario R.; Silva-Junior, Floriano P.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, LaBECFar Lab Bioquim Expt & Computac Farm, Rio De Janeiro, Brazil.
   [Campos, Dulcinea M. B.; Neves, Bruno J.] Ctr Univ Anapolis UniEVANGELICA, Lab Cheminformat, Anapolis, Go, Brazil.
   [Muratov, Eugene] Univ N Carolina, Eshelman Sch Pharm, Div Chem Biol & Med Chem, Lab Mol Modeling, Chapel Hill, NC 27515 USA.
   [Muratov, Eugene] Odessa Natl Polytech Univ, Dept Chem Technol, Odessa, Ukraine.
RP Neves, BJ (corresponding author), Univ Fed Goias UFG, Fac Farm, LabMol Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.; Neves, BJ (corresponding author), Ctr Univ Anapolis UniEVANGELICA, Lab Cheminformat, Anapolis, Go, Brazil.
EM bruno.labmol@gmail.com
RI de Carvalho e Silva, Arthur/S-7803-2018; Neves, Bruno
   Junior/E-6295-2016; Moreira-Filho, Jose Teofilo/S-8333-2018; Andrade,
   Carolina/C-3960-2014
OI de Carvalho e Silva, Arthur/0000-0001-9866-3344; Moreira-Filho, Jose
   Teofilo/0000-0002-0777-280X; Senger, Mario/0000-0003-2384-2692; Andrade,
   Carolina/0000-0003-0101-1492; Neves, Bruno/0000-0002-1309-8743
CR Abdulla MH, 2007, PLOS MED, V4, P130, DOI 10.1371/journal.pmed.0040014
   Abdulla MH, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000478
   Adan A, 2016, CURR PHARM BIOTECHNO, V17, P1213, DOI 10.2174/1389201017666160808160513
   Alger HM, 2002, MOL BIOCHEM PARASIT, V121, P129, DOI 10.1016/S0166-6851(02)00031-2
   Anderson L, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005539
   Andrade LF, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-215
   [Anonymous], 2010, Drug Discov Today Technol, V7, pe147, DOI 10.1016/j.ddtec.2010.11.007
   Asarnow D, 2015, BIOINFORMATICS, V31, P1515, DOI 10.1093/bioinformatics/btu831
   Asarnow DE, 2013, IEEE T MED IMAGING, V32, P1007, DOI 10.1109/TMI.2013.2247412
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Baker M, 2013, NAT REV DRUG DISCOV, V12, P5, DOI 10.1038/nrd3926
   Barelier S, 2011, CURR OPIN CHEM BIOL, V15, P469, DOI 10.1016/j.cbpa.2011.02.020
   Beckmann S, 2010, INT J PARASITOL, V40, P521, DOI 10.1016/j.ijpara.2010.01.007
   Berriman M, 2009, NATURE, V460, P352, DOI 10.1038/nature08160
   Bian YM, 2018, AAPS J, V20, DOI 10.1208/s12248-018-0216-7
   Bjerrum E. J., 2017, SMILES ENUMERATION D
   Bjerrum EJ, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8040131
   Bonilla M, 2011, J BIOL CHEM, V286, P4959, DOI 10.1074/jbc.M110.170761
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1399, DOI 10.2174/1568026614666140506124442
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Brown FK, 1998, ANNU REP MED CHEM, V33, P375, DOI [10.1016/s0065-7743(08)61100-8, DOI 10.1016/S0065-7743(08)61100-8]
   Cabezas-Cruz A, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00317
   Caffrey CR, 2007, CURR OPIN CHEM BIOL, V11, P433, DOI 10.1016/j.cbpa.2007.05.031
   Caffrey CR, 2004, TRENDS PARASITOL, V20, P241, DOI 10.1016/j.pt.2004.03.004
   Caliandro R, 2013, FUTURE MED CHEM, V5, P1121, DOI [10.4155/FMC.13.84, 10.4155/fmc.13.84]
   Capuzzi SJ, 2017, J CHEM INF MODEL, V57, P417, DOI 10.1021/acs.jcim.6b00465
   Cereto-Massague A, 2015, METHODS, V71, P58, DOI 10.1016/j.ymeth.2014.08.005
   Chakrabarti A, 2015, TRENDS PHARMACOL SCI, V36, P481, DOI 10.1016/j.tips.2015.04.013
   Chan DSH, 2017, ESSAYS BIOCHEM, V61, P465, DOI 10.1042/EBC20170071
   Chen HM, 2018, DRUG DISCOV TODAY, V23, P1241, DOI 10.1016/j.drudis.2018.01.039
   Chen HM, 2018, MOL INFORM, V37, DOI 10.1002/minf.201800041
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Chessari G, 2009, DRUG DISCOV TODAY, V14, P668, DOI 10.1016/j.drudis.2009.04.007
   Chua MJ, 2017, INT J PARASITOL-DRUG, V7, P42, DOI 10.1016/j.ijpddr.2016.12.005
   Cioli D, 2014, MOL BIOCHEM PARASIT, V195, P23, DOI 10.1016/j.molbiopara.2014.06.002
   Coley CW, 2018, ACCOUNTS CHEM RES, V51, P1281, DOI 10.1021/acs.accounts.8b00087
   Coley CW, 2017, ACS CENTRAL SCI, V3, P434, DOI 10.1021/acscentsci.7b00064
   Colley DG, 2014, LANCET, V383, P2253, DOI 10.1016/S0140-6736(13)61949-2
   COMLEY JCW, 1989, INT J PARASITOL, V19, P77, DOI 10.1016/0020-7519(89)90024-6
   Congreve M, 2003, DRUG DISCOV TODAY, V8, P876, DOI 10.1016/S1359-6446(03)02831-9
   Congreve M, 2008, J MED CHEM, V51, P3661, DOI 10.1021/jm8000373
   Cowan N, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1023-y
   Crusco A, 2018, EUR J MED CHEM, V152, P87, DOI 10.1016/j.ejmech.2018.04.032
   DAVIES DR, 2011, PREDICTING SUCCESS F, V493, P91, DOI DOI 10.1016/B978-0-12-381274-2.00004-2
   Davis BJ, 2017, ANNU REP MED CHEM, V50, P371, DOI 10.1016/bs.armc.2017.07.002
   Davis BJ, 2013, BIOORG MED CHEM LETT, V23, P2844, DOI 10.1016/j.bmcl.2013.03.028
   Delcroix M, 2006, J BIOL CHEM, V281, P39316, DOI 10.1074/jbc.M607128200
   Dey S, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2544-0
   DiMasi JA, 2010, CLIN PHARMACOL THER, V87, P272, DOI 10.1038/clpt.2009.295
   DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1
   Dubois F, 2009, MOL BIOCHEM PARASIT, V168, P7, DOI 10.1016/j.molbiopara.2009.06.001
   Duffy BC, 2012, BIOORGAN MED CHEM, V20, P5324, DOI 10.1016/j.bmc.2012.04.062
   Durant JL, 2002, J CHEM INF COMP SCI, V42, P1273, DOI 10.1021/ci010132r
   Edwards J, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003604
   Ekins S, 2016, PHARM RES-DORDR, V33, P2594, DOI 10.1007/s11095-016-2029-7
   El-Shehabi F, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001523
   Engkvist O, 2018, DRUG DISCOV TODAY, V23, P1203, DOI 10.1016/j.drudis.2018.02.014
   Erlanson DA, 2016, NAT REV DRUG DISCOV, V15, P605, DOI 10.1038/nrd.2016.109
   Faghiri Z, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010451
   Ferenczy GG, 2013, J MED CHEM, V56, P2478, DOI 10.1021/jm301851v
   Fink T, 2007, J CHEM INF MODEL, V47, P342, DOI 10.1021/ci600423u
   Foloppe N, 2011, FUTURE MED CHEM, V3, P1111, DOI [10.4155/FMC.11.46, 10.4155/fmc.11.46]
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   GADALETA D, 2016, INT J QUANT STRUCT P, V1, P45, DOI DOI 10.4018/IJQSPR.2016010102
   Gasteiger J., 2003, CHEMOINFORMATICS, P1, DOI [10.1002/3527601643.CH1.FRG., DOI 10.1002/3527601643.CH1.FRG]
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   Geary TG, 2015, J PARASITOL, V101, P125, DOI 10.1645/14-703.1
   Giannetti AM, 2011, METHOD ENZYMOL, V493, P169, DOI 10.1016/B978-0-12-381274-2.00008-X
   Giuliani S, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006515
   Godinho LS, 2014, SCI WORLD J, DOI 10.1155/2014/460342
   Goh GB, 2017, J COMPUT CHEM, V38, P1291, DOI 10.1002/jcc.24764
   Gomez-Bombarelli R, 2018, ACS CENTRAL SCI, V4, P268, DOI 10.1021/acscentsci.7b00572
   Gossert AD, 2016, PROG NUCL MAG RES SP, V97, P82, DOI 10.1016/j.pnmrs.2016.09.001
   Goupil LS, 2014, CHEM REV, V114, P11131, DOI 10.1021/cr500546h
   Gouveia MJ, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11010015
   Grevelding CG, 2018, TRENDS PARASITOL, V34, P246, DOI 10.1016/j.pt.2017.12.001
   Gryseels B, 2006, LANCET, V368, P1106, DOI 10.1016/S0140-6736(06)69440-3
   Guidi A, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005994
   Guidi A, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004928
   Han ZG, 2009, ANNU REV GENOM HUM G, V10, P211, DOI 10.1146/annurev-genom-082908-150036
   Hann MM, 2001, J CHEM INF COMP SCI, V41, P856, DOI 10.1021/ci000403i
   HANSCH C, 1964, J AM CHEM SOC, V86, P1616, DOI 10.1021/ja01062a035
   Harner MJ, 2013, J BIOMOL NMR, V56, P65, DOI 10.1007/s10858-013-9740-z
   Heinnburg T, 2016, J MED CHEM, V59, P2423, DOI 10.1021/acs.jmedchem.5b01478
   Hopkins AL, 2004, DRUG DISCOV TODAY, V9, P430, DOI 10.1016/S1359-6446(04)03069-7
   Howe S, 2015, ANTIMICROB AGENTS CH, V59, P1193, DOI 10.1128/AAC.03809-14
   Huang H, 2011, FUSION SCI TECHNOL, V59, P26, DOI 10.13182/FST10-3694
   Hubbard RE, 2011, METHOD ENZYMOL, V493, P509, DOI 10.1016/B978-0-12-381274-2.00020-0
   Hughes JP, 2011, BRIT J PHARMACOL, V162, P1239, DOI 10.1111/j.1476-5381.2010.01127.x
   Hughes SJ, 2011, BIOORG MED CHEM LETT, V21, P6586, DOI 10.1016/j.bmcl.2011.07.117
   Ichihara O, 2011, MOL INFORM, V30, P298, DOI 10.1002/minf.201000174
   Irwin JJ, 2015, J MED CHEM, V58, P7076, DOI 10.1021/acs.jmedchem.5b01105
   Jhoti H, 2013, NAT REV DRUG DISCOV, V12, P644, DOI 10.1038/nrd3926-c1
   Joseph-McCarthy D, 2014, J CHEM INF MODEL, V54, P693, DOI 10.1021/ci400731w
   Jule AM, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004784
   Jurberg AD, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00144
   Kar S, 2013, EXPERT OPIN DRUG DIS, V8, P245, DOI 10.1517/17460441.2013.761204
   Kasny M, 2009, ADV PARASIT, V69, P205, DOI 10.1016/S0065-308X(09)69004-7
   Kassebaum NJ, 2016, LANCET, V388, P1603, DOI 10.1016/S0140-6736(16)31460-X
   Keseru GM, 2016, J MED CHEM, V59, P8189, DOI 10.1021/acs.jmedchem.6b00197
   Kola I, 2004, NAT REV DRUG DISCOV, V3, P711, DOI 10.1038/nrd1470
   Korotcov A, 2017, MOL PHARMACEUT, V14, P4462, DOI 10.1021/acs.molpharmaceut.7b00578
   Kramer R, 2004, NAT REV DRUG DISCOV, V3, P965, DOI 10.1038/nrd1552
   Kuhn I, 2010, BIOORGAN MED CHEM, V18, P7900, DOI 10.1016/j.bmc.2010.09.041
   Kumar S, 2012, INT J BIOMED ENG TEC, V10, P30, DOI 10.1504/IJBET.2012.049323
   Kuntz AN, 2007, PLOS MED, V4, P1071, DOI 10.1371/journal.pmed.0040206
   Kuntz ID, 1999, P NATL ACAD SCI USA, V96, P9997, DOI 10.1073/pnas.96.18.9997
   Lago EM, 2018, FUTURE MED CHEM, V10, P89, DOI 10.4155/fmc-2017-0112
   Lalli C, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003484
   Lamoree B, 2017, ESSAYS BIOCHEM, V61, P453, DOI 10.1042/EBC20170028
   Lea WA, 2008, ASSAY DRUG DEV TECHN, V6, P551, DOI 10.1089/adt.2008.149
   Leach A. R., 2007, INTRO CHEMOINFORMATI, DOI [10.1007/978-1-4020-6291-9, DOI 10.1007/978-1-4020-6291-9]
   Leach AR, 2011, CURR OPIN CHEM BIOL, V15, P489, DOI 10.1016/j.cbpa.2011.05.008
   Lee H, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-S1-S4
   Li X, 2018, MOL PHARMACEUT, V15, P4336, DOI 10.1021/acs.molpharmaceut.8b00110
   Li YZ, 2018, MOL BIOCHEM PARASIT, V226, P1, DOI 10.1016/j.molbiopara.2018.08.005
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Liu WW, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00149
   Lo YC, 2018, DRUG DISCOV TODAY, V23, P1538, DOI 10.1016/j.drudis.2018.05.010
   Long T, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005680
   Long T, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004356
   Luscombe NM, 2001, METHOD INFORM MED, V40, P346
   Mader P, 2018, CHEMMEDCHEM, V13, P2374, DOI 10.1002/cmdc.201800572
   Magalhaes LG, 2009, PARASITOL RES, V104, P1197, DOI 10.1007/s00436-008-1311-y
   Manneck T, 2011, J CLIN MICROBIOL, V49, P1217, DOI 10.1128/JCM.02382-10
   Mansour NR, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004659
   Mansour NR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000795
   Marcellino C, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001494
   Marxer M, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-165
   Mathea M, 2016, MOL INFORM, V35, P160, DOI 10.1002/minf.201501019
   McKerrow JH, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0005850
   Melo CC, 2019, EUR J MED CHEM, V163, P649, DOI 10.1016/j.ejmech.2018.11.062
   Melo CC, 2016, J CHEM INF MODEL, V56, P1357, DOI 10.1021/acs.jcim.6b00055
   Meyer T, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000357
   Moody-Davis Asher, 2011, Advances in Visual Computing. Proceedings 7th International Symposium, ISVC 2011, P43
   Morais ER, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184192
   MORGAN HL, 1965, J CHEM DOC, V5, P107, DOI 10.1021/c160017a018
   Muegge I, 2016, EXPERT OPIN DRUG DIS, V11, P137, DOI 10.1517/17460441.2016.1117070
   NARE B, 1991, BIOCHEM PHARMACOL, V42, P1287, DOI 10.1016/0006-2952(91)90267-9
   Aguiar PHN, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2240-3
   Navratilova I, 2010, ACS MED CHEM LETT, V1, P44, DOI 10.1021/ml900002k
   Netzeva TI, 2005, ATLA-ALTERN LAB ANIM, V33, P155, DOI 10.1177/026119290503300209
   Neves BJ, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01275
   Neves BJ, 2016, J MED CHEM, V59, P7075, DOI 10.1021/acs.jmedchem.5b02038
   Neves B, 2016, MEDCHEMCOMM, V7, P1176, DOI 10.1039/c5md00596e
   Neves BJ, 2016, EXPERT OPIN DRUG DIS, V11, P557, DOI 10.1080/17460441.2016.1178230
   OECD, PRINC VAL REG PURP Q
   Olliaro P, 2014, J ANTIMICROB CHEMOTH, V69, P863, DOI 10.1093/jac/dkt491
   Ouzounis CA, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002487
   Padalino G, 2018, INT J PARASITOL-DRUG, V8, P559, DOI 10.1016/j.ijpddr.2018.10.005
   Panic G, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1233-3
   Pasche V, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2855-z
   Patocka N, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003878
   Paveley RA, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001762
   Peak E, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000759
   Pereira ASA, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006873
   Popova M, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aap7885
   Preston S, 2018, TRENDS PARASITOL, V34, P4, DOI 10.1016/j.pt.2017.07.005
   Price AJ, 2017, ESSAYS BIOCHEM, V61, P475, DOI 10.1042/EBC20170029
   Protasio AV, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001455
   Ramaprasad A, 2012, GENOMICS, V99, P69, DOI 10.1016/j.ygeno.2011.11.006
   Ramirez B, 2007, EXPERT OPIN DRUG DIS, V2, pS53, DOI 10.1517/17460441.2.S1.S53
   Rees DC, 2004, NAT REV DRUG DISCOV, V3, P660, DOI 10.1038/nrd1467
   Mello JDRE, 2017, CHEM BIOL DRUG DES, V90, P1067, DOI 10.1111/cbdd.13030
   Rinaldi G, 2015, INT J PARASITOL-DRUG, V5, P141, DOI 10.1016/j.ijpddr.2015.07.002
   Riniker S, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-43
   Rojo-Arreola L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087594
   Roughley SD, 2011, J MED CHEM, V54, P3989, DOI 10.1021/jm200350g
   Russo DP, 2018, MOL PHARMACEUT, V15, P4361, DOI 10.1021/acs.molpharmaceut.8b00546
   Saha U, 2012, LECT NOTES COMPUT SC, V7432, P104, DOI 10.1007/978-3-642-33191-6_11
   Sayed AA, 2008, NAT MED, V14, P407, DOI 10.1038/nm1737
   Schneider G, 2018, NAT REV DRUG DISCOV, V17, P97, DOI 10.1038/nrd.2017.232
   Scott DE, 2012, BIOCHEMISTRY-US, V51, P4990, DOI 10.1021/bi3005126
   Secor WE, 2015, FUTURE MED CHEM, V7, P681, DOI [10.4155/fmc.15.9, 10.4155/FMC.15.9]
   Segler MHS, 2018, NATURE, V555, P604, DOI 10.1038/nature25978
   Segler MHS, 2017, CHEM-EUR J, V23, P5966, DOI 10.1002/chem.201605499
   Senger MR, 2016, DRUG DISCOV TODAY, V21, P868, DOI 10.1016/j.drudis.2016.02.004
   Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531
   Silva FP, 2002, FEBS LETT, V514, P141, DOI 10.1016/S0014-5793(02)02270-6
   Silvestri I, 2018, ACS CHEM BIOL, V13, P2190, DOI 10.1021/acschembio.8b00349
   Simeonov A, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000127
   Singh R, 2009, COMP MED SY, P198
   Smout MJ, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000885
   Steinmann P, 2006, LANCET INFECT DIS, V6, P411, DOI 10.1016/S1473-3099(06)70521-7
   Sundaraneedi MK, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006134
   Svetnik V, 2003, J CHEM INF COMP SCI, V43, P1947, DOI 10.1021/ci034160g
   Tanrikulu Y, 2013, DRUG DISCOV TODAY, V18, P358, DOI 10.1016/j.drudis.2013.01.007
   Thorne N, 2010, CURR OPIN CHEM BIOL, V14, P315, DOI 10.1016/j.cbpa.2010.03.020
   van Montfort RLM, 2017, ESSAYS BIOCHEM, V61, P431, DOI 10.1042/EBC20170052
   Vapnik V., 2000, NATURE STAT LEARNING
   Wang W, 2012, PARASITOL RES, V111, P1871, DOI 10.1007/s00436-012-3151-z
   Wang YL, 2012, NUCLEIC ACIDS RES, V40, pD400, DOI 10.1093/nar/gkr1132
   Wang YL, 2010, NUCLEIC ACIDS RES, V38, pD255, DOI 10.1093/nar/gkp965
   Wangchuk P, 2016, SCI REP-UK, V6, DOI 10.1038/srep32101
   Wangchuk P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004908
   Weeks JC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18457-w
   Whiteland HL, 2018, INT J PARASITOL-DRUG, V8, P465, DOI 10.1016/j.ijpddr.2018.10.009
   WHO (World Health Organization), SCHIST
   Xu YJ, 2017, J CHEM INF MODEL, V57, P2672, DOI 10.1021/acs.jcim.7b00244
   Yan HB, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.02568-17;e02568-17
   Yepes E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109431
   Young ND, 2012, NAT GENET, V44, P221, DOI 10.1038/ng.1065
   Zhou Y, 2009, NATURE, V460, P345, DOI 10.1038/nature08140
NR 205
TC 0
Z9 0
U1 3
U2 3
PU ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD
PI LONDON
PA 125 LONDON WALL, LONDON EC2Y 5AS, ENGLAND
SN 0065-7743
BN 978-0-12-820551-8; 978-0-12-819866-7
J9 ANNU REP MED CHEM
JI Annu. Rep. Med. Chem.
PY 2019
VL 53
BP 139
EP 180
DI 10.1016/bs.armc.2019.06.004
PG 42
WC Chemistry, Medicinal; Infectious Diseases; Pharmacology & Pharmacy;
   Tropical Medicine
SC Pharmacology & Pharmacy; Infectious Diseases; Tropical Medicine
GA BO4FW
UT WOS:000514116000006
DA 2020-12-01
ER

PT J
AU Borba, JVB
   Silva, AC
   Ramos, PIP
   Grazzia, N
   Miguel, DC
   Muratov, EN
   Furnham, N
   Andrade, CH
AF Borba, Joyce V. B.
   Silva, Arthur C.
   Ramos, Pablo I. P.
   Grazzia, Nathalia
   Miguel, Danilo C.
   Muratov, Eugene N.
   Furnham, Nicholas
   Andrade, Carolina H.
TI Unveiling the Kinomes of Leishmania infantum and L. braziliensis
   Empowers the Discovery of New Kinase Targets and Antileishmanial
   Compounds
SO COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
LA English
DT Article
DE Leishmania infantum; Leishmania braziliensis; Kinome; Kinases; Drug
   repurposing; Target prioritization
ID MULTIPLE SEQUENCE ALIGNMENT; ACTIVATED PROTEIN-KINASE; POLO-LIKE KINASE;
   TRYPANOSOMA-BRUCEI; AURORA KINASE; DRUG DISCOVERY; INHIBITORS;
   IDENTIFICATION; PROMASTIGOTES; TAMOXIFEN
AB Leishmaniasis is a neglected tropical disease caused by parasites of the genus Leishmania (NTD) endemic in 98 countries. Although some drugs are available, current treatments deal with issues such as toxicity, low efficacy, and emergence of resistance. Therefore, there is an urgent need to identify new targets for the development of new antileishmanial drugs. Protein kinases (PKs), which play an essential role in many biological processes, have become potential drug targets for many parasitic diseases. A refined bioin formatics pipeline was applied in order to define and compare the kinomes of L. infantum and L. braziliensis, species that cause cutaneous and visceral manifestations of leishmaniasis in the Americas, the latter being potentially fatal if untreated. Respectively, 224 and 221 PKs were identified in L. infantum and L. braziliensis overall. Almost all unclassified eukalyotic PKs were assigned to six of nine major kinase groups and, consequently, most have been classified into family and subfamily. Furthermore, revealing the kinomes for both Leishmania species allowed for the prioritization of potential drug targets that could be explored for discovering new drugs against leishmaniasis. Finally, we used a drug repurposing approach and prioritized seven approved drugs and investigational compounds to be experimentally tested against Leishmania. Trametinib and NMS-1286937 inhibited the growth of L. infantum and L. braziliensis promastigotes and amastigotes and therefore might be good candidates for the drug repurposing pipeline. (C) 2019 Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.
C1 [Borba, Joyce V. B.; Silva, Arthur C.; Andrade, Carolina H.] Univ Fed Goias, Fac Farm, Labmol Lab Mol Modeling & Drug Design, BR-74605510 Goiania, Go, Brazil.
   [Ramos, Pablo I. P.] Fundacao Oswaldo Cruz FIOCRUZ, Inst Goncalo Moniz, BR-40296710 Salvador, BA, Brazil.
   [Grazzia, Nathalia; Miguel, Danilo C.] State Univ Campinas UNICAMP, Biol Inst, Dept Anim Biol, LEBIL Lab Leishmania Biol Infect Studies, Campinas, SP, Brazil.
   [Muratov, Eugene N.] Univ N Carolina, Eshelman Sch Pharm, Div Chem Biol & Med Chem, Lab Mol Modeling, Chapel Hill, NC 27599 USA.
   [Muratov, Eugene N.] Odessa Natl Polytech Univ, Dept Chem Technol, UA-65000 Odessa, Ukraine.
   [Furnham, Nicholas] London Sch Hyg & Trop Med, Dept Pathogen Mol Biol, London, England.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, Labmol Lab Mol Modeling & Drug Design, BR-74605510 Goiania, Go, Brazil.
EM carolina@ufg.br
RI Ramos, Pablo I. Pereira/H-6276-2019; de Carvalho e Silva,
   Arthur/S-7803-2018; Borba, Joyce V. B./S-7813-2018; Ciccone Miguel,
   Danilo/C-1484-2012; Andrade, Carolina/C-3960-2014
OI Ramos, Pablo I. Pereira/0000-0002-9075-7861; de Carvalho e Silva,
   Arthur/0000-0001-9866-3344; Borba, Joyce V. B./0000-0002-2663-5173;
   Furnham, Nicholas/0000-0002-7532-1269; Ciccone Miguel,
   Danilo/0000-0003-0522-6562; Andrade, Carolina/0000-0003-0101-1492
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [400760/2014-2]; CAPESCAPES; FAPEG; NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [1U01CA207160]; Medical Research CouncilMedical Research Council UK
   (MRC) [MR/K020420/1]; FAPESPFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [2014/21129-4]; L'Oreal-UNESCOABC Para Mulheres na
   Ciencia; L'Oreal-UNESCO International Rising Talents; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [U01CA207160, U01CA207160, U01CA207160] Funding Source: NIH RePORTER
FX The authors are sincerely thankful to Tesia Bobrowski for proofreading
   and correcting the text of the manuscript. We also would like to
   acknowledge CNPq, CAPES, and FAPEG for fellowships and funding this
   work. E.N.M. appreciate support from NIH (grant 1U01CA207160) and CNPq
   (grant 400760/2014-2). NF is supported by the Medical Research Council
   (grantMR/K020420/1). DCM is a recipient of a young investigator award
   from FAPESP (2014/21129-4). CHA has a research fellow in productivity of
   CNPq. CHA also thanks the "L'Oreal-UNESCOABC Para Mulheres na Ciencia"
   and "L'Oreal-UNESCO International Rising Talents" for the awards and
   fellowships received, which partially funded thiswork. Additionally,
   JVBB and ACSwere supported by fellowships from CAPES.
CR Allocco JJ, 2006, INT J PARASITOL, V36, P1249, DOI 10.1016/j.ijpara.2006.06.013
   Altschul S., 1990, BASIC LOCAL ALIGNMEN, P403
   Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
   Amata E, 2016, ACS INFECT DIS, V2, P180, DOI 10.1021/acsinfecdis.5b00136
   Andrade LF, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-215
   Aslett M, 2010, NUCLEIC ACIDS RES, V38, pD457, DOI 10.1093/nar/gkp851
   Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401
   Bates PA, 2007, INT J PARASITOL, V37, P1097, DOI 10.1016/j.ijpara.2007.04.003
   Boynak NY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079364
   Chhajer R, 2016, BBA-GEN SUBJECTS, V1860, P1973, DOI 10.1016/j.bbagen.2016.06.005
   Cleghorn LAT, 2011, CHEMMEDCHEM, V6, P2214, DOI 10.1002/cmdc.201100344
   Cock PJA, 2009, BIOINFORMATICS, V25, P1422, DOI 10.1093/bioinformatics/btp163
   Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773
   DARRIBA D, 2017, EUROPE PMC FUNDERS G, V27, P1164, DOI DOI 10.1093/BIOINFORMATICS/BTR088.PROTTEST
   Deshmukh K, 2010, PROG BIOPHYS MOL BIO, V102, P1, DOI 10.1016/j.pbiomolbio.2009.12.009
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Efstathiou A, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-234
   Erdmann M, 2006, MOL BIOL CELL, V17, P2035, DOI 10.1091/mbc.E05-10-0976
   Fabbro D, 2015, BRIT J PHARMACOL, V172, P2675, DOI 10.1111/bph.13096
   Gilmartin AG, 2011, CLIN CANCER RES, V17, P989, DOI 10.1158/1078-0432.CCR-10-2200
   Goldberg JM, 2013, BIOINFORMATICS, V29, P2387, DOI 10.1093/bioinformatics/btt419
   Grant KM, 2004, ANTIMICROB AGENTS CH, V48, P3033, DOI 10.1128/AAC.48.8.3033-3042.2004
   Hammarton TC, 2007, MOL MICROBIOL, V65, P1229, DOI 10.1111/j.1365-2958.2007.05866.x
   HANKS SK, 1995, FASEB J, V9, P576
   Hassan P, 2001, MOL BIOCHEM PARASIT, V113, P189, DOI 10.1016/S0166-6851(01)00220-1
   Infante JR, 2012, LANCET ONCOL, V13, P773, DOI 10.1016/S1470-2045(12)70270-X
   Jensen BC, 2011, EXP PARASITOL, V128, P250, DOI 10.1016/j.exppara.2011.03.001
   Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436
   Katsuno K, 2015, NAT REV DRUG DISCOV, V14, P751, DOI 10.1038/nrd4683
   Kayode KO, 2011, MOL BIOCHEM PARASIT, V176, P98, DOI 10.1016/j.molbiopara.2010.12.009
   Kolinsky K, 2011, CANCER CHEMOTH PHARM, V68, P1585, DOI 10.1007/s00280-011-1608-x
   LAINSON R, 1987, LEISHMANIASES BIOL M, P1
   Li L, 2003, GENOME RES, V13, P2178, DOI 10.1101/gr.1224503
   Liu JH, 2009, MOL CELL BIOL, V29, P6401, DOI 10.1128/MCB.00478-09
   Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762
   Manning Gerard, 2005, WormBook, P1
   Melnikova I, 2004, NAT REV DRUG DISCOV, V3, P993, DOI 10.1038/nrd1600
   Michalick MSM, 2005, PASITOLOGIA HUMANA11, P41
   Miguel DC, 2007, J ANTIMICROB CHEMOTH, V60, P526, DOI 10.1093/jac/dkm219
   Miguel DC, 2013, INFECT IMMUN, V81, P3620, DOI 10.1128/IAI.00687-13
   Miguel DC, 2009, J ANTIMICROB CHEMOTH, V63, P365, DOI 10.1093/jac/dkn509
   Miranda-Saavedra D, 2007, PROTEINS, V68, P893, DOI 10.1002/prot.21444
   Mottram JC, 1996, MOL MICROBIOL, V22, P573, DOI 10.1046/j.1365-2958.1996.00136.x
   MOTTRAM JC, 1995, GENE, V162, P147, DOI 10.1016/0378-1119(95)00350-F
   Nagle AS, 2014, CHEM REV, V114, P11305, DOI 10.1021/cr500365f
   Naula C, 2005, BBA-PROTEINS PROTEOM, V1754, P151, DOI 10.1016/j.bbapap.2005.08.018
   Nett IRE, 2009, MOL CELL PROTEOMICS, V8, P1527, DOI 10.1074/mcp.M800556-MCP200
   Nett IRE, 2009, EUKARYOT CELL, V8, P617, DOI 10.1128/EC.00366-08
   Neves BJ, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003435
   Ojo KK, 2008, ANTIMICROB AGENTS CH, V52, P3710, DOI 10.1128/AAC.00364-08
   Pace D, 2014, J INFECTION, V69, pS10, DOI 10.1016/j.jinf.2014.07.016
   Parsons M, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-127
   PARSONS M, 1991, MOL BIOCHEM PARASIT, V45, P241, DOI 10.1016/0166-6851(91)90091-J
   Patel G, 2014, MEDCHEMCOMM, V5, P655, DOI 10.1039/c4md00045e
   Rachidi N, 2014, ANTIMICROB AGENTS CH, V58, P1501, DOI 10.1128/AAC.02022-13
   Reznickova E, 2015, BIOORG MED CHEM LETT, V25, P2298, DOI 10.1016/j.bmcl.2015.04.030
   Silverman JM, 2010, J CELL SCI, V123, P842, DOI 10.1242/jcs.056465
   Siman-Tov MM, 2001, BBA-GENE STRUCT EXPR, V1519, P241, DOI 10.1016/S0167-4781(01)00240-8
   Singh N, 2012, ASIAN PAC J TROP MED, V5, P485, DOI 10.1016/S1995-7645(12)60084-4
   Stroehlein AJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep17759
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Tang Y, 2015, BIOSYSTEMS, V127, P67, DOI 10.1016/j.biosystems.2014.11.005
   Tovar C, 2010, CELL CYCLE, V9, P3364, DOI 10.4161/cc.9.16.12732
   Tu XM, 2006, J BIOL CHEM, V281, P9677, DOI 10.1074/jbc.M511504200
   Tu XM, 2005, EUKARYOT CELL, V4, P755, DOI 10.1128/EC.4.4.755-764.2005
   Uindon P.G., 2010, ASSESSING PERFORM PH, V59, P307, DOI DOI 10.1093/SYSBI0/SYQ010
   Urbaniak MD, 2009, MOL BIOCHEM PARASIT, V166, P183, DOI 10.1016/j.molbiopara.2009.03.001
   Valsasina B, 2012, MOL CANCER THER, V11, P1006, DOI 10.1158/1535-7163.MCT-11-0765
   Vieth M, 2005, KINOMICS CHARACTERIZ, V10
   von Freyend SJ, 2010, INT J PARASITOL, V40, P969, DOI 10.1016/j.ijpara.2010.02.004
   Walker RG, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001033
   Ward P, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-79
   WHO, 2015, LEISHMANIASIS
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Xingi E, 2009, INT J PARASITOL, V39, P1289, DOI 10.1016/j.ijpara.2009.04.005
   Zilberstein D, 2013, PHOSPHOPROTEOMIC ANA, V2
NR 76
TC 2
Z9 2
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2001-0370
J9 COMPUT STRUCT BIOTEC
JI Comp. Struct. Biotechnol. J..
PY 2019
VL 17
BP 352
EP 361
DI 10.1016/j.csbj.2019.02.005
PG 10
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA JY1TU
UT WOS:000504205700035
PM 30949306
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-01
ER

PT J
AU Andrade, CH
   Neves, B
   Melo, CC
   Rodrigues, J
   Silva, DC
   Braga, RC
   Cravo, PVL
AF Andrade, Carolina Horta
   Neves, Bruno Junior
   Melo-Filho, Cleber Camilo
   Rodrigues, Juliana
   Silva, Diego Cabral
   Braga, Rodolpho Campos
   Lemos Cravo, Pedro Vitor
TI In Silico Chemogenomics Drug Repositioning Strategies for Neglected
   Tropical Diseases
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
DE Neglected tropical diseases; drug repositioning; chemogenomics;
   similarity search; machine learning; pharmacophores; protein alignment;
   docking
ID HUMAN AFRICAN TRYPANOSOMIASIS; LIPOSOMAL AMPHOTERICIN-B; EFLORNITHINE
   COMBINATION THERAPY; TRANSMITTED HELMINTH INFECTIONS; FINGERPRINT
   SIMILARITY SEARCH; BINDING-SITE SIMILARITY; SCHISTOSOMA-MANSONI;
   CUTANEOUS LEISHMANIASIS; VISCERAL LEISHMANIASIS; QSAR MODELS
AB Only similar to 1% of all drug candidates against Neglected Tropical Diseases (NTDs) have reached clinical trials in the last decades, underscoring the need for new, safe and effective treatments. In such context, drug repositioning, which allows finding novel indications for approved drugs whose pharmacokinetic and safety profiles are already known, is emerging as a promising strategy for tackling NTDs. Chemogenomics is a direct descendent of the typical drug discovery process that involves the systematic screening of chemical compounds against drug targets in high-throughput screening (HTS) efforts, for the identification of lead compounds. However, different to the one-drug-one-target paradigm, chemogenomics attempts to identify all potential ligands for all possible targets and diseases. In this review, we summarize current methodological development efforts in drug repositioning that use state-of-the-art computational ligand- and structure-based chemogenomics approaches. Furthermore, we highlighted the recent progress in computational drug repositioning for some NTDs, based on curation and modeling of genomic, biological, and chemical data. Additionally, we also present in-house and other successful examples and suggest possible solutions to existing pitfalls.
C1 [Andrade, Carolina Horta; Neves, Bruno Junior; Melo-Filho, Cleber Camilo; Rodrigues, Juliana; Silva, Diego Cabral; Braga, Rodolpho Campos] Univ Fed Goias, Fac Pharm, LabMol Lab Mol Modeling & Drug Design, BR-74605170 Goiania, Go, Brazil.
   [Neves, Bruno Junior; Lemos Cravo, Pedro Vitor] Ctr Univ Anapolis UniEVANGELICA, Lab Cheminformat, BR-75083515 Anapolis, Go, Brazil.
   [Rodrigues, Juliana; Braga, Rodolpho Campos; Lemos Cravo, Pedro Vitor] Univ Fed Goias, Inst Trop Pathol & Publ Hlth, GenoBio Lab Genom & Biotechnol, BR-74605220 Goiania, Go, Brazil.
   [Lemos Cravo, Pedro Vitor] Univ Nova Lisboa, Inst Higiene & Med Trop, P-1349008 Lisbon, Portugal.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Pharm, LabMol Lab Mol Modeling & Drug Design, BR-74605170 Goiania, Go, Brazil.
EM andradech@yahoo.com
RI Cravo, Pedro VL/G-3532-2012; Braga, Rodolpho C/A-9655-2011; Melo-Filho,
   Cleber C./V-1119-2018; Neves, Bruno Junior/E-6295-2016; Andrade,
   Carolina/C-3960-2014
OI Cravo, Pedro VL/0000-0003-1675-4504; Braga, Rodolpho
   C/0000-0003-3814-3464; Melo-Filho, Cleber C./0000-0003-0056-6971;
   Andrade, Carolina/0000-0003-0101-1492; Neves, Bruno/0000-0002-1309-8743
FU Brazilian funding agency, CNPqNational Council for Scientific and
   Technological Development (CNPq); Brazilian funding agency, CAPESCAPES;
   Brazilian funding agency, FAPEG; L'Oreal-UNESCO-ABC Para Mulheres na
   Ciencia; L'Oreal-UNESCO International Rising Talents; MCTI/CNPq
   [444001/2014-0]
FX The authors would like to thank Brazilian funding agencies, CNPq, CAPES
   and FAPEG for financial support and fellowships. CHA also thanks the
   "L'Oreal-UNESCO-ABC Para Mulheres na Ciencia" and "L'Oreal-UNESCO
   International Rising Talents" for the awards and fellowships received.
   CHA and PVLC PVLC are research fellows of CNPq. This study was partially
   funded by MCTI/CNPq (#444001/2014-0).
CR Achenbach J, 2011, FUTURE MED CHEM, V3, P961, DOI [10.4155/FMC.11.62, 10.4155/fmc.11.62]
   Aguero F, 2008, NAT REV DRUG DISCOV, V7, P900, DOI 10.1038/nrd2684
   Alirol E, 2013, CLIN INFECT DIS, V56, P195, DOI 10.1093/cid/cis886
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Alves VM, 2015, TOXICOL APPL PHARM, V284, P273, DOI 10.1016/j.taap.2014.12.013
   Alves VM, 2015, TOXICOL APPL PHARM, V284, P262, DOI 10.1016/j.taap.2014.12.014
   Andersen SL, 1998, CLIN INFECT DIS, V26, P146, DOI 10.1086/516281
   Andrews KT, 2014, INT J PARASITOL-DRUG, V4, P95, DOI 10.1016/j.ijpddr.2014.02.002
   [Anonymous], 1998, MED LETT DRUGS THER, V40, P51
   [Anonymous], 1967, Med Lett Drugs Ther, V9, P99
   Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
   Ashkenazy H, 2010, NUCLEIC ACIDS RES, V38, pW529, DOI 10.1093/nar/gkq399
   Aube J, 2012, ACS MED CHEM LETT, V3, P442, DOI 10.1021/ml300114c
   Awadzi K, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002953
   Bahl A, 2003, NUCLEIC ACIDS RES, V31, P212, DOI 10.1093/nar/gkg081
   Barakat R, 2015, AM J TROP MED HYG, V92, P797, DOI 10.4269/ajtmh.14-0675
   Baranski M C, 1966, Rev Bras Med, V23, P233
   Baroni M, 2007, J CHEM INF MODEL, V47, P279, DOI 10.1021/ci600253e
   BARZILAI A, 1995, J AM ACAD DERMATOL, V32, P518, DOI 10.1016/0190-9622(95)90093-4
   Basra A, 2013, CLIN INFECT DIS, V56, pE68, DOI 10.1093/cid/cis976
   Bassat Q, 2016, AM J TROP MED HYG, V95, P62, DOI 10.4269/ajtmh.16-0180
   Batista J. H., 2014, J CHEMINFORMATICS, V6, P57
   Beghyn TB, 2011, J MED CHEM, V54, P3222, DOI 10.1021/jm1014617
   Ben Salah A, 2013, NEW ENGL J MED, V368, P524, DOI 10.1056/NEJMoa1202657
   Berman JD, 1999, CLIN INFECT DIS, V28, P49, DOI 10.1086/515086
   Berman J, 2015, EXPERT OPIN ORPHAN D, V3, P727, DOI 10.1517/21678707.2015.1039510
   Bern C, 2006, CLIN INFECT DIS, V43, P917, DOI 10.1086/507530
   Bethony J, 2006, LANCET, V367, P1521, DOI 10.1016/S0140-6736(06)68653-4
   Binkowski TA, 2008, BMC STRUCT BIOL, V8, DOI 10.1186/1472-6807-8-45
   Bispo NA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059288
   Bland ND, 2011, J MED CHEM, V54, P8188, DOI 10.1021/jm201148s
   Bolgar B, 2013, CURR TOP MED CHEM, V13, P2337, DOI 10.2174/15680266113136660164
   Bostrom J, 2003, J MOL GRAPH MODEL, V21, P449, DOI 10.1016/S1093-3263(02)00204-8
   Boyle JP, 2005, J PARASITOL, V91, P542, DOI 10.1645/GE-432R
   Boyle JP, 2000, EXP PARASITOL, V94, P217, DOI 10.1006/expr.2000.4500
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1899, DOI 10.2174/1568026614666140929120749
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1399, DOI 10.2174/1568026614666140506124442
   Braga RC, 2013, CURR TOP MED CHEM, V13, P1127, DOI 10.2174/1568026611313090010
   Bredel M, 2004, NAT REV GENET, V5, P262, DOI 10.1038/nrg1317
   Brkic D, 1968, Med Glas, V22, P107
   Brown SP, 2006, J CHEM INF MODEL, V46, P999, DOI 10.1021/ci050488t
   Budimulja AS, 1997, MOL BIOCHEM PARASIT, V84, P137, DOI 10.1016/S0166-6851(96)02781-8
   Burr SE, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1176
   Buscaglia CA, 2015, TRENDS GENET, V31, P539, DOI 10.1016/j.tig.2015.06.002
   Caporuscio F, 2011, CURR MED CHEM, V18, P2543, DOI 10.2174/092986711795933669
   Caron PR, 2001, CURR OPIN CHEM BIOL, V5, P464, DOI 10.1016/S1367-5931(00)00229-5
   Centers for Disease Control and Prevention, NEGLECTED TROPICAL D
   Cereto-Massague A, 2015, METHODS, V71, P58, DOI 10.1016/j.ymeth.2014.08.005
   Cerqueira NMFSA, 2015, ARCH BIOCHEM BIOPHYS, V582, P56, DOI 10.1016/j.abb.2015.05.011
   Chakraborty A, 2016, LIFE SCI, V158, P104, DOI 10.1016/j.lfs.2016.06.030
   Chang CY, 2013, J CHEM INF MODEL, V53, P958, DOI 10.1021/ci4000536
   Chavali AK, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752-0509-6-27
   Chavali AK, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.15
   Chen X, 2002, NUCLEIC ACIDS RES, V30, P412, DOI 10.1093/nar/30.1.412
   Chen X, 2001, COMB CHEM HIGH T SCR, V4, P719
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Chong CR, 2007, NATURE, V448, P645, DOI 10.1038/448645a
   Cibulskis RE, 2016, INFECT DIS POVERTY, V5, DOI 10.1186/s40249-016-0151-8
   ClinicalTrials.gov, HIGH DOSE FLUCONAZOL
   Colley DG, 2014, LANCET, V383, P2253, DOI 10.1016/S0140-6736(13)61949-2
   Crisford A, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004062
   Croft SL, 2005, TRENDS PARASITOL, V21, P508, DOI 10.1016/j.pt.2005.08.026
   CROFTS MAJ, 1976, J TROP MED HYG, V79, P111
   Das S, 2009, J CHEM INF MODEL, V49, P2863, DOI 10.1021/ci900317x
   De Franchi E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012214
   DiMasi JA, 2010, CLIN PHARMACOL THER, V87, P272, DOI 10.1038/clpt.2009.295
   DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1
   DITZEL J, 1967, ACTA MED SCAND, V182, P663
   Dobchev DA, 2014, CURR TOP MED CHEM, V14, P1913, DOI 10.2174/1568026614666140929124203
   Dubus E, 2009, FUTURE MED CHEM, V1, P1723, DOI 10.4155/FMC.09.123
   Ehrt C, 2016, J MED CHEM, V59, P4121, DOI 10.1021/acs.jmedchem.6b00078
   Ekins S, 2011, DRUG DISCOV TODAY, V16, P298, DOI 10.1016/j.drudis.2011.02.016
   Emad M, 2011, J AM ACAD DERMATOL, V64, P606, DOI 10.1016/j.jaad.2010.04.014
   Ferreira LG, 2015, MOLECULES, V20, P13384, DOI 10.3390/molecules200713384
   Finn RD, 2016, NUCLEIC ACIDS RES, V44, pD279, DOI 10.1093/nar/gkv1344
   Fontana ACK, 2009, EUR J PHARMACOL, V616, P48, DOI 10.1016/j.ejphar.2009.06.023
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Freitas-Junior LH, 2012, INT J PARASITOL-DRUG, V2, P11, DOI 10.1016/j.ijpddr.2012.01.003
   Galvan-Ramirez ML, 2007, J HELMINTHOL, V81, P255, DOI 10.1017/S0022149X07747466
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163
   GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002
   Goupil LS, 2014, CHEM REV, V114, P11131, DOI 10.1021/cr500546h
   Guimaraes CRW, 2008, J CHEM INF MODEL, V48, P958, DOI 10.1021/ci800004w
   Hart JD, 2014, TROP MED INT HEALTH, V19, P207, DOI 10.1111/tmi.12234
   Hoerauf A, 2008, MED MICROBIOL IMMUN, V197, P295, DOI 10.1007/s00430-007-0062-1
   Hofstraat K, 2016, INT HEALTH, V8, pi53, DOI 10.1093/inthealth/ihv071
   Holliday JD, 1995, QUANT STRUCT-ACT REL, V14, P501, DOI 10.1002/qsar.19950140602
   Hotez PJ, 2007, NEW ENGL J MED, V357, P1018, DOI 10.1056/NEJMra064142
   Hou XB, 2015, J CHEM INF MODEL, V55, P1973, DOI 10.1021/acs.jcim.5b00344
   Hurle MR, 2013, CLIN PHARMACOL THER, V93, P335, DOI 10.1038/clpt.2013.1
   Jin GX, 2014, DRUG DISCOV TODAY, V19, P637, DOI 10.1016/j.drudis.2013.11.005
   Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573
   Jones P, 2014, BIOINFORMATICS, V30, P1236, DOI 10.1093/bioinformatics/btu031
   Berenstein AJ, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004300
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Keiser MJ, 2007, NAT BIOTECHNOL, V25, P197, DOI 10.1038/nbt1284
   Keiser MJ, 2009, NATURE, V462, P175, DOI 10.1038/nature08506
   Kharkar PS, 2014, FUTURE MED CHEM, V6, P333, DOI 10.4155/fmc.13.207
   Kitchen LW, 2006, CLIN INFECT DIS, V43, P67, DOI 10.1086/504873
   Klabunde T, 2007, BRIT J PHARMACOL, V152, P5, DOI 10.1038/sj.bjp.0707308
   Knox C, 2011, NUCLEIC ACIDS RES, V39, pD1035, DOI 10.1093/nar/gkq1126
   Kobets T, 2012, CURR MED CHEM, V19, P1443, DOI 10.2174/092986712799828300
   Koes DR, 2014, J COMPUT CHEM, V35, P1824, DOI 10.1002/jcc.23690
   Kola I, 2004, NAT REV DRUG DISCOV, V3, P711, DOI 10.1038/nrd1470
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   Kortagere S, 2009, TRENDS PHARMACOL SCI, V30, P138, DOI 10.1016/j.tips.2008.12.001
   Koul P A, 2000, J Assoc Physicians India, V48, P402
   Kristensen DM, 2011, BRIEF BIOINFORM, V12, P379, DOI 10.1093/bib/bbr030
   Kuhn M, 2008, NUCLEIC ACIDS RES, V36, pD684, DOI 10.1093/nar/gkm795
   Kuhn M, 2012, NUCLEIC ACIDS RES, V40, pD876, DOI 10.1093/nar/gkr1011
   Kundu CN, 2015, ACTA TROP, V149, P113, DOI 10.1016/j.actatropica.2015.03.028
   Lalloo DG, 2007, J INFECTION, V54, P111, DOI 10.1016/j.jinf.2006.12.003
   Lateef M, 2008, INT J INFECT DIS, V12, P80, DOI 10.1016/j.ijid.2007.04.017
   Sbaraglini ML, 2016, CURR TOP MED CHEM, V16, P2201, DOI 10.2174/1568026616666160216154309
   Lavecchia A, 2015, DRUG DISCOV TODAY, V20, P318, DOI 10.1016/j.drudis.2014.10.012
   Le Bras J, 2003, FUND CLIN PHARMACOL, V17, P147, DOI 10.1046/j.1472-8206.2003.00164.x
   Lessa HA, 2001, AM J TROP MED HYG, V65, P87, DOI 10.4269/ajtmh.2001.65.87
   Li J, 2016, BRIEF BIOINFORM, V17, P2, DOI 10.1093/bib/bbv020
   Li L, 2003, GENOME RES, V13, P2178, DOI 10.1101/gr.1224503
   Liao CZ, 2011, FUTURE MED CHEM, V3, P1057, DOI [10.4155/FMC.11.63, 10.4155/fmc.11.63]
   Lima AN, 2016, EXPERT OPIN DRUG DIS, V11, P225, DOI 10.1517/17460441.2016.1146250
   LINDLEY D, 1987, NATURE, V329, P752, DOI 10.1038/329752a0
   Zumaquero-Rios JL, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002553
   Lionta E, 2014, CURR TOP MED CHEM, V14, P1923, DOI 10.2174/1568026614666140929124445
   Litt E, 2012, TRENDS PARASITOL, V28, P195, DOI 10.1016/j.pt.2012.03.001
   Liu Q, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-294
   Liu YX, 2014, MOLECULES, V19, P15058, DOI 10.3390/molecules190915058
   Logan-Klumpler FJ, 2012, NUCLEIC ACIDS RES, V40, pD98, DOI 10.1093/nar/gkr1032
   Luo M, 2014, J CHEM INF MODEL, V54, P634, DOI 10.1021/ci400460q
   Lyne PD, 2006, J MED CHEM, V49, P4805, DOI 10.1021/jm060522a
   Magarinos MP, 2012, NUCLEIC ACIDS RES, V40, pD1118, DOI 10.1093/nar/gkr1053
   MANSOUR TE, 1984, ADV PARASIT, V23, P1, DOI 10.1016/S0065-308X(08)60284-5
   Marti H, 1996, AM J TROP MED HYG, V55, P477, DOI 10.4269/ajtmh.1996.55.477
   MARTINEZ S, 1992, NEW ENGL J MED, V326, P741, DOI 10.1056/NEJM199203123261105
   Martinez S, 1997, CLIN INFECT DIS, V24, P165, DOI 10.1093/clinids/24.2.165
   Martorana A, 2016, CURR TOP MED CHEM, V16, P2088, DOI 10.2174/1568026616666160216153457
   McFadden GI, 1996, NATURE, V381, P482, DOI 10.1038/381482a0
   MCMAHON JE, 1979, BRIT MED J, V2, P1396, DOI 10.1136/bmj.2.6202.1396
   MCMAHON JE, 1981, ARZNEIMITTEL-FORSCH, V31-1, P592
   Mdachi RE, 2009, ANTIMICROB AGENTS CH, V53, P953, DOI 10.1128/AAC.00831-08
   Melo CC, 2016, J CHEM INF MODEL, V56, P1357, DOI 10.1021/acs.jcim.6b00055
   Melville JL, 2009, COMB CHEM HIGH T SCR, V12, P332, DOI 10.2174/138620709788167980
   Mestres J, 2004, CURR OPIN DRUG DISC, V7, P304
   Milletti F, 2010, J CHEM INF MODEL, V50, P1418, DOI 10.1021/ci1001263
   Mitchell JBO, 2014, WIRES COMPUT MOL SCI, V4, P468, DOI 10.1002/wcms.1183
   Moore RB, 2008, NATURE, V451, P959, DOI 10.1038/nature06635
   Muegge I, 2016, EXPERT OPIN DRUG DIS, V11, P137, DOI 10.1517/17460441.2016.1117070
   Muratov EN, 2010, FUTURE MED CHEM, V2, P1205, DOI 10.4155/FMC.10.194
   Najmanovich R, 2008, BIOINFORMATICS, V24, pI105, DOI 10.1093/bioinformatics/btn263
   NEAL RA, 1994, T ROY SOC TROP MED H, V88, P223, DOI 10.1016/0035-9203(94)90307-7
   Neves BJ, 2016, J MED CHEM, V59, P7075, DOI 10.1021/acs.jmedchem.5b02038
   Neves BJ, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003435
   Neves B, 2016, MEDCHEMCOMM, V7, P1176, DOI 10.1039/c5md00596e
   Neves BJ, 2016, EXPERT OPIN DRUG DIS, V11, P557, DOI 10.1080/17460441.2016.1178230
   Nightingale SL, 1997, JAMA-J AM MED ASSOC, V277, P703
   Nightingale SL, 1998, JAMA-J AM MED ASSOC, V280, P872, DOI 10.1001/jama.280.10.872
   Njoroge M, 2014, CHEM REV, V114, P11138, DOI 10.1021/cr500098f
   Novac N, 2013, TRENDS PHARMACOL SCI, V34, P267, DOI 10.1016/j.tips.2013.03.004
   Nwaka S, 2006, NAT REV DRUG DISCOV, V5, P941, DOI 10.1038/nrd2144
   O'Connell EM, 2015, J INFECT DIS, V212, P684, DOI 10.1093/infdis/jiv065
   Oliveira TD, 2000, MEM I OSWALDO CRUZ, V95, P477, DOI 10.1590/S0074-02762000000400006
   Opigo J, 2009, LANCET, V374, P7, DOI 10.1016/S0140-6736(09)61163-6
   Ottesen EA, 1999, PARASITOL TODAY, V15, P382, DOI 10.1016/S0169-4758(99)01486-6
   PANG L, 1988, J INFECT DIS, V158, P1124, DOI 10.1093/infdis/158.5.1124
   Patocka N, 2007, MOL BIOCHEM PARASIT, V154, P125, DOI 10.1016/j.molbiopara.2007.03.010
   Pedrique B, 2013, LANCET GLOB HEALTH, V1, pE371, DOI 10.1016/S2214-109X(13)70078-0
   del Villar LP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045867
   Perez-Molina JA, 2011, AM J TROP MED HYG, V84, P351, DOI 10.4269/ajtmh.2011.10-0513
   Pohlig G, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004363
   Pollastri MP, 2011, FUTURE MED CHEM, V3, P1307, DOI [10.4155/FMC.11.92, 10.4155/fmc.11.92]
   Priotto G, 2009, LANCET, V374, P56, DOI 10.1016/S0140-6736(09)61117-X
   Protasio AV, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001455
   RAHMAN MS, 1985, EXP PARASITOL, V60, P10, DOI 10.1016/S0014-4894(85)80018-7
   Ralph SA, 2004, NAT REV MICROBIOL, V2, P203, DOI 10.1038/nrmicro843
   Renslo AR, 2006, NAT CHEM BIOL, V2, P701, DOI 10.1038/nchembio837
   RIM H-J, 1978, Korean Journal of Parasitology, V16, P82, DOI 10.3347/kjp.1978.16.2.82
   Rim Han Jong, 1979, Kisaengchunghak Chapchi, V17, P67
   Rognan D, 2007, BRIT J PHARMACOL, V152, P38, DOI 10.1038/sj.bjp.0707307
   Rose PW, 2015, NUCLEIC ACIDS RES, V43, pD345, DOI 10.1093/nar/gku1214
   Rossignol JF, 1998, T ROY SOC TROP MED H, V92, P103, DOI 10.1016/S0035-9203(98)90974-9
   ROSSIGNOL JF, 1984, AM J TROP MED HYG, V33, P511, DOI 10.4269/ajtmh.1984.33.511
   Saeed MEM, 2016, PHARMACOL RES, V110, P216, DOI 10.1016/j.phrs.2016.02.017
   SAMPAIO S A P, 1971, International Journal of Dermatology, V10, P179, DOI 10.1111/j.1365-4362.1971.tb01694.x
   SANTOS AT, 1979, B WORLD HEALTH ORGAN, V57, P793
   Sateriale A, 2014, J AM MED INFORM ASSN, V21, P238, DOI 10.1136/amiajnl-2013-001700
   Schmid C, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001920
   Schmitt S, 2002, J MOL BIOL, V323, P387, DOI 10.1016/S0022-2836(02)00811-2
   Sindermann H, 2004, MED MICROBIOL IMMUN, V193, P173, DOI 10.1007/s00430-003-0201-2
   Singh S, 2007, BIOINFORMATION, V2, P68, DOI 10.6026/97320630002068
   Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L
   Sousa AQ, 2011, CLIN INFECT DIS, V53, P693, DOI 10.1093/cid/cir496
   Sousa AQ, 2016, AM J TROP MED HYG, V94, P1, DOI 10.4269/ajtmh.15-0211
   Speck-Planche A, 2015, CURR TOP MED CHEM, V15, P1801, DOI 10.2174/1568026615666150506144814
   Sundar S, 2002, NEW ENGL J MED, V347, P1739, DOI 10.1056/NEJMoa021556
   Sundar S, 2007, NEW ENGL J MED, V356, P2571, DOI 10.1056/NEJMoa066536
   Sundar S, 2010, NEW ENGL J MED, V362, P504, DOI 10.1056/NEJMoa0903627
   Supali T, 2008, CLIN INFECT DIS, V46, P1385, DOI 10.1086/586753
   Swinton N W Jr, 1965, Lahey Clin Found Bull, V14, P117
   Tagboto SK, 1996, ANN TROP MED PARASIT, V90, P497, DOI 10.1080/00034983.1996.11813075
   Tamarozzi F, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-53
   Tarral A, 2014, CLIN PHARMACOKINET, V53, P565, DOI 10.1007/s40262-014-0136-3
   Taylor CM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003505
   Taylor MJ, 2010, LANCET, V376, P1175, DOI 10.1016/S0140-6736(10)60586-7
   Taylor MJ, 2005, LANCET, V365, P2116, DOI 10.1016/S0140-6736(05)66591-9
   Tibayrenc M, 2012, P NATL ACAD SCI USA, V109, pE3305, DOI 10.1073/pnas.1212452109
   Tilley L, 2016, TRENDS PARASITOL, V32, P682, DOI 10.1016/j.pt.2016.05.010
   Totrov M, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-S1-S35
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Tu HB, 2013, PROTEIN J, V32, P373, DOI 10.1007/s10930-013-9494-1
   Van de Erve J, 1966, J S C Med Assoc, V62, P263
   Vuorinen A, 2015, METHODS, V71, P113, DOI 10.1016/j.ymeth.2014.10.013
   Waheed AA, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0660-0
   Wang JM, 2001, J AM CHEM SOC, V123, P5221, DOI 10.1021/ja003834q
   Wang Q, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004026
   Wang YL, 2012, NUCLEIC ACIDS RES, V40, pD400, DOI 10.1093/nar/gkr1132
   Wang Y, 2015, NUCLEIC ACIDS RES, V43, pW78, DOI 10.1093/nar/gkv487
   Weiss MG, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000237
   WHITE AT, 1987, J INFECT DIS, V156, P463, DOI 10.1093/infdis/156.3.463
   WHO, 2010, WHO TECH REP SER, V949, P1
   WHO, NEGLECTED TROPICAL D
   WILSON RJM, 1994, INFECT AGENT DIS, V3, P29
   Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067
   Wood DJ, 2012, J CHEM INF MODEL, V52, P2031, DOI 10.1021/ci3000776
   Woodrow CJ, 2006, CELL MOL LIFE SCI, V63, P1586, DOI 10.1007/s00018-006-6071-1
   Wyatt PG, 2011, CURR TOP MED CHEM, V11, P1275
   Xiao SH, 2005, ACTA TROP, V96, P153, DOI 10.1016/j.actatropica.2005.07.010
   Yeh E, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001138
   Yeturu K, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-543
   Zakharov AV, 2014, J CHEM INF MODEL, V54, P705, DOI 10.1021/ci400737s
   Zhang LY, 2013, J CHEM INF MODEL, V53, P475, DOI 10.1021/ci300421n
   Zhong SJ, 2010, CURR OPIN DRUG DISC, V13, P326
   Zhu F, 2010, NUCLEIC ACIDS RES, V38, pD787, DOI 10.1093/nar/gkp1014
   Zijlstra EE, 2016, LANCET INFECT DIS, V16, P100, DOI 10.1016/S1473-3099(15)00359-X
   ZWIERZ C, 1985, Bulletin of the Institute of Maritime and Tropical Medicine in Gdynia, V36, P77
NR 237
TC 6
Z9 6
U1 1
U2 4
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PY 2019
VL 26
IS 23
BP 4355
EP 4379
DI 10.2174/0929867325666180309114824
PG 25
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA JC8WB
UT WOS:000489555700004
PM 29521204
DA 2020-12-01
ER

PT J
AU Alves, VM
   Borba, J
   Capuzzi, SJ
   Muratov, E
   Andrade, CH
   Rusyn, I
   Tropsha, A
AF Alves, Vinicius M.
   Borba, Joyce
   Capuzzi, Stephen J.
   Muratov, Eugene
   Andrade, Carolina H.
   Rusyn, Ivan
   Tropsha, Alexander
TI Oy Vey! A Comment on "Machine Learning of Toxicological Big Data Enables
   Read-Across Structure Activity Relationships Outperforming Animal Test
   Reproducibility"
SO TOXICOLOGICAL SCIENCES
LA English
DT Letter
C1 [Alves, Vinicius M.; Borba, Joyce; Capuzzi, Stephen J.; Muratov, Eugene; Tropsha, Alexander] Univ N Carolina, UNC Eshelman Sch Pharm, 100K Beard Hall, Chapel Hill, NC 27599 USA.
   [Borba, Joyce; Andrade, Carolina H.] Univ Fed Goias, Fac Pharm, BR-74605170 Goiania, Go, Brazil.
   [Muratov, Eugene] Odessa Natl Polytech Univ, UA-65000 Odessa, Ukraine.
   [Rusyn, Ivan] Texas A&M Univ, Coll Vet Med & Biomed Sci, 4458 TAMU, College Stn, TX 77843 USA.
RP Tropsha, A (corresponding author), Univ N Carolina, UNC Eshelman Sch Pharm, 100K Beard Hall, Chapel Hill, NC 27599 USA.; Rusyn, I (corresponding author), Texas A&M Univ, Coll Vet Med & Biomed Sci, 4458 TAMU, College Stn, TX 77843 USA.
EM irusyn@tamu.edu; alex_tropsha@unc.edu
RI Tropsha, Alexander/AAB-8324-2020; Alves, Vinicius M./G-7955-2015; Borba,
   Joyce V. B./S-7813-2018; Andrade, Carolina/C-3960-2014
OI Alves, Vinicius M./0000-0002-6182-1748; Borba, Joyce V.
   B./0000-0002-2663-5173; Andrade, Carolina/0000-0003-0101-1492
FU National Institute of Environmental Health SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Environmental Health Sciences (NIEHS)
   [P42 ES027704]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Environmental
   Health Sciences (NIEHS) [P42ES027704, P42ES027704, P42ES027704,
   P42ES027704, P42ES027704, P42ES027704, P42ES027704, P42ES027704,
   P42ES027704, P42ES027704, P42ES027704, P42ES027704, P42ES027704,
   P42ES027704, P42ES027704, P42ES027704, P42ES027704, P42ES027704,
   P42ES027704, P42ES027704, P42ES027704, P42ES027704, P42ES027704,
   P42ES027704, P42ES027704, P42ES027704, P42ES027704, P42ES027704,
   P42ES027704, P42ES027704, P42ES027704, P42ES027704, P42ES027704,
   P42ES027704, P42ES027704, P42ES027704, P42ES027704, P42ES027704,
   P42ES027704, P42ES027704, P42ES027704, P42ES027704, P42ES027704,
   P42ES027704, P42ES027704, P42ES027704, P42ES027704, P42ES027704] Funding
   Source: NIH RePORTER
FX National Institute of Environmental Health Sciences, (Grant/Award
   Number: P42 ES027704).
NR 0
TC 3
Z9 3
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1096-6080
EI 1096-0929
J9 TOXICOL SCI
JI Toxicol. Sci.
PD JAN
PY 2019
VL 167
IS 1
BP 3
EP 4
DI 10.1093/toxsci/kfy286
PG 2
WC Toxicology
SC Toxicology
GA HR1BF
UT WOS:000462862400001
PM 30500930
OA Green Published
DA 2020-12-01
ER

PT J
AU Neves, BJ
   Braga, RC
   Melo, CC
   Moreira, JT
   Muratov, EN
   Andrade, CH
AF Neves, Bruno J.
   Braga, Rodolpho C.
   Melo-Filho, Cleber C.
   Moreira-Filho, Jose Teofilo
   Muratov, Eugene N.
   Andrade, Carolina Horta
TI QSAR-Based Virtual Screening: Advances and Applications in Drug
   Discovery
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE cheminformatics; machine learning; molecular descriptors;
   computer-assisted drug design; virtual screening
ID ALLOSTERIC MODULATORS; SCHISTOSOMA-MANSONI; CHEMOGENOMICS DATA;
   CURATION; MODELS; INTEGRATION; RECEPTORS; CHEMISTRY; VERIFY; TRUST
AB Virtual screening (VS) has emerged in drug discovery as a powerful computational approach to screen large libraries of small molecules for new hits with desired properties that can then be tested experimentally. Similar to other computational approaches, VS intention is not to replace in vitro or in vivo assays, but to speed up the discovery process, to reduce the number of candidates to be tested experimentally, and to rationalize their choice. Moreover, VS has become very popular in pharmaceutical companies and academic organizations due to its time-, cost-, resources-, and labor-saving. Among the VS approaches, quantitative structure-activity relationship (QSAR) analysis is the most powerful method due to its high and fast throughput and good hit rate. As the first preliminary step of a QSAR model development, relevant chemogenomics data are collected from databases and the literature. Then, chemical descriptors are calculated on different levels of representation of molecular structure, ranging from 1D to nD, and then correlated with the biological property using machine learning techniques. Once developed and validated, QSAR models are applied to predict the biological property of novel compounds. Although the experimental testing of computational hits is not an inherent part of QSAR methodology, it is highly desired and should be performed as an ultimate validation of developed models. In this mini-review, we summarize and critically analyze the recent trends of QSAR-based VS in drug discovery and demonstrate successful applications in identifying perspective compounds with desired properties. Moreover, we provide some recommendations about the best practices for QSAR-based VS along with the future perspectives of this approach.
C1 [Neves, Bruno J.; Braga, Rodolpho C.; Melo-Filho, Cleber C.; Moreira-Filho, Jose Teofilo; Andrade, Carolina Horta] Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.
   [Neves, Bruno J.] Ctr Univ Anapolis UniEVANGELICA, Lab Cheminformat, Anapolis, Brazil.
   [Muratov, Eugene N.] Univ N Carolina, Lab Mol Modeling, Div Chem Biol & Med Chem, Eshelman Sch Pharm, Chapel Hill, NC 27515 USA.
   [Muratov, Eugene N.] Odessa Natl Polytech Univ, Dept Chem Technol, Odessa, Ukraine.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.
EM carolina@ufg.br
RI Neves, Bruno Junior/E-6295-2016; Moreira-Filho, Jose
   Teofilo/S-8333-2018; Braga, Rodolpho C/A-9655-2011; Neves,
   Bruno/R-7068-2019; Andrade, Carolina/C-3960-2014; Camilo Melo-Filho,
   Cleber/V-1119-2018
OI Moreira-Filho, Jose Teofilo/0000-0002-0777-280X; Braga, Rodolpho
   C/0000-0003-3814-3464; Neves, Bruno/0000-0002-1309-8743; Andrade,
   Carolina/0000-0003-0101-1492; Camilo Melo-Filho,
   Cleber/0000-0003-0056-6971
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [1U01CA207160]; CNPqNational Council
   for Scientific and Technological Development (CNPq) [400760/2014-2]
FX This work was partially funded by the Grant No. 1U01CA207160 from NIH
   and Grant No. 400760/2014-2 from CNPq. CHA is Research Fellow in
   productivity of CNPq.
CR AlMatar M, 2017, BIOMED PHARMACOTHER, V91, P546, DOI 10.1016/j.biopha.2017.04.105
   [Anonymous], 2018, HIV AIDS
   Bajorath J, 2012, J COMPUT AID MOL DES, V26, P11, DOI 10.1007/s10822-011-9488-z
   Ban FQ, 2017, J CHEM INF MODEL, V57, P1018, DOI 10.1021/acs.jcim.7b00137
   Butkiewicz M, 2013, MOLECULES, V18, P735, DOI 10.3390/molecules18010735
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Cihlar T, 2016, CURR OPIN VIROL, V18, P50, DOI 10.1016/j.coviro.2016.03.004
   Colley DG, 2014, LANCET, V383, P2253, DOI 10.1016/S0140-6736(13)61949-2
   Ekins S, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003878
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Garbelli A, 2017, BIOCHEM J, V474, P1559, DOI 10.1042/BCJ20160772
   Goh GB, 2017, J COMPUT CHEM, V38, P1291, DOI 10.1002/jcc.24764
   Gomes MN, 2017, EUR J MED CHEM, V137, P126, DOI 10.1016/j.ejmech.2017.05.026
   Gorobets NY, 2017, CURR TOP MED CHEM, V17, P2143, DOI 10.2174/1568026617666170130123520
   HANSCH C, 1964, J AM CHEM SOC, V86, P1616, DOI 10.1021/ja01062a035
   Kar S, 2013, EXPERT OPIN DRUG DIS, V8, P245, DOI 10.1517/17460441.2013.761204
   Kuntz AN, 2007, PLOS MED, V4, P1071, DOI 10.1371/journal.pmed.0040206
   Kurczyk A, 2015, J CHEM INF MODEL, V55, P2168, DOI 10.1021/acs.jcim.5b00295
   Laborda P, 2016, MOLECULES, V21, DOI 10.3390/molecules21111513
   Lacivita E, 2012, EXPERT OPIN THER PAT, V22, P887, DOI 10.1517/13543776.2012.703654
   Lian WW, 2016, MOL DIVERS, V20, P439, DOI 10.1007/s11030-015-9641-z
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Luo M, 2014, J CHEM INF MODEL, V54, P634, DOI 10.1021/ci400460q
   Melo CC, 2016, J CHEM INF MODEL, V56, P1357, DOI 10.1021/acs.jcim.6b00055
   Menard D, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a025619
   Mitchell JBO, 2014, WIRES COMPUT MOL SCI, V4, P468, DOI 10.1002/wcms.1183
   Mueller R, 2012, CHEMMEDCHEM, V7, P406, DOI 10.1002/cmdc.201100510
   Mueller R, 2010, ACS CHEM NEUROSCI, V1, P288, DOI 10.1021/cn9000389
   Muratov EN, 2012, MOL INFORM, V31, P202, DOI 10.1002/minf.201100129
   Nantasenamat C, 2015, EXPERT OPIN DRUG DIS, V10, P321, DOI 10.1517/17460441.2015.1016497
   Neves BJ, 2016, J MED CHEM, V59, P7075, DOI 10.1021/acs.jmedchem.5b02038
   Nichols DE, 2008, CHEM REV, V108, P1614, DOI 10.1021/cr078224o
   OECD, 2004, OECD PRIN VALI REG
   Phillips MA, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.50
   Rodriguez AL, 2010, MOL PHARMACOL, V78, P1105, DOI 10.1124/mol.110.067207
   Southan C, 2009, J CHEMINFORMATICS, V1, DOI 10.1186/1758-2946-1-10
   Tanrikulu Y, 2013, DRUG DISCOV TODAY, V18, P358, DOI 10.1016/j.drudis.2013.01.007
   Thorne N, 2010, CURR OPIN CHEM BIOL, V14, P315, DOI 10.1016/j.cbpa.2010.03.020
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   WHO, 2018, MALARIA
   WHO, 2018, INFLUENZA
   WHO, 2018, SCHISTOSOMIASIS
   Williams AJ, 2011, DRUG DISCOV TODAY, V16, P747, DOI 10.1016/j.drudis.2011.07.007
   World Health Organization, 2018, TUBERCULOSIS
   Young D, 2008, QSAR COMB SCI, V27, P1337, DOI 10.1002/qsar.200810084
   Zhang LY, 2013, J CHEM INF MODEL, V53, P475, DOI 10.1021/ci300421n
NR 48
TC 43
Z9 43
U1 5
U2 30
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 13
PY 2018
VL 9
AR 1275
DI 10.3389/fphar.2018.01275
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA HA1LH
UT WOS:000449974000002
PM 30524275
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Mottin, M
   Borba, JVVB
   Braga, RC
   Torres, PHM
   Martini, MC
   Proenca-Modena, JL
   Judice, CC
   Costa, FTM
   Ekins, S
   Perryman, AL
   Andrade, CH
AF Mottin, Melina
   Borba, Joyce V. V. B.
   Braga, Rodolpho C.
   Torres, Pedro H. M.
   Martini, Matheus C.
   Proenca-Modena, Jose Luiz
   Judice, Carla C.
   Costa, Fabio T. M.
   Ekins, Sean
   Perryman, Alexander L.
   Andrade, Carolina Horta
TI The A-Z of Zika drug discovery
SO DRUG DISCOVERY TODAY
LA English
DT Review
ID VIRUS NS2B-NS3 PROTEASE; NORDIHYDROGUAIARETIC ACID NDGA; INTERFERENCE
   COMPOUNDS PAINS; SMALL-MOLECULE INHIBITORS; DEPENDENT RNA-POLYMERASE;
   INFECTION IN-VITRO; DENGUE VIRUS; BROAD-SPECTRUM; CRYSTAL-STRUCTURE;
   ANTIVIRAL ACTIVITY
AB Despite the recent outbreak of Zika virus (ZIKV), there are still no approved treatments, and early-stage compounds are probably many years away from approval. A comprehensive A-Z review of the recent advances in ZIKV drug discovery efforts is presented, highlighting drug repositioning and computationally guided compounds, including discovered viral and host cell inhibitors. Promising ZIKV molecular targets are also described and discussed, as well as targets belonging to the host cell, as new opportunities for ZIKV drug discovery. All this knowledge is not only crucial to advancing the fight against the Zika virus and other flaviviruses but also helps us prepare for the next emerging virus outbreak to which we will have to respond.
C1 [Mottin, Melina; Borba, Joyce V. V. B.; Braga, Rodolpho C.; Andrade, Carolina Horta] Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, BR-74605170 Goiania, Go, Brazil.
   [Torres, Pedro H. M.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Torres, Pedro H. M.] Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.
   [Martini, Matheus C.; Proenca-Modena, Jose Luiz] Univ Estadual Campinas, Lab Emerging Viruses LEVE, Dept Genet Evolut Microbiol & Immunol, Inst Biol, BR-13083864 Campinas, SP, Brazil.
   [Judice, Carla C.; Costa, Fabio T. M.; Andrade, Carolina Horta] Univ Estadual Campinas, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Dept Genet Evolut Microbiol & Immunol, Inst Biol, BR-13083864 Campinas, SP, Brazil.
   [Ekins, Sean] Collaborat Pharmaceut Inc, 840 Main Campus Dr,Lab 3510, Raleigh, NC 27606 USA.
   [Perryman, Alexander L.] Rutgers State Univ, New Jersey Med Sch, Dept Pharmacol Physiol & Neurosci, Newark, NJ 07103 USA.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, BR-74605170 Goiania, Go, Brazil.; Andrade, CH (corresponding author), Univ Estadual Campinas, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Dept Genet Evolut Microbiol & Immunol, Inst Biol, BR-13083864 Campinas, SP, Brazil.
EM carolina@ufg.br
RI Borba, Joyce V. B./S-7813-2018; Braga, Rodolpho C/A-9655-2011; Mottin,
   Melina/D-8700-2016; Modena, Jose Luiz Proenca/C-8231-2014; Torres, Pedro
   Henrique Monteiro/C-7657-2015; Martini, Matheus C/E-9416-2015;
   Proenca-Modena, Jose Luiz/AAU-7622-2020; Costa, Fabio/E-1181-2012;
   Judice, Carla/P-4738-2014
OI Borba, Joyce V. B./0000-0002-2663-5173; Braga, Rodolpho
   C/0000-0003-3814-3464; Mottin, Melina/0000-0003-0878-9029; Modena, Jose
   Luiz Proenca/0000-0002-4996-3153; Torres, Pedro Henrique
   Monteiro/0000-0002-0945-1495; Martini, Matheus C/0000-0003-0135-4364;
   Proenca-Modena, Jose Luiz/0000-0002-4996-3153; Costa,
   Fabio/0000-0001-9969-7300; Judice, Carla/0000-0003-1839-053X
FU Brazilian CNPq/FAPEG DCR [300508/2017-4]; Sao Paulo Research Foundation
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [16/00194-8, 2017/02353-9, 2016/13805-5, 2012/16525-2]; FAPESP Visiting
   Researcher Program [2017/02353-9]; CNPqNational Council for Scientific
   and Technological Development (CNPq); L'Oreal-UNESCO-ABC Para Mulheres
   na Ciencia; L'Oreal-UNESCO International Rising Talents Program
FX This work was partially supported by the Brazilian CNPq/FAPEG DCR Grant
   300508/2017-4 and by the Sao Paulo Research Foundation (FAPESP) Grants
   16/00194-8, 2017/02353-9, 2016/13805-5, 2012/16525-2. C.H.A. thanks the
   FAPESP Visiting Researcher Program (grant 2017/02353-9). F.T.M.C. and
   C.H.A. have CNPq productivity fellowships. C.H.A. also thanks the
   L'Oreal-UNESCO-ABC Para Mulheres na Ciencia and L'Oreal-UNESCO
   International Rising Talents Program for the awards and fellowships
   received. We sincerely thank the OpenZika project
   (http://openzika.ufg.br), the wonderful ongoing support and
   encouragement of the IBM's World Community Grid team and the community
   of volunteers who donate their computer time.
CR Adcock RS, 2017, ANTIVIR RES, V138, P47, DOI 10.1016/j.antiviral.2016.11.018
   Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293
   Albulescu IC, 2017, ANTIVIR RES, V143, P230, DOI 10.1016/j.antiviral.2017.04.016
   Aleshin AE, 2007, PROTEIN SCI, V16, P795, DOI 10.1110/ps.072753207
   Andrae-Marobela K, 2013, CURR DRUG METAB, V14, P392, DOI 10.2174/13892002113149990095
   Ashour J, 2010, CELL HOST MICROBE, V8, P410, DOI 10.1016/j.chom.2010.10.007
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Bahramsoltani R, 2016, EXPERT REV ANTI-INFE, V14, P57, DOI 10.1586/14787210.2016.1120670
   Balasubramanian A, 2017, ANTIVIR RES, V137, P141, DOI 10.1016/j.antiviral.2016.11.015
   Barrow-Grint K, 2016, PLOS NEGLECT TROP D, V10, P1
   Barrows NJ, 2016, CELL HOST MICROBE, V20, P259, DOI 10.1016/j.chom.2016.07.004
   Basavannacharya C, 2014, BIOCHEM BIOPH RES CO, V453, P539, DOI 10.1016/j.bbrc.2014.09.113
   Bekerman E, 2017, J CLIN INVEST, V127, P1338, DOI 10.1172/JCI89857
   Bekerman E, 2015, SCIENCE, V348, P282, DOI 10.1126/science.aaa3778
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Best SM, 2005, J VIROL, V79, P12828, DOI 10.1128/JVI.79.20.12828-12839.2005
   Bhattacharyya S, 2013, CELL HOST MICROBE, V14, P136, DOI 10.1016/j.chom.2013.07.005
   Blazquez AB, 2014, FRONT MICROBIOL, V5, DOI [10.3389/fmicb.2014.00266, 10.3389/fmicb.2014.00797]
   Blecha JE, 2007, BIOORG MED CHEM LETT, V17, P4026, DOI 10.1016/j.bmcl.2007.04.092
   Boldescu V, 2017, NAT REV DRUG DISCOV, V16, P565, DOI 10.1038/nrd.2017.33
   Brecher M, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006411
   Browning DJ, 2014, HYDROXYCHLOROQUINE C
   Byrd CM, 2013, ANTIMICROB AGENTS CH, V57, P1902, DOI 10.1128/AAC.02251-12
   Byrd CM, 2013, ANTIMICROB AGENTS CH, V57, P15, DOI 10.1128/AAC.01429-12
   Cao B, 2017, J EXP MED, V214, P2303, DOI 10.1084/jem.20170957
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Carneiro BM, 2016, VIROLOGY, V496, P215, DOI 10.1016/j.virol.2016.06.012
   Carteaux G, 2016, NEW ENGL J MED, V374, P1595, DOI 10.1056/NEJMc1602964
   Chan JFW, 2017, ANTIVIR RES, V141, P29, DOI 10.1016/j.antiviral.2017.02.002
   Chang JH, 2013, ANTIVIR RES, V99, P251, DOI 10.1016/j.antiviral.2013.06.011
   Ciesek S, 2009, HEPATOLOGY, V50, P1638, DOI 10.1002/hep.23281
   Cihlar T, 2010, ANTIVIR RES, V85, P39, DOI 10.1016/j.antiviral.2009.09.014
   Costello A, 2016, B WORLD HEALTH ORGAN, V94, P406, DOI 10.2471/BLT.16.176990
   Coutard B, 2017, J VIROL, V91, DOI 10.1128/JVI.02202-16
   Crance JM, 2003, ANTIVIR RES, V58, P73, DOI 10.1016/S0166-3542(02)00185-7
   Dai LP, 2016, CELL HOST MICROBE, V19, P696, DOI 10.1016/j.chom.2016.04.013
   Dar HA, 2017, INFECT GENET EVOL, V51, P143, DOI 10.1016/j.meegid.2017.03.027
   De Clercq E, 2011, ANNU REV PHARMACOL, V51, P1, DOI 10.1146/annurev-pharmtox-010510-100228
   Delvecchio R, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8120322
   Denisova OV, 2012, J BIOL CHEM, V287, P35324, DOI 10.1074/jbc.M112.392142
   Duan D, 2015, ACS CHEM BIOL, V10, P978, DOI 10.1021/cb5009487
   Egger D, 2002, J VIROL, V76, P5974, DOI 10.1128/JVI.76.12.5974-5984.2002
   Ekins S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005023
   Ekins Sean, 2016, F1000Res, V5, P275
   Ekins Sean, 2016, F1000Res, V5, P150, DOI 10.12688/f1000research.8013.1
   Eyer L, 2017, ANTIVIR RES, V142, P63, DOI 10.1016/j.antiviral.2017.03.012
   Eyer L, 2016, J INFECT DIS, V214, P707, DOI 10.1093/infdis/jiw226
   Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636
   Fernando S, 2016, MOL BIOTECHNOL, V58, P801, DOI 10.1007/s12033-016-9979-1
   Fonseca BD, 2012, J BIOL CHEM, V287, P17530, DOI 10.1074/jbc.M112.359638
   Food and Drug Administration HHS, 2014, Fed Regist, V79, P72063
   Furtado JM, 2016, NEW ENGL J MED, V375, P394, DOI 10.1056/NEJMc1603618
   Goder V, 2012, CURR PROTEIN PEPT SC, V13, P425, DOI 10.2174/138920312802430572
   Grant A, 2016, CELL HOST MICROBE, V19, P882, DOI 10.1016/j.chom.2016.05.009
   Hazin AN, 2016, NEW ENGL J MED, V374, P2193, DOI 10.1056/NEJMc1603617
   Heaton NS, 2010, P NATL ACAD SCI USA, V107, P17345, DOI 10.1073/pnas.1010811107
   Hedstrom L, 2009, CHEM REV, V109, P2903, DOI 10.1021/cr900021w
   Hercik K, 2017, ARCH VIROL, V162, P2091, DOI 10.1007/s00705-017-3345-x
   Hercik K, 2017, ANTIVIR RES, V137, P131, DOI 10.1016/j.antiviral.2016.11.020
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Hussein HA, 2015, NUCLEIC ACIDS RES, V43, pW436, DOI 10.1093/nar/gkv462
   Ikeda M, 2006, HEPATOLOGY, V44, P117, DOI 10.1002/hep.21232
   Jain R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01756-7
   Jain R, 2016, NAT STRUCT MOL BIOL, V23, P752, DOI 10.1038/nsmb.3258
   Julander JG, 2017, ANTIVIR RES, V137, P14, DOI 10.1016/j.antiviral.2016.11.003
   Jurgeit A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002976
   Kanno Tomoko, 2002, Physiological Chemistry and Physics and Medical NMR, V34, P1
   Kota S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032207
   Kuivanen S, 2017, ANTIVIR RES, V139, P117, DOI 10.1016/j.antiviral.2016.12.022
   Laurent-Rolle M, 2014, CELL HOST MICROBE, V16, P314, DOI 10.1016/j.chom.2014.07.015
   Lee H, 2017, ANTIVIR RES, V139, P49, DOI 10.1016/j.antiviral.2016.12.016
   Lei J, 2016, SCIENCE, V353, P503, DOI 10.1126/science.aag2419
   Leon D, 2016, FEBS OPEN BIO, V6, P1000, DOI 10.1002/2211-5463.12106
   Li CF, 2017, IMMUNITY, V46, P446, DOI 10.1016/j.immuni.2017.02.012
   Li T, 2018, CELL RES, V28, P497, DOI 10.1038/s41422-018-0007-9
   Li Y, 2017, STRUCTURE, V25, P1242, DOI 10.1016/j.str.2017.06.006
   Li Z, 2017, CELL RES, V27, P1046, DOI 10.1038/cr.2017.88
   Liang QM, 2016, CELL STEM CELL, V19, P663, DOI 10.1016/j.stem.2016.07.019
   Lim HJ, 2017, BIOTECHNOL LETT, V39, P415, DOI 10.1007/s10529-016-2261-6
   Lim SP, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005737
   Lim SP, 2015, ANTIVIR RES, V119, P57, DOI 10.1016/j.antiviral.2015.04.010
   Lim SP, 2013, ANTIVIR RES, V100, P500, DOI 10.1016/j.antiviral.2013.09.013
   Lin RJ, 2006, J VIROL, V80, P5908, DOI 10.1128/JVI.02714-05
   Lindenbach BD, 2007, FIELDS VIROLOGY, P1101
   Lu G, 2017, ANTIMICROB AGENTS CH, V61, P1
   Lu J.-M, 2010, MED SCI MONITOR, DOI [10.1111/j.1600-6143.2008.02497.x.Plasma, DOI 10.1111/J.1600-6143.2008.02497.X.PLASMA]
   Lucas-Hourani M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003678
   Luo D, 2008, J VIROL, V82, P173, DOI 10.1128/JVI.01788-07
   Mastrangelo E, 2007, J MOL BIOL, V372, P444, DOI 10.1016/j.jmb.2007.06.055
   Mastrangelo E, 2012, J ANTIMICROB CHEMOTH, V67, P1884, DOI 10.1093/jac/dks147
   McGovern SL, 2002, J MED CHEM, V45, P1712, DOI 10.1021/jm010533y
   McGrath J, 2015, PHARMACOL THERAPEUT, V150, P1, DOI 10.1016/j.pharmthera.2015.01.002
   Mecharles S, 2016, LANCET, V8, P6736, DOI DOI 10.1136/BCR-2012-007094.4
   Meertens L, 2017, CELL REP, V18, P324, DOI 10.1016/j.celrep.2016.12.045
   Meertens L, 2012, CELL HOST MICROBE, V12, P544, DOI 10.1016/j.chom.2012.08.009
   Merino-Ramos T, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00376-17, 10.1128/aac.00376-17]
   Metz JT, 2007, J COMPUT AID MOL DES, V21, P139, DOI 10.1007/s10822-007-9109-z
   Miller S, 2006, J BIOL CHEM, V281, P8854, DOI 10.1074/jbc.M512697200
   Miller S, 2007, J BIOL CHEM, V282, P8873, DOI 10.1074/jbc.M609919200
   Mohr EL, 2015, ANTIVIR RES, V120, P40, DOI 10.1016/j.antiviral.2015.05.003
   Monel B, 2017, EMBO J, V36, P1653, DOI 10.15252/embj.201695597
   Mottin M., 2017, BIOCHEM BIOPH RES CO, V2017, P1
   Mumtaz N, 2017, ANTIVIR RES, V146, P161, DOI 10.1016/j.antiviral.2017.09.004
   Noble CG, 2012, J VIROL, V86, P438, DOI 10.1128/JVI.06225-11
   Park GS, 2007, J VIROL, V81, P6936, DOI 10.1128/JVI.02830-06
   Pascoalino Bruno S, 2016, F1000Res, V5, P2523
   Patkar CG, 2009, ANTIMICROB AGENTS CH, V53, P4103, DOI 10.1128/AAC.00074-09
   Perera R, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002584
   Pernia Sonia, 2016, P T, V41, P713
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pouliot M, 2016, J MED CHEM, V59, P497, DOI 10.1021/acs.jmedchem.5b00361
   Qing M, 2009, ANTIMICROB AGENTS CH, V53, P3226, DOI 10.1128/AAC.00189-09
   Qu XW, 2011, ANTIMICROB AGENTS CH, V55, P1036, DOI 10.1128/AAC.01319-10
   Ram B. M., 1843, BIOCHIM BIOPHYS ACTA, P2497
   Ramharack P, 2018, J BIOMOL STRUCT DYN, V36, P1118, DOI 10.1080/07391102.2017.1313175
   Rausch K, 2017, CELL REP, V18, P804, DOI 10.1016/j.celrep.2016.12.068
   Rishton GM, 2003, DRUG DISCOV TODAY, V8, P86, DOI 10.1016/S1359644602025722
   Rothwell C, 2009, VIROLOGY, V389, P8, DOI 10.1016/j.virol.2009.03.025
   Roy A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170541
   Sahoo Maheswata, 2016, Genomics & Informatics, V14, P104, DOI 10.5808/GI.2016.14.3.104
   Saladino R, 2008, CURR MED CHEM, V15, P1500, DOI 10.2174/092986708784638889
   SALARI H, 1984, PROSTA LEUKOTR MED, V13, P53, DOI 10.1016/0262-1746(84)90102-1
   Samsa MM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000632
   Sarkey JP, 2007, J NEUROCHEM, V100, P1265, DOI 10.1111/j.1471-4159.2006.04309.x
   Savidis G, 2016, CELL REP, V16, P232, DOI 10.1016/j.celrep.2016.06.028
   Saw WG, 2017, ANTIVIR RES, V141, P73, DOI 10.1016/j.antiviral.2017.02.005
   Scaturro P, 2014, J VIROL, V88, P11540, DOI 10.1128/JVI.01745-14
   Shang B.-D., 2015, J GEN VIROL, V96, P1264
   Shang ZF, 2018, J MOL BIOL, V430, P948, DOI 10.1016/j.jmb.2018.02.006
   Sharma N, 2017, INT J BIOL MACROMOL, V104, P1046, DOI 10.1016/j.ijbiomac.2017.06.105
   Shiryaev SA, 2017, ANTIVIR RES, V143, P218, DOI 10.1016/j.antiviral.2017.04.015
   Sirohi D., 2016, SCIENCE, DOI [10.1126/science.aafS316, DOI 10.1126/SCIENCE.AAFS316]
   Smit JM, 2011, VIRUSES-BASEL, V3, P160, DOI 10.3390/v3020160
   Sperandio S, 2004, CELL DEATH DIFFER, V11, P1066, DOI 10.1038/sj.cdd.4401465
   Stephen P, 2016, J AM CHEM SOC, V138, P16212, DOI 10.1021/jacs.6b10399
   Stevens AJ, 2009, J MED CHEM, V52, P7911, DOI 10.1021/jm900652e
   Stevenson B, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001188
   Syed GH, 2011, HEPATOLOGY, V54, P1936, DOI 10.1002/hep.24619
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   Tang WC, 2014, J VIROL, V88, P6793, DOI 10.1128/JVI.00045-14
   Tay MYF, 2013, ANTIVIR RES, V99, P301, DOI 10.1016/j.antiviral.2013.06.002
   Tiwari SK, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.9
   Tritsch D, 2015, BIOORG CHEM, V59, P140, DOI 10.1016/j.bioorg.2015.02.008
   Umareddy I, 2006, J GEN VIROL, V87, P2605, DOI 10.1099/vir.0.81844-0
   van Cleef KWR, 2013, ANTIVIR RES, V99, P165, DOI 10.1016/j.antiviral.2013.05.011
   Varghese FS, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.02227-16, 10.1128/aac.02227-16]
   Versteeg GA, 2010, CURR OPIN MICROBIOL, V13, P508, DOI 10.1016/j.mib.2010.05.009
   Wagstaff K. M., 2012, BIOCHEM J, P443
   Wang BX, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14763
   Wang QY, 2015, J VIROL, V89, P8233, DOI 10.1128/JVI.00855-15
   Wang ZY, 2017, J GEN VIROL, V98, P2061, DOI 10.1099/jgv.0.000886
   Warren TK, 2014, NATURE, V508, P402, DOI 10.1038/nature13027
   Watterson D, 2016, ANTIVIR RES, V130, P7, DOI 10.1016/j.antiviral.2016.02.014
   Whitehorn J, 2016, CLIN INFECT DIS, V62, P468, DOI 10.1093/cid/civ949
   Wu YH, 2016, WORLD J GASTROENTERO, V22, P188, DOI 10.3748/wjg.v22.i1.188
   Xie XP, 2017, J INFECT DIS, V216, pS945, DOI 10.1093/infdis/jix406
   Xie XP, 2015, ANTIVIR RES, V118, P39, DOI 10.1016/j.antiviral.2015.03.007
   Xie XP, 2011, J VIROL, V85, P11183, DOI 10.1128/JVI.05468-11
   Xin QL, 2017, J VIROL, V91, DOI [10.1128/jvi.00554-17, 10.1128/JVI.00554-17]
   Xu HT, 2017, J ANTIMICROB CHEMOTH, V72, P727, DOI 10.1093/jac/dkw514
   Xu M, 2016, NAT MED, V22, P1101, DOI 10.1038/nm.4184
   Yang W, 2013, BIOORGAN MED CHEM, V21, P1050, DOI 10.1016/j.bmc.2013.01.013
   Yokoyama T, 2014, J MED CHEM, V57, P8928, DOI 10.1021/jm500997m
   Youn S, 2012, J VIROL, V86, P7360, DOI 10.1128/JVI.00157-12
   Yu GY, 2006, J VIROL, V80, P6013, DOI 10.1128/JVI.00053-06
   Yuan L, 2017, SCIENCE, V358, P933, DOI 10.1126/science.aam7120
   Yuan SF, 2017, ANTIVIR RES, V145, P33, DOI 10.1016/j.antiviral.2017.07.007
   Zavodovskaya M, 2008, J CELL BIOCHEM, V103, P624, DOI 10.1002/jcb.21435
   Zhang ZZ, 2016, SCIENCE, V354, P1597, DOI 10.1126/science.aai9309
   Zhao BY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14762
   Zmurko J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004695
   Zou J, 2015, J VIROL, V89, P3455, DOI 10.1128/JVI.03453-14
NR 172
TC 15
Z9 16
U1 2
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6446
EI 1878-5832
J9 DRUG DISCOV TODAY
JI Drug Discov. Today
PD NOV
PY 2018
VL 23
IS 11
BP 1833
EP 1847
DI 10.1016/j.drudis.2018.06.014
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA HD5NT
UT WOS:000452577900006
PM 29935345
OA Green Published
DA 2020-12-01
ER

PT J
AU Low, YS
   Alves, VM
   Fourches, D
   Sedykh, A
   Andrade, CH
   Muratov, EN
   Rusyn, I
   Tropsha, A
AF Low, Yen S.
   Alves, Vinicius M.
   Fourches, Denis
   Sedykh, Alexander
   Andrade, Carolina Horta
   Muratov, Eugene N.
   Rusyn, Ivan
   Tropsha, Alexander
TI Chemistry-Wide Association Studies (CWAS): A Novel Framework for
   Identifying and Interpreting Structure-Activity Relationships
SO JOURNAL OF CHEMICAL INFORMATION AND MODELING
LA English
DT Article
ID READ-ACROSS; APPLICABILITY DOMAINS; CHEMICAL-STRUCTURE; QSAR; TOXICITY;
   DRUGS; CHEMINFORMATICS; CLASSIFICATION; VALIDATION; FRAGMENTS
AB Quantitative structure activity relationships (QSAR) models are often seen as a "black box" because they are considered difficult to interpret. Meanwhile, qualitative approaches, e.g., structural alerts (SA) or read-across, provide mechanistic insight, which is preferred for regulatory purposes, but predictive accuracy of such approaches is often low. Herein, we introduce the chemistry-wide association study (CWAS) approach, a novel framework that both addresses such deficiencies and combines advantages of statistical QSAR and alert-based approaches. The CWAS framework consists of the following steps: (i) QSAR model building for an end point of interest, (ii) identification of key chemical features, (iii) determination of communities of such features disproportionately co-occurring more frequently in the active than in the inactive class, and (iv) assembling these communities to form larger (and not necessarily chemically connected) novel structural alerts with high specificity. As a proof-of-concept, we have applied CWAS to model Ames mutagenicity and Stevens Johnson Syndrome (SJS). For the well-studied Ames mutagenicity data set, we identified 76 important individual fragments and assembled co-occurring fragments into SA both replicative of known as well as representing novel mutagenicity alerts. For the SJS data set, we identified 29 important fragments and assembled co-occurring communities into SA including both known and novel alerts. In summary, we demonstrate that CWAS provides a new framework to interpret predictive QSAR models and derive refined structural alerts for more effective design and safety assessment of drugs and drug candidates.
C1 [Low, Yen S.; Alves, Vinicius M.; Muratov, Eugene N.; Tropsha, Alexander] Univ N Carolina, UNC Eshelman Sch Pharm, Lab Mol Modeling, Chapel Hill, NC 27599 USA.
   [Alves, Vinicius M.; Andrade, Carolina Horta] Univ Fed Goias, Dept Pharm, Lab Mol Modeling & Design, BR-74605170 Goiania, Go, Brazil.
   [Fourches, Denis] North Carolina State Univ, Dept Chem, Raleigh, NC 27695 USA.
   [Fourches, Denis] North Carolina State Univ, Bioinformat Res Ctr, Raleigh, NC 27695 USA.
   [Sedykh, Alexander] Sciome LLC, Res Triangle Pk, NC 27709 USA.
   [Muratov, Eugene N.] Odessa Natl Polytech Univ, Dept Chem Technol, UA-65000 Odessa, Ukraine.
   [Rusyn, Ivan] Texas A&M Univ, Dept Vet Integrat Biosci, College Stn, TX 77843 USA.
RP Tropsha, A (corresponding author), Univ N Carolina, UNC Eshelman Sch Pharm, Lab Mol Modeling, Chapel Hill, NC 27599 USA.
EM alex_tropsha@unc.edu
RI Tropsha, Alexander/AAB-8324-2020; Alves, Vinicius M./G-7955-2015;
   Muratov, Eugene/C-4454-2014; Andrade, Carolina/C-3960-2014
OI Alves, Vinicius M./0000-0002-6182-1748; Muratov,
   Eugene/0000-0003-4616-7036; Tropsha, Alexander/0000-0003-3802-8896;
   Fourches, Denis/0000-0001-5642-8303; Andrade,
   Carolina/0000-0003-0101-1492
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [1U01CA207160, P42 ES027704,
   GM5105946]; FAPEG [201310267001095]; CNPqNational Council for Scientific
   and Technological Development (CNPq) [400760/2014-2]; CAPESCAPES;
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [U01CA207160, U01CA207160, U01CA207160] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Environmental Health
   Sciences (NIEHS) [P42ES027704, P42ES027704, P42ES027704, P42ES027704,
   P42ES027704, P42ES027704, P42ES027704, P42ES027704, P42ES027704,
   P42ES027704, P42ES027704, P42ES027704, P42ES027704, P42ES027704,
   P42ES027704, P42ES027704, P42ES027704, P42ES027704, P42ES027704,
   P42ES027704, P42ES027704, P42ES027704, P42ES027704, P42ES027704,
   P42ES027704, P42ES027704, P42ES027704, P42ES027704, P42ES027704,
   P42ES027704, P42ES027704, P42ES027704, P42ES027704, P42ES027704,
   P42ES027704, P42ES027704, P42ES027704, P42ES027704, P42ES027704,
   P42ES027704, P42ES027704, P42ES027704, P42ES027704, P42ES027704,
   P42ES027704, P42ES027704, P42ES027704, P42ES027704, P42ES027704,
   P42ES027704] Funding Source: NIH RePORTER
FX This study was supported in part by the NIH (grants 1U01CA207160, P42
   ES027704, and GM5105946), FAPEG (grant 201310267001095), and CNPq (grant
   400760/2014-2). V.A. thanks CAPES for a graduate scholarship. D.F. also
   thanks the NC State Chancellor's Faculty Excellence Program.
CR Alves VM, 2018, J CHEM INF MODEL, V58, P1214, DOI 10.1021/acs.jcim.8b00124
   Alves VM, 2016, GREEN CHEM, V18, P4348, DOI [10.1039/C6GC01492E, 10.1039/c6gc01492e]
   Benfenati E, 2015, SAR QSAR ENVIRON RES, V26, P605, DOI 10.1080/1062936X.2015.1078408
   Benigni R, 2006, CURR COMPUT-AID DRUG, V2, P169, DOI 10.2174/157340906777441663
   Brackett CC, 2004, PHARMACOTHERAPY, V24, P856, DOI 10.1592/phco.24.9.856.36106
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Bureau A, 2005, GENET EPIDEMIOL, V28, P171, DOI 10.1002/gepi.20041
   Capuzzi SJ, 2017, J CHEM INF MODEL, V57, P417, DOI 10.1021/acs.jcim.6b00465
   Chakravarti SK, 2012, J CHEM INF MODEL, V52, P2609, DOI [10.1021/ci300111r, 10.1021/ci300111rl]
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Cronin MTD, 2013, ISSUES TOXICOL, V17, P1, DOI 10.1039/9781849734400-00001
   Cronin MTD, 2013, ISSUES TOXICOL, V17, P155, DOI 10.1039/9781849734400-00155
   Denny JC, 2010, BIOINFORMATICS, V26, P1205, DOI 10.1093/bioinformatics/btq126
   Enoch SJ, 2013, ISSUES TOXICOL, V17, P30, DOI 10.1039/9781849734400-00030
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Gamage N, 2006, TOXICOL SCI, V90, P5, DOI 10.1093/toxsci/kfj061
   Glowienke S, 2005, MUTAT RES-GEN TOX EN, V581, P23, DOI 10.1016/j.mrgentox.2004.10.004
   Handoko KB, 2008, DRUG SAFETY, V31, P695, DOI 10.2165/00002018-200831080-00006
   Hansen K, 2009, J CHEM INF MODEL, V49, P2077, DOI 10.1021/ci900161g
   Holmes E, 2008, ERNST SCHERING FOUND, V4, P227, DOI 10.1007/2789_2008_096
   Kazius J, 2005, J MED CHEM, V48, P312, DOI 10.1021/jm040835a
   King DE, 2000, AM FAM PHYSICIAN, V61, P2741
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kuz'min VE, 2008, J COMPUT AID MOL DES, V22, P403, DOI 10.1007/s10822-008-9179-6
   Lind PM, 2013, ENVIRON INT, V55, P1, DOI 10.1016/j.envint.2013.01.017
   Lindquist M, 2008, DRUG INF J, V42, P409, DOI 10.1177/009286150804200501
   Low Y, 2013, CHEM RES TOXICOL, V26, P1199, DOI 10.1021/tx400110f
   Low YS, 2016, J AM MED INFORM ASSN, V23, P968, DOI 10.1093/jamia/ocv127
   Lozano S, 2010, J CHEM INF MODEL, V50, P1330, DOI 10.1021/ci100092x
   Naisbitt DJ, 1999, BRIT J PHARMACOL, V126, P1393, DOI 10.1038/sj.bjp.0702453
   OECD, WORKSH STRUCT AL OEC
   Oprisiu I, 2012, MOL INFORM, V31, P491, DOI 10.1002/minf.201200006
   Patel CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010746
   Polishchuk PG, 2013, MOL INFORM, V32, P843, DOI 10.1002/minf.201300029
   Pons P., COMPUTING COMMUNITIE
   Price N, 2014, FOOD CHEM TOXICOL, V71, P136, DOI 10.1016/j.fct.2014.05.022
   Raunio H, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00033
   ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404
   Roujeau JC, 2011, J ALLERGY CLIN IMMUN, V128, P1277, DOI 10.1016/j.jaci.2011.10.015
   Rucker C, 2007, J CHEM INF MODEL, V47, P2345, DOI 10.1021/ci700157b
   Schwarz DF, 2010, BIOINFORMATICS, V26, P1752, DOI 10.1093/bioinformatics/btq257
   Stepan AF, 2011, CHEM RES TOXICOL, V24, P1345, DOI 10.1021/tx200168d
   Strobl C, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-307
   Sushko I, 2010, J CHEM INF MODEL, V50, P2094, DOI 10.1021/ci100253r
   Tetko IV, 2008, J CHEM INF MODEL, V48, P1733, DOI 10.1021/ci800151m
   Toler SM, 2004, ANN PHARMACOTHER, V38, P2166, DOI 10.1345/aph.1E206
   Tropsha A, 2007, CURR PHARM DESIGN, V13, P3494, DOI 10.2174/138161207782794257
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Uetrecht J, 2002, DRUG METAB REV, V34, P651, DOI 10.1081/DMR-120005667
   Valdar W, 2012, GENET EPIDEMIOL, V36, P451, DOI 10.1002/gepi.21639
   Varnek A, 2005, J COMPUT AID MOL DES, V19, P693, DOI 10.1007/s10822-005-9008-0
   Varnek A, 2008, CURR COMPUT-AID DRUG, V4, P191, DOI 10.2174/157340908785747465
NR 54
TC 2
Z9 2
U1 0
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1549-9596
EI 1549-960X
J9 J CHEM INF MODEL
JI J. Chem Inf. Model.
PD NOV
PY 2018
VL 58
IS 11
BP 2203
EP 2213
DI 10.1021/acs.jcim.8b00450
PG 11
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Computer Science,
   Information Systems; Computer Science, Interdisciplinary Applications
SC Pharmacology & Pharmacy; Chemistry; Computer Science
GA HC2RU
UT WOS:000451650400006
PM 30376324
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Ferreira, DD
   Mesquita, JT
   Silva, TAD
   Romanelli, MM
   Batista, DDJ
   da Silva, CF
   da Gama, ANS
   Neves, BJ
   Melo, CC
   Soeiro, MDC
   Andrade, CH
   Tempone, AG
AF Ferreira, Daiane Dias
   Mesquita, Juliana Tonini
   da Costa Silva, Thais Alves
   Romanelli, Maiara Maria
   Jaen Batista, Denise da Gama
   da Silva, Cristiane Franca
   Silva da Gama, Aline Nefertiti
   Neves, Bruno Junior
   Melo-Filho, Cleber Camilo
   Correia Soeiro, Maria de Nazare
   Andrade, Carolina Horta
   Tempone, Andre Gustavo
TI Efficacy of sertraline against Trypanosoma cruzi: an in vitro and in
   silico study
SO JOURNAL OF VENOMOUS ANIMALS AND TOXINS INCLUDING TROPICAL DISEASES
LA English
DT Article
DE Trypanosoma cruzi; Drug; Treatment; Sertraline; Drug repurposing; Drug
   repositioning
ID HEMOFLAGELLATE LEISHMANIA-DONOVANI; PROGRAMMED CELL-DEATH; MITOCHONDRIAL
   DYSFUNCTION; DRUG; PROTEIN; BENZNIDAZOLE; DISEASE; DIFFERENTIATION;
   HOMEOSTASIS; METABOLISM
AB Background: Drug repurposing has been an interesting and cost-effective approach, especially for neglected diseases, such as Chagas disease.
   Methods: In this work, we studied the activity of the antidepressant drug sertraline against Trypanosoma cruzi trypomastigotes and intracellular amastigotes of the Y and Tulahuen strains, and investigated its action mode using cell biology and in silico approaches.
   Results: Sertraline demonstrated in vitro efficacy against intracellular amastigotes of both T. cruzi strains inside different host cells, including cardiomyocytes, with IC50 values between 1 to 10 mu M, and activity against bloodstream trypomastigotes, with IC50 of 14 mu M. Considering the mammalian cytotoxicity, the drug resulted in a selectivity index of 17.8. Sertraline induced a change in the mitochondrial integrity of T. cruzi, resulting in a decrease in ATP levels, but not affecting reactive oxygen levels or plasma membrane permeability. In silico approaches using chemogenomic target fishing, homology modeling and molecular docking suggested the enzyme isocitrate dehydrogenase 2 of T. cruzi (TcIDH2) as a potential target for sertraline.
   Conclusions: The present study demonstrated that sertraline had a lethal effect on different forms and strains of T. cruzi, by affecting the bioenergetic metabolism of the parasite. These findings provide a starting point for future experimental assays and may contribute to the development of new compounds.
C1 [Ferreira, Daiane Dias; Mesquita, Juliana Tonini; da Costa Silva, Thais Alves; Romanelli, Maiara Maria; Tempone, Andre Gustavo] Adolfo Lutz Inst, Ctr Parasitol & Mycol, Ave Dr Arnaldo 351,8 Andar,Sala 9, BR-01246000 Sao Paulo, SP, Brazil.
   [Jaen Batista, Denise da Gama; da Silva, Cristiane Franca; Silva da Gama, Aline Nefertiti; Correia Soeiro, Maria de Nazare] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Biol Celular, Ave Brasil 4365, BR-21040360 Rio De Janeiro, RJ, Brazil.
   [Neves, Bruno Junior; Melo-Filho, Cleber Camilo; Andrade, Carolina Horta] Univ Fed Goias, Fac Farm, Rua 240 Setor Leste Univ, BR-74605170 Goiania, Go, Brazil.
RP Tempone, AG (corresponding author), Adolfo Lutz Inst, Ctr Parasitol & Mycol, Ave Dr Arnaldo 351,8 Andar,Sala 9, BR-01246000 Sao Paulo, SP, Brazil.
EM daiane_bio09@hotmail.com; andre.tempone@ial.sp.gov.br
RI Tempone, Andre/ABA-2231-2020; Neves, Bruno/R-7068-2019; de Nazare
   Correia Soeiro, Maria/S-1894-2019; Neves, Bruno Junior/E-6295-2016;
   Tempone, Andre Gustavo/E-5932-2012; Camilo Melo-Filho,
   Cleber/V-1119-2018; Andrade, Carolina/C-3960-2014
OI Tempone, Andre/0000-0003-2559-7344; Neves, Bruno/0000-0002-1309-8743; de
   Nazare Correia Soeiro, Maria/0000-0003-0078-6106; Tempone, Andre
   Gustavo/0000-0002-9900-1470; Mesquita, Juliana
   Tonini/0000-0002-1734-3400; Camilo Melo-Filho,
   Cleber/0000-0003-0056-6971; Andrade, Carolina/0000-0003-0101-1492
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2015/23403-9]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq); Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES; Fundacao de
   Amparo a Pesquisa do Estado de Goias(FAPEG); Coordination for the
   Improvement of Higher Education Personnel (CAPES)CAPES [13/2016, do
   Auxilio 0722/2017, do Processo 88881.142062/2017-01]; National Council
   for Scientific and Technological Development (CNPq) Programa Editorial
   CNPq/CAPES [26/2017, 440954/2017-7]
FX The authors thank Sao Paulo Research Foundation (FAPESP) for financial
   support (grant 2015/23403-9 for AGT); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq) for scientific awards to
   AGT, CHA, MNCS; and Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES) and Fundacao de Amparo a Pesquisa do Estado de
   Goias(FAPEG) for financial support and fellowships. The authors are also
   grateful to FAPERJ and Fiocruz. MNCS is Cientista do Nosso Estado (CNE
   -FAPERJ). This publication was supported by the Coordination for the
   Improvement of Higher Education Personnel (CAPES) through Programa
   Editoracao CAPES -Edital No. 13/2016, No. do Auxilio 0722/2017, No. do
   Processo 88881.142062/2017-01 and from the National Council for
   Scientific and Technological Development (CNPq) Programa Editorial
   CNPq/CAPES process No. 26/2017, Proc. No. 440954/2017-7.
CR ADROHER FJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P252, DOI 10.1016/0003-9861(88)90030-6
   Ashkenazy H, 2010, NUCLEIC ACIDS RES, V38, pW529, DOI 10.1093/nar/gkq399
   Berman J, 2015, EXPERT OPIN ORPHAN D, V3, P727, DOI 10.1517/21678707.2015.1039510
   Bermudez R, 1997, MOL BIOCHEM PARASIT, V90, P43, DOI 10.1016/S0166-6851(97)00131-X
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Biegert A, 2009, P NATL ACAD SCI USA, V106, P3770, DOI 10.1073/pnas.0810767106
   BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201
   Chen L, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.003012
   da Silva CF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030356
   Duan WZ, 2008, NEUROBIOL DIS, V30, P312, DOI 10.1016/j.nbd.2008.01.015
   Gascon J, 2010, ACTA TROP, V115, P22, DOI 10.1016/j.actatropica.2009.07.019
   Katsuno K, 2015, NAT REV DRUG DISCOV, V14, P751, DOI 10.1038/nrd4683
   Labbe G, 2008, FUND CLIN PHARMACOL, V22, P335, DOI 10.1111/j.1472-8206.2008.00608.x
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Leroux AE, 2011, MOL BIOCHEM PARASIT, V177, P61, DOI 10.1016/j.molbiopara.2011.01.010
   Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158
   Li Y, 2012, TOXICOL SCI, V127, P582, DOI 10.1093/toxsci/kfs100
   Pereira PCM, 2013, J VENOM ANIM TOXINS, V19, DOI 10.1186/1678-9199-19-34
   Martins LF, 2016, J NAT PROD, V79, P2202, DOI 10.1021/acs.jnatprod.6b00256
   Maya JD, 2004, BIOL RES, V37, P61, DOI 10.4067/S0716-97602004000100007
   Maya JD, 2007, COMP BIOCHEM PHYS A, V146, P601, DOI 10.1016/j.cbpa.2006.03.004
   McGann M, 2011, J CHEM INF MODEL, V51, P578, DOI 10.1021/ci100436p
   Mehta A, 2004, J BIOL CHEM, V279, P11798, DOI 10.1074/jbc.M309341200
   MEIRELLES MNL, 1986, EUR J CELL BIOL, V41, P198
   Mesquita JT, 2014, MOL CELL BIOCHEM, V389, P293, DOI 10.1007/s11010-013-1954-6
   Morillo CA, 2015, NEW ENGL J MED, V373, P1295, DOI 10.1056/NEJMoa1507574
   Munoz-Bellido JL, 2000, INT J ANTIMICROB AG, V14, P177, DOI 10.1016/S0924-8579(99)00154-5
   Neves BJ, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003435
   Palit P, 2008, J ANTIMICROB CHEMOTH, V61, P1120, DOI 10.1093/jac/dkn046
   Pecoul B, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004343
   Pupko T, 2002, BIOINFORMATICS, V18, P1116, DOI 10.1093/bioinformatics/18.8.1116
   Reis M, 2007, J ANAL TOXICOL, V31, P254, DOI 10.1093/jat/31.5.254
   Ren JS, 2018, J MED CHEM, V61, P724, DOI 10.1021/acs.jmedchem.7b01249
   Ribeiro GA, 2013, J ANTIMICROB CHEMOTH, V68, P789, DOI 10.1093/jac/dks498
   Rognan D, 2007, BRIT J PHARMACOL, V152, P38, DOI 10.1038/sj.bjp.0707307
   Romanha AJ, 2010, MEM I OSWALDO CRUZ, V105, P233, DOI 10.1590/S0074-02762010000200022
   Menna-Barreto RFS, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/614014
   Sen N, 2004, J BIOL CHEM, V279, P52366, DOI 10.1074/jbc.M406705200
   Sen N, 2004, CELL DEATH DIFFER, V11, P924, DOI 10.1038/sj.cdd.4401435
   Tempone Andre Gustavo, 2007, Cardiovascular & Hematological Agents in Medicinal Chemistry, V5, P222
   Tuynder M, 2004, P NATL ACAD SCI USA, V101, P15364, DOI 10.1073/pnas.0406776101
   VERCESI AE, 1993, BRAZ J MED BIOL RES, V26, P355
   Villa-Bellosta R, 2011, AM J PHYSIOL-HEART C, V301, pH61, DOI 10.1152/ajpheart.01020.2010
   Wang F, 2013, SCIENCE, V340, P622, DOI 10.1126/science.1234769
   Weeks JC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18457-w
   Wilkinson SR, 2008, P NATL ACAD SCI USA, V105, P5022, DOI 10.1073/pnas.0711014105
   Williams RAM, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002695
   Zhai B, 2012, ANTIMICROB AGENTS CH, V56, P3758, DOI 10.1128/AAC.00212-12
   Zhu K, 2014, PROTEINS, V82, P1646, DOI 10.1002/prot.24551
   Zingales B, 2009, MEM I OSWALDO CRUZ, V104, P1051, DOI 10.1590/S0074-02762009000700021
   Zingales B, 2014, MEM I OSWALDO CRUZ, V109, P828, DOI 10.1590/0074-0276140156
NR 51
TC 5
Z9 5
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1678-9199
J9 J VENOM ANIM TOXINS
JI J. Venom. Anim. Toxins Trop. Dis.
PD OCT 30
PY 2018
VL 24
AR 30
DI 10.1186/s40409-018-0165-8
PG 12
WC Toxicology; Tropical Medicine; Zoology
SC Toxicology; Tropical Medicine; Zoology
GA GY9QZ
UT WOS:000448985100001
PM 30450114
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Silva, LC
   Neves, BJ
   Gomes, MN
   Melo, CC
   Soares, CMA
   Andrade, CH
   Pereira, M
AF Silva, Livia C.
   Neves, Bruno J.
   Gomes, Marcelo N.
   Melo-Filho, Cleber C.
   Soares, Celia M. A.
   Andrade, Carolina H.
   Pereira, Maristela
TI Computer-aided identification of novel anti-paracoccidioidomycosis
   compounds
SO FUTURE MICROBIOLOGY
LA English
DT Article
DE 5-nitroheteroaryl chalcones; antifungal activity; computer-aided drug
   design; paracoccidioidomycosis; shape-based
ID CHALCONE DERIVATIVES; GENERATION; DISCOVERY; CURATION; VERIFY; MODELS;
   KNIME; TRUST
AB Aim: The shape-based virtual screening was used for the identification of new compounds anti-paracoccidioidomycosis (PCM). Materials & methods: The study was performed according to the following steps: collection and curation of a dataset of quinolinyl N-oxide chalcones with anti-PCM activity, development and validation of shape-based models, application of the best model for virtual screening, and experimental validation. Results & Conclusion: Among 31 computational hits, eight compounds showed potent antifungal activity and low cytotoxicity for mammalian cells. The checkerboard assay showed that most promising hit (compound 3) displayed additive effects with the antifungal cotrimoxazole and amphotericin B. Therefore, the shape-based virtual screening allowed us to discover promising compounds in prospective hit-to-lead optimization studies for tackling PCM.
C1 [Silva, Livia C.; Soares, Celia M. A.; Pereira, Maristela] Univ Fed Goias, Lab Mol Biol, Goiania, Go, Brazil.
   [Neves, Bruno J.; Gomes, Marcelo N.; Melo-Filho, Cleber C.; Andrade, Carolina H.] Univ Fed Goias, Fac Farmacia, Lab Mol Modeling & Drug Design, BR-74605510 Goiania, Go, Brazil.
   [Neves, Bruno J.] UniEVANGELICA, Ctr Univ Anapolis, Lab Cheminformat, BR-75083515 Anapolis, Go, Brazil.
   [Gomes, Marcelo N.] Univ Estadual Goias, InSiChem Drug Discovery, BR-74643090 Goiania, Go, Brazil.
RP Pereira, M (corresponding author), Univ Fed Goias, Lab Mol Biol, Goiania, Go, Brazil.; Andrade, CH (corresponding author), Univ Fed Goias, Fac Farmacia, Lab Mol Modeling & Drug Design, BR-74605510 Goiania, Go, Brazil.
EM carolhandrade@gmail.com; maristelaufg@gmail.com
RI Neves, Bruno Junior/E-6295-2016; Neves, Bruno/R-7068-2019; Andrade,
   Carolina/C-3960-2014; Camilo Melo-Filho, Cleber/V-1119-2018
OI Neves, Bruno/0000-0002-1309-8743; Andrade, Carolina/0000-0003-0101-1492;
   Camilo Melo-Filho, Cleber/0000-0003-0056-6971
FU MCTI/CNPq (Ministerio da Ciencia e Tecnologia/Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico); FNDCT (Fundo Nacional de
   Desenvolvimento Cientifico e Tecnologico); FAPEG (Fundacao de Amparo a
   Pesquisa do Estado de Goias); CAPES (Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior)CAPES; FINEP (Financiadora de Estudos e
   Projetos)Ciencia Tecnologia e Inovacao (FINEP); PRONEX (Programa de
   Apoio a Nucleos de Excelencia); INCT-IF (Instituto Nacional de Ciencia e
   Tecnologia para Inovacao Farmaceutica)
FX This work was performed at Universidade Federal de Goias supported by
   MCTI/CNPq (Ministerio da Ciencia e Tecnologia/Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico), FNDCT (Fundo Nacional de
   Desenvolvimento Cientifico e Tecnologico), FAPEG (Fundacao de Amparo a
   Pesquisa do Estado de Goias), CAPES (Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior), FINEP (Financiadora de Estudos e Projetos),
   PRONEX (Programa de Apoio a Nucleos de Excelencia) and INCT-IF
   (Instituto Nacional de Ciencia e Tecnologia para Inovacao Farmaceutica).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript. The authors have
   no other relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR ANDERSON S, 1984, J MOL GRAPHICS, V2, P83, DOI 10.1016/0263-7855(84)80060-0
   Bajusz D, 2015, J CHEMINFORMATICS, V7, DOI 10.1186/s13321-015-0069-3
   Beisken S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-257
   Berthold MR, 2008, STUD CLASS DATA ANAL, P319, DOI 10.1145/1656274.1656280
   Braga RC, 2015, MOL INFORM, V34, P698, DOI 10.1002/minf.201500040
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1399, DOI 10.2174/1568026614666140506124442
   Braga RC, 2013, CURR TOP MED CHEM, V13, P1127, DOI 10.2174/1568026611313090010
   Cuenca-Estrella M, 2004, J ANTIMICROB CHEMOTH, V54, P854, DOI 10.1093/jac/dkh434
   Silva ACADE, 2013, J CLIN MICROBIOL, V51, P1250, DOI 10.1128/JCM.02914-12
   Denning DW, 2015, SCIENCE, V347, P1414, DOI 10.1126/science.aaa6097
   Ferreira MS, 2009, PAEDIATR RESPIR REV, V10, P161, DOI 10.1016/j.prrv.2009.08.001
   Fisher MC, 2018, SCIENCE, V360, P739, DOI 10.1126/science.aap7999
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Gomes MN, 2017, MOLECULES, V22, DOI 10.3390/molecules22081210
   Gomes MN, 2017, EUR J MED CHEM, V137, P126, DOI 10.1016/j.ejmech.2017.05.026
   Grant JA, 1996, J COMPUT CHEM, V17, P1653, DOI 10.1002/(SICI)1096-987X(19961115)17:14<1653::AID-JCC7>3.0.CO;2-K
   Hawkins PCD, 2007, J MED CHEM, V50, P74, DOI 10.1021/jm0603365
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Huang ZN, 2016, J CHEM INF MODEL, V56, P21, DOI 10.1021/acs.jcim.5b00299
   Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+
   Jaccard P., 1901, B SOC VAUD SCI NAT, V37, P241, DOI DOI 10.5169/SEALS-266440
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Lavecchia A, 2013, CURR MED CHEM, V20, P2839, DOI 10.2174/09298673113209990001
   Martinez R, 2017, J FUNGI, V3, DOI 10.3390/jof3010001
   Neves BJ, 2016, EXPERT OPIN DRUG DIS, V11, P557, DOI 10.1080/17460441.2016.1178230
   Queiroz-Telles F, 2017, LANCET INFECT DIS, V17, pE367, DOI 10.1016/S1473-3099(17)30306-7
   Reynolds CH, 2014, CURR PHARM DESIGN, V20, P3380, DOI 10.2174/138161282020140528105532
   Rush TS, 2005, J MED CHEM, V48, P1489, DOI 10.1021/jm040163o
   Schwarz P, 2007, ANTIMICROB AGENTS CH, V51, P383, DOI 10.1128/AAC.00446-06
   Shikanai-Yasuda MA, 2017, REV SOC BRAS MED TRO, V50, P715, DOI 10.1590/0037-8682-0230-2017
   Shikanai-Yasuda MA, 2015, REV INST MED TROP SP, V57, P31, DOI 10.1590/S0036-46652015000700007
   Tavares LD, 2011, EUR J MED CHEM, V46, P4448, DOI 10.1016/j.ejmech.2011.07.019
   Teixeira MM, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004397
   Truchon JF, 2007, J CHEM INF MODEL, V47, P488, DOI 10.1021/ci600426e
NR 36
TC 5
Z9 5
U1 1
U2 5
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0913
EI 1746-0921
J9 FUTURE MICROBIOL
JI Future Microbiol.
PD OCT
PY 2018
VL 13
IS 13
BP 1523
EP 1536
DI 10.2217/fmb-2018-0175
PG 14
WC Microbiology
SC Microbiology
GA HD3LW
UT WOS:000452419200009
PM 30311802
DA 2020-12-01
ER

PT J
AU Giuliani, S
   Silva, AC
   Borba, JVVB
   Ramos, PIP
   Paveley, RA
   Muratov, EN
   Andrade, CH
   Furnham, N
AF Giuliani, Sandra
   Silva, Arthur C.
   Borba, Joyce V. V. B.
   Ramos, Pablo I. P.
   Paveley, Ross A.
   Muratov, Eugene N.
   Andrade, Carolina Horta
   Furnham, Nicholas
TI Computationally-guided drug repurposing enables the discovery of kinase
   targets and inhibitors as new schistosomicidal agents
SO PLOS COMPUTATIONAL BIOLOGY
LA English
DT Article
ID MULTIPLE SEQUENCE ALIGNMENT; PROTEIN-KINASE; POTENTIAL TARGETS; GENOME;
   DATABASE; INTEGRATION; NETWORKS; IMATINIB
AB The development of novel therapeutics is urgently required for diseases where existing treatments are failing due to the emergence of resistance. This is particularly pertinent for parasitic infections of the tropics and sub-tropics, referred to collectively as neglected tropical diseases, where the commercial incentives to develop new drugs are weak. One such disease is schistosomiasis, a highly prevalent acute and chronic condition caused by a parasitic helminth infection, with three species of the genus Schistosoma infecting humans. Currently, a single 40-year old drug, praziquantel, is available to treat all infective species, but its use in mass drug administration is leading to signs of drug-resistance emerging. To meet the challenge of developing new therapeutics against this disease, we developed an innovative computational drug repurposing pipeline supported by phenotypic screening. The approach highlighted several protein kinases as interesting new biological targets for schistosomiasis as they play an essential role in many parasite's biological processes. Focusing on this target class, we also report the first elucidation of the kinome of Schistosoma japonicum, as well as updated kinomes of S. mansoni and S. haematobium. In comparison with the human kinome, we explored these kinomes to identify potential targets of existing inhibitors which are unique to Schistosoma species, allowing us to identify novel targets and suggest approved drugs that might inhibit them. These include previously suggested schistosomicidal agents such as bosutinib, dasatinib, and imatinib as well as new inhibitors such as vandetanib, saracatinib, tideglusib, alvocidib, dinaciclib, and 22 newly identified targets such as CHK1, CDC2, WEE, PAKA, MEK1. Additionally, the primary and secondary targets in Schistosoma of those approved drugs are also suggested, allowing for the development of novel therapeutics against this important yet neglected disease.
C1 [Giuliani, Sandra; Paveley, Ross A.; Furnham, Nicholas] London Sch Hyg & Trop Med, Dept Pathogen Mol Biol, London, England.
   [Silva, Arthur C.; Borba, Joyce V. V. B.; Andrade, Carolina Horta] Univ Fed Goias, LabMol Lab Mol Modeling & Drug Design, Fac Farm, Goiania, Go, Brazil.
   [Ramos, Pablo I. P.] Fundacao Oswaldo Cruz, FIOCRUZ, Inst Goncalo Moniz, Salvador, BA, Brazil.
   [Muratov, Eugene N.] Univ N Carolina, Lab Mol Modeling, Div Chem Biol & Med Chem, Chapel Hill, NC 27515 USA.
   [Muratov, Eugene N.] Odessa Natl Polytech Univ, Dept Chem Technol, Odessa, Ukraine.
   [Andrade, Carolina Horta] Univ Estadual Campinas, Inst Biol, Dept Genet Evolut Microbiol & Immunol, Lab Trop Dis, Campinas, SP, Brazil.
RP Furnham, N (corresponding author), London Sch Hyg & Trop Med, Dept Pathogen Mol Biol, London, England.; Andrade, CH (corresponding author), Univ Fed Goias, LabMol Lab Mol Modeling & Drug Design, Fac Farm, Goiania, Go, Brazil.; Andrade, CH (corresponding author), Univ Estadual Campinas, Inst Biol, Dept Genet Evolut Microbiol & Immunol, Lab Trop Dis, Campinas, SP, Brazil.
EM carolina@ufg.br; nick.furnham@lshtm.ac.uk
RI Ramos, Pablo I. Pereira/H-6276-2019; de Carvalho e Silva,
   Arthur/S-7803-2018; Borba, Joyce V. B./S-7813-2018; Andrade,
   Carolina/C-3960-2014
OI Ramos, Pablo I. Pereira/0000-0002-9075-7861; de Carvalho e Silva,
   Arthur/0000-0001-9866-3344; Borba, Joyce V. B./0000-0002-2663-5173;
   Furnham, Nicholas/0000-0002-7532-1269; Giuliani,
   Sandra/0000-0002-2302-414X; Andrade, Carolina/0000-0003-0101-1492
FU Medical Research Council (MRC) Research Methodology FellowshipMedical
   Research Council UK (MRC) [MRC: MR/K020420]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq); Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES; Goias
   Research Support Foundation (FAPEG); CAPES fellowshipsCAPES; National
   Institutes of Health (NIH)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [1U01CA207160];
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [400760/2014-2]; L'Oreal-UNESCO-ABC Para Mulheres na Ciencia;
   L'Oreal-UNESCO International Rising Talents
FX NF is supported by a Medical Research Council (MRC;
   https://mrc.ukri.org) Research Methodology Fellowship (MRC: MR/K020420).
   CHA thanks Brazilian funding agencies Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq;http://www.cnpq.br),
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES;
   http://www.capes.gov.br) and Goias Research Support Foundation (FAPEG;
   Fapeg.go.gov.br) for financial support and fellowships. ACS and JVVBB
   are supported by CAPES fellowships. ENM appreciates support from
   National Institutes of Health (NIH; https://www.nih.gov) (grant
   1U01CA207160) and CNPq (grant 400760/2014-2). CHA is CNPq research
   fellow and supported by "L'Oreal-UNESCO-ABC Para Mulheres na Ciencia"
   and "L'Oreal-UNESCO International Rising Talents"
   (https://www.forwomeninscience.com/en/home).The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Andrade LF, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-215
   Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
   Beckmann S, 2010, INT J PARASITOL, V40, P521, DOI 10.1016/j.ijpara.2010.01.007
   Beckmann S, 2012, CURR PHARM DESIGN, V18, P3579
   Bento AP, 2014, NUCLEIC ACIDS RES, V42, pD1083, DOI 10.1093/nar/gkt1031
   Berriman M, 2009, NATURE, V460, P352, DOI 10.1038/nature08160
   Carvalho TG, 2013, BBA-PROTEINS PROTEOM, V1834, P1336, DOI 10.1016/j.bbapap.2013.02.022
   Chartier M, 2017, BMC PHARMACOL TOXICO, V18, DOI 10.1186/s40360-017-0128-7
   Chen F, 2006, NUCLEIC ACIDS RES, V34, pD363, DOI 10.1093/nar/gkj123
   Cline MS, 2007, NAT PROTOC, V2, P2366, DOI 10.1038/nprot.2007.324
   Colley DG, 2014, LANCET, V383, P2253, DOI 10.1016/S0140-6736(13)61949-2
   Cowan N, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1023-y
   Darriba D, 2011, LECT NOTES COMPUT SC, V6586, P177, DOI 10.1007/978-3-642-21878-1_22
   de Andrade LF, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002949
   de Beer TAP, 2014, NUCLEIC ACIDS RES, V42, pD292, DOI 10.1093/nar/gkt940
   de Saram PSR, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0001988
   del Rio G, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-102
   Dissous C, 2007, BIOESSAYS, V29, P1281, DOI 10.1002/bies.20662
   Dissous C, 2011, AN ACAD BRAS CIENC, V83, P627, DOI 10.1590/S0001-37652011000200022
   Dissous C, 2011, TRENDS PARASITOL, V27, P59, DOI 10.1016/j.pt.2010.09.001
   Doenhoff Michael J, 2006, Expert Rev Anti Infect Ther, V4, P199, DOI 10.1586/14787210.4.2.199
   Doerig C, 2015, BBA-PROTEINS PROTEOM, V1854, P1637, DOI 10.1016/j.bbapap.2015.03.002
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Feng JY, 2014, CHEM BIOL DRUG DES, V83, P174, DOI 10.1111/cbdd.12209
   Finn RD, 2016, NUCLEIC ACIDS RES, V44, pD279, DOI 10.1093/nar/gkv1344
   Gelmedin V, 2015, FUTURE MED CHEM, V7, P737, DOI [10.4155/FMC.15.31, 10.4155/fmc.15.31]
   Goldberg JM, 2013, BIOINFORMATICS, V29, P2387, DOI 10.1093/bioinformatics/btt419
   Grevelding CG, 2018, TRENDS PARASITOL, V34, P246, DOI 10.1016/j.pt.2017.12.001
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Hagan P, 2004, TRENDS PARASITOL, V20, P92, DOI 10.1016/j.pt.2003.11.010
   Huang HH, 2012, CURR PHARM DESIGN, V18, P3595
   Jones P, 2014, BIOINFORMATICS, V30, P1236, DOI 10.1093/bioinformatics/btu031
   Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092
   Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436
   Katz N, 2013, MEM I OSWALDO CRUZ, V108, P850, DOI 10.1590/0074-0276130207
   Keiser J, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1616-0
   Keiser MJ, 2007, NAT BIOTECHNOL, V25, P197, DOI 10.1038/nbt1284
   Kinnings SL, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000423
   Lee EF, 2015, FUTURE MED CHEM, V7, P707, DOI [10.4155/fmc.14.164, 10.4155/FMC.14.164]
   Long T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040045
   Mansour NR, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004659
   Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291
   Martins-Melo FR, 2014, INT J PARASITOL, V44, P1055, DOI 10.1016/j.ijpara.2014.07.009
   Melnikova I, 2004, NAT REV DRUG DISCOV, V3, P993, DOI 10.1038/nrd1600
   Melo CC, 2016, J CHEM INF MODEL, V56, P1357, DOI 10.1021/acs.jcim.6b00055
   Merritt C, 2014, CHEM REV, V114, P11280, DOI 10.1021/cr500197d
   Neves BJ, 2016, J MED CHEM, V59, P7075, DOI 10.1021/acs.jmedchem.5b02038
   Neves BJ, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003435
   Neves B, 2016, MEDCHEMCOMM, V7, P1176, DOI 10.1039/c5md00596e
   Noeske T, 2006, CHEMMEDCHEM, V1, P1066, DOI 10.1002/cmdc.200600147
   Oprea TI, 2015, ASSAY DRUG DEV TECHN, V13, P299, DOI 10.1089/adt.2015.29011.tiodrrr
   Panic G, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003962
   Paveley RA, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001762
   Pundir Sangya, 2016, Curr Protoc Bioinformatics, V53, DOI 10.1002/0471250953.bi0129s53
   Rahman SA, 2009, J CHEMINFORMATICS, V1, DOI 10.1186/1758-2946-1-12
   Ramamoorthi R, 2015, FUTURE MED CHEM, V7, P727, DOI [10.4155/fmc.15.26, 10.4155/FMC.15.26]
   Ramirez B, 2007, EXPERT OPIN DRUG DIS, V2, pS53, DOI 10.1517/17460441.2.S1.S53
   Ressurreicao M, 2011, MOL BIOCHEM PARASIT, V180, P51, DOI 10.1016/j.molbiopara.2011.07.002
   Scardoni G, 2009, BIOINFORMATICS, V25, P2857, DOI 10.1093/bioinformatics/btp517
   Sillitoe I, 2016, NUCLEIC ACIDS RES, V44, pD317, DOI 10.1093/nar/gkv1274
   Sillitoe Ian, 2015, Curr Protoc Bioinformatics, V50, DOI 10.1002/0471250953.bi0128s50
   Stroehlein AJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep17759
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Tamuri AU, 2010, BIOINFORMATICS, V26, P1260, DOI 10.1093/bioinformatics/btq119
   Tang Y, 2015, BIOSYSTEMS, V127, P67, DOI 10.1016/j.biosystems.2014.11.005
   Velankar S, 2016, NUCLEIC ACIDS RES, V44, pD385, DOI 10.1093/nar/gkv1047
   von Mering C, 2005, NUCLEIC ACIDS RES, V33, pD433, DOI 10.1093/nar/gki005
   Wang W, 2012, PARASITOL RES, V111, P1871, DOI 10.1007/s00436-012-3151-z
   Wang Y, 2015, NUCLEIC ACIDS RES, V43, pW78, DOI 10.1093/nar/gkv487
   Xie L, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002037
   Xie L, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000387
   Zhou Y, 2009, NATURE, V460, P345, DOI 10.1038/nature08140
NR 72
TC 5
Z9 5
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
EI 1553-7358
J9 PLOS COMPUT BIOL
JI PLoS Comput. Biol.
PD OCT
PY 2018
VL 14
IS 10
AR e1006515
DI 10.1371/journal.pcbi.1006515
PG 21
WC Biochemical Research Methods; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA HB0NT
UT WOS:000450712400034
PM 30346968
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-01
ER

PT J
AU Mottin, M
   Carvalho, A
   Melo, C
   Neves, B
   Braga, R
   Lima, C
   da Silva, S
   Shimizu, J
   Mesquita, N
   Regasini, L
   Jardim, A
   Muratov, E
   Oliva, G
   Perryman, A
   Ekins, S
   Andrade, C
AF Mottin, Melina
   Carvalho, Amanda
   Melo-Filho, Cleber
   Neves, Bruno
   Braga, Rodolpho
   Lima, Caroline
   da Silva, Suely
   Shimizu, Jacqueline
   Mesquita, Nathalya
   Regasini, Luis
   Jardim, Ana
   Muratov, Eupne
   Oliva, Glaucius
   Perryman, Alexander
   Ekins, Sean
   Andrade, Carolina
TI OpenZika: Discovery of new antiviral candidates against Zika virus
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 256th National Meeting and Exposition of the American-Chemical-Society
   (ACS) - Nanoscience, Nanotechnology and Beyond
CY AUG 19-23, 2018
CL Boston, MA
SP Amer Chem Soc
C1 [Mottin, Melina; Carvalho, Amanda; Melo-Filho, Cleber; Neves, Bruno; Braga, Rodolpho; Andrade, Carolina] Univ Fed Goias, LabMol Lab Mol Modeling & Drug Design, Fac Pharm, Goiania, Go, Brazil.
   [Neves, Bruno] Univ Ctr Anapolis UniEVANGELICA, Lab Cheminformat, Anapolis, Go, Brazil.
   [Lima, Caroline; da Silva, Suely; Shimizu, Jacqueline; Regasini, Luis] Sao Paulo State Univ UNESP, Dept Chem & Environm Sci, Inst Biosci Humanities & Exact Sci, Sao Jose Do Rio Preto, SP, Brazil.
   [da Silva, Suely; Shimizu, Jacqueline; Jardim, Ana] Univ Fed Uberlandia, Virol Lab, Uberlandia, MG, Brazil.
   [Mesquita, Nathalya; Oliva, Glaucius] Univ Sao Paulo, Inst Phys Sao Carlos, Sao Carlos, SP, Brazil.
   [Muratov, Eupne] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC 27515 USA.
   [Muratov, Eupne] Odessa Natl Polytech Univ, Dept Chem Technol, Odessa, Ukraine.
   [Perryman, Alexander] Rutgers State Univ, New Jersey Med Sch, Dept Pharmacol Physiol & Neurosci, Newark, NJ USA.
   [Ekins, Sean] Collaborat Pharmaceut, Fuquay Varina, NC USA.
EM melinamottin@gmail.com
RI Braga, Rodolpho C/A-9655-2011; Mottin, Melina/D-8700-2016; Neves,
   Bruno/R-7068-2019; Oliva, Glaucius/B-9059-2012; Jardim, Ana Carolina
   Gomes/H-3615-2012; Neves, Bruno Junior/E-6295-2016
OI Braga, Rodolpho C/0000-0003-3814-3464; Mottin,
   Melina/0000-0003-0878-9029; Neves, Bruno/0000-0002-1309-8743; Jardim,
   Ana Carolina Gomes/0000-0002-6348-7923; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 19
PY 2018
VL 256
MA 24
PG 2
WC Chemistry, Multidisciplinary
SC Chemistry
GA GX3CY
UT WOS:000447600003335
DA 2020-12-01
ER

PT J
AU Alves, V
   Hwang, D
   Muratov, E
   Sokolsky-Papkov, M
   Varlamova, E
   Vinod, N
   Melo, C
   Marreto, R
   Taveira, S
   Andrade, C
   Tropsha, A
   Kabanov, A
AF Alves, Vinicius
   Hwang, Duhyeong
   Muratov, Eugene
   Sokolsky-Papkov, Marina
   Varlamova, Ekaterina
   Vinod, Natasha
   Melo-Filho, Cleber
   Marreto, Ricardo
   Taveira, Stephania
   Andrade, Carolina
   Tropsha, Alexander
   Kabanov, Alexander
TI Novel computational approach for predicting drug-carrier formulations of
   poorly soluble drugs
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 256th National Meeting and Exposition of the American-Chemical-Society
   (ACS) - Nanoscience, Nanotechnology and Beyond
CY AUG 19-23, 2018
CL Boston, MA
SP Amer Chem Soc
C1 [Alves, Vinicius; Hwang, Duhyeong; Muratov, Eugene; Sokolsky-Papkov, Marina; Vinod, Natasha; Tropsha, Alexander; Kabanov, Alexander] Univ N Carolina, UNC Eshelman Sch Pharm, Chapel Hill, NC 27515 USA.
   [Alves, Vinicius; Varlamova, Ekaterina; Melo-Filho, Cleber; Marreto, Ricardo; Taveira, Stephania; Andrade, Carolina] Univ Fed Goias, Fac Pharm, Goiania, Go, Brazil.
EM viniciusm.alves@gmail.com; murik@email.unc.edu; alex_tropsha@unc.edu
RI Kabanov, Alexander/AAY-5751-2020; Alves, Vinicius M./G-7955-2015;
   MARRETO, RICARDO/ABA-9266-2020; Kabanov, Alexander V/N-3356-2013;
   Tropsha, Alexander/AAB-8324-2020
OI Kabanov, Alexander/0000-0002-3665-946X; Alves, Vinicius
   M./0000-0002-6182-1748; Kabanov, Alexander V/0000-0002-3665-946X; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 19
PY 2018
VL 256
MA 143
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA GX3CY
UT WOS:000447600003451
DA 2020-12-01
ER

PT J
AU Alves, VM
   Golbraikh, A
   Capuzzi, SJ
   Liu, K
   Lam, WI
   Korn, DR
   Pozefsky, D
   Andrade, CH
   Muratov, EN
   Tropsha, A
AF Alves, Vinicius M.
   Golbraikh, Alexander
   Capuzzi, Stephen J.
   Liu, Kammy
   Lam, Wai In
   Korn, Daniel Robert
   Pozefsky, Diane
   Andrade, Carolina Horta
   Muratov, Eugene N.
   Tropsha, Alexander
TI Multi-Descriptor Read Across (MuDRA): A Simple and Transparent Approach
   for Developing Accurate Quantitative Structure-Activity Relationship
   Models
SO JOURNAL OF CHEMICAL INFORMATION AND MODELING
LA English
DT Article
ID SKIN SENSITIZATION; QSAR MODELS; CHEMICAL-STRUCTURE; PREDICTION;
   DISCOVERY; TOXICITY; CHEMINFORMATICS; BIOACTIVITY; CURATION; VERIFY
AB Multiple approaches to quantitative structure-activity relationship (QSAR) modeling using various statistical or machine learning techniques and different types of chemical descriptors have been developed over the years. Oftentimes models are used in consensus to make more accurate predictions at the expense of model interpretation. We propose a simple, fast, and reliable method termed Multi-Descriptor Read Across (MuDRA) for developing both accurate and interpretable models. The method is conceptually related to the well-known kNN approach but uses different types of chemical descriptors simultaneously for similarity assessment. To benchmark the new method, we have built MuDRA models for six different end points (Ames mutagenicity, aquatic toxicity, hepatotoxicity, hERG liability, skin sensitization, and endocrine disruption) and compared the results with those generated with conventional consensus QSAR modeling. We find that models built with MuDRA show consistently high external accuracy similar to that of conventional QSAR models. However, MuDRA models excel in terms of transparency, interpretability, and computational efficiency. We posit that due to its methodological simplicity and reliable predictive accuracy, MuDRA provides a powerful alternative to a much more complex consensus QSAR modeling. MuDRA is implemented and freely available at the Chembench web portal (https://chembench.mml.unc.edu/mudra).
C1 [Alves, Vinicius M.; Golbraikh, Alexander; Capuzzi, Stephen J.; Muratov, Eugene N.; Tropsha, Alexander] Univ N Carolina, Lab Mol Modeling, Div Chem Biol & Med Chem, UNC Eshelman Sch Pharm, Chapel Hill, NC 27599 USA.
   [Alves, Vinicius M.; Andrade, Carolina Horta] Univ Fed Goias, Dept Pharm, Lab Mol Modeling & Design, BR-74605170 Goiania, Go, Brazil.
   [Liu, Kammy; Lam, Wai In; Korn, Daniel Robert; Pozefsky, Diane] Univ N Carolina, Dept Comp Sci, Chapel Hill, NC 27599 USA.
   [Muratov, Eugene N.] Odessa Natl Polytech Univ, Dept Chem Technol, UA-65000 Odessa, Ukraine.
RP Muratov, EN; Tropsha, A (corresponding author), Univ N Carolina, UNC Eshelman Sch Pharm, 100 K Beard Hall, Chapel Hill, NC 27599 USA.
EM murik@email.unc.edu; alex_tropsha@unc.edu
RI Tropsha, Alexander/AAB-8324-2020; Alves, Vinicius M./G-7955-2015;
   Muratov, Eugene/C-4454-2014; Andrade, Carolina/C-3960-2014
OI Alves, Vinicius M./0000-0002-6182-1748; Muratov,
   Eugene/0000-0003-4616-7036; Andrade, Carolina/0000-0003-0101-1492;
   Capuzzi, Stephen/0000-0003-0001-8211; Tropsha,
   Alexander/0000-0003-3802-8896
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [1U01CA207160]; CNPqNational Council
   for Scientific and Technological Development (CNPq) [400760/2014-2];
   CAPESCAPES; FAPEG [201310267001095]; NATIONAL CANCER INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [U01CA207160,
   U01CA207160, U01CA207160] Funding Source: NIH RePORTER
FX This study was supported in part by NIH (grant 1U01CA207160). V.M.A.,
   E.N.M., and C.H.A. thank CNPq (grant 400760/2014-2). V.M.A. also thanks
   CAPES and FAPEG (201310267001095) for partial support.
CR Albert M. K., 1991, AAAI-91. Proceedings Ninth National Conference on Artificial Intelligence, P553
   Alves VM, 2018, ACS SUSTAIN CHEM ENG, V6, P2845, DOI 10.1021/acssuschemeng.7b04220
   Alves VM, 2016, GREEN CHEM, V18, P6501, DOI [10.1039/c6gc01836j, 10.1039/C6GC01836J]
   Alves VM, 2016, GREEN CHEM, V18, P4348, DOI [10.1039/C6GC01492E, 10.1039/c6gc01492e]
   Alves VM, 2015, TOXICOL APPL PHARM, V284, P273, DOI 10.1016/j.taap.2014.12.013
   Alves VM, 2015, TOXICOL APPL PHARM, V284, P262, DOI 10.1016/j.taap.2014.12.014
   Artemenko AG, 2011, SAR QSAR ENVIRON RES, V22, P575, DOI 10.1080/1062936X.2011.569950
   Basketter D, 2013, REGUL TOXICOL PHARM, V67, P531, DOI 10.1016/j.yrtph.2013.10.002
   Bender A, 2010, EXPERT OPIN DRUG DIS, V5, P1141, DOI 10.1517/17460441.2010.517832
   Bienfait B, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-24
   Braga RC, 2017, J CHEM INF MODEL, V57, P1013, DOI 10.1021/acs.jcim.7b00194
   Braga RC, 2015, MOL INFORM, V34, P698, DOI 10.1002/minf.201500040
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Capuzzi SJ, 2016, FRONT ENV SCI-SWITZ, V4, DOI 10.3389/fenvs.2016.00003
   Capuzzi SJ, 2017, J CHEM INF MODEL, V57, P417, DOI 10.1021/acs.jcim.6b00465
   Capuzzi SJ, 2017, J CHEM INF MODEL, V57, P105, DOI 10.1021/acs.jcim.6b00462
   Casati S, 2018, ARCH TOXICOL, V92, P611, DOI 10.1007/s00204-017-2097-4
   Chemical Computing Group, QUASAR DESCR
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Cronin MTD, 2013, ISSUES TOXICOL, V17, P1, DOI 10.1039/9781849734400-00001
   Cronin MTD, 2013, ISSUES TOXICOL, V17, P155, DOI 10.1039/9781849734400-00155
   Enoch SJ, 2013, ISSUES TOXICOL, V17, P30, DOI 10.1039/9781849734400-00030
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   FUJITA T, 1964, J AM CHEM SOC, V86, P5175, DOI 10.1021/ja01077a028
   Golbraikh A, 2002, J MOL GRAPH MODEL, V20, P269, DOI 10.1016/S1093-3263(01)00123-1
   Golbraikh A, 2014, J CHEM INF MODEL, V54, P1, DOI 10.1021/ci400572x
   Griffen E, 2011, J MED CHEM, V54, P7739, DOI 10.1021/jm200452d
   HANSCH C, 1964, J AM CHEM SOC, V86, P1616, DOI 10.1021/ja01062a035
   HANSCH C, 1962, NATURE, V194, P178, DOI 10.1038/194178b0
   Kuz'min VE, 2008, J COMPUT AID MOL DES, V22, P403, DOI 10.1007/s10822-008-9179-6
   Kuz'min VE, 2009, QSAR COMB SCI, V28, P664, DOI 10.1002/qsar.200860117
   Liu J, 2015, CHEM RES TOXICOL, V28, P738, DOI 10.1021/tx500501h
   Low Y, 2013, CHEM RES TOXICOL, V26, P1199, DOI 10.1021/tx400110f
   Low Y, 2011, CHEM RES TOXICOL, V24, P1251, DOI 10.1021/tx200148a
   Mansouri K, 2016, ENVIRON HEALTH PERSP, V124, P1023, DOI 10.1289/ehp.1510267
   Melo CC, 2016, J CHEM INF MODEL, V56, P1357, DOI 10.1021/acs.jcim.6b00055
   Muratov EN, 2010, FUTURE MED CHEM, V2, P1205, DOI 10.4155/FMC.10.194
   Neves BJ, 2016, J MED CHEM, V59, P7075, DOI 10.1021/acs.jmedchem.5b02038
   Organisation for Economic Co-operation and Development and OECD, OECD PRINC VAL REG P
   Pissurlenkar RRS, 2011, J COMPUT CHEM, V32, P2204, DOI 10.1002/jcc.21804
   Pradeep P, 2016, J CHEMINFORMATICS, V8, DOI 10.1186/s13321-016-0164-0
   Raunio H, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00033
   RDKit, MOD MACCSKEYS
   Ruggiu F, 2010, MOL INFORM, V29, P855, DOI 10.1002/minf.201000099
   Russo DP, 2017, BIOINFORMATICS, V33, P464, DOI 10.1093/bioinformatics/btw640
   Shah I, 2016, REGUL TOXICOL PHARM, V79, P12, DOI 10.1016/j.yrtph.2016.05.008
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Sushko I, 2010, J CHEM INF MODEL, V50, P2094, DOI 10.1021/ci100253r
   Svetnik V, 2005, J CHEM INF MODEL, V45, P786, DOI 10.1021/ci0500379
   Talete SRL, DRAGON 7 0
   Tropsha A, 2007, CURR PHARM DESIGN, V13, P3494, DOI 10.2174/138161207782794257
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Wang XS, 2008, J CHEM INF MODEL, V48, P997, DOI 10.1021/ci700404c
   Willett P, 1998, J CHEM INF COMP SCI, V38, P983, DOI 10.1021/ci9800211
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   Yap CW, 2011, J COMPUT CHEM, V32, P1466, DOI 10.1002/jcc.21707
   Zhu H, 2008, J CHEM INF MODEL, V48, P766, DOI 10.1021/ci700443v
NR 59
TC 11
Z9 11
U1 0
U2 14
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1549-9596
EI 1549-960X
J9 J CHEM INF MODEL
JI J. Chem Inf. Model.
PD JUN
PY 2018
VL 58
IS 6
BP 1214
EP 1223
DI 10.1021/acs.jcim.8b00124
PG 10
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Computer Science,
   Information Systems; Computer Science, Interdisciplinary Applications
SC Pharmacology & Pharmacy; Chemistry; Computer Science
GA GK9YN
UT WOS:000436615500009
PM 29809005
DA 2020-12-01
ER

PT J
AU Alves, VM
   Braga, RC
   Muratov, E
   Andrade, CH
AF Alves, Vinicius M.
   Braga, Rodolpho C.
   Muratov, Eugene
   Andrade, Carolina H.
TI Development of Web and Mobile Applications for Chemical Toxicity
   Prediction
SO JOURNAL OF THE BRAZILIAN CHEMICAL SOCIETY
LA English
DT Review
DE web app; mobile; toxicity prediction; QSAR; Pred-hERG; Pred-Skin
ID QSAR MODELS; DRUG; CHEMINFORMATICS; TOXICOLOGY; CHEMISTRY; VALIDATION;
   CURATION; VERIFY; TOXNET; TRUST
AB Computational tools are recognized to provide high-quality predictions for the assessment of chemical toxicity. In the recent years, mobile devices have become ubiquitous, allowing for the development of innovative and useful models implemented as chemical software applications. Here, we will briefly discuss this recent uptick in the development of web-based and mobile applications for chemical problems, focusing on best practices, development, usage and interpretation. As an example, we also describe two innovative apps (Pred-hERG and Pred-Skin) for chemical toxicity prediction developed in our laboratory. These applications are based on predictive quantitative structure-activity relationships (QSAR) models developed using the largest publicly available datasets of structurally diverse compounds. The developed tools ensure both highly accurate predictions and easy interpretation of the models, allowing users to discriminate potential toxicants and to purpose structural modifications to design safer chemicals.
C1 [Alves, Vinicius M.; Braga, Rodolpho C.; Andrade, Carolina H.] Univ Fed Goias, Fac Farm, Lab Planejamento Farmacos & Modelagem Mol, LabMol, BR-74605170 Goiania, Go, Brazil.
   [Alves, Vinicius M.; Muratov, Eugene] Univ N Carolina, UNC Eshelman Sch Pharm, Div Chem Biol & Med Chem, Lab Mol Modeling, Chapel Hill, NC 27599 USA.
   [Muratov, Eugene] Odessa Natl Polytech Univ, Dept Chem Technol, UA-65000 Odessa, Ukraine.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, Lab Planejamento Farmacos & Modelagem Mol, LabMol, BR-74605170 Goiania, Go, Brazil.
EM carolina@ufg.br
RI Alves, Vinicius M./G-7955-2015; Braga, Rodolpho C/A-9655-2011; Andrade,
   Carolina/C-3960-2014
OI Alves, Vinicius M./0000-0002-6182-1748; Braga, Rodolpho
   C/0000-0003-3814-3464; Andrade, Carolina/0000-0003-0101-1492
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES; FAPEG
FX The authors are grateful to CNPq, CAPES and FAPEG for the financial
   support of research projects and scholarships granted. The authors would
   like to thank Prof Alexander Tropsha for valuable contributions for the
   development of this paper. C. H. A. is CNPq research fellow. We are also
   grateful to ChemAxon for providing us with academic licenses for their
   software.
CR Ajmani S, 2006, J CHEM INF MODEL, V46, P24, DOI 10.1021/ci0501286
   Alves VM, 2018, FOOD CHEM TOXICOL, V112, P526, DOI 10.1016/j.fct.2017.04.008
   Alves VM, 2016, GREEN CHEM, V18, P4348, DOI [10.1039/C6GC01492E, 10.1039/c6gc01492e]
   Baig MH, 2016, CURR PHARM DESIGN, V22, P572, DOI 10.2174/1381612822666151125000550
   Ball N, 2016, ALTEX-ALTERN ANIM EX, V33, P149, DOI 10.14573/altex.1601251
   Baskin II, 2002, SAR QSAR ENVIRON RES, V13, P35, DOI 10.1080/10629360290002073
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Bienfait B, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-24
   Blagg J., 2010, BURGERS MED CHEM DRU, P301
   Blobel J., LEAD DESIGNER APP
   Bordoli L, 2009, NAT PROTOC, V4, P1, DOI 10.1038/nprot.2008.197
   Braga RC, 2017, J CHEM INF MODEL, V57, P1013, DOI 10.1021/acs.jcim.7b00194
   Braga RC, 2015, MOL INFORM, V34, P698, DOI 10.1002/minf.201500040
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1399, DOI 10.2174/1568026614666140506124442
   Burden N, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002156
   Capuzzi SJ, 2017, J CHEM INF MODEL, V57, P105, DOI 10.1021/acs.jcim.6b00462
   Chawla S, 2017, INT J SYST ASSUR ENG, V8, P65, DOI 10.1007/s13198-015-0385-z
   Chemical Abstracts Service (CAS), CAS ASS 100 MILL CAS
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Clark A.M., 2013, CHEM BIO INFORM J, V13, P1
   Clark AM, 2012, MOL INFORM, V31, P569, DOI 10.1002/minf.201200010
   Cronin M. T. D., 2013, CHEM TOXICITY PREDIC
   Cronin M. T. D., 2013, CHEM TOXICITY PREDIC
   Dearden JC, 2002, J BRAZIL CHEM SOC, V13, P754, DOI 10.1590/S0103-50532002000600005
   Ekins S, 2013, ACS SUSTAIN CHEM ENG, V1, P8, DOI 10.1021/sc3000509
   Ekins S, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-13
   Enoch S. J., 2013, CHEM TOXICITY PREDIC
   European Chemicals Agency (ECHA), GUID NUTSH CHEM SAF
   FIGUERAS J, 1993, J CHEM INF COMP SCI, V33, P717, DOI 10.1021/ci00015a009
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Fowler S, 2014, AM J NURS, V114, P61, DOI 10.1097/01.NAJ.0000443783.75162.79
   GADALETA D, 2016, INT J QUANT STRUCT P, V1, P45, DOI DOI 10.4018/IJQSPR.2016010102
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   Gonzalez-Medina M, 2017, J CHEM INF MODEL, V57, P1735, DOI 10.1021/acs.jcim.7b00253
   Grace Patlewicz, 2017, Comput Toxicol, V3, P1, DOI 10.1016/j.comtox.2017.05.003
   Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM), US LIM MUR LOC LYMPH
   Irwin JJ, 2012, J CHEM INF MODEL, V52, P1757, DOI 10.1021/ci3001277
   Kuz'min VE, 2011, MOL INFORM, V30, P593, DOI 10.1002/minf.201000173
   Landrum G, RDKIT OPEN SOURCE CH
   Mathea M, 2016, MOL INFORM, V35, P160, DOI 10.1002/minf.201501019
   Mitcheson JS, 2000, P NATL ACAD SCI USA, V97, P12329, DOI 10.1073/pnas.210244497
   MORGAN HL, 1965, J CHEM DOC, V5, P107, DOI 10.1021/c160017a018
   Naven RT, 2015, HUM EXP TOXICOL, V34, P1304, DOI 10.1177/0960327115605440
   OECD, WORKSH STRUCT AL OEC
   Organisation for Economic Co-operation and Development and OECD, OECD PRINC VAL REG P
   Polishchuk P, 2017, J CHEM INF MODEL, V57, P2618, DOI 10.1021/acs.jcim.7b00274
   Polishchuk PG, 2013, MOL INFORM, V32, P843, DOI 10.1002/minf.201300029
   Prinz F, 2011, NAT REV DRUG DISCOV, V10, P712, DOI 10.1038/nrd3439-c1
   Raunio H, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00033
   Riniker S, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-43
   Stanton DT, 2012, CURR COMPUT-AID DRUG, V8, P107
   Tropsha A, 2003, QSAR COMB SCI, V22, P69, DOI 10.1002/qsar.200390007
   Tropsha A, 2007, CURR PHARM DESIGN, V13, P3494, DOI 10.2174/138161207782794257
   Tropsha Alexander, 2012, Exp Suppl, V101, P381, DOI 10.1007/978-3-7643-8340-4_13
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Wang YL, 2014, NUCLEIC ACIDS RES, V42, pD1075, DOI 10.1093/nar/gkt978
   Wang YL, 2012, NUCLEIC ACIDS RES, V40, pD400, DOI 10.1093/nar/gkr1132
   Wexler P, 2001, TOXICOLOGY, V157, P3, DOI 10.1016/S0300-483X(00)00337-1
   Williams AJ, 2011, DRUG DISCOV TODAY, V16, P928, DOI 10.1016/j.drudis.2011.09.002
   Willighagen EL, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-23
NR 62
TC 4
Z9 4
U1 1
U2 8
PU SOC BRASILEIRA QUIMICA
PI SAO PAULO
PA CAIXA POSTAL 26037, 05599-970 SAO PAULO, BRAZIL
SN 0103-5053
EI 1678-4790
J9 J BRAZIL CHEM SOC
JI J. Braz. Chem. Soc.
PD MAY
PY 2018
VL 29
IS 5
BP 982
EP 988
DI 10.21577/0103-5053.20180013
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA FZ5NT
UT WOS:000427641700009
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Andrade, CH
   Kummerle, AE
   Guido, RVC
AF Andrade, Carolina Horta
   Kummerle, Arthur E.
   Guido, Rafael V. C.
TI MEDICINAL CHEMISTRY PERSPECTIVES FOR THE 21ST CENTURY: CHALLENGES AND
   OPPROTUNITIES
SO QUIMICA NOVA
LA Galician
DT Article
DE Medicinal Chemistry; perspectives; future, challenges
ID MULTIDRUG-RESISTANT; ZIKA VIRUS; DRUG; MICROFLUIDICS; DISEASES; FUTURE
AB In the 21st century, medicinal chemists will face many challenges to improve the quality of life of populations. The challenges consist of emerging infectious (ex. bacterial, viral and parasite infections) and non-communicable diseases (ex. autoimmune, Alzheimer disease, Parkinson's disease) that will require innovative technologies (ex. microfluidics, nanotechnology, biotechnology) to be fully understood and combated. In this work, we indicate trends, perspectives and opportunities related to drug discovery as well as highlight the tools and strategies that could be used in drug discovery of the 21st century.
C1 [Andrade, Carolina Horta] Univ Fed Goias, Fac Farm, Rua 240,Qd 87,St Leste Univ, BR-74605170 Goiania, Go, Brazil.
   [Kummerle, Arthur E.] Univ Fed Rural Rio de Janeiro, Dept Quim, BR-23897000 Seropedica, RJ, Brazil.
   [Guido, Rafael V. C.] Univ Sao Paulo, Inst Fis Sao Carlos, Av Joao Dagnone 1100, BR-13563120 Sao Carlos, SP, Brazil.
RP Guido, RVC (corresponding author), Univ Sao Paulo, Inst Fis Sao Carlos, Av Joao Dagnone 1100, BR-13563120 Sao Carlos, SP, Brazil.
EM rvcguido@ifsc.usp.br
RI ; Guido, Rafael/A-7450-2009; Andrade, Carolina/C-3960-2014
OI Kummerle, Arthur/0000-0002-8458-0975; Guido, Rafael/0000-0002-7187-0818;
   Andrade, Carolina/0000-0003-0101-1492
CR Alves V., 2017, QUIM NOVA, VX, P1
   Amaral AT, 2017, QUIM NOVA, V40, P694
   [Anonymous], 2015, WORLD HLTH STAT
   Aziz T, 2011, NATURE, V470, P457, DOI 10.1038/470457a
   Boucher HW, 2009, CLIN INFECT DIS, V48, P1, DOI 10.1086/595011
   Cheng FX, 2016, TRENDS MOL MED, V22, P919, DOI 10.1016/j.molmed.2016.09.006
   CRICK F, 1970, NATURE, V227, P561, DOI 10.1038/227561a0
   de Souza FR, 2012, ANAL CHEM, V84, P9002, DOI 10.1021/ac302506k
   DeMello AJ, 2003, NATURE, V422, P28, DOI 10.1038/422028a
   deMello AJ, 2006, NATURE, V442, P394, DOI 10.1038/nature05062
   Dias LC, 2013, QUIM NOVA, V36, P1552, DOI 10.1590/S0100-40422013001000011
   Ekins S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005023
   Ekins Sean, 2016, F1000Res, V5, P150, DOI 10.12688/f1000research.8013.1
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Fernandez E, 2017, CURR OPIN VIROL, V23, P59, DOI 10.1016/j.coviro.2017.03.006
   Field MC, 2017, NAT REV MICROBIOL, V15, DOI 10.1038/nrmicro.2016.193
   Fitzpatrick AWP, 2017, NATURE, V547, P185, DOI 10.1038/nature23002
   Foye W. O., 2008, FOYES PRINCIPLES MED
   Gasteiger J., 2003, CHEMOINFORMATICS TXB
   Godoy AS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14764
   Goedert M, 2017, J PARKINSON DIS, V7, pS53, DOI 10.3233/JPD-179005
   Gonzalez-Lizarraga F, 2017, SCI REP-UK, V7, DOI 10.1038/srep41755
   Guido Rafael V. C., 2010, Estud. av., V24, P81, DOI 10.1590/S0103-40142010000300006
   Hurwitz B, 2017, LANCET, V389, P2098, DOI 10.1016/S0140-6736(17)31409-5
   Jedrzejewska S, 2014, ALTEX-ALTERN ANIM EX, V31, P371
   Karaiskos I, 2014, EXPERT OPIN PHARMACO, V15, P1351, DOI 10.1517/14656566.2014.914172
   Katsnelson Alla, 2010, NATURE
   Lancaster MA, 2013, NATURE, V501, P373, DOI 10.1038/nature12517
   Laursen L, 2016, NATURE, V533, pS68, DOI 10.1038/533S68a
   Leader B, 2008, NAT REV DRUG DISCOV, V7, P21, DOI 10.1038/nrd2399
   Lima-Camara TN, 2016, REV SAUDE PUBL, V50, DOI [10.1590/S1518-8787.2016050006245, 10.1590/s1518-8787.2016050006245]
   Merk A, 2016, CELL, V165, P1698, DOI 10.1016/j.cell.2016.05.040
   Oliveira KA, 2013, ANALYST, V138, P1114, DOI 10.1039/c2an36532d
   [ONU Suggest. Cit. United Nations Dep. Econ. Soc. Aff. Popul. Div.], 2015, WORLD POP AG, P164
   Peplow M, 2017, NAT REV DRUG DISCOV, V16, P815, DOI 10.1038/nrd.2017.240
   Poulakou G, 2014, FUTURE MICROBIOL, V9, P1053, DOI [10.2217/FMB.14.58, 10.2217/fmb.14.58]
   Riek R, 2016, NATURE, V539, P227, DOI 10.1038/nature20416
   Rioux JD, 2005, NATURE, V435, P584, DOI 10.1038/nature03723
   Sirohi D, 2016, SCIENCE, V352, P467, DOI 10.1126/science.aaf5316
   Sohlenius-Sternbeck AK, 2016, CURR DRUG METAB, V17, P253, DOI 10.2174/1389200217666151210125637
   Sun SY, 2013, ELIFE, V2, DOI 10.7554/eLife.00435
   Coltro WKT, 2014, ELECTROPHORESIS, V35, P2309, DOI 10.1002/elps.201400006
   Tuttle MD, 2016, NAT STRUCT MOL BIOL, V23, P409, DOI 10.1038/nsmb.3194
   Wang L, 2015, J AM CHEM SOC, V137, P2695, DOI 10.1021/ja512751q
   WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0
   Wermuth CG, 2008, PRACTICE OF MEDICINAL CHEMISTRY, 3RD EDITION, P1
   Wong YC, 2017, NAT MED, V23, P151, DOI 10.1038/nm.4269
   Wootton RCR, 2012, NATURE, V483, P43, DOI 10.1038/483043a
   World Health Organization, 2016, WORLD MALARIA REPORT
   Zhang J., 2012, GREEN TECHNIQUES ORG, P631
   Zhang W, 2013, J STRUCT BIOL, V183, P86, DOI 10.1016/j.jsb.2013.04.005
NR 51
TC 2
Z9 4
U1 0
U2 9
PU SOC BRASILEIRA QUIMICA
PI SAO PAULO
PA CAIXA POSTAL 26037, 05599-970 SAO PAULO, BRAZIL
SN 0100-4042
EI 1678-7064
J9 QUIM NOVA
JI Quim. Nova
PD APR
PY 2018
VL 41
IS 4
BP 476
EP 483
DI 10.21577/0100-4042.20170182
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA GI5EL
UT WOS:000434393700016
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Alves, V
   Muratov, E
   Zakharov, A
   Muratov, N
   Andrade, C
   Tropsha, A
AF Alves, Vinicius
   Muratov, Eugene
   Zakharov, Alexey
   Muratov, Nail
   Andrade, Carolina
   Tropsha, Alexander
TI Chemical toxicity prediction for major classes of industrial chemicals:
   Is it possible to develop universal models covering cosmetics, drugs,
   and pesticides?
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 255th National Meeting and Exposition of the American-Chemical-Society
   (ACS) - Nexus of Food, Energy, and Water
CY MAR 18-22, 2018
CL New Orleans, LA
C1 [Alves, Vinicius; Muratov, Eugene; Tropsha, Alexander] Univ N Carolina, Eshelman Sch Pharm, Div Chem Biol & Med Chem, Lab Mol Modeling, Chapel Hill, NC USA.
   [Alves, Vinicius; Andrade, Carolina] Univ Fed Goias, Lab Mol Modeling & Design, Fac Pharm, Goiania, Go, Brazil.
   [Muratov, Eugene; Muratov, Nail] Odessa Natl Polytech Univ, Dept Chem Technol, Odessa, Ukraine.
   [Zakharov, Alexey] NIH, Natl Ctr Adv Translat Sci, Rockville, MD USA.
EM murik@email.unc.edu
RI Tropsha, Alexander/AAB-8324-2020; Alves, Vinicius M./G-7955-2015
OI Alves, Vinicius M./0000-0002-6182-1748
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 18
PY 2018
VL 255
MA 420
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA GJ7BN
UT WOS:000435539901098
DA 2020-12-01
ER

PT J
AU Alves, V
   Golbraikh, A
   Muratov, E
   Capuzzi, S
   Liu, K
   Lam, W
   Pozefsky, D
   Andrade, C
   Tropsha, A
AF Alves, Vinicius
   Golbraikh, Alexander
   Muratov, Eugene
   Capuzzi, Stephen
   Liu, Kammy
   Lam, Wai
   Pozefsky, Diane
   Andrade, Carolina
   Tropsha, Alexander
TI One-click QSAR: A universal approach for developing accurate models
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 255th National Meeting and Exposition of the American-Chemical-Society
   (ACS) - Nexus of Food, Energy, and Water
CY MAR 18-22, 2018
CL New Orleans, LA
C1 [Alves, Vinicius; Andrade, Carolina] Univ Fed Goias, Fac Pharm, Goiania, Go, Brazil.
   [Alves, Vinicius; Golbraikh, Alexander; Muratov, Eugene; Capuzzi, Stephen; Tropsha, Alexander] Univ N Carolina, UNC Eshelman Sch Pharm, Chapel Hill, NC 27515 USA.
   [Liu, Kammy; Lam, Wai; Pozefsky, Diane] Univ N Carolina, Dept Comp Sci, Chapel Hill, NC 27515 USA.
EM viniciusm.alves@gmail.com
RI Tropsha, Alexander/AAB-8324-2020; Alves, Vinicius M./G-7955-2015
OI Alves, Vinicius M./0000-0002-6182-1748
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 18
PY 2018
VL 255
MA 72
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA GJ7AU
UT WOS:000435537705517
DA 2020-12-01
ER

PT J
AU Muratov, E
   Alves, V
   Hwang, D
   Sokolsky, M
   Lebed, E
   Vinod, N
   Andrade, C
   Kabanov, A
   Tropsha, A
AF Muratov, Eugene
   Alves, Vinicius
   Hwang, Duhyeong
   Sokolsky, Marina
   Lebed, Elena
   Vinod, Natasha
   Andrade, Carolina
   Kabanov, Alexander
   Tropsha, Alexander
TI Cheminformatics-driven discovery of polymeric micelle formulations of
   poorly soluble drugs
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 255th National Meeting and Exposition of the American-Chemical-Society
   (ACS) - Nexus of Food, Energy, and Water
CY MAR 18-22, 2018
CL New Orleans, LA
C1 [Alves, Vinicius; Andrade, Carolina] Univ Fed Goias, Fac Pharm, Goiania, Go, Brazil.
   [Tropsha, Alexander] Univ N Carolina, Chapel Hill, NC 27515 USA.
   [Muratov, Eugene; Hwang, Duhyeong; Sokolsky, Marina; Vinod, Natasha; Kabanov, Alexander] Univ N Carolina, Med Chem Nat Prod, Chapel Hill, NC 27515 USA.
   [Lebed, Elena] Odessa Natl Med Univ, Odessa, Ukraine.
EM murik@email.unc.edu
RI Kabanov, Alexander V/N-3356-2013; Tropsha, Alexander/AAB-8324-2020;
   Kabanov, Alexander/AAY-5751-2020; Alves, Vinicius M./G-7955-2015
OI Kabanov, Alexander V/0000-0002-3665-946X; Kabanov,
   Alexander/0000-0002-3665-946X; Alves, Vinicius M./0000-0002-6182-1748
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 18
PY 2018
VL 255
MA 465
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA GJ7AU
UT WOS:000435537701578
DA 2020-12-01
ER

PT J
AU Lima, MNN
   Melo, CC
   Cassiano, GC
   Neves, BJ
   Alves, VM
   Braga, RC
   Cravo, PVL
   Muratov, EN
   Calit, J
   Bargieri, DY
   Costa, FTM
   Andrade, CH
AF Lima, Marilia N. N.
   Melo-Filho, Cleber C.
   Cassiano, Gustavo C.
   Neves, Bruno J.
   Alves, Vinicius M.
   Braga, Rodolpho C.
   Cravo, Pedro V. L.
   Muratov, Eugene N.
   Calit, Juliana
   Bargieri, Daniel Y.
   Costa, Fabio T. M.
   Andrade, Carolina H.
TI QSAR-Driven Design and Discovery of Novel Compounds With Antiplasmodial
   and Transmission Blocking Activities
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE malaria; virtual screening; QSAR; Plasmodium falciparum; dUTPase;
   transmission blocker
ID EFFICIENT GENERATION; NUCLEOSIDE ANALOGS; AM1-BCC MODEL; DRUG DESIGN;
   DERIVATIVES; INHIBITORS; VALIDATION; PREDICTION; TOXICITY; CURATION
AB Malaria is a life-threatening infectious disease caused by parasites of the genus Plasmodium, affecting more than 200 million people worldwide every year and leading to about a half million deaths. Malaria parasites of humans have evolved resistance to all current antimalarial drugs, urging for the discovery of new effective compounds. Given that the inhibition of deoxyuridine triphosphatase of Plasmodium falciparum (PfdUTPase) induces wrong insertions in plasmodial DNA and consequently leading the parasite to death, this enzyme is considered an attractive antimalarial drug target. Using a combi-QSAR (quantitative structure-activity relationship) approach followed by virtual screening and in vitro experimental evaluation, we report herein the discovery of novel chemical scaffolds with in vitro potency against asexual blood stages of both P. falciparum multidrug-resistant and sensitive strains and against sporogonic development of P. berghei. We developed 2D- and 3D-QSAR models using a series of nucleosides reported in the literature as PfdUTPase inhibitors. The best models were combined in a consensus approach and used for virtual screening of the ChemBridge database, leading to the identification of five new virtual PfdUTPase inhibitors. Further in vitro testing on P. falciparum multidrug-resistant (W2) and sensitive (3D7) parasites showed that compounds LabMol-144 and LabMol-146 demonstrated fair activity against both strains and presented good selectivity versus mammalian cells. In addition, LabMol-144 showed good in vitro inhibition of P. berghei ookinete formation, demonstrating that hit-to-lead optimization based on this compound may also lead to new antimalarials with transmission blocking activity.
C1 [Lima, Marilia N. N.; Melo-Filho, Cleber C.; Neves, Bruno J.; Alves, Vinicius M.; Braga, Rodolpho C.; Andrade, Carolina H.] Univ Fed Goias, Fac Pharm, Lab Mol Modeling & Drug Design, LabMol, Goiania, Go, Brazil.
   [Cassiano, Gustavo C.; Costa, Fabio T. M.; Andrade, Carolina H.] Univ Estadual Campinas, Inst Biol, Dept Genet Evolut Microbiol & Immunol, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Campinas, SP, Brazil.
   [Neves, Bruno J.] Univ Ctr Anapolis UniEVANGELICA, SOMA, PPG, Lab Cheminformat, Anapolis, Brazil.
   [Cravo, Pedro V. L.] Univ Nova Lisboa, Inst Higiene & Med Trop, Unidade Parasitol Med, Global Hlth & Trop Med Ctr, Lisbon, Portugal.
   [Muratov, Eugene N.] Univ N Carolina, Eshelman Sch Pharm, Div Chem Biol & Med Chem, Lab Mol Modeling, Chapel Hill, NC USA.
   [Muratov, Eugene N.] Odessa Natl Polytech Univ, Dept Chem Technol, Odessa, Ukraine.
   [Calit, Juliana; Bargieri, Daniel Y.] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Sao Paulo, Brazil.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Pharm, Lab Mol Modeling & Drug Design, LabMol, Goiania, Go, Brazil.; Andrade, CH (corresponding author), Univ Estadual Campinas, Inst Biol, Dept Genet Evolut Microbiol & Immunol, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Campinas, SP, Brazil.
EM carolina@ufg.br
RI Bargieri, Daniel Youssef/A-4461-2013; Cassiano, Gustavo C/G-5728-2013;
   Neves, Bruno Junior/E-6295-2016; Melo-Filho, Cleber C./V-1119-2018;
   Lima, Marilia/S-7810-2018; Cravo, Pedro VL/G-3532-2012; Alves, Vinicius
   M./G-7955-2015; Costa, Fabio/E-1181-2012; Neves, Bruno/R-7068-2019;
   Braga, Rodolpho C/A-9655-2011; Andrade, Carolina/C-3960-2014
OI Bargieri, Daniel Youssef/0000-0003-2564-3742; Cassiano, Gustavo
   C/0000-0002-6971-5974; Melo-Filho, Cleber C./0000-0003-0056-6971; Lima,
   Marilia/0000-0002-7394-0031; Cravo, Pedro VL/0000-0003-1675-4504; Alves,
   Vinicius M./0000-0002-6182-1748; Costa, Fabio/0000-0001-9969-7300;
   Neves, Bruno/0000-0002-1309-8743; Braga, Rodolpho C/0000-0003-3814-3464;
   Andrade, Carolina/0000-0003-0101-1492; Calit,
   Juliana/0000-0002-4835-249X
FU Brazilian funding agency, CNPqNational Council for Scientific and
   Technological Development (CNPq); Brazilian funding agency, FAPEG;
   Brazilian funding agency, FAPESPFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP); Brazilian funding agency, CAPESCAPES;
   FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2012/16525-2, 2015/20774-6, 2017/02353-9, 2013/13119-6, 2016/16649-4];
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [405996/2016-0, 400760/2014-2]; NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [1U01CA207160,
   GM5105946]; Fundacao Nacional de Desenvolvimento do Ensino Superior
   Particular - Funadesp, via UniEvangelica - Centro Universitario de
   Anapolis; NATIONAL CANCER INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [U01CA207160, U01CA207160, U01CA207160] Funding
   Source: NIH RePORTER
FX The authors would like to thank Brazilian funding agencies, CNPq, FAPEG,
   FAPESP, and CAPES for financial support and fellowships. FC, GC, and CA
   were supported by FAPESP (Grants #2012/16525-2, #2015/20774-6, and
   #2017/02353-9, respectively). DB was supported by FAPESP (Grant
   #2013/13119-6) and CNPq (Grant #405996/2016-0). JC was supported by
   FAPESP fellowship (#2016/16649-4). EM appreciates support from NIH
   (Grant 1U01CA207160 and GM5105946) and CNPq (Grant # 400760/2014-2). CA,
   PC, and FC are CNPq research fellows. PC was partially supported by the
   Fundacao Nacional de Desenvolvimento do Ensino Superior Particular -
   Funadesp, via UniEvangelica - Centro Universitario de Anapolis.
CR Alves V. M., 2014, PROCEEDINGS OF THE 2
   [Anonymous], 2016, GLOB TUB REP
   Thu AM, 2017, FEBS J, V284, P2569, DOI 10.1111/febs.14127
   Banks JL, 2005, J COMPUT CHEM, V26, P1752, DOI 10.1002/jcc.20292
   Baragana B, 2011, BIOORGAN MED CHEM, V19, P2378, DOI 10.1016/j.bmc.2011.02.012
   Blagborough M. A., 2012, MALARIA METHODS PROT, V923, P577
   Braga RC, 2015, MOL INFORM, V34, P698, DOI 10.1002/minf.201500040
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1399, DOI 10.2174/1568026614666140506124442
   ChemBridge Online Chemical Store, 2017, ONLINE
   Cheng FX, 2012, J CHEM INF MODEL, V52, P3099, DOI 10.1021/ci300367a
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Doweyko AM, 2004, J COMPUT AID MOL DES, V18, P587, DOI 10.1007/s10822-004-4068-0
   ELHAJJ HH, 1988, J BACTERIOL, V170, P1069, DOI 10.1128/jb.170.3.1069-1075.1988
   Filimonov D.A., 2004, PHARM CHEM J, V38, P21, DOI DOI 10.1023/B:PHAC.0000027639.17115.5D
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   FRIESNER RA, 2004, MURPHY
   GADSDEN MH, 1993, EMBO J, V12, P4425, DOI 10.1002/j.1460-2075.1993.tb06127.x
   Gomes MN, 2017, EUR J MED CHEM, V137, P126, DOI 10.1016/j.ejmech.2017.05.026
   Hampton SE, 2011, CHEMMEDCHEM, V6, P1816, DOI 10.1002/cmdc.201100255
   HARTWIG CL, 2013, RESEARCH, P122
   Hawkins PCD, 2007, J MED CHEM, V50, P74, DOI 10.1021/jm0603365
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Hoffman SL, 2015, AM J PREV MED, V49, pS319, DOI 10.1016/j.amepre.2015.09.011
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Jakalian A, 2000, J COMPUT CHEM, V21, P132, DOI 10.1002/(SICI)1096-987X(20000130)21:2<132::AID-JCC5>3.0.CO;2-P
   Kuz'min VE, 2008, J COMPUT AID MOL DES, V22, P403, DOI 10.1007/s10822-008-9179-6
   Lagunin A, 2011, MOL INFORM, V30, P241, DOI 10.1002/minf.201000151
   Lagunin A, 2009, TOXICOL LETT, V189, pS264, DOI 10.1016/j.toxlet.2009.06.393
   LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287
   Leelananda SP, 2016, BEILSTEIN J ORG CHEM, V12, P2694, DOI 10.3762/bjoc.12.267
   LINDBERG W, 1983, ANAL CHEM, V55, P643, DOI 10.1021/ac00255a014
   Lopez-Barragan MJ, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-587
   McCarthy O, 2009, EUR J MED CHEM, V44, P678, DOI 10.1016/j.ejmech.2008.05.018
   McGann M, 2011, J CHEM INF MODEL, V51, P578, DOI 10.1021/ci100436p
   MELOFILHO CC, 2014, CURR COMPUT AIDED DR, V2174
   MELOFILHO CC, 2016, J CHEM INF MODEL, V55
   METHOD, 1921, J MED CHEM
   Miyakoshi H, 2012, J MED CHEM, V55, P2960, DOI 10.1021/jm201627n
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Neves BJ, 2016, J MED CHEM, V59, P7075, DOI 10.1021/acs.jmedchem.5b02038
   Nguyen C, 2005, J MED CHEM, V48, P5942, DOI [10.1021/jm050111e, 10.1021/jm050091g]
   Nguyen C, 2006, J MED CHEM, V49, P4183, DOI 10.1021/jm060126s
   Nyman PO, 2001, CURR PROTEIN PEPT SC, V2, P277, DOI 10.2174/1389203013381071
   Ojha PK, 2013, COMB CHEM HIGH T SCR, V16, P739
   Otto TD, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0086-0
   Pecsi I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037461
   Recio E, 2011, EUR J MED CHEM, V46, P3309, DOI 10.1016/j.ejmech.2011.04.052
   Ruda GF, 2011, CHEMMEDCHEM, V6, P309, DOI 10.1002/cmdc.201000445
   Sanders JM, 2017, J MED CHEM, V60, P6771, DOI 10.1021/acs.jmedchem.6b01577
   SAVIN NE, 1977, ECONOMETRICA, V45, P1989, DOI 10.2307/1914122
   Shelley JC, 2007, J COMPUT AID MOL DES, V21, P681, DOI 10.1007/s10822-007-9133-z
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   TRIPOS, 2010, HQSAR TM MANUAL SYBY
   *TRIPOS, 2010, QSAR AND COMFASUPSUP, V1, P2010
   Tropsha A, 2003, QSAR COMB SCI, V22, P69, DOI 10.1002/qsar.200390007
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   van de Waterbeemd H, 2003, NAT REV DRUG DISCOV, V2, P192, DOI 10.1038/nrd1032
   Varnek A, 2008, CURR COMPUT-AID DRUG, V4, P191, DOI 10.2174/157340908785747465
   Verma J, 2010, CURR TOP MED CHEM, V10, P95, DOI 10.2174/156802610790232260
   Vogel G, 2014, SCIENCE, V346, P1276, DOI 10.1126/science.346.6215.1276
   Whittingham JL, 2005, STRUCTURE, V13, P329, DOI 10.1016/j.str.2004.11.015
NR 63
TC 7
Z9 7
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAR 6
PY 2018
VL 9
AR 146
DI 10.3389/fphar.2018.00146
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA FY3CH
UT WOS:000426694400001
PM 29559909
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Alves, VM
   Capuzzi, SJ
   Braga, RC
   Borba, JVB
   Silva, AC
   Luechtefeld, T
   Hartung, T
   Andrade, CH
   Muratov, EN
   Tropsha, A
AF Alves, Vinicius M.
   Capuzzi, Stephen J.
   Braga, Rodolpho C.
   Borba, Joyce V. B.
   Silva, Arthur C.
   Luechtefeld, Thomas
   Hartung, Thomas
   Andrade, Carolina Horta
   Muratov, Eugene N.
   Tropsha, Alexander
TI A Perspective and a New Integrated Computational Strategy for Skin
   Sensitization Assessment
SO ACS SUSTAINABLE CHEMISTRY & ENGINEERING
LA English
DT Article
DE Skin sensitization; QSAR; Naive Bayes; Alternative methods
ID NONANIMAL TEST METHODS; LYMPH-NODE ASSAY; QSAR MODELS; PREDICTING SKIN;
   IN-VITRO; SIMPLEX REPRESENTATION; TESTING STRATEGY; TIMES-SS;
   TOXICOLOGY; VALIDATION
AB Traditionally, the skin sensitization potential of chemicals has been assessed using animal models. Due to growing ethical, political, and financial concerns, sustainable alternatives to animal testing need to be developed. As publicly available skin sensitization data continues to grow, computational approaches, such as alert-based systems, read-across, and QSAR models, are expected to reduce or replace animal testing for the prediction of human skin sensitization potential. Herein, we discuss current computational approaches to predicting skin sensitization and provide future perspectives of the field. As a proof-of-concept study, we have compiled the largest skin sensitization data set in the public domain and benchmarked several methods for building skin sensitization models. We propose a new comprehensive approach, which integrates multiple QSAR models developed with in vitro, in chemico, animal, and human data, and a Naive Bayes model for predicting human skin sensitization. Both the data sets and the KNIME implementation of the model allowing skin sensitization prediction for molecules of interest have been made freely available.
C1 [Alves, Vinicius M.; Capuzzi, Stephen J.; Muratov, Eugene N.; Tropsha, Alexander] Univ N Carolina, UNC Eshelman Sch Pharm, Div Chem Biol & Med Chem, Lab Mol Modeling, 301 Beard Hall, Chapel Hill, NC 27599 USA.
   [Alves, Vinicius M.; Braga, Rodolpho C.; Borba, Joyce V. B.; Silva, Arthur C.; Andrade, Carolina Horta] Univ Fed Goias, Lab Mol Modeling & Drug Design, Fac Pharm, Setor Leste Univ, Rua 240,Qd 87, BR-74605170 Goiania, Go, Brazil.
   [Luechtefeld, Thomas; Hartung, Thomas] Johns Hopkins Bloomberg Sch Publ Hlth, CAAT, 615 N Wolfe St, Baltimore, MD 21205 USA.
   [Muratov, Eugene N.] Odessa Natl Polytech Univ, Dept Chem Technol, 1 Shevchenko Ave, UA-65000 Odessa, Ukraine.
RP Muratov, EN; Tropsha, A (corresponding author), Univ N Carolina, UNC Eshelman Sch Pharm, Div Chem Biol & Med Chem, Lab Mol Modeling, 301 Beard Hall, Chapel Hill, NC 27599 USA.; Muratov, EN (corresponding author), Odessa Natl Polytech Univ, Dept Chem Technol, 1 Shevchenko Ave, UA-65000 Odessa, Ukraine.
EM murik@email.unc.edu; alex_tropsha@unc.edu
RI Alves, Vinicius M./G-7955-2015; de Carvalho e Silva, Arthur/S-7803-2018;
   Borba, Joyce V. B./S-7813-2018; Tropsha, Alexander/AAB-8324-2020; Braga,
   Rodolpho C/A-9655-2011; Muratov, Eugene/C-4454-2014; Andrade,
   Carolina/C-3960-2014
OI Alves, Vinicius M./0000-0002-6182-1748; de Carvalho e Silva,
   Arthur/0000-0001-9866-3344; Borba, Joyce V. B./0000-0002-2663-5173;
   Braga, Rodolpho C/0000-0003-3814-3464; Muratov,
   Eugene/0000-0003-4616-7036; Tropsha, Alexander/0000-0003-3802-8896;
   Capuzzi, Stephen/0000-0003-0001-8211; Andrade,
   Carolina/0000-0003-0101-1492
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [1U01CA207160]; CNPqNational Council
   for Scientific and Technological Development (CNPq) [400760/2014-2];
   CAPESCAPES
FX This study was supported in part by NIH (Grant 1U01CA207160) and CNPq
   (Grant 400760/2014-2). J.V.B.B. and A.C.S. thank CAPES for Ph.D.
   scholarships. S.J.C. thanks the organizers of the 22nd Annual Green
   Chemistry & Engineering Conference.
CR Allen TEH, 2014, CHEM RES TOXICOL, V27, P2100, DOI 10.1021/tx500345j
   Alves VM, 2018, FOOD CHEM TOXICOL, V112, P526, DOI 10.1016/j.fct.2017.04.008
   Alves VM, 2016, GREEN CHEM, V18, P6501, DOI [10.1039/c6gc01836j, 10.1039/C6GC01836J]
   Alves VM, 2016, GREEN CHEM, V18, P4348, DOI [10.1039/C6GC01492E, 10.1039/c6gc01492e]
   Alves VM, 2015, TOXICOL APPL PHARM, V284, P273, DOI 10.1016/j.taap.2014.12.013
   Alves VM, 2015, TOXICOL APPL PHARM, V284, P262, DOI 10.1016/j.taap.2014.12.014
   Anderson Stacey E, 2011, J Allergy (Cairo), V2011, P424203, DOI 10.1155/2011/424203
   Api AM, 2015, CUTAN OCUL TOXICOL, V34, P298, DOI 10.3109/15569527.2014.979425
   Artemenko AG, 2011, SAR QSAR ENVIRON RES, V22, P575, DOI 10.1080/1062936X.2011.569950
   Aziz T, 2011, NATURE, V470, P457, DOI 10.1038/470457a
   Baig MH, 2016, CURR PHARM DESIGN, V22, P572, DOI 10.2174/1381612822666151125000550
   Bailey J, 2014, ATLA-ALTERN LAB ANIM, V42, P181, DOI 10.1177/026119291404200306
   Ball N, 2016, ALTEX-ALTERN ANIM EX, V33, P149, DOI 10.14573/altex.1601251
   Basketter DA, 2015, HUM EXP TOXICOL, V34, P1222, DOI 10.1177/0960327115601760
   Basketter DA, 2002, FOOD CHEM TOXICOL, V40, P593, DOI 10.1016/S0278-6915(01)00130-2
   Basketter DA, 2014, DERMATITIS, V25, P11, DOI 10.1097/DER.0000000000000003
   Basketter DA, 2009, CUTAN OCUL TOXICOL, V28, P49, DOI 10.1080/15569520902938032
   Bell SM, 2018, TOXICOL IN VITRO, V47, P213, DOI 10.1016/j.tiv.2017.11.016
   Blagg J., 2010, BURGERS MED CHEM DRU, P301, DOI [10.1002/0471266949.bmc128., DOI 10.1002/0471266949.BMC128]
   Braga RC, 2017, J CHEM INF MODEL, V57, P1013, DOI 10.1021/acs.jcim.7b00194
   Bulusu KC, 2016, DRUG DISCOV TODAY, V21, P225, DOI 10.1016/j.drudis.2015.09.003
   Canipa SJ, 2017, J APPL TOXICOL, V37, P985, DOI 10.1002/jat.3448
   Capuzzi SJ, 2018, J CHEM INF MODEL, V58, P212, DOI 10.1021/acs.jcim.7b00589
   Capuzzi SJ, 2017, J CHEM INF MODEL, V57, P105, DOI 10.1021/acs.jcim.6b00462
   Casati S., EURL ECVAM EXP M
   Casati S., 2017, ARCH TOXICOL, V2017, P1
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Clouet E, 2017, TOXICOL IN VITRO, V45, P374, DOI 10.1016/j.tiv.2017.05.014
   Cockshott A, 2006, HUM EXP TOXICOL, V25, P387, DOI 10.1191/0960327106ht640oa
   CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018
   Dearden J. C., 2016, IJQSPR, V1, P1, DOI DOI 10.4018/IJQSPR.2016010101
   Dimitrov SD, 2005, INT J TOXICOL, V24, P189, DOI 10.1080/10915810591000631
   E. P. A. O. T. Council, 2013, OFF J EUR UNION L, V226, P1
   ECETOC, 116 ECETOC TR
   ECHA, READ ACR ASS FRAM RA
   Emami J, 2006, J PHARM PHARM SCI, V9, P169
   Enoch SJ, 2013, ISSUES TOXICOL, V17, P30, DOI 10.1039/9781849734400-00030
   Enslein K, 1997, FOOD CHEM TOXICOL, V35, P1091, DOI 10.1016/S0278-6915(97)87277-8
   EPA, HLTH EFF TEST GUID O
   EURL ECVAM, REC KERATINOSENSTM A
   EURL ECVAM, REC DIR PEPT REACT A
   EURL ECVAM, REC HUM CELL LIN ACT
   European Union, 2009, OFF J EUR UNION, VL342, P59
   European Union, 2007, OFF J EUR UNION, P3
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Goebel Carsten, 2017, Current Opinion in Toxicology, V5, P46, DOI 10.1016/j.cotox.2017.08.005
   Golbraikh A, 2003, J COMPUT AID MOL DES, V17, P241, DOI 10.1023/A:1025386326946
   Grace Patlewicz, 2017, Comput Toxicol, V3, P1, DOI 10.1016/j.comtox.2017.05.003
   Hartung T, 2016, ALTEX-ALTERN ANIM EX, V33, P83, DOI 10.14573/altex.1603091
   Hartung T, 2013, ALTEX-ALTERN ANIM EX, V30, P275, DOI 10.14573/altex.2013.3.275
   Hartung T, 2009, ALTEX-ALTERN TIEREXP, V26, P155
   ICCVAM, NICEATM MUR LOC LYMP
   Janardhan S, 2018, CURR MED CHEM, V25, P5432, DOI 10.2174/0929867324666171002120647
   Jaworska J, 2013, J APPL TOXICOL, V33, P1353, DOI 10.1002/jat.2869
   Jaworska JS, 2015, ARCH TOXICOL, V89, P2355, DOI 10.1007/s00204-015-1634-2
   Johansson H, 2017, TOXICOL SCI, V159, P3, DOI 10.1093/toxsci/kfx115
   KENNARD RW, 1969, TECHNOMETRICS, V11, P137, DOI 10.2307/1266770
   Kimber I, 2017, REGUL TOXICOL PHARM, V83, P104, DOI 10.1016/j.yrtph.2016.11.020
   Klaric M, 2017, TOXICOL LETT, V280, pS129, DOI 10.1016/j.toxlet.2017.07.359
   Kostal J, 2016, CHEM RES TOXICOL, V29, P58, DOI 10.1021/acs.chemrestox.5b00392
   Kuz'min VE, 2008, J COMPUT AID MOL DES, V22, P403, DOI 10.1007/s10822-008-9179-6
   Kuz'min VE, 2002, ACTA BIOCHIM POL, V49, P157
   Kuz'min VE, 2009, QSAR COMB SCI, V28, P664, DOI 10.1002/qsar.200860117
   Lagunin A, 2011, MOL INFORM, V30, P241, DOI 10.1002/minf.201000151
   Langley G, 2015, ENVIRON HEALTH PERSP, V123, pA268, DOI 10.1289/ehp.1510345
   Luechtefeld T, 2016, ALTEX-ALTERN ANIM EX, V33, P135, DOI 10.14573/altex.1510055
   Muratov EN, 2013, STRUCT CHEM, V24, P1665, DOI 10.1007/s11224-012-0195-8
   Muratov EN, 2012, MOL INFORM, V31, P202, DOI 10.1002/minf.201100129
   Muratov EN, 2010, FUTURE MED CHEM, V2, P1205, DOI 10.4155/FMC.10.194
   Natsch A, 2013, J APPL TOXICOL, V33, P1337, DOI 10.1002/jat.2868
   Naven RT, 2015, HUM EXP TOXICOL, V34, P1304, DOI 10.1177/0960327115605440
   OECD, TEST 406 SKIN SENS
   OECD, TEST 429 SKIN SENS
   OECD, TEST 442E IN VITR SK
   OECD, TEST 411 SUBCHR DERM
   OECD, 2018, OECD GUID TEST CHEM, DOI [10.1787/9789264229822-en, DOI 10.1787/9789264229822-EN]
   OECD, GUID DOC US OECD QSA
   OECD, TEST 442B SKIN SENS
   OECD, 2015, TG 442C CHEM SKIN SE
   Oprisiu I, 2012, MOL INFORM, V31, P491, DOI 10.1002/minf.201200006
   Organisation for Economic Co-operation and Development and OECD, OECD PRINC VAL REG P
   Otsubo Y, 2017, REGUL TOXICOL PHARM, V88, P118, DOI 10.1016/j.yrtph.2017.06.002
   Patlewicz G, 2015, REGUL TOXICOL PHARM, V72, P117, DOI 10.1016/j.yrtph.2015.03.015
   Patlewicz G, 2007, REGUL TOXICOL PHARM, V48, P225, DOI 10.1016/j.yrtph.2007.03.003
   Patlewicz G, 2014, ALTEX-ALTERN ANIM EX, V31, P387, DOI 10.14573/altex.1410071
   Patlewicz G, 2014, REGUL TOXICOL PHARM, V69, P529, DOI 10.1016/j.yrtph.2014.06.001
   Peiser M, 2012, CELL MOL LIFE SCI, V69, P763, DOI 10.1007/s00018-011-0846-8
   Raies AB, 2016, WIRES COMPUT MOL SCI, V6, P147, DOI 10.1002/wcms.1240
   Rani J, 2015, J BIOSCIENCES, V40, P671, DOI 10.1007/s12038-015-9552-2
   Refaeilzadeh P., 2009, ENCY DATABASE SYSTEM, P532, DOI DOI 10.1007/978-0-387-39940-9_565
   Reisinger K, 2015, TOXICOL IN VITRO, V29, P259, DOI 10.1016/j.tiv.2014.10.018
   Riniker S, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-43
   Roberts DW, 2007, CHEM RES TOXICOL, V20, P1321, DOI 10.1021/tx700169w
   Roberts DW, 2018, J APPL TOXICOL, V38, P41, DOI 10.1002/jat.3479
   Rodford R, 2003, ENVIRON TOXICOL CHEM, V22, P1855, DOI 10.1897/01-438
   Sarath Kumar K. L., 2016, PLOS ONE, V11
   Sharma NS, 2012, CELL MOL BIOENG, V5, P52, DOI 10.1007/s12195-011-0189-4
   Stepan AF, 2011, CHEM RES TOXICOL, V24, P1345, DOI 10.1021/tx200168d
   Strickland J, 2017, J APPL TOXICOL, V37, P347, DOI 10.1002/jat.3366
   Strickland J, 2016, J APPL TOXICOL, V36, P1150, DOI 10.1002/jat.3281
   Sturla SJ, 2014, CHEM RES TOXICOL, V27, P314, DOI 10.1021/tx400410s
   Sushko I, 2012, J CHEM INF MODEL, V52, P2310, DOI 10.1021/ci300245q
   Toropova AP, 2017, TOXICOL LETT, V275, P57, DOI 10.1016/j.toxlet.2017.03.023
   Tropsha A, 2007, CURR PHARM DESIGN, V13, P3494, DOI 10.2174/138161207782794257
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Urbisch D, 2016, TOXICOL IN VITRO, V34, P194, DOI 10.1016/j.tiv.2016.04.005
   Urbisch D, 2016, CHEM RES TOXICOL, V29, P901, DOI 10.1021/acs.chemrestox.6b00055
   Urbisch D, 2015, REGUL TOXICOL PHARM, V71, P337, DOI 10.1016/j.yrtph.2014.12.008
   Vityuk N., 1999, PATTERN RECOGNIT IMA, V3, P521
   Zakharov AV, 2014, J CHEM INF MODEL, V54, P713, DOI 10.1021/ci400704f
   Zang QD, 2017, J APPL TOXICOL, V37, P792, DOI 10.1002/jat.3424
NR 113
TC 12
Z9 12
U1 3
U2 15
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2168-0485
J9 ACS SUSTAIN CHEM ENG
JI ACS Sustain. Chem. Eng.
PD MAR
PY 2018
VL 6
IS 3
BP 2845
EP 2859
DI 10.1021/acssuschemeng.7b04220
PG 29
WC Chemistry, Multidisciplinary; Green & Sustainable Science & Technology;
   Engineering, Chemical
SC Chemistry; Science & Technology - Other Topics; Engineering
GA FY8DH
UT WOS:000427092900003
DA 2020-12-01
ER

PT J
AU Alves, VM
   Muratov, EN
   Zakharov, A
   Muratov, NN
   Andrade, CH
   Tropsha, A
AF Alves, Vinicius M.
   Muratov, Eugene N.
   Zakharov, Alexey
   Muratov, Nail N.
   Andrade, Carolina H.
   Tropsha, Alexander
TI Chemical toxicity prediction for major classes of industrial chemicals:
   Is it possible to develop universal models covering cosmetics, drugs,
   and pesticides?
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
DE Cosmetics; Drugs; Pesticides; Chemical space; QSAR models; Prediction
ID QSAR MODELS; CARCINOGENICITY; SENSITIZATION; CURATION; PROGRAM; VERIFY;
   TRUST
AB Computational models have earned broad acceptance for assessing chemical toxicity during early stages of drug discovery or environmental safety assessment. The majority of publicly available QSAR toxicity models have been developed for datasets including mostly drugs or drug -like compounds. We have evaluated and compared chemical spaces occupied by cosmetics, drugs, and pesticides, and explored whether current computational models of toxicity endpoints can be universally applied to all these chemicals. Our analysis of the chemical space overlap and applicability domain (AD) of models built previously for twenty different toxicity endpoints showed that most of these models afforded high coverage (>90%) for all three classes of compounds analyzed herein. Only T. pyriformis models demonstrated lower coverage for drugs and pesticides (38% and 54%, respectively). These results show that, for the most part, historical QSAR models built with data available for different toxicity endpoints can be used for toxicity assessment of novel chemicals irrespective of the intended commercial use; however, the AD restriction is necessary to assure the expected prediction accuracy. Local models may need to be developed to capture chemicals that appear as outliers with respect to global models. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Alves, Vinicius M.; Muratov, Eugene N.; Tropsha, Alexander] Univ N Carolina, Eshelman Sch Pharm, Div Chem Biol & Med Chem, Lab Mol Modeling, Chapel Hill, NC 27599 USA.
   [Alves, Vinicius M.; Andrade, Carolina H.] Univ Fed Goias, Fac Pharm, Lab Mol Modeling & Drug Design, BR-74605170 Goiania, Go, Brazil.
   [Muratov, Eugene N.; Muratov, Nail N.] Odessa Natl Polytech Univ, Dept Chem Technol, UA-65000 Odessa, Ukraine.
   [Zakharov, Alexey] NCATS, NIH, Rockville, MD 20850 USA.
RP Tropsha, A (corresponding author), Univ N Carolina, UNC Eshelman Sch Pharm, 100K Beard Hall, Chapel Hill, NC 27599 USA.
EM alex_tropsha@unc.edu
RI Alves, Vinicius M./G-7955-2015; Tropsha, Alexander/AAB-8324-2020;
   Andrade, Carolina/C-3960-2014; Muratov, Eugene/C-4454-2014
OI Alves, Vinicius M./0000-0002-6182-1748; Andrade,
   Carolina/0000-0003-0101-1492; Muratov, Eugene/0000-0003-4616-7036
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [1U01CA207160]; FAPEG
   [201310267001095]; CNPqNational Council for Scientific and Technological
   Development (CNPq) [400760/2014-2]; CAPESCAPES; Intramural Research
   Program, National Center for Advancing Translational Sciences, National
   Institutes of Health [1ZIATR000058-02]; NATIONAL CANCER INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [U01CA207160,
   U01CA207160, U01CA207160] Funding Source: NIH RePORTER; NATIONAL CENTER
   FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [ZIATR000058,
   ZIATR000058, ZIATR000058, ZIATR000058] Funding Source: NIH RePORTER
FX This study was supported in part by NIH (grant 1U01CA207160). VA thanks
   FAPEG (grant 201310267001095), CNPq (grant 400760/2014-2), and CAPES.
   A.Z. acknowledges Intramural Research Program, National Center for
   Advancing Translational Sciences, National Institutes of Health
   (1ZIATR000058-02). The authors express sincere gratitude to Drs. Glenn
   Myatt and Nora Aptula for providing datasets used in this study. The
   authors are also grateful for Drs. Vladimir Poroikov and Dmitri
   Filimonov providing the GUSAR Software and appreciate ChemAxon for
   providing free academic licenses for their products.
CR Alves VM, 2016, GREEN CHEM, V18, P6501, DOI [10.1039/c6gc01836j, 10.1039/C6GC01836J]
   Alves VM, 2015, TOXICOL APPL PHARM, V284, P273, DOI 10.1016/j.taap.2014.12.013
   Alves VM, 2015, TOXICOL APPL PHARM, V284, P262, DOI 10.1016/j.taap.2014.12.014
   Benfenati E, 2009, J ENVIRON SCI HEAL C, V27, P57, DOI 10.1080/10590500902885593
   Bois F. Y., 2016, TOXICOLOGY
   Braga RC, 2015, MOL INFORM, V34, P698, DOI 10.1002/minf.201500040
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1399, DOI 10.2174/1568026614666140506124442
   Burden N, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002156
   Capuzzi SJ, 2016, FRONT ENV SCI-SWITZ, V4, DOI 10.3389/fenvs.2016.00003
   Chuprina A, 2010, J CHEM INF MODEL, V50, P470, DOI 10.1021/ci900464s
   Collins T, 2003, GREEN CHEM, V5, pG51, DOI 10.1039/b307694f
   Cronin M. T. D., 2012, COSMOS PROJECT FDN F
   Deng ZL, 2013, J CHEM INF MODEL, V53, P2820, DOI 10.1021/ci400432a
   Dix DJ, 2007, TOXICOL SCI, V95, P5, DOI 10.1093/toxsci/kfl103
   Egeghy PP, 2012, SCI TOTAL ENVIRON, V414, P159, DOI 10.1016/j.scitotenv.2011.10.046
   EPA, 2002, METH MEAS AC TOX EFF
   European Commission, 2013, AN TEST MARK BAN STA
   FDA, 2005, E14 CLIN EV QT QTC I
   Feinstein DL, 2016, ANN NY ACAD SCI, V1374, P111, DOI 10.1111/nyas.13085
   Filimonov DA, 2009, SAR QSAR ENVIRON RES, V20, P679, DOI 10.1080/10629360903438370
   Food and Drug Administration (FDA), 2005, S7B NONCL EV POT DEL
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   GADALETA D, 2016, INT J QUANT STRUCT P, V1, P45, DOI DOI 10.4018/IJQSPR.2016010102
   Golbraikh A, 2003, J COMPUT AID MOL DES, V17, P241, DOI 10.1023/A:1025386326946
   HAYAOKA T, 1982, PESTIC BIOCHEM PHYS, V17, P113, DOI 10.1016/0048-3575(82)90015-3
   Hennino Ana, 2005, An. Bras. Dermatol., V80, P335, DOI 10.1590/S0365-05962005000400003
   Kulkarni SA, 2016, SAR QSAR ENVIRON RES, V27, P851, DOI 10.1080/1062936X.2016.1243152
   Kuz'min VE, 2008, J COMPUT AID MOL DES, V22, P403, DOI 10.1007/s10822-008-9179-6
   Lagunin A, 2009, QSAR COMB SCI, V28, P806, DOI 10.1002/qsar.200860192
   Low Y, 2011, CHEM RES TOXICOL, V24, P1251, DOI 10.1021/tx200148a
   Marrs Timothy C., 2003, Toxicological Reviews, V22, P75, DOI 10.2165/00139709-200322020-00002
   Mathea M, 2016, MOL INFORM, V35, P160, DOI 10.1002/minf.201501019
   Melnikov F, 2016, GREEN CHEM, V18, P4432, DOI 10.1039/c6gc00720a
   Mitcheson JS, 2000, P NATL ACAD SCI USA, V97, P12329, DOI 10.1073/pnas.210244497
   Muratov EN, 2010, FUTURE MED CHEM, V2, P1205, DOI 10.4155/FMC.10.194
   Naven RT, 2015, HUM EXP TOXICOL, V34, P1304, DOI 10.1177/0960327115605440
   Netzeva TI, 2005, ATLA-ALTERN LAB ANIM, V33, P155, DOI 10.1177/026119290503300209
   Nicolotti O, 2014, DRUG DISCOV TODAY, V19, P1757, DOI 10.1016/j.drudis.2014.06.027
   Parasuraman S, 2011, J PHARMACOL PHARMACO, V2, P74, DOI 10.4103/0976-500X.81895
   Picard S, 2011, CARDIOVASC TOXICOL, V11, P285, DOI 10.1007/s12012-011-9133-z
   Sander T, 2015, J CHEM INF MODEL, V55, P460, DOI 10.1021/ci500588j
   Schulte PA, 2013, ENVIRON HEALTH-GLOB, V12, DOI 10.1186/1476-069X-12-31
   Sousa-Polezzi RD, 2004, GENET MOL BIOL, V27, P275, DOI 10.1590/S1415-47572004000200024
   Sushko I, 2010, J CHEM INF MODEL, V50, P2094, DOI 10.1021/ci100253r
   Talete SRL, 2007, DRAGON FOR WINDOWS
   Tice RR, 2013, ENVIRON HEALTH PERSP, V121, P756, DOI 10.1289/ehp.1205784
   Tropsha A, 2007, CURR PHARM DESIGN, V13, P3494, DOI 10.2174/138161207782794257
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Vandebriel RJ, 2010, CRIT REV TOXICOL, V40, P389, DOI 10.3109/10408440903524262
   Varnek A, 2008, CURR COMPUT-AID DRUG, V4, P191, DOI 10.2174/157340908785747465
   Vityuk N., 1999, PATTERN RECOGNIT IMA, V3, P521
   Zakharov AV, 2014, J CHEM INF MODEL, V54, P713, DOI 10.1021/ci400704f
   Zhu H, 2008, J CHEM INF MODEL, V48, P766, DOI 10.1021/ci700443v
NR 55
TC 17
Z9 17
U1 0
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-6915
EI 1873-6351
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD FEB
PY 2018
VL 112
BP 526
EP 534
DI 10.1016/j.fct.2017.04.008
PG 9
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA FW8GN
UT WOS:000425568900059
PM 28412406
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Santos, CC
   Lionel, JR
   Peres, RB
   Batista, MM
   da Silva, PB
   de Oliveira, GM
   da Silva, CF
   Batista, DGJ
   Souza, SMO
   Andrade, CH
   Neves, BJ
   Braga, RC
   Patrick, DA
   Bakunova, SM
   Tidwell, RR
   Soeiro, MDC
AF Santos, Camila C.
   Lionel, Jessica R.
   Peres, Raiza B.
   Batista, Marcos M.
   da Silva, Patricia B.
   de Oliveira, Gabriel M.
   da Silva, Cristiane F.
   Batista, Denise G. J.
   Souza, Sandra Maria O.
   Andrade, Carolina H.
   Neves, Bruno J.
   Braga, Rodolpho C.
   Patrick, Donald A.
   Bakunova, Svetlana M.
   Tidwell, Richard R.
   Soeiro, Maria de Nazare C.
TI In Vitro, In Silico, and In Vivo Analyses of Novel Aromatic Amidines
   against Trypanosoma cruzi
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
DE Chagas disease; arylimidamides; experimental chemotherapy; in vivo
ID CHAGAS-DISEASE; PREDICTION; BINDING; MODELS; AGENTS; DNA
AB Five bis-arylimidamides were assayed as anti-Trypanosoma cruzi agents by in vitro, in silico, and in vivo approaches. None were considered to be pan-assay interference compounds. They had a favorable pharmacokinetic landscape and were active against trypomastigotes and intracellular forms, and in combination with benznidazole, they gave no interaction. The most selective agent (28SMB032) tested in vivo led to a 40% reduction in parasitemia (0.1 mg/kg of body weight/5 days intraperitoneally) but without mortality protection. In silico target fishing suggested DNA as the main target, but ultrastructural data did not match.
C1 [Santos, Camila C.; Lionel, Jessica R.; Peres, Raiza B.; Batista, Marcos M.; da Silva, Patricia B.; de Oliveira, Gabriel M.; da Silva, Cristiane F.; Batista, Denise G. J.; Soeiro, Maria de Nazare C.] Oswaldo Cruz Inst Fiocruz, Lab Cellular Biol LBC, Rio De Janeiro, RJ, Brazil.
   [Souza, Sandra Maria O.] Oswaldo Cruz Inst Fiocruz, Lab Struct Biol LBE, Rio De Janeiro, RJ, Brazil.
   [Andrade, Carolina H.; Neves, Bruno J.; Braga, Rodolpho C.] Univ Fed Goias, Fac Farm, Lab Mol Modeling & Drug Design LabMol, Goiania, Go, Brazil.
   [Patrick, Donald A.; Bakunova, Svetlana M.; Tidwell, Richard R.] Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC USA.
RP Soeiro, MDC (corresponding author), Oswaldo Cruz Inst Fiocruz, Lab Cellular Biol LBC, Rio De Janeiro, RJ, Brazil.
EM soeiro@ioc.fiocruz.br
RI Neves, Bruno/R-7068-2019; Braga, Rodolpho C/A-9655-2011; Neves, Bruno
   Junior/E-6295-2016; de Nazare Correia Soeiro, Maria/S-1894-2019;
   Patrick, Donald/Y-2460-2019; Andrade, Carolina/C-3960-2014
OI Neves, Bruno/0000-0002-1309-8743; Braga, Rodolpho C/0000-0003-3814-3464;
   de Nazare Correia Soeiro, Maria/0000-0003-0078-6106; Patrick,
   Donald/0000-0003-0756-0492; Andrade, Carolina/0000-0003-0101-1492
FU Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ); Conselho Nacional Desenvolvimento
   Cientifico e Tecnologico (CNPq)National Council for Scientific and
   Technological Development (CNPq); Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES)CAPES; Fundacao Oswaldo Cruz; PDTIS;
   PAEF/CNPq/Fiocruz; CAPESCAPES; Fortalecimento dos Programas de Gestao
   Estrategica de Pesquisa da Fiocruz Rede de Plataformas Fiocruz
   [VPPLR-001-Fio 14]
FX The present study was supported by grants from the Fundacao Carlos
   Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ),
   Conselho Nacional Desenvolvimento Cientifico e Tecnologico (CNPq),
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES),
   Fundacao Oswaldo Cruz, PDTIS, PAEF/CNPq/Fiocruz, and CAPES. We thank the
   Fortalecimento dos Programas de Gestao Estrategica de Pesquisa da
   Fiocruz Rede de Plataformas Fiocruz (grant VPPLR-001-Fio 14) and the
   Programa de Excelencia Academica (PROEX) from CAPES. M.D.N.C.S. is a
   research fellow of the CNPq and a CNE researcher.
CR Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Braga RC, 2015, MOL INFORM, V34, P698, DOI 10.1002/minf.201500040
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1399, DOI 10.2174/1568026614666140506124442
   Cal M, 2016, INT J PARASITOL-DRUG, V6, P165, DOI 10.1016/j.ijpddr.2016.08.003
   Chai Y, 2014, CHEMBIOCHEM, V15, P68, DOI 10.1002/cbic.201300622
   Cheng FX, 2012, J CHEM INF MODEL, V52, P3099, DOI 10.1021/ci300367a
   Cheng FX, 2011, J CHEM INF MODEL, V51, P996, DOI 10.1021/ci200028n
   Daliry A, 2011, ANTIMICROB AGENTS CH, V55, P4765, DOI 10.1128/AAC.00229-11
   Drwal MN, 2014, NUCLEIC ACIDS RES, V42, pW53, DOI 10.1093/nar/gku401
   ERCOLI N, 1980, CHEMOTHERAPY, V26, P218, DOI 10.1159/000237908
   Fivelman QL, 2004, ANTIMICROB AGENTS CH, V48, P4097, DOI 10.1128/AAC.48.11.4097-4102.2004
   Hansen K, 2009, J CHEM INF MODEL, V49, P2077, DOI 10.1021/ci900161g
   Batista DDJ, 2010, ANTIMICROB AGENTS CH, V54, P2940, DOI 10.1128/AAC.01617-09
   Katsuno K, 2015, NAT REV DRUG DISCOV, V14, P751, DOI 10.1038/nrd4683
   Lagunin A, 2009, QSAR COMB SCI, V28, P806, DOI 10.1002/qsar.200860192
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Maya JD, 2014, CURR MED CHEM, V21, P1757, DOI 10.2174/0929867320666131119122145
   Molina I, 2015, CURR OPIN INFECT DIS, V28, P397, DOI 10.1097/QCO.0000000000000192
   MUSANTE C, 1951, Farmaco Sci Tec, V6, P32
   NUNN CM, 1993, BIOCHEMISTRY-US, V32, P13838, DOI 10.1021/bi00213a012
   Patrick DA, 2013, J MED CHEM, V56, P5473, DOI 10.1021/jm400508e
   Pecoul B, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004343
   Pereira-Chioccola VL, 2000, J CELL SCI, V113, P1299
   Romanha AJ, 2010, MEM I OSWALDO CRUZ, V105, P233, DOI 10.1590/S0074-02762010000200022
   Shen J, 2010, J CHEM INF MODEL, V50, P1034, DOI 10.1021/ci100104j
   Soeiro MNC, 2013, PARASITOLOGY, V140, P929, DOI 10.1017/S0031182013000292
   Stephens CE, 2001, J MED CHEM, V44, P1741, DOI 10.1021/jm000413a
   Urbina JA, 2015, J EUKARYOT MICROBIOL, V62, P149, DOI 10.1111/jeu.12184
   WHO. World Health Organization, 2013, 2 WHO
   Wilkinson SR, 2008, P NATL ACAD SCI USA, V105, P5022, DOI 10.1073/pnas.0711014105
   Wu CY, 2008, J MED CHEM, V51, P6682, DOI 10.1021/jm8003637
NR 32
TC 5
Z9 5
U1 0
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD FEB
PY 2018
VL 62
IS 2
AR e02205-17
DI 10.1128/AAC.02205-17
PG 8
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA FT9AF
UT WOS:000423443600043
PM 29203486
OA Bronze, Green Published
DA 2020-12-01
ER

PT J
AU Alves, VM
   Braga, RC
   Muratov, EN
   Andrade, CH
AF Alves, Vinicius M.
   Braga, Rodolpho C.
   Muratov, Eugene N.
   Andrade, Carolina Horta
TI CHEMINFORMATICS: AN INTRODUCTION
SO QUIMICA NOVA
LA Portuguese
DT Review
DE cheminformatics; QSAR; chemical similarity; structure representation,
   property prediction; virtual screening
ID QUANTITATIVE STRUCTURE-ACTIVITY; DIFFERENT VALIDATION CRITERIA; REAL
   EXTERNAL PREDICTIVITY; VIRTUAL SCREENING METHODS; QSAR MODELS; MEDICINAL
   CHEMISTRY; DRUG DISCOVERY; MOLECULAR DESCRIPTORS; ANTIBIOTIC-ACTIVITY;
   LEAD DISCOVERY
AB Cheminformatics is an interdisciplinary field between chemistry and informatics, which has evolved considerably since its inception in the 1960s. Initially, the cheminformatics community dealt primarily with practical and technical aspects of chemical structure representation, manipulation, and processing, while modern research explores a new role: the exploration and interpretation of large chemical databases and the discovery of new compounds with desired activity and safety profiles. Despite the recent release of several hallmark reviews addressing methods and application of cheminformatics written in Portuguese, so far there are no scientific articles presenting cheminformatics research to the Brazilian scientific community yet. To address this gap, we aim to introduce the field of cheminformatics to both students and researchers in a simple and didactic way by narrating important historical facts and contextualizing information within the scope of various applications.
C1 [Alves, Vinicius M.; Braga, Rodolpho C.; Muratov, Eugene N.; Andrade, Carolina Horta] Univ Fed Goias, Fac Farm, Lab Planejamento Farmacos & Modelagem Mol, BR-74605220 Goiania, Go, Brazil.
   [Muratov, Eugene N.] Univ N Carolina, UNC Eshelman Sch Pharm, Div Chem Biol & Med Chem, Lab Mol Modeling, Chapel Hill, NC 27599 USA.
   [Muratov, Eugene N.] Odessa Natl Polytech Univ, Dept Chem Technol, UA-65000 Odessa, Ukraine.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, Lab Planejamento Farmacos & Modelagem Mol, BR-74605220 Goiania, Go, Brazil.
EM carolina@ufg.br
RI Alves, Vinicius M./G-7955-2015; Braga, Rodolpho C/A-9655-2011; Andrade,
   Carolina/C-3960-2014
OI Alves, Vinicius M./0000-0002-6182-1748; Braga, Rodolpho
   C/0000-0003-3814-3464; Andrade, Carolina/0000-0003-0101-1492
CR Allen TEH, 2014, CHEM RES TOXICOL, V27, P2100, DOI 10.1021/tx500345j
   ALTMAN DG, 1994, BRIT MED J, V308, P1552, DOI 10.1136/bmj.308.6943.1552
   ALTMAN DG, 1994, BRIT MED J, V309, P102, DOI 10.1136/bmj.309.6947.102
   Alves V. M., 2015, TOXICOL APPL PHARM, V284
   Alves V. M., 2017, FOOD CHEM TOXICOL
   Alves VM, 2016, GREEN CHEM, V18, P6501, DOI [10.1039/c6gc01836j, 10.1039/C6GC01836J]
   Alves VM, 2016, GREEN CHEM, V18, P4348, DOI [10.1039/C6GC01492E, 10.1039/c6gc01492e]
   Alves VM, 2015, TOXICOL APPL PHARM, V284, P273, DOI 10.1016/j.taap.2014.12.013
   Anderson E., SMILES LINE NOTATION
   ANDRADE C.H., 2010, REV ELETR FARM, V7, P1
   Andrade JG, 2012, QUIM NOVA, V35, P466, DOI 10.1590/S0100-40422012000300005
   Arroio A, 2010, QUIM NOVA, V33, P694, DOI 10.1590/S0100-40422010000300037
   Ban FQ, 2017, J CHEM INF MODEL, V57, P1018, DOI 10.1021/acs.jcim.7b00137
   Barreiro EJ, 1997, QUIM NOVA, V20, P300, DOI 10.1590/S0100-40421997000300011
   Berman HM, 2000, NAT STRUCT BIOL, V7, P957, DOI 10.1038/80734
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bienfait B, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-24
   Blagg J, 2010, BURGERS MED CHEM DRU
   Braga RC, 2015, MOL INFORM, V34, P698, DOI 10.1002/minf.201500040
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1899, DOI 10.2174/1568026614666140929120749
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1399, DOI 10.2174/1568026614666140506124442
   Braga RC, 2013, CURR TOP MED CHEM, V13, P1127, DOI 10.2174/1568026611313090010
   Brecher J, 2006, PURE APPL CHEM, V78, P1897, DOI 10.1351/pac200678101897
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Brown FK, 1998, ANNU REP MED CHEM, V33, P375, DOI [10.1016/s0065-7743(08)61100-8, DOI 10.1016/S0065-7743(08)61100-8]
   Canny SA, 2012, BIOINFORMATICS, V28, P140, DOI 10.1093/bioinformatics/btr622
   Carvalho I, 2003, QUIM NOVA, V26, P428, DOI 10.1590/S0100-40422003000300023
   Chemical Abstracts Service, INTR CAS DIV AM CHEM
   Chen X, 2018, CURR TOP MED CHEM, V18, P947, DOI 10.2174/156802661812180831120612
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Chirico N, 2012, J CHEM INF MODEL, V52, P2044, DOI 10.1021/ci300084j
   Chirico N, 2011, J CHEM INF MODEL, V51, P2320, DOI 10.1021/ci200211n
   Clark DE, 2008, EXPERT OPIN DRUG DIS, V3, P841, DOI 10.1517/17460441.3.8.841
   Consonni V., 2010, RECENT ADV QSAR STUD
   Cormanich RA, 2012, QUIM NOVA, V35, P1157, DOI 10.1590/S0100-40422012000600017
   CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018
   CRAMER RD, 1988, J AM CHEM SOC, V110, P5959, DOI 10.1021/ja00226a005
   Cramer RD, 2012, J COMPUT AID MOL DES, V26, P35, DOI 10.1007/s10822-011-9495-0
   Cronin M.T.D., 2010, RECENT ADV QSAR STUD
   DALBY A, 1992, J CHEM INF COMP SCI, V32, P244, DOI 10.1021/ci00007a012
   Daylight Inc, SMARTS LANG DESCR MO
   de Almeida VL, 2010, QUIM NOVA, V33, P1482, DOI 10.1590/S0100-40422010000700011
   Dearden JC, 2009, SAR QSAR ENVIRON RES, V20, P241, DOI 10.1080/10629360902949567
   Debnath Asim Kumar, 2001, Mini-Reviews in Medicinal Chemistry, V1, P187, DOI 10.2174/1389557013407061
   Downs GM, 2002, REV COMP CH, V18, P1, DOI 10.1002/0471433519.ch1
   Dreiseitl S, 2002, J BIOMED INFORM, V35, P352, DOI 10.1016/S1532-0464(03)00034-0
   Eckert H, 2007, DRUG DISCOV TODAY, V12, P225, DOI 10.1016/j.drudis.2007.01.011
   El-Kommos ME, 2015, J FLUORESC, V25, P1695, DOI 10.1007/s10895-015-1656-4
   Elsevier MDL, 2005, CTFILE FORMATS
   Enoch S. J., 2013, CHEM TOXICITY PREDIC
   Ferreira MMC, 2002, QUIM NOVA, V25, P439, DOI 10.1590/S0100-40422002000300017
   Ferreira MMC, 2015, QUIMIOMETRIA CONCEIT
   FIGUERAS J, 1993, J CHEM INF COMP SCI, V33, P717, DOI 10.1021/ci00015a009
   Floris M, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/s13321-014-0039-1
   Forli S, 2015, MOLECULES, V20, P18732, DOI 10.3390/molecules201018732
   Fourches D., NANOTOXICOLOGY PROGR
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2016, NANOTOXICOLOGY, V10, P374, DOI 10.3109/17435390.2015.1073397
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   FREE SM, 1964, J MED CHEM, V7, P395, DOI 10.1021/jm00334a001
   Freitas HF, 2009, QUIM NOVA, V32, P2114, DOI 10.1590/S0100-40422009000800024
   Frye SV, 2015, NAT REV DRUG DISCOV, V14, P733, DOI 10.1038/nrd4737
   GADALETA D, 2016, INT J QUANT STRUCT P, V1, P45, DOI DOI 10.4018/IJQSPR.2016010102
   GARZIA A, 1979, J PHARM SCI, V68, P1081, DOI 10.1002/jps.2600680905
   Gasteiger J., 2003, CHEMOINFORMATICS TXB
   Gasteiger J, 2016, MOLECULES, V21, DOI 10.3390/molecules21020151
   Gaudio AC, 2001, QUIM NOVA, V24, P658, DOI 10.1590/S0100-40422001000500013
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   Golbraikh A, 2002, J MOL GRAPH MODEL, V20, P269, DOI 10.1016/S1093-3263(01)00123-1
   Golbraikh A, 2014, J CHEM INF MODEL, V54, P1, DOI 10.1021/ci400572x
   Gramatica P, 2007, QSAR COMB SCI, V26, P694, DOI 10.1002/qsar.200610151
   Guha R, 2008, J CHEM INF MODEL, V48, P646, DOI 10.1021/ci7004093
   Hammett LP, 1937, J AM CHEM SOC, V59, P96, DOI 10.1021/ja01280a022
   HAMMETT LP, 1940, PHYS ORGANIC CHEM RE
   Hann M, 1999, CURR OPIN CHEM BIOL, V3, P379, DOI 10.1016/S1367-5931(99)80057-X
   HANSCH C, 1964, J AM CHEM SOC, V86, P1616, DOI 10.1021/ja01062a035
   Heikamp K, 2011, J CHEM INF MODEL, V51, P2254, DOI 10.1021/ci200275m
   Helgee EA, 2010, J CHEM INF MODEL, V50, P677, DOI 10.1021/ci900471e
   Hinchliffe A, 2003, MOL MODELLING BEGINN
   HOPFINGER AJ, 1980, J AM CHEM SOC, V102, P7196, DOI 10.1021/ja00544a005
   Hopfinger AJ, 1997, J AM CHEM SOC, V119, P10509, DOI 10.1021/ja9718937
   Jaccard P., 1901, B SOC VAUD SCI NAT, VXXXVII, P83
   Johnson M. A., 1990, CONCEPTS APPL MOL SI, V13
   Kaliszan R, 2007, CHEM REV, V107, P3212, DOI 10.1021/cr068412z
   Kar S, 2013, EXPERT OPIN DRUG DIS, V8, P245, DOI 10.1517/17460441.2013.761204
   Kenny PW, 2005, METH PRIN MED CHEM, V22, P271, DOI 10.1002/3527603743.ch11
   Kessel M, 2011, NAT BIOTECHNOL, V29, P27, DOI 10.1038/nbt.1748
   KLEBE G, 1994, J MED CHEM, V37, P4130, DOI 10.1021/jm00050a010
   KUBINYI H, 1977, ARZNEIMITTEL-FORSCH, V27-1, P750
   KUBINYI H, 1979, FARMACO-ED SCI, V34, P248
   Kubinyi H, 1998, PERSPECT DRUG DISCOV, V9-11, P225, DOI 10.1023/A:1027221424359
   Kuz'min VE, 2009, QSAR COMB SCI, V28, P664, DOI 10.1002/qsar.200860117
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Lejon T, 2004, J PEPT SCI, V10, P329, DOI 10.1002/psc.553
   Lejon T, 2001, J PEPT SCI, V7, P74, DOI 10.1002/psc.295
   Ma XH, 2012, CURR MED CHEM, V19, P5562
   Maggiora G, 2014, J MED CHEM, V57, P3186, DOI 10.1021/jm401411z
   Maggiora GM, 2006, J CHEM INF MODEL, V46, P1535, DOI 10.1021/ci060117s
   Mahalanobis P.C., 1936, P NATL I SCI INDIA, V2, P49, DOI DOI 10.1145/1390156.1390302
   Martins JPA, 2013, QUIM NOVA, V36, P554, DOI 10.1590/S0100-40422013000400013
   Mathea M, 2016, MOL INFORM, V35, P160, DOI 10.1002/minf.201501019
   MCCLISH DK, 1989, MED DECIS MAKING, V9, P190, DOI 10.1177/0272989X8900900307
   Melo CC, 2016, J CHEM INF MODEL, V56, P1357, DOI 10.1021/acs.jcim.6b00055
   Melville JL, 2009, COMB CHEM HIGH T SCR, V12, P332, DOI 10.2174/138620709788167980
   Mills N, 2006, J AM CHEM SOC, V128, P13649, DOI 10.1021/ja0697875
   Montanari MLC, 2002, QUIM NOVA, V25, P231, DOI 10.1590/S0100-40422002000200011
   MORGAN HL, 1965, J CHEM DOC, V5, P107, DOI 10.1021/c160017a018
   Muratov EN, 2013, STRUCT CHEM, V24, P1665, DOI 10.1007/s11224-012-0195-8
   Muratov EN, 2012, MOL INFORM, V31, P202, DOI 10.1002/minf.201100129
   Neves BJ, 2016, J MED CHEM, V59, P7075, DOI 10.1021/acs.jmedchem.5b02038
   Oprisiu I, 2012, MOL INFORM, V31, P491, DOI 10.1002/minf.201200006
   Pletnev I, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758-2946-4-39
   Polgar T, 2011, COMB CHEM HIGH T SCR, V14, P889, DOI 10.2174/138620711797537148
   Ripphausen P, 2010, J MED CHEM, V53, P8461, DOI 10.1021/jm101020z
   ROGERS DJ, 1960, SCIENCE, V132, P1115, DOI 10.1126/science.132.3434.1115
   Roy K, 2004, J CHEM INF COMP SCI, V44, P559, DOI 10.1021/ci0342066
   Roy K, 2012, J CHEM INF MODEL, V52, P396, DOI 10.1021/ci200520g
   Roy K, 2011, COMB CHEM HIGH T SCR, V14, P450, DOI 10.2174/138620711795767893
   Sant'Anna CMR, 2009, REV VIRTUAL QUIM, V1, P49, DOI 10.5935/1984-6835.20090007
   Schneider G, 2010, NAT REV DRUG DISCOV, V9, P273, DOI 10.1038/nrd3139
   Sheridan RP, 2014, J CHEM INF MODEL, V54, P1083, DOI 10.1021/ci500084w
   Tavares LC, 2004, QUIM NOVA, V27, P631, DOI 10.1590/S0100-40422004000400018
   Tetko IV, 2016, FUTURE MED CHEM, V8, P1801, DOI 10.4155/fmc-2016-0163
   Todeschini R., 2000, HDB MOL DESCRIPTORS
   Tropsha A, 2003, QSAR COMB SCI, V22, P69, DOI 10.1002/qsar.200390007
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Truchon JF, 2007, J CHEM INF MODEL, V47, P488, DOI 10.1021/ci600426e
   Urbano-Cuadrado M, 2007, J CHEM INF MODEL, V47, P2228, DOI 10.1021/ci700181v
   Varnek A, 2011, MOL INFORM, V30, P20, DOI 10.1002/minf.201000100
   Vedani A, 2005, J MED CHEM, V48, P3700, DOI 10.1021/jm050185q
   Vedani A, 2002, J MED CHEM, V45, P2139, DOI 10.1021/jm011005p
   Walter ME, 2013, QUIM NOVA, V36, P691, DOI 10.1590/S0100-40422013000500014
   Wang XS, 2008, J CHEM INF MODEL, V48, P997, DOI 10.1021/ci700404c
   Wang YL, 2012, NUCLEIC ACIDS RES, V40, pD400, DOI 10.1093/nar/gkr1132
   Warr W. A., 1999, 218 ACA NAT M EXP NE
   WEININGER D, 1988, J CHEM INF COMP SCI, V28, P31, DOI 10.1021/ci00057a005
   Welling M., 2011, 1 ENCOUNTER MACHINE
   Wild D. J., 2013, INTRO CHEMINFORMATIC
   Willett P, 2006, DRUG DISCOV TODAY, V11, P1046, DOI 10.1016/j.drudis.2006.10.005
   Willett P, 2011, WIRES COMPUT MOL SCI, V1, P46, DOI 10.1002/wcms.1
   Willighagen EL, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-23
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067
   WISWESSER WJ, 1982, J CHEM INF COMP SCI, V22, P88, DOI 10.1021/ci00034a005
   Xue L, 2000, COMB CHEM HIGH T SCR, V3, P363, DOI 10.2174/1386207003331454
   Yang SY, 2010, DRUG DISCOV TODAY, V15, P444, DOI 10.1016/j.drudis.2010.03.013
   Young D. C., 2009, COMPUTATIONAL DRUG D, V14
   Zhang L, 2011, CURR MED CHEM, V18, P923, DOI 10.2174/092986711794927702
   Zhang LY, 2013, J CHEM INF MODEL, V53, P475, DOI 10.1021/ci300421n
   Zhu H, 2014, CHEM RES TOXICOL, V27, P1643, DOI 10.1021/tx500145h
NR 151
TC 10
Z9 11
U1 1
U2 1
PU SOC BRASILEIRA QUIMICA
PI SAO PAULO
PA CAIXA POSTAL 26037, 05599-970 SAO PAULO, BRAZIL
SN 0100-4042
EI 1678-7064
J9 QUIM NOVA
JI Quim. Nova
PD FEB
PY 2018
VL 41
IS 2
BP 202
EP 212
DI 10.21577/0100-4042.20170145
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA GA1CK
UT WOS:000428052800012
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Mottin, M
   Borba, JVVB
   Melo, CC
   Neves, BJ
   Muratov, E
   Torres, PHM
   Braga, RC
   Perryman, A
   Ekins, S
   Andrade, CH
AF Mottin, Melina
   Verde Bastos Borba, Joyce Villa
   Melo-Filho, Cleber Camilo
   Neves, Bruno Junior
   Muratov, Eugene
   Monteiro Torres, Pedro Henrique
   Braga, Rodolpho Campos
   Perryman, Alexander
   Ekins, Sean
   Andrade, Carolina Horta
TI Computational drug discovery for the Zika virus
SO BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Review
DE Zika; Flavivirus; Antiviral; Computer-assisted drug design; Virtual
   screening; Drug discovery
ID MOLECULAR-DYNAMICS SIMULATIONS; FINGERPRINT SIMILARITY SEARCH;
   PHARMACOPHORE MODELS; INHIBITORS; DOCKING; PROTEIN; LIGAND; SHAPE;
   IDENTIFICATION; DESIGN
AB Few Zika virus (ZIKV) outbreaks had been reported since its first detection in 1947, until the recent epidemics occurred in South America (2014/2015) and expeditiously became a global public health emergency. This arbovirus reached 0.5-1.3 million cases of ZIKV infection in Brazil in 2015 and rapidly spread in new geographic areas such as the Americas. Despite the mild symptoms of the Zika fever, the major concern is related to the related severe neurological disorders, especially microcephaly in newborns. Advances in ZIKV drug discovery have been made recently and constitute promising approaches to ZIKV treatment. In this review, we summarize current computational drug discovery efforts and their applicability to discovery of anti-ZIKV drugs. Lastly, we present successful examples of the use of computational approaches to ZIKV drug discovery.
C1 [Mottin, Melina; Verde Bastos Borba, Joyce Villa; Melo-Filho, Cleber Camilo; Neves, Bruno Junior; Braga, Rodolpho Campos; Andrade, Carolina Horta] Univ Fed Goias, Fac Pharm, Lab Mol Modeling & Drug Design LabMol, Goiania, Go, Brazil.
   [Neves, Bruno Junior] Univ Ctr Anapolis UniEVANGELICA, Lab Cheminformat, Anapolis, Go, Brazil.
   [Muratov, Eugene] Univ N Carolina, Eshelman Sch Pharm, Lab Mol Modeling, Div Chem Biol & Med Chem, Chapel Hill, NC 27515 USA.
   [Muratov, Eugene] Odessa Natl Polytech Univ, Dept Chem Technol, Odessa, Ukraine.
   [Monteiro Torres, Pedro Henrique] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Rio De Janeiro, RJ, Brazil.
   [Perryman, Alexander] Rutgers State Univ, New Jersey Med Sch, Dept Pharmacol Physiol & Neurosci, Newark, NJ USA.
   [Ekins, Sean] Collaborat Pharmaceut Inc, 840 Main Campus Dr,Lab 3510, Raleigh, NC USA.
   [Andrade, Carolina Horta] Univ Estadual Campinas, Inst Biol, Dept Genet Evolut Microbiol & Immunol, Lab Trop Dis, Campinas, SP, Brazil.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, Lab Modelagem Mol & Desenho Farmacos, Goiania, Go, Brazil.
EM carolhandrade@gmail.com
RI Neves, Bruno Junior/E-6295-2016; Mottin, Melina/D-8700-2016; Braga,
   Rodolpho C/A-9655-2011; Torres, Pedro Henrique Monteiro/C-7657-2015;
   Borba, Joyce V. B./S-7813-2018; Andrade, Carolina/C-3960-2014; Camilo
   Melo-Filho, Cleber/V-1119-2018
OI Mottin, Melina/0000-0003-0878-9029; Braga, Rodolpho
   C/0000-0003-3814-3464; Torres, Pedro Henrique
   Monteiro/0000-0002-0945-1495; Borba, Joyce V. B./0000-0002-2663-5173;
   Andrade, Carolina/0000-0003-0101-1492; Neves, Bruno/0000-0002-1309-8743;
   Camilo Melo-Filho, Cleber/0000-0003-0056-6971
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES; FAPEG; FAPESPFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP); CNPq/FAPEG DCR [300508/2017-4]; NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [1U01CA207160]; CNPqNational Council for Scientific and
   Technological Development (CNPq) [400760/2014-2]; FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2017/023539]
FX The authors would like to thank Brazilian funding agencies, CNPq, CAPES,
   FAPEG and FAPESP for grants and fellowships. This work was partially
   supported by the CNPq/FAPEG DCR (Grant 300508/2017-4). EM thanks the
   financial support from NIH (grant 1U01CA207160) and CNPq (grant
   400760/2014-2). CHA thanks the FAPESP Visiting Researcher Program (grant
   2017/023539). CHA is Research Fellow in productivity of CNPq. We kindly
   acknowledge all our collaborators on the OpenZika project
   (http://openzika.ufg.br), the wonderful ongoing support and
   encouragement of the IBM World Community Grid team, and the community of
   volunteers who donate their computer time.
CR Adcock RS, 2017, ANTIVIR RES, V138, P47, DOI 10.1016/j.antiviral.2016.11.018
   Amato AA, 2012, J BIOL CHEM, V287, P28169, DOI 10.1074/jbc.M111.332106
   Baker NC, 2018, DRUG DISCOV TODAY, V23, P661, DOI 10.1016/j.drudis.2018.01.018
   Barrows NJ, 2016, CELL HOST MICROBE, V20, P259, DOI 10.1016/j.chom.2016.07.004
   Benmansour F, 2017, EUR J MED CHEM, V125, P865, DOI 10.1016/j.ejmech.2016.10.007
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bernardes A, 2013, J MOL BIOL, V425, P2878, DOI 10.1016/j.jmb.2013.05.010
   Braga RC, 2013, CURR TOP MED CHEM, V13, P1127, DOI 10.2174/1568026611313090010
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Byler KG, 2016, J MOL GRAPH MODEL, V69, P78, DOI 10.1016/j.jmgm.2016.08.011
   Caporuscio F, 2011, CURR MED CHEM, V18, P2543, DOI 10.2174/092986711795933669
   Cereto-Massague A, 2015, METHODS, V71, P58, DOI 10.1016/j.ymeth.2014.08.005
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Childers MC, 2017, MOL SYST DES ENG, V2, P9, DOI [10.1039/C6ME00083E, 10.1039/c6me00083e]
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Ekins S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005023
   Ekins Sean, 2016, F1000Res, V5, P275
   Ekins S, 2011, DRUG DISCOV TODAY, V16, P298, DOI 10.1016/j.drudis.2011.02.016
   Ferreira LG, 2015, MOLECULES, V20, P13384, DOI 10.3390/molecules200713384
   Forli S, 2016, NAT PROTOC, V11, P905, DOI 10.1038/nprot.2016.051
   Frimayanti Neni, 2011, In Silico Biology, V11, P29, DOI 10.3233/ISB-2012-0442
   Glaab E, 2016, BRIEF BIOINFORM, V17, P352, DOI 10.1093/bib/bbv037
   Gomes MN, 2017, MOLECULES, V22, DOI 10.3390/molecules22081210
   Gulland A, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i657
   Harris R, 2008, PROTEINS, V70, P1506, DOI 10.1002/prot.21645
   Hawkins PCD, 2007, J MED CHEM, V50, P74, DOI 10.1021/jm0603365
   Hennessey M., 2015, CTR DIS CONTROL PREV, V65, P55, DOI DOI 10.15585/MMWR.MM6503E1
   Kalyaanamoorthy S, 2011, DRUG DISCOV TODAY, V16, P831, DOI 10.1016/j.drudis.2011.07.006
   Kar S, 2013, EXPERT OPIN DRUG DIS, V8, P245, DOI 10.1517/17460441.2013.761204
   Kitchen DB, 2004, NAT REV DRUG DISCOV, V3, P935, DOI 10.1038/nrd1549
   Koes DR, 2014, J COMPUT CHEM, V35, P1824, DOI 10.1002/jcc.23690
   Kortagere S, 2009, TRENDS PHARMACOL SCI, V30, P138, DOI 10.1016/j.tips.2008.12.001
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Lee H, 2017, ANTIVIR RES, V139, P49, DOI 10.1016/j.antiviral.2016.12.016
   Lionta E, 2014, CURR TOP MED CHEM, V14, P1923, DOI 10.2174/1568026614666140929124445
   Macalino SJY, 2015, ARCH PHARM RES, V38, P1686, DOI 10.1007/s12272-015-0640-5
   March-Vila E, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00298
   Melo CC, 2016, J CHEM INF MODEL, V56, P1357, DOI 10.1021/acs.jcim.6b00055
   Mortier J, 2012, CURR TOP MED CHEM, V12, P1935, DOI 10.2174/156802612804547371
   Mottin M, 2017, BIOCHEM BIOPH RES CO, V492, P643, DOI 10.1016/j.bbrc.2017.03.070
   Muegge I, 2016, EXPERT OPIN DRUG DIS, V11, P137, DOI 10.1517/17460441.2016.1117070
   Murray CW, 2010, CURR OPIN STRUC BIOL, V20, P497, DOI 10.1016/j.sbi.2010.04.003
   Musyoka TM, 2016, SCI REP-UK, V6, DOI 10.1038/srep23690
   Neves BJ, 2016, J MED CHEM, V59, P7075, DOI 10.1021/acs.jmedchem.5b02038
   Neves BJ, 2016, EXPERT OPIN DRUG DIS, V11, P557, DOI 10.1080/17460441.2016.1178230
   Oehler E., 2014, Eurosurveillance, V19, P20720
   Pirhadi S, 2013, CURR TOP MED CHEM, V13, P1036, DOI 10.2174/1568026611313090006
   Ramharack P, 2018, J BIOMOL STRUCT DYN, V36, P1118, DOI 10.1080/07391102.2017.1313175
   Reynolds CH, 2014, CURR PHARM DESIGN, V20, P3380, DOI 10.2174/138161282020140528105532
   Ricci CG, 2016, BIOCHEMISTRY-US, V55, P5180, DOI 10.1021/acs.biochem.6b00398
   Ripphausen P, 2011, DRUG DISCOV TODAY, V16, P372, DOI 10.1016/j.drudis.2011.02.011
   Sahoo Maheswata, 2016, Genomics & Informatics, V14, P104, DOI 10.5808/GI.2016.14.3.104
   Salsbury FR, 2010, CURR OPIN PHARMACOL, V10, P738, DOI 10.1016/j.coph.2010.09.016
   Tanrikulu Y, 2013, DRUG DISCOV TODAY, V18, P358, DOI 10.1016/j.drudis.2013.01.007
   Todeschini R., 2000, HDB MOL DESCRIPTORS, V11, DOI [10.1002/9783527613106, DOI 10.1002/9783527613106]
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Vapnik V., 2000, NATURE STAT LEARNING
   Ventura CV, 2016, LANCET, V387, P228, DOI 10.1016/S0140-6736(16)00006-4
   Vuorinen A, 2015, METHODS, V71, P113, DOI 10.1016/j.ymeth.2014.10.013
   Wahid B, 2016, ASIAN PAC J TROP MED, V9, P723, DOI 10.1016/j.apjtm.2016.06.019
   Xu M, 2016, NAT MED, V22, P1101, DOI 10.1038/nm.4184
   Yang SY, 2010, DRUG DISCOV TODAY, V15, P444, DOI 10.1016/j.drudis.2010.03.013
   Zauhar RJ, 2013, J COMPUT AID MOL DES, V27, P1009, DOI 10.1007/s10822-013-9698-7
   Zhu T, 2013, J MED CHEM, V56, P6560, DOI 10.1021/jm301916b
NR 66
TC 1
Z9 1
U1 0
U2 1
PU UNIV SAO PAULO, CONJUNTO QUIMICAS
PI SAO PAULO
PA SERVICO PUBLICACOES E CIRCULACAO, CAIXA POSTAL 66083, SAO PAULO, 00000,
   BRAZIL
SN 1984-8250
EI 2175-9790
J9 BRAZ J PHARM SCI
JI Braz. J. Pharm. Sci.
PY 2018
VL 54
SI SI
AR e01002
DI 10.1590/s2175-97902018000001002
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA HT1DR
UT WOS:000464304700002
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Rogerio, KR
   Carvalho, LJM
   Domingues, LHP
   Neves, BJ
   Moreira, JTM
   Castro, RN
   Bianco, C
   Daniel-Ribeiro, CT
   Andrade, CH
   Graebin, CS
AF Rogerio, Kamilla Rodrigues
   Carvalho, Leonardo J. M.
   Pinto Domingues, Luiza Helena
   Neves, Bruno Junior
   Moreira Filho, Jose Teofilo
   Castro, Rosane Nora
   Bianco Junior, Cesare
   Daniel-Ribeiro, Claudio Tadeu
   Andrade, Carolina Horta
   Graebin, Cedric Stephan
TI Synthesis and molecular modelling studies of pyrimidinones and
   pyrrolo[3,4-d]-pyrimidinodiones as new antiplasmodial compounds
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE Malaria; Plasmodium falciparum; multicomponent reactions; Biginelli
   reaction; pyrimidinones; molecular modelling
ID PLASMODIUM-FALCIPARUM MALARIA; DRUG-RESISTANCE; PROTEIN; PREDICTION;
   INHIBITORS; DIHYDROPYRIMIDONES; CHLOROQUINE; PROGRAM; BERGHEI; SERVER
AB BACKGROUND Malaria is responsible for 429,000 deaths per year worldwide, and more than 200 million cases were reported in 2015. Increasing parasite resistance has imposed restrictions to the currently available antimalarial drugs. Thus, the search for new, effective and safe antimalarial drugs is crucial. Heterocyclic compounds, such as dihydropyrimidinones ( DHPM), synthesised via the Biginelli multicomponent reaction, as well as bicyclic compounds synthesised from DHPMs, have emerged as potential antimalarial candidates in the last few years.
   METHODS Thirty compounds were synthesised employing the Biginelli multicomponent reaction and subsequent one-pot substitution/cyclisation protocol; the compounds were then evaluated in vitro against chloroquine-resistant Plasmodium falciparum parasites (W2 strain). Drug cytotoxicity in baseline kidney African Green Monkey cells (BGM) was also evaluated. The most active in vitro compounds were evaluated against P. berghei parasites in mice. Additionally, we performed an in silico target fishing approach with the most active compounds, aiming to shed some light into the mechanism at a molecular level.
   RESULTS The synthetic route chosen was effective, leading to products with high purity and yields ranging from 10-84%. Three out of the 30 compounds tested were identified as active against the parasite and presented low toxicity. The in silico study suggested that among all the molecular targets identified by our target fishing approach, Protein Kinase 3 (PK5) and Glycogen Synthase Kinase 3 beta ( GSK-3 beta) are the most likely molecular targets for the synthesised compounds.
   CONCLUSIONS We were able to easily obtain a collection of heterocyclic compounds with in vitro anti-P. falciparum activity that can be used as scaffolds for the design and development of new antiplasmodial drugs.
C1 [Rogerio, Kamilla Rodrigues; Pinto Domingues, Luiza Helena; Graebin, Cedric Stephan] Univ Fed Rural Rio de Janeiro, Dept Quim, Lab Diversidade Mol & Quim Med, Seropedica, RJ, Brazil.
   [Carvalho, Leonardo J. M.; Bianco Junior, Cesare; Daniel-Ribeiro, Claudio Tadeu] Fundacao Oswaldo Cruz Fiocruz, Lab Pesquisas Malaria, Inst Oswaldo Cruz, Rio De Janeiro, RJ, Brazil.
   [Neves, Bruno Junior; Moreira Filho, Jose Teofilo; Andrade, Carolina Horta] Univ Fed Goias, Fac Farm, Lab Planejamento Farmacos & Modelagem Mol, Goiania, Go, Brazil.
   [Castro, Rosane Nora] Univ Fed Rural Rio de Janeiro, Inst Ciencias Exatas, Dept Quim, Seropedica, RJ, Brazil.
   [Neves, Bruno Junior] Ctr Univ Anapolis, Lab Quimioinformat, UniEvangelica, Anapolis, Go, Brazil.
   [Andrade, Carolina Horta] Univ Estadual Campinas, Inst Biol, Dept Genet Evolucao & Bioagentes, Lab Doencas Trop Prof Dr Luiz Jacintho da Silva, Campinas, SP, Brazil.
RP Graebin, CS (corresponding author), Univ Fed Rural Rio de Janeiro, Dept Quim, Lab Diversidade Mol & Quim Med, Seropedica, RJ, Brazil.
EM cedric@ufrrj.br
RI Neves, Bruno/R-7068-2019; Daniel-Ribeiro, Claudio Tadeu/G-2216-2015;
   Neves, Bruno Junior/E-6295-2016; Graebin, Cedric S/F-2009-2010; CASTRO,
   ROSANE NORA/V-4309-2019; Carvalho, Leonardo J. M./K-7174-2013;
   Moreira-Filho, Jose Teofilo/S-8333-2018; Andrade, Carolina/C-3960-2014
OI Neves, Bruno/0000-0002-1309-8743; Graebin, Cedric S/0000-0003-1410-1227;
   Moreira-Filho, Jose Teofilo/0000-0002-0777-280X; Rogerio,
   Kamilla/0000-0003-0555-9949; Andrade, Carolina/0000-0003-0101-1492
FU CAPESCAPES; CNPqNational Council for Scientific and Technological
   Development (CNPq); FAPEMIGMinas Gerais State Research Foundation
   (FAPEMIG); FAPEG; FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); CAPES foundationCAPES;
   CNPq scholarshipNational Council for Scientific and Technological
   Development (CNPq)
FX CAPES, CNPq, FAPEMIG, FAPEG, FAPERJ.; KRR was the beneficiary of a
   scholarship of the CAPES foundation; LHPD was the beneficiary of a CNPq
   scholarship; CHA is a CNPq productivity research fellow; LJMC and CTDR
   are recipients of the research productivity fellowships from CNPq and
   FAPERJ ("Cientista do Nosso Estado").
CR Aguiar AC, 2019, CURR MED CHEM, V26, P4380, DOI 10.2174/0929867324666170830103003
   Alecrim MG, 2006, AM J TROP MED HYG, V74, P20, DOI 10.4269/ajtmh.2006.74.20
   Angus BJ, 2002, ANTIMICROB AGENTS CH, V46, P778, DOI 10.1128/AAC.46.3.778-782.2002
   Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131
   Banks JL, 2005, J COMPUT CHEM, V26, P1752, DOI 10.1002/jcc.20292
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Bordoli L, 2009, NAT PROTOC, V4, P1, DOI 10.1038/nprot.2008.197
   Cereto-Massague A, 2015, METHODS, V71, P98, DOI 10.1016/j.ymeth.2014.09.006
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Chiang AN, 2009, BIOORGAN MED CHEM, V17, P1527, DOI 10.1016/j.bmc.2009.01.024
   DEANDRADE JG, 1992, REV I MED TROP, V34, P467, DOI 10.1590/S0036-46651992000500015
   DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6
   Deshmukh AS, 2016, CURR GENET, V62, P481, DOI 10.1007/s00294-015-0562-2
   Deshmukh AS, 2015, MOL MICROBIOL, V98, P17, DOI 10.1111/mmi.13099
   Droucheau E, 2004, BBA-PROTEINS PROTEOM, V1697, P181, DOI 10.1016/j.bbapap.2003.11.023
   Eldridge MD, 1997, J COMPUT AID MOL DES, V11, P425, DOI 10.1023/A:1007996124545
   de Santana FS, 2007, EMERG INFECT DIS, V13, P1125, DOI 10.3201/eid1307.061386
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Jenkins J. L., 2006, DRUG DISCOV TODAY, V3, P413, DOI DOI 10.1016/J.DDTEC.2006.12.008
   Kappe CO, 2000, EUR J MED CHEM, V35, P1043, DOI 10.1016/S0223-5234(00)01189-2
   Kim J, 2012, BIOORG MED CHEM LETT, V22, P2522, DOI 10.1016/j.bmcl.2012.01.133
   Klabunde T, 2007, BRIT J PHARMACOL, V152, P5, DOI 10.1038/sj.bjp.0707308
   Ko J, 2012, NUCLEIC ACIDS RES, V40, pW294, DOI 10.1093/nar/gks493
   LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287
   Leite FHA, 2013, BIOL BIOMED REP, V2, P59
   Liu XF, 2010, NUCLEIC ACIDS RES, V38, pW609, DOI 10.1093/nar/gkq300
   Masch A, 2015, BBA-PROTEINS PROTEOM, V1854, P1644, DOI 10.1016/j.bbapap.2015.03.013
   Merritt C, 2014, CHEM REV, V114, P11280, DOI 10.1021/cr500197d
   Mita T, 2012, JPN J INFECT DIS, V65, P465, DOI 10.7883/yoken.65.465
   NCBI-National Center for Biotechnology Information, 2018, PUBCHEM BIOASSAY DAT
   Noedl H, 2002, EXP PARASITOL, V102, P157, DOI 10.1016/S0014-4894(03)00051-1
   Pedro RS, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-245
   Perez R, 2002, J COMB CHEM, V4, P501, DOI 10.1021/cc0200181
   PETERS W, 1975, ANN TROP MED PARASIT, V69, P155, DOI 10.1080/00034983.1975.11686997
   Raju BC, 2011, BIOORG MED CHEM LETT, V21, P2855, DOI 10.1016/j.bmcl.2011.03.079
   Rognan D, 2007, BRIT J PHARMACOL, V152, P38, DOI 10.1038/sj.bjp.0707307
   Rose PW, 2015, NUCLEIC ACIDS RES, V43, pD345, DOI 10.1093/nar/gku1214
   Rosenthal PJ, 2013, MOL MICROBIOL, V89, P1025, DOI 10.1111/mmi.12349
   Roskoski R, 2016, PHARMACOL RES, V103, P26, DOI 10.1016/j.phrs.2015.10.021
   Sanchez BAM, 2004, INT J PARASITOL, V34, P485, DOI 10.1016/j.ijpara.2003.11.011
   Shelley JC, 2007, J COMPUT AID MOL DES, V21, P681, DOI 10.1007/s10822-007-9133-z
   Singh OM, 2008, BIOORG MED CHEM LETT, V18, P6462, DOI 10.1016/j.bmcl.2008.10.063
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   Wang C, 2010, BIOCHEM BIOPH RES CO, V402, P773, DOI 10.1016/j.bbrc.2010.10.108
   Wang X, 2016, J CHEM INF MODEL, V56, P1175, DOI 10.1021/acs.jcim.5b00690
   World Health Organization, 2016, WORLD MALARIA REPORT
   World Health Organization (WHO), 2010, GUID TREATM MAL
NR 47
TC 3
Z9 3
U1 0
U2 5
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PY 2018
VL 113
IS 8
AR e170452
DI 10.1590/0074-02760170452
PG 9
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA GK3QI
UT WOS:000436059800001
PM 29924131
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Grecco, SS
   Costa-Silva, TA
   Jerz, G
   de Sousa, FS
   Londero, VS
   Galuppo, MK
   Lima, ML
   Neves, BJ
   Andrade, CH
   Tempone, AG
   Lago, JHG
AF Grecco, Simone S.
   Costa-Silva, Thais A.
   Jerz, Gerold
   de Sousa, Fernanda S.
   Londero, Vinicius S.
   Galuppo, Mariana K.
   Lima, Marta L.
   Neves, Bruno J.
   Andrade, Carolina H.
   Tempone, Andre G.
   Lago, Joao Henrique G.
TI Neolignans from leaves of Nectandra leucantha (Lauraceae) display in
   vitro antitrypanosomal activity via plasma membrane and mitochondrial
   damages
SO CHEMICO-BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Nectandra leucantha; Neolignans; Trypanosoma cruzi; Plasma membrane
   permeability; Mitochondrial dysfunctions; ADMET
ID TRYPANOSOMA-CRUZI; ANTIMICROBIAL PEPTIDES; SILICO PREDICTION;
   LEISHMANIA; DISCOVERY; ANALOGS; VIVO
AB Chagas disease is a neglected tropical disease, caused by the protozoan parasite Trypanosoma cruzi, which affects more than eight million people in Tropical and Subtropical countries especially in Latin America. Current treatment is limited to nifurtimox and benznidazole, both with reduced effectiveness and high toxicity. In this work, the n-hexane extract from leaves of Nectandra leucantha (Lauraceae) displayed in vitro antitrypanosomal activity against T. cruzi.
   Using several chromatographic steps, four related neolignans were isolated and chemically characterized as dehydrodieugenol B (1), 1-(8-propenyl)-3-[3'-methoxy-1'-(8-propenyl)-phenoxy]-4,5dimethoxybenzene (2), 1-[(7S)-hydroxy-8-propenyl]-3-[3'-methoxy-1'-(8'-propenyl)-phenoxy]-4hydroxy-5-methoxybenzene (3), and 1-[(7S)-hydroxy-8-propenyl]-3-[3'-methoxy-1'-(8'-propenyl)-phenoxy]-4,5-dimethoxybenzene (4). These compounds were tested against intracellular amastigotes and extracellular trypomastigotes of T. cruzi and for mammalian cytotoxicity. Neolignan 4 showed the higher selectivity index (SI) against trypomastigotes (>5) and amastigotes (>13) of T. cruzi. The investigation of the mechanism of action demonstrated that neolignan 4 caused substantial alteration of the plasma membrane permeability, together with mitochondrial dysfunctions in trypomastigote forms. In silico studies of pharmacokinetics and toxicity (ADMET) properties predicted that all compounds were non-mutagenic, non-carcinogenic, non-genotoxic, weak hERG blockers, with acceptable volume of distribution (1.66-3.32 L/kg), and low rodent oral toxicity (LD50 810-e2200 mg/kg). Considering some clinical events of cerebral Chagas disease, the compounds also demonstrated favorable properties, such as blood-brain barrier penetration. Unfavorable properties were also predicted as high promiscuity for P450 isoforms, high plasma protein binding affinity (>91%), and moderate-to-low oral bioavailability. Finally, none of the isolated neolignans was predicted as interference compounds (PAINS). Considering the promising chemical and biological properties of the isolated neolignans, these compounds could be used as starting points to develop new lead compounds for Chagas disease. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Grecco, Simone S.; Costa-Silva, Thais A.; Lago, Joao Henrique G.] Fed Univ ABC, Ctr Nat Sci & Humanities, BR-09210180 Santo Andre, SP, Brazil.
   [Grecco, Simone S.; Jerz, Gerold] Tech Univ Carolo Wilhelmina Braunschweig, Inst Food Chem, D-38106 Braunschweig, Germany.
   [Grecco, Simone S.] Anhanguera Univ Sao Paulo, Biotechnol & Innovat Hlth Program, BR-05145200 Sao Paulo, Brazil.
   [de Sousa, Fernanda S.; Londero, Vinicius S.] Univ Fed Sao Paulo, Inst Environm Chem & Pharmaceut Sci, BR-09972270 Diadema, SP, Brazil.
   [Galuppo, Mariana K.; Lima, Marta L.; Tempone, Andre G.] Adolfo Lutz Inst, Ctr Parasitol & Mycol, BR-01246902 Sao Paulo, Brazil.
   [Lima, Marta L.] Univ Sao Paulo, Inst Med Trop Sao Paulo, BR-05403000 Sao Paulo, Brazil.
   [Neves, Bruno J.; Andrade, Carolina H.] Univ Fed Goias, Fac Pharm, Lab Mol Modeling & Drug Design, LabMol, BR-74605170 Goiania, Go, Brazil.
   [Neves, Bruno J.] Unievangel Univ Ctr, Postgrad Program Soc Technol & Environm, BR-75083515 Anapolis, Go, Brazil.
RP Lago, JHG (corresponding author), Fed Univ ABC, Ctr Nat Sci & Humanities, BR-09210180 Santo Andre, SP, Brazil.
EM joao.lago@ufabc.edu.br
RI Tempone, Andre/ABA-2231-2020; Grecco, Simone S/I-7608-2016; Neves,
   Bruno/R-7068-2019; Tempone, Andre Gustavo/E-5932-2012; Neves, Bruno
   Junior/E-6295-2016; Lago, Joao/W-5238-2019; Tempone, Andre
   Gustavo/E-5932-2012; Andrade, Carolina/C-3960-2014
OI Tempone, Andre/0000-0003-2559-7344; Grecco, Simone
   S/0000-0003-0716-0368; Neves, Bruno/0000-0002-1309-8743; Tempone, Andre
   Gustavo/0000-0003-2559-7344; Lago, Joao/0000-0002-1193-8374; Jerz,
   Gerold/0000-0003-2685-6723; Tempone, Andre Gustavo/0000-0002-9900-1470;
   Andrade, Carolina/0000-0003-0101-1492
FU Sao Paulo State Research FoundationFundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [FAPESP 2015/11936-2, 2015/50075-2,
   2013/50228-8]; CAPESCAPES; CNPqNational Council for Scientific and
   Technological Development (CNPq)
FX This study is an activity within the Research Network Natural Products
   against Neglected Diseases (ResNetNPND: http://www.resnetnpnd.org/).
   This work was supported by grants from Sao Paulo State Research
   Foundation (FAPESP 2015/11936-2, 2015/50075-2, 2013/50228-8, and
   2013/50228-8). We thank CAPES for scholarships from TACS, MKG and MLL.
   We also thank CNPq for the grant award to JHGL, AGT and CHA. We are
   grateful to ChemAxon for providing academic license of their software.
CR Andrade CH, 2014, CURR DRUG METAB, V15, P514, DOI 10.2174/1389200215666140908102530
   Baell J, 2014, NATURE, V513, P481, DOI 10.1038/513481a
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Braga R.C., 2015, ENCY DRUG METABOLISM, P1
   Braga RC, 2015, MOL INFORM, V34, P698, DOI 10.1002/minf.201500040
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1399, DOI 10.2174/1568026614666140506124442
   Broccatelli F, 2011, J MED CHEM, V54, P1740, DOI 10.1021/jm101421d
   Cheng FX, 2012, J CHEM INF MODEL, V52, P3099, DOI 10.1021/ci300367a
   Cicora F, 2014, TRANSPL INFECT DIS, V16, P813, DOI 10.1111/tid.12265
   Costa EC, 2016, MOLECULES, V21, DOI 10.3390/molecules21060802
   da Costa-Silva TA, 2015, J NAT PROD, V78, P653, DOI 10.1021/np500809a
   Oliveira LGD, 2017, BASIC CLIN PHARMACOL, V120, P52, DOI 10.1111/bcpt.12639
   de Sousa FS, 2017, PHYTOCHEMISTRY, V140, P108, DOI 10.1016/j.phytochem.2017.04.024
   DIAS AD, 1988, PHYTOCHEMISTRY, V27, P3008
   Diaz A. M. P., 1980, PHYTOCHEMISTRY, V19, P681
   Drwal MN, 2014, NUCLEIC ACIDS RES, V42, pW53, DOI 10.1093/nar/gku401
   Ellis D, 2002, J ANTIMICROB CHEMOTH, V49, P7, DOI 10.1093/jac/49.suppl_1.7
   Esperandim VR, 2013, EXP PARASITOL, V133, P442, DOI 10.1016/j.exppara.2012.12.005
   Grecco SS, 2017, PHYTOMEDICINE, V24, P62, DOI 10.1016/j.phymed.2016.11.015
   Hansen K, 2009, J CHEM INF MODEL, V49, P2077, DOI 10.1021/ci900161g
   Irwin JJ, 2015, J MED CHEM, V58, P7076, DOI 10.1021/acs.jmedchem.5b01105
   Lagunin A, 2009, QSAR COMB SCI, V28, P806, DOI 10.1002/qsar.200860192
   Martins LF, 2016, J NAT PROD, V79, P2202, DOI 10.1021/acs.jnatprod.6b00256
   Martins S.C., 2016, MICROBES INFECT, pS1286
   MORGAN HL, 1965, J CHEM DOC, V5, P107, DOI 10.1021/c160017a018
   Neris PLN, 2013, EXP PARASITOL, V135, P307, DOI 10.1016/j.exppara.2013.07.007
   Pelizzaro-Rocha KJ, 2011, MICROBES INFECT, V13, P1018, DOI 10.1016/j.micinf.2011.05.011
   Perry SW, 2011, BIOTECHNIQUES, V50, P98, DOI 10.2144/000113610
   Pinto EG, 2013, EXP PARASITOL, V135, P655, DOI 10.1016/j.exppara.2013.09.016
   Riniker S, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-26
   Rogers D, 2010, J CHEM INF MODEL, V50, P742, DOI 10.1021/ci100050t
   Luque-Ortega JR, 2010, METHODS MOL BIOL, V618, P393, DOI 10.1007/978-1-60761-594-1_25
   Sartorelli P, 2010, PLANTA MED, V76, P1454, DOI 10.1055/s-0029-1240952
   Saubern S, 2011, MOL INFORM, V30, P847, DOI 10.1002/minf.201100076
   SUAREZ M, 1983, PHYTOCHEMISTRY, V22, P609, DOI 10.1016/0031-9422(83)83066-0
   Tasdemir D, 2006, ANTIMICROB AGENTS CH, V50, P1352, DOI 10.1128/AAC.50.4.1352-1364.2006
   van de Waterbeemd H, 2003, NAT REV DRUG DISCOV, V2, P192, DOI 10.1038/nrd1032
   Vial HJ, 2003, MOL BIOCHEM PARASIT, V126, P143, DOI 10.1016/S0166-6851(02)00281-5
   Volpato H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130652
NR 39
TC 9
Z9 9
U1 1
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009-2797
EI 1872-7786
J9 CHEM-BIOL INTERACT
JI Chem.-Biol. Interact.
PD NOV 1
PY 2017
VL 277
BP 55
EP 61
DI 10.1016/j.cbi.2017.08.017
PG 7
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA FN7RM
UT WOS:000416216100006
PM 28864277
DA 2020-12-01
ER

PT J
AU Mottin, M
   Braga, RC
   da Silva, RA
   da Silva, JHM
   Perryman, AL
   Ekins, S
   Andrade, CH
AF Mottin, Melina
   Braga, Rodolpho C.
   da Silva, Roosevelt A.
   Martins da Silva, Joao H.
   Perryman, Alexander L.
   Ekins, Sean
   Andrade, Carolina Horta
TI Molecular dynamics simulations of Zika virus NS3 helicase: Insights into
   RNA binding site activity
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Zika virus; Flavivirus; NS3 helicase; Molecular dynamics; FTMap; Drug
   discovery
ID RELAXED COMPLEX SCHEME; CRYSTAL-STRUCTURE; NS2B-NS3 PROTEASE; DRUG
   DESIGN; RECEPTOR FLEXIBILITY; DENGUE VIRUS; INHIBITOR; PROTEINS;
   REPLICATION
AB America is still suffering with the outbreak of Zika virus (ZIKV) infection. Congenital ZIKV syndrome has already caused a public health emergency of international concern. However, there are still no vaccines to prevent or drugs to treat the infection caused by ZIKV. The ZIKV NS3 helicase (NS3h) protein is a promising target for drug discovery due to its essential role in viral genome replication. NS3h unwinds the viral RNA to enable the replication of the viral genome by the NS5 protein. NS3h contains two important binding sites: the NTPase binding site and the RNA binding site. Here, we used molecular dynamics (MD) simulations to study the molecular behavior of ZIKV NS3h in the presence and absence of ssRNA and the potential implications for NS3h activity and inhibition. Although there is conformational variability and poor electron densities of the RNA binding loop in various apo flaviviruses NS3h crystallographic structures, the MD trajectories of NS3h-ssRNA demonstrated that the RNA binding loop becomes more stable when NS3h is occupied by RNA. Our results suggest that the presence of RNA generates important interactions with the RNA binding loop, and these interactions stabilize the loop sufficiently that it remains in a closed conformation. This closed conformation likely keeps the ssRNA bound to the protein for a sufficient duration to enable the unwinding/replication activities of NS3h to occur. In addition, conformational changes of this RNA binding loop can change the nature and location of the optimal ligand binding site, according to ligand binding site prediction results. These are important findings to help guide the design and discovery of new inhibitors of NS3h as promising compounds to treat the ZIKV infection. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Mottin, Melina; Braga, Rodolpho C.; Andrade, Carolina Horta] Univ Fed Goias, Fac Pharm, LabMol, BR-74605170 Goiania, Go, Brazil.
   [da Silva, Roosevelt A.] Univ Fed Goias, NCBios, BR-74605170 Jatai, Go, Brazil.
   [Martins da Silva, Joao H.] Fiocruz MS, Ceara Fundacao Oswaldo Cruz, Fortaleza, Ceara, Brazil.
   [Perryman, Alexander L.] Rutgers State Univ, New Jersey Med Sch, Dept Pharmacol Physiol & Neurosci, Newark, NJ 07103 USA.
   [Ekins, Sean] Collaborat Pharmaceut Inc, 5616 Hilltop Needmore Rd, Fuquay Varina, NC 27526 USA.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Pharm, LabMol, BR-74605170 Goiania, Go, Brazil.
EM carolhandrade@gmail.com
RI Braga, Rodolpho C/A-9655-2011; da Silva, Roosevelt Alves/AAF-1577-2019;
   Mottin, Melina/D-8700-2016; Andrade, Carolina/C-3960-2014
OI Braga, Rodolpho C/0000-0003-3814-3464; da Silva, Roosevelt
   Alves/0000-0001-5624-4790; Mottin, Melina/0000-0003-0878-9029; Andrade,
   Carolina/0000-0003-0101-1492
FU IBM World Community Grid team
FX We kindly acknowledge all of our collaborators on this project
   (http://openzika.ufg.br), the wonderful ongoing support and
   encouragement from the IBM World Community Grid team, and the community
   of volunteers who donate their computer time to our drug discovery
   efforts. MM is PDJ fellow of Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico in Brazil (CNPq) (150729/2016-2); CHA is
   productivity fellow of CNPq.
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Amaro RE, 2008, J COMPUT AID MOL DES, V22, P693, DOI 10.1007/s10822-007-9159-2
   [Anonymous], 2016, GEN SUMM OUTC EM COM
   Basavannacharya C, 2014, BIOCHEM BIOPH RES CO, V453, P539, DOI 10.1016/j.bbrc.2014.09.113
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Borowski P, 2002, ACTA BIOCHIM POL, V49, P597
   Brown WC, 2016, NAT STRUCT MOL BIOL, V23, P865, DOI 10.1038/nsmb.3268
   Byrd CM, 2013, ANTIMICROB AGENTS CH, V57, P1902, DOI 10.1128/AAC.02251-12
   Cheng LS, 2008, J MED CHEM, V51, P3878, DOI 10.1021/jm8001197
   Coloma J, 2016, CELL REP, V16, P3097, DOI 10.1016/j.celrep.2016.08.091
   CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002
   Costello A, 2016, B WORLD HEALTH ORGAN, V94, P406, DOI 10.2471/BLT.16.176990
   Cox Bryan D., 2015, Antiviral Chemistry & Chemotherapy, V24, P118, DOI 10.1177/2040206616653873
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   Dai LP, 2016, CELL HOST MICROBE, V19, P696, DOI 10.1016/j.chom.2016.04.013
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Ekins S., 2016, F1000RESEARCH, P1
   Ekins S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005023
   Ekins Sean, 2016, F1000Res, V5, P275
   Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297
   Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636
   Forli S, 2016, NAT PROTOC, V11, P905, DOI 10.1038/nprot.2016.051
   Franca GVA, 2016, LANCET, V388, P891, DOI 10.1016/S0140-6736(16)30902-3
   Frick DN, 2007, CURR ISSUES MOL BIOL, V9, P1
   GROMACS, GROMACS V5 1 2
   Gu MG, 2010, P NATL ACAD SCI USA, V107, P521, DOI 10.1073/pnas.0913380107
   Gupta AK, 2016, SCI REP-UK, V6, DOI 10.1038/srep32713
   Hall DR, 2012, METHODS MOL BIOL, V819, P13, DOI 10.1007/978-1-61779-465-0_2
   Harris R, 2008, PROTEINS, V70, P1506, DOI 10.1002/prot.21645
   Hintze B.J., 2016, PROTEINS STRUCT FUNC, V84
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jain R, 2016, NAT STRUCT MOL BIOL, V23, P752, DOI 10.1038/nsmb.3258
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Kostyuchenko VA, 2016, NATURE, V533, P425, DOI 10.1038/nature17994
   Kozakov D, 2015, NAT PROTOC, V10, P733, DOI 10.1038/nprot.2015.043
   Leach A. R., 2001, MOL MODELLING PRINCI
   Lei J, 2016, SCIENCE, V353, P503, DOI 10.1126/science.aag2419
   Lin JH, 2002, J AM CHEM SOC, V124, P5632, DOI 10.1021/ja0260162
   Mastrangelo E, 2007, J MOL BIOL, V372, P444, DOI 10.1016/j.jmb.2007.06.055
   Mastrangelo E, 2012, J ANTIMICROB CHEMOTH, V67, P1884, DOI 10.1093/jac/dks147
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Nichols SE, 2011, J CHEM INF MODEL, V51, P1439, DOI 10.1021/ci200117n
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Phoo WW, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13410
   Sirohi D, 2016, SCIENCE, V352, P467, DOI 10.1126/science.aaf5316
   Song H, 2016, NAT STRUCT MOL BIOL, V23, P456, DOI 10.1038/nsmb.3213
   Sweeney N.L., 2016, BENZOTHIAZOLE PYRROL, V1, P140
   Tian HL, 2016, PROTEIN CELL, V7, P562, DOI 10.1007/s13238-016-0293-2
   Tian HL, 2016, PROTEIN CELL, V7, P450, DOI 10.1007/s13238-016-0275-4
   Trueblood KN, 1996, ACTA CRYSTALLOGR A, V52, P770, DOI 10.1107/S0108767396005697
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Zhang CY, 2017, BIOCHEM BIOPH RES CO, V492, P624, DOI 10.1016/j.bbrc.2016.11.098
   Zhang ZZ, 2016, SCIENCE, V354, P1597, DOI 10.1126/science.aai9309
NR 53
TC 17
Z9 19
U1 0
U2 18
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD OCT 28
PY 2017
VL 492
IS 4
SI SI
BP 643
EP 651
DI 10.1016/j.bbrc.2017.03.070
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA FK3OB
UT WOS:000413393300016
PM 28341122
DA 2020-12-01
ER

PT J
AU Gomes, MN
   Braga, RC
   Grzelak, EM
   Neves, BJ
   Muratov, E
   Ma, R
   Klein, LL
   Cho, S
   Oliveira, GR
   Franzblau, SG
   Andrade, CH
AF Gomes, Marcelo N.
   Braga, Rodolpho C.
   Grzelak, Edyta M.
   Neves, Bruno J.
   Muratov, Eugene
   Ma, Rui
   Klein, Larry L.
   Cho, Sanghyun
   Oliveira, Guilherme R.
   Franzblau, Scott G.
   Andrade, Carolina Horta
TI QSAR-driven design, synthesis and discovery of potent chalcone
   derivatives with antitubercular activity
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Tuberculosis; In silico design; QSAR; Nitroaromatic compounds; Chalcone;
   Anti-TB agents
ID MYCOBACTERIUM-TUBERCULOSIS; IN-VITRO; BIOLOGICAL EVALUATION; INHIBITORY
   PROPERTIES; DRUG DISCOVERY; ANALOGS; 3D-QSAR; SERIES; ASSAY; COMFA
AB New anti-tuberculosis (anti-TB) drugs are urgently needed to battle drug-resistant Mycobacterium tuberculosis strains and to shorten the current 6-12-month treatment regimen. In this work, we have continued the efforts to develop chalcone-based anti-TB compounds by using an in silico design and QSAR-driven approach. Initially, we developed SAR rules and binary QSAR models using literature data for targeted design of new heteroaryl chalcone compounds with anti-TB activity. Using these models, we prioritized 33 compounds for synthesis and biological evaluation. As a result, 10 heteroaryl chalcone compounds (4, 8, 9, 11, 13, 17-20, and 23) were found to exhibit nanomolar activity against replicating mycobacteria, low micromolar activity against nonreplicating bacteria, and nanomolar and micromolar against rifampin (RMP) and isoniazid (INH) monoresistant strains (ERMP and rINH) (<1 mu M and <10 mu M, respectively). The series also show low activity against commensal bacteria and generally show good selectivity toward M. tuberculosis, with very low cytotoxicity against Vero cells (SI = 11-545). Our results suggest that our designed heteroaryl chalcone compounds, due to their high potency and selectivity, are promising anti-TB agents. (C) 2017 Elsevier Masson SAS. All rights reserved.
C1 [Gomes, Marcelo N.; Braga, Rodolpho C.; Neves, Bruno J.; Andrade, Carolina Horta] Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, Rua 240,Qd87, BR-74605510 Goiania, Go, Brazil.
   [Grzelak, Edyta M.; Ma, Rui; Klein, Larry L.; Cho, Sanghyun; Franzblau, Scott G.] Univ Illinois, Inst TB Res, 833 South Wood St, Chicago, IL 60612 USA.
   [Neves, Bruno J.] Univ Ctr Anapolis UniEVANGELICA, Postgrad Program Soc Technol & Environm, BR-75083515 Anapolis, Go, Brazil.
   [Muratov, Eugene] Univ N Carolina, Eshelman Sch Pharm, Lab Mol Modeling, Chapel Hill, NC 27955 USA.
   [Muratov, Eugene] Odessa Natl Polytech Univ, Dept Chem Technol, UA-65000 Odessa, Ukraine.
   [Oliveira, Guilherme R.] Univ Fed Goias, Chem Inst, Goiania, Go, Brazil.
   [Muratov, Eugene] Univ Fed Goias, Goiania, Go, Brazil.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, Rua 240,Qd87, BR-74605510 Goiania, Go, Brazil.; Franzblau, SG (corresponding author), Univ Illinois, Inst TB Res, 833 South Wood St, Chicago, IL 60612 USA.
EM sgf@uic.edu; carolina@ufg.br
RI Grzelak, Edyta/AAI-9692-2020; Braga, Rodolpho C/A-9655-2011; Neves,
   Bruno Junior/E-6295-2016; Neves, Bruno/R-7068-2019; Andrade,
   Carolina/C-3960-2014
OI Braga, Rodolpho C/0000-0003-3814-3464; Neves, Bruno/0000-0002-1309-8743;
   Grzelak, Edyta M/0000-0002-3033-2917; Andrade,
   Carolina/0000-0003-0101-1492
FU Coordination for the Improvement of Higher Education Personnel
   (CAPES-PDSE); State of Goias Research Foundation (FAPEG); National
   Counsel of Technological and Scientific Development (CNPq)National
   Council for Scientific and Technological Development (CNPq); NATIONAL
   CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [U01CA207160, U01CA207160, U01CA207160] Funding Source:
   NIH RePORTER
FX M.N.G. was supported by a sandwich fellowship from the Coordination for
   the Improvement of Higher Education Personnel (CAPES-PDSE) during his
   stay in ITR-UIC. M.N.G. is also supported by a Ph.D. fellowship from the
   State of Goias Research Foundation (FAPEG). This work has been funded by
   the National Counsel of Technological and Scientific Development (CNPq),
   the State of Goias Research Foundation (FAPEG). C.H.A. is CNPq
   productivity fellow. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Albuquerque M. G., 2007, CURRENT METHODS MED, P91
   Andrade CH, 2008, MOL DIVERS, V12, P47, DOI 10.1007/s11030-008-9074-z
   Andreu N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010777
   [Anonymous], 2013, MACCS STRUCT KEYS
   Aoki N, 2008, J NAT PROD, V71, P1308, DOI 10.1021/np800187f
   Avila-Villarreal G., 2013, PHYTOMEDICINE
   Baell J, 2014, NATURE, V513, P481, DOI 10.1038/513481a
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Bajusz D, 2015, J CHEMINFORMATICS, V7, DOI 10.1186/s13321-015-0069-3
   Batovska D, 2009, EUR J MED CHEM, V44, P2211, DOI 10.1016/j.ejmech.2008.05.010
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1899, DOI 10.2174/1568026614666140929120749
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Bukhari SNA, 2013, MINI-REV ORG CHEM, V10, P73
   Carhart R. E., 1985, DEFIN APPL, V13, P8
   Chen M, 2001, ANTIMICROB AGENTS CH, V45, P2023, DOI 10.1128/AAC.45.7.2023-2029.2001
   Chen YH, 2013, MOLECULES, V18, P2052, DOI 10.3390/molecules18022052
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Chiaradia LD, 2008, BIOORG MED CHEM LETT, V18, P6227, DOI 10.1016/j.bmcl.2008.09.105
   Cho SH, 2007, ANTIMICROB AGENTS CH, V51, P1380, DOI 10.1128/AAC.00055-06
   Cho Sanghyun, 2015, Methods Mol Biol, V1285, P281, DOI 10.1007/978-1-4939-2450-9_17
   Cisak A., 2001, REACTIVITY 5 NITRO 2, P427
   Cole ST, 2011, CURR OPIN MICROBIOL, V14, P570, DOI 10.1016/j.mib.2011.07.022
   Collins LA, 1997, ANTIMICROB AGENTS CH, V41, P1004, DOI 10.1128/AAC.41.5.1004
   Dobchev DA, 2014, CURR TOP MED CHEM, V14, P1913, DOI 10.2174/1568026614666140929124203
   Falzari K, 2005, ANTIMICROB AGENTS CH, V49, P1447, DOI 10.1128/AAC.49.4.1447-1454.2005
   Fourches D., 2016, J CHEM INF MODEL
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Franzblau SG, 2012, TUBERCULOSIS, V92, P453, DOI 10.1016/j.tube.2012.07.003
   Franzblau SG, 1998, J CLIN MICROBIOL, V36, P362, DOI 10.1128/JCM.36.2.362-366.1998
   Frecer V, 2011, J COMPUT AID MOL DES, V25, P31, DOI 10.1007/s10822-010-9399-4
   Garcia A, 2012, EUR J MED CHEM, V49, P1, DOI 10.1016/j.ejmech.2011.12.029
   Gedeck P, 2006, J CHEM INF MODEL, V46, P1924, DOI 10.1021/ci050413p
   Guido RVC, 2011, COMB CHEM HIGH T SCR, V14, P830
   Gupta RA, 2013, MED CHEM RES, V22, P3863, DOI 10.1007/s00044-012-0385-3
   Hans RH, 2010, BIOORG MED CHEM LETT, V20, P942, DOI 10.1016/j.bmcl.2009.12.062
   Holliday JD, 1995, QUANT STRUCT-ACT REL, V14, P501, DOI 10.1002/qsar.19950140602
   Hu X., 2012, MMP CLI FF S SYSTEMA, P1
   Jamal H, 2008, FUND CLIN PHARMACOL, V22, P673, DOI 10.1111/j.1472-8206.2008.00639.x
   Joshi SD, 2014, MED CHEM RES, V23, P107, DOI 10.1007/s00044-013-0607-3
   Katsuno K., 2015, NAT REV DRUG DISCOV, P1
   Kenny PW, 2005, METH PRIN MED CHEM, V22, P271, DOI 10.1002/3527603743.ch11
   Khunt RC, 2012, BIOORG MED CHEM LETT, V22, P666, DOI 10.1016/j.bmcl.2011.10.059
   Khunt RC, 2013, CHEM BIOL DRUG DES, V82, P669, DOI 10.1111/cbdd.12178
   Klopman G, 1996, CHEM PHYS, V204, P181, DOI 10.1016/0301-0104(95)00415-7
   Kovalishyn V, 2011, CHEMOMETR INTELL LAB, V107, P69, DOI 10.1016/j.chemolab.2011.01.011
   Kumar A, 2008, J MOL MODEL, V14, P923, DOI 10.1007/s00894-008-0326-8
   Kuz'min VE, 2008, J COMPUT AID MOL DES, V22, P403, DOI 10.1007/s10822-008-9179-6
   Lam KW, 2012, MED CHEM RES, V21, P1953, DOI 10.1007/s00044-011-9706-1
   Landrum G., 2014, RDKIT OPEN SOURCE CH
   Leach AG, 2006, J MED CHEM, V49, P6672, DOI 10.1021/jm0605233
   Lilienkampf A, 2010, J MED CHEM, V53, P678, DOI 10.1021/jm901273n
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Lopez SN, 2001, BIOORGAN MED CHEM, V9, P1999, DOI 10.1016/S0968-0896(01)00116-X
   Mahajan R., 2013, INT J APPL BASIC MED, V2, P124
   Mahapatra DM, 2015, EUR J MED CHEM, V98, P69, DOI 10.1016/j.ejmech.2015.05.004
   Martins F, 2014, EUR J MED CHEM, V81, P119, DOI 10.1016/j.ejmech.2014.04.077
   Mehra R, 2016, ACS COMB SCI, V18, P100, DOI 10.1021/acscombsci.5b00019
   Melo CC, 2014, CURR COMPUT-AID DRUG, V10, P148, DOI 10.2174/1573409910666140410111043
   MORGAN HL, 1965, J CHEM DOC, V5, P107, DOI 10.1021/c160017a018
   Natekin A, 2013, FRONT NEUROROBOTICS, V7, DOI 10.3389/fnbot.2013.00021
   Nayyar A, 2006, BIOORGAN MED CHEM, V14, P847, DOI 10.1016/j.bmc.2005.09.018
   Neves BJ, 2016, J MED CHEM, V59, P7075, DOI 10.1021/acs.jmedchem.5b02038
   Nowakowska Z, 2007, EUR J MED CHEM, V42, P125, DOI 10.1016/j.ejmech.2006.09.019
   OBOYLE NM, 2008, CHEM CENT J, V2, DOI DOI 10.1186/1752-153X-2-5
   Ouattara M, 2011, TROP J PHARM RES, V10, P767, DOI 10.4314/tjpr.v10i6.10
   Palmer BD, 2015, J MED CHEM, V58, P3036, DOI 10.1021/jm501608q
   Pieroni M, 2009, J MED CHEM, V52, P6287, DOI 10.1021/jm900513a
   R Development Core Team, 2008, R LANG ENV STAT COMP
   Ragno R., 2013, J CHEM INF MODEL
   Riniker S, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-26
   Rizvi SUF, 2012, MED CHEM RES, V21, P3741, DOI 10.1007/s00044-011-9912-x
   Rogers D, 2010, J CHEM INF MODEL, V50, P742, DOI 10.1021/ci100050t
   Sato Y, 2007, BIOL PHARM BULL, V30, P145, DOI 10.1248/bpb.30.145
   Song CM, 2009, BRIEF BIOINFORM, V10, P579, DOI 10.1093/bib/bbp023
   Stavrakov G, 2014, J MOL GRAPH MODEL, V51, P7, DOI 10.1016/j.jmgm.2014.04.008
   Syam S, 2012, MOLECULES, V17, P6179, DOI 10.3390/molecules17066179
   Tang JS, 2016, TUBERCULOSIS, V98, P30, DOI 10.1016/j.tube.2016.02.005
   Tawari NR, 2010, BIOORG MED CHEM LETT, V20, P6175, DOI 10.1016/j.bmcl.2010.08.127
   TB ALLIANCE, 2015, TB ALL PUTT SCI WORK
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Vapnik V., 2000, NATURE STAT LEARNING
   Varnek A, 2008, CURR COMPUT-AID DRUG, V4, P191, DOI 10.2174/157340908785747465
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Ventura C, 2013, EUR J MED CHEM, V70, P831, DOI 10.1016/j.ejmech.2013.10.029
   Virsodia V, 2008, EUR J MED CHEM, V43, P2103, DOI 10.1016/j.ejmech.2007.08.004
   Wang L., 2012, J CHEMINFORMATICS, V4, pO20
   WHO, 2015, THE STOP TB STRAT
   WHO, 2015, GLOB TUB 2015
   Wirth M., 2013, NUCLEIC ACIDS RES, V41, P1
   Xavier AS, 2014, J PHARMACOL PHARMACO, V5, P222, DOI 10.4103/0976-500X.136121
   Yamamoto T, 2004, BIOSCI BIOTECH BIOCH, V68, P1706, DOI 10.1271/bbb.68.1706
NR 92
TC 36
Z9 39
U1 1
U2 39
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD SEP 8
PY 2017
VL 137
BP 126
EP 138
DI 10.1016/j.ejmech.2017.05.026
PG 13
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA FD3CX
UT WOS:000407412200011
PM 28582669
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Gomes, MN
   Muratov, EN
   Pereira, M
   Peixoto, JC
   Rosseto, LP
   Cravo, PVL
   Andrade, CH
   Neves, BJ
AF Gomes, Marcelo N.
   Muratov, Eugene N.
   Pereira, Maristela
   Peixoto, Josana C.
   Rosseto, Lucimar P.
   Cravo, Pedro V. L.
   Andrade, Carolina H.
   Neves, Bruno J.
TI Chalcone Derivatives: Promising Starting Points for Drug Design
SO MOLECULES
LA English
DT Review
DE natural products; chalcone derivatives; chalcone synthesis; molecular
   modification strategies; computer-assisted drug design
ID STRUCTURE-BASED PHARMACOPHORES; FINGERPRINT SIMILARITY SEARCH;
   FREE-ENERGY SIMULATIONS; BIOLOGICAL EVALUATION; PROTEIN FLEXIBILITY;
   BIOISOSTERIC REPLACEMENT; RANDOMIZED MULTICENTER; HYDROXYETHYL RUTOSIDE;
   HISTONE DEACETYLASES; PROTONATION STATES
AB Medicinal chemists continue to be fascinated by chalcone derivatives because of their simple chemistry, ease of hydrogen atom manipulation, straightforward synthesis, and a variety of promising biological activities. However, chalcones have still not garnered deserved attention, especially considering their high potential as chemical sources for designing and developing new effective drugs. In this review, we summarize current methodological developments towards the design and synthesis of new chalcone derivatives and state-of-the-art medicinal chemistry strategies (bioisosterism, molecular hybridization, and pro-drug design). We also highlight the applicability of computer-assisted drug design approaches to chalcones and address how this may contribute to optimizing research outputs and lead to more successful and cost-effective drug discovery endeavors. Lastly, we present successful examples of the use of chalcones and suggest possible solutions to existing limitations.
C1 [Gomes, Marcelo N.; Andrade, Carolina H.; Neves, Bruno J.] Univ Fed Goias, Setor Leste Univ, Lab Mol Modeling & Drug Design, Fac Pharm, BR-74605510 Goiania, Go, Brazil.
   [Muratov, Eugene N.] Univ N Carolina, Lab Mol Modeling, Eshelman Sch Pharm, Chapel Hill, NC 27955 USA.
   [Pereira, Maristela; Neves, Bruno J.] Univ Fed Goias, Inst Ciencias Biol, Lab Biol Mol, BR-74001970 Goiania, Go, Brazil.
   [Peixoto, Josana C.; Rosseto, Lucimar P.; Cravo, Pedro V. L.; Neves, Bruno J.] Ctr Univ Anapolis UniEVANGELICA, Programa Posgrad Soc Tecnol & Meio Ambiente, BR-75083515 Anapolis, Brazil.
   [Cravo, Pedro V. L.] Univ Nova Lisboa, GHTM Inst Higiene & Med Trop, P-1349008 Lisbon, Portugal.
RP Neves, BJ (corresponding author), Univ Fed Goias, Setor Leste Univ, Lab Mol Modeling & Drug Design, Fac Pharm, BR-74605510 Goiania, Go, Brazil.; Neves, BJ (corresponding author), Univ Fed Goias, Inst Ciencias Biol, Lab Biol Mol, BR-74001970 Goiania, Go, Brazil.; Neves, BJ (corresponding author), Ctr Univ Anapolis UniEVANGELICA, Programa Posgrad Soc Tecnol & Meio Ambiente, BR-75083515 Anapolis, Brazil.
EM marcelo13farma@yahoo.com.br; murik@email.unc.edu;
   maristelaufg@gmail.com; josana.peixoto@gmail.com;
   lucimar.pinheiro@yahoo.com.br; pedrovcravo@gmail.com;
   andradech@yahoo.com; bruno.labmol@gmail.com
RI Neves, Bruno/R-7068-2019; Neves, Bruno Junior/E-6295-2016; Cravo, Pedro
   VL/G-3532-2012; Andrade, Carolina/C-3960-2014
OI Neves, Bruno/0000-0002-1309-8743; Cravo, Pedro VL/0000-0003-1675-4504;
   Rosseto, Lucimar/0000-0001-6611-4770; Andrade,
   Carolina/0000-0003-0101-1492
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES; FAPEG; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [1U01CA207160];
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [400760/2014-2]; NATIONAL CANCER INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [U01CA207160, U01CA207160, U01CA207160]
   Funding Source: NIH RePORTER
FX The authors would like to thank Brazilian funding agencies, CNPq, CAPES,
   and FAPEG, for financial support and fellowships. Eugene Muratov also
   thanks the financial support from NIH (grant 1U01CA207160) and CNPq
   (grant 400760/2014-2). Maristela Pereira, Carolina H. Andrade, and Pedro
   V. L. Cravo are Research Fellows in productivity of CNPq. We are also
   grateful to OpenEye Scientific Software, Inc. (Santa Fe, NM, USA) and
   ChemAxon (Budapest, Hungary) for providing us with the academic license
   for their software.
CR AlMatar M, 2017, BIOMED PHARMACOTHER, V91, P546, DOI 10.1016/j.biopha.2017.04.105
   Amslinger S, 2013, ORG BIOMOL CHEM, V11, P549, DOI 10.1039/c2ob27163j
   Andricopulo AD, 2009, CURR TOP MED CHEM, V9, P771, DOI 10.2174/156802609789207127
   Aoki N, 2008, J NAT PROD, V71, P1308, DOI 10.1021/np800187f
   Aranha O, 2003, INT J ONCOL, V22, P787
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   BELLEMANN P, 1981, ARZNEIMITTEL-FORSCH, V31-2, P2064
   Beltramino R, 2000, ANGIOLOGY, V51, P535, DOI 10.1177/000331970005100702
   Beltramino R, 1999, INT ANGIOL, V18, P337
   Birari RB, 2011, PHYTOMEDICINE, V18, P795, DOI 10.1016/j.phymed.2011.01.002
   BOHN H, 1995, BRIT J PHARMACOL, V114, P1605, DOI 10.1111/j.1476-5381.1995.tb14946.x
   Braga RC, 2012, MINI-REV MED CHEM, V12, P573
   Braga RC, 2013, CURR TOP MED CHEM, V13, P1127, DOI 10.2174/1568026611313090010
   Braun RU, 2006, CHEM-EUR J, V12, P9081, DOI 10.1002/chem.200600530
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Brown SP, 2006, J CHEM INF MODEL, V46, P999, DOI 10.1021/ci050488t
   Bukhari SNA, 2012, MINI-REV MED CHEM, V12, P1394
   Burger A, 1991, Prog Drug Res, V37, P287
   Burmaoglu S, 2016, BIOORG MED CHEM LETT, V26, P3172, DOI 10.1016/j.bmcl.2016.04.096
   Canela MD, 2017, ONCOTARGET, V8, P14325, DOI 10.18632/oncotarget.9527
   Caporuscio F, 2011, CURR MED CHEM, V18, P2543, DOI 10.2174/092986711795933669
   Capuzzi SJ, 2017, J CHEM INF MODEL, V57, P417, DOI 10.1021/acs.jcim.6b00465
   Cereto-Massague A, 2015, METHODS, V71, P58, DOI 10.1016/j.ymeth.2014.08.005
   Cerqueira NMFSA, 2015, ARCH BIOCHEM BIOPHYS, V582, P56, DOI 10.1016/j.abb.2015.05.011
   CHEN M, 1993, ANTIMICROB AGENTS CH, V37, P2550, DOI 10.1128/AAC.37.12.2550
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Cho S, 2011, BIOCHEM BIOPH RES CO, V413, P637, DOI 10.1016/j.bbrc.2011.09.026
   CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002
   Coronado LM, 2014, BBA-GEN SUBJECTS, V1840, P2032, DOI 10.1016/j.bbagen.2014.02.009
   Cosconati S, 2010, EXPERT OPIN DRUG DIS, V5, P597, DOI 10.1517/17460441.2010.484460
   Damaskos C, 2017, ANTICANCER RES, V37, P35, DOI 10.21873/anticanres.11286
   Daura X, 1998, J COMPUT CHEM, V19, P535, DOI 10.1002/(SICI)1096-987X(19980415)19:5<535::AID-JCC6>3.0.CO;2-N
   DESLYPERE JP, 1994, AM J CARDIOL, V73, pD12, DOI 10.1016/0002-9149(94)90627-0
   Dong XW, 2010, EUR J MED CHEM, V45, P3986, DOI 10.1016/j.ejmech.2010.05.054
   Dong XW, 2009, ARCH PHARM, V342, P428, DOI 10.1002/ardp.200800229
   Ducki S, 2009, ANTI-CANCER AGENT ME, V9, P336, DOI 10.2174/1871520610909030336
   Dumontet C, 2000, EXPERT OPIN INV DRUG, V9, P779, DOI 10.1517/13543784.9.4.779
   Evranos Aksoz B., 2011, FABAD J PHARM SCI, V36, P223
   FERIOLI R, 1995, BRIT J PHARMACOL, V114, P816, DOI 10.1111/j.1476-5381.1995.tb13277.x
   Ferreira LG, 2015, MOLECULES, V20, P13384, DOI 10.3390/molecules200713384
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Fringuelli F, 2004, CHEM COMMUN, P2756, DOI 10.1039/b409808k
   Ganesan A, 2017, DRUG DISCOV TODAY, V22, P249, DOI 10.1016/j.drudis.2016.11.001
   Gasparik V, 2012, ACS MED CHEM LETT, V3, P10, DOI 10.1021/ml200017d
   Glaab E, 2016, BRIEF BIOINFORM, V17, P352, DOI 10.1093/bib/bbv037
   Gomes MN, 2017, EUR J MED CHEM, V137, P126, DOI 10.1016/j.ejmech.2017.05.026
   Gomes MN, 2017, BIOORG MED CHEM LETT, V27, P2459, DOI 10.1016/j.bmcl.2017.04.010
   Grygiel-Gorniak B, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-17
   Guimaraes CRW, 2008, J CHEM INF MODEL, V48, P958, DOI 10.1021/ci800004w
   Hachet-Haas M, 2008, J BIOL CHEM, V283, P23189, DOI 10.1074/jbc.M803947200
   Hagmann WK, 2008, J MED CHEM, V51, P4359, DOI 10.1021/jm800219f
   Higuchi K, 2010, J GASTROEN HEPATOL, V25, pS155, DOI 10.1111/j.1440-1746.2010.06232.x
   Hou XB, 2015, J CHEM INF MODEL, V55, P1973, DOI 10.1021/acs.jcim.5b00344
   Hsieh CT, 2015, CHEMPLUSCHEM, V80, P859, DOI 10.1002/cplu.201402426
   Huggins DJ, 2011, PROTEIN ENG DES SEL, V24, P777, DOI 10.1093/protein/gzr036
   Hughes JP, 2011, BRIT J PHARMACOL, V162, P1239, DOI 10.1111/j.1476-5381.2010.01127.x
   Israf DA, 2007, MOL IMMUNOL, V44, P673, DOI 10.1016/j.molimm.2006.04.025
   Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317
   Jornada DH, 2016, MOLECULES, V21, DOI 10.3390/molecules21010042
   Kakati D, 2011, CHEM CENT J, V5, DOI 10.1186/1752-153X-5-8
   Kalyaanamoorthy S, 2014, PROG BIOPHYS MOL BIO, V114, P123, DOI 10.1016/j.pbiomolbio.2013.06.004
   Kalyaanamoorthy S, 2011, DRUG DISCOV TODAY, V16, P831, DOI 10.1016/j.drudis.2011.07.006
   Kamerlin SCL, 2009, J PHYS CHEM B, V113, P1253, DOI 10.1021/jp8071712
   Kar S, 2013, EXPERT OPIN DRUG DIS, V8, P245, DOI 10.1517/17460441.2013.761204
   Katsiki N, 2013, CURR PHARM DESIGN, V19, P3124
   Kaur J, 2010, J ANTIMICROB CHEMOTH, V65, P1742, DOI 10.1093/jac/dkq189
   Kim DW, 2014, FOOD CHEM, V153, P20, DOI 10.1016/j.foodchem.2013.12.026
   Klabunde T, 2007, BRIT J PHARMACOL, V152, P5, DOI 10.1038/sj.bjp.0707308
   Koziel R, 2010, J PHYSIOL PHARMACOL, V61, P233
   Kumar P, 2008, EXP PARASITOL, V120, P73, DOI 10.1016/j.exppara.2008.05.005
   Lagorce D., 2017, DRUG DISCOV TODAY, P6446
   Langdon SR, 2010, MOL INFORM, V29, P366, DOI 10.1002/minf.201000019
   Lawrence NJ, 2000, ANTI-CANCER DRUG DES, V15, P135
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Li RS, 1996, BIOORGAN MED CHEM, V4, P1421, DOI 10.1016/0968-0896(96)00136-8
   Liao CZ, 2011, FUTURE MED CHEM, V3, P1057, DOI [10.4155/FMC.11.63, 10.4155/fmc.11.63]
   Lima LMA, 2005, CURR MED CHEM, V12, P23, DOI 10.2174/0929867053363540
   Lin JH, 2011, CURR TOP MED CHEM, V11, P171, DOI 10.2174/156802611794863580
   Lionta E, 2014, CURR TOP MED CHEM, V14, P1923, DOI 10.2174/1568026614666140929124445
   Liu XF, 2010, NUCLEIC ACIDS RES, V38, pW609, DOI 10.1093/nar/gkq300
   Lower M, 2011, MOL INFORM, V30, P398, DOI 10.1002/minf.201100007
   Lu XY, 2016, MOL SIMULAT, V42, P1056, DOI 10.1080/08927022.2015.1132317
   Macalino SJY, 2015, ARCH PHARM RES, V38, P1686, DOI 10.1007/s12272-015-0640-5
   MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f
   Mahapatra DK, 2015, EUR J MED CHEM, V101, P496, DOI 10.1016/j.ejmech.2015.06.052
   Fraga CAM, 2009, EXPERT OPIN DRUG DIS, V4, P605, DOI 10.1517/17460440902956636
   Mao ZW, 2016, RSC ADV, V6, P7723, DOI 10.1039/c5ra20197g
   McDonald KJ, 2008, EXPERT OPIN PHARMACO, V9, P1407, DOI 10.1517/14656566.9.8.1407 
   McGann M, 2012, J COMPUT AID MOL DES, V26, P897, DOI 10.1007/s10822-012-9584-8
   Meanwell NA, 2011, J MED CHEM, V54, P2529, DOI 10.1021/jm1013693
   Melo CC, 2016, J CHEM INF MODEL, V56, P1357, DOI 10.1021/acs.jcim.6b00055
   Miclau T, 1998, J ORTHOPAED RES, V16, P509, DOI 10.1002/jor.1100160417
   Millard CJ, 2017, TRENDS PHARMACOL SCI, V38, P363, DOI 10.1016/j.tips.2016.12.006
   Mitchell JBO, 2014, WIRES COMPUT MOL SCI, V4, P468, DOI 10.1002/wcms.1183
   Moskowitz AJ, 2017, LEUKEMIA LYMPHOMA, V58, P1306, DOI 10.1080/10428194.2016.1247956
   Muegge I, 2016, EXPERT OPIN DRUG DIS, V11, P137, DOI 10.1517/17460441.2016.1117070
   Muratov EN, 2010, FUTURE MED CHEM, V2, P1205, DOI 10.4155/FMC.10.194
   Murray HW, 2005, LANCET, V366, P1561, DOI 10.1016/S0140-6736(05)67629-5
   Neves BJ, 2016, J MED CHEM, V59, P7075, DOI 10.1021/acs.jmedchem.5b02038
   Neves BJ, 2016, EXPERT OPIN DRUG DIS, V11, P557, DOI 10.1080/17460441.2016.1178230
   Ni LM, 2004, EXPERT OPIN THER PAT, V14, P1669, DOI 10.1517/13543776.14.12.1669
   Nielsen SF, 2004, BIOORGAN MED CHEM, V12, P3047, DOI 10.1016/j.bmc.2004.03.071
   Niu MM, 2014, ACTA PHARMACOL SIN, V35, P967, DOI 10.1038/aps.2014.34
   Otvos SB, 2016, MOLECULES, V21, DOI 10.3390/molecules21030318
   Pandey AV, 2001, BIOCHEM J, V355, P333, DOI 10.1042/0264-6021:3550333
   Patani GA, 1996, CHEM REV, V96, P3147, DOI 10.1021/cr950066q
   Petukh M, 2013, CURR PHARM DESIGN, V19, P4182, DOI 10.2174/1381612811319230004
   Pirhadi S, 2013, CURR TOP MED CHEM, V13, P1036, DOI 10.2174/1568026611313090006
   Rashid U, 2016, EUR J MED CHEM, V115, P230, DOI 10.1016/j.ejmech.2016.03.022
   Rautio J, 2008, NAT REV DRUG DISCOV, V7, P255, DOI 10.1038/nrd2468
   Reynolds CH, 2014, CURR PHARM DESIGN, V20, P3380, DOI 10.2174/138161282020140528105532
   Ripphausen P, 2011, DRUG DISCOV TODAY, V16, P372, DOI 10.1016/j.drudis.2011.02.011
   Roberts BC, 2008, J CHEM INF MODEL, V48, P397, DOI 10.1021/ci700285e
   Rognan D, 2007, BRIT J PHARMACOL, V152, P38, DOI 10.1038/sj.bjp.0707307
   Romagnoli R, 2008, BIOORGAN MED CHEM, V16, P5367, DOI 10.1016/j.bmc.2008.04.026
   Rose PW, 2015, NUCLEIC ACIDS RES, V43, pD345, DOI 10.1093/nar/gku1214
   Rueping M, 2011, BEILSTEIN J ORG CHEM, V7, P1680, DOI 10.3762/bjoc.7.198
   Sahu NK, 2012, CURR MED CHEM, V19, P209
   Santos L, 2006, ARCH PHARM, V339, P541, DOI 10.1002/ardp.200600034
   Sashidhara KV, 2014, EUR J MED CHEM, V81, P499, DOI 10.1016/j.ejmech.2014.04.085
   Sashidhara KV, 2012, BIOORG MED CHEM LETT, V22, P5455, DOI 10.1016/j.bmcl.2012.07.028
   Sashidhara KV, 2010, BIOORG MED CHEM LETT, V20, P6504, DOI 10.1016/j.bmcl.2010.09.055
   Sato Y, 2007, BIOL PHARM BULL, V30, P145, DOI 10.1248/bpb.30.145
   Schneider G, 2005, NAT REV DRUG DISCOV, V4, P649, DOI 10.1038/nrd1799
   Schwobel JAH, 2010, CHEM RES TOXICOL, V23, P1576, DOI 10.1021/tx100172x
   Selepe MA, 2013, MOLECULES, V18, P4739, DOI 10.3390/molecules18044739
   Senger MR, 2016, DRUG DISCOV TODAY, V21, P868, DOI 10.1016/j.drudis.2016.02.004
   SOMEKH E, 1989, J PHARMACOL EXP THER, V248, P415
   Spyrakis F, 2011, CURR TOP MED CHEM, V11, P192, DOI 10.2174/156802611794863571
   Srivastava Y.K., 2008, RASAYAN J CHEM, V1, P884
   STOEPEL K, 1981, ARZNEIMITTEL-FORSCH, V31-2, P2056
   TAKAHASHI S, 1980, SYNTHESIS-STUTTGART, P627, DOI 10.1055/s-1980-29145
   ten Brink T, 2010, J COMPUT AID MOL DES, V24, P935, DOI 10.1007/s10822-010-9385-x
   Tiuman TS, 2011, INT J INFECT DIS, V15, pE525, DOI 10.1016/j.ijid.2011.03.021
   Todeschini R, 2012, J CHEM INF MODEL, V52, P2884, DOI [10.1021/ci300261r, 10.1021/ci30026tr]
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Vapnik V., 2000, NATURE STAT LEARNING
   Verdonk ML, 2003, PROTEINS, V52, P609, DOI 10.1002/prot.10465
   Viegas-Junior C, 2007, CURR MED CHEM, V14, P1829
   Vuorinen A, 2015, METHODS, V71, P113, DOI 10.1016/j.ymeth.2014.10.013
   Wang Z., 2010, COMPREHENSIVE ORGANI
   WEINDORF N, 1987, Z HAUTKRANKHEITEN, V62, P28
   Wermuth G, 1998, PURE APPL CHEM, V70, P1129
   WONG E, 1968, PHYTOCHEMISTRY, V7, P1751, DOI 10.1016/S0031-9422(00)86646-7
   Wu RB, 2010, J AM CHEM SOC, V132, P9471, DOI 10.1021/ja103932d
   Wu XF, 2010, J AM CHEM SOC, V132, P14596, DOI 10.1021/ja1059922
   Xu LW, 2004, HELV CHIM ACTA, V87, P3080, DOI 10.1002/hlca.200490276
   Xu Mengang, 2013, Drug Discov Today Technol, V10, pe411, DOI 10.1016/j.ddtec.2013.02.003
   Yamamoto T, 2004, BIOSCI BIOTECH BIOCH, V68, P1706, DOI 10.1271/bbb.68.1706
   Yasinzai M, 2013, FUTURE MED CHEM, V5, P1877, DOI [10.4155/FMC.13.143, 10.4155/fmc.13.143]
   Zhong SJ, 2010, CURR OPIN DRUG DISC, V13, P326
   Zhou Bo, 2015, Med Chem (Los Angeles), V5, P388
   Zhou JW, 2015, ACS CHEM BIOL, V10, P687, DOI 10.1021/cb500767c
   Zhou T, 2010, CURR TOP MED CHEM, V10, P33, DOI 10.2174/156802610790232242
NR 157
TC 87
Z9 87
U1 2
U2 34
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD AUG
PY 2017
VL 22
IS 8
AR 1210
DI 10.3390/molecules22081210
PG 25
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA FF0PF
UT WOS:000408602900003
PM 28757583
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU do Amaral, AT
   Andrade, CH
   Kummerle, AE
   Guido, RVC
AF do Amaral, Antonia Tavares
   Andrade, Carolina Horta
   Kummerle, Arthur E.
   Guido, Rafael V. C.
TI MEDICINAL CHEMISTRY PROGRESS IN BRAZIL: ADVANCES IN THE 40 YEARS OF THE
   BRAZILIAN CHEMICAL SOCIETY
SO QUIMICA NOVA
LA English
DT Article
DE Medicinal Chemistry; Brazil; Progress; Evolution
ID NF-KAPPA-B; ANTIPLATELET PROPERTIES; SESQUITERPENE LACTONES;
   QUANTITATIVE STRUCTURE; BIOLOGICAL-ACTIVITY; ALPHA-MELANOTROPIN; DRUG
   DESIGN; DERIVATIVES; ANALOGS; INHIBITORS
AB Medicinal Chemistry includes the invention, discovery, design, identification, and interpretation of the molecular mechanism of action of biologically active compounds. In addition to the discovery of bioactive molecules, Medicinal Chemistry investigates drug metabolism and the relationships between chemical structure and biological activity. The advances achieved in the 20th century have significantly contributed to the better understanding of pathophysiological processes as well as the development of new, safer and more effective drugs for many diseases. In this article, we review the evolution of Medicinal Chemistry in Brazil during the last 40 years and evaluate the impact of the Brazilian contributions in the international context. The analyzed data revealed that Medicinal Chemistry research in Brazil has increased exponentially in the last two decades, the research groups became more well-distributed across the Brazilian regions and our scientific contributions have significant impact in the main journals of the field. Therefore, aiming at evolving steadily and striving for excellence in drug discovery and development, we shall focus on national and international collaborations and investment in translational research, as well.
C1 [do Amaral, Antonia Tavares] Univ Sao Paulo, Inst Quim, Dept Quim Fundamental, Ave Prof Lineu Prestes 748, BR-05508000 Sao Paulo, SP, Brazil.
   [Andrade, Carolina Horta] Univ Fed Goias, Fac Farm, Rua 240,Qd 87, BR-74605170 Goiania, Go, Brazil.
   [Kummerle, Arthur E.] Univ Fed Rural Rio de Janeiro, Dept Quim, BR-23897000 Seropedica, RJ, Brazil.
   [Guido, Rafael V. C.] Univ Sao Paulo, Inst Fis Sao Carlos, Av Joao Dagnone 1100, BR-13563120 Sao Carlos, SP, Brazil.
RP Guido, RVC (corresponding author), Univ Sao Paulo, Inst Fis Sao Carlos, Av Joao Dagnone 1100, BR-13563120 Sao Carlos, SP, Brazil.
EM rvcguido@ifsc.usp.br
RI Amaral, Antonia/C-4423-2012; Guido, Rafael Victorio
   Carvalho/A-7450-2009; Andrade, Carolina/C-3960-2014
OI Amaral, Antonia/0000-0003-2937-5255; Guido, Rafael Victorio
   Carvalho/0000-0002-7187-0818; Kummerle, Arthur/0000-0002-8458-0975;
   Andrade, Carolina/0000-0003-0101-1492
CR ALOBEIDI F, 1989, J MED CHEM, V32, P2555, DOI 10.1021/jm00132a010
   Boeck P, 2006, BIOORGAN MED CHEM, V14, P1538, DOI 10.1016/j.bmc.2005.10.005
   Cabrera M, 2007, BIOORGAN MED CHEM, V15, P3356, DOI 10.1016/j.bmc.2007.03.031
   Costa MS, 2006, BIOORGAN MED CHEM, V14, P8644, DOI 10.1016/j.bmc.2006.08.019
   Cunha AC, 2003, BIOORGAN MED CHEM, V11, P2051, DOI 10.1016/S0968-0896(03)00055-5
   de Andrade-Neto VF, 2004, BIOORG MED CHEM LETT, V14, P1145, DOI 10.1016/j.bmcl.2003.12.069
   deMelo S. J, 1985, QUIM NOVA, V8, P13
   do Amaral AT, 2002, QUIM NOVA, V25, P39, DOI 10.1590/S0100-40422002000800008
   Ferreira E. I., 2013, BRAZ J PHARM SCI, V49, P1
   Ferreira SB, 2010, J MED CHEM, V53, P2364, DOI 10.1021/jm901265h
   FERREIRA SH, 1965, BRIT J PHARM CHEMOTH, V24, P163, DOI 10.1111/j.1476-5381.1965.tb02091.x
   GALDINO SL, 1986, FARMACO, V41, P59
   Goulart MOF, 1997, BIOORG MED CHEM LETT, V7, P2043, DOI 10.1016/S0960-894X(97)00354-5
   Guido RVC, 2008, CURR MED CHEM, V15, P37
   HANSCH C, 1964, J AM CHEM SOC, V86, P1616, DOI 10.1021/ja01062a035
   HRUBY VJ, 1987, J MED CHEM, V30, P2126, DOI 10.1021/jm00394a033
   Hughes JP, 2011, BRIT J PHARMACOL, V162, P1239, DOI 10.1111/j.1476-5381.2010.01127.x
   Korolkovas A, 1978, MEMORIA ENCONTRO NAC
   KOROLKOVAS A, 1976, QUIMICA FARMACEUTICA
   Krystof V, 2006, J MED CHEM, V49, P6500, DOI 10.1021/jm0605740
   Lima LM, 2002, BIOORGAN MED CHEM, V10, P3067, DOI 10.1016/S0968-0896(02)00152-9
   Lima LMA, 2005, CURR MED CHEM, V12, P23, DOI 10.2174/0929867053363540
   Lima PC, 2000, EUR J MED CHEM, V35, P187, DOI 10.1016/S0223-5234(00)00120-3
   Masunari A, 2007, BIOORGAN MED CHEM, V15, P4229, DOI 10.1016/j.bmc.2007.03.068
   Otero L, 2006, J MED CHEM, V49, P3322, DOI 10.1021/jm0512241
   PAIVA TB, 1972, J MED CHEM, V15, P6, DOI 10.1021/jm00271a002
   Pavan F. R., 1998, EUR J MED CHEM, V2010, P45
   Pitta I. R, 1982, REV FARM BIOQUIM U, V18, P99
   Rungeler P, 1999, BIOORGAN MED CHEM, V7, P2343, DOI 10.1016/S0968-0896(99)00195-9
   Siedle B, 2004, J MED CHEM, V47, P6042, DOI 10.1021/jm049937r
   SILVA MRE, 1949, AM J PHYSIOL, V156, P261, DOI 10.1152/ajplegacy.1949.156.2.261
   Smith CG, 2003, FASEB J, V17, P788, DOI 10.1096/fj.03-0093life
   Soares AM, 2005, CURR MED CHEM, V12, P2625, DOI 10.2174/092986705774370655
   Stefani HA, 2006, EUR J MED CHEM, V41, P513, DOI 10.1016/j.ejmech.2006.01.007
   Swinney DC, 2011, NAT REV DRUG DISCOV, V10, P507, DOI 10.1038/nrd3480
   Todeschini AR, 1998, EUR J MED CHEM, V33, P189, DOI 10.1016/S0223-5234(98)80008-1
   TOMINAGA M, 1969, J MED CHEM, V12, P693, DOI 10.1021/jm00304a031
   TOMINAGA M, 1975, J MED CHEM, V18, P130, DOI 10.1021/jm00236a003
   Viegas-Junior C, 2007, CURR MED CHEM, V14, P1829
   Wermuth CG, 2008, PRACTICE OF MEDICINAL CHEMISTRY, 3RD EDITION, P1
NR 40
TC 2
Z9 2
U1 0
U2 11
PU SOC BRASILEIRA QUIMICA
PI SAO PAULO
PA CAIXA POSTAL 26037, 05599-970 SAO PAULO, BRAZIL
SN 0100-4042
EI 1678-7064
J9 QUIM NOVA
JI Quim. Nova
PD JUL
PY 2017
VL 40
IS 6
BP 694
EP 700
DI 10.21577/0100-4042.20170075
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA FB7ZO
UT WOS:000406358700015
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Gomes, MN
   Alcantara, LM
   Neves, BJ
   Melo, CC
   Freitas, LH
   Moraes, CB
   Ma, R
   Franzblau, SG
   Muratov, E
   Andrade, CH
AF Gomes, Marcelo N.
   Alcantara, Laura M.
   Neves, Bruno J.
   Melo-Filho, Cleber C.
   Freitas-Junior, Lucio H.
   Moraes, Carolina B.
   Ma, Rui
   Franzblau, Scott G.
   Muratov, Eugene
   Andrade, Carolina Horta
TI Computer-aided discovery of two novel chalcone-like compounds active and
   selective against Leishmania infantum
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Antileishmanial agents; Nitroheterocycle chalcones; Selectivity;
   Molecular modeling; Target fishing
ID DERIVATIVES; DOCKING; INHIBITION; PRINCIPLES; CURATION; ANALOGS; MODEL
AB Leishmaniasis are infectious diseases caused by parasites of genus Leishmania that affect affects 12 million people in 98 countries mainly in Africa, Asia, and Latin America. Effective treatments for this disease are urgently needed. In this study, we present a computer-aided approach to investigate a set of 32 recently synthesized chalcone and chalcone-like compounds to act as antileishmanial agents. As a result, nine most promising compounds and three potentially inactive compounds were experimentally evaluated against Leishmania infantum amastigotes and mammalian cells. Four compounds exhibited EC50 in the range of 6.2-10.98 mu M. In addition, two compounds, LabMol-65 and LabMol-73, exhibited cytotoxicity in macrophages > 50 mu M that resulted in better selectivity compared to standard drug amphotericin B. These two compounds also demonstrated low cytotoxicity and high selectivity towards Vero cells. The results of target fishing followed by homology modeling and docking studies suggest that these chalcone compounds could act in Leishmania because of their interaction with cysteine proteases, such as procathepsin L. Finally, we have provided structural recommendations for designing new antileishmanial chalcones. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Gomes, Marcelo N.; Neves, Bruno J.; Melo-Filho, Cleber C.; Andrade, Carolina Horta] Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, Rua 240,Qd 87,Setor Leste Univ, BR-74605510 Goiania, Go, Brazil.
   [Alcantara, Laura M.; Moraes, Carolina B.] Brazilian Ctr Res Energy & Mat CNPEM, Brazilian Biosci Natl Lab LNBio, BR-13083970 Campinas, SP, Brazil.
   [Freitas-Junior, Lucio H.] Inst Butantan Sao Paulo, BR-05503900 Sao Paulo, Brazil.
   [Neves, Bruno J.] Univ Ctr Anapolis UniEVANGELICA, Postgrad Program Soc Technol & Enviroment, BR-75083515 Anapolis, Go, Brazil.
   [Ma, Rui; Franzblau, Scott G.] Univ Illinois, Inst TB Res, 833 South Wood St, Chicago, IL 60612 USA.
   [Muratov, Eugene] Univ N Carolina, Eshelman Sch Pharm, Lab Mol Modeling, Chapel Hill, NC 27599 USA.
   [Muratov, Eugene] Odessa Natl Polytech Univ, Dept Chem Technol, UA-65000 Odessa, Ukraine.
   [Muratov, Eugene] Univ Fed Goias, Goiania, Go, Brazil.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, Lab Mol Modeling & Drug Design, LabMol, Rua 240,Qd 87,Setor Leste Univ, BR-74605170 Goiania, Go, Brazil.
EM carolhandrade@gmail.com
RI Freitas-Junior, Lucio H/C-8677-2011; Neves, Bruno/R-7068-2019;
   Melo-Filho, Cleber C./V-1119-2018; Neves, Bruno Junior/E-6295-2016;
   Moraes, Carolina Borsoi/I-4408-2014; Alcantara, Laura Maria/X-8885-2019;
   Andrade, Carolina/C-3960-2014
OI Freitas-Junior, Lucio H/0000-0002-8904-7897; Neves,
   Bruno/0000-0002-1309-8743; Melo-Filho, Cleber C./0000-0003-0056-6971;
   Moraes, Carolina Borsoi/0000-0002-0689-2770; Alcantara, Laura
   Maria/0000-0002-3374-7405; Andrade, Carolina/0000-0003-0101-1492
FU Brazilian funding agency CNPqNational Council for Scientific and
   Technological Development (CNPq); Brazilian funding agency CAPESCAPES;
   Brazilian funding agency FAPEG; NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [1U01CA207160];
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [400760/2014-2]; NATIONAL CANCER INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [U01CA207160, U01CA207160, U01CA207160]
   Funding Source: NIH RePORTER
FX The authors thank Brazilian funding agencies, CNPq, CAPES and FAPEG for
   financial support and fellowships. E.M. acknowledge NIH (grant
   1U01CA207160), and CNPq (grant 400760/2014-2) for partial financial
   support. C.H.A. is productivity fellow of CNPq. We are grateful to
   OpenEye Scientific Software, Inc. and ChemAxon for providing academic
   license of their software.
CR [Anonymous], 2016, NCBI BLAST BASIC LOC
   Aoki N, 2008, J NAT PROD, V71, P1308, DOI 10.1021/np800187f
   Ascenzi P, 2003, BIOCHEM BIOPH RES CO, V309, P659, DOI 10.1016/j.bbrc.2003.08.015
   Ascenzi P, 2001, CURR PROTEIN PEPT SC, V2, P137, DOI 10.2174/1389203013381170
   Avila-Villarreal G., 2013, PHYTOMEDICINE
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Caffrey CR, 2009, MOL BIOCHEM PARASIT, V167, P12, DOI 10.1016/j.molbiopara.2009.04.009
   Capriles PVSZ, 2015, J MOL GRAPH MODEL, V55, P134, DOI 10.1016/j.jmgm.2014.11.002
   Chen M, 2001, ANTIMICROB AGENTS CH, V45, P2023, DOI 10.1128/AAC.45.7.2023-2029.2001
   Chen YH, 2013, MOLECULES, V18, P2052, DOI 10.3390/molecules18022052
   dos Santos MS, 2011, BIOORG MED CHEM LETT, V21, P7451, DOI 10.1016/j.bmcl.2011.09.134
   Ekins S, 2011, DRUG DISCOV TODAY, V16, P298, DOI 10.1016/j.drudis.2011.02.016
   Eric S, 2012, BIOORGAN MED CHEM, V20, P5220, DOI 10.1016/j.bmc.2012.06.051
   Fourches D., 2016, J CHEM INF MODEL
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Gomes MN, 2017, EUR J MED C IN PRESS
   Gupta S, 2014, J MED CHEM, V57, P3342
   Gupta S, 2014, EUR J MED CHEM, V81, P359, DOI 10.1016/j.ejmech.2014.05.034
   Hans RH, 2010, BIOORG MED CHEM LETT, V20, P942, DOI 10.1016/j.bmcl.2009.12.062
   Jamal H, 2008, FUND CLIN PHARMACOL, V22, P673, DOI 10.1111/j.1472-8206.2008.00639.x
   Ko J, 2012, NUCLEIC ACIDS RES, V40, pW294, DOI 10.1093/nar/gks493
   Lam KW, 2012, MED CHEM RES, V21, P1953, DOI 10.1007/s00044-011-9706-1
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Liu X., 2010, NUCLEIC ACIDS RES, V38, P5
   Liu X, PHARMMAPPER
   Lopez SN, 2001, BIOORGAN MED CHEM, V9, P1999, DOI 10.1016/S0968-0896(01)00116-X
   Mahapatra DM, 2015, EUR J MED CHEM, V98, P69, DOI 10.1016/j.ejmech.2015.05.004
   Moreno MA, 2014, INT J PARASITOL-DRUG, V4, P347, DOI 10.1016/j.ijpddr.2014.06.001
   Nicolaou KC, 2000, J AM CHEM SOC, V122, P9939, DOI 10.1021/ja002033k
   Ogungbe IV, 2014, J MOL GRAPH MODEL, V48, P105, DOI 10.1016/j.jmgm.2013.12.010
   Ouattara M, 2011, TROP J PHARM RES, V10, P767, DOI 10.4314/tjpr.v10i6.10
   Passalacqua TG, 2015, BIOORG MED CHEM LETT, V25, P3564, DOI 10.1016/j.bmcl.2015.06.085
   Petri E, 2016, EXP PARASITOL, V163, P68
   Rizvi SUF, 2012, MED CHEM RES, V21, P3741, DOI 10.1007/s00044-011-9912-x
   Rognan D, 2007, BRIT J PHARMACOL, V152, P38, DOI 10.1038/sj.bjp.0707307
   Sato Y, 2007, BIOL PHARM BULL, V30, P145, DOI 10.1248/bpb.30.145
   Syam S, 2012, MOLECULES, V17, P6179, DOI 10.3390/molecules17066179
   Yamamoto T, 2004, BIOSCI BIOTECH BIOCH, V68, P1706, DOI 10.1271/bbb.68.1706
NR 39
TC 15
Z9 15
U1 0
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD JUN 1
PY 2017
VL 27
IS 11
BP 2459
EP 2464
DI 10.1016/j.bmcl.2017.04.010
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA EV8IL
UT WOS:000402023800038
PM 28434763
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Braga, RC
   Alves, VM
   Muratov, EN
   Strickland, J
   Kleinstreuer, N
   Trospsha, A
   Andrade, CH
AF Braga, Rodolpho C.
   Alves, Vinicius M.
   Muratov, Eugene N.
   Strickland, Judy
   Kleinstreuer, Nicole
   Trospsha, Alexander
   Andrade, Carolina Horta
TI Pred-Skin: A Fast and Reliable Web Application to Assess Skin
   Sensitization Effect of Chemicals
SO JOURNAL OF CHEMICAL INFORMATION AND MODELING
LA English
DT Article
ID LYMPH-NODE ASSAY; QSAR MODELS; VALIDATION; CURATION; VERIFY; TRUST
AB Chemically induced skin sensitization is a complex immunological disease with a profound impact on quality of life and working ability. Despite some progress in developing alternative methods for assessing the skin sensitization potential of chemical substances, there is no in vitro test that correlates well with human data. Computational QSAR models provide a rapid screening approach and contribute valuable information for the assessment of chemical toxicity. We describe the development of a freely accessible web-based and mobile application for the identification of potential skin sensitizers. The application is based on previously developed binary QSAR models of skin sensitization potential from human (109 compounds) and murine local lymph node assay (LLNA, 515 compounds) data with good external correct classification rate (0.70-0.81 and 0.72-0.84, respectively). We also included a multiclass skin sensitization potency model based on LLNA data (accuracy ranging between 0.73 and 0.76). When a user evaluates a compound in the web app, the outputs are (i) binary predictions of human and murine skin sensitization potential; (ii) multiclass prediction of murine skin sensitization; and (iii) probability maps illustrating the predicted contribution of chemical fragments. The app is the first tool available that incorporates quantitative structure activity relationship (QSAR) models based on human data as well as multiclass models for LLNA. The Pred-Skin web app version 1.0 is freely available for the web, iOS, and Android (in development) at the LabMol web portal (http://labmol.com.br/predskin/), in the Apple Store, and on Google Play, respectively. We will continuously update the app as new skin sensitization data and respective models become available.
C1 [Braga, Rodolpho C.; Alves, Vinicius M.; Andrade, Carolina Horta] Univ Fed Goias, Lab Mol Modeling & Drug Design, Fac Pharm, BR-74605170 Goiania, Go, Brazil.
   [Alves, Vinicius M.; Muratov, Eugene N.; Trospsha, Alexander] Univ N Carolina, UNC Eshelman Sch Pharm, Div Chem Biol & Med Chem, Lab Mol Modeling, Chapel Hill, NC 27599 USA.
   [Muratov, Eugene N.] Odessa Natl Polytech Univ, Dept Chem Technol, UA-65000 Odessa, Ukraine.
   [Strickland, Judy] Integrated Lab Syst Inc, POB 13501, Res Triangle Pk, NC 27709 USA.
   [Kleinstreuer, Nicole] Natl Inst Environm Hlth Sci, Interagency Ctr Evaluat Alternat Toxicol Methods, Natl Toxicol Program, Res Triangle Pk, NC 27709 USA.
RP Andrade, CH (corresponding author), Univ Fed Goias, Lab Mol Modeling & Drug Design, Fac Pharm, BR-74605170 Goiania, Go, Brazil.
EM carolina@ufg.br
RI Braga, Rodolpho C/A-9655-2011; Alves, Vinicius M./G-7955-2015;
   Kleinstreuer, Nicole/F-7203-2019; Andrade, Carolina/C-3960-2014
OI Braga, Rodolpho C/0000-0003-3814-3464; Alves, Vinicius
   M./0000-0002-6182-1748; Kleinstreuer, Nicole/0000-0002-7914-3682;
   Tropsha, Alexander/0000-0003-3802-8896; Andrade,
   Carolina/0000-0003-0101-1492
FU FAPEG [201310267001095]; CNPqNational Council for Scientific and
   Technological Development (CNPq) [400760/2014-2]; CAPESCAPES; NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [GM66940, GM096967, HHSN273201500010C]
FX The authors gratefully thank Mr. Stephen Capuzzi for his kind help with
   editing the manuscript. This study was supported by Brazilian funding
   agencies FAPEG (grant 201310267001095) and CNPq (grant 400760/2014-2).
   V.M.A. thanks CAPES for a Ph.D. scholarship and CNPq for supporting his
   visit to the University of North Carolina at Chapel Hill. E.N.M. and
   A.T. thank the NIH (grants GM66940 and GM096967) for financial support.
   J.S. was supported by NIH contract HHSN273201500010C to ILS in support
   of NICEATM. C.H.A. thanks CNPq for the productivity fellowship. We are
   also grateful to ChemAxon and Talete for providing us with academic
   licenses for their software.
CR Alves VM, 2016, GREEN CHEM, V18, P6501, DOI [10.1039/c6gc01836j, 10.1039/C6GC01836J]
   Alves VM, 2016, GREEN CHEM, V18, P4348, DOI [10.1039/C6GC01492E, 10.1039/c6gc01492e]
   Alves VM, 2015, TOXICOL APPL PHARM, V284, P262, DOI 10.1016/j.taap.2014.12.014
   Api AM, 2015, CUTAN OCUL TOXICOL, V34, P298, DOI 10.3109/15569527.2014.979425
   Basketter DA, 2002, FOOD CHEM TOXICOL, V40, P593, DOI 10.1016/S0278-6915(01)00130-2
   Bienfait B, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-24
   Braga RC, 2015, MOL INFORM, V34, P698, DOI 10.1002/minf.201500040
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1399, DOI 10.2174/1568026614666140506124442
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Cockshott A, 2006, HUM EXP TOXICOL, V25, P387, DOI 10.1191/0960327106ht640oa
   European Commission, AN TEST MARK BAN STA
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Kuz'min VE, 2008, J COMPUT AID MOL DES, V22, P403, DOI 10.1007/s10822-008-9179-6
   Kuz'min VE, 2009, QSAR COMB SCI, V28, P664, DOI 10.1002/qsar.200860117
   Macan J, 2013, DERMATOLOGY, V227, P321, DOI 10.1159/000354763
   Naven RT, 2015, HUM EXP TOXICOL, V34, P1304, DOI 10.1177/0960327115605440
   Patlewicz G, 2014, REGUL TOXICOL PHARM, V69, P529, DOI 10.1016/j.yrtph.2014.06.001
   Reisinger K, 2015, TOXICOL IN VITRO, V29, P259, DOI 10.1016/j.tiv.2014.10.018
   Riniker S, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-43
   Strickland J, 2016, J APPL TOXICOL, V36, P1150, DOI 10.1002/jat.3281
   Sushko I, 2012, J CHEM INF MODEL, V52, P2310, DOI 10.1021/ci300245q
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
NR 25
TC 30
Z9 30
U1 1
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1549-9596
EI 1549-960X
J9 J CHEM INF MODEL
JI J. Chem Inf. Model.
PD MAY
PY 2017
VL 57
IS 5
BP 1013
EP 1017
DI 10.1021/acs.jcim.7b00194
PG 5
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Computer Science,
   Information Systems; Computer Science, Interdisciplinary Applications
SC Pharmacology & Pharmacy; Chemistry; Computer Science
GA EV8GW
UT WOS:000402019700001
PM 28459556
DA 2020-12-01
ER

PT J
AU Alves, V
   Capuzzi, S
   Muratov, E
   Braga, R
   Thornton, T
   Fourches, D
   Strickland, J
   Kleinstreuer, N
   Andrade, C
   Tropsha, A
AF Alves, Vinicius
   Capuzzi, Stephen
   Muratov, Eugene
   Braga, Rodolpho
   Thornton, Thomas
   Fourches, Denis
   Strickland, Judy
   Kleinstreuer, Nicole
   Andrade, Carolina
   Tropsha, Alexander
TI What works best for predicting human skin sensitization potential of
   chemicals: In vitro data or in silico models?
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 253rd National Meeting of the American-Chemical-Society (ACS) on
   Advanced Materials, Technologies, Systems, and Processes
CY APR 02-06, 2017
CL San Francisco, CA
SP Amer Chem Soc
C1 [Alves, Vinicius; Andrade, Carolina] Univ Fed Goias, Fac Pharm, Goiania, Go, Brazil.
   [Braga, Rodolpho] Univ Fed Goias, Goiania, Go, Brazil.
   [Thornton, Thomas; Tropsha, Alexander] Univ N Carolina, Chapel Hill, NC USA.
   [Fourches, Denis] Univ N Carolina, Lab Mol Modeling, Chapel Hill, NC USA.
   [Muratov, Eugene] Univ N Carolina, Med Chem Nat Prod, Chapel Hill, NC USA.
   [Capuzzi, Stephen] Univ N Carolina, Chem Biol & Med Chem, Chapel Hill, NC USA.
   [Strickland, Judy; Kleinstreuer, Nicole] NIEHS, Res Triangle Pk, NC USA.
EM alex_tropsha@unc.edu
RI Braga, Rodolpho C/A-9655-2011; Alves, Vinicius M./G-7955-2015; Tropsha,
   Alexander/AAB-8324-2020; Kleinstreuer, Nicole/F-7203-2019; Fourches,
   Denis/H-4336-2019
OI Braga, Rodolpho C/0000-0003-3814-3464; Alves, Vinicius
   M./0000-0002-6182-1748; Kleinstreuer, Nicole/0000-0002-7914-3682; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD APR 2
PY 2017
VL 253
MA 1009
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA GD5TH
UT WOS:000430569101578
DA 2020-12-01
ER

PT J
AU Sainas, S
   Pippione, AC
   Giorgis, M
   Lupino, E
   Goyal, P
   Ramondetti, C
   Buccinna, B
   Piccinini, M
   Braga, RC
   Andrade, CH
   Andersson, M
   Moritzer, AC
   Friemann, R
   Mensa, S
   Al-Kadaraghi, S
   Boschi, D
   Lolli, ML
AF Sainas, Stefano
   Pippione, Agnese C.
   Giorgis, Marta
   Lupino, Elisa
   Goyal, Parveen
   Ramondetti, Cristina
   Buccinna, Barbara
   Piccinini, Marco
   Braga, Rodolpho C.
   Andrade, Carolina H.
   Andersson, Mikael
   Moritzer, Ann-Christin
   Friemann, Rosmarie
   Mensa, Stefano
   Al-Kadaraghi, Salam
   Boschi, Donatella
   Lolli, Marco L.
TI Design, synthesis, biological evaluation and X-ray structural studies of
   potent human dihydroorotate dehydrogenase inhibitors based on
   hydroxylated azole scaffolds
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Dihydroorotate dehydrogenase (DHODH) inhibitors; X-ray-crystallography;
   Autoimmune diseases; Leflunomide; Brequinar; Bioisosterism
ID THIAZOLE DERIVATIVES; LEFLUNOMIDE; DRUG; AUTOIMMUNE; BREQUINAR;
   MECHANISM; SYSTEM
AB A new generation of potent hDHODH inhibitors designed by a scaffold-hopping replacement of the quinolinecarboxylate moiety of brequinar, one of the most potent known hDHODH inhibitors, is presented here. Their general structure is characterized by a biphenyl moiety joined through an amide bridge with an acidic hydroxyazole scaffold (hydroxylated thiadiazole, pyrazole and triazole). Molecular modelling suggested that these structures should adopt a brequinar-like binding mode involving interactions with subsites 1, 2 and 4 of the hDHODH binding site. Initially, the inhibitory activity of the compounds was studied on recombinant hDHODH. The most potent compound of the series in the enzymatic assays was the thiadiazole analogue 4 (IC50 16 nM). The activity was found to be dependent on the fluoro substitution pattern at the biphenyl moiety as well as on the choice/substitution of the heterocyclic ring. Structure determination of hDHODH co-crystallized with one representative compound from each series (4, 5 and 6) confirmed the brequinar-like binding mode as suggested by modelling. The specificity of the observed effects of the compound series was tested in cell-based assays for antiproliferation activity using Jurkat cells and PHA-stimulated PBMC. These tests were also verified by addition of exogenous uridine to the culture medium. In particular, the triazole analogue 6 (IC50 against hDHODH: 45 nM) exerted potent in vitro antiproliferative and immunosuppressive activity without affecting cell survival. (C) 2017 Elsevier Masson SAS. All rights reserved.
C1 [Sainas, Stefano; Pippione, Agnese C.; Giorgis, Marta; Boschi, Donatella; Lolli, Marco L.] Univ Torino, Dept Sci & Drug Technol, Via Pietro Giuria 9, I-10125 Turin, Italy.
   [Lupino, Elisa; Ramondetti, Cristina; Buccinna, Barbara; Piccinini, Marco] Univ Torino, Dept Oncol, Via Michelangelo 27-B, I-10126 Turin, Italy.
   [Goyal, Parveen; Andersson, Mikael; Moritzer, Ann-Christin; Friemann, Rosmarie] Univ Gothenburg, Dept Chem & Mol Biol, Box 462, S-40530 Gothenburg, Sweden.
   [Braga, Rodolpho C.; Andrade, Carolina H.] Univ Fed Goias, Fac Pharm, LabMol, BR-74605170 Goiania, Go, Brazil.
   [Moritzer, Ann-Christin] Univ Bielefeld, Dept Chem Biochem, Univ Str 25, D-33615 Bielefeld, Germany.
   [Friemann, Rosmarie] Stanford Univ, Sch Med, Dept Biol Struct, 299 Campus Dr West, Stanford, CA 94305 USA.
   [Mensa, Stefano] Univ Liverpool, Stephenson Inst Renewable Energy, Dept Chem, Liverpool L69 7ZF, Merseyside, England.
   [Al-Kadaraghi, Salam] Lund Univ, Dept Biochem & Struct Biol, S-22100 Lund, Sweden.
RP Lolli, ML (corresponding author), Univ Torino, Dept Sci & Drug Technol, Via Pietro Giuria 9, I-10125 Turin, Italy.
EM marco.lolli@unito.it
RI goyal, parveen/W-6345-2019; Sainas, Stefano/M-8224-2017; Braga, Rodolpho
   C/A-9655-2011; Friemann, Rosmarie/C-1018-2008; Goyal,
   Parveen/J-8435-2014; Andrade, Carolina/C-3960-2014; boschi,
   donatella/M-5812-2014
OI Sainas, Stefano/0000-0001-5010-8536; Braga, Rodolpho
   C/0000-0003-3814-3464; Friemann, Rosmarie/0000-0002-5633-2894; GIORGIS,
   Marta/0000-0002-3282-1220; Goyal, Parveen/0000-0002-7808-8298; LOLLI,
   Marco Lucio/0000-0002-3030-3163; Andersson, Mikael/0000-0002-1188-8127;
   Andrade, Carolina/0000-0003-0101-1492; boschi,
   donatella/0000-0003-4929-4460
FU University of Turin [LOLMAUTO00, LOLM_RIC_LOC_14_01]; Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil)National
   Council for Scientific and Technological Development (CNPq)
   [LOLM_RIC_LOC_14_01, 481392/2013-0]; Fundacao de Amparo a Pesquisa do
   Estado de Goias (FAPEG, Brazil) [201210267001112, 201310267001105]; ESS
   & MAXIV: Cross Border network and postgraduate education programme
   MAX4ESSFUN; CNPqNational Council for Scientific and Technological
   Development (CNPq) [310025/2015-0]; Equal Opportunities Commission of
   the Faculty of Chemistry of Bielefeld University; CAPESCAPES; FAPEG
FX This research was financially supported by the University of Turin
   (Ricerca Locale grant 2015 (LOLMAUTO00) and 2014 (LOLM_RIC_LOC_14_01)).
   CHA and RCB received financial support from (LOLM_RIC_LOC_14_01)
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq,
   Brazil,481392/2013-0) and Fundacao de Amparo a Pesquisa do Estado de
   Goias (FAPEG, Brazil, 201210267001112 and 201310267001105). RF and MA
   acknowledge support from ESS & MAXIV: Cross Border network and
   postgraduate education programme MAX4ESSFUN. CHA is CNPq productivity
   fellow (310025/2015-0) and PG is long term EMBO fellow (ALTF 1163-2014).
   A-CM is thankful for a grant from the Equal Opportunities Commission of
   the Faculty of Chemistry of Bielefeld University. RCB and CHA would like
   to thank ChemAxon for providing the academic license of their software,
   as well as Brazilian funding agencies CNPq, CAPES and FAPEG.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   AUNGST BJ, 1990, J PHARMACOL EXP THER, V253, P230
   BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112
   Baumgartner R, 2006, J MED CHEM, V49, P1239, DOI 10.1021/jm0506975
   Beno BR, 2015, J MED CHEM, V58, P4383, DOI 10.1021/jm501853m
   Bonomo S, 2013, J MOL MODEL, V19, P1099, DOI 10.1007/s00894-012-1643-5
   CHERWINSKI HM, 1995, J PHARMACOL EXP THER, V275, P1043
   Cho AE, 2005, J COMPUT CHEM, V26, P915, DOI 10.1002/jcc.20222
   Ducime A., 2016, THESIS
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   FORREST TL, 1994, TRANSPLANTATION, V58, P920, DOI 10.1097/00007890-199410270-00011
   Fox RI, 1999, CLIN IMMUNOL, V93, P198, DOI 10.1006/clim.1999.4777
   Giorgis M, 2011, EUR J MED CHEM, V46, P383, DOI 10.1016/j.ejmech.2010.10.029
   Herrmann ML, 2000, IMMUNOPHARMACOLOGY, V47, P273, DOI 10.1016/S0162-3109(00)00191-0
   JURSIC B, 1989, SYNTHETIC COMMUN, V19, P2087, DOI 10.1080/00397918908052602
   Knecht W, 1998, BIOCHEM PHARMACOL, V56, P1259, DOI 10.1016/S0006-2952(98)00145-2
   Kraan MC, 2004, ANN RHEUM DIS, V63, P1056, DOI 10.1136/ard.2003.014738
   Kulkarni OP, 2010, AM J PATHOL, V176, P2840, DOI 10.2353/ajpath.2010.091227
   Leban J, 2006, BIOORG MED CHEM LETT, V16, P267, DOI 10.1016/j.bmcl.2005.10.011
   Leban J, 2011, ARZNEIMITTELFORSCH, V61, P66, DOI 10.1055/s-0031-1296169
   Li L, 2013, J NEUROIMMUNOL, V265, P82, DOI 10.1016/j.jneuroim.2013.10.003
   Li SL, 2015, SCI REP-UK, V5, DOI 10.1038/srep14836
   Liu SP, 2000, STRUCT FOLD DES, V8, P25, DOI 10.1016/S0969-2126(00)00077-0
   Lolli ML, 2012, EUR J MED CHEM, V49, P102, DOI 10.1016/j.ejmech.2011.12.038
   Lucas-Hourani M, 2015, J MED CHEM, V58, P5579, DOI 10.1021/acs.jmedchem.5b00606
   MASUDA K, 1981, J CHEM SOC PERK T 1, P1033, DOI 10.1039/p19810001033
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Munier-Lehmann H, 2015, J MED CHEM, V58, P860, DOI 10.1021/jm501446r
   Munier-Lehmann H, 2013, J MED CHEM, V56, P3148, DOI 10.1021/jm301848w
   PETERS GJ, 1987, INVEST NEW DRUG, V5, P235
   Pippione AC, 2015, MEDCHEMCOMM, V6, P1285, DOI 10.1039/c5md00182j
   RAO J, 1992, ANAL BIOCHEM, V207, P186, DOI 10.1016/0003-2697(92)90521-8
   Ruckemann K, 1998, J BIOL CHEM, V273, P21682, DOI 10.1074/jbc.273.34.21682
   Sainas S., 2013, THESIS
   SHEREMETEV AB, 1993, TETRAHEDRON, V49, P5905, DOI 10.1016/S0040-4020(01)87956-4
   Singh A, 2017, EUR J MED CHEM, V125, P640, DOI 10.1016/j.ejmech.2016.09.085
   Talele TT, 2016, J MED CHEM, V59, P8712, DOI 10.1021/acs.jmedchem.6b00472
   Vyas VK, 2014, EUR J MED CHEM, V82, P385, DOI 10.1016/j.ejmech.2014.05.064
   Walse B, 2008, BIOCHEMISTRY-US, V47, P8929, DOI 10.1021/bi8003318
   Wang CZ, 2014, ACS CHEM NEUROSCI, V5, P138, DOI 10.1021/cn400193u
   WEINSTOC.LM, 1967, J ORG CHEM, V32, P2823, DOI 10.1021/jo01284a040
   Zhu JS, 2015, J MED CHEM, V58, P1123, DOI 10.1021/jm501127s
NR 42
TC 24
Z9 25
U1 2
U2 19
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD MAR 31
PY 2017
VL 129
BP 287
EP 302
DI 10.1016/j.ejmech.2017.02.017
PG 16
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA EP1YS
UT WOS:000397180800019
PM 28235702
DA 2020-12-01
ER

PT J
AU Grecco, SS
   Costa-Silva, TA
   Jerz, G
   de Sousa, FS
   Conserva, GAA
   Mesquita, JT
   Galuppo, MK
   Tempone, AG
   Neves, BJ
   Andrade, CH
   Cunha, RLOR
   Uemi, M
   Sartorelli, P
   Lago, JHG
AF Grecco, Simone S.
   Costa-Silva, Thais A.
   Jerz, Gerold
   de Sousa, Fernanda S.
   Alves Conserva, Geanne A.
   Mesquita, Juliana T.
   Galuppo, Mariana K.
   Tempone, Andre G.
   Neves, Bruno J.
   Andrade, Carolina H.
   Cunha, Rodrigo L. O. R.
   Uemi, Miriam
   Sartorelli, Patricia
   Lago, Joao Henrique G.
TI Antitrypanosomal activity and evaluation of the mechanism of action of
   dehydrodieugenol isolated from Nectandra leucantha (Lauraceae) and its
   methylated derivative against Trypanosoma cruzi
SO PHYTOMEDICINE
LA English
DT Article
DE Neolignans; Nectandra leucantha; Antitrypanosomal; Plasma membrane
   permeabilization
ID IN-SILICO PREDICTION; ANTILEISHMANIAL ACTIVITY; PLASMA-MEMBRANE;
   LEISHMANIASIS; DRUGS; PHENYLPROPANOIDS; TARGETS; VITRO
AB Background: From a previous screening of Brazilian biodiversity for antiprotozoal activity, the hexane extract from leaves of Nectandra leucantha (Nees & Mart.) (Lauraceae) demonstrated activity against Trypanosoma cruzi. Chromatographic separation of this extract afforded bioactive dehydrodieugenol (1). Furthermore, methylated derivative 2 (dehydrodieugenol dimethyl ether) was prepared and also tested against T. cruzi.
   Purpose: To examine the therapeutical potential of compounds 1 and 2 against T. cruzi as well as to elucidate the mechanism of action of bioactive compound 1 against T. cruzi.
   Methods/Study design: Crude hexane extract from leaves was subjected to chromatographic steps to afford bioactive compound 1. In order to analyze the effect of additional methyl group in the antiparasitic activity of 1, derivative 2 was prepared (both are no pan-assay interference compounds -PAINS). These compounds were evaluated in vitro against T. cruzi (trypomastigote and amastigote forms) and analyzed for the potential effect in host cells through the production of nitric oxide and reactive oxygen species. Finally, the plasma membrane effect of the most potent compound 1 was investigated in T. cruzi trypomastigotes.
   Results: Compounds 1 and 2 displayed activity against amastigotes of T. cruzi. Although both compounds promoted activity against intracellular amastigotes, the production of nitric oxide and reactive oxygen species of host cells were unaltered, suggesting an antiparasitic activity other than host cell activation. Considering 1 the most effective compound against T. cruzi, the interference in the plasma membrane of the trypomastigotes was investigated using the fluorescent probe SYTOX r Green. After a short-term incubation, the fluidity and integrity of the plasma membrane was completely altered, suggesting it as a primary target for compound 1 in T. cruzi.
   Conclusion: Compounds 1 and 2 selectively eliminated the intracellular parasites without host cell activation and could be important scaffolds for the search of new hit compounds. (C) 2016 Elsevier GmbH. All rights reserved.
C1 [Grecco, Simone S.; Alves Conserva, Geanne A.; Cunha, Rodrigo L. O. R.; Lago, Joao Henrique G.] Fed Univ ABC, Ctr Nat Sci & Humanities, BR-09210180 Santo Andre, SP, Brazil.
   [Grecco, Simone S.; Jerz, Gerold] Tech Univ Carolo Wilhelmina Braunschweig, Inst Food Chem, D-38106 Braunschweig, Germany.
   [Costa-Silva, Thais A.; Mesquita, Juliana T.; Galuppo, Mariana K.; Tempone, Andre G.] Adolfo Lutz Inst, Ctr Parasitol & Mycol, BR-01246902 Sao Paulo, Brazil.
   [de Sousa, Fernanda S.; Alves Conserva, Geanne A.; Uemi, Miriam; Sartorelli, Patricia] Univ Fed Sao Paulo, Inst Environm Chem & Pharmaceut Sci, BR-09972270 Diadema, SP, Brazil.
   [Neves, Bruno J.; Andrade, Carolina H.] Univ Fed Goias, Fac Pharm, LabMol, Lab Mol Modeling & Drug Design, BR-74605170 Goiania, Go, Brazil.
RP Lago, JHG (corresponding author), Fed Univ ABC, Ctr Nat Sci & Humanities, BR-09210180 Santo Andre, SP, Brazil.
EM joao.lago@ufabc.edu.br
RI Neves, Bruno Junior/E-6295-2016; Tempone, Andre/ABA-2231-2020;
   Sartorelli, Patricia/AAN-2911-2020; Tempone, Andre Gustavo/E-5932-2012;
   Lago, Joao/W-5238-2019; Grecco, Simone S/I-7608-2016; Neves,
   Bruno/R-7068-2019; Tempone, Andre Gustavo/E-5932-2012; Andrade,
   Carolina/C-3960-2014
OI Tempone, Andre/0000-0003-2559-7344; Tempone, Andre
   Gustavo/0000-0003-2559-7344; Lago, Joao/0000-0002-1193-8374; Grecco,
   Simone S/0000-0003-0716-0368; Neves, Bruno/0000-0002-1309-8743; Jerz,
   Gerold/0000-0003-2685-6723; Tempone, Andre Gustavo/0000-0002-9900-1470;
   Mesquita, Juliana Tonini/0000-0002-1734-3400; Andrade,
   Carolina/0000-0003-0101-1492
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2015/11936-2];
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [470853/2012-3, 471458/2012-0]; FAPESP scholarshipFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2013/07275-5-TACS];
   CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES
FX This work was funded by grants and fellowships provided from Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP-Project 2015/11936-2)
   and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq-Project 470853/2012-3 and 471458/2012-0). We thank Rodrigo
   Guimaraes Queiroz for technical assistance. Authors also thank CNPq
   scientific research award to JHGL and AGT as well as to FAPESP
   scholarship (2013/07275-5-TACS) and CAPES scholarships to JTM, MKG and
   SSG. This publication is part of the activities of the Research Network
   Natural Products against Neglected Diseases (ResNetNPND):
   http://www.uni-muenster.de/ResNetNPND/.
CR Andrade CH, 2014, CURR DRUG METAB, V15, P514, DOI 10.2174/1389200215666140908102530
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Bettiol E, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000384
   Bonney KM, 2014, PARASITE, V21, DOI 10.1051/parasite/2014012
   Bou DD, 2014, PHYTOMEDICINE, V21, P676, DOI 10.1016/j.phymed.2014.01.004
   Braga RC, 2015, MOL INFORM, V34, P698, DOI 10.1002/minf.201500040
   Carneiro PP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148084
   Carvalho L, 2010, ANTIMICROB AGENTS CH, V54, P5344, DOI 10.1128/AAC.00790-10
   Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748
   Cheng FX, 2012, J CHEM INF MODEL, V52, P3099, DOI 10.1021/ci300367a
   Cheng FX, 2011, J CHEM INF MODEL, V51, P996, DOI 10.1021/ci200028n
   da Costa-Silva TA, 2015, J NAT PROD, V78, P653, DOI 10.1021/np500809a
   de Beer D, 2009, J CHROMATOGR A, V1216, P4282, DOI 10.1016/j.chroma.2009.02.056
   Drwal MN, 2014, NUCLEIC ACIDS RES, V42, pW53, DOI 10.1093/nar/gku401
   Duarte MC, 2016, VET PARASITOL, V217, P81, DOI 10.1016/j.vetpar.2016.01.002
   The HP, 2011, MOL INFORM, V30, P376, DOI 10.1002/minf.201000118
   Hammer KA, 2012, INT J ANTIMICROB AG, V40, P239, DOI 10.1016/j.ijantimicag.2012.05.015
   Hansen K, 2009, J CHEM INF MODEL, V49, P2077, DOI 10.1021/ci900161g
   Joshi D.C., 2011, JOVE-J VIS EXP, V23, P51
   Kaminski DM, 2014, EUR BIOPHYS J BIOPHY, V43, P453, DOI 10.1007/s00249-014-0983-8
   Karlsen M, 2014, J LABELLED COMPD RAD, V57, P378, DOI 10.1002/jlcr.3193
   Lagunin A, 2009, QSAR COMB SCI, V28, P806, DOI 10.1002/qsar.200860192
   Lezama-Davila CM, 2008, IMMUNOL CELL BIOL, V86, P539, DOI 10.1038/icb.2008.39
   Mangoni ML, 2005, J BIOL CHEM, V280, P984, DOI 10.1074/jbc.M410795200
   Mikus Judith, 2000, Parasitology International, V48, P265, DOI 10.1016/S1383-5769(99)00020-3
   Miyazawa M, 2003, J AGR FOOD CHEM, V51, P6413, DOI 10.1021/jf030247q
   Fidalgo LM, 2011, PHARM RES-DORDR, V28, P2758, DOI 10.1007/s11095-011-0586-3
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   Ouellette M, 2004, DRUG RESIST UPDATE, V7, P257, DOI 10.1016/j.drup.2004.07.002
   Rea A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002556
   Rodrigues LC, 2016, CHEM BIODIVERS, V13, P870, DOI 10.1002/cbdv.201500280
   Shen J, 2010, J CHEM INF MODEL, V50, P1034, DOI 10.1021/ci100104j
   Silva CF, 2007, BIOCHEM PHARMACOL, V73, P1939, DOI 10.1016/j.bcp.2007.03.020
   van de Waterbeemd H, 2003, NAT REV DRUG DISCOV, V2, P192, DOI 10.1038/nrd1032
   Zhang DX, 2007, AM J PHYSIOL-HEART C, V292, pH2023, DOI 10.1152/ajpheart.01283.2006
NR 35
TC 13
Z9 13
U1 0
U2 11
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0944-7113
J9 PHYTOMEDICINE
JI Phytomedicine
PD JAN 15
PY 2017
VL 24
BP 62
EP 67
DI 10.1016/j.phymed.2016.11.015
PG 6
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA EO0NF
UT WOS:000396394100008
PM 28160863
DA 2020-12-01
ER

PT J
AU Teixeira, SF
   de Azevedo, RA
   Silva, AC
   Braga, RC
   Jorge, SD
   Barbuto, JAM
   Andrade, CH
   Ferreira, AK
AF Teixeira, Sarah Fernandes
   de Azevedo, Ricardo Alexandre
   Silva, Arthur Carvalho
   Braga, Rodolpho Campos
   Jorge, Salomao Doria
   Marzagao Barbuto, Jose Alexandre
   Andrade, Carolina Horta
   Ferreira, Adilson Kleber
TI Evaluation of cytotoxic effect of the combination of a pyridinyl
   carboxamide derivative and oxaliplatin on NCI-H1299 human non-small cell
   lung carcinoma cells
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Lung cancer; Pyridinyl carboxamide derivative; Apoptosis; Synergism;
   Oxaliplatin
ID METASTATIC COLORECTAL-CANCER; TRYPANOSOMA-CRUZI CYP51; PHASE-III TRIAL;
   CHAGAS-DISEASE; 1ST-LINE TREATMENT; 4-AMINOPYRIDYL-BASED INHIBITORS;
   DRUG; EFFICACY; FLUOROURACIL; MULTICENTER
AB Even with all improvements in both diagnostic and therapeutic techniques, lung cancer remains as the most lethal and prevalent cancer in the world. Therefore, new therapeutic drugs and new strategies of drug combination are necessary to provide treatments that are more efficient. Currently, standard therapy regimen for lung cancer includes platinum drugs, such as cisplatin, oxaliplatin, and carboplatin. Besides of the better toxicity profile of oxaliplatin when compared with cisplatin, peripheral neuropathy remains as a limitation of oxaliplatin dose. This study presents LabMol-12, a new pyridinyl carboxamide derivative with antileishmanial and antichagasic activity, as a new hit for lung cancer treatment, which induces apoptosis dependent of caspases in NCI-H1299 lung cancer cells both in monolayer and 3D culture. Moreover, LabMol-12 allows a reduction of oxaliplatin dose when they are combined, thereby, it is a relevant strategy for reducing the side effects of oxaliplatin with the same response. Molecular modeling studies corroborated the biological findings and suggested that the combined therapy can provide a better therapeutically profile effects against NSCLC. All these findings support the fact that the combination of oxaliplatin and LabMol-12 is a promising drug combination for lung cancer. (C) 2016 Elsevier Masson SAS. All rights reserved.
C1 [Teixeira, Sarah Fernandes] Univ Sao Paulo, Inst Biomed Sci, Dept Pharmacol, Prof Lineu Prestes Ave 1730, Sao Paulo, SP, Brazil.
   [de Azevedo, Ricardo Alexandre; Jorge, Salomao Doria; Marzagao Barbuto, Jose Alexandre; Ferreira, Adilson Kleber] Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Lab Tumor Immunol, Prof Lineu Prestes Ave 1730, Sao Paulo, SP, Brazil.
   [Silva, Arthur Carvalho; Braga, Rodolpho Campos; Andrade, Carolina Horta] Univ Fed Goias, Fac Pharm, LabMol Lab Mol Modeling & Drug Design, 240 St, BR-74605170 Goiania, Go, Brazil.
RP Ferreira, AK (corresponding author), Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Lab Tumor Immunol, Prof Lineu Prestes Ave 1730, Sao Paulo, SP, Brazil.
EM ferreira-kleber@usp.br
RI Teixeira, Sarah Fernandes/Y-9280-2019; de Carvalho e Silva,
   Arthur/S-7803-2018; /ABB-6790-2020; Jorge, Salomao/D-8338-2013; Braga,
   Rodolpho C/A-9655-2011; Teixeira, Sarah/A-9977-2018; Barbuto, Jose A.
   M./H-5299-2011; Ferreira, Adilson/K-1991-2013; Andrade,
   Carolina/C-3960-2014; Azevedo, Ricardo Alexandre/J-7016-2014
OI Teixeira, Sarah Fernandes/0000-0002-9710-3676; de Carvalho e Silva,
   Arthur/0000-0001-9866-3344; /0000-0002-0716-2403; Jorge,
   Salomao/0000-0002-0716-2403; Braga, Rodolpho C/0000-0003-3814-3464;
   Teixeira, Sarah/0000-0002-9710-3676; Barbuto, Jose A.
   M./0000-0001-9526-6781; Ferreira, Adilson/0000-0002-2605-1899; Andrade,
   Carolina/0000-0003-0101-1492; Azevedo, Ricardo
   Alexandre/0000-0003-4381-797X
FU Sao Paulo Research Foundation - (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2009/54599-5, 2013/07273-2, 2013/05396-0,
   2014/07341-0, 2014/14267-1, 2014/24455-0, 2015/18528-7, 2016/05351-4];
   National Counsel of Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); State of Goias Research Foundation (FAPEG)
FX This work was supported by Sao Paulo Research Foundation - (FAPESP),
   grant (2009/54599-5, 2013/07273-2, 2013/05396-0, 2014/07341-0,
   2014/14267-1, 2014/24455-0 2015/18528-7 and 2016/05351-4) the National
   Counsel of Technological and Scientific Development (CNPq) and the State
   of Goias Research Foundation (FAPEG).
CR Adjei AA, 2001, CLIN CANCER RES, V7, P1438
   Al-Batran SE, 2008, J CLIN ONCOL, V26, P1435, DOI 10.1200/JCO.2007.13.9378
   Amissah F, 2014, AM J CANCER RES, V4, P116
   Appels NMGM, 2005, ONCOLOGIST, V10, P565, DOI 10.1634/theoncologist.10-8-565
   Ashley AC, 2007, CANCER, V110, P670, DOI 10.1002/cncr.22831
   Atmaca A, 2013, BRIT J CANCER, V108, P265, DOI 10.1038/bjc.2012.555
   Baines AT, 2011, FUTURE MED CHEM, V3, P1787, DOI [10.4155/FMC.11.121, 10.4155/fmc.11.121]
   BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913
   Bhatt S., 2015, CLIN T MED, V4, P1
   Bidoli P, 2007, ANN ONCOL, V18, P461, DOI 10.1093/annonc/mdl415
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1899, DOI 10.2174/1568026614666140929120749
   Buckner FS, 2012, INT J PARASITOL-DRUG, V2, P236, DOI 10.1016/j.ijpddr.2011.12.002
   Chen CK, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000372
   Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775
   Choi JY, 2014, ACS MED CHEM LETT, V5, P434, DOI 10.1021/ml500010m
   Choi JY, 2013, J MED CHEM, V56, P7651, DOI 10.1021/jm401067s
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Dans PD, 2009, J CHEM INF MODEL, V49, P1407, DOI 10.1021/ci800421w
   DITCHFIELD R, 1971, J CHEM PHYS, V54, P724, DOI 10.1063/1.1674902
   Doyle PS, 2010, ANTIMICROB AGENTS CH, V54, P2480, DOI 10.1128/AAC.00281-10
   Falcone A, 2007, J CLIN ONCOL, V25, P1670, DOI 10.1200/JCO.2006.09.0928
   Ferlay J, 2015, EUR J CANCER, V51, P1201, DOI 10.1016/j.ejca.2015.05.004
   Ferreira AK, 2016, TOXICOL APPL PHARM, V295, P56, DOI 10.1016/j.taap.2016.02.008
   Gerber D. E., 2013, J CLIN ONCOL, V43, P7459, DOI DOI 10.1200/JC0.2012.43.7459
   HAY PJ, 1985, J CHEM PHYS, V82, P270, DOI 10.1063/1.448799
   Hucke O, 2005, J MED CHEM, V48, P5415, DOI 10.1021/jm050441z
   Johnson BE, 2004, CLIN CANCER RES, V10, p4254S, DOI 10.1158/1078-0432.CCR-040016
   Kraus JM, 2010, J MED CHEM, V53, P3887, DOI 10.1021/jm9013136
   Kraus JM, 2009, J MED CHEM, V52, P1639, DOI 10.1021/jm801313t
   MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0
   Nativi C, 2013, SCI REP-UK, V3, DOI 10.1038/srep02005
   Neese F, 2012, WIRES COMPUT MOL SCI, V2, P73, DOI 10.1002/wcms.81
   Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236
   Raez LE, 2006, LUNG CANCER, V53, P347, DOI 10.1016/j.lungcan.2006.05.023
   Scagliotti GV, 2005, CLIN CANCER RES, V11, P690
   Siegel R, 2012, CA-CANCER J CLIN, V62, P220, DOI 10.3322/caac.21149
   Suvitha A, 2010, J INCL PHENOM MACRO, V66, P213, DOI 10.1007/s10847-009-9601-2
   Tekchandani P., 2016, MINI REV MED CHEM
   Tetko IV, 2009, QSAR COMB SCI, V28, P845, DOI 10.1002/qsar.200960003
   Tieche CC, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2117-4
   Tyagi P, 2008, POLYHEDRON, V27, P3567, DOI 10.1016/j.poly.2008.08.025
   Vandal G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084745
   Varbanov HP, 2013, J MED CHEM, V56, P330, DOI 10.1021/jm3016427
   Weissman CH, 2011, J THORAC ONCOL, V6, P358, DOI 10.1097/JTO.0b013e3181ffe8ef
   Wu YB, 2004, J MOL BIOL, V341, P1251, DOI 10.1016/j.jmb.2004.06.066
   Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006
   Zhang G., 2015, J BIOL CHEM M, VM115
NR 47
TC 1
Z9 1
U1 0
U2 6
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD DEC
PY 2016
VL 84
BP 1019
EP 1028
DI 10.1016/j.biopha.2016.10.025
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA EF6JU
UT WOS:000390438100118
PM 27768927
DA 2020-12-01
ER

PT J
AU Ekins, S
   Perryman, AL
   Andrade, CH
AF Ekins, Sean
   Perryman, Alexander L.
   Andrade, Carolina Horta
TI OpenZika: An IBM World Community Grid Project to Accelerate Zika Virus
   Drug Discovery
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
AB The Zika virus outbreak in the Americas has caused global concern. To help accelerate this fight against Zika, we launched the OpenZika project. OpenZika is an IBM World Community Grid Project that uses distributed computing on millions of computers and Android devices to run docking experiments, in order to dock tens of millions of drug-like compounds against crystal structures and homology models of Zika proteins (and other related flavivirus targets). This will enable the identification of new candidates that can then be tested in vitro, to advance the discovery and development of new antiviral drugs against the Zika virus. The docking data is being made openly accessible so that all members of the global research community can use it to further advance drug discovery studies against Zika and other related flaviviruses.
C1 [Ekins, Sean] Collaborat Pharmaceut Inc, Fuquay Varina, NC 27526 USA.
   [Perryman, Alexander L.] Rutgers State Univ, New Jersey Med Sch, Dept Pharmacol Physiol & Neurosci, Newark, NJ 07102 USA.
   [Andrade, Carolina Horta] Univ Fedral Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.
RP Ekins, S (corresponding author), Collaborat Pharmaceut Inc, Fuquay Varina, NC 27526 USA.; Perryman, AL (corresponding author), Rutgers State Univ, New Jersey Med Sch, Dept Pharmacol Physiol & Neurosci, Newark, NJ 07102 USA.; Andrade, CH (corresponding author), Univ Fedral Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.
EM ekinssean@yahoo.com; Alex.L.Perryman@njms.rutgers.edu; carolina@ufg.br
CR [Anonymous], 2016, WHO DIRECTOR GEN SUM
   Ekins Sean, 2016, F1000Res, V5, P275
   Ekins Sean, 2016, F1000Res, V5, P150, DOI 10.12688/f1000research.8013.1
   Ekins S, 2016, PHARM RES-DORDR, V33, P809, DOI 10.1007/s11095-015-1841-9
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Kincaid VA, 2015, ACS CHEM BIOL, V10, P2209, DOI 10.1021/acschembio.5b00370
   Malone RW, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004530
   Shan C, 2016, ACS INFECT DIS, V2, P170, DOI 10.1021/acsinfecdis.6b00030
   Sirohi D, 2016, SCIENCE, V352, P467, DOI 10.1126/science.aaf5316
NR 9
TC 16
Z9 16
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD OCT
PY 2016
VL 10
IS 10
AR e0005023
DI 10.1371/journal.pntd.0005023
PG 5
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA EA5QH
UT WOS:000386676200017
PM 27764115
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Martins, LF
   Mesquita, JT
   Pinto, EG
   Costa-Silva, TA
   Borborema, SET
   Galisteo, AJ
   Neves, BJ
   Andrade, CH
   Al Shuhaib, Z
   Bennett, EL
   Black, GP
   Harper, PM
   Evans, DM
   Fituri, HS
   Leyland, JP
   Martin, C
   Roberts, TD
   Thornhill, AJ
   Vale, SA
   Howard-Jones, A
   Thomas, DA
   Williams, HL
   Overman, LE
   Berlinck, RGS
   Murphy, PJ
   Tempone, AG
AF Martins, Ligia F.
   Mesquita, Juliana T.
   Pinto, Erika G.
   Costa-Silva, Thais A.
   Borborema, Samanta E. T.
   Galisteo Junior, Andres J.
   Neves, Bruno J.
   Andrade, Carolina H.
   Al Shuhaib, Zainab
   Bennett, Elliot L.
   Black, Gregory P.
   Harper, Philip M.
   Evans, Daniel M.
   Fituri, Hisham S.
   Leyland, John P.
   Martin, Claire
   Roberts, Terence D.
   Thornhill, Andrew J.
   Vale, Stephen A.
   Howard-Jones, Andrew
   Thomas, Dafydd A.
   Williams, Harri L.
   Overman, Larry E.
   Berlinck, Roberto G. S.
   Murphy, Patrick J.
   Tempone, Andre G.
TI Analogues of Marine Guanidine Alkaloids Are in Vitro Effective against
   Trypanosoma cruzi and Selectively Eliminate Leishmania (L.) infantum
   Intracellular Amastigotes
SO JOURNAL OF NATURAL PRODUCTS
LA English
DT Article
ID ENANTIOSELECTIVE TOTAL-SYNTHESIS; SHORT SYNTHETIC ROUTE; CUTANEOUS
   LEISHMANIASIS; BATZELLADINE ALKALOIDS; BIOLOGICAL EVALUATION; DRUGS;
   PENTOXIFYLLINE; AMAZONENSIS; MEXICANA; CORE
AB Synthetic analogues of marine sponge guanidine alkaloids showed in vitro antiparasitic activity against Leishmania (L.) infantum and Trypanosoma cruzi. Guanidines 10 and 11 presented the highest selectivity index when tested against Leishmania. The antiparasitic activity of 10 and 11 was investigated in host cells and in parasites. Both compounds induced depolarization of mitochondrial membrane potential, upregulation of reactive oxygen species levels, and increased plasma membrane permeability in Leishmania parasites. Immunomodulatory assays suggested an NO-independent effect of guanidines 10 and 11 on macrophages. The same compounds also promoted anti-inflammatory activity in L. (L.) infantum-infected macrophages cocultived with splenocytes, reducing the production of cytokines MCP-1 and IFN-gamma. Guanidines 10 and 11 affect the bioenergetic metabolism of Leishmania, with selective elimination of parasites via a host-independent mechanism.
C1 [Martins, Ligia F.; Mesquita, Juliana T.; Pinto, Erika G.; Costa-Silva, Thais A.; Borborema, Samanta E. T.; Tempone, Andre G.] Adolfo Lutz Inst, Ctr Parasitol & Mycol, Ave Dr Arnaldo 351,8 Andar, BR-01246000 Sao Paulo, SP, Brazil.
   [Pinto, Erika G.; Galisteo Junior, Andres J.] Univ Sao Paulo, Inst Med Trop, Ave Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, SP, Brazil.
   [Neves, Bruno J.; Andrade, Carolina H.] Univ Fed Goias, Lab Mol Modeling & Drug Design, LabMol, Fac Farm, Goiania, Go, Brazil.
   [Al Shuhaib, Zainab; Bennett, Elliot L.; Black, Gregory P.; Harper, Philip M.; Evans, Daniel M.; Fituri, Hisham S.; Leyland, John P.; Martin, Claire; Roberts, Terence D.; Thornhill, Andrew J.; Vale, Stephen A.; Howard-Jones, Andrew; Thomas, Dafydd A.; Williams, Harri L.; Murphy, Patrick J.] Bangor Univ, Sch Chem, Bangor LL57 2UW, Gwynedd, Wales.
   [Overman, Larry E.] Univ Calif Irvine, 4042A Frederick Reines Hall, Irvine, CA 92697 USA.
   [Berlinck, Roberto G. S.] Univ Sao Paulo, Inst Quim Sao Carlos, CP 780, BR-13560970 Sao Carlos, SP, Brazil.
RP Tempone, AG (corresponding author), Adolfo Lutz Inst, Ctr Parasitol & Mycol, Ave Dr Arnaldo 351,8 Andar, BR-01246000 Sao Paulo, SP, Brazil.
EM atempone@usp.br
RI Berlinck, Roberto G. S./G-4756-2010; Bennett, Elliot Leon L/S-1691-2018;
   Tempone, Andre/ABA-2231-2020; Neves, Bruno/R-7068-2019; Bennett, Elliot
   Leon/L-7765-2019; Tempone, Andre Gustavo/E-5932-2012; Galisteo, Andres
   J/F-6639-2012; borborema, samanta etel treiger/I-8063-2012; Neves, Bruno
   Junior/E-6295-2016; Pinto, Erika/Z-1585-2019; AlShuhaib,
   Zainab/N-6662-2019; Tempone, Andre Gustavo/E-5932-2012; Andrade,
   Carolina/C-3960-2014
OI Berlinck, Roberto G. S./0000-0003-0118-2523; Bennett, Elliot Leon
   L/0000-0003-3798-4296; Tempone, Andre/0000-0003-2559-7344; Neves,
   Bruno/0000-0002-1309-8743; Bennett, Elliot Leon/0000-0003-3798-4296;
   Tempone, Andre Gustavo/0000-0003-2559-7344; Galisteo, Andres
   J/0000-0003-1611-6721; borborema, samanta etel
   treiger/0000-0003-0696-9800; Tempone, Andre Gustavo/0000-0002-9900-1470;
   Mesquita, Juliana Tonini/0000-0002-1734-3400; Murphy,
   Patrick/0000-0002-0790-0242; Andrade, Carolina/0000-0003-0101-1492
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2012/18756-1, 2013/50228-8, 2011/23703-1,
   2013/07275-5]; Conselho Nacional de Desenvolvimento Cientifico e
   TecnologicoNational Council for Scientific and Technological Development
   (CNPq); Engineering and Physical Sciences Research CouncilEngineering &
   Physical Sciences Research Council (EPSRC) [EP/J01821X/1] Funding
   Source: researchfish
FX The authors thank the Sao Paulo Research Foundation (FAPESP) for
   financial support (grants 2012/18756-1 and 2013/50228-8 for A.G.T. and
   R.G.S.B., respectively; scholarships 2011/23703-1 and 2013/07275-5).
   A.G.T., R.G.S.B., and C.H.A. thank the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico for scientific awards. ERDF
   BEACON project (P.J.M.), the European Social Fund KESS project (E.L.B.),
   the EPSRC (G.P.B., D.A.T., D.M.E.), AstraZeneca (D.A.T.), Pfizer
   (G.P.B.), and the Libyan Authority for Research, Science & Technology
   are also gratefully acknowledged. The authors would like to thank Goias
   Research Foundation (FAPEG) and ACD/I-Laboratories for providing credits
   to use their server.
CR Agarwal KC, 2009, BIOORG MED CHEM LETT, V19, P5474, DOI 10.1016/j.bmcl.2009.07.081
   Ahmed N, 2013, CHEM BIOL DRUG DES, V81, P491, DOI [10.1111/cbdd.1427, 10.1111/j.1747-0285.2012.01427.x]
   Allingham MT, 2003, TETRAHEDRON LETT, V44, P8677, DOI 10.1016/j.tetlet.2003.09.162
   ALTUWAIJRI AS, 1990, J MED MICROBIOL, V32, P189, DOI 10.1099/00222615-32-3-189
   Santarem AAA, 2014, REV SOC BRAS MED TRO, V47, P517, DOI 10.1590/0037-8682-0202-2013
   Ansari NA, 2006, CLIN IMMUNOL, V119, P339, DOI 10.1016/j.clim.2006.01.017
   Aulner N, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002154
   Barrett MP, 2014, PARASITOLOGY, V141, P1, DOI 10.1017/S0031182013001224
   Barrosa KH, 2014, PLANTA MED, V80, P1310, DOI 10.1055/s-0034-1382994
   Bennett EL, 2013, TETRAHEDRON, V69, P3061, DOI 10.1016/j.tet.2013.01.083
   Black GP, 2001, TETRAHEDRON LETT, V42, P3377, DOI 10.1016/S0040-4039(01)00400-2
   Black GP, 1996, TETRAHEDRON LETT, V37, P6943, DOI 10.1016/0040-4039(96)01523-7
   Black GP, 1998, TETRAHEDRON, V54, P9481, DOI 10.1016/S0040-4020(98)00576-6
   Brandonisio O, 2002, CLIN EXP MED, V2, P125, DOI 10.1007/s102380200017
   Bridges H. R., 2014, BIOCHEM J, V15, P475
   Brito G, 2014, AM J TROP MED HYG, V90, P617, DOI 10.4269/ajtmh.12-0729
   Castro H, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002325
   Caukett P., 1999, J ORG CHEM, V64, P1039
   Cohen F, 2006, J AM CHEM SOC, V128, P2594, DOI 10.1021/ja0574320
   Cohen F, 2006, J AM CHEM SOC, V128, P2604, DOI 10.1021/ja057433s
   Cohen F, 1999, ORG LETT, V1, P2169, DOI 10.1021/ol991269u
   Coimbra ES, 2002, PARASITOLOGY, V124, P137, DOI 10.1017/S0031182001001056
   COLEMAN RE, 1989, ANN TROP MED PARASIT, V83, P339, DOI 10.1080/00034983.1989.11812354
   Costa DL, 2013, PATHOG GLOB HEALTH, V107, P78, DOI 10.1179/2047773213Y.0000000078
   Croft SL, 2006, CLIN MICROBIOL REV, V19, P111, DOI [10.1128/CMR.19.1.111-126.2006, 10.4103/0974-777X.62887]
   da Silva AA, 2009, FITOTERAPIA, V80, P478, DOI 10.1016/j.fitote.2009.06.007
   Dardonville C, 2003, BIOORGAN MED CHEM, V11, P3205, DOI 10.1016/S0968-0896(03)00191-3
   Santo RDD, 2014, CURR ORG CHEM, V18, P2572
   Don R, 2014, PARASITOLOGY, V141, P140, DOI 10.1017/S003118201300142X
   Franklin AS, 1999, J ORG CHEM, V64, P1512, DOI 10.1021/jo981971o
   Gonzalez JL, 2007, EUR J MED CHEM, V42, P552, DOI 10.1016/j.ejmech.2006.11.006
   Hua HM, 2004, BIOORGAN MED CHEM, V12, P6461, DOI 10.1016/j.bmc.2004.09.026
   Jhingran A, 2009, MOL BIOCHEM PARASIT, V164, P111, DOI 10.1016/j.molbiopara.2008.12.007
   Joshi D. C., 2011, J VISUALIZED EXP, V23, P2704
   Katsuno K, 2015, NAT REV DRUG DISCOV, V14, P751, DOI 10.1038/nrd4683
   KEDZIERSKI L, 2014, PARASITOLOGY, V30, P1
   Krauth-Siegel Luise R., 2007, V44, P231
   Kulkarni MM, 2013, PARASITOL RES, V112, P2095, DOI 10.1007/s00436-013-3274-x
   Lee N, 2002, CELL DEATH DIFFER, V9, P53, DOI 10.1038/sj.cdd.4400952
   Lezama-Davila CM, 2008, IMMUNOL CELL BIOL, V86, P539, DOI 10.1038/icb.2008.39
   Luque-Ortega JR, 2001, ANTIMICROB AGENTS CH, V45, P1121, DOI 10.1128/AAC.45.4.1121-1125.2001
   Mangoni ML, 2005, J BIOL CHEM, V280, P984, DOI 10.1074/jbc.M410795200
   Mehlotra RK, 1996, CRIT REV MICROBIOL, V22, P295, DOI 10.3109/10408419609105484
   Mesquita JT, 2013, ACTA TROP, V128, P666, DOI 10.1016/j.actatropica.2013.09.018
   Mikus Judith, 2000, Parasitology International, V48, P265, DOI 10.1016/S1383-5769(99)00020-3
   Fidalgo LM, 2011, PHARM RES-DORDR, V28, P2758, DOI 10.1007/s11095-011-0586-3
   Olin-Sandoval V, 2010, CURR DRUG TARGETS, V11, P1614, DOI 10.2174/1389450111009011614
   Oliveira TD, 2000, MEM I OSWALDO CRUZ, V95, P477, DOI 10.1590/S0074-02762000000400006
   Regasini LO, 2009, J NAT PROD, V72, P473, DOI 10.1021/np800612x
   Luque-Ortega JR, 2010, METHODS MOL BIOL, V618, P393, DOI 10.1007/978-1-60761-594-1_25
   Saczewski F, 2013, EXPERT OPIN THER PAT, V23, P965, DOI 10.1517/13543776.2013.788645
   Saczewski F, 2009, EXPERT OPIN THER PAT, V19, P1417, DOI 10.1517/13543770903216675
   Santos MFC, 2015, J NAT PROD, V78, P1101, DOI 10.1021/acs.jnatprod.5b00070
   SARAIVA EMB, 1989, J CELL SCI, V93, P481
   Stephens CE, 2003, BIOORG MED CHEM LETT, V13, P2065, DOI 10.1016/S0960-894X(03)00319-6
   TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3
   Tempone AG, 2011, PLANTA MED, V77, P572, DOI 10.1055/s-0030-1250663
   Tempone Andre Gustavo, 2007, Cardiovascular & Hematological Agents in Medicinal Chemistry, V5, P222
   Verma S., 2010, PLOS ONE, V9
   Vickers TJ, 2004, J BIOL CHEM, V279, P27246, DOI 10.1074/jbc.M311039200
   World Health Organization, 2015, 3 WHO
   World Health Organization Food and Agriculture Organization of the United Nations Evaluation of Certain Food Additives, 2010, WHO TECHN REP SER
NR 62
TC 20
Z9 20
U1 0
U2 27
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0163-3864
EI 1520-6025
J9 J NAT PROD
JI J. Nat. Prod.
PD SEP
PY 2016
VL 79
IS 9
BP 2202
EP 2210
DI 10.1021/acs.jnatprod.6b00256
PG 9
WC Plant Sciences; Chemistry, Medicinal; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy
GA DX1WC
UT WOS:000384156700008
PM 27586460
DA 2020-12-01
ER

PT J
AU Neves, BJ
   Dantas, RF
   Senger, MR
   Melo, CC
   Valente, WCG
   de Almeida, ACM
   Rezende-Neto, JM
   Lima, EFC
   Paveley, R
   Furnham, N
   Muratov, E
   Kamentsky, L
   Carpenter, AE
   Braga, RC
   Silva, FP
   Andrade, CH
AF Neves, Bruno J.
   Dantas, Rafael F.
   Senger, Mario R.
   Melo-Filho, Cleber C.
   Valente, Walter C. G.
   de Almeida, Ana C. M.
   Rezende-Neto, Joao M.
   Lima, Elid F. C.
   Paveley, Ross
   Furnham, Nicholas
   Muratov, Eugene
   Kamentsky, Lee
   Carpenter, Anne E.
   Braga, Rodolpho C.
   Silva-Junior, Floriano P.
   Andrade, Carolina Horta
TI Discovery of New Anti-Schistosomal Hits by Integration of QSAR-Based
   Virtual Screening and High Content Screening
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID THIOREDOXIN GLUTATHIONE-REDUCTASE; ANTICANCER DRUGS; IN-VITRO; MANSONI;
   GENOME; PRAZIQUANTEL; FEATURES; MODELS; LIGAND; SELENOCYSTEINE
AB Schistosomiasis is a debilitating neglected tropical disease, caused by flatworms of Schistosoma genus. The treatment relies on a single drug, praziquantel (PZQ), making the discovery of new compounds extremely urgent. In this work, we integrated QSAR-based virtual screening (VS) of Schistosoma mansoni thioredoxin glutathione reductase (SmTGR) inhibitors and high content screening (HCS) aiming to discover new antischistosomal agents. Initially, binary QSAR models for inhibition of SmTGR were developed and validated using the Organization for Economic Co-operation and Development (OECD) guidance. Using these models, we prioritized 29 compounds for further testing in two HCS platforms based on image analysis of assay plates. Among them, 2-[2-(3-methyl-4-nitro-5-isoxazolyl)vinyl]pyridine and 2-(benzylsulfonyl)-1,3-benzothiazole, two compounds representing new chemical scaffolds have activity against schistosomula and adult worms at low micromolar concentrations and therefore represent promising antischistosomal hits for further hit-to-lead optimization.
C1 [Neves, Bruno J.; Melo-Filho, Cleber C.; Braga, Rodolpho C.; Andrade, Carolina Horta] Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, Rua 240,Qd 87,Setor Leste Univ, BR-74605510 Goiania, Go, Brazil.
   [Dantas, Rafael F.; Senger, Mario R.; Valente, Walter C. G.; de Almeida, Ana C. M.; Rezende-Neto, Joao M.; Lima, Elid F. C.; Silva-Junior, Floriano P.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, LaBECFar Lab Bioquim Expt & Computac Farm, Ave Brasil,4365, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Paveley, Ross; Furnham, Nicholas] London Sch Hyg & Trop Med, Dept Infect & Immun, London WC1E 7HT, England.
   [Muratov, Eugene] Univ N Carolina, Eshelman Sch Pharm, Lab Mol Modeling, Chapel Hill, NC 27955 USA.
   [Kamentsky, Lee; Carpenter, Anne E.] Broad Inst Massachusetts Inst Technol & Harvard, Imaging Platform, Cambridge, MA 02142 USA.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, Rua 240,Qd 87,Setor Leste Univ, BR-74605510 Goiania, Go, Brazil.; Silva, FP (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, LaBECFar Lab Bioquim Expt & Computac Farm, Ave Brasil,4365, BR-21040900 Rio De Janeiro, RJ, Brazil.
EM floriano@ioc.fiocruz.br; carolina@ufg.br
RI Carpenter, Anne/C-4982-2008; Silva-Jr, Floriano/B-1343-2013; Neves,
   Bruno/R-7068-2019; Braga, Rodolpho C/A-9655-2011; Melo-Filho, Cleber
   C./V-1119-2018; Neves, Bruno Junior/E-6295-2016; Senger,
   Mario/B-7273-2013; Andrade, Carolina/C-3960-2014
OI Carpenter, Anne/0000-0003-1555-8261; Silva-Jr,
   Floriano/0000-0003-4560-1291; Neves, Bruno/0000-0002-1309-8743; Braga,
   Rodolpho C/0000-0003-3814-3464; Melo-Filho, Cleber
   C./0000-0003-0056-6971; Senger, Mario/0000-0003-2384-2692; Furnham,
   Nicholas/0000-0002-7532-1269; Andrade, Carolina/0000-0003-0101-1492
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [400760/2014-2]; CAPESCAPES; FAPEG; FAPERJCarlos Chagas Filho Foundation
   for Research Support of the State of Rio de Janeiro (FAPERJ); FIOCRUZ;
   Coordination for the Improvement of Higher Education Personnel
   (CAPES)CAPES; National Counsel of Technological and Scientific
   Development (CNPq)National Council for Scientific and Technological
   Development (CNPq); State of Goias Research Foundation (FAPEG); State of
   Rio de Janeiro Research Foundation (FAPERJ)Carlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ);
   U.S. National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [GM095672];
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [GM66940, GM096967]; UNC for Junior
   Faculty Development Award; Medical Research CouncilMedical Research
   Council UK (MRC) [MR/M026221/1] Funding Source: researchfish; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of General Medical Sciences (NIGMS) [R01GM096967, R01GM095672,
   R01GM066940, R01GM066940, R01GM095672, R01GM066940, R01GM096967,
   R01GM066940, R01GM066940, R01GM066940, R01GM066940, R01GM066940,
   R01GM095672, R01GM066940, R01GM095672, R01GM096967, R01GM066940,
   R01GM095672, R01GM096967] Funding Source: NIH RePORTER
FX We thank Brazilian funding agencies, CNPq, CAPES, FAPEG, FAPERJ, and
   FIOCRUZ for financial support and fellowships. We are grateful to
   ChemAxon for providing academic license of their program. We also thank
   the Malacology Laboratory (Dr. Silvana C. Thiengo) from IOC/FIOCRUZ for
   providing S. mansoni cercariae, and the Bioassays and Drug Screening
   Platform (FIOCRUZ RPT11-I subunit), and NIH R01 GM095672 (Automated
   image analysis for high-throughput phenotypic screening in
   Caenorhabditis elegans) for technological support. B.J.N. was supported
   by a fellowship from the Coordination for the Improvement of Higher
   Education Personnel (CAPES). This work has been funded by the National
   Counsel of Technological and Scientific Development (CNPq), the State of
   Goias Research Foundation (FAPEG), and State of Rio de Janeiro Research
   Foundation (FAPERJ). C.H.A. and F.P.S.Jr are CNPq productivity fellows.
   L.E.K. and A.E.C. were supported by a grant from the U.S. National
   Institutes of Health (GM095672). E.M. also acknowledges NIH (grants
   GM66940 and GM096967), CNPq (grant 400760/2014-2), and UNC for Junior
   Faculty Development Award for partial financial support. Authors also
   thank Molecular Devices for providing access to the HCS equipment. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abdulla MH, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000478
   Alger HM, 2002, MOL BIOCHEM PARASIT, V121, P129, DOI 10.1016/S0166-6851(02)00031-2
   ALTMAN NS, 1992, AM STAT, V46, P175, DOI 10.2307/2685209
   Alves V. M., 2014, 248 ACS NAT M EXP SA
   Alves VM, 2015, TOXICOL APPL PHARM, V284, P273, DOI 10.1016/j.taap.2014.12.013
   Alves VM, 2015, TOXICOL APPL PHARM, V284, P262, DOI 10.1016/j.taap.2014.12.014
   ANDERSON S, 1984, J MOL GRAPHICS, V2, P83, DOI 10.1016/0263-7855(84)80060-0
   [Anonymous], 2011, QIKPROP VERS 3 4
   Artemenko AG, 2007, J ANTIMICROB CHEMOTH, V60, P68, DOI 10.1093/jac/dkm172
   Baell J, 2014, NATURE, V513, P481, DOI 10.1038/513481a
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Barker M, 2003, J CHEMOMETR, V17, P166, DOI 10.1002/cem.785
   Berriman M, 2009, NATURE, V460, P352, DOI 10.1038/nature08160
   Bonilla M, 2008, J BIOL CHEM, V283, P17898, DOI 10.1074/jbc.M710609200
   Bonilla M, 2011, J BIOL CHEM, V286, P4959, DOI 10.1074/jbc.M110.170761
   Braga RC, 2015, MOL INFORM, V34, P698, DOI 10.1002/minf.201500040
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1899, DOI 10.2174/1568026614666140929120749
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1399, DOI 10.2174/1568026614666140506124442
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Breiman L., 1984, CLASSIFICATION REGRE
   Bueno RV, 2013, J MOL MODEL, V19, P179, DOI 10.1007/s00894-012-1527-8
   CALLAHAN HL, 1988, PARASITOL TODAY, V4, P218, DOI 10.1016/0169-4758(88)90162-7
   CARHART RE, 1985, J CHEM INF COMP SCI, V25, P64, DOI 10.1021/ci00046a002
   Cheng FX, 2012, J CHEM INF MODEL, V52, P3099, DOI 10.1021/ci300367a
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104
   Colley DG, 2014, LANCET, V383, P2253, DOI 10.1016/S0140-6736(13)61949-2
   Cowan N, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1023-y
   Dill J. D., 1981, 182 NAT M AM CHEM SO, P23
   Durant JL, 2002, J CHEM INF COMP SCI, V42, P1273, DOI 10.1021/ci010132r
   FALLON PG, 1995, AM J TROP MED HYG, V53, P61, DOI 10.4269/ajtmh.1995.53.61
   Ferreira LG, 2015, FUTURE MED CHEM, V7, P753, DOI [10.4155/FMC.15.21, 10.4155/fmc.15.21]
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Friedman JH, 2001, ANN STAT, V29, P1189, DOI 10.1214/aos/1013203451
   FRIEDMAN JH, 1991, ANN STAT, V19, P1, DOI 10.1214/aos/1176347963
   Gasco A, 2004, PURE APPL CHEM, V76, P973, DOI 10.1351/pac200476050973
   GONNERT R, 1977, Z PARASITENKD, V52, P129, DOI 10.1007/BF00389899
   Gryseels B, 2006, LANCET, V368, P1106, DOI 10.1016/S0140-6736(06)69440-3
   Hagan P, 2004, TRENDS PARASITOL, V20, P92, DOI 10.1016/j.pt.2003.11.010
   Hall SL, 2011, MOL BIOCHEM PARASIT, V179, P18, DOI 10.1016/j.molbiopara.2011.05.002
   Han YH, 2014, J PARASITOL, V100, P463, DOI 10.1645/13-397.1
   He YY, 2013, J COMPUT CHEM, V34, P604, DOI 10.1002/jcc.23173
   Huang HH, 2011, BIOCHEMISTRY-US, V50, P5870, DOI 10.1021/bi200107n
   Ingram-Sieber K, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002610
   Irwin JJ, 2015, J MED CHEM, V58, P7076, DOI 10.1021/acs.jmedchem.5b01105
   Ismail M, 1996, AM J TROP MED HYG, V55, P214, DOI 10.4269/ajtmh.1996.55.214
   Johansson L, 2005, BBA-GEN SUBJECTS, V1726, P1, DOI 10.1016/j.bbagen.2005.05.010
   Kamentsky L, 2011, BIOINFORMATICS, V27, P1179, DOI 10.1093/bioinformatics/btr095
   King CH, 2009, NEW ENGL J MED, V360, P106, DOI 10.1056/NEJMp0808041
   Kuntz AN, 2007, PLOS MED, V4, P1071, DOI 10.1371/journal.pmed.0040206
   Kuz'min VE, 2007, J MED CHEM, V50, P4205, DOI 10.1021/jm0704806
   Lagunin A, 2009, QSAR COMB SCI, V28, P806, DOI 10.1002/qsar.200860192
   Landrum G., 2014, RDKIT OPEN SOURCE CH
   Liew CY, 2011, J COMPUT AID MOL DES, V25, P855, DOI 10.1007/s10822-011-9468-3
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Long T, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004356
   Loukas A, 2008, NAT MED, V14, P365, DOI 10.1038/nm0408-365
   LoVerde PT, 1998, PARASITOL TODAY, V14, P284, DOI 10.1016/S0169-4758(98)01261-7
   Mansour NR, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004659
   Mansour NR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000795
   Marxer M, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-165
   Melman SD, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000504
   Melo CC, 2016, J CHEM INF MODEL, V56, P1357, DOI 10.1021/acs.jcim.6b00055
   Melo CC, 2014, CURR COMPUT-AID DRUG, V10, P148, DOI 10.2174/1573409910666140410111043
   MKOJI GM, 1988, INT J PARASITOL, V18, P667, DOI 10.1016/0020-7519(88)90102-6
   NARE B, 1990, EXP PARASITOL, V70, P389, DOI 10.1016/0014-4894(90)90122-S
   Nauser T, 2012, AMINO ACIDS, V42, P39, DOI 10.1007/s00726-010-0602-7
   Neves BJ, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003435
   Neves BJ, 2013, BIOORG MED CHEM LETT, V23, P2436, DOI 10.1016/j.bmcl.2013.02.006
   Neves B, 2016, MEDCHEMCOMM, V7, P1176, DOI 10.1039/c5md00596e
   Neves BJ, 2016, EXPERT OPIN DRUG DIS, V11, P557, DOI 10.1080/17460441.2016.1178230
   Organization for Economic Co-operation and Development, 2004, OECD PRINC VAL REG P
   Owen SC, 2012, ACS CHEM BIOL, V7, P1429, DOI 10.1021/cb300189b
   Panic G, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1233-3
   Panic G, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003962
   Paveley RA, 2013, PARASITE IMMUNOL, V35, P302, DOI 10.1111/pim.12037
   Paveley RA, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001762
   Protasio AV, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001455
   R Development Core Team, 2008, R LANG ENV STAT COMP
   Rai G, 2009, J MED CHEM, V52, P6474, DOI 10.1021/jm901021k
   Riniker S, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-43
   Riniker S, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-26
   Rogers D, 2010, J CHEM INF MODEL, V50, P742, DOI 10.1021/ci100050t
   Rosenblatt F., 1962, PRINCIPLES NEURODYNA
   Ross AGP, 2002, NEW ENGL J MED, V346, P1212, DOI 10.1056/NEJMra012396
   Saubern S, 2011, MOL INFORM, V30, P847, DOI 10.1002/minf.201100076
   Song LJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031456
   TIMMS AR, 1959, BRIT J PHARM CHEMOTH, V14, P68, DOI 10.1111/j.1476-5381.1959.tb00930.x
   Todeschini R., 2000, METHODS PRINCIPLES M
   Triboulet S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067831
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Vapnik V., 2000, NATURE STAT LEARNING
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Wang W, 2012, PARASITOL RES, V111, P1871, DOI 10.1007/s00436-012-3151-z
   Williams DL, 2013, ANTIOXID REDOX SIGN, V19, P735, DOI 10.1089/ars.2012.4670
   World Health Organization, 2016, SCHISTOSOMIASIS
   Yap CW, 2011, J COMPUT CHEM, V32, P1466, DOI 10.1002/jcc.21707
   Young ND, 2012, NAT GENET, V44, P221, DOI 10.1038/ng.1065
   Zakharov AV, 2014, J CHEM INF MODEL, V54, P705, DOI 10.1021/ci400737s
   Zanella F, 2010, TRENDS BIOTECHNOL, V28, P237, DOI 10.1016/j.tibtech.2010.02.005
   Zhang LY, 2013, J CHEM INF MODEL, V53, P475, DOI 10.1021/ci300421n
   Zhang SX, 2006, J CHEM INF MODEL, V46, P1984, DOI 10.1021/ci060132x
   Zhou Y, 2009, NATURE, V460, P345, DOI 10.1038/nature08140
NR 104
TC 30
Z9 30
U1 3
U2 27
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD AUG 11
PY 2016
VL 59
IS 15
BP 7075
EP 7088
DI 10.1021/acs.jmedchem.5b02038
PG 14
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA DT4LM
UT WOS:000381452600006
PM 27396732
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Melo, CC
   Dantas, RF
   Braga, RC
   Neves, BJ
   Senger, MR
   Valente, WCG
   Rezende-Neto, JM
   Chaves, WT
   Muratov, EN
   Paveley, RA
   Furnham, N
   Kamentsky, L
   Carpenter, AE
   Silva, FP
   Andrade, CH
AF Melo-Filho, Cleber C.
   Dantas, Rafael F.
   Braga, Rodolpho C.
   Neves, Bruno J.
   Senger, Mario R.
   Valente, Walter C. G.
   Rezende-Neto, Joao M.
   Chaves, Willian T.
   Muratov, Eugene N.
   Paveley, Ross A.
   Furnham, Nicholas
   Kamentsky, Lee
   Carpenter, Anne E.
   Silva-Junior, Floriano P.
   Andrade, Carolina H.
TI QSAR-Driven Discovery of Novel Chemical Scaffolds Active against
   Schistosoma mansoni
SO JOURNAL OF CHEMICAL INFORMATION AND MODELING
LA English
DT Article
ID THIOREDOXIN GLUTATHIONE-REDUCTASE; PROTEIN DATA-BANK; DRUG DISCOVERY;
   EFFICIENT GENERATION; ATOMIC CHARGES; AM1-BCC MODEL; COMFA MODELS;
   DESIGN; QUALITY; PREDICTION
AB Schistosomiasis is a neglected tropical disease that affects millions of people worldwide. Thioredoxin glutathione reductase of Schistosoma mansoni (SmTGR) is a validated drug target that plays a crucial role in the redox homeostasis of the parasite. We report the discovery of new chemical scaffolds against S. mansoni using a combi-QSAR approach followed by virtual screening of a commercial database and confirmation of top ranking compounds by in vitro experimental evaluation with automated imaging of schistosomula and adult worms. We constructed 2D and 3D quantitative structure activity relationship (QSAR) models using a series of oxadiazoles-2-oxides reported in the literature as SmTGR inhibitors and combined the best models in a consensus QSAR model. This model was used for a virtual screening of Hit2Lead set of ChemBridge database and allowed the identification of ten new potential SmTGR inhibitors. Further experimental testing on both shistosomula and adult worms showed that 4-nitro-3,5-bis(1-nitro-1H-pyrazol-4-yl)-1H-pyrdzole (LabMol-17) and 3-nitro-4-{[(4-nitro-1,2,5-oxadiazol-3-yl)oxy]methyl}-1,2,5-oxadiazole (LabMol-19), two compounds representing new chemical scaffolds, have high activity in both systems. These compounds will be the subjects for additional testing and, if necessary, modification to serve as new schistosomicidal agents.
C1 [Melo-Filho, Cleber C.; Braga, Rodolpho C.; Neves, Bruno J.; Andrade, Carolina H.] Univ Fed Goias, LabMol Lab Mol Modeling & Drug Design, Fac Pharm, Rua 240,Qd 87, BR-74605510 Goiania, Go, Brazil.
   [Dantas, Rafael F.; Senger, Mario R.; Valente, Walter C. G.; Rezende-Neto, Joao M.; Chaves, Willian T.; Silva-Junior, Floriano P.] Inst Oswaldo Cruz, Lab Expt & Computat Biochem Drugs, Av Brasil 4365, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Muratov, Eugene N.] Univ N Carolina, Lab Mol Modeling, Div Chem Biol & Med Chem, Eshelman Sch Pharm, Chapel Hill, NC 27599 USA.
   [Muratov, Eugene N.] Odessa Natl Polytech Univ, Dept Chem Technol, 1 Shevchenko Ave, UA-65000 Odessa, Ukraine.
   [Paveley, Ross A.; Furnham, Nicholas] London Sch Hyg & Trop Med, Dept Pathogen Mol Biol, London WC1E 7HT, England.
   [Paveley, Ross A.; Furnham, Nicholas] London Sch Hyg & Trop Med, Dept Infect & Immun, London WC1E 7HT, England.
   [Kamentsky, Lee; Carpenter, Anne E.] Broad Inst Massachusetts Inst Technol & Harvard, Imaging Platform, Cambridge, MA 02142 USA.
   [Muratov, Eugene N.] Univ Fed Goias, Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.
RP Andrade, CH (corresponding author), Univ Fed Goias, LabMol Lab Mol Modeling & Drug Design, Fac Pharm, Rua 240,Qd 87, BR-74605510 Goiania, Go, Brazil.; Silva, FP (corresponding author), Inst Oswaldo Cruz, Lab Expt & Computat Biochem Drugs, Av Brasil 4365, BR-21040900 Rio De Janeiro, RJ, Brazil.
EM floriano@ioc.fiocruz.br; carolina@ufg.br
RI Braga, Rodolpho C/A-9655-2011; Senger, Mario/B-7273-2013; Neves,
   Bruno/R-7068-2019; Neves, Bruno Junior/E-6295-2016; Carpenter,
   Anne/C-4982-2008; Silva-Jr, Floriano/B-1343-2013; Melo-Filho, Cleber
   C./V-1119-2018; Andrade, Carolina/C-3960-2014
OI Braga, Rodolpho C/0000-0003-3814-3464; Senger,
   Mario/0000-0003-2384-2692; Neves, Bruno/0000-0002-1309-8743; Carpenter,
   Anne/0000-0003-1555-8261; Silva-Jr, Floriano/0000-0003-4560-1291;
   Melo-Filho, Cleber C./0000-0003-0056-6971; Andrade,
   Carolina/0000-0003-0101-1492; Furnham, Nicholas/0000-0002-7532-1269
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES; FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); FAPEG; National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01 GM095672];
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [GM 096967, GM66940]; CNPqNational
   Council for Scientific and Technological Development (CNPq)
   [400760/2014-2]; UNCSecretaria de Ciencia y Tecnologia (SECYT); NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of General Medical Sciences (NIGMS) [R01GM096967, R01GM066940,
   R01GM066940, R01GM066940, R01GM066940, R01GM066940, R01GM096967,
   R01GM066940, R01GM066940, R01GM095672, R01GM096967, R01GM095672,
   R01GM066940, R01GM066940, R01GM066940, R01GM095672, R01GM095672,
   R01GM095672, R01GM096967] Funding Source: NIH RePORTER; Medical Research
   CouncilMedical Research Council UK (MRC) [MR/M026221/1] Funding Source:
   researchfish
FX The authors would like to thank Brazilian funding agencies, CNPq, CAPES,
   FAPERJ, and FAPEG for financial support and fellowships. A.E.C. and L.K
   were supported by the National Institutes of Health (R01 GM095672).
   E.N.M. thanks the NIH (GM 096967 and GM66940) and CNPq (grant
   400760/2014-2) for financial support and UNC for a Junior Faculty
   Development Award. C.H.A. is a CNPq productivity fellow. We are grateful
   for Molecular Devices for providing the HCS equipment for this study as
   well as OpenEye Scientific Software Inc. and ChemAxon for providing is
   with academic licenses for their software. The authors also thank the
   Bioassays and Drug Screening Platform (FIOCRUZ RPT11-I subunit) for
   technological support and the Malacology Laboratory (Dr. Silvana C.
   Thiengo) from IOC/FIOCRUZ for providing S. mansoni cercariae.
CR ANDERSON S, 1984, J MOL GRAPHICS, V2, P83, DOI 10.1016/0263-7855(84)80060-0
   Andrade CH, 2010, MOLECULES, V15, P3281, DOI 10.3390/molecules15053281
   Andrade CH, 2010, J COMPUT AID MOL DES, V24, P157, DOI 10.1007/s10822-010-9323-y
   Angelucci F, 2008, PROTEINS, V72, P936, DOI 10.1002/prot.21986
   Angelucci F, 2010, J BIOL CHEM, V285, P32557, DOI 10.1074/jbc.M110.141960
   [Anonymous], 2014, MAESTR VERS 10 0
   [Anonymous], 2013, OMEGA 2 5 1 4
   [Anonymous], 2014, EP VERS 3 0
   [Anonymous], 2015, ROCS 3 2 1 4
   [Anonymous], 2015, MARVINSKETCH 15 10 2
   [Anonymous], 2015, OEDOCKING 3 2 0 2
   [Anonymous], 2013, QUACPAC 1 6 3 1
   [Anonymous], 2014, LIGPREP VERS 3 2
   [Anonymous], 2010, SYBYL X 1 2
   Bajorath J, 2012, BIOORGAN MED CHEM, V20, P5316, DOI 10.1016/j.bmc.2012.08.051
   Banks JL, 2005, J COMPUT CHEM, V26, P1752, DOI 10.1002/jcc.20292
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Berriman M, 2009, NATURE, V460, P352, DOI 10.1038/nature08160
   Bisignano P, 2015, J CHEM INF MODEL, V55, P1836, DOI 10.1021/acs.jcim.5b00388
   Bohm Hans-Joachim, 2004, Drug Discov Today Technol, V1, P217, DOI 10.1016/j.ddtec.2004.10.009
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1899, DOI 10.2174/1568026614666140929120749
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1399, DOI 10.2174/1568026614666140506124442
   Caffrey CR, 2007, CURR OPIN CHEM BIOL, V11, P433, DOI 10.1016/j.cbpa.2007.05.031
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Colley DG, 2014, LANCET, V383, P2253, DOI 10.1016/S0140-6736(13)61949-2
   Cramer RD, 2003, J MED CHEM, V46, P374, DOI 10.1021/jm020194o
   CRAMER RD, 1988, J AM CHEM SOC, V110, P5959, DOI 10.1021/ja00226a005
   Dill J. D., 1981, 182 NAT M AM CHEM SO, P23
   Doweyko AM, 2004, J COMPUT AID MOL DES, V18, P587, DOI 10.1007/s10822-004-4068-0
   Duffy BC, 2012, BIOORGAN MED CHEM, V20, P5324, DOI 10.1016/j.bmc.2012.04.062
   Durant JL, 2002, J CHEM INF COMP SCI, V42, P1273, DOI 10.1021/ci010132r
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Gardiner EJ, 2011, FUTURE MED CHEM, V3, P405, DOI [10.4155/FMC.11.4, 10.4155/fmc.11.4]
   Gasco A, 2004, PURE APPL CHEM, V76, P973, DOI 10.1351/pac200476050973
   GASTEIGER J, 1978, TETRAHEDRON LETT, P3181
   Gryseels B, 2006, LANCET, V368, P1106, DOI 10.1016/S0140-6736(06)69440-3
   Gryseels B, 2012, INFECT DIS CLIN N AM, V26, P383, DOI 10.1016/j.idc.2012.03.004
   Ha H, 2015, J CHEM INF MODEL, V55, P1720, DOI 10.1021/acs.jcim.5b00181
   Hagan P, 2004, TRENDS PARASITOL, V20, P92, DOI 10.1016/j.pt.2003.11.010
   Han YH, 2014, J PARASITOL, V100, P463, DOI 10.1645/13-397.1
   Hawkins PCD, 2007, J MED CHEM, V50, P74, DOI 10.1021/jm0603365
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Heikamp K, 2012, FUTURE MED CHEM, V4, P1945, DOI [10.4155/FMC.12.126, 10.4155/fmc.12.126]
   Ingram-Sieber K, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002610
   Iskar M, 2012, CURR OPIN BIOTECH, V23, P609, DOI 10.1016/j.copbio.2011.11.010
   Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613
   Jacobson MP, 2002, J MOL BIOL, V320, P597, DOI 10.1016/S0022-2836(02)00470-9
   Jain AN, 2004, J MED CHEM, V47, P947, DOI 10.1021/jm030520f
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Jakalian A, 2000, J COMPUT CHEM, V21, P132, DOI 10.1002/(SICI)1096-987X(20000130)21:2<132::AID-JCC5>3.0.CO;2-P
   Jorgensen WL, 2012, ANGEW CHEM INT EDIT, V51, P11680, DOI 10.1002/anie.201204625
   Jorgensen WL, 2004, SCIENCE, V303, P1813, DOI 10.1126/science.1096361
   Kamentsky L, 2011, BIOINFORMATICS, V27, P1179, DOI 10.1093/bioinformatics/btr095
   Kroemer RT, 1998, QSAR THR DIM QUAN ST, V3, P41
   Kubinyi H, 1997, DRUG DISCOV TODAY, V2, P457, DOI 10.1016/S1359-6446(97)01079-9
   Kuntz AN, 2007, PLOS MED, V4, P1071, DOI 10.1371/journal.pmed.0040206
   Kuz'min VE, 2005, J MOL MODEL, V11, P457, DOI 10.1007/s00894-005-0237-x
   LINDBERG W, 1983, ANAL CHEM, V55, P643, DOI 10.1021/ac00255a014
   Loukas A, 2008, NAT MED, V14, P365, DOI 10.1038/nm0408-365
   Lowis D. R., 1997, TRIPOS TECHNICAL NOT, V1, P1
   Mansour NR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000795
   Marxer M, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-165
   Melo CC, 2014, CURR COMPUT-AID DRUG, V10, P148, DOI 10.2174/1573409910666140410111043
   NARE B, 1991, INT J PARASITOL, V21, P919, DOI 10.1016/0020-7519(91)90167-6
   Neves BJ, 2015, MOLECULES, V20, P1872, DOI 10.3390/molecules20021872
   Neves BJ, 2013, BIOORG MED CHEM LETT, V23, P2436, DOI 10.1016/j.bmcl.2013.02.006
   Paveley RA, 2013, PARASITE IMMUNOL, V35, P302, DOI 10.1111/pim.12037
   Paveley RA, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001762
   Protasio AV, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001455
   PURCELL WP, 1967, J CHEM ENG DATA, V12, P235, DOI 10.1021/je60033a020
   Rai G, 2009, J MED CHEM, V52, P6474, DOI 10.1021/jm901021k
   Ramirez B, 2007, EXPERT OPIN DRUG DIS, V2, pS53, DOI 10.1517/17460441.2.S1.S53
   Sayed AA, 2008, NAT MED, V14, P407, DOI 10.1038/nm1737
   Seel M, 1999, QUANT STRUCT-ACT REL, V18, P245, DOI 10.1002/(SICI)1521-3838(199907)18:3<245::AID-QSAR245>3.0.CO;2-O
   Shelley JC, 2007, J COMPUT AID MOL DES, V21, P681, DOI 10.1007/s10822-007-9133-z
   Song LJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031456
   Sun HM, 2012, DRUG DISCOV TODAY, V17, P310, DOI 10.1016/j.drudis.2011.10.024
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Tsai KC, 2010, EUR J MED CHEM, V45, P1544, DOI 10.1016/j.ejmech.2009.12.063
   van de Waterbeemd H, 2003, NAT REV DRUG DISCOV, V2, P192, DOI 10.1038/nrd1032
   Wang W, 2012, PARASITOL RES, V111, P1871, DOI 10.1007/s00436-012-3151-z
   Wold S, 2001, CHEMOMETR INTELL LAB, V58, P109, DOI 10.1016/S0169-7439(01)00155-1
   World Health Organization, 2012, PROGR REP 2001 2011
   Zanella F, 2010, TRENDS BIOTECHNOL, V28, P237, DOI 10.1016/j.tibtech.2010.02.005
NR 85
TC 28
Z9 28
U1 1
U2 16
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1549-9596
EI 1549-960X
J9 J CHEM INF MODEL
JI J. Chem Inf. Model.
PD JUL
PY 2016
VL 56
IS 7
BP 1357
EP 1372
DI 10.1021/acs.jcim.6b00055
PG 16
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Computer Science,
   Information Systems; Computer Science, Interdisciplinary Applications
SC Pharmacology & Pharmacy; Chemistry; Computer Science
GA DS1ZA
UT WOS:000380422500012
PM 27253773
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Alves, V
   Zakharov, A
   Muratov, E
   Fourches, D
   Kleinstreuer, N
   Strickland, J
   Andrade, C
   Tropsha, A
AF Alves, Vinicius
   Zakharov, Alexey
   Muratov, Eugene
   Fourches, Denis
   Kleinstreuer, Nicole
   Strickland, Judy
   Andrade, Carolina
   Tropsha, Alexander
TI Development and application of multiclass QSAR models for predicting
   human skin sensitization
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 [Zakharov, Alexey] NCI, CADD Grp, Biol Chem Lab, Ctr Canc Res, Frederick, MD 21701 USA.
   [Alves, Vinicius; Andrade, Carolina] Univ Fed Goias, Fac Pharm, Goiania, Go, Brazil.
   [Alves, Vinicius; Muratov, Eugene; Tropsha, Alexander] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC USA.
   [Kleinstreuer, Nicole; Strickland, Judy] ILS Inc, NICEATM, Res Triangle Pk, NC USA.
   [Fourches, Denis] North Carolina State Univ, Dept Chem, Chapel Hill, NC USA.
   [Fourches, Denis] North Carolina State Univ, Bioinformat Res Ctr, Chapel Hill, NC USA.
EM viniciusm.alves@gmail.com
RI Fourches, Denis/H-4336-2019; Alves, Vinicius M./G-7955-2015; Tropsha,
   Alexander/AAB-8324-2020; Kleinstreuer, Nicole/F-7203-2019
OI Alves, Vinicius M./0000-0002-6182-1748; Kleinstreuer,
   Nicole/0000-0002-7914-3682
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 13
PY 2016
VL 251
MA 40
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA VC1WO
UT WOS:000431903804847
DA 2020-12-01
ER

PT J
AU Alves, VM
   Capuzzi, SJ
   Muratov, EN
   Braga, RC
   Thornton, TE
   Fourches, D
   Strickland, J
   Kleinstreuer, N
   Andrade, CH
   Tropsha, A
AF Alves, Vinicius M.
   Capuzzi, Stephen J.
   Muratov, Eugene N.
   Braga, Rodolpho C.
   Thornton, Thomas E.
   Fourches, Denis
   Strickland, Judy
   Kleinstreuer, Nicole
   Andrade, Carolina H.
   Tropsha, Alexander
TI QSAR models of human data can enrich or replace LLNA testing for human
   skin sensitization
SO GREEN CHEMISTRY
LA English
DT Article
ID LYMPH-NODE ASSAY; DIVERSE ORGANIC-CHEMICALS; ALLERGIC
   CONTACT-DERMATITIS; INSULT PATCH TEST; RISK-ASSESSMENT; HAZARD
   IDENTIFICATION; GREEN CHEMISTRY; APPLICABILITY DOMAIN; CHEMOGENOMICS
   DATA; MAXIMIZATION TEST
AB Skin sensitization is a major environmental and occupational health hazard. Although many chemicals have been evaluated in humans, there have been no efforts to model these data to date. We have compiled, curated, analyzed, and compared the available human and LLNA data. Using these data, we have developed reliable computational models and applied them for the virtual screening of chemical libraries to identify putative skin sensitizers. The overall concordance between murine LLNA and human skin sensitization responses for a set of 135 unique chemicals was low (R = 28-43%), although several chemical classes had high concordance. We have succeeded to develop predictive QSAR models of all available human data with the external correct classification rate of 71%. A consensus model integrating concordant QSAR predictions and LLNA results afforded a higher CCR of 82% but at the expense of the reduced external dataset coverage (52%). We used the developed QSAR models for the virtual screening of the CosIng database and identified 1061 putative skin sensitizers; for seventeen of these compounds, we found published evidence of their skin sensitization effects. Models reported herein provide more accurate alternatives to LLNA testing for human skin sensitization assessment across diverse chemical data. In addition, they can also be used to guide the structural optimization of toxic compounds to reduce their skin sensitization potential.
C1 [Alves, Vinicius M.; Capuzzi, Stephen J.; Muratov, Eugene N.; Thornton, Thomas E.; Tropsha, Alexander] Univ N Carolina, UNC Eshelman Sch Pharm, Div Chem Biol & Med Chem, Lab Mol Modeling, Chapel Hill, NC 27599 USA.
   [Alves, Vinicius M.; Braga, Rodolpho C.; Andrade, Carolina H.] Univ Fed Goias, Lab Mol Modeling & Design, Fac Pharm, BR-74605170 Goiania, Go, Brazil.
   [Muratov, Eugene N.] Odessa Natl Polytech Univ, Dept Chem Technol, UA-65000 Odessa, Ukraine.
   [Fourches, Denis] North Carolina State Univ, Bioinformat Res Ctr, Dept Chem, Raleigh, NC 27695 USA.
   [Strickland, Judy] Integrated Lab Syst Inc, POB 13501, Res Triangle Pk, NC 27709 USA.
   [Kleinstreuer, Nicole] Natl Inst Environm Hlth Sci, Res Triangle Pk, NC 27709 USA.
   [Tropsha, Alexander] Kazan Fed Univ, AM Butlerov Inst Chem, 18 Kremlyovskaya Str, Kazan 420008, Russia.
RP Tropsha, A (corresponding author), Univ N Carolina, UNC Eshelman Sch Pharm, Div Chem Biol & Med Chem, Lab Mol Modeling, Chapel Hill, NC 27599 USA.; Tropsha, A (corresponding author), Kazan Fed Univ, AM Butlerov Inst Chem, 18 Kremlyovskaya Str, Kazan 420008, Russia.
EM alex_tropsha@unc.edu
RI Kleinstreuer, Nicole/F-7203-2019; Tropsha, Alexander/AAB-8324-2020;
   Alves, Vinicius M./G-7955-2015; Braga, Rodolpho C/A-9655-2011; Fourches,
   Denis/H-4336-2019; Andrade, Carolina/C-3960-2014
OI Kleinstreuer, Nicole/0000-0002-7914-3682; Alves, Vinicius
   M./0000-0002-6182-1748; Braga, Rodolpho C/0000-0003-3814-3464; Andrade,
   Carolina/0000-0003-0101-1492
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [GM096967]; FAPEG [201310267001095];
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [400760/2014-2]; Russian Scientific FoundationRussian Science Foundation
   (RSF) [14-43-00024]; Russian Government Program for Competitive Growth
   of the Kazan Federal University; NIEHS, NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Environmental Health Sciences (NIEHS)
   [HHSN273201500010C]; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [R01GM096967, R01GM096967, R01GM096967,
   R01GM096967] Funding Source: NIH RePORTER
FX This study was supported in part by NIH (GM096967), FAPEG (grant
   201310267001095), CNPq (grant 400760/2014-2), Russian Scientific
   Foundation (Agreement No. 14-43-00024 from October 1, 2014) and Russian
   Government Program for Competitive Growth of the Kazan Federal
   University. J. S. is supported by the NIEHS, NIH under Contract No.
   HHSN273201500010C to ILS in support of NICEATM. ILS staff provide
   technical support for NICEATM, but do not represent NIEHS, NTP, or the
   official positions of any federal agency. This article may be the work
   product of an employee or a group of employees of the NIEHS, NIH, or
   other organizations; however, the statements, opinions, or conclusions
   contained therein do not necessarily represent the statements, opinions,
   or conclusions of NIEHS, NIH, the United States government, or other
   organizations. The use of commercial product names is for comparative
   purposes only and does not constitute endorsement by any of the authors,
   organizations, or agencies. The authors express sincere gratitude to Drs
   Vladimir Poroikov, Dmitri Filimonov, and Alexey Zakharov for providing
   the GUSAR software.
CR Ade Nadege, 2006, J Immunotoxicol, V3, P189, DOI 10.1080/15476910600978038
   Adler S, 2011, ARCH TOXICOL, V85, P367, DOI 10.1007/s00204-011-0693-2
   Alves VM, 2016, GREEN CHEM, V18, P4348, DOI [10.1039/C6GC01492E, 10.1039/c6gc01492e]
   Alves VM, 2015, TOXICOL APPL PHARM, V284, P273, DOI 10.1016/j.taap.2014.12.013
   Alves VM, 2015, TOXICOL APPL PHARM, V284, P262, DOI 10.1016/j.taap.2014.12.014
   Anastas P, 2010, CHEM SOC REV, V39, P301, DOI 10.1039/b918763b
   Anderson Stacey E, 2011, J Allergy (Cairo), V2011, P424203, DOI 10.1155/2011/424203
   Api A. M., 2014, CUTAN OCUL TOXICOL, V34, P1
   Ashikaga T, 2006, TOXICOL IN VITRO, V20, P767, DOI 10.1016/j.tiv.2005.10.012
   Asturiol D, 2016, TOXICOL IN VITRO, V36, P197, DOI 10.1016/j.tiv.2016.07.014
   Bailey J, 2014, ATLA-ALTERN LAB ANIM, V42, P181, DOI 10.1177/026119291404200306
   Baker NC, 2010, J BIOMED INFORM, V43, P510, DOI 10.1016/j.jbi.2010.03.008
   Basketter DA, 2015, HUM EXP TOXICOL, V34, P1222, DOI 10.1177/0960327115601760
   Basketter DA, 2000, CONTACT DERMATITIS, V42, P344, DOI 10.1034/j.1600-0536.2000.042006344.x
   Basketter DA, 2002, FOOD CHEM TOXICOL, V40, P593, DOI 10.1016/S0278-6915(01)00130-2
   Basketter D, 2016, REGUL TOXICOL PHARM, V74, P105, DOI 10.1016/j.yrtph.2015.11.013
   Basketter DA, 2014, DERMATITIS, V25, P11, DOI 10.1097/DER.0000000000000003
   Basketter DA, 2009, CUTAN OCUL TOXICOL, V28, P49, DOI 10.1080/15569520902938032
   Bishop P. L., 2012, ENV HLTH PERSPECT, VC, P1631
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1399, DOI 10.2174/1568026614666140506124442
   Burton GA, 2002, HUM ECOL RISK ASSESS, V8, P1657, DOI 10.1080/20028091057547
   Casati S., 2016, 27752 EUR EN
   Chaudhry Q, 2010, CHEM CENT J, V4, DOI 10.1186/1752-153X-4-S1-S5
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Cockshott A, 2006, HUM EXP TOXICOL, V25, P387, DOI 10.1191/0960327106ht640oa
   Collins T, 2003, GREEN CHEM, V5, pG51, DOI 10.1039/b307694f
   Dearden JC, 2015, CHEM RES TOXICOL, V28, P1975, DOI 10.1021/acs.chemrestox.5b00197
   Dearden J. C., 2016, IJQSPR, V1, P1, DOI DOI 10.4018/IJQSPR.2016010101
   DeVito SC, 2016, GREEN CHEM, V18, P4332, DOI 10.1039/c6gc00526h
   Dumont C, 2016, TOXICOL IN VITRO, V34, P220, DOI 10.1016/j.tiv.2016.04.008
   Dunn PJ, 2012, CHEM SOC REV, V41, P1452, DOI 10.1039/c1cs15041c
   *EPA, 2003, HLTH EFF TEST GUID O
   Estrada E, 2003, CHEM RES TOXICOL, V16, P1226, DOI 10.1021/tx034093k
   EURL ECVAM, 2013, REC DIR PEPT REACT A
   European Commission, 2013, AN TEST MARK BAN STA
   European Union, 2007, OFF J EUR UNION, P3
   Fedorowicz A, 2005, CHEM RES TOXICOL, V18, P954, DOI 10.1021/tx0497806
   Fedorowicz A, 2004, INT J MOL SCI, V5, P56, DOI 10.3390/i5020056
   Filimonov DA, 2009, SAR QSAR ENVIRON RES, V20, P679, DOI 10.1080/10629360903438370
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Fyhrquist N, 2014, CURR OPIN ALLERGY CL, V14, P430, DOI 10.1097/ACI.0000000000000092
   GADALETA D, 2016, INT J QUANT STRUCT P, V1, P45, DOI DOI 10.4018/IJQSPR.2016010102
   Gerberick G F, 2001, Am J Contact Dermat, V12, P156, DOI 10.1053/ajcd.2001.23926
   Gerberick GF, 2004, TOXICOL SCI, V81, P332, DOI 10.1093/toxsci/kfh213
   Golla S, 2009, TOXICOL IN VITRO, V23, P454, DOI 10.1016/j.tiv.2008.12.025
   Gramatica P, 2016, GREEN CHEM, V18, P4393, DOI 10.1039/c5gc02818c
   Griem P, 2003, REGUL TOXICOL PHARM, V38, P269, DOI 10.1016/j.yrtph.2003.07.001
   Griffith J. F., 1969, TOXICOL APPL PHARM, V14, P90
   Gunturi SB, 2010, SAR QSAR ENVIRON RES, V21, P305, DOI 10.1080/10629361003773955
   Hartung T, 2013, ALTEX-ALTERN ANIM EX, V30, P275, DOI 10.14573/altex.2013.3.275
   Helgee EA, 2010, J CHEM INF MODEL, V50, P677, DOI 10.1021/ci900471e
   Hennino Ana, 2005, An. Bras. Dermatol., V80, P335, DOI 10.1590/S0365-05962005000400003
   Hoffmann S, 2015, ALTEX-ALTERN ANIM EX, V32, P379, DOI [10.14573/altex.1505051, http://dx.doi.org/10.14573/altex.1505051]
   ICCVAM, 2009, RED MUR LOC LYMPH NO
   ICCVAM, 2013, EV NON SKIN SENS TES
   ICCVAM and NICEATM, 1999, MUR LOC LYMPH NOD AS
   Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM), 2011, US LIM MUR LOC LYMPH
   Kimber I, 2001, TOXICOL SCI, V59, P198, DOI 10.1093/toxsci/59.2.198
   Kligman A M, 1975, Contact Dermatitis, V1, P231, DOI 10.1111/j.1600-0536.1975.tb05389.x
   KLIGMAN AM, 1966, J INVEST DERMATOL, V47, P369, DOI 10.1038/jid.1966.158
   KLIGMAN AM, 1966, J INVEST DERMATOL, V47, P393, DOI 10.1038/jid.1966.160
   Kostal J, 2016, CHEM RES TOXICOL, V29, P58, DOI 10.1021/acs.chemrestox.5b00392
   Kuz'min VE, 2008, J COMPUT AID MOL DES, V22, P403, DOI 10.1007/s10822-008-9179-6
   Kuz'min VE, 2009, QSAR COMB SCI, V28, P664, DOI 10.1002/qsar.200860117
   Lagunin A, 2011, MOL INFORM, V30, P241, DOI 10.1002/minf.201000151
   Lagunin A, 2009, QSAR COMB SCI, V28, P806, DOI 10.1002/qsar.200860192
   Langley G, 2015, ENVIRON HEALTH PERSP, V123, pA268, DOI 10.1289/ehp.1510345
   Li SQ, 2005, J CHEM INF MODEL, V45, P952, DOI 10.1021/ci050049u
   Li Y, 2007, CHEM RES TOXICOL, V20, P114, DOI 10.1021/tx6002535
   Lu J, 2011, J COMPUT AID MOL DES, V25, P885, DOI 10.1007/s10822-011-9472-7
   Macan J, 2013, DERMATOLOGY, V227, P321, DOI 10.1159/000354763
   MacKay C, 2013, ALTEX-ALTERN ANIM EX, V30, P473, DOI 10.14573/altex.2013.4.473
   Maertens A, 2014, ALTEX-ALTERN ANIM EX, V31, P243, DOI 10.14573/altex.1406181
   MAGNUSSON B, 1969, J INVEST DERMATOL, V52, P268, DOI 10.1038/jid.1969.42
   Mangipudy R, 2014, REGUL TOXICOL PHARM, V70, P439, DOI 10.1016/j.yrtph.2014.07.014
   MARZULLI FN, 1976, CONTACT DERMATITIS, V2, P325, DOI 10.1111/j.1600-0536.1976.tb03069.x
   Mathea M, 2016, MOL INFORM, V35, P160, DOI 10.1002/minf.201501019
   Matura M, 2005, CONTACT DERMATITIS, V52, P320, DOI 10.1111/j.0105-1873.2005.00605.x
   Melnikov F, 2016, GREEN CHEM, V18, P4432, DOI 10.1039/c6gc00720a
   Miller MD, 2005, J CHEM INF MODEL, V45, P924, DOI 10.1021/ci050018z
   Nandy A, 2013, SAR QSAR ENVIRON RES, V24, P1009, DOI 10.1080/1062936X.2013.821422
   Nandy A, 2014, MOL SIMULAT, V40, P261, DOI 10.1080/08927022.2013.801076
   Nandy A, 2013, MOL SIMULAT, V39, P432, DOI 10.1080/08927022.2012.738421
   Naven RT, 2015, HUM EXP TOXICOL, V34, P1304, DOI 10.1177/0960327115605440
   OECD, 2012, ADV OUTC PATHW SKI 1
   Patlewicz G, 2014, REGUL TOXICOL PHARM, V69, P529, DOI 10.1016/j.yrtph.2014.06.001
   Politano VT, 2008, REGUL TOXICOL PHARM, V52, P35, DOI 10.1016/j.yrtph.2007.11.004
   Ramirez T, 2014, TOXICOL IN VITRO, V28, P1482, DOI 10.1016/j.tiv.2014.08.002
   Reisinger K, 2015, TOXICOL IN VITRO, V29, P259, DOI 10.1016/j.tiv.2014.10.018
   Roberts DW, 2007, CHEM RES TOXICOL, V20, P1321, DOI 10.1021/tx700169w
   Roberts DW, 2007, CHEM RES TOXICOL, V20, P1019, DOI 10.1021/tx700024w
   Roberts DW, 2006, CHEM RES TOXICOL, V19, P1228, DOI 10.1021/tx060102o
   Roberts DW, 2015, REGUL TOXICOL PHARM, V71, P437, DOI 10.1016/j.yrtph.2015.01.009
   Ryan CA, 2000, CONTACT DERMATITIS, V43, P95, DOI 10.1034/j.1600-0536.2000.043002095.x
   Schneider K, 2004, REGUL TOXICOL PHARM, V39, P245, DOI 10.1016/j.yrtph.2004.02.002
   SCHOLES EW, 1992, J APPL TOXICOL, V12, P217, DOI 10.1002/jat.2550120312
   Schulte PA, 2013, ENVIRON HEALTH-GLOB, V12, DOI 10.1186/1476-069X-12-31
   SCHWARTZ L, 1946, J Natl Assoc Chirop, V36, P7
   Sheridan RP, 2014, J CHEM INF MODEL, V54, P1083, DOI 10.1021/ci500084w
   Strickland J, 2016, J APPL TOXICOL, V36, P1150, DOI 10.1002/jat.3281
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Urbisch D, 2016, TOXICOL IN VITRO, V34, P194, DOI 10.1016/j.tiv.2016.04.005
   Urbisch D, 2015, REGUL TOXICOL PHARM, V71, P337, DOI 10.1016/j.yrtph.2014.12.008
   van der Veen JW, 2014, REGUL TOXICOL PHARM, V69, P371, DOI 10.1016/j.yrtph.2014.04.018
   Varnek A, 2008, CURR COMPUT-AID DRUG, V4, P191, DOI 10.2174/157340908785747465
   Vocanson M, 2006, INT ARCH ALLERGY IMM, V140, P231, DOI 10.1159/000093248
   Wang XS, 2008, J CHEM INF MODEL, V48, P997, DOI 10.1021/ci700404c
   Yuan H, 2009, INT J MOL SCI, V10, P3237, DOI 10.3390/ijms10073237
   Zakharov AV, 2016, MOL PHARMACEUT, V13, P545, DOI 10.1021/acs.molpharmaceut.5b00762
   Zakharov AV, 2014, J CHEM INF MODEL, V54, P713, DOI 10.1021/ci400704f
   Zakharov AV, 2012, CHEM RES TOXICOL, V25, P2378, DOI 10.1021/tx300247r
   Zhu H, 2008, J CHEM INF MODEL, V48, P766, DOI 10.1021/ci700443v
   Zimmerman JB, 2014, TOXICOL SCI, V141, P4, DOI 10.1093/toxsci/kfu135
NR 115
TC 19
Z9 20
U1 0
U2 7
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1463-9262
EI 1463-9270
J9 GREEN CHEM
JI Green Chem.
PY 2016
VL 18
IS 24
BP 6501
EP 6515
DI 10.1039/c6gc01836j
PG 15
WC Chemistry, Multidisciplinary; Green & Sustainable Science & Technology
SC Chemistry; Science & Technology - Other Topics
GA EE1LA
UT WOS:000389341800011
PM 28630595
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Neves, BJ
   Muratov, E
   Machado, RB
   Andrade, CH
   Cravo, PVL
AF Neves, Bruno Junior
   Muratov, Eugene
   Machado, Renato Beilner
   Andrade, Carolina Horta
   Lemos Cravo, Pedro Vitor
TI Modern approaches to accelerate discovery of new antischistosomal drugs
SO EXPERT OPINION ON DRUG DISCOVERY
LA English
DT Review
DE Schistosomiasis; drug discovery; computer-aided molecular design;
   automated assays; data quality; virtual screening; perspectives
ID MOLECULAR-DYNAMICS SIMULATIONS; VIRTUAL SCREENING STRATEGIES;
   SCHISTOSOMA-MANSONI; HIGH-THROUGHPUT; IN-VITRO; PHARMACOPHORE MODELS;
   PROTEIN FLEXIBILITY; INHIBITORS; ASSAY; GENOME
AB Introduction: The almost exclusive use of only praziquantel for the treatment of schistosomiasis has raised concerns about the possible emergence of drug-resistant schistosomes. Consequently, there is an urgent need for new antischistosomal drugs. The identification of leads and the generation of high quality data are crucial steps in the early stages of schistosome drug discovery projects.
   Areas covered: Herein, the authors focus on the current developments in antischistosomal lead discovery, specifically referring to the use of automated in vitro target-based and whole-organism screens and virtual screening of chemical databases. They highlight the strengths and pitfalls of each of the above-mentioned approaches, and suggest possible roadmaps towards the integration of several strategies, which may contribute for optimizing research outputs and led to more successful and cost-effective drug discovery endeavors.
   Expert opinion: Increasing partnerships and access to funding for drug discovery have strengthened the battle against schistosomiasis in recent years. However, the authors believe this battle also includes innovative strategies to overcome scientific challenges. In this context, significant advances of in vitro screening as well as computer-aided drug discovery have contributed to increase the success rate and reduce the costs of drug discovery campaigns. Although some of these approaches were already used in current antischistosomal lead discovery pipelines, the integration of these strategies in a solid workflow should allow the production of new treatments for schistosomiasis in the near future.
C1 [Neves, Bruno Junior; Andrade, Carolina Horta] Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.
   [Muratov, Eugene] Univ N Carolina, Eshelman Sch Pharm, Lab Mol Modeling, Chapel Hill, NC USA.
   [Machado, Renato Beilner; Lemos Cravo, Pedro Vitor] Univ Fed Goias, Inst Patol Trop & Saude Publ, GenoBio Lab Genom & Biotechnol, Goiania, Go, Brazil.
   [Lemos Cravo, Pedro Vitor] Univ Nova Lisboa, Inst Higiene & Med Trop, P-1200 Lisbon, Portugal.
RP Cravo, PVL (corresponding author), Univ Fed Goias, Inst Patol Trop & Saude Publ, GenoBio Lab Genom & Biotechnol, Goiania, Go, Brazil.; Cravo, PVL (corresponding author), Univ Nova Lisboa, Inst Higiene & Med Trop, P-1200 Lisbon, Portugal.
EM pedrovcravo@gmail.com
RI Neves, Bruno Junior/E-6295-2016; Neves, Bruno/R-7068-2019; Cravo, Pedro
   VL/G-3532-2012; Andrade, Carolina/C-3960-2014
OI Neves, Bruno/0000-0002-1309-8743; Cravo, Pedro VL/0000-0003-1675-4504;
   Andrade, Carolina/0000-0003-0101-1492
FU Brazilian funding agency, CNPqNational Council for Scientific and
   Technological Development (CNPq); Brazilian funding agency, CAPESCAPES;
   Brazilian funding agency, FAPEG; NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [GM 096967,
   GM66940]; CNPqNational Council for Scientific and Technological
   Development (CNPq) [400760/2014-2]; UNC; NATIONAL INSTITUTE OF GENERAL
   MEDICAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [R01GM066940, R01GM096967,
   R01GM066940, R01GM096967, R01GM066940, R01GM096967, R01GM066940,
   R01GM066940, R01GM096967, R01GM066940, R01GM066940, R01GM066940,
   R01GM066940, R01GM066940] Funding Source: NIH RePORTER
FX The authors would like to thank Brazilian funding agencies, CNPq, CAPES,
   and FAPEG, for financial support and fellowships. E Muratov thanks the
   financial support from NIH (GM 096967 and GM66940), CNPq (grant
   400760/2014-2), and UNC for Junior Faculty Development Award. CH Andrade
   and PVL Cravo are Research Fellows in productivity of CNPq. The authors
   have no other relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Alves VM, 2015, TOXICOL APPL PHARM, V284, P262, DOI 10.1016/j.taap.2014.12.014
   Asarnow D, 2015, BIOINFORMATICS, V31, P1515, DOI 10.1093/bioinformatics/btu831
   Asarnow DE, 2013, IEEE T MED IMAGING, V32, P1007, DOI 10.1109/TMI.2013.2247412
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Berriman M, 2009, NATURE, V460, P352, DOI 10.1038/nature08160
   Borhani DW, 2012, J COMPUT AID MOL DES, V26, P15, DOI 10.1007/s10822-011-9517-y
   Braga RC, 2015, MOL INFORM, V34, P698, DOI 10.1002/minf.201500040
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1899, DOI 10.2174/1568026614666140929120749
   Braga RC, 2013, CURR TOP MED CHEM, V13, P1127, DOI 10.2174/1568026611313090010
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Caffrey CR, 2011, CURR OPIN INFECT DIS, V24, P410, DOI 10.1097/QCO.0b013e328349156f
   Caporuscio F, 2011, CURR MED CHEM, V18, P2543, DOI 10.2174/092986711795933669
   Cereto-Massague A, 2015, METHODS, V71, P58, DOI 10.1016/j.ymeth.2014.08.005
   Cerqueira NMFSA, 2015, ARCH BIOCHEM BIOPHYS, V582, P56, DOI 10.1016/j.abb.2015.05.011
   Chang CY, 2013, J CHEM INF MODEL, V53, P958, DOI 10.1021/ci4000536
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Colley DG, 2014, LANCET, V383, P2253, DOI 10.1016/S0140-6736(13)61949-2
   Dahlin JL, 2014, FUTURE MED CHEM, V6, P1265, DOI [10.4155/fmc.14.60, 10.4155/FMC.14.60]
   Drwal Malgorzata N, 2013, Drug Discov Today Technol, V10, pe395, DOI 10.1016/j.ddtec.2013.02.002
   Dubois F, 2009, MOL BIOCHEM PARASIT, V168, P7, DOI 10.1016/j.molbiopara.2009.06.001
   FALLON PG, 1995, AM J TROP MED HYG, V53, P61, DOI 10.4269/ajtmh.1995.53.61
   Ferreira LG, 2015, MOLECULES, V20, P13384, DOI 10.3390/molecules200713384
   Ferreira LG, 2015, FUTURE MED CHEM, V7, P753, DOI [10.4155/FMC.15.21, 10.4155/fmc.15.21]
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Frearson JA, 2009, DRUG DISCOV TODAY, V14, P1150, DOI 10.1016/j.drudis.2009.09.004
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   Geary TG, 2015, J PARASITOL, V101, P125, DOI 10.1645/14-703.1
   Ghemtio L, 2012, COMB CHEM HIGH T SCR, V15, P749, DOI 10.2174/138620712803519707
   Goldmann D, 2014, FUTURE MED CHEM, V6, P503, DOI 10.4155/fmc.14.13
   GONNERT R, 1977, Z PARASITENKD, V52, P129, DOI 10.1007/BF00389899
   Hotez PJ, 2016, ANNU REV MED, V67, P405, DOI 10.1146/annurev-med-051214-024241
   Hou XB, 2015, J CHEM INF MODEL, V55, P1973, DOI 10.1021/acs.jcim.5b00344
   Howe S, 2015, ANTIMICROB AGENTS CH, V59, P1193, DOI 10.1128/AAC.03809-14
   Huang N, 2006, J MED CHEM, V49, P6789, DOI 10.1021/jm0608356
   Ismail M, 1996, AM J TROP MED HYG, V55, P214, DOI 10.4269/ajtmh.1996.55.214
   Jacques SA, 2015, J MED CHEM, V58, P3582, DOI 10.1021/acs.jmedchem.5b00203
   Kalliokoski T, 2009, J CHEM INF MODEL, V49, P2742, DOI 10.1021/ci900364w
   Kannan S, 2014, J CHEM INF MODEL, V54, P3005, DOI 10.1021/ci5004653
   Kar S, 2013, EXPERT OPIN DRUG DIS, V8, P245, DOI 10.1517/17460441.2013.761204
   Karthikeyan M, 2015, COMB CHEM HIGH T SCR, V18, P528, DOI 10.2174/1386207318666150703111911
   Keiser J, 2010, PARASITOLOGY, V137, P589, DOI 10.1017/S0031182009991739
   Koes DR, 2014, J COMPUT CHEM, V35, P1824, DOI 10.1002/jcc.23690
   Kortagere S, 2009, TRENDS PHARMACOL SCI, V30, P138, DOI 10.1016/j.tips.2008.12.001
   Kuhn I, 2010, BIOORGAN MED CHEM, V18, P7900, DOI 10.1016/j.bmc.2010.09.041
   Kuntz AN, 2007, PLOS MED, V4, P1071, DOI 10.1371/journal.pmed.0040206
   Lalli C, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003484
   Lavecchia A, 2013, CURR MED CHEM, V20, P2839, DOI 10.2174/09298673113209990001
   Liao CZ, 2011, FUTURE MED CHEM, V3, P1057, DOI [10.4155/FMC.11.63, 10.4155/fmc.11.63]
   Lin JH, 2011, CURR TOP MED CHEM, V11, P171, DOI 10.2174/156802611794863580
   Lionta E, 2014, CURR TOP MED CHEM, V14, P1923, DOI 10.2174/1568026614666140929124445
   Liu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064984
   Liu J, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-162
   Liu TQ, 2007, NUCLEIC ACIDS RES, V35, pD198, DOI 10.1093/nar/gkl999
   Manneck T, 2011, J CLIN MICROBIOL, V49, P1217, DOI 10.1128/JCM.02382-10
   Mansour NR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000795
   Marcellino C, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001494
   Marek M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003645
   Marxer M, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-165
   Muegge I, 2016, EXPERT OPIN DRUG DIS, V11, P137, DOI 10.1517/17460441.2016.1117070
   Muratov EN, 2012, MOL INFORM, V31, P202, DOI 10.1002/minf.201100129
   Muratov EN, 2010, FUTURE MED CHEM, V2, P1205, DOI 10.4155/FMC.10.194
   Nantasenamat C, 2015, EXPERT OPIN DRUG DIS, V10, P321, DOI 10.1517/17460441.2015.1016497
   Neves BJ, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003435
   Njoroge M, 2014, CHEM REV, V114, P11138, DOI 10.1021/cr500098f
   Nwaka S, 2006, NAT REV DRUG DISCOV, V5, P941, DOI 10.1038/nrd2144
   Panic G, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1233-3
   Paveley RA, 2013, PARASITE IMMUNOL, V35, P302, DOI 10.1111/pim.12037
   Paveley RA, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001762
   Peak E, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000759
   Pirhadi S, 2013, CURR TOP MED CHEM, V13, P1036, DOI 10.2174/1568026611313090006
   Postigo MP, 2010, J CHEM INF MODEL, V50, P1693, DOI 10.1021/ci100128k
   Protasio AV, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001455
   Ramirez B, 2007, EXPERT OPIN DRUG DIS, V2, pS53, DOI 10.1517/17460441.2.S1.S53
   Rees S, 2015, FUTURE MED CHEM, V7, P1835, DOI 10.4155/fmc.15.125
   Rinaldi G, 2015, INT J PARASITOL-DRUG, V5, P141, DOI 10.1016/j.ijpddr.2015.07.002
   Ripphausen P, 2011, DRUG DISCOV TODAY, V16, P372, DOI 10.1016/j.drudis.2011.02.011
   Rose PW, 2015, NUCLEIC ACIDS RES, V43, pD345, DOI 10.1093/nar/gku1214
   Salsbury FR, 2010, CURR OPIN PHARMACOL, V10, P738, DOI 10.1016/j.coph.2010.09.016
   Sayed AA, 2008, NAT MED, V14, P407, DOI 10.1038/nm1737
   Schierz AC, 2009, J CHEMINFORMATICS, V1, DOI 10.1186/1758-2946-1-21
   Scior T, 2012, J CHEM INF MODEL, V52, P867, DOI 10.1021/ci200528d
   Simeonov A, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000127
   Smout MJ, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000885
   Stroud R. M., 2007, COMPUTATIONAL APPROA, P24
   Tanrikulu Y, 2013, DRUG DISCOV TODAY, V18, P358, DOI 10.1016/j.drudis.2013.01.007
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Uniting to Combat NTDs, LOND DECL
   van de Waterbeemd H, 2003, NAT REV DRUG DISCOV, V2, P192, DOI 10.1038/nrd1032
   Vapnik V.N., 1995, NATURE STAT LEARNING, DOI [10.1007/978-1-4757-3264-1, DOI 10.1007/978-1-4757-3264-1]
   Vuorinen A, 2015, METHODS, V71, P113, DOI 10.1016/j.ymeth.2014.10.013
   Wang W, 2012, PARASITOL RES, V111, P1871, DOI 10.1007/s00436-012-3151-z
   Wang YL, 2012, NUCLEIC ACIDS RES, V40, pD400, DOI 10.1093/nar/gkr1132
   Williams AJ, 2011, DRUG DISCOV TODAY, V16, P747, DOI 10.1016/j.drudis.2011.07.007
   World Health Organization, SCHISTOSOMIASIS
   Xu Mengang, 2013, Drug Discov Today Technol, V10, pe411, DOI 10.1016/j.ddtec.2013.02.003
   Young ND, 2012, NAT GENET, V44, P221, DOI 10.1038/ng.1065
   Zakharov AV, 2014, J CHEM INF MODEL, V54, P705, DOI 10.1021/ci400737s
   Zhou Y, 2009, NATURE, V460, P345, DOI 10.1038/nature08140
   Zhu T, 2013, J MED CHEM, V56, P6560, DOI 10.1021/jm301916b
NR 100
TC 9
Z9 9
U1 0
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1746-0441
EI 1746-045X
J9 EXPERT OPIN DRUG DIS
JI Expert. Opin. Drug Discov.
PY 2016
VL 11
IS 6
BP 557
EP 567
DI 10.1080/17460441.2016.1178230
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DL7RZ
UT WOS:000375839100004
PM 27073973
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Alves, VM
   Muratov, EN
   Capuzzi, SJ
   Politi, R
   Low, Y
   Braga, RC
   Zakharov, AV
   Sedykh, A
   Mokshyna, E
   Farag, S
   Andrade, CH
   Kuz'min, VE
   Fourches, D
   Tropsha, A
AF Alves, Vinicius M.
   Muratov, Eugene N.
   Capuzzi, Stephen J.
   Politi, Regina
   Low, Yen
   Braga, Rodolpho C.
   Zakharov, Alexey V.
   Sedykh, Alexander
   Mokshyna, Elena
   Farag, Sherif
   Andrade, Carolina H.
   Kuz'min, Victor E.
   Fourches, Denis
   Tropsha, Alexander
TI Alarms about structural alerts
SO GREEN CHEMISTRY
LA English
DT Article
ID READ-ACROSS; QSAR MODELS; SIMPLEX REPRESENTATION; MOLECULAR-STRUCTURE;
   SKIN SENSITIZATION; CHEMICAL-STRUCTURE; TOXICITY; PREDICTION;
   CARCINOGENICITY; NITROAROMATICS
AB Structural alerts are widely accepted in chemical toxicology and regulatory decision support as a simple and transparent means to flag potential chemical hazards or group compounds into categories for read-across. However, there has been a growing concern that alerts disproportionally flag chemicals as toxic, which questions their reliability as toxicity markers. Conversely, rigorously developed and properly validated statistical QSAR models can accurately and reliably predict the toxicity of a chemical; however, their use in regulatory toxicology has been hampered by a lack of transparency and interpretability. We demonstrate that contrary to the common perception of QSAR models as "black boxes" they can be used to identify statistically significant chemical substructures (QSAR-based alerts) that influence toxicity. We show through several case studies, however, that the mere presence of structural alerts in a chemical, irrespective of the derivation method (expert-based or QSAR-based), should be perceived only as hypotheses of possible toxicological effect. We propose a new approach that synergistically integrates structural alerts and rigorously validated QSAR models for a more transparent and accurate safety assessment of new chemicals.
C1 [Alves, Vinicius M.; Muratov, Eugene N.; Capuzzi, Stephen J.; Politi, Regina; Farag, Sherif; Tropsha, Alexander] Univ N Carolina, Lab Mol Modeling, Div Chem Biol & Med Chem, UNC Eshelman Sch Pharm, Chapel Hill, NC 27599 USA.
   [Alves, Vinicius M.; Braga, Rodolpho C.; Andrade, Carolina H.] Univ Fed Goias, Dept Pharm, Lab Mol Modeling & Design, BR-74605170 Goiania, Go, Brazil.
   [Muratov, Eugene N.] Odessa Natl Polytech Univ, Dept Chem Technol, UA-65000 Odessa, Ukraine.
   [Low, Yen] Netflix, San Francisco, CA 94123 USA.
   [Zakharov, Alexey V.] NIH, NCATS, Rockville, MD 20850 USA.
   [Sedykh, Alexander] Sciome LLC, Res Triangle Pk, NC 27709 USA.
   [Mokshyna, Elena; Kuz'min, Victor E.] NAS Ukraine, AV Bogatsky Phys Chem Inst, Lab Theoret Chem, UA-65080 Odessa, Ukraine.
   [Fourches, Denis] North Carolina State Univ, Dept Chem, Raleigh, NC 27695 USA.
   [Fourches, Denis] North Carolina State Univ, Bioinformat Res Ctr, Raleigh, NC 27695 USA.
RP Tropsha, A (corresponding author), Univ N Carolina, Lab Mol Modeling, Div Chem Biol & Med Chem, UNC Eshelman Sch Pharm, Chapel Hill, NC 27599 USA.
EM alex_tropsha@unc.edu
RI Mokshyna, Olena/K-2068-2019; Fourches, Denis/H-4336-2019; Braga,
   Rodolpho C/A-9655-2011; Tropsha, Alexander/AAB-8324-2020; Alves,
   Vinicius M./G-7955-2015; Andrade, Carolina/C-3960-2014
OI Mokshyna, Olena/0000-0002-9712-2535; Braga, Rodolpho
   C/0000-0003-3814-3464; Alves, Vinicius M./0000-0002-6182-1748; Andrade,
   Carolina/0000-0003-0101-1492; Farag, Sherif/0000-0002-0324-5738;
   Fourches, Denis/0000-0001-5642-8303
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [GM096967]; FAPEG [201310267001095];
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [400760/2014-2]; CAPESCAPES; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [R01GM096967, R01GM096967, R01GM096967,
   R01GM096967] Funding Source: NIH RePORTER
FX This study was supported in part by NIH (GM096967). VA thanks FAPEG
   (grant 201310267001095), CNPq (grant 400760/2014-2), and CAPES.
CR Ajmani S, 2006, J CHEM INF MODEL, V46, P24, DOI 10.1021/ci0501286
   Allen TEH, 2014, CHEM RES TOXICOL, V27, P2100, DOI 10.1021/tx500345j
   Alves VM, 2015, TOXICOL APPL PHARM, V284, P273, DOI 10.1016/j.taap.2014.12.013
   Alves VM, 2015, TOXICOL APPL PHARM, V284, P262, DOI 10.1016/j.taap.2014.12.014
   Artemenko AG, 2007, J ANTIMICROB CHEMOTH, V60, P68, DOI 10.1093/jac/dkm172
   Artemenko AG, 2011, SAR QSAR ENVIRON RES, V22, P575, DOI 10.1080/1062936X.2011.569950
   ASHBY J, 1985, ENVIRON MUTAGEN, V7, P919, DOI 10.1002/em.2860070613
   ASHBY J, 1991, MUTAT RES, V257, P229, DOI 10.1016/0165-1110(91)90003-E
   ASHBY J, 1988, MUTAT RES, V204, P17, DOI 10.1016/0165-1218(88)90114-0
   Ball N, 2016, ALTEX-ALTERN ANIM EX, V33, P149, DOI 10.14573/altex.1601251
   Baskin II, 2002, SAR QSAR ENVIRON RES, V13, P35, DOI 10.1080/10629360290002073
   Benfenati E, 2015, SAR QSAR ENVIRON RES, V26, P605, DOI 10.1080/1062936X.2015.1078408
   Benigni R, 2006, CURR COMPUT-AID DRUG, V2, P169, DOI 10.2174/157340906777441663
   Blagg J., 2010, BURGERS MED CHEM DRU, P301
   Braga RC, 2015, MOL INFORM, V34, P698, DOI 10.1002/minf.201500040
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1399, DOI 10.2174/1568026614666140506124442
   Burden N, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002156
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Collins T, 2003, GREEN CHEM, V5, pG51, DOI 10.1039/b307694f
   Cronin MTD, 2013, ISSUES TOXICOL, V17, P155, DOI 10.1039/9781849734400-00155
   Cronin M. T. D., 2013, CHEM TOXICITY PREDIC, P1
   Diepgen T, 2012, KANERVAS OCCUPATIONA, P51
   Enoch SJ, 2013, ISSUES TOXICOL, V17, P30, DOI 10.1039/9781849734400-00030
   Enoch SJ, 2010, CHEM RES TOXICOL, V23, P1547, DOI 10.1021/tx100218h
   Enoch SJ, 2008, CHEM RES TOXICOL, V21, P513, DOI 10.1021/tx700322g
   European Court of Human Rights, 2007, OFF J EUR UNION, P3
   Gonzalez C, 2003, COGNITIVE SCI, V27, P591, DOI 10.1016/S0364-0213(03)00031-4
   Greek R, 2013, INT J MED SCI, V10, P206, DOI 10.7150/ijms.5529
   Hewitt M, 2013, CRIT REV TOXICOL, V43, P537, DOI 10.3109/10408444.2013.811215
   Kuz'min VE, 2008, J COMPUT AID MOL DES, V22, P403, DOI 10.1007/s10822-008-9179-6
   Kuz'min VE, 2008, CHEMOSPHERE, V72, P1373, DOI 10.1016/j.chemosphere.2008.04.045
   Kuz'min VE, 2005, SAR QSAR ENVIRON RES, V16, P219, DOI 10.1080/10659360500037206
   Kuz'min VE, 2002, ACTA BIOCHIM POL, V49, P157
   Kuz'min VE, 2008, J COMPUT AID MOL DES, V22, P747, DOI 10.1007/s10822-008-9211-x
   Kuz'min VE, 2007, J MED CHEM, V50, P4205, DOI 10.1021/jm0704806
   Kuz'min VE, 2011, MOL INFORM, V30, P593, DOI 10.1002/minf.201000173
   Kuz'min VE, 2009, QSAR COMB SCI, V28, P664, DOI 10.1002/qsar.200860117
   Li QY, 2008, MOL PHARMACEUT, V5, P117, DOI 10.1021/mp700124e
   Liu RF, 2015, J CHEMINFORMATICS, V7, DOI 10.1186/s13321-015-0053-y
   Low Y. S., 2015, J AM MED INFORM ASSN
   Low Y, 2013, CHEM RES TOXICOL, V26, P1199, DOI 10.1021/tx400110f
   Lozano S, 2010, J CHEM INF MODEL, V50, P1330, DOI 10.1021/ci100092x
   MCGREGOR D, 1989, MUTAT RES, V222, P302, DOI 10.1016/0165-1218(89)90103-1
   Mitcheson JS, 2000, P NATL ACAD SCI USA, V97, P12329, DOI 10.1073/pnas.210244497
   Muratov EN, 2011, FUTURE MED CHEM, V3, P15, DOI 10.4155/FMC.10.278
   Muratov EN, 2010, FUTURE MED CHEM, V2, P1205, DOI 10.4155/FMC.10.194
   Naven RT, 2015, HUM EXP TOXICOL, V34, P1304, DOI 10.1177/0960327115605440
   OECD, 2009, REP WORKSH STRUCT AL
   OECD, 2014, QSAR TOOLB V 3 2
   OECD Environment Health and Safety Publications, 2009, GUID DOC US OECD Q S, P5
   OXEA, 2013, N HEPTANOL
   Patlewicz G, 2015, REGUL TOXICOL PHARM, V72, P117, DOI 10.1016/j.yrtph.2015.03.015
   Patlewicz G, 2014, ALTEX-ALTERN ANIM EX, V31, P387, DOI 10.14573/altex.1410071
   Picard S, 2011, CARDIOVASC TOXICOL, V11, P285, DOI 10.1007/s12012-011-9133-z
   Pizzo F, 2015, CHEM CENT J, V9, DOI 10.1186/s13065-015-0139-7
   Polishchuk PG, 2013, MOL INFORM, V32, P843, DOI 10.1002/minf.201300029
   Politi R, 2014, TOXICOL APPL PHARM, V280, P177, DOI 10.1016/j.taap.2014.07.009
   Price N, 2014, FOOD CHEM TOXICOL, V71, P136, DOI 10.1016/j.fct.2014.05.022
   RANNAR S, 1994, J CHEMOMETR, V8, P111, DOI 10.1002/cem.1180080204
   Raunio H, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00033
   Ridings JE, 1996, TOXICOLOGY, V106, P267, DOI 10.1016/0300-483X(95)03190-Q
   ROSENKRANZ HS, 1990, MUTAGENESIS, V5, P333, DOI 10.1093/mutage/5.4.333
   Schulte PA, 2013, ENVIRON HEALTH-GLOB, V12, DOI 10.1186/1476-069X-12-31
   Springer C, 2013, CHEM CENT J, V7, DOI 10.1186/1752-153X-7-167
   Stanton DT, 2012, CURR COMPUT-AID DRUG, V8, P107
   Stepan AF, 2011, CHEM RES TOXICOL, V24, P1345, DOI 10.1021/tx200168d
   Sushko I, 2012, J CHEM INF MODEL, V52, P2310, DOI 10.1021/ci300245q
   Tinkov OV, 2016, STRUCT CHEM, V27, P191, DOI 10.1007/s11224-015-0715-4
   Tropsha A, 2003, QSAR COMB SCI, V22, P69, DOI 10.1002/qsar.200390007
   Zakharov AV, 2012, CHEM RES TOXICOL, V25, P2378, DOI 10.1021/tx300247r
NR 70
TC 45
Z9 46
U1 2
U2 26
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1463-9262
EI 1463-9270
J9 GREEN CHEM
JI Green Chem.
PY 2016
VL 18
IS 16
BP 4348
EP 4360
DI 10.1039/c6gc01492e
PG 13
WC Chemistry, Multidisciplinary; Green & Sustainable Science & Technology
SC Chemistry; Science & Technology - Other Topics
GA DT4HM
UT WOS:000381440800004
PM 28503093
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Neves, B
   Dantas, RF
   Senger, MR
   Valente, WCG
   Rezende-Neto, JD
   Chaves, WT
   Kamentsky, L
   Carpenter, A
   Silva, FP
   Andrade, CH
AF Neves, Bruno Junior
   Dantas, Rafael Ferreira
   Senger, Mario Roberto
   Goes Valente, Walter Cesar
   Rezende-Neto, Joao de Mello
   Chaves, Willian Tavora
   Kamentsky, Lee
   Carpenter, Anne
   Silva-Junior, Floriano Paes
   Andrade, Carolina Horta
TI The antidepressant drug paroxetine as a new lead candidate in
   schistosome drug discovery
SO MEDCHEMCOMM
LA English
DT Article
ID SEROTONIN TRANSPORTER; DOPAMINE TRANSPORTER; MANSONI; PRAZIQUANTEL;
   SUSCEPTIBILITY; GENERATION; RESISTANCE; PROGRAM; MODEL; ASSAY
AB Recently, our in silico repositioning-chemogenomics approach predicted paroxetine (PAR), an antidepressant drug, as a inhibitor of Schistosoma mansoni serotonin transporters (SmSERTs), and consequently, a new anti-schistosomal candidate. With the aim of determining the anti-schistosomal activity of this drug, we initially used a spectrophotometric assay to determine activity against schistosomula worms. During this investigation, we verified that PAR showed a pronounced effect on schistosomula viability (IC50 = 2.5 mu M) after 72 h of incubation. Then, we performed ex vivo studies with adult S. mansoni worms using a new automated image-based assay to accurately measure worm motility. As expected from the PAR's predicted mechanism of action, both male and female worms treated with low concentrations of PAR exhibited enhanced motility followed by reduction in motility as incubation time increased. PAR EC50 values for motility reduction in male and female worms were 5.1 mu M and 9.9 mu M after 24 h of exposure, respectively, and this effect was maintained until the end of the experiment (72 h). Lastly, homology modeling and docking studies with SmSERT-A and human SERT (hSERT) revealed insights into the chemical basis of PAR anti-schistosomal activity. These results provide crucial guidance for further studies to optimize PAR in terms of potency and selectivity.
C1 [Neves, Bruno Junior; Andrade, Carolina Horta] Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Design, Goiania, Go, Brazil.
   [Dantas, Rafael Ferreira; Senger, Mario Roberto; Goes Valente, Walter Cesar; Rezende-Neto, Joao de Mello; Chaves, Willian Tavora; Silva-Junior, Floriano Paes] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, LaBECFar Lab Bioquim Expt & Computac Farmacos, Rio De Janeiro, RJ, Brazil.
   [Kamentsky, Lee; Carpenter, Anne] Broad Inst Massachusetts Inst Technol & Harvard, Imaging Platform, Cambridge, MA USA.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Design, Goiania, Go, Brazil.; Silva, FP (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, LaBECFar Lab Bioquim Expt & Computac Farmacos, Rio De Janeiro, RJ, Brazil.
EM floriano@ioc.fiocruz.br; carolina@ufg.br
RI Neves, Bruno/R-7068-2019; Neves, Bruno Junior/E-6295-2016; Senger,
   Mario/B-7273-2013; Silva-Jr, Floriano/B-1343-2013; Andrade,
   Carolina/C-3960-2014
OI Neves, Bruno/0000-0002-1309-8743; Senger, Mario/0000-0003-2384-2692;
   Silva-Jr, Floriano/0000-0003-4560-1291; Andrade,
   Carolina/0000-0003-0101-1492
FU Brazilian funding agency, CNPqNational Council for Scientific and
   Technological Development (CNPq); Brazilian funding agency, CAPESCAPES;
   Brazilian funding agency, FAPEG; Brazilian funding agency, FAPERJCarlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Brazilian funding agency, FIOCRUZ; US National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [NIH GM095672]
FX The authors would like to thank Brazilian funding agencies, CNPq, CAPES,
   FAPEG, FAPERJ and FIOCRUZ for financial support and fellowships, as well
   as the US National Institutes of Health (grant NIH GM095672 to AEC). We
   are grateful to OpenEye Scientific Software Inc. for providing academic
   license of their software. The authors also thank the Malacology
   Laboratory (Dr. Silvana C. Thiengo) from IOC/FIOCRUZ for providing S.
   mansoni cercarie and the Bioassays and Drug Screening Platform (FIOCRUZ
   RPT11-I subunit) for technological support. Special thanks to Molecular
   Devices for providing acess to HCS equipment.
CR Abdulla MH, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000478
   Angelucci F, 2011, CURR TOP MED CHEM, V11, P2012, DOI 10.2174/156802611796575939
   Aragon AD, 2009, MOL BIOCHEM PARASIT, V164, P57, DOI 10.1016/j.molbiopara.2008.11.007
   Banks JL, 2005, J COMPUT CHEM, V26, P1752, DOI 10.1002/jcc.20292
   Benson DA, 2013, NUCLEIC ACIDS RES, V41, pD36, DOI [10.1093/nar/gkr1202, 10.1093/nar/gkt1030, 10.1093/nar/gks1195]
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Boyle JP, 2005, J PARASITOL, V91, P542, DOI 10.1645/GE-432R
   Boyle JP, 2000, EXP PARASITOL, V94, P217, DOI 10.1006/expr.2000.4500
   Cioli D, 2014, MOL BIOCHEM PARASIT, V195, P23, DOI 10.1016/j.molbiopara.2014.06.002
   Colley DG, 2014, LANCET, V383, P2253, DOI 10.1016/S0140-6736(13)61949-2
   COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916
   Couto FFB, 2011, MEM I OSWALDO CRUZ, V106, P153, DOI 10.1590/S0074-02762011000200006
   Cowan N, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1023-y
   Darmon Michele, 2015, Prog Mol Biol Transl Sci, V132, P97, DOI 10.1016/bs.pmbts.2015.02.009
   FALLON PG, 1995, AM J TROP MED HYG, V53, P61, DOI 10.4269/ajtmh.1995.53.61
   FALLON PG, 1994, AM J TROP MED HYG, V51, P83, DOI 10.4269/ajtmh.1994.51.83
   Fontana ACK, 2009, EUR J PHARMACOL, V616, P48, DOI 10.1016/j.ejphar.2009.06.023
   GONNERT R, 1977, Z PARASITENKD, V52, P129, DOI 10.1007/BF00389899
   Gryseels B, 2006, LANCET, V368, P1106, DOI 10.1016/S0140-6736(06)69440-3
   Hoffman BJ, 1998, FRONT NEUROENDOCRIN, V19, P187, DOI 10.1006/frne.1998.0168
   Ingram-Sieber K, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002610
   Ismail M, 1996, AM J TROP MED HYG, V55, P214, DOI 10.4269/ajtmh.1996.55.214
   Ismail Magdi M., 1994, Journal of the Egyptian Society of Parasitology, V24, P685
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Kamentsky L, 2011, BIOINFORMATICS, V27, P1179, DOI 10.1093/bioinformatics/btr095
   King CH, 2009, NEW ENGL J MED, V360, P106, DOI 10.1056/NEJMp0808041
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Mansour NR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000795
   MANSOUR TE, 1984, ADV PARASIT, V23, P1, DOI 10.1016/S0065-308X(08)60284-5
   Marxer M, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-165
   McGann M, 2012, J COMPUT AID MOL DES, V26, P897, DOI 10.1007/s10822-012-9584-8
   McGann M, 2011, J CHEM INF MODEL, V51, P578, DOI 10.1021/ci100436p
   McGann MR, 2003, BIOPOLYMERS, V68, P76, DOI 10.1002/bip.10207
   Melman SD, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000504
   Neves BJ, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003435
   OpenEye Scientific Software Inc, 2013, QUACPAC V 1 6 3
   OpenEye Scientific Software Inc, 2012, OEDOCKING V 3 0 1
   OpenEye Scientific Software Inc, 2013, OMEGA V 2 5 1
   Panic G, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1233-3
   Panic G, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003962
   Patocka N, 2007, MOL BIOCHEM PARASIT, V154, P125, DOI 10.1016/j.molbiopara.2007.03.010
   Patocka N, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003878
   Patocka N, 2013, MOL BIOCHEM PARASIT, V187, P32, DOI 10.1016/j.molbiopara.2012.11.008
   Paveley RA, 2013, PARASITE IMMUNOL, V35, P302, DOI 10.1111/pim.12037
   Penmatsa A, 2015, NAT STRUCT MOL BIOL, V22, P506, DOI 10.1038/nsmb.3029
   Penmatsa A, 2013, NATURE, V503, P85, DOI 10.1038/nature12533
   Pica-Mattoccia L, 2004, INT J PARASITOL, V34, P527, DOI 10.1016/j.ijpara.2003.12.003
   RAHMAN MS, 1985, EXP PARASITOL, V60, P10, DOI 10.1016/S0014-4894(85)80018-7
   Ribeiro P, 2013, PARASITOL INT, V62, P629, DOI 10.1016/j.parint.2013.06.003
   Ross AGP, 2002, NEW ENGL J MED, V346, P1212, DOI 10.1056/NEJMra012396
   SABAH AA, 1986, EXP PARASITOL, V61, P294, DOI 10.1016/0014-4894(86)90184-0
   Schmidt T, 2014, DRUG DISCOV TODAY, V19, P890, DOI 10.1016/j.drudis.2013.10.027
   Shelley JC, 2007, J COMPUT AID MOL DES, V21, P681, DOI 10.1007/s10822-007-9133-z
   Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008
   World Health Organization, 2015, SCHISTOSOMIASIS
NR 55
TC 11
Z9 11
U1 0
U2 5
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-2503
EI 2040-2511
J9 MEDCHEMCOMM
JI MedChemComm
PY 2016
VL 7
IS 6
BP 1176
EP 1182
DI 10.1039/c5md00596e
PG 7
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA DP1JJ
UT WOS:000378246000015
OA Green Published
DA 2020-12-01
ER

PT J
AU Braga, RC
   Alves, VM
   Silva, MFB
   Muratov, E
   Fourches, D
   Liao, LM
   Tropsha, A
   Andrade, CH
AF Braga, Rodolpho C.
   Alves, Vinicius M.
   Silva, Meryck F. B.
   Muratov, Eugene
   Fourches, Denis
   Liao, Luciano M.
   Tropsha, Alexander
   Andrade, Carolina H.
TI Pred-hERG: A Novel web-Accessible Computational Tool for Predicting
   Cardiac Toxicity
SO MOLECULAR INFORMATICS
LA English
DT Article
DE hERG; QSAR models; web-Server; Screening
ID POTASSIUM CHANNEL; DRUG
AB The blockage of the hERG K+ channels is closely associated with lethal cardiac arrhythmia. The notorious ligand promiscuity of this channel earmarked hERG as one of the most important antitargets to be considered in early stages of drug development process. Herein we report on the development of an innovative and freely accessible web server for early identification of putative hERG blockers and non-blockers in chemical libraries. We have collected the largest publicly available curated hERG dataset of 5,984 compounds. We succeed in developing robust and externally predictive binary (CCR approximate to 0.8) and multiclass models (accuracy approximate to 0.7). These models are available as a web-service freely available for public at http://labmol. farma cia. ufg. br/predherg/. Three following outcomes are available for the users: prediction by binary model, prediction by multi-class model, and the probability maps of atomic contribution. The Pred-hERG will be continuously updated and upgraded as new information became available.
C1 [Braga, Rodolpho C.; Alves, Vinicius M.; Silva, Meryck F. B.; Andrade, Carolina H.] Univ Fed Goias, Fac Pharm, Labmol Lab Mol Modeling & Drug Design, BR-74605170 Goiania, Go, Brazil.
   [Braga, Rodolpho C.; Liao, Luciano M.] Univ Fed Goias, Inst Chem, BR-74001970 Goiania, Go, Brazil.
   [Muratov, Eugene; Tropsha, Alexander] Univ N Carolina, Eshelman Sch Pharm, Lab Mol Modeling, Div Chem Biol & Med Chem, Chapel Hill, NC 27599 USA.
   [Fourches, Denis] N Carolina State Univ, Dept Chem, Bioinformat Res Ctr, Raleigh, NC 27695 USA.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Pharm, Labmol Lab Mol Modeling & Drug Design, BR-74605170 Goiania, Go, Brazil.
EM carolina@ufg.br
RI Muratov, Eugene/C-4454-2014; Liao, Luciano Morais M./F-1487-2015; Braga,
   Rodolpho C/A-9655-2011; Tropsha, Alexander/AAB-8324-2020; Alves,
   Vinicius M./G-7955-2015; Fourches, Denis/H-4336-2019; Liao, Luciano
   Morais/M-3030-2019; Andrade, Carolina/C-3960-2014
OI Muratov, Eugene/0000-0003-4616-7036; Liao, Luciano Morais
   M./0000-0001-9985-2980; Braga, Rodolpho C/0000-0003-3814-3464; Alves,
   Vinicius M./0000-0002-6182-1748; Liao, Luciano
   Morais/0000-0001-9985-2980; Andrade, Carolina/0000-0003-0101-1492;
   Fourches, Denis/0000-0001-5642-8303
FU State of Goias Research Foundation [FAPEG 201310267001095]; Coordination
   for the Improvement of Higher Education Personnel [CAPES]CAPES; National
   Council for Scientific and Technological Development (CNPq)National
   Council for Scientific and Technological Development (CNPq); National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [GM66940, GM096967];
   Environmental Protection AgencyUnited States Environmental Protection
   Agency [RD 83499901]; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [R01GM096967, R01GM066940, R01GM066940,
   R01GM066940, R01GM066940, R01GM066940, R01GM066940, R01GM096967,
   R01GM096967, R01GM066940, R01GM066940, R01GM066940, R01GM066940,
   R01GM096967] Funding Source: NIH RePORTER
FX The authors would like to thank ChemAxon for providing the academic
   license of their software. This work was supported by the State of Goias
   Research Foundation [FAPEG 201310267001095 to VMA]; the Coordination for
   the Improvement of Higher Education Personnel [CAPES fellowships to RCB
   and VMA]; the National Council for Scientific and Technological
   Development (CNPq); the National Institutes of Health [GM66940 and
   GM096967]; and the Environmental Protection Agency (Grant RD 83499901).
CR Alvarez PA, 2010, CURR DRUG SAF, V5, P97, DOI 10.2174/157488610789869265
   Bienfait B, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-24
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1399, DOI 10.2174/1568026614666140506124442
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997
   Hancox JC, 2008, PHARMACOL THERAPEUT, V119, P118, DOI 10.1016/j.pharmthera.2008.05.009
   Heijman J, 2014, CURR OPIN PHARMACOL, V15, P16, DOI 10.1016/j.coph.2013.11.004
   Martin TM, 2012, J CHEM INF MODEL, V52, P2570, DOI 10.1021/ci300338w
   Mazanetz MP, 2012, CURR TOP MED CHEM, V12, P1965
   Mitcheson JS, 2000, P NATL ACAD SCI USA, V97, P12329, DOI 10.1073/pnas.210244497
   Picard S, 2011, CARDIOVASC TOXICOL, V11, P285, DOI 10.1007/s12012-011-9133-z
   Rampe D, 1997, FEBS LETT, V417, P28, DOI 10.1016/S0014-5793(97)01249-0
   Riniker S, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-43
   Steinbeck C, 2003, J CHEM INF COMP SCI, V43, P493, DOI 10.1021/ci025584y
   Vapnik V., 2000, NATURE STAT LEARNING
   Wen DS, 2012, J APPL TOXICOL, V32, P834, DOI 10.1002/jat.2755
   Woosley RL, 1996, ANNU REV PHARMACOL, V36, P233, DOI 10.1146/annurev.pa.36.040196.001313
NR 18
TC 54
Z9 56
U1 2
U2 11
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1868-1743
EI 1868-1751
J9 MOL INFORM
JI Mol. Inf.
PD OCT
PY 2015
VL 34
IS 10
BP 698
EP 701
DI 10.1002/minf.201500040
PG 4
WC Chemistry, Medicinal; Computer Science, Interdisciplinary Applications;
   Mathematical & Computational Biology
SC Pharmacology & Pharmacy; Computer Science; Mathematical & Computational
   Biology
GA CW9LJ
UT WOS:000365319900005
PM 27490970
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Reis, CD
   de Andrade, DML
   Neves, BJ
   Oliveira, LDR
   Pinho, JF
   da Silva, LP
   Cruz, JD
   Bara, MTF
   Andrade, CH
   Rocha, ML
AF Reis, Carolina de Fatima
   Lobo de Andrade, Daniela Medeiros
   Neves, Bruno Junior
   Ribeiro Oliveira, Leandra de Almeida
   Pinho, Jose Felippe
   da Silva, Leidiane Pinha
   Cruz, Jader Dos Santos
   Freitas Bara, Maria Teresa
   Andrade, Carolina Horta
   Rocha, Matheus Lavorenti
TI Blocking the L-type Ca2+ channel (Ca-V 1.2) is the key mechanism for the
   vascular relaxing effect of Pterodon spp. and its isolated diterpene
   methyl-6 alpha-acetoxy-7 beta-hydroxyvouacapan-17 beta-oate
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE Pterodon spp.; Diterpene; Ca2+ channel; Ca2+ channel blocker;
   Vasodilation
ID MOLECULAR DETERMINANTS; PHYSIOLOGICAL ROLES; CALCIUM-CHANNELS; PUBESCENS
   BENTH; GLOBAL BURDEN; ESSENTIAL OIL; PORE REGION; CONTRACTION; EXTRACT;
   PHENYLALKYLAMINE
AB Pterodon spp. Vogel (Fabaceae), popularly known as "sucupira", has ethnopharmacological application which is described as having antispasmodic and relaxant effects. Hence, it was hypothesized that sucupira oil-resin (SOR) could induce smooth muscle relaxation. So, this study investigated the mechanisms involved in the vasorelaxant effect of SOR and its isolated diterpene (methyl-6 alpha-acetoxy-7 beta-hydroxyvouacapan-17 beta-oate). Vascular reactivity experiments were performed using rat aortic rings (n = 5-8) with (E+) or without endothelium (E-) in an isolated bath organ. The SOR (0-56 mu g/mL) relaxed phenylephrine (E+: 86.7 +/- 7.1%; E-: 92.3 +/- 4.7%) and KCl contracted rings (E-: 97.1 +/- 2.8%). In the same way, diterpene (0-48 mu g/mL) also relaxed phenylephrine (E+: 94.5 +/- 3.6%; E-: 92.2 +/- 3.4%) and KCl contracted rings (E-: 99.7 +/- 0.2%). The pre-incubation of arterial rings with cyclopiazonic acid (reticular Ca2+-ATPase inhibitor), tetraethylammonium (K+ channels blocker) or MDL-12,330A (adenylyl cyclesinhibitor) did not modify either SOR- or diterpeneinduced vasorelaxation. However, ODQ (guanylylcyclase inhibitor) impaired only diterpene-induced vasorelaxation. SOR and diterpene significantly reduced CaCl2-induced contraction stimulated by Bay K8644 (1 mu M), phenylephrine (0.1 mu M) or KCl solution (40 mM). Computational molecular docking studies demonstrated that the vasodilator effect of diterpene relies on blocking the Ca-V 1.2 channel, and patch clamp results showed that diterpene substantially decreased the ionic current through Ca-V 1.2 in freshly dissociated vascular smooth muscle cells. These findings suggest that SOR and its isolated diterpene induce endothelium-independent vascular relaxation by blocking the L-type Ca2+ channel (Cav 1.2). (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Reis, Carolina de Fatima; Lobo de Andrade, Daniela Medeiros; Rocha, Matheus Lavorenti] Univ Fed Goias, Fac Pharm, Lab Cardiovasc Pharmacol, Goiania, Go, Brazil.
   [Ribeiro Oliveira, Leandra de Almeida; Freitas Bara, Maria Teresa] Univ Fed Goias, Fac Pharm, Lab Nat Prod Res, Goiania, Go, Brazil.
   [Neves, Bruno Junior; Andrade, Carolina Horta] Univ Fed Goias, Fac Pharm, Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.
   [Pinho, Jose Felippe; da Silva, Leidiane Pinha; Cruz, Jader Dos Santos] Univ Fed Minas Gerais, UFMG, Inst Biol Sci, Lab Excitable Membranes & Cardiovasc Biol,Dept Bi, Belo Horizonte, MG, Brazil.
RP Rocha, ML (corresponding author), UFG Fac Pharm, Rua 240 Esquina Com 5a Ave S-N,Setor Univ, BR-74605170 Goiania, Go, Brazil.
EM matheusroch@yahoo.com.br
RI Neves, Bruno/R-7068-2019; Cruz, Jader/AAO-5284-2020; rocha,
   matheus/I-6396-2016; Felippe, Jose Pinho/D-1137-2019; Neves, Bruno
   Junior/E-6295-2016
OI Neves, Bruno/0000-0002-1309-8743; Cruz, Jader/0000-0003-1365-2318;
   rocha, matheus/0000-0002-7883-5003; 
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado de Goias (FAPEG)
FX This study was supported by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), and Fundacao de Amparo a Pesquisa do
   Estado de Goias (FAPEG).
CR Ap Simplicio J, 2014, EUR J PHARMACOL, V726, P66, DOI 10.1016/j.ejphar.2014.01.018
   Baker EH, 2000, BRIT J CLIN PHARMACO, V49, P185, DOI 10.1046/j.1365-2125.2000.00159.x
   Banks JL, 2005, J COMPUT CHEM, V26, P1752, DOI 10.1002/jcc.20292
   Belinelo VJ, 2002, J BRAZIL CHEM SOC, V13, P830, DOI 10.1590/S0103-50532002000600016
   BRAZ FILHO R, 1971, PHYTOCHEMISTRY, V10, P2835, DOI 10.1016/S0031-9422(00)97301-1
   Brito TS, 2013, BIOCHEM PHARMACOL, V85, P780, DOI 10.1016/j.bcp.2012.12.012
   CAMPOS AM, 1994, PHYTOCHEMISTRY, V36, P403, DOI 10.1016/S0031-9422(00)97084-5
   CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143
   Carvalho JCT, 1999, J ETHNOPHARMACOL, V64, P127, DOI 10.1016/S0378-8741(98)00116-0
   Cheng RCK, 2009, J BIOL CHEM, V284, P28332, DOI 10.1074/jbc.M109.027326
   Coelho LP, 2005, J ETHNOPHARMACOL, V98, P109, DOI 10.1016/j.jep.2005.01.014
   Coelho MGP, 2001, J ETHNOPHARMACOL, V77, P159, DOI 10.1016/S0378-8741(01)00288-4
   Dilmac N, 2004, MOL PHARMACOL, V66, P1236, DOI 10.1124/mol.104.000893
   Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745
   Eckert RE, 2000, UROL RES, V28, P122, DOI 10.1007/s002400050149
   El Bardai S, 2003, PLANTA MED, V69, P75, DOI 10.1055/s-2003-37042
   Eldridge MD, 1997, J COMPUT AID MOL DES, V11, P425, DOI 10.1023/A:1007996124545
   Evangelista GL, 2007, J ETHNOPHARMACOL, V109, P515, DOI 10.1016/j.jep.2006.08.028
   FASCIO M, 1976, PHYTOCHEMISTRY, V15, P201, DOI 10.1016/S0031-9422(00)89084-6
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   GODFRAIND T, 1969, BRIT J PHARMACOL, V36, P549, DOI 10.1111/j.1476-5381.1969.tb08010.x
   Hering S, 1997, P NATL ACAD SCI USA, V94, P13323, DOI 10.1073/pnas.94.24.13323
   Hipolito UV, 2009, EUR J PHARMACOL, V616, P183, DOI 10.1016/j.ejphar.2009.06.010
   Hockerman GH, 1997, J BIOL CHEM, V272, P18759, DOI 10.1074/jbc.272.30.18759
   Hoscheid J, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/272795
   Huber IG, 2004, J BIOL CHEM, V279, P55211, DOI 10.1074/jbc.M409008200
   Ihara E, 2007, CAN J PHYSIOL PHARM, V85, P79, DOI 10.1139/Y06-103
   Kearney PM, 2005, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)70151-3
   Ko Eun A., 2008, Journal of Smooth Muscle Research, V44, P65, DOI 10.1540/jsmr.44.65
   Lacinova L, 2005, GEN PHYSIOL BIOPHYS, V24, P3
   Lee CH, 2001, J PHYSIOL-LONDON, V534, P641, DOI 10.1111/j.1469-7793.2001.t01-1-00641.x
   Lee CN, 2001, PLANTA MED, V67, P796, DOI 10.1055/s-2001-18841
   Leonhardt V, 2010, FUND CLIN PHARMACOL, V24, P749, DOI 10.1111/j.1472-8206.2009.00800.x
   Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8
   MAHAJAN JR, 1973, J CHEM SOC PERK T 1, P520, DOI 10.1039/p19730000520
   de Sa LZCM, 2014, J FUNCT FOODS, V8, P169, DOI 10.1016/j.jff.2014.03.009
   McNeill JR, 2006, CAN J PHYSIOL PHARM, V84, P803, DOI 10.1139/Y06-028
   Michiels CF, 2014, EUR J PHARMACOL, V738, P170, DOI 10.1016/j.ejphar.2014.05.036
   NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799
   Nucci C, 2012, J ETHNOPHARMACOL, V143, P170, DOI 10.1016/j.jep.2012.06.020
   Oliveira L.A.R., 2014, THESIS FEDERAL U GOI
   Pimenta Antonia T.A., 2006, Rev. bras. farmacogn., V16, P501, DOI 10.1590/S0102-695X2006000400011
   Pinho JF, 2010, BRIT J PHARMACOL, V161, P1458, DOI 10.1111/j.1476-5381.2010.00955.x
   Schlossmann J, 2003, ANN MED, V35, P21, DOI 10.1080/07853890310004093
   Shelley JC, 2007, J COMPUT AID MOL DES, V21, P681, DOI 10.1007/s10822-007-9133-z
   Silva MCC, 2004, J PHARM PHARMACOL, V56, P135, DOI 10.1211/0022357022485
   SOMLYO AV, 1985, P NATL ACAD SCI USA, V82, P5231, DOI 10.1073/pnas.82.15.5231
   SOMLYO AV, 1968, J PHARMACOL EXP THER, V159, P129
   Spindola HM, 2009, J BRAZIL CHEM SOC, V20, P569, DOI 10.1590/S0103-50532009000300024
   Tikhonov DB, 2008, J BIOL CHEM, V283, P17594, DOI 10.1074/jbc.M800141200
   Tirapelli CR, 2002, FITOTERAPIA, V73, P56, DOI 10.1016/S0367-326X(01)00365-3
   Watts KS, 2010, J CHEM INF MODEL, V50, P534, DOI 10.1021/ci100015j
NR 52
TC 4
Z9 5
U1 0
U2 12
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD OCT
PY 2015
VL 100
BP 242
EP 249
DI 10.1016/j.phrs.2015.08.007
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CU8VQ
UT WOS:000363822600022
DA 2020-12-01
ER

PT J
AU Alves, V
   Braga, R
   Muratov, E
   Fourches, D
   Kleinstreuer, N
   Strickland, J
   Andrade, C
   Tropsha, A
AF Alves, Vinicius
   Braga, Rodolpho
   Muratov, Eugene
   Fourches, Denis
   Kleinstreuer, Nicole
   Strickland, Judy
   Andrade, Carolina
   Tropsha, Alexander
TI QSAR models could replace LLNA test for predicting human skin
   sensitization potential of chemicals
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 [Alves, Vinicius; Braga, Rodolpho; Andrade, Carolina] Univ Fed Goias, Fac Pharm, Goiania, Go, Brazil.
   [Tropsha, Alexander] Univ N Carolina, Chapel Hill, NC USA.
   [Muratov, Eugene] Univ N Carolina, Med Chem Nat Prod, Chapel Hill, NC USA.
   [Fourches, Denis] North Carolina State Univ, Raleigh, NC USA.
   [Kleinstreuer, Nicole; Strickland, Judy] NICEATM, ILS, Raleigh, NC USA.
EM viniciusm.alves@gmail.com; murik@email.unc.edu; alex_tropsha@unc.edu
RI Kleinstreuer, Nicole/F-7203-2019; Alves, Vinicius M./G-7955-2015;
   Tropsha, Alexander/AAB-8324-2020; Fourches, Denis/H-4336-2019; Braga,
   Rodolpho C/A-9655-2011
OI Kleinstreuer, Nicole/0000-0002-7914-3682; Alves, Vinicius
   M./0000-0002-6182-1748; Braga, Rodolpho C/0000-0003-3814-3464
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 16
PY 2015
VL 250
MA 133
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA VC2BR
UT WOS:000432475502852
DA 2020-12-01
ER

PT J
AU Braga, R
   Alves, V
   Silva, M
   Muratov, E
   Fourches, D
   Liao, L
   Tropsha, A
   Andrade, C
AF Braga, Rodolpho
   Alves, Vinicius
   Silva, Meryck
   Muratov, Eugene
   Fourches, Denis
   Liao, Luciano
   Tropsha, Alexander
   Andrade, Carolina
TI Pred-hERG 2: An updated web-accessible computational tool for predicting
   cardiac toxicity
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 [Muratov, Eugene; Tropsha, Alexander] Univ N Carolina, Eshelman Sch Pharm, Div Chem Biol & Med Chem, Lab Mol Modeling, Chapel Hill, NC USA.
   [Braga, Rodolpho; Alves, Vinicius; Silva, Meryck; Andrade, Carolina] Univ Fed Goias, Fac Pharm, Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.
   [Braga, Rodolpho; Liao, Luciano] Univ Fed Goias, Inst Chem, Goiania, Go, Brazil.
   [Fourches, Denis] North Carolina State Univ, Bioinformat Res Ctr, Dept Chem, Raleigh, NC USA.
EM rodolphobraga@yahoo.com; viniciusm.alves@gmail.com; carolhandrade@me.com
RI Alves, Vinicius M./G-7955-2015; Fourches, Denis/H-4336-2019; Liao,
   Luciano Morais/M-3030-2019; Braga, Rodolpho C/A-9655-2011; Tropsha,
   Alexander/AAB-8324-2020
OI Alves, Vinicius M./0000-0002-6182-1748; Liao, Luciano
   Morais/0000-0001-9985-2980; Braga, Rodolpho C/0000-0003-3814-3464; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 16
PY 2015
VL 250
MA 171
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA VC2BR
UT WOS:000432475503684
DA 2020-12-01
ER

PT J
AU Alves, VM
   Muratov, E
   Fourches, D
   Strickland, J
   Kleinstreuer, N
   Andrade, CH
   Tropsha, A
AF Alves, Vinicius M.
   Muratov, Eugene
   Fourches, Denis
   Strickland, Judy
   Kleinstreuer, Nicole
   Andrade, Carolina H.
   Tropsha, Alexander
TI Predicting chemically-induced skin reactions. Part I: QSAR models of
   skin sensitization and their application to identify potentially
   hazardous compounds
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Skin sensitization; QSAR; Virtual screening; Skin toxicants
ID LYMPH-NODE ASSAY; ADVERSE OUTCOME PATHWAYS; QUANTITATIVE STRUCTURE;
   PEPTIDE REACTIVITY; CLASSIFICATION; VALIDATION; SILICO; ALLERGENS;
   TOXICITY
AB Repetitive exposure to a chemical agent can induce an immune reaction in inherently susceptible individuals that leads to skin sensitization. Although many chemicals have been reported as skin sensitizers, there have been very few rigorously validated QSAR models with defined applicability domains (AD) that were developed using a large group of chemically diverse compounds. In this study, we have aimed to compile, curate, and integrate the largest publicly available dataset related to chemically-induced skin sensitization, use this data to generate rigorously validated and QSAR models for skin sensitization, and employ these models as a virtual screening tool for identifying putative sensitizers among environmental chemicals. We followed best practices for model building and validation implemented with our predictive QSAR workflow using Random Forest modeling technique in combination with SiRMS and Dragon descriptors. The Correct Classification Rate (CCR) for QSAR models discriminating sensitizers from non-sensitizers was 71-88% when evaluated on several external validation sets, within a broad AD, with positive (for sensitizers) and negative (for non-sensitizers) predicted rates of 85% and 79% respectively. When compared to the skin sensitization module included in the OECD QSAR Toolbox as well as to the skin sensitization model in publicly available VEGA software, our models showed a significantly higher prediction accuracy for the same sets of external compounds as evaluated by Positive Predicted Rate, Negative Predicted Rate, and CCR. These models were applied to identify putative chemical hazards in the Scorecard database of possible skin or sense organ toxicants as primary candidates for experimental validation. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Alves, Vinicius M.; Andrade, Carolina H.] Univ Fed Goias, Fac Pharm, Lab Mol Modeling & Design, BR-74605220 Goiania, Go, Brazil.
   [Alves, Vinicius M.; Muratov, Eugene; Fourches, Denis; Tropsha, Alexander] Univ N Carolina, Eshelman Sch Pharm, Div Chem Biol & Med Chem, Lab Mol Modeling, Chapel Hill, NC 27599 USA.
   [Muratov, Eugene] NAS Ukraine, AV Bogatsky Phys Chem Inst, Lab Theoret Chem, UA-65080 Odessa, Ukraine.
   [Strickland, Judy; Kleinstreuer, Nicole] NICEATM, ILS Contractor Supporting, Res Triangle Pk, NC 27709 USA.
RP Tropsha, A (corresponding author), Univ N Carolina, Eshelman Sch Pharm, 100K Beard Hall, Chapel Hill, NC 27599 USA.
EM alex_tropsha@unc.edu
RI Alves, Vinicius M./G-7955-2015; Kleinstreuer, Nicole/F-7203-2019;
   Tropsha, Alexander/AAB-8324-2020; Fourches, Denis/H-4336-2019; Muratov,
   Eugene/C-4454-2014; Andrade, Carolina/C-3960-2014
OI Alves, Vinicius M./0000-0002-6182-1748; Kleinstreuer,
   Nicole/0000-0002-7914-3682; Muratov, Eugene/0000-0003-4616-7036;
   Fourches, Denis/0000-0001-5642-8303; Andrade,
   Carolina/0000-0003-0101-1492
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [GM66940, GM096967]; EPAUnited States
   Environmental Protection Agency [RD 83499901]; FAPEG [201310267001095];
   Russian Scientific FoundationRussian Science Foundation (RSF)
   [14-43-00024]; CNPqNational Council for Scientific and Technological
   Development (CNPq); Science without Borders program; STCU [P407]; CNPq
   (PVE) [400760/2014-2]; NIEHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Environmental Health Sciences (NIEHS) [N01-ES 35504]; Intramural
   Research Program of the NIEHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Environmental Health Sciences (NIEHS); NATIONAL INSTITUTE OF GENERAL
   MEDICAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [R01GM096967, R01GM096967,
   R01GM096967, R01GM066940, R01GM066940, R01GM066940, R01GM066940,
   R01GM066940, R01GM066940, R01GM066940, R01GM066940, R01GM066940,
   R01GM096967, R01GM066940] Funding Source: NIH RePORTER
FX This study was supported in part by NIH (grants GM66940 and GM096967),
   EPA (grant RD 83499901), and FAPEG (grant 201310267001095). A.T.
   acknowledges partial support from the Russian Scientific Foundation
   (project 14-43-00024). V.A. thanks CNPq and Science without Borders
   program for the financial support of his visit to the University of
   North Carolina at Chapel Hill. E.M. acknowledges partial support from
   STCU (Grant P407). E.M., V.A., and C.H.A. acknowledge partial support
   from CNPq (PVE, Grant 400760/2014-2). N.K. and IS. are supported by the
   NIEHS contract N01-ES 35504 and the Intramural Research Program of the
   NIEHS. This article may be the work product of an employee or group of
   employees of the NIEHS, NIH, or other organizations; however, the
   statements, opinions, or conclusions contained therein do not
   necessarily represent the statements, opinions, or conclusions of NIEHS,
   NIH, the United States government, or other organizations. The use of
   commercial product names is for comparative purposes only and does not
   constitute endorsement by any of the authors, organizations, or
   agencies.
CR Adler S, 2011, ARCH TOXICOL, V85, P367, DOI 10.1007/s00204-011-0693-2
   Aeby P, 2010, TOXICOL IN VITRO, V24, P1465, DOI 10.1016/j.tiv.2010.07.005
   Alves VM, 2015, TOXICOL APPL PHARM, V284, P273, DOI 10.1016/j.taap.2014.12.013
   Anderson S.E., 2011, J ALLERGY, P1
   Ankley GT, 2010, ENVIRON TOXICOL CHEM, V29, P730, DOI 10.1002/etc.34
   Artemenko AG, 2011, SAR QSAR ENVIRON RES, V22, P575, DOI 10.1080/1062936X.2011.569950
   Basketter DA, 2002, FOOD CHEM TOXICOL, V40, P593, DOI 10.1016/S0278-6915(01)00130-2
   BASKETTER DA, 1992, CONTACT DERMATITIS, V27, P137, DOI 10.1111/j.1600-0536.1992.tb05241.x
   Bos JD, 2000, EXP DERMATOL, V9, P165, DOI 10.1034/j.1600-0625.2000.009003165.x
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Breiman L., 1984, CLASSIFICATION REGRE
   BUEHLER EV, 1965, ARCH DERMATOL, V91, P171, DOI 10.1001/archderm.1965.01600080079017
   Chaudhry Q, 2010, CHEM CENT J, V4, DOI 10.1186/1752-153X-4-S1-S5
   Chuprina A, 2010, J CHEM INF MODEL, V50, P470, DOI 10.1021/ci900464s
   Cronin M T, 1994, SAR QSAR Environ Res, V2, P159, DOI 10.1080/10629369408029901
   Dearman RJ, 2007, CONTACT DERMATITIS, V57, P242, DOI 10.1111/j.1600-0536.2007.01215.x
   Dearman RJ, 2001, CONTACT DERMATITIS, V44, P357, DOI 10.1034/j.1600-0536.2001.044006357.x
   Devillers J, 2000, TOXICOL METHOD, V10, P181, DOI 10.1080/10517230050121598
   Dickel Heinrich, 2002, Am J Clin Dermatol, V3, P283, DOI 10.2165/00128071-200203040-00006
   Downs GM, 2002, REV COMP CH, V18, P1, DOI 10.1002/0471433519.ch1
   ECHA, 2010, CHLOROBENZENE
   ECHA, 2010, ETHYLENEDIAMINE
   ECHA, 2010, OX AC
   Egeghy PP, 2012, SCI TOTAL ENVIRON, V414, P159, DOI 10.1016/j.scitotenv.2011.10.046
   Estrada E, 2003, CHEM RES TOXICOL, V16, P1226, DOI 10.1021/tx034093k
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Gerberick GF, 2009, TOXICOL SCI, V112, P164, DOI 10.1093/toxsci/kfp192
   Gerberick GF, 2005, DERMATITIS, V16, P157, DOI 10.2310/6620.2005.05040
   Gerberick GF, 2004, TOXICOL SCI, V81, P332, DOI 10.1093/toxsci/kfh213
   Gleeson MP, 2012, CURR PHARM DESIGN, V18, P1266
   Golbraikh A, 2002, J MOL GRAPH MODEL, V20, P269, DOI 10.1016/S1093-3263(01)00123-1
   Golla S, 2009, TOXICOL IN VITRO, V23, P454, DOI 10.1016/j.tiv.2008.12.025
   GRANDJEAN P, 1988, AM J IND MED, V14, P97, DOI 10.1002/ajim.4700140111
   Hennino Ana, 2005, An. Bras. Dermatol., V80, P335, DOI 10.1590/S0365-05962005000400003
   Hostynek JJ, 1997, TOXICOL IN VITRO, V11, P377, DOI 10.1016/S0887-2333(97)00031-3
   ICCVAM, 2009, RED MUR LOC LYMPH NO
   ICCVAM NICEATM, 1999, MUR LOC LYMPH NOD AS
   Jaworska J, 2011, ALTEX-ALTERN ANIM EX, V28, P211, DOI 10.14573/altex.2011.3.211
   Johansson H, 2014, BASIC CLIN PHARMACOL, V115, P110, DOI 10.1111/bcpt.12199
   Johansson H, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-399
   Karlberg AT, 2008, CHEM RES TOXICOL, V21, P53, DOI 10.1021/tx7002239
   Keegel T, 2009, INT J DERMATOL, V48, P571, DOI 10.1111/j.1365-4632.2009.04004.x
   Kern PS, 2010, DERMATITIS, V21, P8, DOI 10.2310/6620.2009.09038
   Kimber I, 2002, INT IMMUNOPHARMACOL, V2, P201, DOI 10.1016/S1567-5769(01)00173-4
   Kimber I, 2011, TOXICOL SCI, V120, pS238, DOI 10.1093/toxsci/kfq346
   Knudsen TB, 2011, BIRTH DEFECTS RES C, V93, P312, DOI 10.1002/bdrc.20223
   Kuz'min VE, 2008, J COMPUT AID MOL DES, V22, P403, DOI 10.1007/s10822-008-9179-6
   Kuz'min VE, 2007, J MED CHEM, V50, P4205, DOI 10.1021/jm0704806
   Lepoittevin JP, 2011, CONTACT DERMATITIS, FIFTH EDITION, P91, DOI 10.1007/978-3-642-03827-3_4
   Li SQ, 2005, J CHEM INF MODEL, V45, P952, DOI 10.1021/ci050049u
   Low Y, 2013, CHEM RES TOXICOL, V26, P1199, DOI 10.1021/tx400110f
   Low Y, 2011, CHEM RES TOXICOL, V24, P1251, DOI 10.1021/tx200148a
   MAGEE PS, 1994, QUANT STRUCT-ACT REL, V13, P22, DOI 10.1002/qsar.19940130106
   Maggiora GM, 2006, J CHEM INF MODEL, V46, P1535, DOI 10.1021/ci060117s
   MAGNUSSON B, 1969, J INVEST DERMATOL, V52, P268, DOI 10.1038/jid.1969.42
   Magnusson BM, 2004, PHARM RES-DORDR, V21, P1047, DOI 10.1023/B:PHAM.0000029295.38564.e1
   Matura M, 2005, CONTACT DERMATITIS, V52, P320, DOI 10.1111/j.0105-1873.2005.00605.x
   Mercier D., 2003, ELECT REV LINACRE CO
   Miller MD, 2005, J CHEM INF MODEL, V45, P924, DOI 10.1021/ci050018z
   Muir DCG, 2006, ENVIRON SCI TECHNOL, V40, P7157, DOI 10.1021/es061677a
   Muratov EN, 2010, FUTURE MED CHEM, V2, P1205, DOI 10.4155/FMC.10.194
   Nandy A, 2014, MOL SIMULAT, V40, P261, DOI 10.1080/08927022.2013.801076
   OECD, 2014, OECD QSAR TOOLB V 3
   OECD, 2010, 429 OECD
   OECD, 2004, OECD PRINC VAL REG P
   OECD, 2012, ADV OUCT PATHW SKI 1
   Polishchuk PG, 2009, J CHEM INF MODEL, V49, P2481, DOI 10.1021/ci900203n
   Raunio H, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00033
   Roberts DW, 2008, J APPL TOXICOL, V28, P377, DOI 10.1002/jat.1289
   Roberts DW, 2007, CHEM RES TOXICOL, V20, P1321, DOI 10.1021/tx700169w
   Roberts DW, 2007, CHEM RES TOXICOL, V20, P44, DOI 10.1021/tx060121y
   Saint-Mezard P, 2004, EUR J DERMATOL, V14, P284
   Schlede E, 2003, TOXICOLOGY, V193, P219, DOI 10.1016/S0300-483X(03)00266-X
   SCHOLES EW, 1992, J APPL TOXICOL, V12, P217, DOI 10.1002/jat.2550120312
   Scorecard, 2011, SKIN SENS ORG TOX
   Siegel PD, 2009, TOXICOL SCI, V107, P78, DOI 10.1093/toxsci/kfn212
   Strid Jessica, 2005, Current Drug Targets - Inflammation and Allergy, V4, P531, DOI 10.2174/156801005774322199
   Todeschini R., 2000, HDB MOL DESCRIPTORS
   Tropsha A, 2007, CURR PHARM DESIGN, V13, P3494, DOI 10.2174/138161207782794257
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Varnek A, 2007, SOLVENT EXTR ION EXC, V25, P1, DOI 10.1080/07366290601067481
   Varnek A, 2008, CURR COMPUT-AID DRUG, V4, P191, DOI 10.2174/157340908785747465
   VEGA, 2014, SKIN SENS MOD V 2 1
   Watanabe KH, 2011, ENVIRON TOXICOL CHEM, V30, P9, DOI 10.1002/etc.373
NR 84
TC 37
Z9 40
U1 0
U2 23
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0041-008X
EI 1096-0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD APR 15
PY 2015
VL 284
IS 2
BP 262
EP 272
DI 10.1016/j.taap.2014.12.014
PG 11
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA CH2OH
UT WOS:000353864000017
PM 25560674
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Alves, VM
   Muratov, E
   Fourches, D
   Strickland, J
   Kleinstreuer, N
   Andrade, CH
   Tropsha, A
AF Alves, Vinicius M.
   Muratov, Eugene
   Fourches, Denis
   Strickland, Judy
   Kleinstreuer, Nicole
   Andrade, Carolina H.
   Tropsha, Alexander
TI Predicting chemically-induced skin reactions. Part II: QSAR models of
   skin permeability and the relationships between skin permeability and
   skin sensitization
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Skin sensitization; Skin permeability; QSAR; Virtual screening; Skin
   toxicants
ID VITRO DATA ASSESSMENT; IN-SILICO PREDICTION; QUANTITATIVE STRUCTURE;
   PHYSICOCHEMICAL PROPERTIES; MOLECULAR-SIZE; PERMEATION; INHIBITORS; FLUX
AB Skin permeability is widely considered to be mechanistically implicated in chemically-induced skin sensitization. Although many chemicals have been identified as skin sensitizers, there have been very few reports analyzing the relationships between molecular structure and skin permeability of sensitizers and non-sensitizers. The goals of this study were to: (i) compile, curate, and integrate the largest publicly available dataset of chemicals studied for their skin permeability; (ii) develop and rigorously validate QSAR models to predict skin permeability; and (iii) explore the complex relationships between skin sensitization and skin permeability. Based on the largest publicly available dataset compiled in this study, we found no overall correlation between skin permeability and skin sensitization. In addition, cross-species correlation coefficient between human and rodent permeability data was found to be as low as R-2 = 0.44. Human skin permeability models based on the random forest method have been developed and validated using OECD-compliant QSAR modeling workflow. Their external accuracy was high (Q(ext)(2) = 0.73 for 63% of external compounds inside the applicability domain). The extended analysis using both experimentally-measured and QSAR-imputed data still confirmed the absence of any overall concordance between skin permeability and skin sensitization. This observation suggests that chemical modifications that affect skin permeability should not be presumed a priori to modulate the sensitization potential of chemicals. The models reported herein as well as those developed in the companion paper on skin sensitization suggest that it may be possible to rationally design compounds with the desired high skin permeability but low sensitization potential. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Alves, Vinicius M.; Andrade, Carolina H.] Univ Fed Goias, Fac Pharm, Lab Mol Modeling & Design, BR-74605220 Goiania, Go, Brazil.
   [Alves, Vinicius M.; Muratov, Eugene; Fourches, Denis; Tropsha, Alexander] Univ N Carolina, Eshelman Sch Pharm, Div Chem Biol & Med Chem, Lab Mol Modeling, Chapel Hill, NC 27599 USA.
   [Muratov, Eugene] NAS Ukraine, AV Bogatsky Phys Chem Inst, Lab Theoret Chem, UA-65080 Odessa, Ukraine.
   [Strickland, Judy; Kleinstreuer, Nicole] NTP Interagency Ctr Evaluat Alternat Toxicol Meth, ILS Contractor Supporting, Res Triangle Pk, NC 27709 USA.
RP Tropsha, A (corresponding author), Univ N Carolina, Eshelman Sch Pharm, 100K Beard Hall, Chapel Hill, NC 27599 USA.
EM alex_tropsha@unc.edu
RI Muratov, Eugene/C-4454-2014; Tropsha, Alexander/AAB-8324-2020; Fourches,
   Denis/H-4336-2019; Alves, Vinicius M./G-7955-2015; Kleinstreuer,
   Nicole/F-7203-2019; Andrade, Carolina/C-3960-2014
OI Muratov, Eugene/0000-0003-4616-7036; Alves, Vinicius
   M./0000-0002-6182-1748; Kleinstreuer, Nicole/0000-0002-7914-3682;
   Fourches, Denis/0000-0001-5642-8303; Andrade,
   Carolina/0000-0003-0101-1492
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [GM66940, GM096967]; EPAUnited States
   Environmental Protection Agency [RD 83499901]; FAPEG [201310267001095];
   Russian Scientific FoundationRussian Science Foundation (RSF)
   [14-43-00024]; STCU [P407]; CNPq (PVE) [400760/2014-2]; CNPqNational
   Council for Scientific and Technological Development (CNPq); Science
   without Borders program; NIEHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Environmental Health Sciences (NIEHS) [N01-ES 35504]; Intramural
   Research Program of the NIEHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Environmental Health Sciences (NIEHS); NATIONAL INSTITUTE OF GENERAL
   MEDICAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [R01GM066940, R01GM066940,
   R01GM066940, R01GM066940, R01GM066940, R01GM096967, R01GM066940,
   R01GM096967, R01GM096967, R01GM066940, R01GM066940, R01GM096967,
   R01GM066940, R01GM066940] Funding Source: NIH RePORTER
FX This study was supported in part by NIH (grants GM66940 and GM096967),
   EPA (grant RD 83499901), and FAPEG (grant 201310267001095). A.T.
   acknowledges partial support from Russian Scientific Foundation (project
   14-43-00024). E.M. acknowledges partial support from STCU (Grant P407)
   E.M, V.A., and C.H.A acknowledge partial support from CNPq (PVE, Grant
   400760/2014-2). V.A. thanks CNPq and Science without Borders program for
   the financial support of his visit to the University of North Carolina
   at Chapel Hill. N.K. and J.S. are supported by the NIEHS contract N01-ES
   35504 and the Intramural Research Program of the NIEHS. This article may
   be the work product of an employee or group of employees of the NIEHS,
   NIH, or other organizations; however, the statements, opinions, or
   conclusions contained therein do not necessarily represent the
   statements, opinions, or conclusions of NIEHS, NIH, the United States
   government, or other organizations. The use of commercial product names
   is for comparative purposes only and does not constitute endorsement by
   any of the authors, organizations, or agencies.
CR Abraham MH, 1999, PESTIC SCI, V55, P78, DOI 10.1002/(SICI)1096-9063(199901)55:1<78::AID-PS853>3.0.CO;2-7
   Alves VM, 2015, TOXICOL APPL PHARM, V284, P262, DOI 10.1016/j.taap.2014.12.014
   Artemenko AG, 2011, SAR QSAR ENVIRON RES, V22, P575, DOI 10.1080/1062936X.2011.569950
   BARRATT MD, 1995, TOXICOL IN VITRO, V9, P27, DOI 10.1016/0887-2333(94)00190-6
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Breiman L., 1984, CLASSIFICATION REGRE
   Brown MB, 2012, J PHARM PHARMACOL, V64, P566, DOI 10.1111/j.2042-7158.2011.01436.x
   Chauhan P, 2010, SAR QSAR ENVIRON RES, V21, P481, DOI 10.1080/1062936X.2010.501819
   Chen LJ, 2007, ACTA PHARMACOL SIN, V28, P591, DOI 10.1111/j.1745-7254.2007.00528.x
   Chen LJ, 2013, ADV DRUG DELIVER REV, V65, P295, DOI 10.1016/j.addr.2012.05.001
   Chen LJ, 2010, AICHE J, V56, P1136, DOI 10.1002/aic.12048
   Cronin MTD, 1999, EUR J PHARM SCI, V7, P325, DOI 10.1016/S0928-0987(98)00041-4
   Downs GM, 2002, REV COMP CH, V18, P1, DOI 10.1002/0471433519.ch1
   Flynn G.L., 1990, PRINCIPLES ROUTE TO, P93
   Fong P, 2014, NAT PROD COMMUN, V9, P189
   Fong P, 2012, NAT PROD COMMUN, V7, P1287
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Hostynek JJ, 1997, TOXICOL IN VITRO, V11, P377, DOI 10.1016/S0887-2333(97)00031-3
   ICCVAM, 2009, RED MUR LOC LYMPH NO
   Jaworska J, 2013, J APPL TOXICOL, V33, P1353, DOI 10.1002/jat.2869
   Jaworska J, 2011, ALTEX-ALTERN ANIM EX, V28, P211, DOI 10.14573/altex.2011.3.211
   Johansen JD, 2011, CONTACT DERMATITIS, FIFTH EDITION, P241, DOI 10.1007/978-3-642-03827-3_14
   Karlberg AT, 2008, CHEM RES TOXICOL, V21, P53, DOI 10.1021/tx7002239
   Kuz'min VE, 2008, J COMPUT AID MOL DES, V22, P403, DOI 10.1007/s10822-008-9179-6
   Kuz'min VE, 2007, J MED CHEM, V50, P4205, DOI 10.1021/jm0704806
   LIEN EJ, 1995, PHARMACEUT RES, V12, P583, DOI 10.1023/A:1016266316100
   MacKay C, 2013, ALTEX-ALTERN ANIM EX, V30, P473, DOI 10.14573/altex.2013.4.473
   Magnusson BM, 2004, J INVEST DERMATOL, V122, P993, DOI 10.1111/j.0022-202X.2004.22413.x
   MERCIER D, 2003, CLUSTERING LARGE DAT
   Moss GP, 2002, INT J PHARM, V238, P105, DOI 10.1016/S0378-5173(02)00057-1
   Mossa GP, 2011, J PHARM PHARMACOL, V63, P1411, DOI 10.1111/j.2042-7158.2011.01345.x
   Muratov EN, 2010, FUTURE MED CHEM, V2, P1205, DOI 10.4155/FMC.10.194
   OECD, 2004, OECD VAL REG PURP QU
   OECD Organization for Economic Co-operation and Development, 2012, ADV OUTC PATHW SKIN
   OXEA, 2013, N HEPTANOL
   Patel H, 2002, CHEMOSPHERE, V48, P603, DOI 10.1016/S0045-6535(02)00114-5
   Polishchuk PG, 2009, J CHEM INF MODEL, V49, P2481, DOI 10.1021/ci900203n
   POTTS RO, 1995, PHARMACEUT RES, V12, P1628, DOI 10.1023/A:1016236932339
   POTTS RO, 1992, PHARMACEUT RES, V9, P663, DOI 10.1023/A:1015810312465
   Riviere JE, 2011, COMPARATIVE PHARMACOKINETICS: PRINCIPLES, TECHNIQUES, AND APPLICATIONS, 2ND EDITION, P27
   Roberts DW, 2008, J APPL TOXICOL, V28, P377, DOI 10.1002/jat.1289
   Roberts DW, 2010, J APPL TOXICOL, V30, P286, DOI 10.1002/jat.1508
   ten Berge W, 2009, CHEMOSPHERE, V75, P1440, DOI 10.1016/j.chemosphere.2009.02.043
   Todeschini R., 2000, HDB MOL DESCRIPTORS
   Tropsha A, 2007, CURR PHARM DESIGN, V13, P3494, DOI 10.2174/138161207782794257
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   USEPA, 2004, RISK ASS GUID SUP RA, VI, P1
   Varnek A, 2007, SOLVENT EXTR ION EXC, V25, P1, DOI 10.1080/07366290601067481
   Varnek A, 2008, CURR COMPUT-AID DRUG, V4, P191, DOI 10.2174/157340908785747465
   Zhang F, 2013, J HAZARD MATER, V263, P618, DOI 10.1016/j.jhazmat.2013.10.024
NR 50
TC 31
Z9 31
U1 2
U2 17
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0041-008X
EI 1096-0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD APR 15
PY 2015
VL 284
IS 2
BP 273
EP 280
DI 10.1016/j.taap.2014.12.013
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA CH2OH
UT WOS:000353864000018
PM 25560673
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Neves, BJ
   Andrade, CH
   Cravo, PVL
AF Neves, Bruno J.
   Andrade, Carolina H.
   Cravo, Pedro V. L.
TI Natural Products as Leads in Schistosome Drug Discovery
SO MOLECULES
LA English
DT Review
ID PROTEIN-LIGAND DOCKING; THIOREDOXIN GLUTATHIONE-REDUCTASE; DIFFERENT
   VALIDATION CRITERIA; RANDOMIZED CONTROLLED-TRIAL; REAL EXTERNAL
   PREDICTIVITY; QSAR MODEL DEVELOPMENT; MANSONI ADULT WORMS; IN-VITRO;
   ANTISCHISTOSOMAL ACTIVITY; ARTEMISININ DERIVATIVES
AB Schistosomiasis is a neglected parasitic tropical disease that claims around 200,000 human lives every year. Praziquantel (PZQ), the only drug recommended by the World Health Organization for the treatment and control of human schistosomiasis, is now facing the threat of drug resistance, indicating the urgent need for new effective compounds to treat this disease. Therefore, globally, there is renewed interest in natural products (NPs) as a starting point for drug discovery and development for schistosomiasis. Recent advances in genomics, proteomics, bioinformatics, and cheminformatics have brought about unprecedented opportunities for the rapid and more cost-effective discovery of new bioactive compounds against neglected tropical diseases. This review highlights the main contributions that NP drug discovery and development have made in the treatment of schistosomiasis and it discusses how integration with virtual screening (VS) strategies may contribute to accelerating the development of new schistosomidal leads, especially through the identification of unexplored, biologically active chemical scaffolds and structural optimization of NPs with previously established activity.
C1 [Neves, Bruno J.; Andrade, Carolina H.] Univ Fed Goias, Fac Farm, LabMol Lab Drug Design & Mol Modeling, BR-74605170 Goiania, Go, Brazil.
   [Cravo, Pedro V. L.] Univ Fed Goias, Inst Patol Trop & Saude Publ, GenoBioLab Genom & Biotechnol, BR-74605050 Goiania, Go, Brazil.
RP Neves, BJ (corresponding author), Univ Fed Goias, Fac Farm, LabMol Lab Drug Design & Mol Modeling, BR-74605170 Goiania, Go, Brazil.
EM bruno.labmol@gmail.com; carolina@ufg.br; pedrovcravo@gmail.com
RI Neves, Bruno Junior/E-6295-2016; Andrade, Carolina/C-3960-2014; Neves,
   Bruno/R-7068-2019; Cravo, Pedro VL/G-3532-2012
OI Andrade, Carolina/0000-0003-0101-1492; Neves, Bruno/0000-0002-1309-8743;
   Cravo, Pedro VL/0000-0003-1675-4504
FU FAPEG; CAPESCAPES; CNPqNational Council for Scientific and Technological
   Development (CNPq)
FX We are grateful to FAPEG, CAPES, and CNPq for their financial support
   and for awarding us fellowships. We are also grateful to OpenEye
   Scientific Software, Inc. (Santa Fe, NM, USA) and ChemAxon (Budapest,
   Hungary) for providing us with the academic license for their programs.
   The funders had no role in the study design, data collection, analysis,
   decision to publish, or preparation of this manuscript.
CR Abdel-Hafeez EH, 2012, PARASITOL RES, V111, P577, DOI 10.1007/s00436-012-2871-4
   Abdulla MH, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000478
   Angelucci F, 2011, CURR TOP MED CHEM, V11, P2012, DOI 10.2174/156802611796575939
   [Anonymous], 2014, OEDOCKING VERS 3 0 1
   Ansari MT, 2013, MINI-REV MED CHEM, V13, P1879, DOI 10.2174/13895575113136660097
   Asarnow DE, 2013, IEEE T MED IMAGING, V32, P1007, DOI 10.1109/TMI.2013.2247412
   Ashfaq UA, 2013, BIOINFORMATION, V9, P993, DOI 10.6026/97320630009993
   Baker DD, 2007, NAT PROD REP, V24, P1225, DOI 10.1039/b602241n
   Bandeira SO, 2001, PHARM BIOL, V39, P70, DOI [10.1076/phbi.39.7.70.5873, 10.1076/phbi.39.s1.70.0002]
   Barnum D, 1996, J CHEM INF COMP SCI, V36, P563, DOI 10.1021/ci950273r
   Barth LR, 1997, MEM I OSWALDO CRUZ, V92, P427, DOI 10.1590/S0074-02761997000300022
   Beckmann S, 2012, CURR PHARM DESIGN, V18, P3579
   Berriman M, 2009, NATURE, V460, P352, DOI 10.1038/nature08160
   Bhullar KS, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/891748
   Bohlin L, 2010, PHYTOCHEM REV, V9, P279, DOI 10.1007/s11101-009-9160-6
   Bonilla M, 2011, J BIOL CHEM, V286, P4959, DOI 10.1074/jbc.M110.170761
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1899, DOI 10.2174/1568026614666140929120749
   Braga RC, 2013, CURR TOP MED CHEM, V13, P1127, DOI 10.2174/1568026611313090010
   Braguine CG, 2012, PHARM BIOL, V50, P925, DOI 10.3109/13880209.2011.649857
   Bucar F, 2013, NAT PROD REP, V30, P525, DOI 10.1039/c3np20106f
   Bueno RV, 2013, J MOL MODEL, V19, P179, DOI 10.1007/s00894-012-1527-8
   Buer CS, 2010, J INTEGR PLANT BIOL, V52, P98, DOI 10.1111/j.1744-7909.2010.00905.x
   Butler MS, 2004, J NAT PROD, V67, P2141, DOI 10.1021/np040106y
   Caporuscio F, 2011, CURR MED CHEM, V18, P2543, DOI 10.2174/092986711795933669
   Chen CYC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015939
   Chen D.J., 1980, CHIN MED J, V60, P4222
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Chirico N, 2012, J CHEM INF MODEL, V52, P2044, DOI 10.1021/ci300084j
   Chirico N, 2011, J CHEM INF MODEL, V51, P2320, DOI 10.1021/ci200211n
   Cichewicz RH, 2002, TETRAHEDRON, V58, P8597, DOI 10.1016/S0040-4020(02)00802-5
   ClinicalTrials, 2014, AR AC TREATM SCH INF
   Colley DG, 2014, LANCET, V383, P2253, DOI 10.1016/S0140-6736(13)61949-2
   Soares JBRC, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000477
   Couto FFB, 2011, MEM I OSWALDO CRUZ, V106, P153, DOI 10.1590/S0074-02762011000200006
   Cunha NL, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/173614
   Datry A, 2002, PRESSE MED, V31, P607
   Davis GDJ, 2011, BIOINFORMATION, V5, P361, DOI 10.6026/97320630005361
   de Lima O G, 1968, Rev Inst Antibiot (Recife), V8, P95
   de Moraes J, 2013, PLANTA MED, V79, P253, DOI 10.1055/s-0032-1328173
   de Moraes J, 2011, EXP PARASITOL, V127, P357, DOI 10.1016/j.exppara.2010.08.021
   Dixon SL, 2006, J COMPUT AID MOL DES, V20, P647, DOI 10.1007/s10822-006-9087-6
   dos Santos AF, 2014, PARASITOL RES, V113, P1077, DOI 10.1007/s00436-013-3743-2
   Du JF, 2014, CHEM BIOL DRUG DES, V83, P37, DOI 10.1111/cbdd.12202
   Dunkel M, 2006, NUCLEIC ACIDS RES, V34, pD678, DOI 10.1093/nar/gkj132
   Ehrman TM, 2007, J CHEM INF MODEL, V47, P2316, DOI 10.1021/ci700155t
   El Ridi R, 2006, J PARASITOL, V92, P730, DOI 10.1645/GE-745R1.1
   El Ridi R, 2010, ANTIMICROB AGENTS CH, V54, P3383, DOI 10.1128/AAC.00173-10
   El-Beshbishi SN, 2013, EXP PARASITOL, V135, P240, DOI 10.1016/j.exppara.2013.07.006
   ERASMUS DA, 1973, PARASITOLOGY, V67, P165, DOI 10.1017/S0031182000046394
   FALLON PG, 1995, AM J TROP MED HYG, V53, P61, DOI 10.4269/ajtmh.1995.53.61
   FALLON PG, 1994, AM J TROP MED HYG, V51, P83, DOI 10.4269/ajtmh.1994.51.83
   Feher M, 2006, DRUG DISCOV TODAY, V11, P421, DOI 10.1016/j.drudis.2006.03.009
   Frezza Tarsila Ferraz, 2013, Revista de Patologia Tropical, V42, P309, DOI 10.5216/rpt.v42i3.26930
   Geldenhuys WJ, 2012, CURR PHARM BIOTECHNO, V13, P117
   GONNERT R, 1977, Z PARASITENKD, V52, P129, DOI 10.1007/BF00389899
   Gramatica Paola, 2013, Methods Mol Biol, V930, P499, DOI 10.1007/978-1-62703-059-5_21
   Gryseels B, 2006, LANCET, V368, P1106, DOI 10.1016/S0140-6736(06)69440-3
   Guido RVC, 2011, COMB CHEM HIGH T SCR, V14, P830
   Guner O, 2004, CURR MED CHEM, V11, P2991, DOI 10.2174/0929867043364036
   Han ZG, 2009, ANNU REV GENOM HUM G, V10, P211, DOI 10.1146/annurev-genom-082908-150036
   Harvey AL, 2008, DRUG DISCOV TODAY, V13, P894, DOI 10.1016/j.drudis.2008.07.004
   Harvey AL, 2010, EXPERT OPIN DRUG DIS, V5, P559, DOI 10.1517/17460441.2010.488263
   Ho WE, 2014, PHARMACOL THERAPEUT, V142, P126, DOI 10.1016/j.pharmthera.2013.12.001
   Huang M, 2012, EXPERT OPIN INV DRUG, V21, P1801, DOI 10.1517/13543784.2012.727395
   Huang YX, 2011, PARASITOL RES, V109, P1453, DOI 10.1007/s00436-011-2485-2
   Ingram K, 2012, ANTIMICROB AGENTS CH, V56, P3207, DOI 10.1128/AAC.06177-11
   Ismail M, 1996, AM J TROP MED HYG, V55, P214, DOI 10.4269/ajtmh.1996.55.214
   Ismail Magdi M., 1994, Journal of the Egyptian Society of Parasitology, V24, P685
   Jana NR, 2004, J BIOL CHEM, V279, P11680, DOI 10.1074/jbc.M310369200
   Ji XJ, 2014, CRIT REV BIOTECHNOL, V34, P197, DOI 10.3109/07388551.2013.778229
   Jiraungkoorskul W, 2005, PARASITOL INT, V54, P177, DOI 10.1016/j.parint.2005.04.001
   JISAKA M, 1992, BIOSCI BIOTECH BIOCH, V56, P845, DOI 10.1271/bbb.56.845
   Johann S, 2012, MED MYCOL, V50, P843, DOI 10.3109/13693786.2012.678903
   Kannan S, 2014, J CHEM INF MODEL, V54, P3005, DOI 10.1021/ci5004653
   Keiser J, 2010, PARASITOLOGY, V137, P589, DOI 10.1017/S0031182009991739
   Keiser J, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000350
   Keiser J, 2011, J ANTIMICROB CHEMOTH, V66, P1791, DOI 10.1093/jac/dkr178
   Keiser J, 2010, CLIN INFECT DIS, V50, P1205, DOI 10.1086/651682
   Klebe G, 2006, DRUG DISCOV TODAY, V11, P580, DOI 10.1016/j.drudis.2006.05.012
   Kuhn I, 2010, BIOORGAN MED CHEM, V18, P7900, DOI 10.1016/j.bmc.2010.09.041
   Kuntz AN, 2007, PLOS MED, V4, P1071, DOI 10.1371/journal.pmed.0040206
   Lancelot J, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002428
   Lauro G, 2012, BIOORGAN MED CHEM, V20, P3596, DOI 10.1016/j.bmc.2012.03.072
   Lauro G, 2011, J NAT PROD, V74, P1401, DOI 10.1021/np100935s
   Lea WA, 2008, ASSAY DRUG DEV TECHN, V6, P551, DOI 10.1089/adt.2008.149
   Ledwitch K, 2013, MINI-REV MED CHEM, V13, P509, DOI 10.2174/1389557511313040004
   Lee H, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-S1-S4
   Li HJ, 2011, ANN TROP MED PARASIT, V105, P181, DOI 10.1179/136485911X12899838683287
   Li HJ, 2012, PARASITOL RES, V110, P1727, DOI 10.1007/s00436-011-2692-x
   Li HJ, 2011, PARASITOL RES, V109, P515, DOI 10.1007/s00436-011-2474-5
   Li Y, 2012, ACTA PHARMACOL SIN, V33, P1141, DOI 10.1038/aps.2012.104
   Lin YC, 2013, SCI WORLD J, V2013, DOI DOI 10.1155/2013/736386
   Lionta E, 2014, CURR TOP MED CHEM, V14, P1923, DOI 10.2174/1568026614666140929124445
   Liu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064984
   Liu R, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-201
   Liu X, 2012, APPL BIOCHEM BIOTECH, V168, P1516, DOI 10.1007/s12010-012-9874-6
   Liu YX, 2014, MOLECULES, V19, P15058, DOI 10.3390/molecules190915058
   Lu SH, 2006, PARASITOL INT, V55, P63, DOI 10.1016/j.parint.2005.10.001
   Lyddiard JRA, 2002, J PARASITOL, V88, P163, DOI 10.1645/0022-3395(2002)088[0163:ABOIFM]2.0.CO;2
   Ma DL, 2011, CHEM SCI, V2, P1656, DOI 10.1039/c1sc00152c
   Ma XH, 2012, CURR MED CHEM, V19, P5562
   Magalhaes LG, 2010, PARASITOL RES, V106, P395, DOI 10.1007/s00436-009-1674-8
   Magalhaes LG, 2009, PARASITOL RES, V104, P1197, DOI 10.1007/s00436-008-1311-y
   Mangal M, 2013, NUCLEIC ACIDS RES, V41, pD1124, DOI 10.1093/nar/gks1047
   Manneck T, 2010, PARASITOLOGY, V137, P85, DOI 10.1017/S0031182009990965
   Manneck T, 2011, EXP PARASITOL, V127, P260, DOI 10.1016/j.exppara.2010.08.011
   Mansour NR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000795
   McGann M, 2012, J COMPUT AID MOL DES, V26, P897, DOI 10.1007/s10822-012-9584-8
   McGann M, 2011, J CHEM INF MODEL, V51, P578, DOI 10.1021/ci100436p
   Mei HP, 1997, EXP PARASITOL, V86, P69, DOI 10.1006/expr.1997.4150
   Melman SD, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000504
   Melo CC, 2014, CURR COMPUT-AID DRUG, V10, P148, DOI 10.2174/1573409910666140410111043
   Mierziak J, 2014, MOLECULES, V19, P16240, DOI 10.3390/molecules191016240
   Milacic V, 2008, CANCER RES, V68, P7283, DOI 10.1158/0008-5472.CAN-07-6246
   Miranda MA, 2012, PARASITOL RES, V111, P257, DOI 10.1007/s00436-012-2827-8
   Mohamed AA, 2009, T ROY SOC TROP MED H, V103, P1062, DOI 10.1016/j.trstmh.2009.01.026
   N'Goran EK, 2003, AM J TROP MED HYG, V68, P24, DOI 10.4269/ajtmh.2003.68.24
   Ndjonka D, 2013, INT J MOL SCI, V14, P3395, DOI 10.3390/ijms14023395
   Neves BJ, 2013, BIOORG MED CHEM LETT, V23, P2436, DOI 10.1016/j.bmcl.2013.02.006
   Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s
   Obonyo CO, 2010, LANCET INFECT DIS, V10, P603, DOI 10.1016/S1473-3099(10)70161-4
   Ojima I, 2008, J MED CHEM, V51, P2587, DOI 10.1021/jm701291u
   Oliveira MF, 2002, FEBS LETT, V512, P139, DOI 10.1016/S0014-5793(02)02243-3
   Oliveira MF, 2000, MOL BIOCHEM PARASIT, V111, P217, DOI 10.1016/S0166-6851(00)00299-1
   Panic G, 2014, INT J PARASITOL-DRUG, V4, P185, DOI 10.1016/j.ijpddr.2014.07.002
   Park H, 2014, J CHEM INF MODEL, V54, P2139, DOI 10.1021/ci500214e
   Patocka N, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003878
   Paveley RA, 2013, PARASITE IMMUNOL, V35, P302, DOI 10.1111/pim.12037
   Paveley RA, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001762
   Peak E, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000759
   del Villar LP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045867
   Porto TS, 2012, CHEM BIODIVERS, V9, P1465, DOI 10.1002/cbdv.201100336
   Postigo MP, 2010, J CHEM INF MODEL, V50, P1693, DOI 10.1021/ci100128k
   Qiu DS, 2013, SCI WORLD J, DOI 10.1155/2013/304047
   Ramalhete C, 2012, PLANTA MED, V78, P1912, DOI 10.1055/s-0032-1327832
   Ramalhete C, 2011, BIOORGAN MED CHEM, V19, P7474, DOI 10.1016/j.bmc.2011.10.044
   Ramalhete C, 2011, BIOORGAN MED CHEM, V19, P330, DOI 10.1016/j.bmc.2010.11.015
   Ramirez B, 2007, EXPERT OPIN DRUG DIS, V2, pS53, DOI 10.1517/17460441.2.S1.S53
   Ramos HP, 2013, NAT PROD RES, V27, P2240, DOI 10.1080/14786419.2013.811659
   Ravishankar D, 2013, INT J BIOCHEM CELL B, V45, P2821, DOI 10.1016/j.biocel.2013.10.004
   Ray D, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001168
   Ribeiro P, 2013, PARASITOL INT, V62, P629, DOI 10.1016/j.parint.2013.06.003
   Richmond NJ, 2006, J COMPUT AID MOL DES, V20, P567, DOI 10.1007/s10822-006-9082-y
   Ross AGP, 2002, NEW ENGL J MED, V346, P1212, DOI 10.1056/NEJMra012396
   Ross F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035033
   Roy K, 2012, MINI-REV MED CHEM, V12, P491, DOI 10.2174/138955712800493861
   Roy K, 2012, CHEMOMETR INTELL LAB, V118, P200, DOI 10.1016/j.chemolab.2012.06.004
   Roy K, 2012, J CHEM INF MODEL, V52, P396, DOI 10.1021/ci200520g
   Sanderson K, 2011, NAT MED, V17, P1531, DOI 10.1038/nm1211-1531a
   Schellhammer I, 2004, PROTEINS, V57, P504, DOI 10.1002/prot.20217
   Schmidt TJ, 2012, CURR MED CHEM, V19, P2176
   Schomburg KT, 2014, J CHEM INF MODEL, V54, P1676, DOI 10.1021/ci500130e
   Schuffenhauer A, 2011, MOL INFORM, V30, P646, DOI 10.1002/minf.201100078
   Schuster D, 2010, CURR PHARM DESIGN, V16, P1666, DOI 10.2174/138161210791164072
   Silva MPN, 2014, MOLECULES, V19, P3793, DOI 10.3390/molecules19033793
   Silva-Moraes V, 2013, MEM I OSWALDO CRUZ, V108, P600, DOI 10.1590/0074-0276108052013011
   Singh S, 2014, J BIOMOL SCREEN, V19, P640, DOI 10.1177/1087057114528537
   Spyrakis F, 2011, CURR TOP MED CHEM, V11, P192, DOI 10.2174/156802611794863571
   Steindl TM, 2006, J COMPUT AID MOL DES, V20, P703, DOI 10.1007/s10822-006-9066-y
   Sticher O, 2008, NAT PROD REP, V25, P517, DOI 10.1039/b700306b
   Tallima H, 2005, J PARASITOL, V91, P1094, DOI 10.1645/GE-514R.1
   ten Brink T, 2010, J COMPUT AID MOL DES, V24, P935, DOI 10.1007/s10822-010-9385-x
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Tung C.W., 2014, DATABASE, V2014
   Utzinger J, 2000, LANCET, V355, P1320, DOI 10.1016/S0140-6736(00)02114-0
   Valli M, 2013, J NAT PROD, V76, P439, DOI 10.1021/np3006875
   van Agtmael MA, 1999, TRENDS PHARMACOL SCI, V20, P199, DOI 10.1016/S0165-6147(99)01302-4
   van Dam RM, 2013, CURR OPIN LIPIDOL, V24, P25, DOI 10.1097/MOL.0b013e32835bcdff
   Veras LM, 2012, CURR MED CHEM, V19, P2051
   Verdonk ML, 2003, PROTEINS, V52, P609, DOI 10.1002/prot.10465
   Wang W, 2014, PARASITOL RES, V113, P925, DOI 10.1007/s00436-013-3724-5
   Warshaviak DT, 2014, J CHEM INF MODEL, V54, P1941, DOI 10.1021/ci500175r
   Waszkowycz B, 2011, WIRES COMPUT MOL SCI, V1, P229, DOI 10.1002/wcms.18
   Wermuth G, 1998, PURE APPL CHEM, V70, P1129
   WHO Schistosomiasis, 2014, WHO SCH
   Williams DL, 2013, ANTIOXID REDOX SIGN, V19, P735, DOI 10.1089/ars.2012.4670
   Wolber G, 2005, J CHEM INF MODEL, V45, P160, DOI 10.1021/ci049885e
   Wu WY, 2012, ACTA PHARMACOL SIN, V33, P1119, DOI 10.1038/aps.2012.126
   Xiao SH, 2000, INT J PARASITOL, V30, P1001, DOI 10.1016/S0020-7519(00)00091-6
   Xiao SH, 2000, PARASITOL INT, V49, P19, DOI 10.1016/S1383-5769(00)00028-3
   Xiao SH, 2003, PARASITOL RES, V89, P459, DOI 10.1007/s00436-002-0786-1
   Xiao SH, 2001, T ROY SOC TROP MED H, V95, P67, DOI 10.1016/S0035-9203(01)90336-0
   Xiao Shu-Hua, 2006, Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi, V24, P425
   Ye H, 2011, NUCLEIC ACIDS RES, V39, pD1055, DOI 10.1093/nar/gkq1165
   You JY, 2011, BIORESOURCE TECHNOL, V102, P6088, DOI 10.1016/j.biortech.2011.01.074
   Yue Y, 2014, BMC PLANT BIOL, V14, DOI 10.1186/s12870-014-0243-1
   Zhang LY, 2013, J CHEM INF MODEL, V53, P475, DOI 10.1021/ci300421n
   Zhang SM, 2013, INT J PARASITOL-DRUG, V3, P28, DOI 10.1016/j.ijpddr.2012.12.001
   Zhou LM, 2005, J CLIN PHARMACOL, V45, P1345, DOI 10.1177/0091270005282630
   Zhou Y, 2009, NATURE, V460, P345, DOI 10.1038/nature08140
   Ziniel PD, 2013, ANTIMICROB AGENTS CH, V57, P5969, DOI 10.1128/AAC.00699-13
NR 191
TC 37
Z9 38
U1 0
U2 50
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1420-3049
J9 MOLECULES
JI Molecules
PD FEB
PY 2015
VL 20
IS 2
BP 1872
EP 1903
DI 10.3390/molecules20021872
PG 32
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA CD0GH
UT WOS:000350748200007
PM 25625682
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Neves, BJ
   Braga, RC
   Bezerra, JCB
   Cravo, PVL
   Andrade, CH
AF Neves, Bruno J.
   Braga, Rodolpho C.
   Bezerra, Jose C. B.
   Cravo, Pedro V. L.
   Andrade, Carolina H.
TI In Silico Repositioning-Chemogenomics Strategy Identifies New Drugs with
   Potential Activity against Multiple Life Stages of Schistosoma mansoni
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID ENOYL-ACP REDUCTASE; CHEMICAL SPACE; CALCIUM; GRISEOFULVIN; PROTEIN;
   DESIGN; QSAR; PRAZIQUANTEL; INHIBITORS; TARGETS
AB Morbidity and mortality caused by schistosomiasis are serious public health problems in developing countries. Because praziquantel is the only drug in therapeutic use, the risk of drug resistance is a concern. In the search for new schistosomicidal drugs, we performed a target-based chemogenomics screen of a dataset of 2,114 proteins to identify drugs that are approved for clinical use in humans that may be active against multiple life stages of Schistosoma mansoni. Each of these proteins was treated as a potential drug target, and its amino acid sequence was used to interrogate three databases: Therapeutic Target Database (TTD), DrugBank and STITCH. Predicted drug-target interactions were refined using a combination of approaches, including pairwise alignment, conservation state of functional regions and chemical space analysis. To validate our strategy, several drugs previously shown to be active against Schistosoma species were correctly predicted, such as clonazepam, auranofin, nifedipine, and artesunate. We were also able to identify 115 drugs that have not yet been experimentally tested against schistosomes and that require further assessment. Some examples are aprindine, gentamicin, clotrimazole, tetrabenazine, griseofulvin, and cinnarizine. In conclusion, we have developed a systematic and focused computer-aided approach to propose approved drugs that may warrant testing and/or serve as lead compounds for the design of new drugs against schistosomes.
C1 [Neves, Bruno J.; Braga, Rodolpho C.; Andrade, Carolina H.] Univ Fed Goias, Fac Farm, LabMol Lab Drug Design & Modeling, Goiania, Go, Brazil.
   [Neves, Bruno J.; Bezerra, Jose C. B.; Cravo, Pedro V. L.; Andrade, Carolina H.] Univ Fed Goias, Inst Patol Trop & Saude Publ, Goiania, Go, Brazil.
   [Braga, Rodolpho C.] Univ Fed Goias, Inst Quim, Goiania, Go, Brazil.
   [Cravo, Pedro V. L.] Univ Nova Lisboa, Inst Higiene & Med Trop, Ctr Malaria & Doencas Trop, P-1200 Lisbon, Portugal.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, LabMol Lab Drug Design & Modeling, Goiania, Go, Brazil.
EM carolina@ufg.br
RI Andrade, Carolina/C-3960-2014; Braga, Rodolpho C/A-9655-2011; Cravo,
   Pedro VL/G-3532-2012; Neves, Bruno/R-7068-2019; Neves, Bruno
   Junior/E-6295-2016
OI Andrade, Carolina/0000-0003-0101-1492; Braga, Rodolpho
   C/0000-0003-3814-3464; Cravo, Pedro VL/0000-0003-1675-4504; Neves,
   Bruno/0000-0002-1309-8743; Bezerra, Jose Clecildo
   Barreto/0000-0003-4691-9074
FU Coordination for the Improvement of Higher Education Personnel
   (CAPES)CAPES; National Counsel of Technological and Scientific
   Development (CNPq)National Council for Scientific and Technological
   Development (CNPq); State of Goias Research Foundation (FAPEG)
FX BJN was supported by a fellowship from the Coordination for the
   Improvement of Higher Education Personnel (CAPES). This work has been
   funded by the National Counsel of Technological and Scientific
   Development (CNPq) and the State of Goias Research Foundation (FAPEG).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abdulla MH, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000478
   Agarwal P, 1998, BIOINFORMATICS, V14, P40, DOI 10.1093/bioinformatics/14.1.40
   Aguero F, 2008, NAT REV DRUG DISCOV, V7, P900, DOI 10.1038/nrd2684
   Alves VM, 2014, 248 ACS NAT M EXP SA
   Andrade CH, 2008, MOL DIVERS, V12, P47, DOI 10.1007/s11030-008-9074-z
   Andrade CH, 2014, CURR TOP MED CHEM, V14, P1323, DOI 10.2174/1568026614666140506114019
   Andrade CH, 2010, MOLECULES, V15, P3281, DOI 10.3390/molecules15053281
   Andrade CH, 2009, J CHEM INF MODEL, V49, P1070, DOI 10.1021/ci8004622
   Andrade CH, 2008, LETT DRUG DES DISCOV, V5, P377, DOI 10.2174/157018008785777289
   Andrade CH, 2008, REV BRAS CIENC FARM, V44, P167, DOI 10.1590/S1516-93322008000200002
   Andrade CH, 2010, J COMPUT AID MOL DES, V24, P157, DOI 10.1007/s10822-010-9323-y
   Andrade CH, 2014, CURR DRUG METAB
   Angelucci F, 2009, J BIOL CHEM, V284, P28977, DOI 10.1074/jbc.M109.020701
   [Anonymous], 2014, NAT REV DRUG DISCOV, V13, P565
   Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131
   Ashkenazy H, 2010, NUCLEIC ACIDS RES, V38, pW529, DOI 10.1093/nar/gkq399
   Audisio D, 2010, EUR J MED CHEM, V45, P2000, DOI 10.1016/j.ejmech.2010.01.048
   Berriman M, 2009, NATURE, V460, P352, DOI 10.1038/nature08160
   Bispo NA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059288
   Bon RS, 2010, ACCOUNTS CHEM RES, V43, P1103, DOI 10.1021/ar100014h
   Braga RC, 2012, MINI-REV MED CHEM, V12, P573
   Braga RC, 2012, 244 AM CHEM SOC NAT
   Braga RC, 2014, 248 ACS NAT M EXP SA
   Braga RC, 2014, CURR TOP MED CHEM, V14
   Braga RC, 2010, 240 AM CHEM SOC NAT
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1399, DOI 10.2174/1568026614666140506124442
   Braga RC, 2013, CURR TOP MED CHEM, V13, P1127, DOI 10.2174/1568026611313090010
   BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909
   Bredel M, 2004, NAT REV GENET, V5, P262, DOI 10.1038/nrg1317
   BRIAN PW, 1949, ANN BOT-LONDON, V13, P59, DOI 10.1093/oxfordjournals.aob.a083206
   BRUGNARA C, 1993, J CLIN INVEST, V92, P520, DOI 10.1172/JCI116597
   Bueno RV, 2014, CURR PHARM DESIGN, V20, P4474
   Bueno RV, 2013, J MOL MODEL, V19, P179, DOI 10.1007/s00894-012-1527-8
   Burke ML, 2009, PARASITE IMMUNOL, V31, P163, DOI 10.1111/j.1365-3024.2009.01098.x
   Caffrey CR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004413
   Carneiro EO, 2010, BIOORG MED CHEM LETT, V20, P3734, DOI 10.1016/j.bmcl.2010.04.073
   Chantree P, 2013, EXP PARASITOL, V135, P102, DOI 10.1016/j.exppara.2013.06.010
   Chaudhuri AR, 1996, BIOCHEM PHARMACOL, V51, P903
   Clark PM, 2012, INFLAMM BOWEL DIS, V18, P2315, DOI 10.1002/ibd.22958
   COHEN CJ, 1992, J GEN PHYSIOL, V100, P703, DOI 10.1085/jgp.100.4.703
   Colley DG, 2014, LANCET, V383, P2253, DOI 10.1016/S0140-6736(13)61949-2
   Czymmek KJ, 2005, PROTOPLASMA, V225, P23, DOI 10.1007/s00709-004-0081-3
   Barros MED, 2007, J MED MICROBIOL, V56, P514, DOI 10.1099/jmm.0.46542-0
   Dobson CM, 2004, NATURE, V432, P824, DOI 10.1038/nature03192
   Doenhoff MJ, 2008, CURR OPIN INFECT DIS, V21, P659, DOI 10.1097/QCO.0b013e328318978f
   Dong YQ, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/718491
   Edfeldt FNB, 2011, DRUG DISCOV TODAY, V16, P284, DOI 10.1016/j.drudis.2011.02.002
   Ekins S, 2011, DRUG DISCOV TODAY, V16, P298, DOI 10.1016/j.drudis.2011.02.016
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   FUSCO AC, 1991, J PARASITOL, V77, P649, DOI 10.2307/3282693
   Gobert GN, 2007, PARASITOLOGY, V134, P453, DOI 10.1017/S0031182006001648
   GONNERT R, 1977, Z PARASITENKD, V52, P129, DOI 10.1007/BF00389899
   Gryseels B, 2001, TROP MED INT HEALTH, V6, P864, DOI 10.1046/j.1365-3156.2001.00811.x
   Gryseels B, 2006, LANCET, V368, P1106, DOI 10.1016/S0140-6736(06)69440-3
   Halacli SO, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0575-y
   He YX, 2005, TRENDS PARASITOL, V21, P201, DOI 10.1016/j.pt.2005.03.003
   Hertz-Fowler C, 2004, NUCLEIC ACIDS RES, V32, pD339, DOI 10.1093/nar/gkh007
   Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892
   Iorio F, 2010, AUTOPHAGY, V6, P1204, DOI [10.1073/pnas.1000138107, 10.4161/auto.6.8.13551]
   Ismail M, 1996, AM J TROP MED HYG, V55, P214, DOI 10.4269/ajtmh.1996.55.214
   JAFFE JJ, 1972, BIOCHEM PHARMACOL, V21, P719, DOI 10.1016/0006-2952(72)90064-0
   Jankovic J, 2011, EXPERT REV NEUROTHER, V11, P1509, DOI [10.1586/ERN.11.149, 10.1586/ern.11.149]
   Katoh Kazutaka, 2005, Genome Inform, V16, P22
   KATSUMATA T, 1989, PARASITOL RES, V76, P90, DOI 10.1007/BF00931079
   KATSUMATA T, 1988, J PARASITOL, V74, P1040, DOI 10.2307/3282230
   King CH, 2005, LANCET, V365, P1561, DOI 10.1016/S0140-6736(05)66457-4
   Kuhn M, 2012, NUCLEIC ACIDS RES, V40, pD876, DOI 10.1093/nar/gkr1011
   Lachance H, 2012, J MED CHEM, V55, P5989, DOI 10.1021/jm300288g
   Landrum G., 2014, RDKIT OPEN SOURCE CH
   LEVINE SN, 1983, J CARDIOVASC PHARM, V5, P151, DOI 10.1097/00005344-198301000-00023
   LEWERT RM, 1966, AM J TROP MED HYG, V15, P314, DOI 10.4269/ajtmh.1966.15.314
   Li SW, 1996, CHINESE MED J-PEKING, V109, P848
   Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158
   Li YY, 2012, GENOME MED, V4, DOI 10.1186/gm326
   Lipinski C, 2004, NATURE, V432, P855, DOI 10.1038/nature03193
   Ma DL, 2013, CHEM SOC REV, V42, P2130, DOI 10.1039/c2cs35357a
   Mayrose I, 2004, MOL BIOL EVOL, V21, P1781, DOI 10.1093/molbev/msh194
   Melman SD, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000504
   Melo CC, 2014, CURR COMPUT-AID DRUG, V10, P148, DOI 10.2174/1573409910666140410111043
   Menezes CMS, 2012, CHEM BIOL DRUG DES, V79, P943, DOI 10.1111/j.1747-0285.2012.01354.x
   Miyazaki T, 2004, J BIOL CHEM, V279, P17295, DOI 10.1074/jbc.M312217200
   Nessim NG, 2000, ARZNEIMITTELFORSCH, V50, P1129
   Neves BJ, 2013, BIOORG MED CHEM LETT, V23, P2436, DOI 10.1016/j.bmcl.2013.02.006
   Oxford AE, 1939, BIOCHEM J, V33, P240, DOI 10.1042/bj0330240
   del Villar LP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045867
   Protasio AV, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001455
   Pupko T, 2002, BIOINFORMATICS, V18, P1116, DOI 10.1093/bioinformatics/18.8.1116
   R Development Core Team, 2008, R LANG ENV STAT COMP
   Rathinasamy K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-213
   Rebacz B, 2007, CANCER RES, V67, P6342, DOI 10.1158/0008-5472.CAN-07-0663
   Ribeiro P, 2013, PARASITOL INT, V62, P629, DOI 10.1016/j.parint.2013.06.003
   Rognan D, 2007, BRIT J PHARMACOL, V152, P38, DOI 10.1038/sj.bjp.0707307
   Rollinson D, 2013, ACTA TROP, V128, P423, DOI 10.1016/j.actatropica.2012.04.013
   Ruge E, 2005, INT J ANTIMICROB AG, V26, P427, DOI 10.1016/j.ijantimicag.2005.09.006
   Russ AP, 2005, DRUG DISCOV TODAY, V10, P1607, DOI 10.1016/S1359-6446(05)03666-4
   Salathe M, 2007, ANNU REV PHYSIOL, V69, P401, DOI 10.1146/annurev.physiol.69.040705.141253
   Silva-Moraes V, 2013, MEM I OSWALDO CRUZ, V108, P600, DOI 10.1590/0074-0276108052013011
   SINGH BN, 1986, BRIT J CLIN PHARMACO, V21, pS109, DOI 10.1111/j.1365-2125.1986.tb02860.x
   Smout MJ, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000885
   Sundar S, 2002, NEW ENGL J MED, V347, P1739, DOI 10.1056/NEJMoa021556
   Taft AS, 2010, EXP PARASITOL, V125, P84, DOI 10.1016/j.exppara.2009.12.021
   Tidow H, 2013, FEBS J, V280, P5551, DOI 10.1111/febs.12296
   Uen YH, 2007, J CELL BIOCHEM, V101, P1165, DOI 10.1002/jcb.21240
   Wang W, 2012, PARASITOL RES, V111, P1871, DOI 10.1007/s00436-012-3151-z
   Wang YL, 2012, NUCLEIC ACIDS RES, V40, pD400, DOI 10.1093/nar/gkr1132
   WHO, 2014, SCHISTOSOMIASIS
   Wimalasena K, 2011, MED RES REV, V31, P483, DOI 10.1002/med.20187
   Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067
   World Health Organization, 2012, PROGR REP 2001 2011
   Yang J, 2012, PARASITOL RES, V110, P1785, DOI 10.1007/s00436-011-2700-1
   Yang ZH, 2013, INFECT IMMUN, V81, P1905, DOI 10.1128/IAI.00053-13
   Yazejian B, 2000, NAT NEUROSCI, V3, P566
   Zhu F, 2010, NUCLEIC ACIDS RES, V38, pD787, DOI 10.1093/nar/gkp1014
NR 113
TC 24
Z9 26
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JAN
PY 2015
VL 9
IS 1
AR e3435
DI 10.1371/journal.pntd.0003435
PG 12
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CB0LR
UT WOS:000349318100035
PM 25569258
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Alves, VM
   Braga, RC
   Silva, MB
   Muratov, E
   Fourches, D
   Tropsha, A
   Andrade, CH
AF Alves, Vinicius M.
   Braga, Rodolpho C.
   Silva, Meryck B.
   Muratov, Eugene
   Fourches, Denis
   Tropsha, Alexander
   Andrade, Carolina H.
TI Pred-hERG: A novel web-accessible computational tool for predicting
   cardiac toxicity of drug candidates
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 248th National Meeting of the American-Chemical-Society (ACS)
CY AUG 10-14, 2014
CL San Francisco, CA
SP Amer Chem Soc
C1 [Alves, Vinicius M.; Braga, Rodolpho C.; Silva, Meryck B.; Andrade, Carolina H.] Univ Fed Goias, Fac Pharm, Lab Mol Modeling & Drug Design, BR-74605170 Goiania, Go, Brazil.
   [Muratov, Eugene; Fourches, Denis; Tropsha, Alexander] Univ N Carolina, Div Chem Biol & Med Chem, Lab Mol Modeling, Chapel Hill, NC 27599 USA.
EM viniciusm.alves@gmail.com; rodolphobraga@yahoo.com; carolina@ufg.br
RI Muratov, Eugene/C-4454-2014; Tropsha, Alexander/AAB-8324-2020; Fourches,
   Denis/H-4336-2019; Andrade, Carolina/C-3960-2014; Braga, Rodolpho
   C/A-9655-2011; Alves, Vinicius M./G-7955-2015
OI Muratov, Eugene/0000-0003-4616-7036; Andrade,
   Carolina/0000-0003-0101-1492; Braga, Rodolpho C/0000-0003-3814-3464;
   Alves, Vinicius M./0000-0002-6182-1748
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 10
PY 2014
VL 248
MA 40-CINF
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA CA8JN
UT WOS:000349165103325
DA 2020-12-01
ER

PT J
AU Braga, RC
   Pinto, EG
   Martins, LF
   Tempone, AG
   Liao, LM
   Andrade, CH
AF Braga, Rodolpho C.
   Pinto, Erika G.
   Martins, Ligia F.
   Tempone, Andre G.
   Liao, Luciano M.
   Andrade, Carolina H.
TI Multitarget virtual screening approach: Identification of new hit
   compounds against Leishmania infantum
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 248th National Meeting of the American-Chemical-Society (ACS)
CY AUG 10-14, 2014
CL San Francisco, CA
SP Amer Chem Soc
C1 [Braga, Rodolpho C.; Andrade, Carolina H.] Univ Fed Goias, Fac Pharm, LabMol Lab Mol Modeling & Drug Design, Setor Leste Univ, BR-74605170 Goiania, Go, Brazil.
   [Braga, Rodolpho C.; Liao, Luciano M.] Univ Fed Goias, Inst Chem, Nucl Magnet Resonance Lab, BR-74001970 Goiania, Go, Brazil.
   [Pinto, Erika G.; Martins, Ligia F.; Tempone, Andre G.] Adolfo Lutz Inst, Dept Parasitol, BR-01246000 Sao Paulo, Brazil.
EM rodolphobraga@yahoo.com; carolina@ufg.br
RI Andrade, Carolina/C-3960-2014; Tempone, Andre/ABA-2231-2020; Braga,
   Rodolpho C/A-9655-2011; Pinto, Erika/Z-1585-2019; Liao, Luciano
   Morais/M-3030-2019; Liao, Luciano Morais M./F-1487-2015
OI Andrade, Carolina/0000-0003-0101-1492; Tempone,
   Andre/0000-0003-2559-7344; Braga, Rodolpho C/0000-0003-3814-3464; Liao,
   Luciano Morais/0000-0001-9985-2980; Liao, Luciano Morais
   M./0000-0001-9985-2980
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 10
PY 2014
VL 248
MA 322-COMP
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA CA8JN
UT WOS:000349165104547
DA 2020-12-01
ER

PT J
AU Andrade, CH
   Silva, DC
   Braga, RC
AF Andrade, Carolina H.
   Silva, Diego C.
   Braga, Rodolpho C.
TI In silico Prediction of Drug Metabolism by P450
SO CURRENT DRUG METABOLISM
LA English
DT Article
DE Cytochrome P450; docking; drug discovery; ligand-based; metabolism;
   prediction; structure-based
ID CYTOCHROME-P450 ACTIVE-SITES; PREGNANE-X-RECEPTOR; COMPUTATIONAL
   PREDICTION; EXPERIMENTAL VALIDATION; SARCOPLASMIC-RETICULUM; DIETARY
   FLAVONOIDS; RITONAVIR ANALOGS; CRYSTAL-STRUCTURE; DIVERSE LIGANDS; RIGHT
   QUERY
AB In the drug discovery cascade, metabolism studies should be performed as early as possible to allow an early evaluation of the metabolism profiles of drug candidates. To help design new drug candidates with improved pharmacokinetics, the knowledge of the site of metabolism is necessary. Computational or in silico metabolism approaches can be broadly classified into (i) ligand-based methods, and (ii) structure-based methods. This review highlight tools used to predict P450-mediated metabolism including ligand-based and structure-based approaches. Some examples of successful application of an integrated in silico approach for the prediction of Phase I metabolism for some flavonoids and lead compounds are presented. Moreover, an integrated in silico approach for the prediction of P450mediated metabolism is described.
C1 [Andrade, Carolina H.; Silva, Diego C.; Braga, Rodolpho C.] Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, BR-74605170 Goiania, Go, Brazil.
   [Braga, Rodolpho C.] Univ Fed Goias, Inst Quim, BR-74001970 Goiania, Go, Brazil.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, LabMol, Rua 240,Qd 87,Setor Leste Univ, BR-74605170 Goiania, Go, Brazil.
EM carolina@ufg.br
RI Braga, Rodolpho C/A-9655-2011; Andrade, Carolina/C-3960-2014
OI Braga, Rodolpho C/0000-0003-3814-3464; Andrade,
   Carolina/0000-0003-0101-1492
FU CNPq (The National Council for Scientific and Technological
   Development)National Council for Scientific and Technological
   Development (CNPq); FAPEG (The State of Goias Research Foundation);
   CAPES (Coordination for the Improvement of Higher Education Personnel),
   BrazilCAPES
FX We gratefully acknowledge financial support from CNPq (The National
   Council for Scientific and Technological Development), FAPEG (The State
   of Goias Research Foundation) and CAPES (Coordination for the
   Improvement of Higher Education Personnel), Brazil. We are also grateful
   fo OpenEye Scientific Software Inc. and ChemAxon for providing academic
   licenses of their software.
CR Afzelius L, 2007, DRUG METAB REV, V39, P61, DOI 10.1080/03602530600969374
   Almond LM, 2009, CURR DRUG METAB, V10, P420, DOI 10.2174/138920009788498978
   Andrade CH, 2010, MOLECULES, V15, P3281, DOI 10.3390/molecules15053281
   Andrade CH, 2009, J CHEM INF MODEL, V49, P1070, DOI 10.1021/ci8004622
   [Anonymous], OEDOCKING 3 0 1
   Barreiro EJ, 2013, REV VIRTUAL QUIM, V5, P266, DOI 10.5935/1984-6835.20130026
   Bazeley PS, 2006, J CHEM INF MODEL, V46, P2698, DOI 10.1021/ci600267k
   Bikadi Z, 2008, BBA-GEN SUBJECTS, V1780, P1070, DOI 10.1016/j.bbagen.2008.06.001
   Bostrom J, 2003, J MOL GRAPH MODEL, V21, P449, DOI 10.1016/S1093-3263(02)00204-8
   Boyer S, 2007, J CHEM INF MODEL, V47, P583, DOI 10.1021/ci600376q
   Braga RC, 2012, MINI-REV MED CHEM, V12, P573
   Braga RC, 2012, J MOL MODEL, V18, P2065, DOI 10.1007/s00894-011-1219-9
   Braga RC, 2011, J PHARMACEUT BIOMED, V55, P1024, DOI 10.1016/j.jpba.2011.02.031
   Breinholt VM, 2002, FOOD CHEM TOXICOL, V40, P609, DOI 10.1016/S0278-6915(01)00125-9
   Buchwald P, 2002, DRUG FUTURE, V27, P577, DOI 10.1358/dof.2002.027.06.856934
   Bugrim A, 2004, DRUG DISCOV TODAY, V9, P127, DOI 10.1016/S1359-6446(03)02971-4
   Carneiro EO, 2010, BIOORG MED CHEM LETT, V20, P3734, DOI 10.1016/j.bmcl.2010.04.073
   Castro-Perez JM, 2007, DRUG DISCOV TODAY, V12, P249, DOI 10.1016/j.drudis.2007.01.007
   Chu V, 2009, DRUG METAB DISPOS, V37, P1339, DOI 10.1124/dmd.109.027029
   Conrado DJ, 2008, J PHARM PHARMACOL, V60, P699, DOI 10.1211/jpp.60.6.0004
   Costa DG, 2010, AM J HYPERTENS, V23, P1220, DOI 10.1038/ajh.2010.157
   Czodrowski P, 2009, EXPERT OPIN DRUG MET, V5, P15, DOI [10.1517/17425250802568009, 10.1517/17425250802568009 ]
   da Silva EL, 1998, FEBS LETT, V430, P405, DOI 10.1016/S0014-5793(98)00709-1
   De Benedetti PG, 2010, DRUG DISCOV TODAY, V15, P859, DOI 10.1016/j.drudis.2010.08.003
   de Graaf C, 2006, J MED CHEM, V49, P2417, DOI 10.1021/jm0508538
   de Graaf C, 2005, J MED CHEM, V48, P2725, DOI 10.1021/jm040180d
   de Groot MJ, 2006, DRUG DISCOV TODAY, V11, P601, DOI 10.1016/j.drudis.2006.05.001
   de Groot MJ, 2004, CURR TOP MED CHEM, V4, P1803, DOI 10.2174/1568026043387061
   de Groot MJ, 1999, J MED CHEM, V42, P1515, DOI 10.1021/jm981118h
   de Montellano P. R. O., 2010, CYTOCHROME P450 STRU, P664
   Dudek AZ, 2006, COMB CHEM HIGH T SCR, V9, P213, DOI 10.2174/138620706776055539
   Ekins S, 2001, DRUG METAB DISPOS, V29, P936
   Ekroos M, 2006, P NATL ACAD SCI USA, V103, P13682, DOI 10.1073/pnas.0603236103
   Figueiredo JM, 2000, BIOORGAN MED CHEM, V8, P2243, DOI 10.1016/S0968-0896(00)00152-8
   Gomes TF, 2013, EUR J MED CHEM, V62, P214, DOI 10.1016/j.ejmech.2012.08.011
   Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Hopfinger AJ, 1997, J AM CHEM SOC, V119, P10509, DOI 10.1021/ja9718937
   Hosea NA, 2000, BIOCHEMISTRY-US, V39, P5929, DOI 10.1021/bi992765t
   Hosny M, 2001, J NAT PROD, V64, P462, DOI 10.1021/np000457m
   Jones BC, 2009, PROGR MED CHEM, V47, P239, DOI 10.1016/S0079-6468(08)00206-3
   Julsing MK, 2008, EUR J MED CHEM, V43, P1171, DOI 10.1016/j.ejmech.2007.09.005
   Jung J, 2008, J CHEM INF MODEL, V48, P1074, DOI 10.1021/ci800001m
   Kanth BK, 2010, COMPUT BIOL CHEM, V34, P226, DOI 10.1016/j.compbiolchem.2010.08.002
   Keizers PHJ, 2005, J MED CHEM, V48, P6117, DOI 10.1021/jm050338+
   Khandelwal A, 2008, CHEM RES TOXICOL, V21, P1457, DOI 10.1021/tx800102e
   Kirchmair J, 2007, J CHEM INF MODEL, V47, P2182, DOI 10.1021/ci700024q
   Kirchmair J, 2012, J CHEM INF MODEL, V52, P617, DOI 10.1021/ci200542m
   Kirchmair J, 2009, J CHEM INF MODEL, V49, P678, DOI 10.1021/ci8004226
   Kitchen DB, 2004, NAT REV DRUG DISCOV, V3, P935, DOI 10.1038/nrd1549
   Korzekwa KR, 1998, BIOCHEMISTRY-US, V37, P4137, DOI 10.1021/bi9715627
   Kristam R, 2005, J CHEM INF MODEL, V45, P461, DOI 10.1021/ci049731z
   Kroemer RT, 2007, CURR PROTEIN PEPT SC, V8, P312
   Kumar GN, 2001, MED RES REV, V21, P397, DOI 10.1002/med.1016
   Liu X, 2013, PROTEIN PEPTIDE LETT, V20, P279
   Ma BY, 2002, PROTEIN SCI, V11, P184, DOI 10.1110/ps.21302
   Manly CJ, 2001, DRUG DISCOV TODAY, V6, P1101, DOI 10.1016/S1359-6446(01)01990-0
   Marechal JD, 2006, DRUG METAB DISPOS, V34, P534, DOI 10.1124/dmd.105.007625
   McGann M, 2012, J COMPUT AID MOL DES, V26, P897, DOI 10.1007/s10822-012-9584-8
   McGann M, 2011, J CHEM INF MODEL, V51, P578, DOI 10.1021/ci100436p
   McLaughlin LA, 2005, J BIOL CHEM, V280, P38617, DOI 10.1074/jbc.M505974200
   Melo CC, 2014, CURR DRUG METAB, V15, P120, DOI 10.2174/1389200215666140130125339
   Menegatti R, 2003, BIOORGAN MED CHEM, V11, P4807, DOI 10.1016/S0968-0896(03)00487-5
   Modi S, 1997, BIOCHEMISTRY-US, V36, P4461, DOI 10.1021/bi962633p
   Moroy G, 2012, DRUG DISCOV TODAY, V17, P44, DOI 10.1016/j.drudis.2011.10.023
   Nebert DW, 2000, PHARMACOLOGY, V61, P124, DOI 10.1159/000028393
   Neves G, 2008, PHARMACOL BIOCHEM BE, V89, P23, DOI 10.1016/j.pbb.2007.10.018
   Perez-Nueno VI, 2011, J CHEM INF MODEL, V51, P1233, DOI 10.1021/ci100492r
   Poulos TL, 2003, P NATL ACAD SCI USA, V100, P13121, DOI 10.1073/pnas.2336095100
   Putta S, 2007, CURR TOP MED CHEM, V7, P1514, DOI 10.2174/156802607782194770
   Reynald RL, 2012, J BIOL CHEM, V287, P44581, DOI 10.1074/jbc.M112.424895
   Rydberg P, 2010, BIOINFORMATICS, V26, P2988, DOI 10.1093/bioinformatics/btq584
   Sander T, 2009, J CHEM INF MODEL, V49, P232, DOI 10.1021/ci800305f
   Sansen S, 2007, J BIOL CHEM, V282, P14348, DOI 10.1074/jbc.M611692200
   Sevrioukova IF, 2013, BIOCHEMISTRY-US, V52, P4474, DOI 10.1021/bi4005396
   Sevrioukova IF, 2013, J MED CHEM, V56, P3733, DOI 10.1021/jm400288z
   Sevrioukova IF, 2012, ARCH BIOCHEM BIOPHYS, V520, P108, DOI 10.1016/j.abb.2012.02.018
   Sevrioukova IF, 2012, J BIOL CHEM, V287, P3510, DOI 10.1074/jbc.M111.317081
   Sevrioukova IF, 2010, P NATL ACAD SCI USA, V107, P18422, DOI 10.1073/pnas.1010693107
   Sousa MC, 2013, FOOD RES INT, V50, P102, DOI 10.1016/j.foodres.2012.09.027
   Stjernschantz E, 2008, EXPERT OPIN DRUG MET, V4, P513, DOI [10.1517/17425255.4.5.513, 10.1517/17425255.4.5.513 ]
   Sun H, 2010, CHEM BIOL DRUG DES, V75, P3, DOI 10.1111/j.1747-0285.2009.00899.x
   Testa B, 2004, PURE APPL CHEM, V76, P907, DOI 10.1351/pac200476050907
   Todeschini R., 2008, HDB MOL DESCRIPTORS
   Tompkins LM, 2007, J BIOCHEM MOL TOXIC, V21, P176, DOI 10.1002/jbt.20180
   van de Waterbeemd H, 2003, NAT REV DRUG DISCOV, V2, P192, DOI 10.1038/nrd1032
   Vedani A, 2000, J MED CHEM, V43, P4416, DOI 10.1021/jm000986n
   Vedani A, 2005, J MED CHEM, V48, P3700, DOI 10.1021/jm050185q
   Vedani A, 2002, J MED CHEM, V45, P2139, DOI 10.1021/jm011005p
   Wang A, 2012, J BIOL CHEM, V287, P10834, DOI 10.1074/jbc.M111.307918
   Wester MR, 2004, J BIOL CHEM, V279, P35630, DOI 10.1074/jbc.M405427200
   Wester MR, 2003, BIOCHEMISTRY-US, V42, P6370, DOI 10.1021/bi0273922
   Williams PA, 2003, NATURE, V424, P464, DOI 10.1038/nature01862
   Williams PA, 2004, SCIENCE, V305, P683, DOI 10.1126/science.1099736
   Yasuda K, 2008, DRUG METAB DISPOS, V36, P1689, DOI 10.1124/dmd.108.020701
   Young D., 2009, COMPUTATIONAL DRUG D
   Zamora I, 2003, J MED CHEM, V46, P2313, DOI 10.1021/jm021104i
   Zapata-Sudo G, 2003, EUR J PHARMACOL, V470, P79, DOI 10.1016/S0014-2999(03)01757-6
   Zhang L, 2009, AAPS J, V11, P300, DOI 10.1208/s12248-009-9106-3
   Zhang T, 2011, COMB CHEM HIGH T SCR, V14, P388, DOI 10.2174/138620711795508412
   Zhou SF, 2008, CURR DRUG METAB, V9, P310, DOI 10.2174/138920008784220664
NR 101
TC 10
Z9 10
U1 0
U2 14
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2002
EI 1875-5453
J9 CURR DRUG METAB
JI Curr. Drug Metab.
PY 2014
VL 15
IS 5
BP 514
EP 525
DI 10.2174/1389200215666140908102530
PG 12
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA AW8SZ
UT WOS:000346533100004
PM 25204822
DA 2020-12-01
ER

PT J
AU Bueno, RV
   Braga, RC
   Segretti, ND
   Ferreira, EI
   Trossini, GHG
   Andrade, CH
AF Bueno, Renata V.
   Braga, Rodolpho C.
   Segretti, Natanael D.
   Ferreira, Elizabeth I.
   Trossini, Gustavo H. G.
   Andrade, Carolina H.
TI New Tuberculostatic Agents Targeting Nucleic Acid Biosynthesis: Drug
   Design using QSAR Approaches
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Tuberculosis; new targets; DNA synthesis; drug design; QSAR
ID THYMIDINE MONOPHOSPHATE KINASE; MYCOBACTERIAL ATP SYNTHASE; DNA GYRASE
   INHIBITORS; MULTIDRUG-RESISTANT TUBERCULOSIS; CATALASE-PEROXIDASE GENE;
   ENOYL-ACP REDUCTASE; RIBONUCLEOTIDE REDUCTASE; THYMIDYLATE KINASE;
   ANTIBACTERIAL ACTIVITY; RATIONAL DESIGN
AB Worldwide, tuberculosis (TB) is the leading cause of death among curable infectious diseases. The emergence of multidrug resistant (MDR) and extensively drug resistant (XDR) TB is a growing global health concern and there is an urgent need for new anti-TB drugs. Enzymes involved in DNA and ATP biosynthesis are potential targets for tuberculostatic drug design, since these enzymes are essential for Mycobacterium tuberculosis growth. This review presents the current progress and applications of structure-activity relationship analysis for the discovery of innovative tuberculostatic agents as inhibitors of ribonucleotide reductase, DNA gyrase, ATP synthase, and thymidylate kinase enzymes, highlighting present challenges and new opportunities in TB drug design.
C1 [Bueno, Renata V.; Braga, Rodolpho C.; Andrade, Carolina H.] Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Design, Setor Univ, BR-74605220 Goiania, Go, Brazil.
   [Braga, Rodolpho C.] Univ Fed Goias, Inst Quim, BR-74001970 Goiania, Go, Brazil.
   [Segretti, Natanael D.; Ferreira, Elizabeth I.; Trossini, Gustavo H. G.] Univ Sao Paulo, Fac Ciencias Farmaceut, LAPEN, BR-05508900 Sao Paulo, Brazil.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, LabMol, Setor Univ, 1a Av Com Praca Univ, BR-74605220 Goiania, Go, Brazil.
EM carolina@ufg.br
RI Trossini, Gustavo/A-5789-2013; Trossini, Gustavo/AAQ-2537-2020; Braga,
   Rodolpho C/A-9655-2011; Andrade, Carolina/C-3960-2014; Ferreira,
   Elizabeth I/C-4038-2012
OI Trossini, Gustavo/0000-0003-3634-2531; Trossini,
   Gustavo/0000-0003-3634-2531; Braga, Rodolpho C/0000-0003-3814-3464;
   Andrade, Carolina/0000-0003-0101-1492; Ferreira, Elizabeth
   I/0000-0003-2087-033X
FU CAPESCAPES; CNPqNational Council for Scientific and Technological
   Development (CNPq); FAPEG; FAPESPFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [2011/11499-0]
FX The authors thank Brazilian Funding Agencies CAPES, CNPq, FAPEG and
   FAPESP (project 2011/11499-0) for financial support and fellowships. We
   are also grateful to OpenEye Scientific Software, Inc. for providing us
   with the academic licenses for their software.
CR Aboul-Fadl T, 2011, MOLECULES, V16, P7864, DOI 10.3390/molecules16097864
   Andrade CH, 2008, MOL DIVERS, V12, P47, DOI 10.1007/s11030-008-9074-z
   Andrade CH, 2010, MOLECULES, V15, P3281, DOI 10.3390/molecules15053281
   Andrade CH, 2009, J CHEM INF MODEL, V49, P1070, DOI 10.1021/ci8004622
   Andrade CH, 2008, LETT DRUG DES DISCOV, V5, P377, DOI 10.2174/157018008785777289
   Andrade CH, 2008, REV BRAS CIENC FARM, V44, P167, DOI 10.1590/S1516-93322008000200002
   Andrade CH, 2010, J COMPUT AID MOL DES, V24, P157, DOI 10.1007/s10822-010-9323-y
   Andries K, 2005, SCIENCE, V307, P223, DOI 10.1126/science.1106753
   [Anonymous], 2012, OED VER 3 0 0
   Anquetin G, 2006, EUR J MED CHEM, V41, P1478, DOI 10.1016/j.ejmech.2006.07.003
   Aparna V, 2006, BIOORG MED CHEM LETT, V16, P1014, DOI 10.1016/j.bmcl.2005.10.086
   Arbex MA, 2010, J BRAS PNEUMOL, V36, P641, DOI 10.1590/S1806-37132010000500017
   Aubry A, 2004, ANTIMICROB AGENTS CH, V48, P1281, DOI 10.1128/AAC.48.4.1281-1288.2004
   Aubry A, 2006, BIOCHEM BIOPH RES CO, V348, P158, DOI 10.1016/j.bbrc.2006.07.017
   Aziz MA, 2006, LANCET, V368, P2142, DOI 10.1016/S0140-6736(06)69863-2
   Bald D, 2010, FEMS MICROBIOL LETT, V308, P1, DOI 10.1111/j.1574-6968.2010.01959.x
   Beyer R, 2000, ANTIMICROB AGENTS CH, V44, P798, DOI 10.1128/AAC.44.3.798-801.2000
   Boehm HJ, 2000, J MED CHEM, V43, P2664, DOI 10.1021/jm000017s
   Boyer PD, 2002, J BIOL CHEM, V277, P39045, DOI 10.1074/jbc.X200001200
   BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L
   Braga RC, 2012, MINI-REV MED CHEM, V12, P573
   Braga RC, 2013, CURR TOP MED CHEM, V13, P1127, DOI 10.2174/1568026611313090010
   Bueno RV, 2013, J MOL MODEL, V19, P179, DOI 10.1007/s00894-012-1527-8
   Carter AP, 2000, NATURE, V407, P340, DOI 10.1038/35030019
   Cerqueira NMFSA, 2005, CURR MED CHEM, V12, P1283, DOI 10.2174/0929867054020981
   Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369
   Charifson PS, 2008, J MED CHEM, V51, P5243, DOI 10.1021/jm800318d
   CHU DTW, 1989, ANTIMICROB AGENTS CH, V33, P131, DOI 10.1128/AAC.33.2.131
   Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159
   Conde MB, 2009, LANCET, V373, P1183, DOI 10.1016/S0140-6736(09)60333-0
   Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357
   Corbett KD, 2004, P NATL ACAD SCI USA, V101, P7293, DOI 10.1073/pnas.0401595101
   Cramer R D 3rd, 1989, Prog Clin Biol Res, V291, P161
   CRAMER RD, 1988, J AM CHEM SOC, V110, P5959, DOI 10.1021/ja00226a005
   Dalton T, 2012, LANCET, V380, P1406, DOI 10.1016/S0140-6736(12)60734-X
   Dawes SS, 2003, INFECT IMMUN, V71, P6124, DOI 10.1128/IAI.71.11.6124-6131.2003
   de la Sierra IL, 2001, J MOL BIOL, V311, P87, DOI 10.1006/jmbi.2001.4843
   Diacon AH, 2009, NEW ENGL J MED, V360, P2397, DOI 10.1056/NEJMoa0808427
   DOMAGALA JM, 1994, J ANTIMICROB CHEMOTH, V33, P685, DOI 10.1093/jac/33.4.685
   Ericsson DJ, 2010, J PEPT SCI, V16, P159, DOI 10.1002/psc.1214
   Familiar O, 2008, CHEMMEDCHEM, V3, P1083, DOI 10.1002/cmdc.200800060
   Familiar O, 2010, EUR J MED CHEM, V45, P5910, DOI 10.1016/j.ejmech.2010.09.056
   GARVIN RT, 1974, P NATL ACAD SCI USA, V71, P3814, DOI 10.1073/pnas.71.10.3814
   GAUDREAU P, 1987, J BIOL CHEM, V262, P12413
   GAUDREAU P, 1992, J MED CHEM, V35, P346, DOI 10.1021/jm00080a021
   Ginsburg AS, 2003, LANCET INFECT DIS, V3, P432, DOI 10.1016/S1473-3099(03)00671-6
   Guasch L, 2012, J MOL GRAPH MODEL, V36, P1, DOI 10.1016/j.jmgm.2012.03.001
   Haagsma AC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023575
   Haagsma AC, 2010, FEMS MICROBIOL LETT, V313, P68, DOI 10.1111/j.1574-6968.2010.02123.x
   Haagsma AC, 2009, ANTIMICROB AGENTS CH, V53, P1290, DOI 10.1128/AAC.01393-08
   Hogbom M, 2004, SCIENCE, V305, P245, DOI 10.1126/science.1098419
   Jiang W, 2007, SCIENCE, V316, P1188, DOI 10.1126/science.1141179
   Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897
   Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71
   Junge W, 2009, NATURE, V459, P364, DOI 10.1038/nature08145
   Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375
   Khan SR, 2013, INT J ANTIMICROB AG, V41, P41, DOI 10.1016/j.ijantimicag.2012.09.012
   Kontoyianni M, 2004, J MED CHEM, V47, P558, DOI 10.1021/jm0302997
   Koul A, 2008, J BIOL CHEM, V283, P25273, DOI 10.1074/jbc.M803899200
   Koul A, 2007, NAT CHEM BIOL, V3, P323, DOI 10.1038/nchembio884
   Levine C, 1998, BBA-GENE STRUCT EXPR, V1400, P29, DOI 10.1016/S0167-4781(98)00126-2
   Llorente B, 1996, BIOORGAN MED CHEM, V4, P61, DOI 10.1016/0968-0896(96)83749-7
   LoBue P, 2009, CURR OPIN INFECT DIS, V22, P167, DOI 10.1097/QCO.0b013e3283229fab
   Lubbers T, 2007, BIOORG MED CHEM LETT, V17, P4708, DOI 10.1016/j.bmcl.2006.12.065
   Ma ZK, 1999, J MED CHEM, V42, P4202, DOI 10.1021/jm990191k
   MCCLURE WR, 1978, J BIOL CHEM, V253, P8949
   McGann M, 2012, J COMPUT AID MOL DES, V26, P897, DOI 10.1007/s10822-012-9584-8
   McGann M, 2011, J CHEM INF MODEL, V51, P578, DOI 10.1021/ci100436p
   McGann MR, 2003, BIOPOLYMERS, V68, P76, DOI 10.1002/bip.10207
   Minovski N, 2012, J COMPUT CHEM, V4111, P1
   MIYAMOTO T, 1990, J MED CHEM, V33, P1645, DOI 10.1021/jm00168a018
   Munier-Lehmann H, 2001, PROTEIN SCI, V10, P1195, DOI 10.1110/ps.45701
   Musser JM, 1996, J INFECT DIS, V173, P196, DOI 10.1093/infdis/173.1.196
   Neves BJ, 2013, BIOORG MED CHEM LETT, V23, P2436, DOI 10.1016/j.bmcl.2013.02.006
   Nordlund N, 2006, ANNU REV BIOCHEM, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443
   Nurbo J, 2007, J PEPT SCI, V13, P822, DOI 10.1002/psc.906
   Oblak M, 2005, BIOORG MED CHEM LETT, V15, P5207, DOI 10.1016/j.bmcl.2005.08.068
   Osborne R, 2013, NAT BIOTECHNOL, V31, P89, DOI 10.1038/nbt0213-89
   Ostermann N, 2000, STRUCTURE, V8, P629, DOI 10.1016/S0969-2126(00)00149-0
   Pender BA, 2001, J MED CHEM, V44, P36, DOI 10.1021/jm000335r
   Pestova E, 2000, J ANTIMICROB CHEMOTH, V45, P583, DOI 10.1093/jac/45.5.583
   Piddock LJV, 1998, ANTIMICROB AGENTS CH, V42, P2956, DOI 10.1128/AAC.42.11.2956
   Poissy J, 2010, ANTIMICROB AGENTS CH, V54, P4765, DOI 10.1128/AAC.00968-10
   Poole AM, 2002, J MOL EVOL, V55, P180, DOI 10.1007/s00239-002-2315-3
   Pranger AD, 2011, CURR PHARM DESIGN, V17, P2900, DOI 10.2174/138161211797470200
   Rao SPS, 2008, P NATL ACAD SCI USA, V105, P11945, DOI 10.1073/pnas.0711697105
   Rawat R, 2003, P NATL ACAD SCI USA, V100, P13881, DOI 10.1073/pnas.2235848100
   Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98
   Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x
   Schatz A, 1944, P SOC EXP BIOL MED, V57, P244, DOI 10.3181/00379727-57-14769
   Smith I, 2003, CLIN MICROBIOL REV, V16, P463, DOI 10.1128/CMR.16.3.463-496.2003
   Speck-Planche A, 2010, CURR PHARM DESIGN, V16, P2656, DOI 10.2174/138161210792389289
   TAKIFF HE, 1994, ANTIMICROB AGENTS CH, V38, P773, DOI 10.1128/AAC.38.4.773
   Tanitame A, 2004, J MED CHEM, V47, P3693, DOI 10.1021/jm030394f
   THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025
   Tillotson GS, 1996, J MED MICROBIOL, V44, P320, DOI 10.1099/00222615-44-5-320
   Tosco P, 2012, J CHEM INF MODEL, V52, P302, DOI 10.1021/ci200411s
   Tran SL, 2005, J BACTERIOL, V187, P5023, DOI 10.1128/JB.187.14.5023-5028.2005
   Upadhayaya RS, 2010, EUR J MED CHEM, V45, P1854, DOI 10.1016/j.ejmech.2010.01.024
   Upadhayaya RS, 2009, BIOORGAN MED CHEM, V17, P4681, DOI 10.1016/j.bmc.2009.04.069
   Van Calenbergh S, 2012, CURR TOP MED CHEM, V12, P694, DOI 10.2174/156802612799984580
   Van Daele I, 2007, J MED CHEM, V50, P5281, DOI 10.1021/jm0706158
   Van Daele I, 2006, CHEMMEDCHEM, V1, P1081, DOI 10.1002/cmdc.200600028
   Vanheusden V, 2004, J MED CHEM, V47, P6187, DOI 10.1021/jm040847w
   Vanheusden V, 2003, BIOORG MED CHEM LETT, V13, P3045, DOI 10.1016/S0960-894X(03)00643-7
   Vanheusden V, 2003, J MED CHEM, V46, P3811, DOI 10.1021/jm021108n
   Vanheusden V, 2002, BIOORG MED CHEM LETT, V12, P2695, DOI 10.1016/S0960-894X(02)00551-6
   Verdonk ML, 2003, PROTEINS, V52, P609, DOI 10.1002/prot.10465
   Voevodskaya N, 2007, FEBS LETT, V581, P3351, DOI 10.1016/j.febslet.2007.06.023
   WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665
   Warren GL, 2006, J MED CHEM, V49, P5912, DOI 10.1021/jm050362n
   WHO, GLOB TUB CONTR 2012
   YANG FD, 1990, FEBS LETT, V272, P61, DOI 10.1016/0014-5793(90)80449-S
   Yoshida T, 1996, CHEM PHARM BULL, V44, P1074
   ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0
NR 115
TC 15
Z9 16
U1 0
U2 17
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2014
VL 20
IS 27
BP 4474
EP 4485
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AK6AL
UT WOS:000338509300011
PM 24245758
DA 2020-12-01
ER

PT J
AU Andrade, CH
   Braga, RC
AF Andrade, Carolina H.
   Braga, Rodolpho C.
TI Drug Metabolism, Toxicology Experimental Determination and Theoretical
   Prediction: Challenges and Perspectives from a Medicinal Chemistry Point
   of View
SO CURRENT TOPICS IN MEDICINAL CHEMISTRY
LA English
DT Editorial Material
C1 [Andrade, Carolina H.; Braga, Rodolpho C.] Univ Fed Goias, Fac Pharm, LabMol Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Pharm, LabMol Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.
EM carolina@ufg.br; rodolphobraga@yahoo.com
RI Braga, Rodolpho C/A-9655-2011; Andrade, Carolina/C-3960-2014
OI Braga, Rodolpho C/0000-0003-3814-3464; Andrade,
   Carolina/0000-0003-0101-1492
NR 0
TC 1
Z9 1
U1 1
U2 5
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0266
EI 1873-4294
J9 CURR TOP MED CHEM
JI Curr. Top. Med. Chem.
PY 2014
VL 14
IS 11
BP 1323
EP 1324
DI 10.2174/1568026614666140506114019
PG 2
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA AI8MF
UT WOS:000337169800001
PM 24805067
DA 2020-12-01
ER

PT J
AU Braga, RC
   Alves, VM
   Silva, MFB
   Muratov, E
   Fourches, D
   Tropsha, A
   Andrade, CH
AF Braga, Rodolpho C.
   Alves, Vinicius M.
   Silva, Meryck F. B.
   Muratov, Eugene
   Fourches, Denis
   Tropsha, Alexander
   Andrade, Carolina H.
TI Tuning hERG Out: Antitarget QSAR Models for Drug Development
SO CURRENT TOPICS IN MEDICINAL CHEMISTRY
LA English
DT Review
DE Antitarget; drug development; hERG; QSAR modeling; virtual screening
ID K+ CHANNEL BLOCKERS; EXCELLENT CELL POTENCY; HIGH-AFFINITY BLOCKADE;
   VECTOR MACHINE METHOD; LONG-QT-SYNDROME; IN-SILICO; ION-CHANNEL;
   TETRAHYMENA-PYRIFORMIS; METABOLISM PREDICTION; CLASSIFICATION MODEL
AB Several non-cardiovascular drugs have been withdrawn from the market due to their inhibition of hERG K+ channels that can potentially lead to severe heart arrhythmia and death. As hERG safety testing is a mandatory FDA-required procedure, there is a considerable interest for developing predictive computational tools to identify and filter out potential hERG blockers early in the drug discovery process. In this study, we aimed to generate predictive and well-characterized quantitative structure-activity relationship (QSAR) models for hERG blockage using the largest publicly available dataset of 11,958 compounds from the ChEMBL database. The models have been developed and validated according to OECD guidelines using four types of descriptors and four different machine-learning techniques. The classification accuracies discriminating blockers from non-blockers were as high as 0.83-0.93 on external set. Model interpretation revealed several SAR rules, which can guide structural optimization of some hERG blockers into non-blockers. We have also applied the generated models for screening the World Drug Index (WDI) database and identify putative hERG blockers and non-blockers among currently marketed drugs. The developed models can reliably identify blockers and non-blockers, which could be useful for the scientific community. A freely accessible web server has been developed allowing users to identify putative hERG blockers and non-blockers in chemical libraries of their interest (http://labmol.farmacia.ufg.br/predherg).
C1 [Braga, Rodolpho C.; Alves, Vinicius M.; Silva, Meryck F. B.; Andrade, Carolina H.] Univ Fed Goias, Fac Farm, LabMol, Lab Mol Modeling & Drug Design, BR-74605170 Goiania, Go, Brazil.
   [Braga, Rodolpho C.] Univ Fed Goias, Inst Chem, Lab Nucl Magnet Resonance, BR-74001970 Goiania, Go, Brazil.
   [Muratov, Eugene; Fourches, Denis; Tropsha, Alexander] Univ N Carolina, Eshelman Sch Pharm, Div Chem Biol & Med Chem, Lab Mol Modeling, Chapel Hill, NC 27599 USA.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, LabMol, Setor Leste Univ, Rua 240,Qd 87, BR-74605170 Goiania, Go, Brazil.
EM carolina@ufg.br
RI Braga, Rodolpho C/A-9655-2011; Fourches, Denis/H-4336-2019; Alves,
   Vinicius M./G-7955-2015; Muratov, Eugene/C-4454-2014; Andrade,
   Carolina/C-3960-2014; Tropsha, Alexander/AAB-8324-2020
OI Braga, Rodolpho C/0000-0003-3814-3464; Alves, Vinicius
   M./0000-0002-6182-1748; Muratov, Eugene/0000-0003-4616-7036; Andrade,
   Carolina/0000-0003-0101-1492; Fourches, Denis/0000-0001-5642-8303
FU FAPEG [201310267001095]; CAPESCAPES; CNPqNational Council for Scientific
   and Technological Development (CNPq); NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [GM66940, GM096967]; EPAUnited States Environmental Protection Agency
   [RD 83499901]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of General Medical Sciences
   (NIGMS) [R01GM066940, R01GM066940, R01GM066940, R01GM066940,
   R01GM066940, R01GM066940, R01GM096967, R01GM096967, R01GM066940,
   R01GM066940, R01GM096967, R01GM096967, R01GM066940, R01GM066940] Funding
   Source: NIH RePORTER
FX The authors would like to thank Brazilian Funding Agencies FAPEG (grant
   201310267001095), CAPES and CNPq for financial support and fellowships.
   We are also grateful to ChemAxon for providing us with academic licenses
   for their software. DF, EM, and AT thank NIH (grants GM66940 and
   GM096967) and EPA (grant RD 83499901) for financial support.
CR Andrade C.H., 2014, CURR DRUG M IN PRESS
   Andrade CH, 2011, BRAZ J PHARM SCI, V47, P209, DOI 10.1590/S1984-82502011000200003
   [Anonymous], 2013, MACCS STRUCT KEYS
   [Anonymous], 2005, FDA E14 CLIN EVALUAT, P1
   Alvarez PA, 2010, CURR DRUG SAF, V5, P97, DOI 10.2174/157488610789869265
   Aronov AM, 2004, BIOORGAN MED CHEM, V12, P2307, DOI 10.1016/j.bmc.2004.02.003
   Bains W, 2004, PROG BIOPHYS MOL BIO, V86, P205, DOI 10.1016/j.pbiomolbio.2003.09.001
   Bell IM, 2002, J MED CHEM, V45, P2388, DOI 10.1021/jm010531d
   Bell IM, 2001, J MED CHEM, V44, P2933, DOI 10.1021/jm010156p
   Berk R. A, 2008, STAT LEARNING REGRES, P360
   Berlin M, 2010, BIOORG MED CHEM LETT, V20, P2359, DOI 10.1016/j.bmcl.2010.01.121
   Bilodeau MT, 2004, J MED CHEM, V47, P6363, DOI 10.1021/jm049697f
   Blum CA, 2004, J MED CHEM, V47, P2318, DOI 10.1021/jm030490g
   Braga RC, 2012, MINI-REV MED CHEM, V12, P573
   Braga R.C., 2014, CURR TOP ME IN PRESS
   Braga R.C., 2012, 244 AM CHEM SOC NAT
   Braga R.C., 2010, 240 AM CHEM SOC NAT
   Braga RC, 2012, J MOL MODEL, V18, P2065, DOI 10.1007/s00894-011-1219-9
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Breiman L, 1996, MACH LEARN, V24, P123, DOI 10.1007/bf00058655
   Breiman L., 1984, STAT PROBABILITY SER, V19, P368
   Broccatelli F, 2012, MOL PHARMACEUT, V9, P2290, DOI 10.1021/mp300156r
   Brown AM, 2004, CELL CALCIUM, V35, P543, DOI 10.1016/j.ceca.2004.01.008
   Brugel TA, 2010, BIOORG MED CHEM LETT, V20, P5847, DOI 10.1016/j.bmcl.2010.07.113
   Brugel TA, 2010, BIOORG MED CHEM LETT, V20, P5405, DOI 10.1016/j.bmcl.2010.07.112
   Bueno R.V, 2014, CURR PHARM DESIGN, V20, P1
   Carneiro EO, 2010, BIOORG MED CHEM LETT, V20, P3734, DOI 10.1016/j.bmcl.2010.04.073
   Cavalli A, 2002, J MED CHEM, V45, P3844, DOI 10.1021/jm0208875
   Chekmarev DS, 2008, CHEM RES TOXICOL, V21, P1304, DOI 10.1021/tx800063r
   Cherkasov A., 2014, J MED CHEM
   Cianchetta G, 2005, BIOORG MED CHEM LETT, V15, P3637, DOI 10.1016/j.bmcl.2005.03.062
   Coi A, 2006, BIOORGAN MED CHEM, V14, P3153, DOI 10.1016/j.bmc.2005.12.030
   Coi A, 2013, J MOL GRAPH MODEL, V46, P93, DOI 10.1016/j.jmgm.2013.10.001
   Czodrowski P, 2013, J CHEM INF MODEL, V53, P2240, DOI 10.1021/ci400308z
   De Ponti F, 2001, EUR J CLIN PHARMACOL, V57, P185, DOI 10.1007/s002280100290
   Doddareddy MR, 2010, CHEMMEDCHEM, V5, P716, DOI 10.1002/cmdc.201000024
   Du-Cuny L, 2011, J CHEM INF MODEL, V51, P2948, DOI 10.1021/ci200271d
   Duan JX, 2010, J MOL GRAPH MODEL, V29, P157, DOI 10.1016/j.jmgm.2010.05.008
   Dubus E, 2006, CHEMMEDCHEM, V1, P622, DOI 10.1002/cmdc.200500099
   Ekins S, 2006, J MED CHEM, V49, P5059, DOI 10.1021/jm060076r
   Elkins RC, 2013, J PHARMACOL TOX MET, V68, P112, DOI 10.1016/j.vascn.2013.04.007
   Ermondi G, 2009, EUR J MED CHEM, V44, P1926, DOI 10.1016/j.ejmech.2008.11.009
   Ertl P, 2000, J MED CHEM, V43, P3714, DOI 10.1021/jm000942e
   FDA Guidance for industry, 2005, FDA GUIDANCE IND S7B, P1
   Fenu LA, 2009, J COMPUT AID MOL DES, V23, P883, DOI 10.1007/s10822-009-9306-z
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Garg D, 2008, J MOL GRAPH MODEL, V26, P966, DOI 10.1016/j.jmgm.2007.08.002
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   Gavaghan CL, 2007, J COMPUT AID MOL DES, V21, P189, DOI 10.1007/s10822-006-9095-6
   Gepp MM, 2006, BIOORGAN MED CHEM, V14, P5325, DOI 10.1016/j.bmc.2006.03.043
   Gil ED, 2012, J BRAZIL CHEM SOC, V23, P565, DOI 10.1590/S0103-50532012000300025
   Gleeson MP, 2012, CURR PHARM DESIGN, V18, P1266
   Golbraikh A, 2002, J MOL GRAPH MODEL, V20, P269, DOI 10.1016/S1093-3263(01)00123-1
   Gunturi SB, 2008, QSAR COMB SCI, V27, P1305, DOI 10.1002/qsar.200810072
   Haga Y, 2011, BIOORGAN MED CHEM, V19, P883, DOI 10.1016/j.bmc.2010.12.002
   HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997
   Hansen K, 2009, J CHEM INF MODEL, V49, P1486, DOI 10.1021/ci9000794
   Inanobe A, 2008, J PHYSIOL SCI, V58, P459, DOI [10.2170/physiolsci.RV011408, 10.2170/physiolsci.RV-0114-08-07-R1]
   Jia L, 2008, BIOORGAN MED CHEM, V16, P6252, DOI 10.1016/j.bmc.2008.04.028
   Kang JS, 2000, EUR J PHARMACOL, V392, P137, DOI 10.1016/S0014-2999(00)00123-0
   Kar S, 2012, MOL INFORM, V31, P879, DOI 10.1002/minf.201200039
   Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4
   Keseru GM, 2003, BIOORG MED CHEM LETT, V13, P2773, DOI 10.1016/S0960-894X(03)00492-X
   Kim JH, 2011, B KOREAN CHEM SOC, V32, P1237, DOI 10.5012/bkcs.2011.32.4.1237
   Kiss L, 2003, ASSAY DRUG DEV TECHN, V1, P127, DOI 10.1089/154065803762851298
   Kramer C, 2008, CHEMMEDCHEM, V3, P254, DOI 10.1002/cmdc.200700221
   Kuz'min VE, 2009, QSAR COMB SCI, V28, P664, DOI 10.1002/qsar.200860117
   Labute P, 2000, J MOL GRAPH MODEL, V18, P464, DOI 10.1016/S1093-3263(00)00068-1
   Leong MK, 2007, CHEM RES TOXICOL, V20, P217, DOI 10.1021/tx060230c
   Li QY, 2008, MOL PHARMACEUT, V5, P117, DOI 10.1021/mp700124e
   Lynch JK, 2006, J MED CHEM, V49, P6569, DOI 10.1021/jm060683e
   Marquis RW, 2009, J MED CHEM, V52, P6599, DOI 10.1021/jm900563e
   Mazanetz MP, 2012, CURR TOP MED CHEM, V12, P1965
   Melo CC, 2014, CURR DRUG METAB, V15, P120, DOI 10.2174/1389200215666140130125339
   Mitcheson JS, 2000, P NATL ACAD SCI USA, V97, P12329, DOI 10.1073/pnas.210244497
   Moorthy N S Hari Narayana, 2013, Curr Drug Discov Technol, V10, P47
   MORGAN HL, 1965, J CHEM DOC, V5, P107, DOI 10.1021/c160017a018
   Neves BJ, 2013, BIOORG MED CHEM LETT, V23, P2436, DOI 10.1016/j.bmcl.2013.02.006
   Nisius B, 2009, J CHEM INF MODEL, V49, P247, DOI 10.1021/ci800304t
   O'Brien SE, 2005, J MED CHEM, V48, P1287, DOI 10.1021/jm049254b
   Obiol-Pardo C, 2011, J CHEM INF MODEL, V51, P483, DOI 10.1021/ci100423z
   Obrezanova O, 2007, J CHEM INF MODEL, V47, P1847, DOI 10.1021/ci7000633
   Olah M, 2008, CHEM BIOL, P760
   Pazini F, 2010, BIOORG MED CHEM LETT, V20, P2888, DOI 10.1016/j.bmcl.2010.03.034
   Pearlstein RA, 2003, BIOORG MED CHEM LETT, V13, P1829, DOI 10.1016/S0960-894X(03)00196-3
   Peukert S, 2003, J MED CHEM, V46, P486, DOI 10.1021/jm0210461
   Picard S, 2011, CARDIOVASC TOXICOL, V11, P285, DOI 10.1007/s12012-011-9133-z
   Polak S, 2013, J APPL TOXICOL, V33, P723, DOI 10.1002/jat.2719
   Polak S, 2009, J APPL TOXICOL, V29, P183, DOI 10.1002/jat.1395
   Polonchuk L, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00003
   Pourbasheer E, 2013, MED CHEM RES, V22, P4047, DOI 10.1007/s00044-012-0412-4
   Rampe D, 1997, FEBS LETT, V417, P28, DOI 10.1016/S0014-5793(97)01249-0
   Raunio H, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00033
   Robinson RLM, 2011, MOL INFORM, V30, P443, DOI 10.1002/minf.201000159
   Roche O, 2002, CHEMBIOCHEM, V3, P455, DOI 10.1002/1439-7633(20020503)3:5<455::AID-CBIC455>3.0.CO;2-L
   Roden DM, 2004, NEW ENGL J MED, V350, P1013, DOI 10.1056/NEJMra032426
   Rogers D, 2010, J CHEM INF MODEL, V50, P742, DOI 10.1021/ci100050t
   Rowley M, 2001, J MED CHEM, V44, P1603, DOI 10.1021/jm0004998
   Seierstad M, 2006, CHEM BIOL DRUG DES, V67, P284, DOI 10.1111/j.1747-0285.2006.00379.x
   Sinha N, 2011, EUR J MED CHEM, V46, P618, DOI 10.1016/j.ejmech.2010.11.042
   Solov'ev VP, 2000, J CHEM INF COMP SCI, V40, P847, DOI 10.1021/ci9901340
   Song MH, 2006, J CHEM INF MODEL, V46, P392, DOI 10.1021/ci050308f
   Sousa MC, 2013, FOOD RES INT, V50, P102, DOI 10.1016/j.foodres.2012.09.027
   Springer C, 2013, CHEM CENT J, V7, DOI 10.1186/1752-153X-7-167
   Steinbeck C, 2003, J CHEM INF COMP SCI, V43, P493, DOI 10.1021/ci025584y
   Stumpfe D, 2012, J MED CHEM, V55, P2932, DOI 10.1021/jm201706b
   Su BH, 2012, J CHEM INF MODEL, V52, P1660, DOI 10.1021/ci300060b
   Su BH, 2010, J CHEM INF MODEL, V50, P1304, DOI 10.1021/ci100081j
   Sun HM, 2006, CHEMMEDCHEM, V1, P315, DOI 10.1002/cmdc.200500047
   Tan YY, 2012, J MOL MODEL, V18, P1023, DOI 10.1007/s00894-011-1136-y
   Tarasova OA, 2008, SAR QSAR ENVIRON RES, V19, P81, DOI 10.1080/10629360701844183
   Thai KM, 2008, BIOORGAN MED CHEM, V16, P4107, DOI 10.1016/j.bmc.2008.01.017
   Thai KM, 2009, MOL DIVERS, V13, P321, DOI 10.1007/s11030-009-9117-0
   Tobita M, 2005, BIOORG MED CHEM LETT, V15, P2886, DOI 10.1016/j.bmcl.2005.03.080
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Vandenberg JI, 2012, PHYSIOL REV, V92, P1393, DOI 10.1152/physrev.00036.2011
   Vapnik V.N., 2000, NATURE STAT LEARNING, DOI [DOI 10.1007/978-1-4757-3264-1, 10.1007/978-1-4757-3264-1]
   Varnek A, 2008, CURR COMPUT-AID DRUG, V4, P191, DOI 10.2174/157340908785747465
   Wang SC, 2012, MOL PHARMACEUT, V9, P996, DOI 10.1021/mp300023x
   Wang Z, 2012, MOL INFORM, V31, P679, DOI 10.1002/minf.201200011
   Wen DS, 2012, J APPL TOXICOL, V32, P834, DOI 10.1002/jat.2755
   Wisniowska B, 2009, TOXICOL MECH METHOD, V19, P278, DOI 10.1080/15376510902777194
   Witchel HJ, 2002, J PHARMACOL TOX MET, V48, P65, DOI 10.1016/S1056-8719(03)00041-8
   Woosley RL, 1996, ANNU REV PHARMACOL, V36, P233, DOI 10.1146/annurev.pa.36.040196.001313
   Xue CB, 2011, ACS MED CHEM LETT, V2, P450, DOI 10.1021/ml200030q
   Yang SY, 2010, DRUG DISCOV TODAY, V15, P444, DOI 10.1016/j.drudis.2010.03.013
   Yap CW, 2004, TOXICOL SCI, V79, P170, DOI 10.1093/toxsci/kfh082
   Zhang SX, 2006, J CHEM INF MODEL, V46, P1984, DOI 10.1021/ci060132x
   Zhu H, 2008, J CHEM INF MODEL, V48, P766, DOI 10.1021/ci700443v
NR 129
TC 51
Z9 58
U1 5
U2 29
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0266
EI 1873-5294
J9 CURR TOP MED CHEM
JI Curr. Top. Med. Chem.
PY 2014
VL 14
IS 11
BP 1399
EP 1415
DI 10.2174/1568026614666140506124442
PG 17
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA AI8MF
UT WOS:000337169800009
PM 24805060
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Melo, CC
   Braga, RC
   Andrade, CH
AF Melo-Filho, Cleber Camilo
   Braga, Rodolpho Campos
   Andrade, Carolina Horta
TI Advances in Methods for Predicting Phase I Metabolism of Polyphenols
SO CURRENT DRUG METABOLISM
LA English
DT Article
DE Cytochrome P450; docking; flavonoids; ligand-based; metabolism;
   structure-based
ID CYTOCHROME-P450 METABOLISM; DIETARY FLAVONOIDS; PERFORMANCE; DOCKING;
   VALIDATION; QUERCETIN; SMARTCYP; BINDING; P4502C9; OMEGA
AB Flavonoids are natural polyphenols that can be found in many vegetables, citric fruits and dietary supplements and are widely consumed worldwide in the human diet. Over the past 30 years, studies have demonstrated that these compounds present significant biological activities, and their antioxidant properties may be responsible for the prevention of many diseases such as neurodegeneration, atherosclerosis, tumor generation, and microbial infections. Moreover, studies have shown that flavonoids may be substrates of cytochrome P450 enzymes and undergo bioactivation to metabolites that inhibit tumor cell growth. Therefore, it is important to understand the CYP450-mediated metabolic profiles of polyphenolic compounds during drug discovery and development processes. This review highlights ligand-based and structure-based methods to predict the Phase I metabolism of polyphenols. Moreover, an integrated in silico approach for the prediction of Phase I metabolism of the flavonoids quercetin, rutin, naringenin and naringin, which provided useful information about the most likely metabolites of these flavonoids and their interactions with amino acid residues of CYP2C9, is described.
C1 [Melo-Filho, Cleber Camilo; Braga, Rodolpho Campos; Andrade, Carolina Horta] Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, Setor Univ, BR-74605220 Goiania, Go, Brazil.
   [Braga, Rodolpho Campos] Univ Fed Goias, Inst Quim, BR-74001970 Goiania, Go, Brazil.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, LabMol, Setor Univ, 1a Av Com Praca Univ, BR-74605220 Goiania, Go, Brazil.
EM carolina@ufg.br
RI Melo-Filho, Cleber C./V-1119-2018; Braga, Rodolpho C/A-9655-2011;
   Andrade, Carolina/C-3960-2014
OI Melo-Filho, Cleber C./0000-0003-0056-6971; Braga, Rodolpho
   C/0000-0003-3814-3464; Andrade, Carolina/0000-0003-0101-1492
FU CAPES Brailian Funding AgencyCAPES; CNPq Brazilian Funding
   AgencyNational Council for Scientific and Technological Development
   (CNPq); FAPEG Brazilian Funding Agency
FX The authors thanks to the Brazilian Funding Agencies CAPES, CNPq and
   FAPEG for financial support and fellowships. We also thank OpenEye
   Scientific Software Inc. and ChemAxon for providing Academic Licenses of
   their software.
CR Andres A, 2009, J NUTR BIOCHEM, V20, P563, DOI 10.1016/j.jnutbio.2009.04.004
   Androutsopoulos VP, 2010, PHARMACOL THERAPEUT, V126, P9, DOI 10.1016/j.pharmthera.2010.01.009
   Androutsopoulos VP, 2009, ONCOL REP, V21, P1525, DOI 10.3892/or_00000384
   [Anonymous], 2012, OEDOCKING VERS 3 0 0
   [Anonymous], REG TOX EFF CHEM SUB
   [Anonymous], 2011, QUACPAC VERS 1 5 0
   [Anonymous], 2012, OMEGA VERS 2 4 6
   Arroo RRJ, 2009, PHYTOCHEM REV, V8, P375, DOI 10.1007/s11101-009-9128-6
   Beecher GR, 2003, J NUTR, V133, p3248S
   Bostrom J, 2003, J MOL GRAPH MODEL, V21, P449, DOI 10.1016/S1093-3263(02)00204-8
   Boyer S, 2007, J CHEM INF MODEL, V47, P583, DOI 10.1021/ci600376q
   Braga RC, 2012, MINI-REV MED CHEM, V12, P573
   Braga RC, 2012, J MOL MODEL, V18, P2065, DOI 10.1007/s00894-011-1219-9
   Breinholt VM, 2002, FOOD CHEM TOXICOL, V40, P609, DOI 10.1016/S0278-6915(01)00125-9
   Carlsson L, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-362
   Castro-Perez JM, 2007, DRUG DISCOV TODAY, V12, P249, DOI 10.1016/j.drudis.2007.01.007
   Cavalla D, 2008, PRACTICE OF MEDICINAL CHEMISTRY, 3RD EDITION, P255, DOI 10.1016/B978-0-12-374194-3.00013-5
   Cohen SD, 2010, CRIT REV FOOD SCI, V50, P620, DOI 10.1080/10408390802603441
   Cote J, 2010, CRIT REV FOOD SCI, V50, P666, DOI 10.1080/10408390903044107
   da Silva EL, 1998, FEBS LETT, V430, P405, DOI 10.1016/S0014-5793(98)00709-1
   De Montellano P. R. O., 2010, CYTOCHROME P450 STRU, P664
   Deng GF, 2013, CRIT REV FOOD SCI, V53, P296, DOI 10.1080/10408398.2010.529624
   Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Hodek P, 2002, CHEM-BIOL INTERACT, V139, P1, DOI 10.1016/S0009-2797(01)00285-X
   Hosny M, 2001, J NAT PROD, V64, P462, DOI 10.1021/np000457m
   Jones BC, 2009, PROGR MED CHEM, V47, P239, DOI 10.1016/S0079-6468(08)00206-3
   Kagawa H, 2004, XENOBIOTICA, V34, P797, DOI 10.1080/00498250400005708
   Kumar GS, 2001, PROF ENG, V14, P21
   McGann M, 2012, J COMPUT AID MOL DES, V26, P897, DOI 10.1007/s10822-012-9584-8
   McGann M, 2011, J CHEM INF MODEL, V51, P578, DOI 10.1021/ci100436p
   McGann MR, 2003, BIOPOLYMERS, V68, P76, DOI 10.1002/bip.10207
   Miners JO, 1998, BRIT J CLIN PHARMACO, V45, P525, DOI 10.1046/j.1365-2125.1998.00721.x
   Nebert DW, 2000, PHARMACOLOGY, V61, P124, DOI 10.1159/000028393
   Pan MH, 2010, FOOD FUNCT, V1, P15, DOI 10.1039/c0fo00103a
   Quideau S, 2011, ANGEW CHEM INT EDIT, V50, P586, DOI 10.1002/anie.201000044
   Rathee Permender, 2009, Inflammation & Allergy Drug Targets, V8, P229
   Rice-Evans C, 2001, CURR MED CHEM, V8, P797, DOI 10.2174/0929867013373011
   Rydberg P, 2010, BIOINFORMATICS, V26, P2988, DOI 10.1093/bioinformatics/btq584
   Rydberg P, 2010, ACS MED CHEM LETT, V1, P96, DOI 10.1021/ml100016x
   Sander T, 2009, J CHEM INF MODEL, V49, P232, DOI 10.1021/ci800305f
   Scalbert A, 2000, J NUTR, V130, p2073S, DOI 10.1093/jn/130.8.2073S
   Sousa MC, 2013, FOOD RES INT, V50, P102, DOI 10.1016/j.foodres.2012.09.027
   Stjernschantz E, 2008, EXPERT OPIN DRUG MET, V4, P513, DOI [10.1517/17425255.4.5.513, 10.1517/17425255.4.5.513 ]
   Sun H, 2010, CHEM BIOL DRUG DES, V75, P3, DOI 10.1111/j.1747-0285.2009.00899.x
   van Dorsten FA, 2010, MOL NUTR FOOD RES, V54, P897, DOI 10.1002/mnfr.200900212
   Vauzour D, 2008, GENES NUTR, V3, P115, DOI 10.1007/s12263-008-0091-4
   von Korff M, 2006, J CHEM INF MODEL, V46, P536, DOI 10.1021/ci050358k
   Wang RX, 2002, J COMPUT AID MOL DES, V16, P11, DOI 10.1023/A:1016357811882
   Wester MR, 2004, J BIOL CHEM, V279, P35630, DOI 10.1074/jbc.M405427200
   Xiao JB, 2013, CRIT REV FOOD SCI, V53, P497, DOI 10.1080/10408398.2010.548108
   Xiao JB, 2011, MOL NUTR FOOD RES, V55, P310, DOI 10.1002/mnfr.201000208
NR 52
TC 14
Z9 14
U1 0
U2 28
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2002
EI 1875-5453
J9 CURR DRUG METAB
JI Curr. Drug Metab.
PD JAN
PY 2014
VL 15
IS 1
BP 120
EP 126
DI 10.2174/1389200215666140130125339
PG 7
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA AE1RS
UT WOS:000333748000012
PM 24479689
DA 2020-12-01
ER

PT J
AU Melo, CC
   Braga, RC
   Andrade, CH
AF Melo-Filho, Cleber Camilo
   Braga, Rodolpho Campos
   Andrade, Carolina Horta
TI 3D-QSAR Approaches in Drug Design: Perspectives to Generate Reliable
   CoMFA Models
SO CURRENT COMPUTER-AIDED DRUG DESIGN
LA English
DT Article
DE 3D-QSAR; alignment; CoMFA; docking; drug design; pharmacophore
ID MOLECULAR-FORCE FIELD; QUANTITATIVE STRUCTURE-ACTIVITY; THIOREDOXIN
   GLUTATHIONE-REDUCTASE; DIFFERENT VALIDATION CRITERIA; REAL EXTERNAL
   PREDICTIVITY; ENOYL-ACP REDUCTASE; 3D QSAR; GENETIC ALGORITHM; WHIM
   DESCRIPTORS; CONFORMATIONAL ENERGIES
AB Drug discovery is mostly guided by innovative and knowledge by the application of experimental and computational approaches. Quantitative structure-activity relationships (QSAR) have a critical task in the discovery and optimization of lead compounds, thereby contributing to the development of new chemical entities. 3D-QSAR methods use the information of the tridimensional molecular structure of ligands and can be applied to elucidate the relationships between 3D molecular interactions and their measured biological property, therefore, providing a rational approach for the development of new potential compounds. The purpose of this review is to provide a perspective of the utility of 3D-QSAR approaches in drug design, focusing on progress, challenges and future orientations. The essential steps involved to generate reliable and predictive CoMFA models are discussed. Moreover, we present an example of application of a CoMFA study to derive 3D-QSAR models for a series of oxadiazoles inhibitors of Schistosoma mansoni Thioredoxin Glutathione Reductase (SmTGR).
C1 [Melo-Filho, Cleber Camilo; Braga, Rodolpho Campos; Andrade, Carolina Horta] Univ Fed Goias, Fac Farm, LabMol, BR-74605170 Goiania, Go, Brazil.
   [Braga, Rodolpho Campos] Univ Fed Goias, Inst Quim, BR-74001970 Goiania, Go, Brazil.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, LabMol, Rua 240,Qd 87,Setor Leste Univ, BR-74605170 Goiania, Go, Brazil.
EM carolina@ufg.br
RI Andrade, Carolina/C-3960-2014; Braga, Rodolpho C/A-9655-2011;
   Melo-Filho, Cleber C./V-1119-2018
OI Andrade, Carolina/0000-0003-0101-1492; Braga, Rodolpho
   C/0000-0003-3814-3464; Melo-Filho, Cleber C./0000-0003-0056-6971
FU CAPESCAPES; CNPqNational Council for Scientific and Technological
   Development (CNPq); FAPEG
FX The authors would like to thank Brazilian Funding Agencies CAPES, CNPq
   and FAPEG for financial support and fellowships. We are also grateful to
   OpenEye Scientific Software, Inc. and ChemAxon for providing us with the
   academic licenses for their software.
CR Albuquerque M. G., 2007, CURRENT METHODS MED, P91
   ALMOND, MULT INF AN
   Andrade CH, 2008, MOL DIVERS, V12, P47, DOI 10.1007/s11030-008-9074-z
   Andrade CH, 2010, MOLECULES, V15, P3281, DOI 10.3390/molecules15053281
   Andrade CH, 2009, J CHEM INF MODEL, V49, P1070, DOI 10.1021/ci8004622
   Andrade CH, 2008, LETT DRUG DES DISCOV, V5, P377, DOI 10.2174/157018008785777289
   Andrade CH, 2008, REV BRAS CIENC FARM, V44, P167, DOI 10.1590/S1516-93322008000200002
   Andrade CH, 2010, J COMPUT AID MOL DES, V24, P157, DOI 10.1007/s10822-010-9323-y
   Angelucci F, 2010, J BIOL CHEM, V285, P32557, DOI 10.1074/jbc.M110.141960
   [Anonymous], SYBYL X 1 2
   [Anonymous], GUID DOC VAL QUANT S
   [Anonymous], TRIP BOOKSH 8 0
   Bleicher KH, 2003, NAT REV DRUG DISCOV, V2, P369, DOI 10.1038/nrd1086
   Bostrom J, 2003, J MOL GRAPH MODEL, V21, P449, DOI 10.1016/S1093-3263(02)00204-8
   Braga RC, 2012, MINI-REV MED CHEM, V12, P573
   Braga R.C., 2010, 240 AM CHEM SOC NAT
   Braga R.C., 2012, 244 AM CHEM SOC NAT, pCINF
   Braga RC, 2013, CURR TOP MED CHEM, V13, P1127, DOI 10.2174/1568026611313090010
   Braga RC, 2012, J MOL MODEL, V18, P2065, DOI 10.1007/s00894-011-1219-9
   Bueno RV, 2013, J MOL MODEL, V19, P179, DOI 10.1007/s00894-012-1527-8
   Chirico N, 2012, J CHEM INF MODEL, V52, P2044, DOI 10.1021/ci300084j
   Chirico N, 2011, J CHEM INF MODEL, V51, P2320, DOI 10.1021/ci200211n
   Cho SJ, 1996, J MED CHEM, V39, P5064, DOI 10.1021/jm950771r
   Clark RD, 2004, J COMPUT AID MOL DES, V18, P563, DOI 10.1007/s10822-004-4077-z
   Clark RD, 2003, J COMPUT AID MOL DES, V17, P265, DOI 10.1023/A:1025366721142
   Clark RD, 2009, CURR TOP MED CHEM, V9, P791, DOI 10.2174/156802609789207118
   Cohen N.C., 1996, GUIDEBOOK MOL MODELI, P361
   Consonni V, 2010, J CHEMOMETR, V24, P194, DOI 10.1002/cem.1290
   Consonni V, 2009, J CHEM INF MODEL, V49, P1669, DOI 10.1021/ci900115y
   CORNELL WD, 1993, J AM CHEM SOC, V115, P9620, DOI 10.1021/ja00074a030
   Cramer RD, 2003, J MED CHEM, V46, P374, DOI 10.1021/jm020194o
   CRAMER RD, 1988, J AM CHEM SOC, V110, P5959, DOI 10.1021/ja00226a005
   Cramer RD, 2008, J CHEM INF MODEL, V48, P2180, DOI 10.1021/ci8001556
   Cross S, 2010, DRUG DISCOV TODAY, V15, P23, DOI 10.1016/j.drudis.2008.12.006
   CRUCIANI G, 1994, J MED CHEM, V37, P2589, DOI 10.1021/jm00042a012
   Dearden JC, 2009, SAR QSAR ENVIRON RES, V20, P241, DOI 10.1080/10629360902949567
   DELRE G, 1958, J CHEM SOC, P4031, DOI 10.1039/jr9580004031
   DELRE G, 1963, BIOCHIM BIOPHYS ACTA, V75, P153, DOI 10.1016/0006-3002(63)90595-X
   DEWAR MJS, 1977, J AM CHEM SOC, V99, P4899, DOI 10.1021/ja00457a004
   DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024
   Doweyko AM, 2004, J COMPUT AID MOL DES, V18, P587, DOI 10.1007/s10822-004-4068-0
   Duda-Seiman C, 2006, INT J MOL SCI, V7, P537, DOI 10.3390/i7110537
   Duda-Seiman DM, 2011, J SERB CHEM SOC, V76, P85, DOI 10.2298/JSC100601019D
   Duffy BC, 2012, BIOORGAN MED CHEM, V20, P5324, DOI 10.1016/j.bmc.2012.04.062
   Eriksson L, 2003, ENVIRON HEALTH PERSP, V111, P1361, DOI 10.1289/ehp.5758
   Esposito Emilio Xavier, 2004, Methods Mol Biol, V275, P131
   Federsel HJ, 2010, BIOORGAN MED CHEM, V18, P5775, DOI 10.1016/j.bmc.2010.06.029
   FREE SM, 1964, J MED CHEM, V7, P395, DOI 10.1021/jm00334a001
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   GASTEIGER J, 1978, TETRAHEDRON LETT, P3181
   GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2
   Golbraikh A, 2002, J MOL GRAPH MODEL, V20, P269, DOI 10.1016/S1093-3263(01)00123-1
   Gomes TF, 2013, EUR J MED CHEM, V62, P214, DOI 10.1016/j.ejmech.2012.08.011
   GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002
   Halgren TA, 1996, J COMPUT CHEM, V17, P520, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<520::AID-JCC2>3.0.CO;2-W
   Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P
   Halgren TA, 1999, J COMPUT CHEM, V20, P730, DOI 10.1002/(SICI)1096-987X(199905)20:7<730::AID-JCC8>3.3.CO;2-K
   Halgren TA, 1996, J COMPUT CHEM, V17, P616, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<616::AID-JCC5>3.0.CO;2-X
   Halgren TA, 1996, J COMPUT CHEM, V17, P553
   Halgren TA, 1996, J COMPUT CHEM, V17, P587, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<587::AID-JCC4>3.0.CO;2-Q
   HANSCH C, 1964, J AM CHEM SOC, V86, P1616, DOI 10.1021/ja01062a035
   Hawkins DM, 2004, J CHEM INF COMP SCI, V44, P1, DOI 10.1021/ci0342472
   Hawkins PCD, 2007, J MED CHEM, V50, P74, DOI 10.1021/jm0603365
   Hawkins PCD, 2012, J CHEM INF MODEL, V52, P2919, DOI 10.1021/ci300314k
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   HOPFINGER AJ, 1980, J AM CHEM SOC, V102, P7196, DOI 10.1021/ja00544a005
   Hopfinger AJ, 1997, J AM CHEM SOC, V119, P10509, DOI 10.1021/ja9718937
   Huang HH, 2011, BIOCHEMISTRY-US, V50, P5870, DOI 10.1021/bi200107n
   Jain AN, 2004, J MED CHEM, V47, P947, DOI 10.1021/jm030520f
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Jakalian A, 2000, J COMPUT CHEM, V21, P132, DOI 10.1002/(SICI)1096-987X(20000130)21:2<132::AID-JCC5>3.0.CO;2-P
   JONES G, 1995, J MOL BIOL, V245, P43, DOI 10.1016/S0022-2836(95)80037-9
   Jones G, 1995, J COMPUT AID MOL DES, V9, P532, DOI 10.1007/BF00124324
   Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897
   Jones G, 2009, J CHEM INF MODEL, V49, P1847, DOI 10.1021/ci900109n
   Jorgensen WL, 2004, SCIENCE, V303, P1813, DOI 10.1126/science.1096361
   Kapetanovic IM, 2008, CHEM-BIOL INTERACT, V171, P165, DOI 10.1016/j.cbi.2006.12.006
   Kiralj R, 2009, J BRAZIL CHEM SOC, V20, P770, DOI 10.1590/S0103-50532009000400021
   Klabunde T, 2012, J CHEM INF MODEL, V52, P2022, DOI 10.1021/ci3000369
   KLEBE G, 1994, J MED CHEM, V37, P4130, DOI 10.1021/jm00050a010
   Kristam R, 2005, J CHEM INF MODEL, V45, P461, DOI 10.1021/ci049731z
   Kroemer RT, 1998, PERSPECT DRUG DISCOV, V12, P41, DOI 10.1023/A:1017061417516
   Kubinyi H, 1997, DRUG DISCOV TODAY, V2, P457, DOI 10.1016/S1359-6446(97)01079-9
   Kubinyi H, 1997, DRUG DISCOV TODAY, V2, P538, DOI 10.1016/S1359-6446(97)01084-2
   Kubinyi H., 1993, HANSCH ANAL RELATED, P1
   Kubinyi H., 1993, 3D QSAR DRUG DESIGN, P759
   Kuntz AN, 2007, PLOS MED, V4, P1071, DOI 10.1371/journal.pmed.0040206
   Lemmen C, 2000, J COMPUT AID MOL DES, V14, P215, DOI 10.1023/A:1008194019144
   Lemmen C, 1998, J MED CHEM, V41, P4502, DOI 10.1021/jm981037l
   LINDBERG W, 1983, ANAL CHEM, V55, P643, DOI 10.1021/ac00255a014
   MAPLE JR, 1994, J COMPUT CHEM, V15, P162, DOI 10.1002/jcc.540150207
   Martin TM, 2012, J CHEM INF MODEL, V52, P2570, DOI 10.1021/ci300338w
   Martin YC, 1998, PERSPECT DRUG DISCOV, V12, P3, DOI 10.1023/A:1017037831628
   McGaughey GB, 2007, J CHEM INF MODEL, V47, P1504, DOI 10.1021/ci700052x
   Mittal RR, 2009, J CHEM INF MODEL, V49, P704, DOI 10.1021/ci800390m
   Neves BJ, 2013, BIOORG MED CHEM LETT, V23, P2436, DOI 10.1016/j.bmcl.2013.02.006
   Ooms F, 2000, CURR MED CHEM, V7, P141, DOI 10.2174/0929867003375317
   Pastor M, 2000, J MED CHEM, V43, P3233, DOI 10.1021/jm000941m
   Perkins R, 2003, ENVIRON TOXICOL CHEM, V22, P1666, DOI 10.1897/01-171
   Perola E, 2004, J MED CHEM, V47, P2499, DOI 10.1021/jm030563w
   Prast-Nielsen S, 2011, BBA-GEN SUBJECTS, V1810, P1262, DOI 10.1016/j.bbagen.2011.06.024
   PURCELL WP, 1967, J CHEM ENG DATA, V12, P235, DOI 10.1021/je60033a020
   Putz MV, 2007, INT J MOL SCI, V8, P363, DOI 10.3390/i8050363
   Rai G, 2009, J MED CHEM, V52, P6474, DOI 10.1021/jm901021k
   Rester U, 2008, CURR OPIN DRUG DISC, V11, P559
   Richmond NJ, 2004, J MOL GRAPH MODEL, V23, P199, DOI 10.1016/j.jmgm.2004.04.004
   Roy PP, 2008, CHEMOMETR INTELL LAB, V90, P31, DOI 10.1016/j.chemolab.2007.07.004
   Scior T, 2009, CURR MED CHEM, V16, P4297, DOI 10.2174/092986709789578213
   Silverman BD, 1996, J MED CHEM, V39, P2129, DOI 10.1021/jm950589q
   Silverman BD, 1998, PERSPECT DRUG DISCOV, V12, P183, DOI 10.1023/A:1017046424785
   Silverman DB, 2000, QUANT STRUCT-ACT REL, V19, P237
   Simon Z., 1984, MTD METHOD QSAR STUD, P173
   Sippl W, 2010, CHALL ADV COMPUT CHE, V8, P103, DOI 10.1007/978-1-4020-9783-6_4
   Smith G. M., 1990, TETRAHEDRON COMPUT M, V3, P615
   Sousa MC, 2013, FOOD RES INT, V50, P102, DOI 10.1016/j.foodres.2012.09.027
   Stanton DT, 2012, CURR COMPUT-AID DRUG, V8, P107
   Stewart JJP, 2013, J MOL MODEL, V19, P1, DOI 10.1007/s00894-012-1667-x
   Stouch TR, 2003, J COMPUT AID MOL DES, V17, P83, DOI 10.1023/A:1025358319677
   Talele TT, 2010, CURR TOP MED CHEM, V10, P127, DOI 10.2174/156802610790232251
   Todeschini R, 1998, PERSPECT DRUG DISCOV, V9-11, P355, DOI 10.1023/A:1027284627085
   Todeschini R, 1996, CHEMOSPHERE, V32, P1527, DOI 10.1016/0045-6535(96)00060-4
   Todeschini R, 1996, CHEMOSPHERE, V33, P71, DOI 10.1016/0045-6535(96)00153-1
   Todeschini R, 1997, QUANT STRUCT-ACT REL, V16, P113, DOI 10.1002/qsar.19970160203
   TODESCHINI R, 1995, CHEMOMETR INTELL LAB, V27, P221, DOI 10.1016/0169-7439(94)00025-E
   TODESCHINI R, 1994, J CHEMOMETR, V8, P263, DOI 10.1002/cem.1180080405
   Tosco P, 2011, J MOL MODEL, V17, P201, DOI 10.1007/s00894-010-0684-x
   Tropsha A, 1998, PERSPECT DRUG DISCOV, V12, P57, DOI 10.1023/A:1017017601586
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Tsai KC, 2010, EUR J MED CHEM, V45, P1544, DOI 10.1016/j.ejmech.2009.12.063
   Turner DB, 1999, J COMPUT AID MOL DES, V13, P271, DOI 10.1023/A:1008012732081
   Weaver S, 2008, J MOL GRAPH MODEL, V26, P1315, DOI 10.1016/j.jmgm.2008.01.002
   Wold S, 2001, CHEMOMETR INTELL LAB, V58, P109, DOI 10.1016/S0169-7439(01)00155-1
NR 132
TC 30
Z9 31
U1 1
U2 38
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1573-4099
EI 1875-6697
J9 CURR COMPUT-AID DRUG
JI Curr. Comput.-Aided Drug Des.
PY 2014
VL 10
IS 2
BP 148
EP 159
DI 10.2174/1573409910666140410111043
PG 12
WC Chemistry, Medicinal; Computer Science, Interdisciplinary Applications
SC Pharmacology & Pharmacy; Computer Science
GA AN7XW
UT WOS:000340815300007
PM 24724896
DA 2020-12-01
ER

PT J
AU Braga, RC
   Alves, VM
   Silva, AC
   Nascimento, MN
   Silva, FC
   Liao, LM
   Andrade, CH
AF Braga, Rodolpho C.
   Alves, Vincius M.
   Silva, Arthur C.
   Nascimento, Marilia N.
   Silva, Flavia C.
   Liao, Luciano M.
   Andrade, Carolina H.
TI Virtual Screening Strategies in Medicinal Chemistry: The State of the
   Art and Current Challenges
SO CURRENT TOPICS IN MEDICINAL CHEMISTRY
LA English
DT Review
DE Drug design; lead discovery; ligand-based; machine learning;
   pharmacophore model; performance evaluation; structure-based; virtual
   screening
ID QUANTITATIVE STRUCTURE-ACTIVITY; ENOYL-ACP REDUCTASE; DRUG DISCOVERY; 2D
   FINGERPRINTS; CONFORMER GENERATION; TRYPANOSOMA-CRUZI;
   BAYESIAN-APPROACH; CHAGAS-DISEASE; LEAD DISCOVERY; MDL KEYS
AB Virtual screening (VS) techniques are well-established tools in the modern drug discovery process, mainly used for hit finding in drug discovery. The availability of knowledge of structural information, which includes an increasing number of 3D protein structures and the readiness of free databases of commercially available small-molecules, provides a broad platform for VS. This review summarizes the current developments in VS regarding chemical databases and highlights the achievements as well as the challenges with an emphasis on a recent example of the successful application for the identification of new hits for sterol 14 alpha-demethylase (CYP51) of Trypanosoma cruzi.
C1 [Braga, Rodolpho C.; Alves, Vincius M.; Silva, Arthur C.; Nascimento, Marilia N.; Silva, Flavia C.; Andrade, Carolina H.] Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, BR-74605510 Goiania, Go, Brazil.
   [Braga, Rodolpho C.; Liao, Luciano M.] Univ Fed Goias, Inst Quim, Lab Ressonancia Magnet Nucl, BR-74001970 Goiania, Go, Brazil.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, LabMol, Rua 240,Qd 87, BR-74605510 Goiania, Go, Brazil.
EM carolina@ufg.br
RI Andrade, Carolina/C-3960-2014; de Carvalho e Silva, Arthur/S-7803-2018;
   Liao, Luciano Morais/M-3030-2019; Braga, Rodolpho C/A-9655-2011; Liao,
   Luciano Morais M./F-1487-2015; Alves, Vinicius M./G-7955-2015; Lima,
   Marilia/S-7810-2018
OI Andrade, Carolina/0000-0003-0101-1492; de Carvalho e Silva,
   Arthur/0000-0001-9866-3344; Liao, Luciano Morais/0000-0001-9985-2980;
   Braga, Rodolpho C/0000-0003-3814-3464; Liao, Luciano Morais
   M./0000-0001-9985-2980; Alves, Vinicius M./0000-0002-6182-1748; Lima,
   Marilia/0000-0002-7394-0031
FU CAPESCAPES; CNPqNational Council for Scientific and Technological
   Development (CNPq); FAPEG
FX The authors would like to thank the Brazilian Funding Agencies CAPES,
   CNPq and FAPEG for financial support and fellowships. We are also
   grateful to OpenEye Scientific Software, Inc. and ChemAxon for providing
   us with academic licenses for their software.
CR Alves V. M., 2014, 248 ACS NAT M EXP SA
   Andrade CH, 2008, MOL DIVERS, V12, P47, DOI 10.1007/s11030-008-9074-z
   Andrade CH, 2009, J CHEM INF MODEL, V49, P1070, DOI 10.1021/ci8004622
   Andrade CH, 2008, LETT DRUG DES DISCOV, V5, P377, DOI 10.2174/157018008785777289
   Andrade CH, 2008, REV BRAS CIENC FARM, V44, P167, DOI 10.1590/S1516-93322008000200002
   Andrade CH, 2010, J COMPUT AID MOL DES, V24, P157, DOI 10.1007/s10822-010-9323-y
   ARTURSSON P, 1990, J PHARM SCI-US, V79, P476, DOI 10.1002/jps.2600790604
   Baldi P, 2000, BIOINFORMATICS, V16, P412, DOI 10.1093/bioinformatics/16.5.412
   Barbosa AJM, 2012, CURR TOP MED CHEM, V12, P866
   Bhattachar SN, 2006, J PHARMACEUT BIOMED, V41, P152, DOI 10.1016/j.jpba.2005.11.009
   Bostrom J, 2003, J MOL GRAPH MODEL, V21, P449, DOI 10.1016/S1093-3263(02)00204-8
   Bostrom J, 1998, J COMPUT AID MOL DES, V12, P383, DOI 10.1023/A:1008007507641
   Braga R.C., 2014, 248 ACS NAT M EXP SA
   Braga R.C., 2012, 244 AM CHEM SOC NAT
   Braga R.C., 2010, 240 AM CHEM SOC NAT
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1399, DOI 10.2174/1568026614666140506124442
   Braga RC, 2013, CURR TOP MED CHEM, V13, P1127, DOI 10.2174/1568026611313090010
   Brown SP, 2006, J CHEM INF MODEL, V46, P999, DOI 10.1021/ci050488t
   Buckner FS, 2010, CURR OPIN INFECT DIS, V23, P609, DOI 10.1097/QCO.0b013e3283402956
   Bueno RV, 2013, J MOL MODEL, V19, P179, DOI 10.1007/s00894-012-1527-8
   Caporuscio F, 2011, CURR MED CHEM, V18, P2543, DOI 10.2174/092986711795933669
   Carneiro EO, 2010, BIOORG MED CHEM LETT, V20, P3734, DOI 10.1016/j.bmcl.2010.04.073
   Cereto-Massague A, 2012, BIOINFORMATICS, V28, P1661, DOI 10.1093/bioinformatics/bts249
   Chawla NV, 2002, J ARTIF INTELL RES, V16, P321, DOI 10.1613/jair.953
   Chen CK, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000651
   Cheng TJ, 2012, AAPS J, V14, P133, DOI 10.1208/s12248-012-9322-0
   Cheng TJ, 2011, J CHEM INF MODEL, V51, P229, DOI 10.1021/ci100364a
   Coupez B, 2006, CURR MED CHEM, V13, P2995, DOI 10.2174/092986706778521797
   DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082
   Dearden JC, 2009, SAR QSAR ENVIRON RES, V20, P241, DOI 10.1080/10629360902949567
   Doyle S, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-424
   Drummond C, 2006, MACH LEARN, V65, P95, DOI 10.1007/s10994-006-8199-5
   Duan JX, 2010, J MOL GRAPH MODEL, V29, P157, DOI 10.1016/j.jmgm.2010.05.008
   Durant JL, 2002, J CHEM INF COMP SCI, V42, P1273, DOI 10.1021/ci010132r
   Eckert H, 2007, DRUG DISCOV TODAY, V12, P225, DOI 10.1016/j.drudis.2007.01.011
   Ewing T, 2006, J CHEM INF MODEL, V46, P2423, DOI 10.1021/ci060155b
   Feher M, 2006, DRUG DISCOV TODAY, V11, P421, DOI 10.1016/j.drudis.2006.03.009
   Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753
   Flower DR, 1998, J CHEM INF COMP SCI, V38, P379, DOI 10.1021/ci970437z
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Gamerdinger M, 2012, CELL, V151, P469, DOI 10.1016/j.cell.2012.10.015
   Gao H, 1999, J CHEM INF COMP SCI, V39, P164, DOI 10.1021/ci980140g
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   Glen RC, 2006, IDRUGS, V9, P199
   Godden JW, 2000, J CHEM INF COMP SCI, V40, P163, DOI 10.1021/ci990316u
   Good AC, 2008, J COMPUT AID MOL DES, V22, P169, DOI 10.1007/s10822-007-9167-2
   Grant JA, 1996, J COMPUT CHEM, V17, P1653, DOI 10.1002/(SICI)1096-987X(19961115)17:14<1653::AID-JCC7>3.0.CO;2-K
   Gray KC, 2012, P NATL ACAD SCI USA, V109, P2234, DOI 10.1073/pnas.1117280109
   Guerry P, 2011, Q REV BIOPHYS, V44, P257, DOI 10.1017/S0033583510000326
   Guner Osman F., 2002, Current Topics in Medicinal Chemistry, V2, P1321, DOI 10.2174/1568026023392940
   The HP, 2011, MOL INFORM, V30, P376, DOI 10.1002/minf.201000118
   Hastie T., 2009, ELEMENTS STAT LEARNI, DOI [10.1007/b94608., DOI 10.1007/B94608]
   Hawkins PCD, 2012, J CHEM INF MODEL, V52, P2919, DOI 10.1021/ci300314k
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Heikamp K, 2011, J CHEM INF MODEL, V51, P2254, DOI 10.1021/ci200275m
   Holte RC, 2008, LECT NOTES ARTIF INT, V5012, P26, DOI 10.1007/978-3-540-68125-0_4
   Huang N, 2006, J MED CHEM, V49, P6789, DOI 10.1021/jm0608356
   Huang SY, 2010, PHYS CHEM CHEM PHYS, V12, P12899, DOI 10.1039/c0cp00151a
   HURST T, 1994, J CHEM INF COMP SCI, V34, P190, DOI 10.1021/ci00017a025
   Irwin JJ, 2008, J COMPUT AID MOL DES, V22, P193, DOI 10.1007/s10822-008-9189-4
   Irwin JJ, 2012, J CHEM INF MODEL, V52, P1757, DOI 10.1021/ci3001277
   Jacobsson M, 2003, J MED CHEM, V46, P5781, DOI 10.1021/jm030896t
   Jain AN, 2008, J COMPUT AID MOL DES, V22, P201, DOI 10.1007/s10822-007-9151-x
   Jain AN, 2008, J COMPUT AID MOL DES, V22, P133, DOI 10.1007/s10822-008-9196-5
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Jakalian A, 2000, J COMPUT CHEM, V21, P132, DOI 10.1002/(SICI)1096-987X(20000130)21:2<132::AID-JCC5>3.0.CO;2-P
   Johnson M.A., 1990, CONCEPTS APPL MOL SI, V13, P393
   Jorissen RN, 2005, J CHEM INF MODEL, V45, P549, DOI 10.1021/ci049641u
   Kalliokoski T, 2009, J CHEM INF MODEL, V49, P2742, DOI 10.1021/ci900364w
   Kar S, 2013, EXPERT OPIN DRUG DIS, V8, P245, DOI 10.1517/17460441.2013.761204
   Kessel M, 2011, NAT BIOTECHNOL, V29, P27, DOI 10.1038/nbt.1748
   Kirchmair J, 2008, J COMPUT AID MOL DES, V22, P213, DOI 10.1007/s10822-007-9163-6
   Kitchen DB, 2004, NAT REV DRUG DISCOV, V3, P935, DOI 10.1038/nrd1549
   Klebe G, 2006, DRUG DISCOV TODAY, V11, P580, DOI 10.1016/j.drudis.2006.05.012
   Knox AJS, 2005, J CHEM INF MODEL, V45, P1908, DOI 10.1021/ci050185z
   Kolb P, 2009, CURR TOP MED CHEM, V9, P755, DOI 10.2174/156802609789207091
   Kubinyi H, 1998, PERSPECT DRUG DISCOV, V9-11, P225, DOI 10.1023/A:1027221424359
   Laza R, 2011, J INTEGR BIOINFORMAT, V8, DOI 10.2390/biecoll-jib-2011-177
   Leach AR, 2010, J MED CHEM, V53, P539, DOI 10.1021/jm900817u
   Lepesheva G.I., 2011, ADV PARASIT, P7565
   Lepesheva GI, 2010, J BIOL CHEM, V285, P25582, DOI 10.1074/jbc.M110.133215
   Li S, 2007, SAR QSAR ENVIRON RES, V18, P423, DOI 10.1080/10629360701428474
   Liu TQ, 2007, NUCLEIC ACIDS RES, V35, pD198, DOI 10.1093/nar/gkl999
   Low Y, 2011, CHEM RES TOXICOL, V24, P1251, DOI 10.1021/tx200148a
   Calle ML, 2011, HUM HERED, V72, P121, DOI 10.1159/000330778
   Ma DL, 2013, CHEM SOC REV, V42, P2130, DOI 10.1039/c2cs35357a
   Ma XH, 2012, CURR MED CHEM, V19, P5562
   Macarron R, 2011, NAT REV DRUG DISCOV, V10, P188, DOI 10.1038/nrd3368
   Maheshwari S., 2011, INT J SCI ENG RES, V2, P1
   Martins IF, 2012, J CHEM INF MODEL, V52, P1686, DOI 10.1021/ci300124c
   Mazanetz MP, 2012, CURR TOP MED CHEM, V12, P1965
   MCCLISH DK, 1989, MED DECIS MAKING, V9, P190, DOI 10.1177/0272989X8900900307
   McGann M, 2012, J COMPUT AID MOL DES, V26, P897, DOI 10.1007/s10822-012-9584-8
   McGann M, 2011, J CHEM INF MODEL, V51, P578, DOI 10.1021/ci100436p
   McGregor MJ, 1997, J CHEM INF COMP SCI, V37, P443, DOI 10.1021/ci960151e
   Melville JL, 2009, COMB CHEM HIGH T SCR, V12, P332, DOI 10.2174/138620709788167980
   Moncayo A, 2009, MEM I OSWALDO CRUZ, V104, P17, DOI 10.1590/S0074-02762009000900005
   Muchmore SW, 2008, J CHEM INF MODEL, V48, P941, DOI 10.1021/ci7004498
   Neves BJ, 2013, BIOORG MED CHEM LETT, V23, P2436, DOI 10.1016/j.bmcl.2013.02.006
   Nguyen G. H., 2009, PATTERN RECOGN, P16
   Nicholls A, 2008, J COMPUT AID MOL DES, V22, P239, DOI 10.1007/s10822-008-9170-2
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Ozcift A, 2011, COMPUT BIOL MED, V41, P265, DOI 10.1016/j.compbiomed.2011.03.001
   Polgar T, 2011, COMB CHEM HIGH T SCR, V14, P889, DOI 10.2174/138620711797537148
   Polishchuk PG, 2009, J CHEM INF MODEL, V49, P2481, DOI 10.1021/ci900203n
   Ripphausen P, 2011, DRUG DISCOV TODAY, V16, P372, DOI 10.1016/j.drudis.2011.02.011
   Ripphausen P, 2010, J MED CHEM, V53, P8461, DOI 10.1021/jm101020z
   Ritchie TJ, 2009, J CHEM INF MODEL, V49, P1025, DOI 10.1021/ci800429e
   Rogers D, 2010, J CHEM INF MODEL, V50, P742, DOI 10.1021/ci100050t
   Rush TS, 2005, J MED CHEM, V48, P1489, DOI 10.1021/jm040163o
   Schiller DS, 2007, CLIN THER, V29, P1862, DOI 10.1016/j.clinthera.2007.09.015
   Schluter PJ, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-6
   Schneider G, 2010, NAT REV DRUG DISCOV, V9, P273, DOI 10.1038/nrd3139
   Seifert MHJ, 2009, DRUG DISCOV TODAY, V14, P562, DOI 10.1016/j.drudis.2009.03.013
   Shepherd AJ, 1999, PROTEIN SCI, V8, P1045, DOI 10.1110/ps.8.5.1045
   Sheridan RP, 2008, J COMPUT AID MOL DES, V22, P257, DOI 10.1007/s10822-008-9168-9
   Sheridan RP, 2001, J CHEM INF COMP SCI, V41, P1395, DOI 10.1021/ci0100144
   Sherman W, 2006, CHEM BIOL DRUG DES, V67, P83, DOI 10.1111/j.1747-0285.2005.00327.x
   Swann SL, 2011, J MED CHEM, V54, P1223, DOI 10.1021/jm1013677
   Tao Q, 2005, IEEE T NEURAL NETWOR, V16, P1561, DOI [10.1109/TNN.2005.857955, 10.1109/tnn.2005.857955]
   Teague SJ, 1999, ANGEW CHEM INT EDIT, V38, P3743, DOI 10.1002/(SICI)1521-3773(19991216)38:24<3743::AID-ANIE3743>3.3.CO;2-L
   Triballeau N, 2005, J MED CHEM, V48, P2534, DOI 10.1021/jm049092j
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Truchon JF, 2007, J CHEM INF MODEL, V47, P488, DOI 10.1021/ci600426e
   Urbina J.A., 2009, MEM I O CRUZ, V1043, P11
   Ursu O, 2011, WIRES COMPUT MOL SCI, V1, P760, DOI 10.1002/wcms.52
   van de Waterbeemd H, 2003, NAT REV DRUG DISCOV, V2, P192, DOI 10.1038/nrd1032
   Voet D., 2012, FUNDAMENTALS BIOCH, P1200
   Wang YL, 2012, NUCLEIC ACIDS RES, V40, pD400, DOI 10.1093/nar/gkr1132
   Wang YL, 2010, NUCLEIC ACIDS RES, V38, pD255, DOI 10.1093/nar/gkp965
   Waszkowycz B, 2011, WIRES COMPUT MOL SCI, V1, P229, DOI 10.1002/wcms.18
   Welling M., 2011, 1 ENCOUNTER MACHINE, P1
   Wermuth G, 1998, PURE APPL CHEM, V70, P1129
   WHO, 2010, 1 WHO REP NEGL TROP
   Willett P, 1998, J CHEM INF COMP SCI, V38, P983, DOI 10.1021/ci9800211
   Willett P, 2006, DRUG DISCOV TODAY, V11, P1046, DOI 10.1016/j.drudis.2006.10.005
   Wolber G, 2006, J COMPUT AID MOL DES, V20, P773, DOI 10.1007/s10822-006-9078-7
   Xu CY, 2012, J CHEM INF MODEL, V52, P2840, DOI 10.1021/ci300400a
   Yang SY, 2010, DRUG DISCOV TODAY, V15, P444, DOI 10.1016/j.drudis.2010.03.013
   Yoshida N, 2009, MEM I OSWALDO CRUZ, V104, P101, DOI 10.1590/S0074-02762009000900015
   Young D, 2008, QSAR COMB SCI, V27, P1337, DOI 10.1002/qsar.200810084
   Zhang LY, 2013, J CHEM INF MODEL, V53, P475, DOI 10.1021/ci300421n
   Zhang Q, 2006, J MED CHEM, V49, P1536, DOI 10.1021/jm050468i
NR 144
TC 30
Z9 30
U1 4
U2 62
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0266
EI 1873-5294
J9 CURR TOP MED CHEM
JI Curr. Top. Med. Chem.
PY 2014
VL 14
IS 16
BP 1899
EP 1912
DI 10.2174/1568026614666140929120749
PG 14
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA AQ8YC
UT WOS:000343125300005
PM 25262801
DA 2020-12-01
ER

PT J
AU Martins, DR
   Pazini, F
   Alves, VD
   de Moura, SS
   Liao, LM
   de Magalhaes, MTQ
   Valadares, MC
   Andrade, CH
   Menegatti, R
   Rocha, ML
AF Martins, Daniella Ramos
   Pazini, Francine
   Alves, Vinicius de Medeiros
   de Moura, Soraya Santana
   Liao, Luciano Morais
   Quezado de Magalhaes, Mariana Torquato
   Valadares, Marize Campos
   Andrade, Carolina Horta
   Menegatti, Ricardo
   Rocha, Matheus Lavorenti
TI Synthesis, Docking Studies, Pharmacological Activity and Toxicity of a
   Novel Pyrazole Derivative (LQFM 021)-Possible Effects on
   Phosphodiesterase
SO CHEMICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE pyrazole; phosphodiesterase; relaxation; aorta; cyclic nucleotide
ID K+ CHANNEL; AMRINONE; CAMP; CA2+; RECEPTOR; CALCIUM; ROLES; CONTRACTION;
   INHIBITION; RELAXATION
AB This study describes the synthetic route and molecular computational docking of LQFM 021, as well as examines its biological effects and toxicity. The docking studies revealed strong interaction of LQFM 021 to phosphodiesterase-3 (PDE-3). In isolated arteries, the presence of endothelium potentiates the relaxation for LQFM 021 and the inhibition cyclic nucleotides reduced the relaxation. Pre-contraction with KCl (45 mM), the treatment with tetraethylammonium (TEA) (5 mM) and inhibition of reticular Ca2+-ATPase showed an inhibitory effect on relaxation. Moreover, the compound reduced the contraction evoked by the Ca2+ influx. Acute toxicity tests revealed that the compound was practically nontoxic. In conclusion, this study showed that a new synthetic derivative of pyrazole is a possible PDE-3 inhibitor and has vasorelaxant activity and low toxicity.
C1 [Martins, Daniella Ramos; Alves, Vinicius de Medeiros; de Moura, Soraya Santana; Valadares, Marize Campos; Andrade, Carolina Horta; Menegatti, Ricardo; Rocha, Matheus Lavorenti] Univ Fed Goias, Fac Pharm, BR-74605220 Goiania, Go, Brazil.
   [Pazini, Francine; Liao, Luciano Morais] Univ Fed Goias, Inst Chem, BR-74001970 Goiania, Go, Brazil.
   [Quezado de Magalhaes, Mariana Torquato] Embrapa Recursos Genet & Biotecnol Brasilia, Lab Mass Spectrometry LEM, BR-70849970 Brasilia, DF, Brazil.
RP Rocha, ML (corresponding author), Univ Fed Goias, Fac Pharm, Av Univ S-N, BR-74605220 Goiania, Go, Brazil.
EM matheusroch@yahoo.com.br
RI Menegatti, Ricardo/U-4702-2019; rocha, matheus/I-6396-2016; Liao,
   Luciano Morais M./F-1487-2015; Andrade, Carolina/C-3960-2014; Liao,
   Luciano Morais/M-3030-2019; Alves, Vinicius M./G-7955-2015
OI Menegatti, Ricardo/0000-0001-5044-9234; rocha,
   matheus/0000-0002-7883-5003; Liao, Luciano Morais
   M./0000-0001-9985-2980; Andrade, Carolina/0000-0003-0101-1492; Liao,
   Luciano Morais/0000-0001-9985-2980; Alves, Vinicius
   M./0000-0002-6182-1748; Valadares, Marize Campos/0000-0002-0379-1325
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES
FX This study was supported by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq) and Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES). We would like to thank Dr. Carlos
   Bloch Jr. of Embrapa Recursos Geneticos e Biotecnologia.
CR Ahmad F, 2012, HORM METAB RES, V44, P776, DOI 10.1055/s-0032-1312646
   [Anonymous], 2012, OMEGA VERS 2 4 6
   Ballini R, 2003, SYNLETT, P1841, DOI 10.1055/s-2003-41408
   BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H
   Borne RF, 1995, NONSTEROIDAL ANTIINF
   Boswell-Smith V, 2006, BRIT J PHARMACOL, V147, pS252, DOI 10.1038/sj.bjp.0706495
   CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143
   Card GL, 2004, STRUCTURE, V12, P2233, DOI 10.1016/j.str.2004.10.004
   Cardillo C, 1997, HYPERTENSION, V30, P918, DOI 10.1161/01.HYP.30.4.918
   FINAR IL, 1954, J CHEM SOC, P2293, DOI 10.1039/jr9540002293
   Fotakis G, 2006, TOXICOL LETT, V160, P171, DOI 10.1016/j.toxlet.2005.07.001
   Gursoy A, 2000, EUR J MED CHEM, V35, P359, DOI 10.1016/S0223-5234(00)00117-3
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Hirata S, 1998, BRIT J ANAESTH, V81, P578, DOI 10.1093/bja/81.4.578
   HYSLOP S, 1991, WIEN KLIN WOCHENSCHR, V103, P422
   ITOH H, 1992, EUR J PHARMACOL, V218, P347, DOI 10.1016/0014-2999(92)90190-F
   Johansson A, 2003, INORG CHEM, V42, P7502, DOI 10.1021/ic0344822
   Komalavilas P, 1996, J BIOL CHEM, V271, P21933, DOI 10.1074/jbc.271.36.21933
   Lalehzari A, 2008, INORG CHEM, V47, P1120, DOI 10.1021/ic702015u
   Lee CH, 2001, J PHYSIOL-LONDON, V534, P641, DOI 10.1111/j.1469-7793.2001.t01-1-00641.x
   LEE TS, 1995, CHEST, V108, P1364, DOI 10.1378/chest.108.5.1364
   LINCOLN TM, 1990, AM J PHYSIOL, V258, pC399
   LINDGREN S, 1991, GEN PHARMACOL, V22, P617, DOI 10.1016/0306-3623(91)90066-F
   Lugnier C, 2006, PHARMACOL THERAPEUT, V109, P366, DOI 10.1016/j.pharmthera.2005.07.003
   Malone M. H., 1977, NEW NATURAL PRODUCTS, P23
   MALONE MH, 1962, LLOYD, V25, P320
   MEISHERI KD, 1980, EUR J PHARMACOL, V61, P159, DOI 10.1016/0014-2999(80)90158-2
   MINAMI K, 1993, LIFE SCI, V53, P1129, DOI 10.1016/0024-3205(93)90549-I
   MIYOSHI H, 1994, FEBS LETT, V345, P47, DOI 10.1016/0014-5793(94)00417-X
   Mori K, 1996, EUR HEART J, V17, P308
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799
   Scapin G, 2004, BIOCHEMISTRY-US, V43, P6091, DOI 10.1021/bi049868i
   Shaur Y., 2001, PROG NUCL ACID RES M, V66, P241
   Smolenski A, 2012, J THROMB HAEMOST, V10, P167, DOI 10.1111/j.1538-7836.2011.04576.x
   Takuwa Y, 1996, JPN HEART J, V37, P793
   Tejerina T., 1998, EUR J PHARMACOL, V148, P239
   Thomas AP, 1996, FASEB J, V10, P1505
   van der Zypp A, 2000, GEN PHARMACOL-VASC S, V34, P245, DOI 10.1016/S0306-3623(00)00071-9
   Vandeput F, 2009, J PHARMACOL EXP THER, V330, P884, DOI 10.1124/jpet.109.154468
   Wang RX, 2002, J COMPUT AID MOL DES, V16, P11, DOI 10.1023/A:1016357811882
   WANG YX, 1993, EUR J PHARMACOL, V250, P335
   Xu RX, 2004, J MOL BIOL, V337, P355, DOI 10.1016/j.jmb.2004.01.040
   Zhang W, 2002, MOL PHARMACOL, V62, P514, DOI 10.1124/mol.62.3.514
   Zwaagstra ME, 1997, J MED CHEM, V40, P1075, DOI 10.1021/jm960628d
NR 45
TC 15
Z9 15
U1 1
U2 12
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN
SN 0009-2363
J9 CHEM PHARM BULL
JI Chem. Pharm. Bull.
PD MAY
PY 2013
VL 61
IS 5
BP 524
EP 531
DI 10.1248/cpb.c12-01016
PG 8
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA 136AH
UT WOS:000318331300005
PM 23649195
OA Green Published
DA 2020-12-01
ER

PT J
AU Braga, RC
   Andrade, CH
AF Braga, Rodolpho C.
   Andrade, Carolina H.
TI Assessing the Performance of 3D Pharmacophore Models in Virtual
   Screening: How Good are They?
SO CURRENT TOPICS IN MEDICINAL CHEMISTRY
LA English
DT Review
DE Drug design; Enrichment descriptors; Pharmacophore model; Performance
   evaluation; Virtual screening; InhA
ID CARRIER PROTEIN REDUCTASE; ENOYL-ACP REDUCTASE; DRUG DISCOVERY;
   COMPUTATIONAL CHEMISTRY; GENETIC ALGORITHM; BAYESIAN-APPROACH;
   NEURAL-NETWORKS; INHIBITORS; DOCKING; LIGAND
AB Pharmacophore approaches have evolved to be one of the most successful tools in drug discovery, especially since the past two decades. 3D pharmacophore methods are now commonly used as part of more complex workflows in drug discovery campaigns, and have been successfully and extensively applied in virtual screening (VS) approaches. This review provides a perspective of how to assess the performance of 3D pharmacophore models to be used in VS. Since 3D VS protocols are in general assessed by their ability to discriminate between active and inactive compounds, we summarize the impact of the composition and preparation of modeling and external sets on the outcome of evaluations. Moreover, we highlight the significance of both classic enrichment parameters and advanced descriptors for the performance of 3D pharmacophore-based virtual screening methods.
C1 [Braga, Rodolpho C.; Andrade, Carolina H.] Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, Setor Univ, BR-74605220 Goiania, Go, Brazil.
   [Braga, Rodolpho C.] Univ Fed Goias, Inst Quim, BR-74001970 Goiania, Go, Brazil.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, LabMol, Setor Univ, 1A Av Com Praca Univ, BR-74605220 Goiania, Go, Brazil.
EM carolina@farmacia.ufg.br
RI Braga, Rodolpho C/A-9655-2011; Andrade, Carolina/C-3960-2014
OI Braga, Rodolpho C/0000-0003-3814-3464; Andrade,
   Carolina/0000-0003-0101-1492
FU Brazilian Funding Agency CAPESCAPES; Brazilian Funding Agency
   CNPqNational Council for Scientific and Technological Development
   (CNPq); Brazilian Funding Agency FAPEG
FX The authors would like to thank Brazilian Funding Agencies CAPES, CNPq
   and FAPEG for financial support and fellowships. We also thank OpenEye
   Scientific Software Inc. for providing Academic License of the software.
CR Abdo A, 2010, J CHEM INF MODEL, V50, P1012, DOI 10.1021/ci100090p
   Amaro RE, 2010, CURR TOP MED CHEM, V10, P3, DOI 10.2174/156802610790232279
   Andrade CH, 2008, MOL DIVERS, V12, P47, DOI 10.1007/s11030-008-9074-z
   Andrade CH, 2010, MOLECULES, V15, P3281, DOI 10.3390/molecules15053281
   Andrade CH, 2009, J CHEM INF MODEL, V49, P1070, DOI 10.1021/ci8004622
   Andrade CH, 2008, LETT DRUG DES DISCOV, V5, P377, DOI 10.2174/157018008785777289
   Andrade CH, 2010, J COMPUT AID MOL DES, V24, P157, DOI 10.1007/s10822-010-9323-y
   Angelopoulos N, 2009, J CHEM INF MODEL, V49, P1547, DOI 10.1021/ci900046u
   [Anonymous], 2010, Drug Discov Today Technol, V7, pe203, DOI 10.1016/j.ddtec.2010.11.004
   [Anonymous], 2012, OMEGA VERS 2 4 6
   [Anonymous], 2011, QUACPAC VERS 1 5 0
   [Anonymous], 2012, OEDOCKING VERS 3 0 0
   [Anonymous], 2011, ROCS VERS 3 1 2
   Barril X, 2004, MINI-REV MED CHEM, V4, P779
   Bissantz C, 2000, J MED CHEM, V43, P4759, DOI 10.1021/jm001044l
   Bostrom J, 2003, J MOL GRAPH MODEL, V21, P449, DOI 10.1016/S1093-3263(02)00204-8
   Braga R.C., 2012, 244 AM CHEM SOC NAT
   Braga R.C., 2010, 240 AM CHEM SOC NAT
   Braga RC, 2012, J MOL MODEL, V18, P2065, DOI 10.1007/s00894-011-1219-9
   Bueno RV, 2013, J MOL MODEL, V19, P179, DOI 10.1007/s00894-012-1527-8
   Burden Frank, 2008, V458, P25
   Caporuscio F, 2011, CURR MED CHEM, V18, P2543, DOI 10.2174/092986711795933669
   Carneiro EO, 2010, BIOORG MED CHEM LETT, V20, P3734, DOI 10.1016/j.bmcl.2010.04.073
   Cavasotto CN, 2007, CURR TOP MED CHEM, V7, P1006, DOI 10.2174/156802607780906753
   Cereto-Massague A, 2012, BIOINFORMATICS, V28, P1661, DOI 10.1093/bioinformatics/bts249
   *CHEM COMP GROUP, MOL OP ENV
   Chin DN, 2004, MINI-REV MED CHEM, V4, P1053, DOI 10.2174/1389557043403044
   Cho SJ, 2006, J CHEM INF MODEL, V46, P298, DOI 10.1021/ci0503107
   Cohen N.C., 1996, GUIDEBOOK MOL MODELI, P361
   Cross S, 2012, J CHEM INF MODEL, V52, P2587, DOI 10.1021/ci300153d
   Desaphy J, 2012, J CHEM INF MODEL, V52, P2287, DOI 10.1021/ci300184x
   Diller DJ, 2003, J MED CHEM, V46, P4638, DOI 10.1021/jm020503a
   Dixon SL, 2006, J COMPUT AID MOL DES, V20, P647, DOI 10.1007/s10822-006-9087-6
   Doyle S, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-424
   Drummond C, 2006, MACH LEARN, V65, P95, DOI 10.1007/s10994-006-8199-5
   Durant JL, 2002, J CHEM INF COMP SCI, V42, P1273, DOI 10.1021/ci010132r
   Ebalunode JO, 2010, CURR TOP MED CHEM, V10, P669
   Fechner N, 2010, J CHEMINFORMATICS, V2, DOI 10.1186/1758-2946-2-2
   Foo LK, 2012, J BIOPHARM STAT, V22, P1193, DOI 10.1080/10543406.2011.580484
   Freundlich JS, 2009, CHEMMEDCHEM, V4, P241, DOI 10.1002/cmdc.200800261
   Gao H, 1999, J CHEM INF COMP SCI, V39, P164, DOI 10.1021/ci980140g
   GASTEIGER J, 1993, ANGEW CHEM INT EDIT, V32, P503, DOI 10.1002/anie.199305031
   Gil ED, 2012, J BRAZIL CHEM SOC, V23, P565, DOI 10.1590/S0103-50532012000300025
   Gobbi A, 2003, J CHEM INF COMP SCI, V43, P317, DOI 10.1021/ci025554v
   Gomes TF, 2013, EUR J MED CHEM, V62, P214, DOI 10.1016/j.ejmech.2012.08.011
   Guner O, 2004, CURR MED CHEM, V11, P2991, DOI 10.2174/0929867043364036
   GUNER O, 2000, PHARMACOPHORE PERCEP, P560
   Guner Osman F., 2002, Current Topics in Medicinal Chemistry, V2, P1321, DOI 10.2174/1568026023392940
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   He X, 2006, J MED CHEM, V49, P6308, DOI 10.1021/jm060715y
   Hea X, 2007, BIOORGAN MED CHEM, V15, P6649, DOI 10.1016/j.bmc.2007.08.013
   Hecker EA, 2002, J CHEM INF COMP SCI, V42, P1204, DOI 10.1021/ci020368a
   Holte RC, 2008, LECT NOTES ARTIF INT, V5012, P26, DOI 10.1007/978-3-540-68125-0_4
   Hsieh JH, 2012, J CHEM INF MODEL, V52, P16, DOI 10.1021/ci2002507
   Hu B., 2012, J CHEM INF MODEL
   Huang DN, 2012, J CHEM INF MODEL, V52, P1356, DOI 10.1021/ci300067q
   Huang N, 2006, J MED CHEM, V49, P6789, DOI 10.1021/jm0608356
   Hudson BD, 1996, QUANT STRUCT-ACT REL, V15, P285, DOI 10.1002/qsar.19960150402
   HURST T, 1994, J CHEM INF COMP SCI, V34, P190, DOI 10.1021/ci00017a025
   Irwin J. J., 2012, J CHEM INF MODEL
   Irwin JJ, 2008, J COMPUT AID MOL DES, V22, P193, DOI 10.1007/s10822-008-9189-4
   Jacobsson M, 2003, J MED CHEM, V46, P5781, DOI 10.1021/jm030896t
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Jalaie M, 2006, MINI-REV MED CHEM, V6, P1159, DOI 10.2174/138955706778560157
   Jiang YL, 1996, RADIOLOGY, V201, P745, DOI 10.1148/radiology.201.3.8939225
   Jones G, 1995, J COMPUT AID MOL DES, V9, P532, DOI 10.1007/BF00124324
   Jones G, 2010, J CHEM INF MODEL, V50, P2001, DOI 10.1021/ci100194k
   KENNARD RW, 1969, TECHNOMETRICS, V11, P137, DOI 10.2307/1266770
   Kier L. B., 1970, FUNDAMENTAL CONCEPTS
   KIER LB, 1967, MOL PHARMACOL, V3, P487
   KIER LB, 1971, MO THEORY DRUG RES, P164
   Kim HJ, 2008, BIOORGAN MED CHEM, V16, P636, DOI 10.1016/j.bmc.2007.10.047
   Koes DR, 2011, J CHEM INF MODEL, V51, P1307, DOI 10.1021/ci200097m
   Kolb P, 2009, CURR TOP MED CHEM, V9, P755, DOI 10.2174/156802609789207091
   Kontoyianni M, 2008, CURR MED CHEM, V15, P107, DOI 10.2174/092986708783330566
   Korb O, 2010, J CHEM INF MODEL, V50, P1669, DOI 10.1021/ci1000218
   Kuo MR, 2003, J BIOL CHEM, V278, P20851, DOI 10.1074/jbc.M211968200
   Kurogi Y, 2001, CURR MED CHEM, V8, P1035, DOI 10.2174/0929867013372481
   Langer T, 2004, Drug Discov Today Technol, V1, P203, DOI 10.1016/j.ddtec.2004.11.015
   Langer T, 2001, CURR PHARM DESIGN, V7, P509, DOI 10.2174/1381612013397861
   Langer T., 2006, PHARMACOPHORES PHARM, P395
   Langer T, 2010, MOL INFORM, V29, P470, DOI 10.1002/minf.201000022
   Lasko TA, 2005, J BIOMED INFORM, V38, P404, DOI 10.1016/j.jbi.2005.02.008
   Laza R, 2011, J INTEGR BIOINFORMAT, V8, DOI 10.2390/biecoll-jib-2011-177
   Leach AR, 2010, J MED CHEM, V53, P539, DOI 10.1021/jm900817u
   Li S, 2007, SAR QSAR ENVIRON RES, V18, P423, DOI 10.1080/10629360701428474
   Lin JH, 2012, CURR TOP MED CHEM, V12, P1903, DOI 10.2174/156802612804547362
   Luckner SR, 2010, J BIOL CHEM, V285, P14330, DOI 10.1074/jbc.M109.090373
   Maheshwari S., 2011, INT J SCI ENG RES, V2, P1
   Martin TM, 2012, J CHEM INF MODEL, V52, P2570, DOI 10.1021/ci300338w
   Martins IF, 2012, J CHEM INF MODEL, V52, P1686, DOI 10.1021/ci300124c
   MCCLISH DK, 1989, MED DECIS MAKING, V9, P190, DOI 10.1177/0272989X8900900307
   McGann M, 2012, J COMPUT AID MOL DES, V26, P897, DOI 10.1007/s10822-012-9584-8
   McGann M, 2011, J CHEM INF MODEL, V51, P578, DOI 10.1021/ci100436p
   McGann MR, 2003, BIOPOLYMERS, V68, P76, DOI 10.1002/bip.10207
   McGaughey GB, 2007, J CHEM INF MODEL, V47, P1504, DOI 10.1021/ci700052x
   Melville JL, 2009, COMB CHEM HIGH T SCR, V12, P332, DOI 10.2174/138620709788167980
   Muchmore SW, 2008, J CHEM INF MODEL, V48, P941, DOI 10.1021/ci7004498
   Muegge I, 2008, MINI-REV MED CHEM, V8, P927, DOI 10.2174/138955708785132792
   Neves BJ, 2013, BIOORG MED CHEM LETT, V23, P2436, DOI 10.1016/j.bmcl.2013.02.006
   Nguyen G. H., 2009, PATTERN RECOGN, P16
   Nilakantan R, 1997, J COMPUT AID MOL DES, V11, P447, DOI 10.1023/A:1007937308615
   Nunes CA, 2012, J BRAZIL CHEM SOC, V23, P2003, DOI 10.1590/S0103-50532012005000073
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Obuchowski NA, 2005, AM J ROENTGENOL, V184, P364, DOI 10.2214/ajr.184.2.01840364
   Ozcift A, 2011, COMPUT BIOL MED, V41, P265, DOI 10.1016/j.compbiomed.2011.03.001
   Pan P, 2012, CURR TOP MED CHEM, V12, P672, DOI 10.2174/156802612799984535
   Perola E, 2004, J MED CHEM, V47, P2499, DOI 10.1021/jm030563w
   Ranu S, 2011, J CHEM INF MODEL, V51, P1106, DOI 10.1021/ci100503y
   Reddy AS, 2007, CURR PROTEIN PEPT SC, V8, P329
   Richmond NJ, 2006, J COMPUT AID MOL DES, V20, P567, DOI 10.1007/s10822-006-9082-y
   Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77
   Robin X, 2009, EXPERT REV PROTEOMIC, V6, P675, DOI 10.1586/EPR.09.83
   Roche O, 2005, MINI-REV MED CHEM, V5, P677, DOI 10.2174/1389557054368826
   Sanders MPA, 2011, J CHEM INF MODEL, V51, P2277, DOI 10.1021/ci200088d
   Schluter PJ, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-6
   Schneider G, 1999, ANGEW CHEM INT EDIT, V38, P2894, DOI 10.1002/(SICI)1521-3773(19991004)38:19<2894::AID-ANIE2894>3.3.CO;2-6
   Seifert MHJ, 2008, MINI-REV MED CHEM, V8, P63, DOI 10.2174/138955708783331540
   Shepherd AJ, 1999, PROTEIN SCI, V8, P1045, DOI 10.1110/ps.8.5.1045
   Sheridan RP, 2001, J CHEM INF COMP SCI, V41, P1395, DOI 10.1021/ci0100144
   Snarey M, 1997, J MOL GRAPH MODEL, V15, P372, DOI 10.1016/S1093-3263(98)00008-4
   Sonego P, 2008, BRIEF BIOINFORM, V9, P198, DOI 10.1093/bib/bbm064
   Streiner DL, 2007, CAN J PSYCHIAT, V52, P121, DOI 10.1177/070674370705200210
   Sullivan TJ, 2006, ACS CHEM BIOL, V1, P43, DOI 10.1021/cb0500042
   Swann SL, 2011, J MED CHEM, V54, P1223, DOI 10.1021/jm1013677
   Tao Q, 2005, IEEE T NEURAL NETWOR, V16, P1561, DOI [10.1109/TNN.2005.857955, 10.1109/tnn.2005.857955]
   Townsend JA, 2012, J CHEM INF MODEL, V52, P2494, DOI 10.1021/ci200303m
   Triballeau N, 2005, J MED CHEM, V48, P2534, DOI 10.1021/jm049092j
   Truchon JF, 2007, J CHEM INF MODEL, V47, P488, DOI 10.1021/ci600426e
   Van Drie JH, 2007, INTERNET ELECT J MOL, V6, P271
   von Korff M, 2012, J CHEM INF MODEL, V52, P380, DOI 10.1021/ci200402r
   Wallach I, 2011, J CHEM INF MODEL, V51, P196, DOI 10.1021/ci100374f
   Wang Y, 2011, BIOORG MED CHEM LETT, V21, P7064, DOI 10.1016/j.bmcl.2011.09.094
   Watson P, 2008, J CHEM INF MODEL, V48, P166, DOI 10.1021/ci7003253
   Wermuth G, 1998, PURE APPL CHEM, V70, P1129
   Wolber G, 2005, J CHEM INF MODEL, V45, P160, DOI 10.1021/ci049885e
   Wolber G, 2006, J COMPUT AID MOL DES, V20, P773, DOI 10.1007/s10822-006-9078-7
   Wood DJ, 2012, J CHEM INF MODEL, V52, P2031, DOI 10.1021/ci3000776
   Xu Huafeng, 2002, Current Topics in Medicinal Chemistry, V2, P1305, DOI 10.2174/1568026023392869
   Yang SY, 2010, DRUG DISCOV TODAY, V15, P444, DOI 10.1016/j.drudis.2010.03.013
   Zhang DD, 2002, STAT MED, V21, P701, DOI 10.1002/sim.1011
   Zhao W, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-225
   Zupan J, 1997, CHEMOMETR INTELL LAB, V38, P1, DOI 10.1016/S0169-7439(97)00030-0
NR 143
TC 67
Z9 68
U1 2
U2 36
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0266
EI 1873-5294
J9 CURR TOP MED CHEM
JI Curr. Top. Med. Chem.
PD MAY
PY 2013
VL 13
IS 9
BP 1127
EP 1138
DI 10.2174/1568026611313090010
PG 12
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 150JR
UT WOS:000319387000010
PM 23651486
DA 2020-12-01
ER

PT J
AU Neves, BJ
   Bueno, RV
   Braga, RC
   Andrade, CH
AF Neves, Bruno J.
   Bueno, Renata V.
   Braga, Rodolpho C.
   Andrade, Carolina H.
TI Discovery of new potential hits of Plasmodium falciparum enoyl-ACP
   reductase through ligand- and structure-based drug design approaches
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Enoyl-ACP reductase; Plasmodium falciparum; Drug design; QSAR; New
   inhibitors
ID CARRIER PROTEIN REDUCTASE; DIFFERENT ALIGNMENT METHODS; MOLECULAR
   TARGETS; 3D QSAR; INHIBITORS; MALARIA; TRICLOSAN; VALIDATION; PROSPECTS;
   PROGRESS
AB We here report the discovery of novel Plasmodium falciparum enoyl-ACP reductase (PfENR) inhibitors as new antimalarial hits through ligand-and structure-based drug design approaches. We performed 2D and 3D QSAR studies on a set of rhodanine analogues using hologram QSAR (HQSAR), comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) techniques. Statistical and satisfactory results were obtained for the best HQSAR (r(2) of 0.968 and q(LOO)(2) of 0.751), CoMFA (r(2) of 0.955 and q(LOO)(2) of 0.806) and CoMSIA (r(2) of 0.965 and q(LOO)(2) of 0.659) models. The information gathered from the QSAR models guided us to design new PfENR inhibitors. Three new hits were predicted with potency in the submicromolar range and presented drug-like properties. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Neves, Bruno J.; Bueno, Renata V.; Braga, Rodolpho C.; Andrade, Carolina H.] Univ Fed Goias, Fac Farm, Lab Planejamento Farmacos & Estudos Metab Modelag, BR-74605220 Goiania, Go, Brazil.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, Lab Planejamento Farmacos & Estudos Metab Modelag, Praca Univ Com 1A Av, BR-74605220 Goiania, Go, Brazil.
EM carolina@farmacia.ufg.br
RI Braga, Rodolpho C/A-9655-2011; Neves, Bruno Junior/E-6295-2016; Neves,
   Bruno/R-7068-2019; Andrade, Carolina/C-3960-2014
OI Braga, Rodolpho C/0000-0003-3814-3464; Neves, Bruno/0000-0002-1309-8743;
   Andrade, Carolina/0000-0003-0101-1492
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES; FAPEG
FX The authors would like to thank Brazilian funding agencies, CNPq, CAPES,
   and FAPEG for financial support and fellowships. We also thank OpenEye
   Scientific Software Inc. for the Academic License of the software.
CR Andrade CH, 2010, MOLECULES, V15, P3281, DOI 10.3390/molecules15053281
   Andrade CH, 2009, J CHEM INF MODEL, V49, P1070, DOI 10.1021/ci8004622
   Andrade CH, 2010, J COMPUT AID MOL DES, V24, P157, DOI 10.1007/s10822-010-9323-y
   Andricopulo AD, 2009, CURR TOP MED CHEM, V9, P771, DOI 10.2174/156802609789207127
   [Anonymous], 2010, BROOD VERS 2 0
   [Anonymous], 2011, QUACPAC VERS 1 5 0
   [Anonymous], 2012, OEDOCKING VERS 3 0 0
   [Anonymous], 2011, ROCS VERS 3 1 2
   Aparna V, 2006, BIOORG MED CHEM LETT, V16, P1014, DOI 10.1016/j.bmcl.2005.10.086
   Bueno RV, 2013, J MOL MODEL, V19, P179, DOI 10.1007/s00894-012-1527-8
   Feachem RGA, 2010, LANCET, V376, P1566, DOI 10.1016/S0140-6736(10)61270-6
   Freundlich JS, 2005, BIOORG MED CHEM LETT, V15, P5247, DOI 10.1016/j.bmcl.2005.08.044
   Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097
   Greenwood BM, 2008, J CLIN INVEST, V118, P1266, DOI 10.1172/JCI33996
   Gupta AK, 2010, BIOORG MED CHEM LETT, V20, P4779, DOI 10.1016/j.bmcl.2010.06.120
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Jana S, 2007, INT J ANTIMICROB AG, V30, P4, DOI 10.1016/j.ijantimicag.2007.01.002
   Kubinyi H, 1997, DRUG DISCOV TODAY, V2, P457, DOI 10.1016/S1359-6446(97)01079-9
   Kumar G, 2010, IUBMB LIFE, V62, P204, DOI 10.1002/iub.306
   Lemmen C, 2000, J COMPUT AID MOL DES, V14, P215, DOI 10.1023/A:1008194019144
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Mackinnon MJ, 2010, SCIENCE, V328, P866, DOI 10.1126/science.1185410
   McGaughey GB, 2007, J CHEM INF MODEL, V47, P1504, DOI 10.1021/ci700052x
   Pan XL, 2010, EUR J MED CHEM, V45, P667, DOI 10.1016/j.ejmech.2009.11.010
   Perozzo R, 2002, J BIOL CHEM, V277, P13106, DOI 10.1074/jbc.M112000200
   Sahu NK, 2008, CHEM BIOL DRUG DES, V71, P287, DOI 10.1111/j.1747-0285.2008.00640.x
   Schuurmann G, 2008, J CHEM INF MODEL, V48, P2140, DOI 10.1021/ci800253u
   Scior T, 2009, CURR MED CHEM, V16, P4297, DOI 10.2174/092986709789578213
   Surolia N, 2001, NAT MED, V7, P167, DOI 10.1038/84612
   Swann SL, 2011, J MED CHEM, V54, P1223, DOI 10.1021/jm1013677
   Verma J, 2010, CURR TOP MED CHEM, V10, P95, DOI 10.2174/156802610790232260
   Waller RF, 2003, ANTIMICROB AGENTS CH, V47, P297, DOI 10.1128/AAC.47.1.297-301.2003
   Wang L., 2012, J CHEMINFORMATICS, V4, pO20
   White NJ, 2004, J CLIN INVEST, V113, P1084, DOI 10.1172/JCI200421682
   WHO, 2011, WORLD MALARIA REPORT 2011, P1
NR 35
TC 19
Z9 20
U1 0
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD APR 15
PY 2013
VL 23
IS 8
BP 2436
EP 2441
DI 10.1016/j.bmcl.2013.02.006
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 117DZ
UT WOS:000316934000033
PM 23499236
DA 2020-12-01
ER

PT J
AU Gomes, TF
   Pompeu, TET
   Rodrigues, DA
   Noel, F
   Menegatti, R
   Andrade, CH
   Sabino, JR
   Gil, ES
   Dalla Costa, T
   Betti, AH
   Antonio, CB
   Rates, SMK
   Fraga, CAM
   Barreiro, EJ
   de Oliveira, V
AF Gomes, Tatiana F.
   Pompeu, Thais E. T.
   Rodrigues, Daniel A.
   Noel, Francois
   Menegatti, Ricardo
   Andrade, Carolina H.
   Sabino, Jose R.
   Gil, Eric S.
   Dalla Costa, Teresa
   Betti, Andresa H.
   Antonio, Camila B.
   Rates, Stela M. K.
   Fraga, Carlos A. M.
   Barreiro, Eliezer J.
   de Oliveira, Valeria
TI Biotransformation of LASSBio-579 and pharmacological evaluation of
   p-hydroxylated metabolite a N-phenylpiperazine antipsychotic lead
   compound
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Biotransformation; Filamentous fungi; Pharmacological evaluation;
   LASSBio-579; Schizophrenia
ID BIOSYNTHESIS; PREDICTIONS; DYNAMICS; LIGANDS; PROFILE; DESIGN; DRUGS
AB Using a combination of docking and molecular dynamics simulations, we predicted that p-hydroxylation by CYP1A2 would be the main metabolic pathway for the 1-[1-(4-chlorophenyl)-1H-4pyrazolylmethyl]phenylhexahydropiperazine, LASSBio-579 (3). As the result of a screening process with strains of filamentous fungi, Cunninghamella echinulata ATCC 9244 was chosen to scale up the preparation of the p-hydroxylated metabolite (4). About 30 min after i.p. administration of (3) to rats was identified as the p-hydroxylated metabolite, confirming our in silico previsions. Chemical synthesis of the metabolite was performed and allowed its pharmacological evaluation in binding assays revealing its high affinity for D2 and D4 receptors, indicating that this metabolite should participate to the antipsychotic effect of (3) in vivo. Furthermore, we report here that both (3) and its p-hydroxylated metabolite (4) have a much lower affinity than clozapine for two receptors involved in adverse reactions. Voltammetric assays were useful to understand the redox profile of (3). (C) 2012 Elsevier Masson SAS. All rights reserved.
C1 [Gomes, Tatiana F.; Rodrigues, Daniel A.; Menegatti, Ricardo; Andrade, Carolina H.; Gil, Eric S.; de Oliveira, Valeria] Univ Fed Goias, Fac Farm, LabMol, Lab Bioconversao, BR-74605220 Goiania, Go, Brazil.
   [Gomes, Tatiana F.; Rodrigues, Daniel A.; Menegatti, Ricardo; Andrade, Carolina H.; Gil, Eric S.; de Oliveira, Valeria] Univ Fed Goias, Fac Farm, Lab Quim Farmaceut Med, BR-74605220 Goiania, Go, Brazil.
   [Pompeu, Thais E. T.; Noel, Francois] Univ Fed Rio de Janeiro, Dept Farmacol Basica & Clin, Lab Farmacol Bioquim & Mol, Rio De Janeiro, RJ, Brazil.
   [Sabino, Jose R.] Univ Fed Goias, Inst Fis, Goiania, Go, Brazil.
   [Dalla Costa, Teresa; Betti, Andresa H.; Antonio, Camila B.; Rates, Stela M. K.] Univ Fed Rio Grande do Sul, Programa Posgrad Ciencias Farmaceut, Porto Alegre, RS, Brazil.
   [Fraga, Carlos A. M.; Barreiro, Eliezer J.] Univ Fed Rio de Janeiro, Fac Farm, Lab Avaliacao & Sintese Subst Bioat LASSBio, Rio De Janeiro, RJ, Brazil.
RP de Oliveira, V (corresponding author), Univ Fed Goias, Fac Farm, Setor Univ, Ave Esquina C Praca Univ,S-N Caixa Postal 131, BR-74605220 Goiania, Go, Brazil.
EM valeria@farmacia.ufg.br
RI Costa, Teresa CT Dalla/A-6617-2013; Fraga, Carlos/G-3495-2012; Betti,
   Andresa/AAX-1637-2020; Gil, Eric/M-2083-2017; Rodrigues, Daniel
   Alencar/K-4986-2018; Andrade, Carolina/C-3960-2014; Oliveira,
   Valeria/B-8056-2016; Menegatti, Ricardo/U-4702-2019; Inofar,
   Inct/J-8605-2013; Barreiro, Eliezer J/B-1131-2011; Noel,
   Francois/C-3402-2009
OI Costa, Teresa CT Dalla/0000-0001-9227-2991; Fraga,
   Carlos/0000-0001-6733-7079; Betti, Andresa/0000-0002-7116-5465; Gil,
   Eric/0000-0001-9161-0127; Rodrigues, Daniel Alencar/0000-0001-7898-7093;
   Andrade, Carolina/0000-0003-0101-1492; Oliveira,
   Valeria/0000-0001-9800-4883; Menegatti, Ricardo/0000-0001-5044-9234;
   Noel, Francois/0000-0001-6813-1347; RATES, STELA/0000-0001-7952-7830
FU FAPEG; CAPESCAPES; CNPqNational Council for Scientific and Technological
   Development (CNPq); INCT-INOFAR [573.564/2008-6]
FX The authors thank FAPEG, CAPES, CNPq and INCT-INOFAR (#573.564/2008-6)
   for financial support and fellowships.
CR Bruker, 2007, SMART APEX2 SAINT
   Carneiro E. O., 2005, BRAZ J PHARM SCI, V41, P392
   Carneiro EO, 2010, BIOORG MED CHEM LETT, V20, P3734, DOI 10.1016/j.bmcl.2010.04.073
   Clark AM, 2007, J CHEM INF MODEL, V47, P1933, DOI 10.1021/ci7001473
   Conrado DJ, 2008, J PHARM PHARMACOL, V60, P699, DOI 10.1211/jpp.60.6.0004
   Costa EMDB, 2008, BRAZ J MICROBIOL, V39, P405, DOI 10.1590/S1517-838220080002000036
   Dias L.E.S., 2005, BRAZ J PHARM SCI, V41, P133
   Farah A, 2005, J CLIN PSYCHIAT, V7, P268, DOI DOI 10.4088/PCC.V07N0602
   Farrugia LJ, 1998, POLYHEDRON, V17, P2877, DOI 10.1016/S0277-5387(98)00018-7
   Gardner DM, 2005, CAN MED ASSOC J, V172, P1703, DOI 10.1503/cmaj.1041064
   Harms K., 1995, XCAD4
   Herrick-Davis K, 2000, J PHARMACOL EXP THER, V295, P226
   Hirose T, 2004, J PSYCHOPHARMACOL, V18, P375, DOI 10.1177/026988110401800308
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760
   Knox C, 2011, NUCLEIC ACIDS RES, V39, pD1035, DOI 10.1093/nar/gkq1126
   Labute P, 2008, J COMPUT CHEM, V29, P1693, DOI 10.1002/jcc.20933
   Leucht S, 2009, LANCET, V373, P31, DOI 10.1016/S0140-6736(08)61764-X
   Luo GL, 2004, BIOORG MED CHEM LETT, V14, P5975, DOI 10.1016/j.bmcl.2004.10.005
   MELTZER HY, 1995, CLIN NEUROSCI, V3, P64
   Menegatti R, 2003, BIOORGAN MED CHEM, V11, P4807, DOI 10.1016/S0968-0896(03)00487-5
   Moody JD, 2002, DRUG METAB DISPOS, V30, P1274, DOI 10.1124/dmd.30.11.1274
   Neves G, 2003, BRAZ J MED BIOL RES, V36, P625, DOI 10.1590/S0100-879X2003000500010
   Neves G, 2008, PHARMACOL BIOCHEM BE, V89, P23, DOI 10.1016/j.pbb.2007.10.018
   Neves G, 2010, BIOORGAN MED CHEM, V18, P1925, DOI 10.1016/j.bmc.2010.01.040
   Olesen OV, 2001, J CLIN PHARMACOL, V41, P823, DOI 10.1177/00912700122010717
   Owens DGC, 1996, DRUGS, V51, P895
   Park JY, 2003, J MED CHEM, V46, P1645, DOI 10.1021/jm020538a
   Pazini F, 2010, BIOORG MED CHEM LETT, V20, P2888, DOI 10.1016/j.bmcl.2010.03.034
   Sansen S, 2007, J BIOL CHEM, V282, P14348, DOI 10.1074/jbc.M611692200
   Shaw DE, 2010, SCIENCE, V330, P341, DOI 10.1126/science.1187409
   SMITH RV, 1975, J PHARM SCI-US, V64, P1737, DOI 10.1002/jps.2600641104
   Sun H, 2010, CHEM BIOL DRUG DES, V75, P3, DOI 10.1111/j.1747-0285.2009.00899.x
   Wood MD, 2001, DRUG DEVELOP RES, V54, P88, DOI 10.1002/ddr.1208
   Yuan W. Ji, 2008, BMC NEUROSCI, V9, P75
   Zhang DL, 2006, DRUG METAB DISPOS, V34, P267, DOI 10.1124/dmd.105.007153
NR 35
TC 11
Z9 11
U1 1
U2 15
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD APR
PY 2013
VL 62
BP 214
EP 221
DI 10.1016/j.ejmech.2012.08.011
PG 8
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 139IX
UT WOS:000318577500023
PM 23353740
DA 2020-12-01
ER

PT J
AU Costa, EA
   Lino, RC
   Comes, MN
   Nascimento, MVM
   Fiorentino, IF
   Galdino, PM
   Andrade, CH
   Rezehde, KR
   Magalhaes, LO
   Menegatti, R
AF Costa, E. A.
   Lino, R. C.
   Comes, M. N.
   Nascimento, M. V. M.
   Fiorentino, I. F.
   Galdino, P. M.
   Andrade, C. H.
   Rezehde, K. R.
   Magalhaes, L. O.
   Menegatti, R.
TI Anti-inflammatory and antinociceptive activities of LQFM002 - A
   4-nerolidylcatechol derivative
SO LIFE SCIENCES
LA English
DT Article
DE Antinociception; Anti-inflammatory; PLA(2) activity; TNF-alpha
ID CARRAGEENAN-INDUCED PLEURISY; FORMALIN TEST; PHOSPHOLIPASE A(2);
   ACETIC-ACID; INTRAPERITONEAL INJECTION; NOCICEPTIVE RESPONSE; NARCOTIC
   ANALGESICS; NATURAL-PRODUCTS; MICE; RECEPTOR
AB Aims: The current study describes the synthesis and pharmacological evaluation of (E)-N-(3,7-dimethylocta2,6-dienyl)-1,3-dimethyl-1H-pyrazol-5-amine (LQFM002), a compound originally designed through a molecular simplification strategy from 4-nerolidylcatechol. LQFM002 was evaluated for preservation of the PLA(2) enzyme inhibitory effects of the lead compound, 4-nerolidylcatechol, using in vitro and in vivo models.
   Main methods: Rota-rod, open field and pentobarbital-induced sleeping tests were used to evaluate the effects of LQFM002 on the central nervous system. A gel plate assay of PLA(2) activity, carrageenan-induced pleurisy and TNF-alpha levels was used to assay anti-inflammatory activity. Antinociceptive activities of LQFM002 were evaluated with acetic acid-induced writhing, formalin and hot-plate tests, while involvement of the opioid pathway in the LQFM002 antinociceptive effect was investigated with naloxone pre-treatment.
   Key findings: LQFM002 inhibited PLA(2) activity, cell migration into the pleural cavity, and capillary permeability (Evan's blue concentration) and reduced TNF-alpha levels in pleural exudates. LQFM002 also reduced acetic acid-induced writhing and the licking time in both phases of the formalin test and increased latency in the hot-plate test. Pre-treatment with 8.25 mu mol/kg naloxone (3 mg/kg) reversed the analgesic effects of LQFM002 in the early phase of the formalin test.
   Significance: LQFM002 showed anti-inflammatory activity, which possibly involved reduction of leukocyte migration and TNF-alpha levels. LQFM002 also demonstrated inhibition of PLA(2) activity in vitro. LQFM002 had an antinociceptive effect that involved the opioidergic system. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Costa, E. A.; Lino, R. C.; Nascimento, M. V. M.; Fiorentino, I. F.; Galdino, P. M.] Univ Fed Goias, Dept Physiol Sci, Inst Biol Sci, BR-74001970 Goiania, Go, Brazil.
   [Comes, M. N.; Magalhaes, L. O.; Menegatti, R.] Univ Fed Goias, Fac Pharm, Lab Med Pharmaceut Chem, BR-74001970 Goiania, Go, Brazil.
   [Andrade, C. H.] Univ Fed Goias, Fac Pharm, Lab Mol Modeling, BR-74001970 Goiania, Go, Brazil.
   [Rezehde, K. R.] Univ Fed Goias, Fac Pharm, Lab Biopharm & Pharmacokinet, BR-74001970 Goiania, Go, Brazil.
RP Costa, EA (corresponding author), Univ Fed Goias, Lab Farmacol Prod Nat, Sala 216,ICB 2,CP 131, BR-74001970 Goiania, Go, Brazil.
EM xico@icb.ufg.br
RI Galdino, Pablinny/D-9695-2014; Menegatti, Ricardo/U-4702-2019; Andrade,
   Carolina/C-3960-2014; Rezende, Kennia R/D-2622-2011; REZENDE, KENNIA
   ROCHA/E-4090-2019
OI Galdino, Pablinny/0000-0003-2836-5565; Menegatti,
   Ricardo/0000-0001-5044-9234; Andrade, Carolina/0000-0003-0101-1492;
   Rezende, Kennia R/0000-0002-3813-8545; REZENDE, KENNIA
   ROCHA/0000-0002-3813-8545; NASCIMENTO, MARCUS/0000-0003-3360-4698
FU FAPEG; CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES
FX The authors are grateful to FAPEG, CNPq and CAPES for financial support.
CR Abrams WB, 1964, ANIMAL CLIN PHARM TE, P36
   AKENDENGUE B, 1994, J ETHNOPHARMACOL, V41, P193, DOI 10.1016/0378-8741(94)90032-9
   ARCHER J, 1973, ANIM BEHAV, V21, P205, DOI 10.1016/S0003-3472(73)80065-X
   Barbosa DBM, 2012, REV BRAS FARMACOGN, V22, P137, DOI 10.1590/S0102-695X2011005000154
   BERKENKOPF JW, 1988, PROSTAGLANDINS, V36, P693, DOI 10.1016/0090-6980(88)90014-7
   Bhatia M, 2005, PANCREATOLOGY, V5, P132, DOI 10.1159/000085265
   Borges MH, 2005, J ETHNOPHARMACOL, V98, P21, DOI 10.1016/j.jep.2004.12.014
   Brennan FM, 2008, J CLIN INVEST, V118, P3537, DOI 10.1172/JCI36389
   Burian M, 2005, PHARMACOL THERAPEUT, V107, P139, DOI 10.1016/j.pharmthera.2005.02.004
   Carlini EA, 1979, REV ASS BRAS PSIQ SA, V1, P25
   Cawthorn WP, 2008, FEBS LETT, V582, P117, DOI 10.1016/j.febslet.2007.11.051
   Chau TT., 1989, PHARM METHODS CONTRO, P195
   CORREA CR, 1993, BRIT J PHARMACOL, V110, P193, DOI 10.1111/j.1476-5381.1993.tb13791.x
   Cotrim CA, 2011, CHEM-BIOL INTERACT, V189, P9, DOI 10.1016/j.cbi.2010.10.016
   Da Silva SL, 2008, TOXICON, V52, P655, DOI 10.1016/j.toxicon.2008.07.011
   de Barros BS, 2011, J NAT MED-TOKYO, V65, P526, DOI 10.1007/s11418-011-0534-x
   De Melo GO, 2005, J ETHNOPHARMACOL, V102, P217, DOI 10.1016/j.jep.2005.06.015
   Desmarchelier C., 2000, Fitoterapia, V71, P556, DOI 10.1016/S0367-326X(00)00166-0
   Duarte FS, 2007, PHARMACOL BIOCHEM BE, V86, P150, DOI 10.1016/j.pbb.2006.12.019
   DUBUISSON D, 1977, PAIN, V4, P161, DOI 10.1016/0304-3959(77)90130-0
   DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322
   FIDECKA S, 1978, POL J PHARMACOL PHAR, V30, P5
   FIDECKA S, 1978, POL J PHARMACOL PHAR, V30, P537
   Fortes-Dias CL, 1999, TOXICON, V37, P1747, DOI 10.1016/S0041-0101(99)00116-6
   Galdino PM, 2012, PROG NEURO-PSYCHOPH, V38, P276, DOI 10.1016/j.pnpbp.2012.04.012
   Galdino PM, 2010, BRAZ J PHARM SCI, V46, P455, DOI 10.1590/S1984-82502010000300008
   Graf Marton, 2006, Neuropsychopharmacol Hung, V8, P23
   GUSTAFSON KR, 1992, J ORG CHEM, V57, P2809, DOI 10.1021/jo00036a010
   GUTIERREZ JM, 1988, TOXICON, V26, P411, DOI 10.1016/0041-0101(88)90010-4
   HABERMANN E, 1972, ANAL BIOCHEM, V50, P163, DOI 10.1016/0003-2697(72)90495-2
   HAMBLETON P, 1989, BRIT J EXP PATHOL, V70, P425
   HENRIQUES MGMO, 1987, BRAZ J MED BIOL RES, V20, P243
   Hopkins S.J., 2003, INT J LEGAL MED, V5, P45
   HUNSKAAR S, 1985, J NEUROSCI METH, V14, P69, DOI 10.1016/0165-0270(85)90116-5
   HUNSKAAR S, 1987, PAIN, V30, P103, DOI 10.1016/0304-3959(87)90088-1
   Ikeda Y, 2001, LIFE SCI, V69, P2911, DOI 10.1016/S0024-3205(01)01374-1
   Irwin S, 1964, ANIMAL CLIN PHARM TE, P55
   Kalkan A, 1999, MEM I OSWALDO CRUZ, V94, P383, DOI 10.1590/S0074-02761999000300018
   KOSTER R, 1959, FED PROC, V18, P412
   Le Bars D, 2001, PHARMACOL REV, V53, P597
   Lewanowitsch T, 2003, BRAIN RES, V964, P302, DOI 10.1016/S0006-8993(02)04117-3
   LINDQUIST MP, 1977, PSYCHOPHARMACOLOGY, V55, P129, DOI 10.1007/BF01457847
   Luchese C, 2012, INFLAMM RES, V61, P1117, DOI 10.1007/s00011-012-0504-0
   Luo GL, 2004, BIOORG MED CHEM LETT, V14, P5975, DOI 10.1016/j.bmcl.2004.10.005
   Malone MH, 1977, NEW NATURAL PRODUCTS, P24, DOI DOI 10.1007/978-3-642-66682-7
   Nascimento MVM, 2011, J NAT MED-TOKYO, V65, P448, DOI 10.1007/s11418-011-0517-y
   Mattei R, 2006, PSICOFARMACOLOGIA FU, P138
   Moghe VV, 2008, BOMBAY HOSP J, V50, P446
   Moore AR, 2010, METHODS MOL BIOL, V644, P201, DOI 10.1007/978-1-59745-364-6_17
   Munro G, 2007, EUR J PHARMACOL, V575, P66, DOI 10.1016/j.ejphar.2007.07.062
   Murakami M, 2005, J BIOL CHEM, V280, P24987, DOI 10.1074/jbc.M502088200
   Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021/np030096l
   Nicoletti F, 2010, AUTOIMMUN DIS, V2010, DOI 10.4061/2010/757432
   Nunez V, 2005, PHYTOCHEMISTRY, V66, P1017, DOI 10.1016/j.phytochem.2005.03.026
   Peura DA, 2005, ARTHRITIS RES THER, V7, pS7, DOI 10.1186/ar1793
   Ponce-Soto LA, 2002, J PROTEIN CHEM, V21, P131, DOI 10.1023/A:1015332314389
   Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229
   Ribeiro RA, 2000, EUR J PHARMACOL, V387, P111, DOI 10.1016/S0014-2999(99)00790-6
   ROSLAND JH, 1990, PAIN, V42, P235, DOI 10.1016/0304-3959(90)91167-H
   Saleh TSF, 1999, PEPTIDES, V20, P949
   Saleh TSF, 1997, EUR J PHARMACOL, V331, P43, DOI 10.1016/S0014-2999(97)01005-4
   Sato H, 2009, BIOCHEM J, V421, P17, DOI 10.1042/BJ20082429
   Sato H, 2008, J BIOL CHEM, V283, P33483, DOI 10.1074/jbc.M804628200
   SHIBATA M, 1989, PAIN, V38, P347, DOI 10.1016/0304-3959(89)90222-4
   Sokal R.R., 1981, BIOMETRY PRINCIPLES
   STEELE RH, 1966, BRIT J EXP PATHOL, V47, P612
   Steinke JW, 2001, RESP RES, V2, P66, DOI 10.1186/rr40
   Vianna RMJ, 1998, BRIT J PHARMACOL, V123, P281, DOI 10.1038/sj.bjp.0701590
   VINEGAR R, 1973, P SOC EXP BIOL MED, V143, P711
   Wermuth G, 1998, PURE APPL CHEM, V70, P1129
   WHITTLE BA, 1964, INT J NEUROPHARMACOL, V3, P369
   Willoughby DA, 2000, INT J IMMUNOPHARMACO, V22, P1131, DOI 10.1016/S0192-0561(00)00064-3
   Woolfe G, 1944, J PHARMACOL EXP THER, V80, P300
   YAKSH TL, 1977, J PHARMACOL EXP THER, V202, P411
   Yu L, 1998, ANAL BIOCHEM, V265, P35, DOI 10.1006/abio.1998.2887
   ZAMORAMARTINEZ MC, 1992, J ETHNOPHARMACOL, V35, P229, DOI 10.1016/0378-8741(92)90021-I
NR 76
TC 19
Z9 19
U1 0
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD FEB 27
PY 2013
VL 92
IS 3
BP 237
EP 244
DI 10.1016/j.lfs.2012.12.003
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 091RL
UT WOS:000315067400009
PM 23295958
DA 2020-12-01
ER

PT J
AU Ferreira, EI
   Barreiro, EL
   Andrade, CH
AF Ferreira, Elizabeth Igne
   Barreiro, Eliezer L.
   Andrade, Carolina Horta
TI XII National Meeting of Pharmaceutical Chemistry Professors: could we
   have now a subarea of Pharmaceutical and Medicinal Chemistry in the CNPq
   Pharmacy Comittee?
SO BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Editorial Material
RI Barreiro, Eliezer J/B-1131-2011; Andrade, Carolina/C-3960-2014;
   Ferreira, Elizabeth I/C-4038-2012
OI Andrade, Carolina/0000-0003-0101-1492; Ferreira, Elizabeth
   I/0000-0003-2087-033X
NR 0
TC 0
Z9 0
U1 0
U2 2
PU UNIV SAO PAULO, CONJUNTO QUIMICAS
PI SAO PAULO
PA SERVICO PUBLICACOES E CIRCULACAO, CAIXA POSTAL 66083, SAO PAULO, 00000,
   BRAZIL
SN 1984-8250
J9 BRAZ J PHARM SCI
JI Braz. J. Pharm. Sci.
PD JAN-MAR
PY 2013
VL 49
IS 1
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 220LU
UT WOS:000324586200001
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Sousa, MC
   Braga, RC
   Cintra, BAS
   de Oliveira, V
   Andrade, CH
AF Sousa, Mariana C.
   Braga, Rodolpho C.
   Cintra, Bertilha A. S.
   de Oliveira, Valeria
   Andrade, Carolina H.
TI In silico metabolism studies of dietary flavonoids by CYP1A2 and CYP2C9
SO FOOD RESEARCH INTERNATIONAL
LA English
DT Article
DE Dietary flavonoids; Metabolism; Cytochrome P450; Docking
ID CYTOCHROME P4502C9; FORCE-FIELD; COMPUTATIONAL PREDICTION;
   DRUG-METABOLISM; DOCKING; 1A2; BIOTRANSFORMATION; PHARMACOPHORE;
   INHIBITORS; ISOENZYMES
AB Dietary flavonoids are important contributors to cancer prevention, due to their interactions with CYP family enzymes. This study describes the application of in silico tools to study the metabolism of dietary flavonoid compounds such as quercetin, rutin, naringenin and naringin, aiming to propose their potential metabolites and chemical structures and also to investigate the abilities of these compounds to interact with cytochrome P450 CYP1A2 and CYP2C9 isoforms. The reactions founded suggest that the presence of the sugar chain may account for significant change in the position of the flavonoid in the active site, due to the steric contacts. Another important finding is the participation of the amino acid residues in the metabolism. In CYP2C9, the Asn474, Ser209, Thr304 and Arg108 residues participated almost in all of the metabolically active conformations, suggesting that these residues are important for the regioselectivity and positioning of the substrate. The same was observed for the Asp313, Phe226, Phe256 and Phe260 residues of the CYP1A2 isoform. The results presented here afford new opportunities for improving the application of dietary flavonoids for the prevention of chronic disorders, as they're capable to be readily metabolized by CYP450 family. (c) 2012 Elsevier Ltd. All rights reserved.
C1 [Sousa, Mariana C.; Braga, Rodolpho C.; Cintra, Bertilha A. S.; de Oliveira, Valeria; Andrade, Carolina H.] Univ Fed Goias, Fac Farm, BR-74605220 Goiania, Go, Brazil.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, Praca Univ Com 1A Ave, BR-74605220 Goiania, Go, Brazil.
EM carolina@farmacia.ufg.br
RI Andrade, Carolina/C-3960-2014; Braga, Rodolpho C/A-9655-2011; Oliveira,
   Valeria/B-8056-2016
OI Andrade, Carolina/0000-0003-0101-1492; Braga, Rodolpho
   C/0000-0003-3814-3464; Oliveira, Valeria/0000-0001-9800-4883
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Fundacao de Amparo a Pesquisa do Estado de Goias (FAPEG)
FX The authors would like to thank Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES) and Fundacao de Amparo a Pesquisa do
   Estado de Goias (FAPEG) for financial support.
CR Adams S. E., 2010, THESIS U CAMBRIDGE C
   Andres A, 2009, J NUTR BIOCHEM, V20, P563, DOI 10.1016/j.jnutbio.2009.04.004
   Androutsopoulos VP, 2011, BIOORGAN MED CHEM, V19, P2842, DOI 10.1016/j.bmc.2011.03.042
   Androutsopoulos VP, 2010, PHARMACOL THERAPEUT, V126, P9, DOI 10.1016/j.pharmthera.2010.01.009
   Androutsopoulos VP, 2009, ONCOL REP, V21, P1525, DOI 10.3892/or_00000384
   Arroo RRJ, 2009, PHYTOCHEM REV, V8, P375, DOI 10.1007/s11101-009-9128-6
   Bowers K.J., 2006, P 2006 ACM IEEE C SU, P84, DOI DOI 10.1109/SC.2006.54
   Boyer S, 2007, J CHEM INF MODEL, V47, P583, DOI 10.1021/ci600376q
   Braga RC, 2012, J MOL MODEL, V18, P2065, DOI 10.1007/s00894-011-1219-9
   Breinholt VM, 2003, PHARMACOL TOXICOL, V93, P14, DOI 10.1034/j.1600-0773.2003.930102.x
   Breinholt VM, 2002, FOOD CHEM TOXICOL, V40, P609, DOI 10.1016/S0278-6915(01)00125-9
   Carlsson L, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-362
   Czodrowski P, 2009, EXPERT OPIN DRUG MET, V5, P15, DOI [10.1517/17425250802568009, 10.1517/17425250802568009 ]
   da Silva EL, 1998, FEBS LETT, V430, P405, DOI 10.1016/S0014-5793(98)00709-1
   Dai RK, 1998, J PROTEIN CHEM, V17, P643, DOI 10.1007/BF02780965
   de Groot MJ, 2002, ADV DRUG DELIVER REV, V54, P367, DOI 10.1016/S0169-409X(02)00009-1
   de Montellano P. R. O., 2010, CYTOCHROME P450 STRU, P664
   Doostdar H, 2000, TOXICOLOGY, V144, P31, DOI 10.1016/S0300-483X(99)00215-2
   Ekins S, 2001, DRUG METAB DISPOS, V29, P936
   Hadjokas NE, 2002, BRIT J PHARMACOL, V136, P347, DOI 10.1038/sj.bjp.0704711
   Heim KE, 2002, J NUTR BIOCHEM, V13, P572, DOI 10.1016/S0955-2863(02)00208-5
   Hodek P, 2002, CHEM-BIOL INTERACT, V139, P1, DOI 10.1016/S0009-2797(01)00285-X
   Hosny M, 2001, J NAT PROD, V64, P462, DOI 10.1021/np000457m
   Huey R, 2007, J COMPUT CHEM, V28, P1145, DOI 10.1002/jcc.20634
   Iori F, 2005, BIOORGAN MED CHEM, V13, P4366, DOI 10.1016/j.bmc.2005.04.066
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760
   Kagawa H, 2004, XENOBIOTICA, V34, P797, DOI 10.1080/00498250400005708
   Kirchmair J, 2012, J CHEM INF MODEL, V52, P617, DOI 10.1021/ci200542m
   Kroemer RT, 2007, CURR PROTEIN PEPT SC, V8, P312
   Lampila P, 2009, FOOD RES INT, V42, P122, DOI 10.1016/j.foodres.2008.09.002
   Lewis DFV, 2004, XENOBIOTICA, V34, P501, DOI 10.1080/00498250410001691316
   Liu JG, 2004, ARCH BIOCHEM BIOPHYS, V424, P33, DOI 10.1016/j.abb.2003.12.040
   Miners JO, 1998, BRIT J CLIN PHARMACO, V45, P525, DOI 10.1046/j.1365-2125.1998.00721.x
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Nebert DW, 2000, PHARMACOLOGY, V61, P124, DOI 10.1159/000028393
   Nielsen SE, 1998, XENOBIOTICA, V28, P389, DOI 10.1080/004982598239498
   Oda A, 2005, J COMPUT CHEM, V26, P818, DOI 10.1002/jcc.20221
   Rathee Permender, 2009, Inflammation & Allergy Drug Targets, V8, P229
   Rice-Evans C, 2001, CURR MED CHEM, V8, P797, DOI 10.2174/0929867013373011
   Rydberg P, 2009, CHEMMEDCHEM, V4, P2070, DOI 10.1002/cmdc.200900363
   Sansen S, 2007, J BIOL CHEM, V282, P14348, DOI 10.1074/jbc.M611692200
   Scalbert A, 2000, J NUTR, V130, p2073S, DOI 10.1093/jn/130.8.2073S
   Smith DA, 1996, MED RES REV, V16, P243
   Smith DA, 1997, DRUG DISCOV TODAY, V2, P406, DOI 10.1016/S1359-6446(97)01081-7
   Smith DA, 1997, DRUG DISCOV TODAY, V2, P479, DOI 10.1016/S1359-6446(97)01085-4
   Stjernschantz E, 2008, EXPERT OPIN DRUG MET, V4, P513, DOI [10.1517/17425255.4.5.513, 10.1517/17425255.4.5.513 ]
   Sun H, 2010, CHEM BIOL DRUG DES, V75, P3, DOI 10.1111/j.1747-0285.2009.00899.x
   Sykes MJ, 2008, J MED CHEM, V51, P780, DOI 10.1021/jm7009793
   Tarcsay A, 2011, EXPERT OPIN DRUG MET, V7, P299, DOI 10.1517/17425255.2011.553599
   Vauzour D, 2008, GENES NUTR, V3, P115, DOI 10.1007/s12263-008-0091-4
   Wang RX, 2002, J COMPUT AID MOL DES, V16, P11, DOI 10.1023/A:1016357811882
   Wester MR, 2004, J BIOL CHEM, V279, P35630, DOI 10.1074/jbc.M405427200
NR 52
TC 13
Z9 14
U1 0
U2 36
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0963-9969
EI 1873-7145
J9 FOOD RES INT
JI Food Res. Int.
PD JAN
PY 2013
VL 50
IS 1
BP 102
EP 110
DI 10.1016/j.foodres.2012.09.027
PG 9
WC Food Science & Technology
SC Food Science & Technology
GA 099IE
UT WOS:000315613900013
DA 2020-12-01
ER

PT J
AU Bueno, RV
   Toledo, NR
   Neves, BJ
   Braga, RC
   Andrade, CH
AF Bueno, Renata V.
   Toledo, Ney R.
   Neves, Bruno J.
   Braga, Rodolpho C.
   Andrade, Carolina H.
TI Structural and chemical basis for enhanced affinity to a series of
   mycobacterial thymidine monophosphate kinase inhibitors: fragment-based
   QSAR and QM/MM docking studies
SO JOURNAL OF MOLECULAR MODELING
LA English
DT Article
DE Fragment-based; HQSAR; QM/MM docking; Thymidine monophosphate kinase;
   Tuberculosis
ID TUBERCULOSIS THYMIDYLATE KINASE; DRUG DESIGN; RATIONAL DESIGN; ANALOGS;
   PERSPECTIVES; NUCLEOSIDES; GENERATION; COMPLEXES; DISCOVERY; LIGANDS
AB Tuberculosis (TB) still remains one of the most deadly infectious diseases. Mycobacterium tuberculosis thymidine monophosphate kinase (TMPKmt) has emerged as an attractive molecular target for the design of a novel class of anti-TB agents since blocking it will affect the pathways involved in DNA replication. Aiming at shedding some light on structural and chemical features that are important for the affinity of thymidine derivatives to TMPKmt, we have employed a special fragment-based method to develop robust quantitative structure-activity relationship models for a large and chemically diverse series of thymidine-based analogues. Significant statistical parameters (r (2) = 0.94, q (2) = 0.76, r (2) (pred) = 0.89) were obtained, indicating the reliability of the hologram QSAR model in predicting the biological activity of untested compounds. The 2D model was then used to predict the potency of an external test set, and the predicted values obtained from the HQSAR model were in good agreement with the experimental results. We have accordingly designed novel TMPKmt inhibitors by utilizing the fragments proposed by HQSAR analysis and predicted with good activity in the developed models. The new designed compounds also presented drug-like characteristics based on Lipinski's rule of 5. The generated molecular recognition patterns gathered from the HQSAR analysis combined with quantum mechanics/molecular mechanics (QM/MM) docking studies, provided important insights into the chemical and structural basis involved in the molecular recognition process of this series of thymidine analogues and should be useful for the design of new potent anti-TB agents.
C1 [Bueno, Renata V.; Toledo, Ney R.; Neves, Bruno J.; Braga, Rodolpho C.; Andrade, Carolina H.] Univ Fed Goias, Fac Farm, Lab Planejamento Farmacos & Estudos Metab Modelag, BR-74605220 Goiania, Go, Brazil.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, Lab Planejamento Farmacos & Estudos Metab Modelag, BR-74605220 Goiania, Go, Brazil.
EM carolina@farmacia.ufg.br
RI Andrade, Carolina/C-3960-2014; Braga, Rodolpho C/A-9655-2011; Neves,
   Bruno Junior/E-6295-2016; Bueno, Renata/B-6865-2013; Neves,
   Bruno/R-7068-2019
OI Andrade, Carolina/0000-0003-0101-1492; Braga, Rodolpho
   C/0000-0003-3814-3464; Bueno, Renata/0000-0002-9802-331X; Neves,
   Bruno/0000-0002-1309-8743
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Fundacao de Amparo a Pesquisa do Estado de Goias (FAPEG)
FX The authors would like to thank Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES) and Fundacao de Amparo a Pesquisa do
   Estado de Goias (FAPEG) for financial support.
CR Andrade CH, 2010, MOLECULES, V15, P3281, DOI 10.3390/molecules15053281
   Andrade CH, 2009, J CHEM INF MODEL, V49, P1070, DOI 10.1021/ci8004622
   Andrade CH, 2008, LETT DRUG DES DISCOV, V5, P377, DOI 10.2174/157018008785777289
   Andrade CH, 2008, REV BRAS CIENC FARM, V44, P167, DOI 10.1590/S1516-93322008000200002
   Andrade CH, 2010, J COMPUT AID MOL DES, V24, P157, DOI 10.1007/s10822-010-9323-y
   Aparna V, 2006, BIOORG MED CHEM LETT, V16, P1014, DOI 10.1016/j.bmcl.2005.10.086
   Banks JL, 2005, J COMPUT CHEM, V26, P1752, DOI 10.1002/jcc.20292
   BLONDIN C, 1994, ANAL BIOCHEM, V220, P219, DOI 10.1006/abio.1994.1326
   Burki T, 2010, LANCET INFECT DIS, V10, P297, DOI 10.1016/S1473-3099(10)70083-9
   Cho AE, 2005, J COMPUT CHEM, V26, P915, DOI 10.1002/jcc.20222
   de la Sierra IL, 2001, J MOL BIOL, V311, P87, DOI 10.1006/jmbi.2001.4843
   Dorman SE, 2007, NAT MED, V13, P295, DOI 10.1038/nm0307-295
   Eldridge MD, 1997, J COMPUT AID MOL DES, V11, P425, DOI 10.1023/A:1007996124545
   Familiar O, 2008, CHEMMEDCHEM, V3, P1083, DOI 10.1002/cmdc.200800060
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Munier-Lehmann H, 2001, PROTEIN SCI, V10, P1195, DOI 10.1110/ps.45701
   Ostermann N, 2000, STRUCTURE, V8, P629, DOI 10.1016/S0969-2126(00)00149-0
   Salum LB, 2009, J BRAZIL CHEM SOC, V20, P693, DOI 10.1590/S0103-50532009000400013
   Salum LB, 2009, MOL DIVERS, V13, P277, DOI 10.1007/s11030-009-9112-5
   Salum LB, 2010, J COMPUT AID MOL DES, V24, P803, DOI 10.1007/s10822-010-9375-z
   Shelley JC, 2007, J COMPUT AID MOL DES, V21, P681, DOI 10.1007/s10822-007-9133-z
   Van Calenbergh S, 2012, CURR TOP MED CHEM, V12, P694, DOI 10.2174/156802612799984580
   Van Calenbergh S, 2006, Verh K Acad Geneeskd Belg, V68, P223
   Van Daele I, 2007, J MED CHEM, V50, P5281, DOI 10.1021/jm0706158
   Van Daele I, 2006, CHEMMEDCHEM, V1, P1081, DOI 10.1002/cmdc.200600028
   Vanheusden V, 2004, J MED CHEM, V47, P6187, DOI 10.1021/jm040847w
   Vanheusden V, 2003, BIOORG MED CHEM LETT, V13, P3045, DOI 10.1016/S0960-894X(03)00643-7
   Vanheusden V, 2003, J MED CHEM, V46, P3811, DOI 10.1021/jm021108n
   WHO, 2010, WHOHTMTB20107
   Young D., 2009, COMPUTATIONAL DRUG D
NR 32
TC 17
Z9 17
U1 0
U2 31
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1610-2940
J9 J MOL MODEL
JI J. Mol. Model.
PD JAN
PY 2013
VL 19
IS 1
BP 179
EP 192
DI 10.1007/s00894-012-1527-8
PG 14
WC Biochemistry & Molecular Biology; Biophysics; Chemistry,
   Multidisciplinary; Computer Science, Interdisciplinary Applications
SC Biochemistry & Molecular Biology; Biophysics; Chemistry; Computer
   Science
GA 064LS
UT WOS:000313077100016
PM 22846924
DA 2020-12-01
ER

PT J
AU Lino, RC
   Martins, FI
   Florentino, IF
   Nascimento, MVM
   Galdino, PM
   Andrade, CH
   Rezende, KR
   Menegatti, R
   Costa, EA
AF Lino, Roberta Campos
   Martins, Fabiula Ines
   Florentino, Iziara Ferreira
   Mariano Nascimento, Marcus Vinicius
   Galdino, Pablinny Moreira
   Andrade, Carolina H.
   Rezende, Kennia Rocha
   Menegatti, Ricardo
   Costa, Elson Alves
TI Anti-inflammatory effect of
   (E)-4-(3,7-dimethylocta-2,6-dienylamino)phenol, a new derivative of
   4-nerolidylcatechol
SO JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Article
DE anti-inflammatory; COX inhibition; docking; PLA2 inhibition
ID FORMALIN TEST; PHOSPHOLIPASE A(2); NATURAL-PRODUCTS; SNAKE-VENOMS; MOUSE
   MODEL; CARRAGEENAN; DRUGS; INFLAMMATION; RECEPTORS; PLEURISY
AB Objectives We have investigated the anti-inflammatory and antinociceptive effects of (E)-4-(3,7-dimethylocta-2,6-dienylamino)phenol (LQFM-015), which was designed through molecular simplification strategy from 4-nerolidylcatechol. Methods The possible anti-inflammatory and antinociceptive effects were assayed on carrageenan-induced paw oedema and pleurisy, acetic acid-induced abdominal writhing and formalin tests in mice. Key findings LQFM-015 reduced the activity of PLA2 enzyme in vitro by 18%. Docking studies into the catalytic site of PLA2 were used to identify the binding mode of the LQFM-015. LQFM-015 showed a moderate antinociceptive effect, since this compound reduced the number of writhings by approximately up to 40% in the acetic acid-induced pain model; this antinociceptive activity also emerged in the second phase of the formalin-induced pain model (58% of inhibition). The anti-inflammatory action of LQFM-015 was confirmed in acute inflammation models, in which it reduced the formation of oedema to 52.78 +/- 8.6 and 46.64 +/- 5.2 at the second and third hour of carrageenan-induced paw oedema, respectively. Also in the carrageenan-induced pleurisy model, LQFM-015 reduced the migration of leucocytes by 26.0% and decrease myeloperoxidase activity by 50%. LQFM-015 showed different concentrations to inhibit 50% of isoenzyme cyclooxygenase activity (IC50); COX-1 IC50?=?36 mu m) and COX-2 IC50?=?28 mu m. Conclusions LQFM-015 demonstrated inhibition of both PLA2 and COX enzymes; thus, the moderate antinociceptive effect of this compound could be attributed to its anti-inflammatory activity.
C1 [Lino, Roberta Campos; Galdino, Pablinny Moreira; Costa, Elson Alves] Univ Fed Goias, Dept Physiol Sci, Inst Biol Sci, BR-74001970 Goiania, Go, Brazil.
   [Martins, Fabiula Ines; Florentino, Iziara Ferreira; Mariano Nascimento, Marcus Vinicius; Menegatti, Ricardo] Univ Fed Goias, Fac Pharm, Lab Med Pharmaceut Chem, BR-74001970 Goiania, Go, Brazil.
   [Andrade, Carolina H.] Univ Fed Goias, Fac Pharm, Lab Mol Modeling, BR-74001970 Goiania, Go, Brazil.
   [Rezende, Kennia Rocha] Univ Fed Goias, Fac Pharm, Lab Biopharm & Pharmacokinet, BR-74001970 Goiania, Go, Brazil.
RP Costa, EA (corresponding author), Univ Fed Goias, Dept Physiol Sci, Inst Biol Sci, Campus Samambaia,Caixa Postal 131, BR-74001970 Goiania, Go, Brazil.
EM xico@icb.ufg.br
RI Galdino, Pablinny/D-9695-2014; REZENDE, KENNIA ROCHA/E-4090-2019;
   Rezende, Kennia R/D-2622-2011; Andrade, Carolina/C-3960-2014; Menegatti,
   Ricardo/U-4702-2019
OI Galdino, Pablinny/0000-0003-2836-5565; REZENDE, KENNIA
   ROCHA/0000-0002-3813-8545; Rezende, Kennia R/0000-0002-3813-8545;
   Andrade, Carolina/0000-0003-0101-1492; Menegatti,
   Ricardo/0000-0001-5044-9234; NASCIMENTO, MARCUS/0000-0003-3360-4698
FU FAPEG; CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES
FX This work was supported by FAPEG, CNPq and CAPES.
CR AKENDENGUE B, 1994, J ETHNOPHARMACOL, V41, P193, DOI 10.1016/0378-8741(94)90032-9
   Barbosa DBM, 2012, REV BRAS FARMACOGN, V22, P137, DOI 10.1590/S0102-695X2011005000154
   Burian M, 2005, PHARMACOL THERAPEUT, V107, P139, DOI 10.1016/j.pharmthera.2005.02.004
   CAMPOS MM, 1995, BRIT J PHARMACOL, V114, P1005, DOI 10.1111/j.1476-5381.1995.tb13305.x
   Chandra V, 2002, J MOL BIOL, V320, P215, DOI 10.1016/S0022-2836(02)00473-4
   COLLIER HOJ, 1968, BRIT J PHARMACOL, V32, P295, DOI 10.1111/j.1476-5381.1968.tb00973.x
   CORREA CR, 1993, BRIT J PHARMACOL, V110, P193, DOI 10.1111/j.1476-5381.1993.tb13791.x
   da Cunha FM, 2001, LIFE SCI, V70, P159, DOI 10.1016/S0024-3205(01)01387-X
   de Queiroz AC, 2010, J ETHNOPHARMACOL, V128, P377, DOI 10.1016/j.jep.2010.01.041
   Dennis E.A., 1983, ENZYMES, P307
   Desmarchelier C., 2000, Fitoterapia, V71, P556, DOI 10.1016/S0367-326X(00)00166-0
   Desmarchelier C, 1997, PLANTA MED, V63, P561, DOI 10.1055/s-2006-957767
   Eddouks M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/142087
   Evangelista JSAM, 2008, TOXICON, V52, P737, DOI 10.1016/j.toxicon.2008.08.014
   Farsam H, 2000, J ETHNOPHARMACOL, V71, P443, DOI 10.1016/S0378-8741(00)00174-4
   Fortes-Dias CL, 1999, TOXICON, V37, P1747, DOI 10.1016/S0041-0101(99)00116-6
   Frode TS, 2001, CYTOKINE, V13, P162, DOI 10.1006/cyto.2000.0816
   Frode US, 2002, CYTOKINE, V17, P149, DOI 10.1006/cyto.2001.0980
   GUSTAFSON KR, 1992, J ORG CHEM, V57, P2809, DOI 10.1021/jo00036a010
   GUTIERREZ JM, 1988, TOXICON, V26, P411, DOI 10.1016/0041-0101(88)90010-4
   HABERMANN E, 1972, ANAL BIOCHEM, V50, P163, DOI 10.1016/0003-2697(72)90495-2
   Halperin I, 2002, PROTEINS, V47, P409, DOI 10.1002/prot.10115
   HUNSKAAR S, 1985, J NEUROSCI METH, V14, P69, DOI 10.1016/0165-0270(85)90116-5
   HUNSKAAR S, 1987, PAIN, V30, P103, DOI 10.1016/0304-3959(87)90088-1
   KOSTER R, 1959, FED PROC, V18, P412
   Liew FY, 2002, MOL IMMUNOL, V38, P887, DOI 10.1016/S0161-5890(02)00014-7
   Luo GL, 2004, BIOORG MED CHEM LETT, V14, P5975, DOI 10.1016/j.bmcl.2004.10.005
   Malone MH, 1977, NEW NATURAL PRODUCTS, P24, DOI DOI 10.1007/978-3-642-66682-7
   Moghe VV, 2008, BOMBAY HOSP J, V50, P472
   Murakami M, 2011, J BIOCHEM, V150, P233, DOI 10.1093/jb/mvr088
   Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021/np030096l
   Nunez V, 2005, PHYTOCHEMISTRY, V66, P1017, DOI 10.1016/j.phytochem.2005.03.026
   Paszcuk AF, 2008, EUR J PHARMACOL, V581, P204, DOI 10.1016/j.ejphar.2007.11.025
   Pereira R, 2006, TRANSPL IMMUNOL, V16, P105, DOI 10.1016/j.trim.2006.04.001
   Silva LFRE, 2011, PHYTOTHER RES, V25, P1181, DOI 10.1002/ptr.3424
   Saleh TSF, 1999, PEPTIDES, V20, P949
   Sedgwick AD, 1995, HDB INFLAMMATION, P253
   SHIBATA M, 1989, PAIN, V38, P347, DOI 10.1016/0304-3959(89)90222-4
   Smith T, 2000, J BIOL CHEM, V275, P40407, DOI 10.1074/jbc.M005563200
   Soares AM, 2003, TOXICON, V42, P855, DOI 10.1016/j.toxicon.2003.11.004
   Sokal R.R., 1981, BIOMETRY, P859
   TJOLSEN A, 1992, PAIN, V51, P5, DOI 10.1016/0304-3959(92)90003-T
   Tjolsen A, 1997, HANDB EXP PHARM, V130, P1
   Vane JR, 1998, INFLAMM RES, V47, pS78
   Verma PR, 2005, J ETHNOPHARMACOL, V102, P298, DOI 10.1016/j.jep.2005.05.039
   VILLAR A, 1987, J PHARM PHARMACOL, V39, P502, DOI 10.1111/j.2042-7158.1987.tb03166.x
   VINEGAR R, 1973, P SOC EXP BIOL MED, V143, P711
   VINEGAR R, 1987, FASEB J, V46, P118
   Wermuth G, 1998, PURE APPL CHEM, V70, P1129
   WINTER CA, 1962, P SOC EXP BIOL MED, V111, P544
   ZAMORAMARTINEZ MC, 1992, J ETHNOPHARMACOL, V35, P229, DOI 10.1016/0378-8741(92)90021-I
NR 51
TC 9
Z9 9
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3573
EI 2042-7158
J9 J PHARM PHARMACOL
JI J. Pharm. Pharmacol.
PD JAN
PY 2013
VL 65
IS 1
BP 133
EP 141
DI 10.1111/j.2042-7158.2012.01582.x
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 051PY
UT WOS:000312140700016
PM 23215696
DA 2020-12-01
ER

PT J
AU Braga, RC
   Liao, LM
   Bezerra, JCB
   Vinaud, MCB
   Andrade, CH
AF Braga, Rodolpho C.
   Liao, Luciano M.
   Bezerra, Jose C. B.
   Vinaud, Marina C. B.
   Andrade, Carolina H.
TI Integrated Chemoinformatics approaches to virtual screening in the
   search of new lead compounds against Leishmania
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 244th National Fall Meeting of the American-Chemical-Society (ACS)
CY AUG 19-23, 2012
CL Philadelphia, PA
SP Amer Chem Soc, Div Hist Chem, Amer Chem Soc
C1 [Braga, Rodolpho C.; Andrade, Carolina H.] Univ Fed Goias, Fac Farm, BR-74605220 Goiania, Go, Brazil.
   [Braga, Rodolpho C.; Liao, Luciano M.] Univ Fed Goias, Inst Quim, BR-74001970 Goiania, Go, Brazil.
   [Bezerra, Jose C. B.; Vinaud, Marina C. B.] Univ Fed Goias, IPTSP, BR-74605050 Goiania, Go, Brazil.
EM rcbraga@gmail.com; carolina@farmacia.ufg.br
RI Braga, Rodolpho C/A-9655-2011; Andrade, Carolina/C-3960-2014; Liao,
   Luciano Morais M./F-1487-2015; Liao, Luciano Morais/M-3030-2019; Vinaud,
   Marina Clare/X-3380-2019
OI Braga, Rodolpho C/0000-0003-3814-3464; Andrade,
   Carolina/0000-0003-0101-1492; Liao, Luciano Morais
   M./0000-0001-9985-2980; Liao, Luciano Morais/0000-0001-9985-2980; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 19
PY 2012
VL 244
MA 46-CINF
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 220XX
UT WOS:000324621802126
DA 2020-12-01
ER

PT J
AU Braga, RC
   Andrade, CH
AF Braga, R. C.
   Andrade, C. H.
TI QSAR and QM/MM Approaches Applied to Drug Metabolism Prediction
SO MINI-REVIEWS IN MEDICINAL CHEMISTRY
LA English
DT Review
DE QSAR; QM/MM; drug metabolism prediction; cytochrome P450; docking
ID MOLECULAR-DYNAMICS SIMULATIONS; MM3 FORCE-FIELD;
   UDP-GLUCURONOSYLTRANSFERASE 2B7; CYTOCHROMES P450; BIOMOLECULAR
   SIMULATION; DIHYDROFOLATE-REDUCTASE; CATALYZED-REACTIONS;
   NEURAL-NETWORKS; COMPOUND-I; BINDING
AB In modern drug discovery process, ADME/Tox properties should be determined as early as possible in the test cascade to allow a timely assessment of their property profiles. To help medicinal chemists in designing new compounds with improved pharmacokinetics, the knowledge of the soft spot position or the site of metabolism (SOM) is needed. In recent years, large number of in silico approaches for metabolism prediction have been developed and reported. Among these methods, QSAR models and combined quantum mechanics/molecular mechanics (QM/MM) methods for predicting drug metabolism have undergone significant advances. This review provides a perspective of the utility of QSAR and QM/MM approaches on drug metabolism prediction, highlighting the present challenges, limitations, and future perspectives in medicinal chemistry.
C1 [Braga, R. C.; Andrade, C. H.] Univ Fed Goias, Fac Pharm, Lab Mol Modeling & Design LabMol, BR-74605220 Goiania, Go, Brazil.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Pharm, LabMol, Ave Univ Com 1A Ave S-N,POB 131, BR-74605220 Goiania, Go, Brazil.
EM carolina@farmacia.ufg.br
RI Braga, Rodolpho C/A-9655-2011; Andrade, Carolina/C-3960-2014
OI Braga, Rodolpho C/0000-0003-3814-3464; Andrade,
   Carolina/0000-0003-0101-1492
FU CAPESCAPES; CNPqNational Council for Scientific and Technological
   Development (CNPq); FAPEG
FX The authors thank Brazilian Funding Agencies CAPES, CNPq and FAPEG for
   financial support and fellowships.
CR ALLINGER NL, 1989, J AM CHEM SOC, V111, P8551, DOI 10.1021/ja00205a001
   ALLINGER NL, 1988, J COMPUT CHEM, V9, P591, DOI 10.1002/jcc.540090602
   Andrade CH, 2010, MOLECULES, V15, P3281, DOI 10.3390/molecules15053281
   Bathelt CM, 2008, J PHYS CHEM A, V112, P13149, DOI 10.1021/jp8016908
   Bathelt CM, 2005, J AM CHEM SOC, V127, P12900, DOI 10.1021/ja0520924
   Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287
   Bugrim A, 2004, DRUG DISCOV TODAY, V9, P127, DOI 10.1016/S1359-6446(03)02971-4
   Cohen N. C., 1996, GUIDEBOOK MOL MODELI
   CRAMER RD, 1988, J AM CHEM SOC, V110, P5959, DOI 10.1021/ja00226a005
   Crivori P, 2004, J COMPUT AID MOL DES, V18, P155, DOI 10.1023/B:JCAM.0000035184.11906.c2
   Cruciani C, 2000, J MOL STRUC-THEOCHEM, V503, P17, DOI 10.1016/S0166-1280(99)00360-7
   Cui Q, 2001, J PHYS CHEM B, V105, P569, DOI 10.1021/jp0029109
   Czernik PJ, 2000, DRUG METAB DISPOS, V28, P1210
   Czodrowski P, 2009, EXPERT OPIN DRUG MET, V5, P15, DOI [10.1517/17425250802568009, 10.1517/17425250802568009 ]
   Daggett V, 2003, NAT REV MOL CELL BIO, V4, P497, DOI 10.1038/nrm1126
   de Graaf C, 2005, J MED CHEM, V48, P2308, DOI 10.1021/jm049650u
   de Groot MJ, 2006, DRUG DISCOV TODAY, V11, P601, DOI 10.1016/j.drudis.2006.05.001
   de Groot MJ, 2004, CURR TOP MED CHEM, V4, P1803, DOI 10.2174/1568026043387061
   de Groot MJ, 2002, ADV DRUG DELIVER REV, V54, P367, DOI 10.1016/S0169-409X(02)00009-1
   de Julian-Ortiz JV, 2005, SAR QSAR ENVIRON RES, V16, P263, DOI 10.1080/10659360500036927
   de Montellano P. R. O., 2010, CYTOCHROME P450 STRU, P664
   de Montellano PRO, 2002, NAT PROD REP, V19, P477, DOI 10.1039/b101297p
   DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024
   Dudek AZ, 2006, COMB CHEM HIGH T SCR, V9, P213, DOI 10.2174/138620706776055539
   Dunn III W.J., 1989, TETRAHEDRON COMPUT M, V2, P349, DOI DOI 10.1016/0898-5529(89)90004-3
   Ekins S, 2001, DRUG METAB DISPOS, V29, P936
   Eleftheriou M, 2007, BIOPHYS J, p193A
   Esposito Emilio Xavier, 2004, Methods Mol Biol, V275, P131
   Fernandez M, 2006, J MOL GRAPH MODEL, V25, P410, DOI 10.1016/j.jmgm.2006.02.005
   FIELD MJ, 1990, J COMPUT CHEM, V11, P700, DOI 10.1002/jcc.540110605
   Field MJ, 2002, J COMPUT CHEM, V23, P48, DOI 10.1002/jcc.1156
   FREE SM, 1964, J MED CHEM, V7, P395, DOI 10.1021/jm00334a001
   Freitas RF, 2010, J CHEM INF MODEL, V50, P97, DOI 10.1021/ci900074t
   Gleeson MP, 2007, J COMPUT AID MOL DES, V21, P559, DOI 10.1007/s10822-007-9139-6
   Golbraikh A, 2002, J COMPUT AID MOL DES, V16, P357, DOI 10.1023/A:1020869118689
   Goulon A, 2007, SAR QSAR ENVIRON RES, V18, P141, DOI 10.1080/10629360601054313
   Hansch C, 2004, DRUG METAB REV, V36, P105, DOI 10.1081/DMR-120028428
   HANSCH C, 1964, J AM CHEM SOC, V86, P1616, DOI 10.1021/ja01062a035
   Hansch C, 2004, BIOORGAN MED CHEM, V12, P3391, DOI 10.1016/j.bmc.2003.11.037
   Harvey JN, 2006, J PHYS ORG CHEM, V19, P608, DOI 10.1002/poc.1030
   Harvey JN, 2006, J COMPUT CHEM, V27, P1352, DOI 10.1002/jcc.20446
   Hemmateenejad B, 2005, CHEMOMETR INTELL LAB, V75, P231, DOI 10.1016/j.chemolab.2004.09.005
   HIRST JD, 1994, J COMPUT AID MOL DES, V8, P421, DOI 10.1007/BF00125376
   Hopfinger AJ, 1997, J AM CHEM SOC, V119, P10509, DOI 10.1021/ja9718937
   Hou TJ, 2006, CURR MED CHEM, V13, P2653, DOI 10.2174/092986706778201558
   Hum D.W., 1999, J STEROID BIOCHEM, V69, P413
   Khan MTH, 2010, CURR DRUG METAB, V11, P285
   KING RD, 1992, P NATL ACAD SCI USA, V89, P11322, DOI 10.1073/pnas.89.23.11322
   Kirton SB, 2005, PROTEINS, V58, P836, DOI 10.1002/prot.20389
   Kubinyi H., 1993, METHODS PRINCIPLES M, V1, P240
   Kumar GN, 2001, MED RES REV, V21, P397, DOI 10.1002/med.1016
   Li AP, 2001, DRUG DISCOV TODAY, V6, P357, DOI 10.1016/S1359-6446(01)01712-3
   Li HY, 2008, J COMPUT AID MOL DES, V22, P843, DOI 10.1007/s10822-008-9225-4
   LII JH, 1989, J AM CHEM SOC, V111, P8576, DOI 10.1021/ja00205a003
   LII JH, 1989, J AM CHEM SOC, V111, P8566, DOI 10.1021/ja00205a002
   Lonsdale R, 2010, J PHYS CHEM LETT, V1, P3232, DOI 10.1021/jz101279n
   Lonsdale R, 2010, CHEM COMMUN, V46, P2354, DOI 10.1039/b925647d
   Lyne PD, 1999, J PHYS CHEM A, V103, P3462, DOI 10.1021/jp982115j
   Madden JC, 2006, EXPERT OPIN DRUG MET, V2, P545, DOI 10.1517/17425255.2.4.545
   MARSHALL GR, 1988, TRENDS PHARMACOL SCI, V9, P285, DOI 10.1016/0165-6147(88)90012-0
   McGeagh J.D., 2011, BIOCH BIOPH IN PRESS
   Menikarachchi LC, 2010, CURR TOP MED CHEM, V10, P46, DOI 10.2174/156802610790232297
   Miley MJ, 2007, J MOL BIOL, V369, P498, DOI 10.1016/j.jmb.2007.03.066
   Miners JO, 2004, ANNU REV PHARMACOL, V44, P1, DOI 10.1146/annurev.pharmtox.44.101802.121546
   Mishra Nitish K., 2010, BMC Pharmacology, V10, P8, DOI 10.1186/1471-2210-10-8
   Morra G, 2008, CURR PROTEIN PEPT SC, V9, P181, DOI 10.2174/138920308783955234
   Mulholland AJ, 2005, DRUG DISCOV TODAY, V10, P1393, DOI 10.1016/S1359-6446(05)03611-1
   Obrezanova O, 2010, J CHEM INF MODEL, V50, P1053, DOI 10.1021/ci900406x
   Pan DH, 2003, J CHEM INF COMP SCI, V43, P1591, DOI 10.1021/ci0340714
   Paneth P., 2010, CHALLENGES ADV COMPU, P575
   Park JY, 2003, J MED CHEM, V46, P1645, DOI 10.1021/jm020538a
   Pirmohamed M, 2003, TOXICOLOGY, V192, P23, DOI 10.1016/S0300-483X(03)00247-6
   Prado-Prado FJ, 2008, BIOORGAN MED CHEM, V16, P5871, DOI 10.1016/j.bmc.2008.04.068
   Ranaghan KE, 2010, INT REV PHYS CHEM, V29, P65, DOI 10.1080/01442350903495417
   Ren SJ, 2003, J CHEM INF COMP SCI, V43, P2106, DOI 10.1021/ci034092y
   Ridder L, 2000, J AM CHEM SOC, V122, P8728, DOI 10.1021/ja0007814
   Roca M, 2009, BIOCHEMISTRY-US, V48, P3046, DOI 10.1021/bi802191b
   ROGERS D, 1994, J CHEM INF COMP SCI, V34, P854, DOI 10.1021/ci00020a020
   Roy K, 2009, EUR J MED CHEM, V44, P1941, DOI 10.1016/j.ejmech.2008.11.010
   Roy PP, 2010, MOL SIMULAT, V36, P887, DOI 10.1080/08927022.2010.492834
   Santos OA, 2009, MED CHEM, V5, P359, DOI 10.2174/157340609788681458
   Senn HM, 2009, ANGEW CHEM INT EDIT, V48, P1198, DOI 10.1002/anie.200802019
   Shaik S, 2005, CHEM REV, V105, P2279, DOI 10.1021/cr030722j
   Shaik S, 2010, CHEM REV, V110, P949, DOI 10.1021/cr900121s
   Siegbahn PEM, 2006, ACCOUNTS CHEM RES, V39, P729, DOI 10.1021/ar050123u
   Smith G. M., 1990, TETRAHEDRON COMPUT M, V3, P615
   Smith PA, 2004, J MOL GRAPH MODEL, V22, P507, DOI 10.1016/j.jmgm.2004.03.011
   Smith PA, 2003, J MED CHEM, V46, P1617, DOI 10.1021/jm020397c
   Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500
   STEWART JJP, 1989, J COMPUT CHEM, V10, P209, DOI 10.1002/jcc.540100208
   Sun H, 2010, CHEM BIOL DRUG DES, V75, P3, DOI 10.1111/j.1747-0285.2009.00899.x
   Terfloth L, 2007, J CHEM INF MODEL, V47, P1688, DOI 10.1021/ci700010t
   Todeschini R., 2000, HDB MOL DESCRIPTORS
   Toscano MD, 2007, ANGEW CHEM INT EDIT, V46, P3212, DOI 10.1002/anie.200604205
   van de Waterbeemd H, 2003, NAT REV DRUG DISCOV, V2, P192, DOI 10.1038/nrd1032
   Vedani A, 2000, J MED CHEM, V43, P4416, DOI 10.1021/jm000986n
   Vedani A, 2005, J MED CHEM, V48, P3700, DOI 10.1021/jm050185q
   Vedani A, 2002, J MED CHEM, V45, P2139, DOI 10.1021/jm011005p
   Wang JF, 2010, CURR DRUG METAB, V11, P342, DOI 10.2174/138920010791514180
   Wienkers LC, 2005, NAT REV DRUG DISCOV, V4, P825, DOI 10.1038/nrd1851
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   Woodcock HL, 2003, THEOR CHEM ACC, V109, P140, DOI 10.1007/s00214-002-0421-3
   Woods CJ, 2005, PHILOS T R SOC A, V363, P2017, DOI 10.1098/rsta.2005.1626
   Yang AYC, 2008, J COMPUT AID MOL DES, V22, P799, DOI 10.1007/s10822-008-9215-6
   Yoshizawa K, 2002, COORDIN CHEM REV, V226, P251, DOI 10.1016/S0010-8545(01)00464-7
   Yuan H, 2007, J CHEM INF MODEL, V47, P159, DOI 10.1021/ci600299j
   Zheng WF, 2000, J CHEM INF COMP SCI, V40, P185, DOI 10.1021/ci980033m
NR 107
TC 18
Z9 18
U1 1
U2 42
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-5575
EI 1875-5607
J9 MINI-REV MED CHEM
JI Mini-Rev. Med. Chem.
PD JUN
PY 2012
VL 12
IS 6
BP 573
EP 582
PG 10
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 964XU
UT WOS:000305730800012
PM 22587770
DA 2020-12-01
ER

PT J
AU Braga, RC
   Alves, VM
   Fraga, CAM
   Barreiro, EJ
   de Oliveira, V
   Andrade, CH
AF Braga, Rodolpho C.
   Alves, Vinicius M.
   Fraga, Carlos A. M.
   Barreiro, Eliezer J.
   de Oliveira, Valeria
   Andrade, Carolina H.
TI Combination of docking, molecular dynamics and quantum mechanical
   calculations for metabolism prediction of
   3,4-methylenedioxybenzoyl-2-thienylhydrazone
SO JOURNAL OF MOLECULAR MODELING
LA English
DT Article
DE Cytochrome P450; Docking; Metabolism prediction; Molecular dynamics; QM
   calculations
ID HUMAN CYTOCHROME P4502C9; DRUG-METABOLISM; COMPOUND-I;
   SARCOPLASMIC-RETICULUM; BENZENE HYDROXYLATION; SUBSTRATE-SPECIFICITY;
   QM/MM CALCULATIONS; LIGAND COMPLEXES; FORCE-FIELD; MODELS
AB In modern drug discovery process, ADME/Tox properties should be determined as early as possible in the test cascade to allow a timely assessment of their property profiles. To help medicinal chemists in designing new compounds with improved pharmacokinetics, the knowledge of the soft spot position or the site of metabolism (SOM) is needed. In silico methods based on docking, molecular dynamics and quantum chemical calculations can bring us closer to understand drug metabolism and predict drug-drug interactions. We report herein on a combined methodology to explore the site of metabolism prediction of a new cardioactive drug prototype, LASSBio-294 (1), using MetaPrint2D to predict the most likely metabolites, combined with structure-based tools using docking, molecular dynamics and quantum mechanical calculations to predict the binding of the substrate to CYP2C9 enzyme, to estimate the binding free energy and to study the energy profiles for the oxidation of (1). Additionally, the computational study was correlated with a metabolic fingerprint profiling using LC-MS analysis. The results obtained using the computational methods gave valuable information about the probable metabolites of (1) (qualitatively) and also about the important interactions of this lead compound with the amino acid residues of the active site of CYP2C9. Moreover, using a combination of different levels of theory sheds light on the understanding of (1) metabolism by CYP2C9 and its mechanisms. The metabolic fingerprint profiling of (1) has shown that the metabolites founded in highest concentration in different species were metabolites M1, M2 and M3, whereas M8 was found to be a minor metabolite. Therefore, our computational study allowed a qualitative prediction for the metabolism of (1). The approach presented here has afforded new opportunities to improve metabolite identification strategies, mediated by not only CYP2C9 but also other CYP450 family enzymes.
C1 [Braga, Rodolpho C.; Alves, Vinicius M.; de Oliveira, Valeria; Andrade, Carolina H.] Univ Fed Goias, Fac Pharm, BR-74605220 Goiania, Go, Brazil.
   [Fraga, Carlos A. M.; Barreiro, Eliezer J.] Univ Fed Rio de Janeiro, Fac Pharm, LASSBio, BR-21941902 Rio De Janeiro, Brazil.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Pharm, Av Com Praca Univ,POB 131, BR-74605220 Goiania, Go, Brazil.
EM carolina@farmacia.ufg.br
RI Oliveira, Valeria/B-8056-2016; Braga, Rodolpho C/A-9655-2011; Alves,
   Vinicius M./G-7955-2015; Andrade, Carolina/C-3960-2014; Fraga,
   Carlos/G-3495-2012; Inofar, Inct/J-8605-2013; Barreiro, Eliezer
   J/B-1131-2011
OI Oliveira, Valeria/0000-0001-9800-4883; Braga, Rodolpho
   C/0000-0003-3814-3464; Alves, Vinicius M./0000-0002-6182-1748; Andrade,
   Carolina/0000-0003-0101-1492; Fraga, Carlos/0000-0001-6733-7079; 
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Fundacao de Amparo a Pesquisa do Estado de Goias (FAPEG)
FX The authors would like to thank Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES) and Fundacao de Amparo a Pesquisa do
   Estado de Goias (FAPEG) for financial support and fellowships.
CR [Anonymous], 2009, JAG
   Baranczewski P, 2006, PHARMACOL REP, V58, P453
   Bathelt CM, 2008, J PHYS CHEM A, V112, P13149, DOI 10.1021/jp8016908
   Bathelt CM, 2005, J AM CHEM SOC, V127, P12900, DOI 10.1021/ja0520924
   Boyer S, 2007, J CHEM INF MODEL, V47, P583, DOI 10.1021/ci600376q
   Braga RC, 2011, J PHARMACEUT BIOMED, V55, P1024, DOI 10.1016/j.jpba.2011.02.031
   Carlsson L, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-362
   Carneiro EO, 2010, BIOORG MED CHEM LETT, V20, P3734, DOI 10.1016/j.bmcl.2010.04.073
   Castro-Perez JM, 2007, DRUG DISCOV TODAY, V12, P249, DOI 10.1016/j.drudis.2007.01.007
   Chiavarino B, 2008, J AM CHEM SOC, V130, P3208, DOI 10.1021/ja077286t
   Clark AM, 2007, J CHEM INF MODEL, V47, P1933, DOI 10.1021/ci7001473
   Clodfelter KH, 2006, BIOCHEMISTRY-US, V45, P9393, DOI 10.1021/bi060343v
   Cornell WD, 1996, J AM CHEM SOC, V118, P2309, DOI 10.1021/ja955032e
   Costa DG, 2010, AM J HYPERTENS, V23, P1220, DOI 10.1038/ajh.2010.157
   Costa EMDB, 2008, BRAZ J MICROBIOL, V39, P405, DOI 10.1590/S1517-838220080002000036
   Crestoni ME, 2009, CHEM-EUR J, V15, P7863, DOI 10.1002/chem.200901361
   Czodrowski P, 2009, EXPERT OPIN DRUG MET, V5, P15, DOI [10.1517/17425250802568009, 10.1517/17425250802568009 ]
   de Graaf C, 2005, J MED CHEM, V48, P2308, DOI 10.1021/jm049650u
   de Groot MJ, 2002, J MED CHEM, V45, P1983, DOI 10.1021/jm0110791
   de Montellano PRO, 2010, CYTOCHROME P450 STRU
   de Visser SP, 2003, J AM CHEM SOC, V125, P7413, DOI 10.1021/ja034142f
   DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024
   Figueiredo JM, 2000, BIOORGAN MED CHEM, V8, P2243, DOI 10.1016/S0968-0896(00)00152-8
   Fraga AGM, 2007, 30 REUN AN SOC BRAS
   Jones BC, 2009, PROGR MED CHEM, V47, P239, DOI 10.1016/S0079-6468(08)00206-3
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760
   Kellner DG, 2002, J BIOL CHEM, V277, P9641, DOI 10.1074/jbc.C100745200
   Khan MTH, 2010, CURR DRUG METAB, V11, P285
   Labute P, 2008, J COMPUT CHEM, V29, P1693, DOI 10.1002/jcc.20933
   Lewis DFV, 2008, EXPERT OPIN DRUG MET, V4, P1181, DOI [10.1517/17425255.4.9.1181, 10.1517/17425255.4.9.1181 ]
   Lewis DFV, 2000, BIOCHEM PHARMACOL, V60, P293, DOI 10.1016/S0006-2952(00)00335-X
   Lonsdale R, 2010, CHEM COMMUN, V46, P2354, DOI 10.1039/b925647d
   Miners JO, 1998, BRIT J CLIN PHARMACO, V45, P525, DOI 10.1046/j.1365-2125.1998.00721.x
   Mulholland AJ, 2005, DRUG DISCOV TODAY, V10, P1393, DOI 10.1016/S1359-6446(05)03611-1
   Oda A, 2005, J COMPUT CHEM, V26, P818, DOI 10.1002/jcc.20221
   Park JY, 2003, J MED CHEM, V46, P1645, DOI 10.1021/jm020538a
   Paterlini MG, 1998, CHEM PHYS, V236, P243, DOI 10.1016/S0301-0104(98)00214-6
   Pazini F, 2010, BIOORG MED CHEM LETT, V20, P2888, DOI 10.1016/j.bmcl.2010.03.034
   Polgar T, 2007, J COMPUT AID MOL DES, V21, P539, DOI 10.1007/s10822-007-9137-8
   Porro CS, 2009, J PHYS CHEM A, V113, P11635, DOI 10.1021/jp9023926
   Rydberg P, 2008, J CHEM THEORY COMPUT, V4, P1369, DOI 10.1021/ct800101v
   Rydberg P, 2007, J PHYS CHEM B, V111, P5445, DOI 10.1021/jp070390c
   Rydberg P, 2009, CHEMMEDCHEM, V4, P2070, DOI 10.1002/cmdc.200900363
   Santos R, 2010, J CHEM INF MODEL, V50, P146, DOI 10.1021/ci900293e
   Schoneboom JC, 2002, J AM CHEM SOC, V124, P8142, DOI 10.1021/ja026279w
   Shaik S, 2011, J CHEM THEORY COMPUT, V7, P327, DOI 10.1021/ct100554g
   Shaik S, 2010, CHEM REV, V110, P949, DOI 10.1021/cr900121s
   Shaw DE, 2010, SCIENCE, V330, P341, DOI 10.1126/science.1187409
   Smith CA, 2005, THER DRUG MONIT, V27, P747, DOI 10.1097/01.ftd.0000179845.53213.39
   Stjernschantz E, 2008, EXPERT OPIN DRUG MET, V4, P513, DOI [10.1517/17425255.4.5.513, 10.1517/17425255.4.5.513 ]
   Sun H, 2010, CHEM BIOL DRUG DES, V75, P3, DOI 10.1111/j.1747-0285.2009.00899.x
   Sykes MJ, 2008, J MED CHEM, V51, P780, DOI 10.1021/jm7009793
   SZYBKI, 2010, SZYBKI
   Tarcsay A, 2010, J COMPUT AID MOL DES, V24, P399, DOI 10.1007/s10822-010-9347-3
   Ts P, 2010, BMC BIOINFORMATICS, V11, P395, DOI DOI 10.1186/1471-2105-11-395
   Usmani KA, 2004, DRUG METAB DISPOS, V32, P333, DOI 10.1124/dmd.32.3.333
   Vistoli G, 2008, DRUG DISCOV TODAY, V13, P285, DOI 10.1016/j.drudis.2007.11.007
   Watanabe Y, 2001, J BIOL INORG CHEM, V6, P846, DOI 10.1007/s007750100278
   Wester MR, 2004, J BIOL CHEM, V279, P35630, DOI 10.1074/jbc.M405427200
   Williams PA, 2003, NATURE, V424, P464, DOI 10.1038/nature01862
   Wlodek S, 2010, J CHEM THEORY COMPUT, V6, P2140, DOI 10.1021/ct100095p
   young dc, 2009, COMPUTATIONAL DRUG D, V1
   Zapata-Sudo G, 2003, EUR J PHARMACOL, V470, P79, DOI 10.1016/S0014-2999(03)01757-6
NR 63
TC 20
Z9 20
U1 2
U2 31
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1610-2940
J9 J MOL MODEL
JI J. Mol. Model.
PD MAY
PY 2012
VL 18
IS 5
BP 2065
EP 2078
DI 10.1007/s00894-011-1219-9
PG 14
WC Biochemistry & Molecular Biology; Biophysics; Chemistry,
   Multidisciplinary; Computer Science, Interdisciplinary Applications
SC Biochemistry & Molecular Biology; Biophysics; Chemistry; Computer
   Science
GA 935SW
UT WOS:000303541900035
PM 21901409
DA 2020-12-01
ER

PT J
AU Gil, ED
   Andrade, CH
   Barbosa, NL
   Braga, RC
   Serrano, SHP
AF Gil, Eric de S.
   Andrade, Carolina H.
   Barbosa, Nusia L.
   Braga, Rodolpho C.
   Serrano, Silvia H. P.
TI Cyclic Voltammetry and Computational Chemistry Studies on the Evaluation
   of the Redox Behavior of Parabens and other Analogues
SO JOURNAL OF THE BRAZILIAN CHEMICAL SOCIETY
LA English
DT Article
DE preservatives; electroanalysis; computational chemistry; substituent
   pattern; phenolic compounds
ID ZETA VALENCE QUALITY; ANTIOXIDANT ACTIVITY; PERTURBATION-THEORY;
   BASIS-SETS; DENSITY; EFFICIENT
AB Parabens are antimicrobial preservatives widely used in pharmaceutical, cosmetic and food industries. The alkyl chain connected to the ester group defines some important physicochemical characteristics of these compounds, including the partition coefficient and redox properties. The voltammetric and computational analyses were carried out in order to evaluate the redox behavior of these compounds and other phenolic analogues. A strong correlation between chemical substituents inductive effects of parabens with redox potentials was observed. Using cyclic voltammetry and glassy carbon working electrode, only one irreversible anodic peak was observed around 0.8 V for methylparaben (MP), ethylparaben (EP), propylparaben (PP), butylparaben (BP), benzylparaben (BzP) and p-substituted phenolic analogues. The electrodonating inductive effect of alkyl groups was demonstrated by the anodic oxidation potential shift to lower values as the carbon number increases and, therefore the parabens (and other phenolic analogues) oxidation processes to the quinonoidic forms showed great dependence on the substituent pattern.
C1 [Gil, Eric de S.; Andrade, Carolina H.; Barbosa, Nusia L.; Braga, Rodolpho C.] Univ Fed Goias, Fac Farm, BR-74605220 Goiania, Go, Brazil.
   [Serrano, Silvia H. P.] Univ Sao Paulo, Inst Quim, BR-05508000 Sao Paulo, Brazil.
RP Gil, ED (corresponding author), Univ Fed Goias, Fac Farm, 1A Av C Praca Univ, BR-74605220 Goiania, Go, Brazil.
EM ericsgil@gmail.com
RI Gil, Eric/M-2083-2017; Braga, Rodolpho C/A-9655-2011; Andrade,
   Carolina/C-3960-2014; SERRANO, SILVIA HELENA/C-6870-2012
OI Gil, Eric/0000-0001-9161-0127; Braga, Rodolpho C/0000-0003-3814-3464;
   Andrade, Carolina/0000-0003-0101-1492; SERRANO, SILVIA
   HELENA/0000-0002-2428-0751
CR Ahlrichs R., 2011, TURBOMOLE BASIS SET
   ALSHAMMA A, 1981, J NAT PROD, V44, P745, DOI 10.1021/np50018a025
   Blanco E, 2009, ANAL CHIM ACTA, V647, P104, DOI 10.1016/j.aca.2009.05.024
   Byford JR, 2002, J STEROID BIOCHEM, V80, P49, DOI 10.1016/S0960-0760(01)00174-1
   ELDER RL, 1984, J AM COLL TOXICOL, V3, P1
   Eriksson E, 2008, J HAZARD MATER, V156, P240, DOI 10.1016/j.jhazmat.2007.12.022
   Gunckel S, 1998, CHEM-BIOL INTERACT, V114, P45, DOI 10.1016/S0009-2797(98)00041-6
   Kang H.S., 1997, J PHARM BIOMED ANAL, V15, P1359
   Korotkova EI, 2005, ELECTROCHIM ACTA, V51, P324, DOI 10.1016/j.electacta.2005.04.031
   Kossmann S, 2010, J PHYS CHEM A, V114, P11768, DOI 10.1021/jp105647c
   Kossmann S, 2010, J CHEM THEORY COMPUT, V6, P2325, DOI 10.1021/ct100199k
   Kurlancheek W, 2009, MOL PHYS, V107, P1223, DOI 10.1080/00268970902835637
   Lemini C, 2003, TOXICOL IND HEALTH, V19, P69, DOI 10.1191/0748233703th177oa
   Leopoldini M, 2004, J PHYS CHEM A, V108, P4916, DOI 10.1021/jp037247d
   Lien EJ, 1999, FREE RADICAL BIO MED, V26, P285, DOI 10.1016/S0891-5849(98)00190-7
   Mandado M, 2004, CHEM PHYS LETT, V400, P169, DOI 10.1016/j.cplett.2004.10.097
   Martins I, 2011, TALANTA, V85, P1, DOI 10.1016/j.talanta.2011.04.047
   Neese F., 2010, ORCA AB INITIO DENSI
   Neese F, 2012, WIRES COMPUT MOL SCI, V2, P73, DOI 10.1002/wcms.81
   Neese F, 2009, J CHEM THEORY COMPUT, V5, P3060, DOI 10.1021/ct9003299
   Neese F, 2009, CHEM PHYS, V356, P98, DOI 10.1016/j.chemphys.2008.10.036
   Nicoli S, 2008, EUR J PHARM BIOPHARM, V69, P613, DOI 10.1016/j.ejpb.2007.12.008
   North MA, 2010, J PHYS CHEM B, V114, P14907, DOI 10.1021/jp108024b
   Osorio G, 2004, J PHYS ORG CHEM, V17, P439, DOI 10.1002/poc.751
   Politzer P, 1998, THEOR CHEM ACC, V99, P83, DOI 10.1007/s002140050307
   Radovan C, 2008, SENSORS-BASEL, V8, P4330, DOI 10.3390/s8074330
   Regueiro J, 2009, J CHROMATOGR A, V1216, P4693, DOI 10.1016/j.chroma.2009.04.025
   SCHAFER A, 1994, J CHEM PHYS, V100, P5829, DOI 10.1063/1.467146
   Shen LA, 2008, J MOL STRUC-THEOCHEM, V856, P119, DOI 10.1016/j.theochem.2008.01.023
   Soni MG, 2002, FOOD CHEM TOXICOL, V40, P1335, DOI 10.1016/S0278-6915(02)00107-2
   Vessecchi R, 2011, J PHYS CHEM A, V115, P5453, DOI 10.1021/jp202322n
   Weigend F, 2005, PHYS CHEM CHEM PHYS, V7, P3297, DOI 10.1039/b508541a
   Wright JS, 2001, J AM CHEM SOC, V123, P1173, DOI 10.1021/ja002455u
   Xiuping Z., 2007, ENVIRON SCI TECHNOL, V41, P6541
NR 34
TC 27
Z9 27
U1 0
U2 19
PU SOC BRASILEIRA QUIMICA
PI SAO PAULO
PA CAIXA POSTAL 26037, 05599-970 SAO PAULO, BRAZIL
SN 0103-5053
EI 1678-4790
J9 J BRAZIL CHEM SOC
JI J. Braz. Chem. Soc.
PD MAR
PY 2012
VL 23
IS 3
BP 565
EP 572
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA 921EQ
UT WOS:000302461200025
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Andrade, CH
   de Freitas, LM
   de Oliveira, V
AF Andrade, Carolina Horta
   de Freitas, Lenis Medeiros
   de Oliveira, Valeria
TI Twenty-Six Years of HIV science: an overview of anti-HIV drugs
   metabolism
SO BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Review
DE AIDS/treatment; Drugs/anti-HIV; Drugs/metabolism; Antiretroviral drugs;
   Biotransformation
ID HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE INHIBITOR; HUMAN
   LIVER-MICROSOMES; EXPERIENCED HIV-1-INFECTED PATIENTS; TANDEM
   MASS-SPECTROMETRY; PLACEBO-CONTROLLED TRIAL; PROTEASE INHIBITOR;
   IN-VITRO; SPECIES-DIFFERENCES; MAMMALIAN METABOLISM
AB From the identification of HIV as the agent causing AIDS, to the development of effective antiretroviral drugs, the scientific achievements in HIV research over the past twenty-six years have been formidable. Currently, there are twenty-five anti-HIV compounds which have been formally approved for clinical use in the treatment of AIDS. These compounds fall into six categories: nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse transcriptase inhibitors (NtRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), cell entry inhibitors or fusion inhibitors (FIs), co-receptor inhibitors (CRIs), and integrase inhibitors (INIs). Metabolism by the host organism is one of the most important determinants of the pharmacokinetic profile of a drug. Formation of active or toxic metabolites will also have an impact on the pharmacological and toxicological outcomes. Therefore, it is widely recognized that metabolism studies of a new chemical entity need to be addressed early in the drug discovery process. This paper describes an overview of the metabolism of currently available anti-HIV drugs.
C1 [Andrade, Carolina Horta] Univ Fed Goias, Lab Modelagem Mol, Fac Farm, BR-74605220 Goiania, Go, Brazil.
   [de Freitas, Lenis Medeiros] Univ Fed Goias, Programa Posgrad Ciencias Farmaceut, Fac Farm, BR-74605220 Goiania, Go, Brazil.
   [de Oliveira, Valeria] Univ Fed Goias, Lab Bioconverseio, Fac Farm, BR-74605220 Goiania, Go, Brazil.
RP Andrade, CH (corresponding author), Univ Fed Goias, Lab Modelagem Mol LabMol, Lab Bioconversao LaBioCon, Fac Farm, Ave Univ C-1 Ave S-N,Caixa Postal 131, BR-74605220 Goiania, Go, Brazil.
EM carolina@farmacia.ufg.br; valeria@farmacia.ufg.br
RI Oliveira, Valeria/B-8056-2016; Andrade, Carolina/C-3960-2014
OI Oliveira, Valeria/0000-0001-9800-4883; Andrade,
   Carolina/0000-0003-0101-1492
FU CNPq (The National Council for Scientific and Technological
   Development)National Council for Scientific and Technological
   Development (CNPq); CAPES (The Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior)CAPES; FAPEG (The State of Goias Research Foundation),
   Brazil
FX The authors gratefully acknowledge financial support from CNPq (The
   National Council for Scientific and Technological Development), CAPES
   (The Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior) and
   FAPEG (The State of Goias Research Foundation), Brazil.
CR Abel S, 2008, BRIT J CLIN PHARMACO, V65, P60, DOI 10.1111/j.1365-2125.2008.03137.x
   Adamson CS, 2009, MOL INTERV, V9, P70, DOI 10.1124/mi.9.2.5
   Afzelius L, 2007, DRUG METAB REV, V39, P61, DOI 10.1080/03602530600969374
   Anari MR, 2004, ANAL CHEM, V76, P823, DOI 10.1021/ac034980s
   Aninat C, 2006, DRUG METAB DISPOS, V34, P75, DOI 10.1124/dmd.105.006759
   Anonymous, 2005, Antiviral Chemistry & Chemotherapy, V16, P339
   Asha S, 2009, BIOTECHNOL ADV, V27, P16, DOI 10.1016/j.biotechadv.2008.07.005
   AZERAD R., 1999, ADV BIOCHEM ENG BIOT, V63, P163
   BALANI SK, 1995, DRUG METAB DISPOS, V23, P266
   Balzarini J, 1995, NUCLEOS NUCLEOT, V14, P1861, DOI 10.1080/15257779508010709
   BALZARINI J, 1993, ANTIMICROB AGENTS CH, V37, P332, DOI 10.1128/AAC.37.2.332
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   Braga RC, 2011, J PHARMACEUT BIOMED, V55, P1024, DOI 10.1016/j.jpba.2011.02.031
   BRUZZESE VL, 1995, ANTIMICROB AGENTS CH, V39, P1050, DOI 10.1128/AAC.39.5.1050
   Bumpus NN, 2006, J PHARMACOL EXP THER, V318, P345, DOI 10.1124/jpet.106.102525
   Canavan N., 2007, DRUG DISCOV DEV, V10, P34
   Carneiro E. O., 2005, BRAZ J PHARM SCI, V41, P392
   Carneiro EO, 2010, BIOORG MED CHEM LETT, V20, P3734, DOI 10.1016/j.bmcl.2010.04.073
   Chang M, 1997, DRUG METAB DISPOS, V25, P814
   Chang M, 1997, DRUG METAB DISPOS, V25, P228
   Chang M, 1997, DRUG METAB DISPOS, V25, P828
   Chiba M, 1996, DRUG METAB DISPOS, V24, P307
   Chiba M, 1997, BIOCHEM PHARMACOL, V53, P1187, DOI 10.1016/S0006-2952(97)00100-7
   Chiba M, 2000, XENOBIOTICA, V30, P117, DOI 10.1080/004982500237721
   Chiu TK, 2004, CURR TOP MED CHEM, V4, P965, DOI 10.2174/1568026043388547
   Cohen MS, 2008, J CLIN INVEST, V118, P1244, DOI 10.1172/JCI34706
   Collins JM, 2001, CHEM-BIOL INTERACT, V134, P237, DOI 10.1016/S0009-2797(01)00158-2
   Cooper DA, 2008, NEW ENGL J MED, V359, P355, DOI 10.1056/NEJMoa0708978
   Costa EMDB, 2008, BRAZ J MICROBIOL, V39, P405, DOI 10.1590/S1517-838220080002000036
   Court MH, 2003, DRUG METAB DISPOS, V31, P1125, DOI 10.1124/dmd.31.9.1125
   CRETTON EM, 1993, ANTIMICROB AGENTS CH, V37, P1816, DOI 10.1128/AAC.37.9.1816
   CRETTON EM, 1991, ANTIMICROB AGENTS CH, V35, P801, DOI 10.1128/AAC.35.5.801
   Cruciani G, 2005, J MED CHEM, V48, P6970, DOI 10.1021/jm050529c
   DARVAS F, 1988, J MOL GRAPHICS, V6, P80, DOI 10.1016/0263-7855(88)85004-5
   De Clercq E, 2007, Verh K Acad Geneeskd Belg, V69, P81
   De Clercq Eric, 2003, Expert Rev Anti Infect Ther, V1, P21, DOI 10.1586/14787210.1.1.21
   de Graaf C, 2005, J MED CHEM, V48, P2725, DOI 10.1021/jm040180d
   Decker CJ, 1998, J PHARM SCI, V87, P803, DOI 10.1021/js980029p
   Denissen JF, 1997, DRUG METAB DISPOS, V25, P489
   Dias L.E.S., 2005, BRAZ J PHARM SCI, V41, P133
   Dorr P, 2005, ANTIMICROB AGENTS CH, V49, P4721, DOI 10.1128/AAC.49.11.4721-4732.2005
   Eagling VA, 2002, XENOBIOTICA, V32, P1, DOI 10.1080/00498250110085845
   Ekins S, 2006, DRUG METAB DISPOS, V34, P495, DOI 10.1124/dmd.105.008458
   Erickson DA, 1999, DRUG METAB DISPOS, V27, P1488
   Faletto MB, 1997, ANTIMICROB AGENTS CH, V41, P1099, DOI 10.1128/AAC.41.5.1099
   Fauci AS, 2003, NAT MED, V9, P839, DOI 10.1038/nm0703-839
   FERRAIOLO BL, 1992, PROTEIN PHARMACOKINE, P1
   Fitzsimmons ME, 1997, DRUG METAB DISPOS, V25, P256
   Fletcher CV, 2003, LANCET, V361, P1577, DOI 10.1016/S0140-6736(03)13323-5
   FREITAS L.M., 2009, THESIS U FEDERAL GOI
   FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333
   GOMES T.C.F., 2006, ENC REG BIOC BIOTR 2, V2, P51
   Gomez-Lechon MJ, 2004, CURR DRUG METAB, V5, P443, DOI 10.2174/1389200043335414
   Grinsztejn B, 2007, LANCET, V369, P1261, DOI 10.1016/S0140-6736(07)60597-2
   Guengerich FP, 2006, AAPS J, V8, pE101, DOI 10.1208/aapsj080112
   Hammer SM, 2006, JAMA-J AM MED ASSOC, V296, P827, DOI 10.1001/jama.296.7.827
   Hesse LM, 2001, DRUG METAB DISPOS, V29, P100
   Hirani VN, 2004, DRUG METAB DISPOS, V32, P1462, DOI 10.1124/dmd.104.001743
   HORWITZ JP, 1964, J ORG CHEM, V29, P2076, DOI 10.1021/jo01030a546
   Hyland R, 2008, BRIT J CLIN PHARMACO, V66, P498, DOI 10.1111/j.1365-2125.2008.03198.x
   Iwamoto M, 2008, J CLIN PHARMACOL, V48, P209, DOI 10.1177/0091270007310382
   Johnson MA, 1998, EUR J CLIN PHARMACOL, V54, P363, DOI 10.1007/s002280050476
   Kassahun K, 2007, DRUG METAB DISPOS, V35, P1657, DOI 10.1124/dmd.107.016196
   KAUL S, 1993, DRUG METAB DISPOS, V21, P447
   Khaliq Y, 2000, BRIT J CLIN PHARMACO, V50, P108, DOI 10.1046/j.1365-2125.2000.00238.x
   KLOPMAN G, 1994, J CHEM INF COMP SCI, V34, P1320, DOI 10.1021/ci00022a014
   Kruszewska H, 2003, J MOL STRUCT, V651, P645, DOI 10.1016/S0022-2860(03)00118-2
   Kumar GN, 1999, DRUG METAB DISPOS, V27, P902
   Kumar GN, 2001, MED RES REV, V21, P397, DOI 10.1002/med.1016
   Kumar GN, 1996, J PHARMACOL EXP THER, V277, P423
   Lazzarin A, 2007, LANCET, V370, P39, DOI 10.1016/S0140-6736(07)61048-4
   Le Vee M, 2006, EUR J PHARM SCI, V28, P109, DOI 10.1016/j.ejps.2006.01.004
   Lee JS, 2003, DRUG METABOLIZING EN
   Li AP, 1997, CHEM-BIOL INTERACT, V107, P5, DOI 10.1016/S0009-2797(97)00070-7
   Li XL, 1999, ADV DRUG DELIVER REV, V39, P81, DOI 10.1016/S0169-409X(99)00021-6
   Lillibridge JH, 1998, DRUG METAB DISPOS, V26, P609
   Lin JH, 1996, DRUG METAB DISPOS, V24, P1111
   Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001
   Madruga JV, 2007, LANCET, V370, P29, DOI 10.1016/S0140-6736(07)61047-2
   Matthews T, 2004, NAT REV DRUG DISCOV, V3, P215, DOI 10.1038/nrd1331
   McDowell JA, 1999, ANTIMICROB AGENTS CH, V43, P2855, DOI 10.1128/AAC.43.12.2855
   Mehellou Y, 2010, J MED CHEM, V53, P521, DOI 10.1021/jm900492g
   Meijer DKF, 1997, J CONTROL RELEASE, V46, P139, DOI 10.1016/S0168-3659(96)01587-8
   MERCK & CO. Inc., 2007, RALT TABL FDA ADV CO, P19
   MERTA A, 1992, BIOCHEM PHARMACOL, V44, P2067, DOI 10.1016/0006-2952(92)90110-5
   MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096
   Moda TL, 2008, BIOINFORMATICS, V24, P2270, DOI 10.1093/bioinformatics/btn415
   Mouly S, 2002, CLIN PHARMACOL THER, V72, P1, DOI 10.1067/mcp.2002.124519
   Mutlib AE, 1999, DRUG METAB DISPOS, V27, P1319
   Naritomi Y, 2003, DRUG METAB DISPOS, V31, P580, DOI 10.1124/dmd.31.5.580
   NAVE JF, 1994, BIOCHEM PHARMACOL, V48, P1105, DOI 10.1016/0006-2952(94)90146-5
   NUNES E. S., 2008, THESIS U FEDERAL GOI
   Omura T, 1999, BIOCHEM BIOPH RES CO, V266, P690, DOI 10.1006/bbrc.1999.1887
   PAZINI F., 2005, REV ELETR FARM S2, V2, P157
   Pazini F, 2010, BIOORG MED CHEM LETT, V20, P2888, DOI 10.1016/j.bmcl.2010.03.034
   Pelkonen O, 2005, BASIC CLIN PHARMACOL, V96, P167, DOI 10.1111/j.1742-7843.2005.pto960305.x
   Perros M, 2007, ADV ANTIV D, V5, P185, DOI 10.1016/S1075-8593(06)05005-2
   PRAKASH C., 2009, NUCL RECEPTORS DRUG, P1
   RAMANATHAN S., 2007, INT WORKSH CLIN PHAR, V8, P30
   Ramanathan S, 2007, JAIDS-J ACQ IMM DEF, V45, P274
   RAVITCH J.R., 1998, C RETR OPP INF 5 CHI, V5, P199
   Riska P, 1999, DRUG METAB DISPOS, V27, P895
   Riska PS, 1999, DRUG METAB DISPOS, V27, P1434
   Rodriguez-Novoa S, 2005, CLIN INFECT DIS, V40, P1358, DOI 10.1086/429327
   SCHINAZI RF, 1990, ANTIMICROB AGENTS CH, V34, P1214, DOI 10.1128/AAC.34.6.1214
   SMITH RV, 1974, ARCH BIOCHEM BIOPHYS, V161, P551, DOI 10.1016/0003-9861(74)90338-5
   SMITH RV, 1975, J PHARM SCI-US, V64, P1737, DOI 10.1002/jps.2600641104
   Steigbigel RT, 2008, NEW ENGL J MED, V359, P339, DOI 10.1056/NEJMoa0708975
   Stjernschantz E, 2008, EXPERT OPIN DRUG MET, V4, P513, DOI [10.1517/17425255.4.5.513, 10.1517/17425255.4.5.513 ]
   Symonds W. T., 1995, ANTIVIR RES, V26, pA229
   Testa B, 2005, CHEM BIODIVERS, V2, P872, DOI 10.1002/cbdv.200590064
   Trapnell CB, 1998, ANTIMICROB AGENTS CH, V42, P1592, DOI 10.1128/AAC.42.7.1592
   Treluyer JM, 2003, DRUG METAB DISPOS, V31, P275, DOI 10.1124/dmd.31.3.275
   *UNAIDS, 2008, REP GLOB AIDS EP, P1
   Veal GJ, 1995, GEN PHARMACOL, V26, P1469, DOI 10.1016/0306-3623(95)00047-X
   Vitoria M, 2009, AM J CLIN PATHOL, V131, P844, DOI 10.1309/AJCP5XHDB1PNAEYT
   Voorman RL, 1998, J PHARMACOL EXP THER, V287, P381
   Voorman RL, 1998, DRUG METAB DISPOS, V26, P631
   Voorman RL, 2001, DRUG METAB DISPOS, V29, P41
   Walker DK, 2005, DRUG METAB DISPOS, V33, P587, DOI 10.1124/dmd.104.002626
   Ward BA, 2003, J PHARMACOL EXP THER, V306, P287, DOI 10.1124/jpet.103.049601
   Wu E, 1998, INT ISSX M 5 CAIRNS, V13, P110
   Yoshitomi S, 2001, TOXICOL IN VITRO, V15, P245, DOI 10.1016/S0887-2333(01)00011-X
   Yu X, 1999, J AM SOC MASS SPECTR, V10, P175, DOI 10.1016/S1044-0305(98)00132-9
   ZHANG K., 1998, INT ISSX M 5 CAIRNS, V5, P112
   Zhang KYE, 2001, ANTIMICROB AGENTS CH, V45, P1086, DOI 10.1128/AAC.45.4.1086-1093.2001
   Zmijewski M, 2006, DRUG METAB DISPOS, V34, P925, DOI 10.1124/dmd.106.009522
NR 127
TC 8
Z9 8
U1 0
U2 13
PU UNIV SAO PAULO, CONJUNTO QUIMICAS
PI SAO PAULO
PA SERVICO PUBLICACOES E CIRCULACAO, CAIXA POSTAL 66083, SAO PAULO, 00000,
   BRAZIL
SN 1984-8250
EI 2175-9790
J9 BRAZ J PHARM SCI
JI Braz. J. Pharm. Sci.
PD APR-JUN
PY 2011
VL 47
IS 2
BP 209
EP 230
DI 10.1590/S1984-82502011000200003
PG 22
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 816JP
UT WOS:000294594800003
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Braga, RC
   Sabino, JR
   de Oliveira, V
   Andrade, CH
AF Braga, Rodolpho C.
   Sabino, Jose R.
   de Oliveira, Valeria
   Andrade, Carolina H.
TI Discovery of novel hit compounds for Trypanosoma cruzi sterol
   14a-demethylase through structure-based virtual screening
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 Univ Fed Goias, Dept Pharm, Goiania, Go, Brazil.
   Univ Fed Goias, Inst Phys, Goiania, Go, Brazil.
RI Braga, Rodolpho C/A-9655-2011; Andrade, Carolina/C-3960-2014
OI Braga, Rodolpho C/0000-0003-3814-3464; Andrade,
   Carolina/0000-0003-0101-1492
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 22
PY 2010
VL 240
MA 379-MEDI
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA V20UK
UT WOS:000208164704280
DA 2020-12-01
ER

PT J
AU Carneiro, EO
   Andrade, CH
   Braga, RC
   Torres, ACB
   Alves, RO
   Liao, LM
   Fraga, CAM
   Barreiro, EJ
   de Oliveira, V
AF Carneiro, Emmanuel O.
   Andrade, Carolina H.
   Braga, Rodolpho C.
   Torres, Andrea C. B.
   Alves, Rosangela O.
   Liao, Luciano M.
   Fraga, Carlos A. M.
   Barreiro, Eliezer J.
   de Oliveira, Valeria
TI Structure-based prediction and biosynthesis of the major mammalian
   metabolite of the cardioactive prototype LASSBio-294
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Biosynthesis; Drug metabolism; Structure-based; LASSBio-294; Cytochrome
   P450
ID MODELS
AB A new bioactive compound of the N-acylhydrazone class, LASSBio-294, was shown to produce a cardioinotropic effect and vasodilation. In this study, we report the structure-based drug metabolism prediction, biosynthesis and identification of the major mammalian metabolite of LASSBio-294. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Carneiro, Emmanuel O.; Andrade, Carolina H.; Braga, Rodolpho C.; de Oliveira, Valeria] Univ Fed Goias, Fac Farm, Lab Bioconversao, BR-74605220 Goiania, Go, Brazil.
   [Torres, Andrea C. B.; Alves, Rosangela O.] Univ Fed Goias, Escola Vet, BR-74605220 Goiania, Go, Brazil.
   [Liao, Luciano M.] Univ Fed Goias, Inst Quim, Lab Ressonancia Magnet Nucl, BR-74605220 Goiania, Go, Brazil.
   [Fraga, Carlos A. M.; Barreiro, Eliezer J.] Univ Fed Rio de Janeiro, Fac Farm, LASSBio, Rio De Janeiro, Brazil.
RP de Oliveira, V (corresponding author), Univ Fed Goias, Fac Farm, Lab Bioconversao, 1A Ave Esquina,C Praca Univ S-N,Caixa Postal 131,, BR-74605220 Goiania, Go, Brazil.
EM valeria@farmacia.ufg.br
RI Oliveira, Valeria/B-8056-2016; Liao, Luciano Morais M./F-1487-2015;
   Barreiro, Eliezer J/B-1131-2011; Andrade, Carolina/C-3960-2014; Liao,
   Luciano Morais/M-3030-2019; Fraga, Carlos/G-3495-2012; Braga, Rodolpho
   C/A-9655-2011; Inofar, Inct/J-8605-2013
OI Oliveira, Valeria/0000-0001-9800-4883; Liao, Luciano Morais
   M./0000-0001-9985-2980; Andrade, Carolina/0000-0003-0101-1492; Liao,
   Luciano Morais/0000-0001-9985-2980; Fraga, Carlos/0000-0001-6733-7079;
   Braga, Rodolpho C/0000-0003-3814-3464; 
FU CAPESCAPES; CNPqNational Council for Scientific and Technological
   Development (CNPq); INCT-INOFAR [573.564/2008-6]
FX The authors thank CAPES, CNPq and INCT-INOFAR (# 573.564/2008-6) for
   financial support and fellowships.
CR ALBUQUERQUE EX, 2000, Patent No. 200007875
   Andersson T, 1996, CLIN PHARMACOKINET, V31, P9, DOI 10.2165/00003088-199631010-00002
   Asha S, 2009, BIOTECHNOL ADV, V27, P16, DOI 10.1016/j.biotechadv.2008.07.005
   Buchanan GO, 2000, PHYTOCHEMISTRY, V54, P39, DOI 10.1016/S0031-9422(00)00024-8
   Figueiredo JM, 2000, BIOORGAN MED CHEM, V8, P2243, DOI 10.1016/S0968-0896(00)00152-8
   FRAGA AGM, 2007, 30 REUN AN SOC BRAS
   Jacob S, 1998, AM J HYPERTENS, V11, P1258, DOI 10.1016/S0895-7061(98)00141-1
   Lima PC, 2000, EUR J MED CHEM, V35, P187, DOI 10.1016/S0223-5234(00)00120-3
   LIN G, 1993, XENOBIOTICA, V23, P1059, DOI 10.3109/00498259309059422
   Lombardo F, 2003, MINI-REV MED CHEM, V3, P861, DOI 10.2174/1389557033487629
   MODA TL, 2008, 236 NAT M AM CHEM SO
   Parshikov IA, 2002, FEMS MICROBIOL LETT, V214, P133, DOI 10.1016/S0378-1097(02)00858-3
   Silva CLM, 2002, BRIT J PHARMACOL, V135, P293, DOI 10.1038/sj.bjp.0704473
   SMITH RV, 1974, ARCH BIOCHEM BIOPHYS, V161, P551, DOI 10.1016/0003-9861(74)90338-5
   SMITH RV, 1975, J PHARM SCI-US, V64, P1737, DOI 10.1002/jps.2600641104
   Stokes Gordon S, 2004, J Clin Hypertens (Greenwich), V6, P192, DOI 10.1111/j.1524-6175.2004.03508.x
   Sudo RT, 2001, BRIT J PHARMACOL, V134, P603, DOI 10.1038/sj.bjp.0704291
   Sun H, 2010, CHEM BIOL DRUG DES, V75, P3, DOI 10.1111/j.1747-0285.2009.00899.x
   VILLAVERDE C, 1995, XENOBIOTICA, V25, P433, DOI 10.3109/00498259509061863
NR 19
TC 15
Z9 15
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD JUN 15
PY 2010
VL 20
IS 12
BP 3734
EP 3736
DI 10.1016/j.bmcl.2010.04.073
PG 3
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 603KT
UT WOS:000278208200061
PM 20488703
DA 2020-12-01
ER

PT J
AU Pazini, F
   Menegatti, R
   Sabino, JR
   Andrade, CH
   Neves, G
   Rates, SMK
   Noel, F
   Fraga, CAM
   Barreiro, EJ
   de Oliveira, V
AF Pazini, Francine
   Menegatti, Ricardo
   Sabino, Jose R.
   Andrade, Carolina H.
   Neves, Gilda
   Rates, Stela M. K.
   Noel, Francois
   Fraga, Carlos A. M.
   Barreiro, Eliezer J.
   de Oliveira, Valeria
TI Design of new dopamine D2 receptor ligands: Biosynthesis and
   pharmacological evaluation of the hydroxylated metabolite of LASSBio-581
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Dopamine D2 receptor ligands; LASSBio-581; Antipsychotic prototype;
   Microbial hydroxylation; Biosynthesis; Cunninghamella echinulata
ID CUNNINGHAMELLA-ELEGANS; BIOTRANSFORMATION; PROFILE; RATS
AB LASSBio-581 is a N-phenylpiperazine derivative designed for the treatment of schizophrenia. In this study, four strains of filamentous fungi were screened for their capabilities to biotransform LASSBio-581. Cunninghamella echinulata ATCC 9244 was chosen to scale up the biosynthesis of the p-hydroxylated metabolite of LASSBio-581. The chemical structure of the metabolite was confirmed by NMR, LC-MS and X-ray crystallography. Binding studies performed on brain homogenate indicated that the p-hydroxylated metabolite can be considered more selective for dopamine receptors than LASSBio-581, and, therefore, can be used to design new selective dopamine inhibitors. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Pazini, Francine; Menegatti, Ricardo; Andrade, Carolina H.; de Oliveira, Valeria] Univ Fed Goias, Fac Farm, Lab Bioconversao, Goiania, Go, Brazil.
   [Neves, Gilda; Rates, Stela M. K.] Univ Fed Rio Grande do Sul, Fac Farm, Lab Psicofarmacol Expt, Porto Alegre, RS, Brazil.
   [Sabino, Jose R.] Univ Fed Goias, Inst Fis, Goiania, Go, Brazil.
   [Neves, Gilda; Noel, Francois] Univ Fed Rio de Janeiro, Lab Farmacol Bioquim & Mol, Rio De Janeiro, Brazil.
   [Pazini, Francine; Fraga, Carlos A. M.; Barreiro, Eliezer J.] Univ Fed Rio de Janeiro, Fac Farm, LASSBio, Rio De Janeiro, Brazil.
RP de Oliveira, V (corresponding author), Ave Esquina C Praca Univ,S-N Caixa Postal 131,Set, BR-74605220 Goiania, Go, Brazil.
EM valeria@farmacia.ufg.br
RI Andrade, Carolina/C-3960-2014; Noel, Francois/C-3402-2009; Fraga,
   Carlos/G-3495-2012; Oliveira, Valeria/B-8056-2016; Neves, Gilda
   A./U-1622-2019; Menegatti, Ricardo/U-4702-2019; Inofar,
   Inct/J-8605-2013; Neves, Gilda A./K-7573-2012; Barreiro, Eliezer
   J/B-1131-2011
OI Andrade, Carolina/0000-0003-0101-1492; Noel,
   Francois/0000-0001-6813-1347; Fraga, Carlos/0000-0001-6733-7079;
   Oliveira, Valeria/0000-0001-9800-4883; Menegatti,
   Ricardo/0000-0001-5044-9234; Neves, Gilda A./0000-0002-7027-3851; RATES,
   STELA/0000-0001-7952-7830
FU PROCAD/CAPES, BrazilCAPES [0092/05-3]
FX This work was supported by Grants from PROCAD/CAPES, Brazil (Process
   0092/05-3). The authors are also grateful for the fellowships granted by
   CAPES.
CR Alarcon J, 2007, J MOL CATAL B-ENZYM, V48, P23, DOI 10.1016/j.molcatb.2007.06.001
   Baldessarini RJ, 1996, PHARMACOL BASIS THER, P399
   Carneiro E. O., 2005, BRAZ J PHARM SCI, V41, P392
   Costa EMDB, 2008, BRAZ J MICROBIOL, V39, P405, DOI 10.1590/S1517-838220080002000036
   DEOLIVEIRA V, 2001, EUR J PHARM SCI, V13, P41
   Dias L.E.S., 2005, BRAZ J PHARM SCI, V41, P133
   Manosroi J, 2007, ENZYME MICROB TECH, V41, P322, DOI 10.1016/j.enzmictec.2007.02.014
   Menegatti R, 2003, BIOORGAN MED CHEM, V11, P4807, DOI 10.1016/S0968-0896(03)00487-5
   Moody JD, 2002, DRUG METAB DISPOS, V30, P1274, DOI 10.1124/dmd.30.11.1274
   Neves G, 2003, BRAZ J MED BIOL RES, V36, P625, DOI 10.1590/S0100-879X2003000500010
   Neves G, 2008, PHARMACOL BIOCHEM BE, V89, P23, DOI 10.1016/j.pbb.2007.10.018
   Neves G, 2010, BIOORGAN MED CHEM, V18, P1925, DOI 10.1016/j.bmc.2010.01.040
   Parker TJ, 2001, BRIT J PHARMACOL, V132, P151, DOI 10.1038/sj.bjp.0703791
   RIOS DP, 2005, BRAZ J PHARM SCI, V41, P133
   SMITH RV, 1974, ARCH BIOCHEM BIOPHYS, V161, P551, DOI 10.1016/0003-9861(74)90338-5
   Tasso L, 2005, EUR J PHARM SCI, V26, P194, DOI 10.1016/j.ejps.2005.06.002
   Zhang DL, 2006, DRUG METAB DISPOS, V34, P267, DOI 10.1124/dmd.105.007153
NR 17
TC 6
Z9 6
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD MAY 1
PY 2010
VL 20
IS 9
BP 2888
EP 2891
DI 10.1016/j.bmcl.2010.03.034
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 585HT
UT WOS:000276816600042
PM 20363131
DA 2020-12-01
ER

PT J
AU Andrade, CH
   Pasqualoto, KFM
   Ferreira, EI
   Hopfinger, AJ
AF Andrade, Carolina H.
   Pasqualoto, Kerly F. M.
   Ferreira, Elizabeth I.
   Hopfinger, Anton J.
TI 4D-QSAR: Perspectives in Drug Design
SO MOLECULES
LA English
DT Review
DE QSAR; 4D-QSAR; Structure-based QSAR; Drug Design
ID MOLECULAR SHAPE-ANALYSIS; ALPHA-THYMIDINE ANALOGS; QSAR ANALYSIS;
   MEDICINAL CHEMISTRY; RATIONAL DESIGN; DIHYDROFOLATE-REDUCTASE;
   GLYCOGEN-PHOSPHORYLASE; GABA(A) RECEPTOR; LEAD GENERATION; INHIBITORS
AB Drug design is a process driven by innovation and technological breakthroughs involving a combination of advanced experimental and computational methods. A broad variety of medicinal chemistry approaches can be used for the identification of hits, generation of leads, as well as to accelerate the optimization of leads into drug candidates. The quantitative structure-activity relationship (QSAR) formalisms are among the most important strategies that can be applied for the successful design new molecules. This review provides a comprehensive review on the evolution and current status of 4D-QSAR, highlighting present challenges and new opportunities in drug design.
C1 [Andrade, Carolina H.] Univ Fed Goias, Fac Pharm, Lab Mol Modeling, BR-74605220 Goiania, Go, Brazil.
   [Andrade, Carolina H.; Hopfinger, Anton J.] Univ New Mexico, Coll Pharm, Albuquerque, NM 87131 USA.
   [Pasqualoto, Kerly F. M.; Ferreira, Elizabeth I.] Univ Sao Paulo, Fac Pharmaceut Sci, BR-05508900 Sao Paulo, Brazil.
   [Hopfinger, Anton J.] Chem21 Grp Inc, Lake Forest, IL 60045 USA.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Pharm, Lab Mol Modeling, 1A Av C Praca Univ S-N, BR-74605220 Goiania, Go, Brazil.
EM carolhandrade@gmail.com; kerly@usp.br; hajudan@usp.br; hopfingr@unm.edu
RI Andrade, Carolina/C-3960-2014; Pasqualoto, Kerly/A-6161-2014; Ferreira,
   Elizabeth I/C-4038-2012
OI Andrade, Carolina/0000-0003-0101-1492; Pasqualoto,
   Kerly/0000-0002-7532-4283; Ferreira, Elizabeth I/0000-0003-2087-033X
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES; FAPESPFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP); FAPEG
FX The authors would like to thank the Brazilian funding agencies CNPq,
   CAPES, FAPESP and FAPEG for financial support.
CR ALBUQUERQUE M, 2007, CURR METHODS MED CHE, V1, P91
   Albuquerque MG, 1998, J CHEM INF COMP SCI, V38, P925, DOI 10.1021/ci980093s
   Andrade CH, 2009, J CHEM INF MODEL, V49, P1070, DOI 10.1021/ci8004622
   Andricopulo AD, 2009, CURR TOP MED CHEM, V9, P771, DOI 10.2174/156802609789207127
   Bleicher KH, 2003, NAT REV DRUG DISCOV, V2, P369, DOI 10.1038/nrd1086
   CLEMENTI S, 1995, GOLPE 3 0
   COHEN N, 1996, GUIDEBOOK MOL MODELI, V1, P361
   CRAMER RD, 1988, J AM CHEM SOC, V110, P5959, DOI 10.1021/ja00226a005
   de la Sierra IL, 2001, J MOL BIOL, V311, P87, DOI 10.1006/jmbi.2001.4843
   Duca JS, 2001, J CHEM INF COMP SCI, V41, P1367, DOI 10.1021/ci0100090
   Duca JS, 2001, ADV MATER, V13, P1713, DOI 10.1002/1521-4095(200111)13:22<1713::AID-ADMA1713>3.0.CO;2-C
   Duca JS, 2000, CHEM MATER, V12, P3821, DOI 10.1021/cm000398y
   Esposito Emilio Xavier, 2004, Methods Mol Biol, V275, P131
   FREE SM, 1964, J MED CHEM, V7, P395, DOI 10.1021/jm00334a001
   Goodford P, 1996, J CHEMOMETR, V10, P107
   GOODFORD P, 2000, GRID
   Guido RVC, 2008, CURR MED CHEM, V15, P37
   HANSCH C, 1964, J AM CHEM SOC, V86, P1616, DOI 10.1021/ja01062a035
   Hong X, 2003, J CHEM INF COMP SCI, V43, P324, DOI 10.1021/ci0200321
   Hopfinger A, 2001, 4D QSAR PACKAGE USER
   Hopfinger AJ, 1999, J CHEM INF COMP SCI, V39, P1151, DOI 10.1021/ci990032+
   HOPFINGER AJ, 1981, J MED CHEM, V24, P818, DOI 10.1021/jm00139a010
   HOPFINGER AJ, 1980, J AM CHEM SOC, V102, P7196, DOI 10.1021/ja00544a005
   Hopfinger AJ, 1997, J AM CHEM SOC, V119, P10509, DOI 10.1021/ja9718937
   Hopfinger AJ, 2000, CURR OPIN BIOTECH, V11, P97, DOI 10.1016/S0958-1669(99)00061-0
   Iyer M, 2002, PHARMACEUT RES, V19, P1611, DOI 10.1023/A:1020792909928
   Iyer M, 2007, J CHEM INF MODEL, V47, P1945, DOI 10.1021/ci700153g
   Keseru GM, 2001, J CHEM INF COMP SCI, V41, P120, DOI 10.1021/ci000043z
   Krasowski MD, 2002, J MED CHEM, V45, P3210, DOI 10.1021/jm010461a
   Kubinyi H., 1993, 3D QSAR DRUG DESIGN, P759
   Kubinyi H., 1993, METHODS PRINCIPLES M, V1, P240
   Liu JZ, 2003, J CHEM INF COMP SCI, V43, P2170, DOI 10.1021/ci034142z
   Lombardino JG, 2004, NAT REV DRUG DISCOV, V3, P853, DOI 10.1038/nrd1523
   Lombardo F, 2003, MINI-REV MED CHEM, V3, P861, DOI 10.2174/1389557033487629
   Ooms F, 2000, CURR MED CHEM, V7, P141, DOI 10.2174/0929867003375317
   Pan DH, 2004, J CHEM INF COMP SCI, V44, P2083, DOI 10.1021/ci0498057
   Pan DH, 2003, J CHEM INF COMP SCI, V43, P1591, DOI 10.1021/ci0340714
   Pasqualoto KFM, 2004, J MED CHEM, V47, P3755, DOI 10.1021/jm049913k
   Platts JA, 2001, EUR J MED CHEM, V36, P719, DOI 10.1016/S0223-5234(01)01269-7
   Ravi M, 2001, J CHEM INF COMP SCI, V41, P1587, DOI 10.1021/ci010076u
   ROGERS D, 1994, J CHEM INF COMP SCI, V34, P854, DOI 10.1021/ci00020a020
   Romeiro NC, 2005, J COMPUT AID MOL DES, V19, P385, DOI 10.1007/s10822-005-7927-4
   Salum LB, 2009, MOL DIVERS, V13, P277, DOI 10.1007/s11030-009-9112-5
   Santos OA, 2006, J CHEM INF MODEL, V46, P345, DOI 10.1021/ci050326x
   Santos OA, 2009, MED CHEM, V5, P359, DOI 10.2174/157340609788681458
   Senese CL, 2004, J CHEM INF COMP SCI, V44, P1526, DOI 10.1021/ci049898s
   Smith G. M., 1990, TETRAHEDRON COMPUT M, V3, P615
   Subramaniam S, 2008, BIOINFORMATION, V3, P14, DOI 10.6026/97320630003014
   Taylor JB, 2007, COMPREHENSIVE MED CH
   TERFLOTH L, 2003, CHEMOINFORMATICS, P401
   Thipnate P, 2009, J CHEM INF MODEL, V49, P2312, DOI 10.1021/ci9002427
   Van Daele I, 2007, J MED CHEM, V50, P5281, DOI 10.1021/jm0706158
   van de Waterbeemd H, 2003, NAT REV DRUG DISCOV, V2, P192, DOI 10.1038/nrd1032
   Zhao HY, 2007, DRUG DISCOV TODAY, V12, P149, DOI 10.1016/j.drudis.2006.12.003
NR 54
TC 71
Z9 71
U1 1
U2 41
PU MOLECULAR DIVERSITY PRESERVATION INTERNATIONAL-MDPI
PI BASEL
PA KANDERERSTRASSE 25, CH-4057 BASEL, SWITZERLAND
SN 1420-3049
J9 MOLECULES
JI Molecules
PD MAY
PY 2010
VL 15
IS 5
BP 3281
EP 3294
DI 10.3390/molecules15053281
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA 601YY
UT WOS:000278105400023
PM 20657478
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Andrade, CH
   Pasqualoto, KFM
   Ferreira, EI
   Hopfinger, AJ
AF Andrade, Carolina Horta
   Pasqualoto, Kerly F. M.
   Ferreira, Elizabeth I.
   Hopfinger, Anton J.
TI 3D-Pharmacophore mapping of thymidine-based inhibitors of TMPK as
   potential antituberculosis agents
SO JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
LA English
DT Article
DE 4D-QSAR; 3D-Pharmacophore; Thymidine monophosphate kinase; TMPK
   inhibitors; Antituberculosis agents
ID MONOPHOSPHATE KINASE INHIBITORS; TUBERCULOSIS THYMIDYLATE KINASE;
   MYCOBACTERIUM-TUBERCULOSIS; RATIONAL DESIGN;
   THYMIDINE-5'-O-MONOPHOSPHATE ANALOGS; MODELS; EPIDEMIOLOGY;
   CONSTRUCTION; 3D-QSAR
AB Tuberculosis (TB) is the primary cause of mortality among infectious diseases. Mycobacterium tuberculosis monophosphate kinase (TMPKmt) is essential to DNA replication. Thus, this enzyme represents a promising target for developing new drugs against TB. In the present study, the receptor-independent, RI, 4D-QSAR method has been used to develop QSAR models and corresponding 3D-pharmacophores for a set of 81 thymidine analogues, and two corresponding subsets, reported as inhibitors of TMPKmt. The resulting optimized models are not only statistically significant with r (2) ranging from 0.83 to 0.92 and q (2) from 0.78 to 0.88, but also are robustly predictive based on test set predictions. The most and the least potent inhibitors in their respective postulated active conformations, derived from each of the models, were docked in the active site of the TMPKmt crystal structure. There is a solid consistency between the 3D-pharmacophore sites defined by the QSAR models and interactions with binding site residues. Moreover, the QSAR models provide insights regarding a probable mechanism of action of the analogues.
C1 [Andrade, Carolina Horta; Pasqualoto, Kerly F. M.; Ferreira, Elizabeth I.] Univ Sao Paulo, Dept Pharm, Fac Pharmaceut Sci, BR-05586900 Sao Paulo, Brazil.
   [Andrade, Carolina Horta; Hopfinger, Anton J.] Univ New Mexico, Coll Pharm, Albuquerque, NM 87131 USA.
   [Hopfinger, Anton J.] Chem21 Grp Inc, Lake Forest, IL 60045 USA.
RP Andrade, CH (corresponding author), Univ Sao Paulo, Dept Pharm, Fac Pharmaceut Sci, Av Prof Lineu Prestes 580,Bloco 13, BR-05586900 Sao Paulo, Brazil.
EM carolhorta@usp.br
RI Pasqualoto, Kerly/A-6161-2014; Ferreira, Elizabeth I/C-4038-2012;
   Andrade, Carolina/C-3960-2014
OI Pasqualoto, Kerly/0000-0002-7532-4283; Ferreira, Elizabeth
   I/0000-0003-2087-033X; Andrade, Carolina/0000-0003-0101-1492
FU CAPES FoundationCAPES; federal scientific agency of Brazil; National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [1 R21 GM075775];
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [R21GM075775,
   R21GM075775, R21GM075775] Funding Source: NIH RePORTER
FX The authors are grateful to the CAPES Foundation, a federal scientific
   agency of Brazil, for scholarship support. This work was also funded by
   the National Institutes of Health through the NIH Roadmap for Medical
   Research, Grant 1 R21 GM075775. Information on Novel Preclinical Tools
   for Predictive ADME-Toxicology can be found at
   http://grants.nih.gov/grants/guide/rfa-files/RFA-RM04-023.html. Links to
   nine initiatives are found here
   http://nihroadmap.nih.gov/initiatives.asp. Resources of the Laboratory
   of Molecular Modeling and Design at UNM and The Chem21 Group, Inc. were
   used in performing this work.
CR *ACC SOFTW INC, 2007, DISC STUD VIS VERS 2
   Andrade CH, 2009, J CHEM INF MODEL, V49, P1070, DOI 10.1021/ci8004622
   Andrade CH, 2008, LETT DRUG DES DISCOV, V5, P377, DOI 10.2174/157018008785777289
   Andrade CH, 2008, REV BRAS CIENC FARM, V44, P167, DOI 10.1590/S1516-93322008000200002
   [Anonymous], 2005, HYPERCHEM PROGR REL
   Aparna V, 2006, BIOORG MED CHEM LETT, V16, P1014, DOI 10.1016/j.bmcl.2005.10.086
   Aziz MA, 2006, LANCET, V368, P2142, DOI 10.1016/S0140-6736(06)69863-2
   BLONDIN C, 1994, ANAL BIOCHEM, V220, P219, DOI 10.1006/abio.1994.1326
   *CHEM21 GROUP INC, 1997, 4D QSAR PACK VERS 2
   de la Sierra IL, 2001, J MOL BIOL, V311, P87, DOI 10.1006/jmbi.2001.4843
   DELANO WL, 2004, PYM MOL GRAPH SYST V
   DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024
   DOHERTY DC, 2001, MOLSIM PACKAGE VERSI
   Dunn III W.J., 1996, GENETIC ALGORITHMS M
   Dye C, 2006, LANCET, V367, P938, DOI 10.1016/S0140-6736(06)68384-0
   DYE C, 2008, WHOHTMTB2008393
   FRIEDMAN JH, 1991, ANN STAT, V19, P1, DOI 10.1214/aos/1176347963
   GHOSE AK, 1988, J COMPUT CHEM, V9, P80, DOI 10.1002/jcc.540090111
   GLEN WG, 1989, TETRAHEDRON COMPUT M, V2, P349, DOI DOI 10.1016/0898-5529(89)90004-3
   Gopalakrishnan B, 2005, J CHEM INF MODEL, V45, P1101, DOI 10.1021/ci050064z
   Haouz A, 2003, J BIOL CHEM, V278, P4963, DOI 10.1074/jbc.M209630200
   Hopfinger AJ, 1997, J AM CHEM SOC, V119, P10509, DOI 10.1021/ja9718937
   Munier-Lehmann H, 2001, PROTEIN SCI, V10, P1195, DOI 10.1110/ps.45701
   Pasqualoto KFM, 2004, J MED CHEM, V47, P3755, DOI 10.1021/jm049913k
   ROGERS D, 1994, J CHEM INF COMP SCI, V34, P854, DOI 10.1021/ci00020a020
   Romeiro NC, 2005, J COMPUT AID MOL DES, V19, P385, DOI 10.1007/s10822-005-7927-4
   Van Daele I, 2007, J MED CHEM, V50, P5281, DOI 10.1021/jm0706158
   Vanheusden V, 2004, J MED CHEM, V47, P6187, DOI 10.1021/jm040847w
   Vanheusden V, 2003, BIOORG MED CHEM LETT, V13, P3045, DOI 10.1016/S0960-894X(03)00643-7
   Vanheusden V, 2002, BIOORG MED CHEM LETT, V12, P2695, DOI 10.1016/S0960-894X(02)00551-6
NR 30
TC 24
Z9 24
U1 0
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0920-654X
J9 J COMPUT AID MOL DES
JI J. Comput.-Aided Mol. Des.
PD FEB
PY 2010
VL 24
IS 2
BP 157
EP 172
DI 10.1007/s10822-010-9323-y
PG 16
WC Biochemistry & Molecular Biology; Biophysics; Computer Science,
   Interdisciplinary Applications
SC Biochemistry & Molecular Biology; Biophysics; Computer Science
GA 570DK
UT WOS:000275651700006
PM 20217185
DA 2020-12-01
ER

PT J
AU Andrade, CH
   Pasqualoto, KFM
   Ferreira, EI
   Hopfinger, AJ
AF Andrade, Carolina H.
   Pasqualoto, Kerly F. M.
   Ferreira, Elizabeth I.
   Hopfinger, Anton J.
TI Rational Design and 3D-Pharmacophore Mapping of 5 '-Thiourea-Substituted
   alpha-Thymidine Analogues as Mycobacterial TMPK Inhibitors
SO JOURNAL OF CHEMICAL INFORMATION AND MODELING
LA English
DT Article
ID TUBERCULOSIS THYMIDYLATE KINASE; MONOPHOSPHATE KINASE;
   THYMIDINE-5'-O-MONOPHOSPHATE ANALOGS; MECHANISM; INSIGHTS; MODELS
AB Thymidine monophosphate kinase (TMPK) has emerged as an attractive target for developing inhibitors of Mycobacterium tuberculosis growth. In this study the receptor-independent (RI) 4D-QSAR formalism has been used to develop QSAR models and corresponding 3D-pharmacophores for a set of 5'-thiourea-substituted alpha-thymidine inhibitors. Models were developed for the entire training set and for a subset of the training set consisting of the most potent inhibitors. The optimized (RI) 4D-QSAR models are statistically significant (r(2) = 0.90, q(2) = 0.83 entire set, r(2) = 0.86, q(2) = 0.80 high potency subset) and also possess good predictivity based on test set predictions. The most and least potent inhibitors, in their respective postulated active conformations derived from the models, were docked in the active site of the TMPK crystallographic structure. There is a solid consistency between the 3D-pharmacophore sites defined by the QSAR models and interactions with binding site residues. This model identifies new regions of the inhibitors that contain pharmacophore sites, such as the sugar-pyrimidine ring structure and the region of the 5'-arylthiourea moiety. These new regions of the ligands can be further explored and possibly exploited to identify new, novel, and, perhaps, better antituberculosis inhibitors of TMPKmt. Furthermore, the 3D-pharmacophores defined by these models can be used as a starting point for future receptor-dependent antituberculosis drug design as well as to elucidate candidate sites for substituent addition to optimize ADMET properties of analog inhibitors.
C1 [Andrade, Carolina H.] Univ Sao Paulo, Fac Pharmaceut Sci, Dept Pharm, BR-05508900 Sao Paulo, Brazil.
   [Andrade, Carolina H.; Hopfinger, Anton J.] Univ New Mexico, Coll Pharm, Albuquerque, NM 87131 USA.
RP Andrade, CH (corresponding author), Univ Sao Paulo, Fac Pharmaceut Sci, Dept Pharm, Av Prof Lineu Prestes 580,Bloco 13, BR-05508900 Sao Paulo, Brazil.
EM carolhorta@usp.br
RI Ferreira, Elizabeth I/C-4038-2012; Pasqualoto, Kerly/A-6161-2014;
   Andrade, Carolina/C-3960-2014
OI Ferreira, Elizabeth I/0000-0003-2087-033X; Pasqualoto,
   Kerly/0000-0002-7532-4283; Andrade, Carolina/0000-0003-0101-1492
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [1 R21 GM075775];
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [R21GM075775,
   R21GM075775, R21GM075775] Funding Source: NIH RePORTER
FX C.H.A. is grateful to the CAPES foundation for scholarship support. This
   work was also funded by the National Institutes of Health through the
   NIH Roadmap for Medical Research, Grant 1 R21 GM075775. Information on
   Novel Preclinical Tools for Predictive ADME-Toxicology can be found at
   http://grants.nih.gov/grants/gui(le/rfa-files/RFA-RM-04-023.html. Links
   to nine initiatives are found at
   http://nihroadmap.nih.gov/initiatives.asp. Resources of the Laboratory
   of Molecular Modeling and Design at UNM and The Chem21 Group, Inc. were
   used In performing this work.
CR *ACC SOFTW INC, 2007, DISC STUD VIS VERS 2
   BLONDIN C, 1994, ANAL BIOCHEM, V220, P219, DOI 10.1006/abio.1994.1326
   *CHEM21 GROUP INC, 1997, 4D QSAR PACK VERS 2
   De Lano W. L., 2004, PYMOL MOL GRAPHICS S
   DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024
   DOHERTY DC, 2001, MOLSIM PACKAGE VERSI
   Dunn III W, 1996, GENETIC ALGORITHMS M, P109
   Dye C, 2006, LANCET, V367, P938, DOI 10.1016/S0140-6736(06)68384-0
   DYE C, 2008, WHOHTMTB2008393
   Friedman J., 1988, 102 STANF U DEP STAT
   GHOSE AK, 1988, J COMPUT CHEM, V9, P80, DOI 10.1002/jcc.540090111
   GLEN WG, 1989, TETRAHEDRON COMPUT M, V2, P349, DOI DOI 10.1016/0898-5529(89)90004-3
   Haouz A, 2003, J BIOL CHEM, V278, P4963, DOI 10.1074/jbc.M209630200
   Hopfinger AJ, 1997, J AM CHEM SOC, V119, P10509, DOI 10.1021/ja9718937
   *HYP INC, 2005, HYPERCHEM PROGR REL
   Lavie A, 1997, NAT MED, V3, P922, DOI 10.1038/nm0897-922
   Li de la Sierra I, 2001, J Mol Biol, V311, P87, DOI 10.1006/jmbi.2001.4843
   Mannhold R, 2001, J COMPUT AID MOL DES, V15, P337, DOI 10.1023/A:1011107422318
   Munier-Lehmann H, 2001, PROTEIN SCI, V10, P1195, DOI 10.1110/ps.45701
   Ostermann N, 2000, STRUCTURE, V8, P629, DOI 10.1016/S0969-2126(00)00149-0
   Pochet S, 2003, CHEMBIOCHEM, V4, P742, DOI 10.1002/cbic.200300608
   ROGERS D, 1994, J CHEM INF COMP SCI, V34, P854, DOI 10.1021/ci00020a020
   Rogers D., 1991, P 4 INT C GEN ALG SA, P38
   ROGERS D, 1994, REFERENCE MANUAL VER
   Van Calenbergh S, 2006, Verh K Acad Geneeskd Belg, V68, P223
   Van Daele I, 2007, J MED CHEM, V50, P5281, DOI 10.1021/jm0706158
   Vanheusden V, 2004, J MED CHEM, V47, P6187, DOI 10.1021/jm040847w
   Vanheusden V, 2003, BIOORG MED CHEM LETT, V13, P3045, DOI 10.1016/S0960-894X(03)00643-7
   Vanheusden V, 2002, BIOORG MED CHEM LETT, V12, P2695, DOI 10.1016/S0960-894X(02)00551-6
   Vilcheze C, 2005, ANTIMICROB AGENTS CH, V49, P708, DOI 10.1128/AAC.49.2.708-720.2005
NR 30
TC 38
Z9 38
U1 0
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1549-9596
EI 1549-960X
J9 J CHEM INF MODEL
JI J. Chem Inf. Model.
PD APR
PY 2009
VL 49
IS 4
BP 1070
EP 1078
DI 10.1021/ci8004622
PG 9
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Computer Science,
   Information Systems; Computer Science, Interdisciplinary Applications
SC Pharmacology & Pharmacy; Chemistry; Computer Science
GA 438AN
UT WOS:000265528400030
PM 19296716
DA 2020-12-01
ER

PT J
AU Andrade, CH
   Salum, LD
   Pasqualoto, KFM
   Ferreira, EI
   Andricopulo, AD
AF Andrade, Carolina Horta
   Salum, Livia de Barros
   Mesquita Pasqualoto, Kerly Fernanda
   Ferreira, Elizabeth Igne
   Andricopulo, Adriano Defini
TI Three-dimensional quantitative structure-activity relationships for a
   large series of potent antitubercular agents
SO LETTERS IN DRUG DESIGN & DISCOVERY
LA English
DT Article
DE tuberculosis; hydrazides; drug design; QSAR; CoMFA; Galahad
ID PHARMACOPHORE IDENTIFICATION; HOLOGRAM QSAR; TUBERCULOSIS; INHIBITORS;
   GALAHAD; DESIGN; 3D
AB Comparative molecular field analysis (CoMFA) studies were conducted on a series of 100 isoniazid derivatives as anti-tuberculosis agents using two receptor-independent structural data set alignment strategies: (1) rigid-body fit, and (2) pharmacophore-based. Significant cross-validated correlation coefficients were obtained (CoMFA(1), q(2) = 0,75 and CoMFA(2), q(2) = 0.74), indicating the potential of the models for untested compounds. The models were then used to predict the inhibitory potency of 20 test set compounds that were not included in the training set, and the predicted values were in good agreement with the experimental results.
C1 [Salum, Livia de Barros; Andricopulo, Adriano Defini] Univ Sao Paulo, Inst Fis Sao Carlos, Ctr Biotecnol Mol Estrutural, Lab Quim Med & Computac, BR-13560970 Sao Carlos, SP, Brazil.
   [Andrade, Carolina Horta; Ferreira, Elizabeth Igne] Univ Sao Paulo, Fac Ciencias Farmaceut, Lab Planejamento & Sintese Quimioterap Potenciais, BR-05508900 Sao Paulo, Brazil.
   [Mesquita Pasqualoto, Kerly Fernanda] Univ Estadual Campinas, Inst Quim, Lab Quimiometria Teor & Aplicada, BR-13084971 Campinas, SP, Brazil.
RP Andricopulo, AD (corresponding author), Univ Sao Paulo, Inst Fis Sao Carlos, Ctr Biotecnol Mol Estrutural, Lab Quim Med & Computac, Av Trabalhador Sao Carlense 400, BR-13560970 Sao Carlos, SP, Brazil.
EM aandrico@if.sc.usp.br
RI 4, INCT/H-4499-2013; Ferreira, Elizabeth I/C-4038-2012; Pasqualoto,
   Kerly/A-6161-2014; Andrade, Carolina/C-3960-2014; Inbeqmedi,
   Inct/I-1929-2013; Andricopulo, Adriano D/B-7672-2012
OI Ferreira, Elizabeth I/0000-0003-2087-033X; Pasqualoto,
   Kerly/0000-0002-7532-4283; Andrade, Carolina/0000-0003-0101-1492;
   Andricopulo, Adriano D/0000-0002-0457-818X
FU National Council for Scientific and Technological DevelopmentNational
   Council for Scientific and Technological Development (CNPq); CNPq,
   Conselho Nacional de Pesquisa e DesenvolvimentoNational Council for
   Scientific and Technological Development (CNPq); State of Sao Paulo
   Research Foundation (FAPESP, Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo), BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)
FX We gratefully acknowledge financial support from the National Council
   for Scientific and Technological Development (CNPq, Conselho Nacional de
   Pesquisa e Desenvolvimento) and The State of Sao Paulo Research
   Foundation (FAPESP, Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo), Brazil.
CR Andrade CH, 2008, MOL DIVERS, V12, P47, DOI 10.1007/s11030-008-9074-z
   Andricopulo AD, 2005, MINI-REV MED CHEM, V5, P585, DOI 10.2174/1389557054023224
   BERNSTEIN J, 1953, AM REV TUBERC PULM, V67, P366
   BERNSTEIN J, 1953, AM REV TUBERC PULM, V67, P354
   Castilho MS, 2006, BIOORGAN MED CHEM, V14, P516, DOI 10.1016/j.bmc.2005.08.055
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009
   Dye C, 2006, LANCET, V367, P938, DOI 10.1016/S0140-6736(06)68384-0
   Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4
   Guido RVC, 2008, J CHEM INF MODEL, V48, P918, DOI 10.1021/ci700453j
   Guido RVC, 2008, CURR MED CHEM, V15, P37
   Honorio KM, 2006, LETT DRUG DES DISCOV, V3, P261, DOI 10.2174/157018006776743206
   Klopman G, 1996, CHEM PHYS, V204, P181, DOI 10.1016/0301-0104(95)00415-7
   Moda TL, 2007, BIOORGAN MED CHEM, V15, P7738, DOI 10.1016/j.bmc.2007.08.060
   Patel Y, 2002, J COMPUT AID MOL DES, V16, P653, DOI 10.1023/A:1021954728347
   Richmond NJ, 2006, J COMPUT AID MOL DES, V20, P567, DOI 10.1007/s10822-006-9082-y
   Salum LD, 2007, J MOL GRAPH MODEL, V26, P434, DOI 10.1016/j.jmgm.2007.02.001
   Shepphird JK, 2006, J COMPUT AID MOL DES, V20, P763, DOI 10.1007/s10822-006-9070-2
   *WHO, 2005, FACT SHEET TUB
   Ying Z, 2005, ANNU REV PHARMACOL, V45, P529, DOI 10.1146/annurev.pharmtox.45.120403.100120
NR 19
TC 22
Z9 22
U1 1
U2 8
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-1808
EI 1875-628X
J9 LETT DRUG DES DISCOV
JI Lett. Drug Des. Discov.
PD SEP
PY 2008
VL 5
IS 6
BP 377
EP 387
DI 10.2174/157018008785777289
PG 11
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 352OG
UT WOS:000259506000005
DA 2020-12-01
ER

PT J
AU Andrade, CH
   Pasqualoto, KFM
   Zaim, MH
   Ferreira, EI
AF Andrade, Carolina Horta
   Mesquita Pasqualoto, Kerly Fernanda
   Zaim, Marcio Henrique
   Ferreira, Elizabeth Igne
TI Rational approach in the new antituberculosis agent design: inhibitors
   of InhA, the enoyl-ACP reductase from Mycobacterium tuberculosis
SO REVISTA BRASILEIRA DE CIENCIAS FARMACEUTICAS
LA Portuguese
DT Review
DE tuberculosis; fatty acid/biosynthesis; mycolic acids; mycobacteria drug
   resistance; drugs/structure-based design; enoyl-act reductase/inhibitors
ID CARRIER PROTEIN REDUCTASE; FATTY-ACID SYNTHESIS; PEPTIDOMETIC RENIN
   INHIBITORS; CATALASE-PEROXIDASE GENE; ISONIAZID RESISTANCE;
   CRYSTAL-STRUCTURE; DRUG-RESISTANCE; NAD ADDUCT; CELL-WALL; WILD-TYPE
AB In conjunction with the spread of HIV infection, tuberculosis (TB) has been among the worldwide health threats. Mycobacteria resistance to the drugs currently used in the therapeutics is the main cause of TB resurgence. In view of this severe situation, the new and selective anti-TB design is of utmost importance. Fatty acid biosynthesis is a prokariontes and eucariontes biochemical process that supplies essential precursors for the assembly of important cellular components, such As phospholipids, lipoproteins, lipopolysaccharides, mycolic acids and cellular envelope. However; the biochemical and functional differences between the bacterial and mammals fatty, acid synthetic path way have endowed the mycobacterial enzymes with distinct properties. These provide valuable opportunities structure- or catalytic mechanism-based design of selective inhibitors as novel anti-TB drugs with improved properties. The enoyl-reductases are essential enzymes in the fatty acids elongation pathway towards the mycolic acids, the main micobacteria cell wall constituents, biosynthyesis and so they are potential targets to the rational new antimycobacteria drug design. This paper highlights recent approaches regarding the design of new anti-TB agents, particularly the enoyl-ACP reductase inhibitors.
C1 [Andrade, Carolina Horta; Ferreira, Elizabeth Igne] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Farm, LAPEN, BR-05508900 Sao Paulo, Brazil.
   [Mesquita Pasqualoto, Kerly Fernanda] Univ Estadual Campinas, Inst Quim, Dept Quim Fis, Lab Quim Teor & Aplicada, BR-13081970 Campinas, SP, Brazil.
   [Zaim, Marcio Henrique] Sintefina Ind & Comercio Ltda, Sao Paulo, Brazil.
RP Andrade, CH (corresponding author), Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Farm, LAPEN, Av Prof Lineu Prestes,580,Bloco 13,Cidade Univ, BR-05508900 Sao Paulo, Brazil.
EM carolhorta@usp.br
RI Pasqualoto, Kerly/A-6161-2014; Andrade, Carolina/C-3960-2014; Ferreira,
   Elizabeth I/C-4038-2012
OI Pasqualoto, Kerly/0000-0002-7532-4283; Andrade,
   Carolina/0000-0003-0101-1492; Ferreira, Elizabeth I/0000-0003-2087-033X
CR [Anonymous], 2007, GLOB TUB CONTR SURV
   Baldock C, 1998, BIOCHEM PHARMACOL, V55, P1541
   Baldock C, 1996, SCIENCE, V274, P2107, DOI 10.1126/science.274.5295.2107
   Banerjee A, 1998, MICROBIOL-SGM, V144, P2697, DOI 10.1099/00221287-144-10-2697
   BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673
   Barry CE, 1996, TRENDS MICROBIOL, V4, P275, DOI 10.1016/0966-842X(96)10031-7
   Barry CE, 1998, PROG LIPID RES, V37, P143, DOI 10.1016/S0163-7827(98)00008-3
   BERNSTEIN J, 1953, AM REV TUBERC PULM, V67, P366
   BERNSTEIN J, 1953, AM REV TUBERC PULM, V67, P354
   BERNSTEIN J, 1952, AM REV TUBERC PULM, V65, P357
   Bhargava HN, 1996, AM J INFECT CONTROL, V24, P209, DOI 10.1016/S0196-6553(96)90017-6
   BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333
   Cohen N. C., 1996, GUIDEBOOK MOL MODELI
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009
   DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450
   Dias MVB, 2007, J STRUCT BIOL, V159, P369, DOI 10.1016/j.jsb.2007.04.009
   DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213
   Espinal MA, 2003, TUBERCULOSIS, V83, P44, DOI 10.1016/S1472-9792(02)00058-6
   Gandy M, 2002, SOC SCI MED, V55, P385, DOI 10.1016/S0277-9536(01)00176-9
   GRASSBERGER MA, 1984, J MED CHEM, V27, P947, DOI 10.1021/jm00374a003
   He X, 2006, J MED CHEM, V49, P6308, DOI 10.1021/jm060715y
   Heath RJ, 2000, NATURE, V406, P145
   Heath RJ, 2002, APPL MICROBIOL BIOT, V58, P695, DOI 10.1007/s00253-001-0918-z
   Heath RJ, 1998, J BIOL CHEM, V273, P30316, DOI 10.1074/jbc.273.46.30316
   Heath RJ, 2000, J BIOL CHEM, V275, P4654, DOI 10.1074/jbc.275.7.4654
   Heath RJ, 2001, PROG LIPID RES, V40, P467, DOI 10.1016/S0163-7827(01)00012-1
   HEYM B, 1994, LANCET, V344, P293, DOI 10.1016/S0140-6736(94)91338-2
   Hopfinger AJ, 1997, J AM CHEM SOC, V119, P10509, DOI 10.1021/ja9718937
   Janin YL, 2007, BIOORGAN MED CHEM, V15, P2479, DOI 10.1016/j.bmc.2007.01.030
   JARLIER V, 1994, FEMS MICROBIOL LETT, V123, P11, DOI 10.1016/0378-1097(94)90267-4
   Klebe G, 2006, DRUG DISCOV TODAY, V11, P580, DOI 10.1016/j.drudis.2006.05.012
   Kremer L, 2003, J BIOL CHEM, V278, P20547, DOI 10.1074/jbc.M302435200
   Kruh NA, 2007, PROTEIN SCI, V16, P1617, DOI 10.1110/ps.062749007
   Kuo MR, 2003, J BIOL CHEM, V278, P20851, DOI 10.1074/jbc.M211968200
   Larsen MH, 2002, MOL MICROBIOL, V46, P453, DOI 10.1046/j.1365-2958.2002.03162.x
   Levy CW, 2001, J MOL BIOL, V309, P171, DOI 10.1006/jmbi.2001.4643
   Macarron R, 2006, DRUG DISCOV TODAY, V11, P277, DOI 10.1016/j.drudis.2006.02.001
   Marrakchi H, 2002, BIOCHEM SOC T, V30, P1050, DOI 10.1042/bst0301050
   McMurry LM, 1998, NATURE, V394, P531, DOI 10.1038/28970
   MIDDLEBROOK G, 1953, SCIENCE, V118, P297, DOI 10.1126/science.118.3063.297
   Morlock GP, 2003, ANTIMICROB AGENTS CH, V47, P3799, DOI 10.1128/AAC.47.12.3799-3805.2003
   Musser JM, 1996, J INFECT DIS, V173, P196, DOI 10.1093/infdis/173.1.196
   Nayyar A, 2005, CURR MED CHEM, V12, P1873, DOI 10.2174/0929867054546654
   Oliveira JS, 2007, CURR DRUG TARGETS, V8, P399, DOI 10.2174/138945007780058942
   Oliveira JS, 2006, J MOL BIOL, V359, P646, DOI 10.1016/j.jmb.2006.03.055
   Pan DH, 2004, J MED CHEM, V47, P3075, DOI 10.1021/jm030586a
   Pan DH, 2003, J CHEM INF COMP SCI, V43, P1591, DOI 10.1021/ci0340714
   Parikh SL, 2000, BIOCHEMISTRY-US, V39, P7645, DOI 10.1021/bi0008940
   Pasqualoto KFM, 2004, J MED CHEM, V47, P3755, DOI 10.1021/jm049913k
   Pasqualoto KFM, 2001, CURR DRUG TARGETS, V2, P427, DOI 10.2174/1389450013348227
   PASQUALOTO KFM, 2003, THESIS U SAO PAULO
   PATRICK GL, 2005, INTRO MED CHEM, P163
   Payne DJ, 2002, ANTIMICROB AGENTS CH, V46, P3118, DOI 10.1128/AAC.46.10.3118-3124.2002
   QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004
   Ramaswamy SV, 2003, ANTIMICROB AGENTS CH, V47, P1241, DOI 10.1128/AAC.47.4.1241-1250.2003
   Rawat R, 2003, P NATL ACAD SCI USA, V100, P13881, DOI 10.1073/pnas.2235848100
   Rozwarski DA, 1999, J BIOL CHEM, V274, P15582, DOI 10.1074/jbc.274.22.15582
   Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98
   Scior T, 2006, CURR MED CHEM, V13, P2205, DOI 10.2174/092986706777935249
   Singh S, 2004, CURR ANAESTH CRIT CA, V15, P165
   Stewart MJ, 1999, J MOL BIOL, V290, P859, DOI 10.1006/jmbi.1999.2907
   Sullivan TJ, 2006, ACS CHEM BIOL, V1, P43, DOI 10.1021/cb0500042
   Tokarski JS, 1997, J CHEM INF COMP SCI, V37, P779, DOI 10.1021/ci970005o
   Tokarski JS, 1997, J CHEM INF COMP SCI, V37, P792, DOI 10.1021/ci970006g
   Vilcheze C, 2000, J BACTERIOL, V182, P4059, DOI 10.1128/JB.182.14.4059-4067.2000
   Vilcheze C, 2005, ANTIMICROB AGENTS CH, V49, P708, DOI 10.1128/AAC.49.2.708-720.2005
   Vilcheze C, 2007, ANNU REV MICROBIOL, V61, P35, DOI 10.1146/annurev.micro.61.111606.122346
   Vilcheze C, 2006, NAT MED, V12, P1027, DOI 10.1038/nm1466
   Wermuth CG, 2003, PRACTICE MED CHEM, P69, DOI [10. 1016/B978-0-12-744481-9. X5000-4, DOI 10.1016/B978-0-12-744481-9.X5000-4]
   YALE HL, 1953, J AM CHEM SOC, V75, P1933, DOI 10.1021/ja01104a046
   Ying Z, 2005, ANNU REV PHARMACOL, V45, P529, DOI 10.1146/annurev.pharmtox.45.120403.100120
   Zhang Y, 2006, DRUG DISCOV TODAY, V11, P21, DOI 10.1016/S1359-6446(05)03626-3
   ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0
NR 73
TC 14
Z9 15
U1 0
U2 10
PU UNIV SAO PAULO, CONJUNTO QUIMICAS
PI SAO PAULO
PA SERVICO PUBLICACOES E CIRCULACAO, CAIXA POSTAL 66083, SAO PAULO, 00000,
   BRAZIL
SN 1516-9332
J9 REV BRAS CIENC FARM
JI Rev. Bras. Cienc. Farm.
PD APR-JUN
PY 2008
VL 44
IS 2
BP 167
EP 179
DI 10.1590/S1516-93322008000200002
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 344ZV
UT WOS:000258966700002
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Andrade, CH
   Salum, LD
   Castilho, MS
   Pasqualoto, KFM
   Ferreira, EI
   Andricopulo, AD
AF Andrade, Carolina H.
   Salum, Livia de B.
   Castilho, Marcelo S.
   Pasqualoto, Kerly F. M.
   Ferreira, Elizabeth I.
   Andricopulo, Adriano D.
TI Fragment-based and classical quantitative structure-activity
   relationships for a series of hydrazides as antituberculosis agents
SO MOLECULAR DIVERSITY
LA English
DT Article
DE tuberculosis; infectious diseases; hydrazides; drug design; QSAR
ID PURINE NUCLEOSIDE PHOSPHORYLASE; X RECEPTOR ACTIVATORS; TOPOLOGICAL
   INDEXES; CHARGE INDEXES; HOLOGRAM QSAR; INHIBITORS; TUBERCULOSIS;
   DESCRIPTORS; DERIVATIVES; DESIGN
AB Worldwide, tuberculosis (TB) is the leading cause of death among curable infectious diseases. Multidrug-resistant Mycobacterium tuberculosis is an emerging problem of great importance to public health, and there is an urgent need for new anti-TB drugs. In the present work, classical 2D quantitative structure-activity relationships (QSAR) and hologram QSAR (HQSAR) studies were performed on a training set of 91 isoniazid derivatives. Significant statistical models (classical QSAR, q(2) = 0.68 and r(2) = 0.72; HQSAR, q(2) = 0.63 and r(2) = 0.86) were obtained, indicating their consistency for untested compounds. The models were then used to evaluate an external test set containing 24 compounds which were not included in the training set, and the predicted values were in good agreement with the experimental results (HQSAR, r(pred)(2) = 0.87; classical QSAR, r(pred)(2) = 0.75).
C1 [Salum, Livia de B.; Andricopulo, Adriano D.] Univ Sao Paulo, Inst Fis, Ctr Biotecnol Mol Estrutural, Lab Quim Med & Computac, BR-13560970 Sao Carlos, SP, Brazil.
   [Andrade, Carolina H.; Ferreira, Elizabeth I.] Univ Sao Paulo, Fac Ciencias Farmaceut, Lab Planejamento & Sintese Quimioterapicos Potenc, BR-05508900 Sao Paulo, Brazil.
   [Castilho, Marcelo S.] Univ Fed Bahia, Fac Farm, Lab Bioinformat & Modelagem Mol, BR-40170290 Salvador, BA, Brazil.
   [Pasqualoto, Kerly F. M.] Univ Estadual Campinas, Inst Quim, Lab Quimiometria Teor & Aplicada, BR-13084971 Campinas, SP, Brazil.
RP Andricopulo, AD (corresponding author), Univ Sao Paulo, Inst Fis, Ctr Biotecnol Mol Estrutural, Lab Quim Med & Computac, Av Trabalhador Sao Carlense, BR-13560970 Sao Carlos, SP, Brazil.
EM aandrico@if.sc.usp.br
RI Castilho, Marcelo/AAB-5453-2019; Andrade, Carolina/C-3960-2014;
   Castilho, Marcelo S/A-2176-2008; Inbeqmedi, Inct/I-1929-2013;
   Andricopulo, Adriano D/B-7672-2012; 4, INCT/H-4499-2013; Ferreira,
   Elizabeth I/C-4038-2012; Pasqualoto, Kerly/A-6161-2014
OI Castilho, Marcelo/0000-0002-9563-5679; Andrade,
   Carolina/0000-0003-0101-1492; Castilho, Marcelo S/0000-0002-9563-5679;
   Andricopulo, Adriano D/0000-0002-0457-818X; Ferreira, Elizabeth
   I/0000-0003-2087-033X; Pasqualoto, Kerly/0000-0002-7532-4283
CR Andricopulo AD, 2005, MINI-REV MED CHEM, V5, P585, DOI 10.2174/1389557054023224
   Andricopulo AD, 2001, CHEM PHARM BULL, V49, P10, DOI 10.1248/cpb.49.10
   Basak SC, 2000, J CHEM INF COMP SCI, V40, P891, DOI 10.1021/ci990114y
   BERNSTEIN J, 1953, AM REV TUBERC PULM, V67, P366
   BERNSTEIN J, 1953, AM REV TUBERC PULM, V67, P354
   BERSTEIN J, 1952, AM REV TUBERC, V65, P357
   Caballero J, 2005, J COMPUT AID MOL DES, V19, P771, DOI 10.1007/s10822-005-9025-z
   Castilho MS, 2007, LETT DRUG DES DISCOV, V4, P106, DOI 10.2174/157018007779422505
   Castilho MS, 2007, BIOORGAN MED CHEM, V15, P6242, DOI 10.1016/j.bmc.2007.06.021
   Castilho MS, 2006, BIOORGAN MED CHEM, V14, P516, DOI 10.1016/j.bmc.2005.08.055
   de Jong BC, 2004, ANNU REV MED, V55, P283, DOI 10.1146/annurev.med.55.091902.103753
   Farutin V, 1999, J MED CHEM, V42, P2422, DOI 10.1021/jm990037y
   Ferreira LG, 2007, LETT DRUG DES DISCOV, V4, P356, DOI 10.2174/157018007780867825
   Furin JJ, 2005, CURR OPIN PULM MED, V11, P189
   GALVEZ J, 1994, J CHEM INF COMP SCI, V34, P520, DOI 10.1021/ci00019a008
   Golbraikh A, 2002, J MOL GRAPH MODEL, V20, P269, DOI 10.1016/S1093-3263(01)00123-1
   Guido RVC, 2008, J CHEM INF MODEL, V48, P918, DOI 10.1021/ci700453j
   Guido RVC, 2008, CURR MED CHEM, V15, P37
   Honorio KM, 2006, LETT DRUG DES DISCOV, V3, P261, DOI 10.2174/157018006776743206
   Honorio KM, 2005, BIOORG MED CHEM LETT, V15, P3119, DOI 10.1016/j.bmcl.2005.04.017
   *INF INC, 2001, PIR MULT DAT AN IBM
   Ivanciuc O, 1998, J CHEM INF COMP SCI, V38, P395, DOI 10.1021/ci970021l
   Klopman G, 1996, CHEM PHYS, V204, P181, DOI 10.1016/0301-0104(95)00415-7
   Krogh R, 2000, FARMACO, V55, P730, DOI 10.1016/S0014-827X(00)00094-X
   Lo Piparo E, 2006, J MED CHEM, V49, P5702, DOI 10.1021/jm060526f
   OLIVEIRA DB, 2000, QUANT STRUCT-ACT REL, V19, P599
   Salum LD, 2007, J MOL GRAPH MODEL, V26, P434, DOI 10.1016/j.jmgm.2007.02.001
   Sonnenberg P, 2005, J INFECT DIS, V191, P150, DOI 10.1086/426827
   Tong W, 1998, J CHEM INF COMP SCI, V38, P669, DOI 10.1021/ci980008g
   Vilcheze C, 2005, ANTIMICROB AGENTS CH, V49, P708, DOI 10.1128/AAC.49.2.708-720.2005
   Vilcheze C, 2006, NAT MED, V12, P1027, DOI 10.1038/nm1466
   *WHO, 2005, FACT SHEET TUB
   Ying Z, 2005, ANNU REV PHARMACOL, V45, P529, DOI 10.1146/annurev.pharmtox.45.120403.100120
NR 33
TC 28
Z9 28
U1 0
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1381-1991
EI 1573-501X
J9 MOL DIVERS
JI Mol. Divers.
PD FEB
PY 2008
VL 12
IS 1
BP 47
EP 59
DI 10.1007/s11030-008-9074-z
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Applied; Chemistry,
   Medicinal; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA 316QJ
UT WOS:000256964500005
PM 18373208
DA 2020-12-01
ER

EF